1 0 0 9360520 -DOCSTART- -X- -X- O

1 0 9 9360520 Autosomal JJ B-NP B-Disease
2 10 18 9360520 dominant JJ I-NP I-Disease
3 19 35 9360520 neurohypophyseal JJ I-NP I-Disease
4 36 44 9360520 diabetes NN I-NP I-Disease
5 45 54 9360520 insipidus NN I-NP I-Disease
6 55 65 9360520 associated VBN B-VP O
7 66 70 9360520 with IN B-PP O
8 71 72 9360520 a DT B-NP O
9 73 81 9360520 missense JJ I-NP O
10 82 90 9360520 mutation NN I-NP O
11 91 99 9360520 encoding VBG B-VP O
12 100 105 9360520 Gly23 NN B-NP O
13 105 106 9360520 - HYPH O O
14 106 107 9360520 - SYM B-NP O
15 107 108 9360520 > SYM B-VP O
16 108 111 9360520 Val NN B-NP O
17 112 114 9360520 in IN B-PP O
18 115 126 9360520 neurophysin NN B-NP O
19 127 129 9360520 II CD I-NP O
20 129 130 9360520 . . I-NP O
21 131 140 9360520 Autosomal JJ I-NP B-Disease
22 141 149 9360520 dominant JJ I-NP I-Disease
23 150 166 9360520 neurohypophyseal JJ I-NP I-Disease
24 167 175 9360520 diabetes NN I-NP I-Disease
25 176 185 9360520 insipidus NN I-NP I-Disease
26 186 187 9360520 ( ( O O
27 187 192 9360520 ADNDI NN B-NP B-Disease
28 192 193 9360520 ) ) O O
29 194 196 9360520 is VBZ B-VP O
30 197 199 9360520 an DT B-NP O
31 200 209 9360520 inherited VBN I-NP B-Disease
32 210 217 9360520 disease NN I-NP I-Disease
33 218 224 9360520 caused VBN B-VP O
34 225 227 9360520 by IN B-PP O
35 228 239 9360520 progressive JJ B-NP O
36 240 252 9360520 degeneration NN I-NP O
37 253 255 9360520 of IN B-PP O
38 256 259 9360520 the DT B-NP O
39 260 273 9360520 magnocellular JJ I-NP O
40 274 281 9360520 neurons NNS I-NP O
41 282 284 9360520 of IN B-PP O
42 285 288 9360520 the DT B-NP O
43 289 301 9360520 hypothalamus NN I-NP O
44 302 309 9360520 leading VBG B-VP O
45 310 312 9360520 to TO B-PP O
46 313 322 9360520 decreased VBN B-NP O
47 323 330 9360520 ability NN I-NP O
48 331 333 9360520 to TO B-VP O
49 334 341 9360520 produce VB I-VP O
50 342 345 9360520 the DT B-NP O
51 346 353 9360520 hormone NN I-NP O
52 354 362 9360520 arginine NN I-NP O
53 363 374 9360520 vasopressin NN I-NP O
54 375 376 9360520 ( ( O O
55 376 379 9360520 AVP NN B-NP O
56 379 380 9360520 ) ) O O
57 380 381 9360520 . . O O

1 382 390 9360520 Affected JJ B-NP O
2 391 402 9360520 individuals NNS I-NP O
3 403 406 9360520 are VBP B-VP O
4 407 410 9360520 not RB O O
5 411 422 9360520 symptomatic JJ B-ADJP O
6 423 425 9360520 at IN B-PP O
7 426 431 9360520 birth NN B-NP O
8 431 432 9360520 , , O O
9 433 436 9360520 but CC O O
10 437 444 9360520 usually RB B-VP O
11 445 452 9360520 develop VBP I-VP O
12 453 461 9360520 diabetes NN B-NP B-Disease
13 462 471 9360520 insipidus NN I-NP I-Disease
14 472 474 9360520 at IN B-PP O
15 475 476 9360520 1 CD B-NP O
16 476 477 9360520 - HYPH I-NP O
17 477 478 9360520 6 CD I-NP O
18 479 481 9360520 yr NN I-NP O
19 482 484 9360520 of IN B-PP O
20 485 488 9360520 age NN B-NP O
21 488 489 9360520 . . O O

1 490 493 9360520 The DT B-NP O
2 494 501 9360520 genetic JJ I-NP O
3 502 507 9360520 locus NN I-NP O
4 508 510 9360520 of IN B-PP O
5 511 514 9360520 the DT B-NP O
6 515 522 9360520 disease NN I-NP O
7 523 525 9360520 is VBZ B-VP O
8 526 529 9360520 the DT B-NP O
9 530 533 9360520 AVP NN I-NP O
10 533 534 9360520 - HYPH O O
11 534 545 9360520 neurophysin NN B-NP O
12 546 548 9360520 II CD I-NP O
13 549 550 9360520 ( ( O O
14 550 554 9360520 NPII NN B-NP O
15 554 555 9360520 ) ) O O
16 556 560 9360520 gene NN B-NP O
17 560 561 9360520 , , O O
18 562 565 9360520 and CC O O
19 566 575 9360520 mutations NNS B-NP O
20 576 580 9360520 that WDT B-NP O
21 581 586 9360520 cause VBP B-VP O
22 587 592 9360520 ADNDI NNP B-NP B-Disease
23 593 597 9360520 have VBP B-VP O
24 598 602 9360520 been VBN I-VP O
25 603 608 9360520 found VBN I-VP O
26 609 611 9360520 in IN B-PP O
27 612 616 9360520 both CC O O
28 617 620 9360520 the DT B-NP O
29 621 627 9360520 signal NN I-NP O
30 628 635 9360520 peptide NN I-NP O
31 636 638 9360520 of IN B-PP O
32 639 642 9360520 the DT B-NP O
33 643 649 9360520 prepro AFX I-NP O
34 649 650 9360520 - HYPH I-NP O
35 650 653 9360520 AVP NN I-NP O
36 653 654 9360520 - HYPH I-NP O
37 654 658 9360520 NPII NN I-NP O
38 659 668 9360520 precursor NN I-NP O
39 669 672 9360520 and CC B-PP O
40 673 679 9360520 within IN B-PP O
41 680 684 9360520 NPII NN B-NP O
42 685 691 9360520 itself PRP B-NP O
43 691 692 9360520 . . O O

1 693 695 9360520 An DT B-NP O
2 696 704 9360520 affected VBN I-NP O
3 705 709 9360520 girl NN I-NP O
4 710 713 9360520 who WP B-NP O
5 714 723 9360520 presented VBD B-VP O
6 724 726 9360520 at IN B-PP O
7 727 728 9360520 9 CD B-NP O
8 729 735 9360520 months NNS I-NP O
9 736 738 9360520 of IN B-PP O
10 739 742 9360520 age NN B-NP O
11 743 746 9360520 and CC O O
12 747 750 9360520 her PRP B-NP O
13 751 760 9360520 similarly RB B-VP O
14 761 769 9360520 affected VBD I-VP O
15 770 777 9360520 younger JJR B-NP O
16 778 785 9360520 brother NN I-NP O
17 786 789 9360520 and CC I-NP O
18 790 796 9360520 father NN I-NP O
19 797 801 9360520 were VBD B-VP O
20 802 805 9360520 all DT O O
21 806 811 9360520 found VBN B-VP O
22 812 814 9360520 to TO I-VP O
23 815 819 9360520 have VB I-VP O
24 820 821 9360520 a DT B-NP O
25 822 827 9360520 novel JJ I-NP O
26 828 836 9360520 missense JJ I-NP O
27 837 845 9360520 mutation NN I-NP O
28 846 847 9360520 ( ( O O
29 847 852 9360520 G1758 NN B-NP O
30 852 853 9360520 - SYM O O
31 853 854 9360520 - HYPH O O
32 855 856 9360520 > SYM O O
33 857 858 9360520 T NN B-NP O
34 858 859 9360520 ) ) O O
35 860 868 9360520 encoding VBG B-VP O
36 869 872 9360520 the DT B-NP O
37 873 878 9360520 amino JJ I-NP O
38 879 883 9360520 acid NN I-NP O
39 884 896 9360520 substitution NN I-NP O
40 897 902 9360520 Gly23 NN I-NP O
41 902 903 9360520 - SYM B-NP O
42 903 904 9360520 - HYPH B-NP O
43 905 906 9360520 > SYM I-NP O
44 907 910 9360520 Val NN I-NP O
45 911 917 9360520 within IN B-PP O
46 918 922 9360520 NPII NN B-NP O
47 922 923 9360520 . . O O

1 924 927 9360520 The DT B-NP O
2 928 936 9360520 mutation NN I-NP O
3 937 940 9360520 was VBD B-VP O
4 941 950 9360520 confirmed VBN I-VP O
5 951 953 9360520 by IN B-PP O
6 954 965 9360520 restriction NN B-NP O
7 966 978 9360520 endonuclease NN I-NP O
8 979 987 9360520 analysis NN I-NP O
9 987 988 9360520 . . O O

1 989 990 9360520 A DT B-NP O
2 991 993 9360520 T1 NN I-NP O
3 993 994 9360520 - HYPH B-VP O
4 994 1002 9360520 weighted VBN I-VP O
5 1003 1011 9360520 magnetic JJ B-NP O
6 1012 1021 9360520 resonance NN I-NP O
7 1022 1029 9360520 imaging NN I-NP O
8 1030 1032 9360520 of IN B-PP O
9 1033 1036 9360520 the DT B-NP O
10 1037 1044 9360520 fathers NNS I-NP O
11 1045 1054 9360520 pituitary JJ B-NP O
12 1055 1060 9360520 gland NN I-NP O
13 1061 1073 9360520 demonstrates VBZ B-VP O
14 1074 1076 9360520 an DT B-NP O
15 1077 1087 9360520 attenuated VBN I-NP O
16 1088 1097 9360520 posterior JJ I-NP O
17 1098 1107 9360520 pituitary JJ I-NP O
18 1108 1114 9360520 bright JJ I-NP O
19 1115 1119 9360520 spot NN I-NP O
20 1119 1120 9360520 . . O O

1 1121 1125 9360520 This DT B-NP O
2 1126 1134 9360520 mutation NN I-NP O
3 1135 1138 9360520 may MD B-VP O
4 1139 1141 9360520 be VB I-VP O
5 1142 1150 9360520 valuable JJ B-ADJP O
6 1151 1154 9360520 for IN B-PP O
7 1155 1165 9360520 developing VBG B-VP O
8 1166 1172 9360520 models NNS B-NP O
9 1173 1175 9360520 of IN B-PP O
10 1176 1186 9360520 dominantly RB B-NP B-Disease
11 1187 1196 9360520 inherited VBN I-NP I-Disease
12 1197 1214 9360520 neurodegeneration NN I-NP I-Disease
13 1214 1215 9360520 , , O O
14 1216 1218 9360520 as IN B-PP O
15 1219 1222 9360520 the DT B-NP O
16 1223 1228 9360520 early JJ I-NP O
17 1229 1232 9360520 age NN I-NP O
18 1233 1235 9360520 of IN B-PP O
19 1236 1241 9360520 onset NN B-NP O
20 1242 1244 9360520 of IN B-PP O
21 1245 1253 9360520 symptoms NNS B-NP O
22 1254 1262 9360520 suggests VBZ B-VP O
23 1263 1267 9360520 that IN B-SBAR O
24 1268 1272 9360520 this DT B-NP O
25 1273 1281 9360520 mutation NN I-NP O
26 1282 1285 9360520 may MD B-VP O
27 1286 1288 9360520 be VB I-VP O
28 1289 1301 9360520 particularly RB B-ADJP O
29 1302 1313 9360520 deleterious JJ I-ADJP O
30 1314 1316 9360520 to TO B-PP O
31 1317 1320 9360520 the DT B-NP O
32 1321 1334 9360520 magnocellular JJ I-NP O
33 1335 1341 9360520 neuron NN I-NP O
34 1341 1342 9360520 . . O O
35 1342 1343 9360520 . . O O

1 0 0 9465301 -DOCSTART- -X- -X- O

1 0 7 9465301 Genomic JJ B-NP O
2 8 20 9465301 organization NN I-NP O
3 21 23 9465301 of IN B-PP O
4 24 27 9465301 the DT B-NP O
5 28 33 9465301 UBE3A NN I-NP O
6 33 34 9465301 / SYM B-NP O
7 34 36 9465301 E6 NN I-NP O
8 36 37 9465301 - HYPH B-NP O
9 37 39 9465301 AP NN I-NP O
10 40 44 9465301 gene NN I-NP O
11 45 48 9465301 and CC O O
12 49 56 9465301 related JJ B-NP O
13 57 68 9465301 pseudogenes NNS I-NP O
14 68 69 9465301 . . O O
15 70 73 9465301 The DT B-NP O
16 74 79 9465301 UBE3A NN I-NP O
17 80 84 9465301 gene NN I-NP O
18 85 92 9465301 encodes VBZ B-VP O
19 93 96 9465301 the DT B-NP O
20 97 99 9465301 E6 NN I-NP O
21 99 100 9465301 - HYPH O O
22 100 102 9465301 AP NN B-NP O
23 103 112 9465301 ubiquitin NN I-NP O
24 112 113 9465301 - HYPH B-NP O
25 113 120 9465301 protein NN I-NP O
26 121 127 9465301 ligase NN I-NP O
27 128 131 9465301 and CC O O
28 132 135 9465301 has VBZ B-VP O
29 136 144 9465301 recently RB I-VP O
30 145 149 9465301 been VBN I-VP O
31 150 155 9465301 shown VBN I-VP O
32 156 158 9465301 to TO I-VP O
33 159 161 9465301 be VB I-VP O
34 162 169 9465301 mutated VBN I-VP O
35 170 172 9465301 in IN B-PP O
36 173 181 9465301 Angelman NNP B-NP B-Disease
37 182 190 9465301 syndrome NN I-NP I-Disease
38 191 199 9465301 patients NNS I-NP O
39 200 203 9465301 who WP B-NP O
40 204 208 9465301 lack VBP B-VP O
41 209 214 9465301 15q11 CD B-NP O
42 214 215 9465301 - HYPH I-NP O
43 215 218 9465301 q13 NN I-NP O
44 219 228 9465301 deletions NNS I-NP O
45 229 231 9465301 or CC O O
46 232 242 9465301 chromosome NN B-NP O
47 243 245 9465301 15 CD I-NP O
48 246 254 9465301 paternal JJ I-NP O
49 255 266 9465301 uniparental JJ I-NP B-Disease
50 267 273 9465301 disomy NN I-NP I-Disease
51 273 274 9465301 . . O O

1 275 283 9465301 Previous JJ B-NP O
2 284 289 9465301 UBE3A NN I-NP O
3 290 294 9465301 cDNA NN I-NP O
4 295 303 9465301 analysis NN I-NP O
5 304 307 9465301 has VBZ B-VP O
6 308 313 9465301 shown VBN I-VP O
7 314 315 9465301 a DT B-NP O
8 316 322 9465301 coding VBG I-NP O
9 323 329 9465301 region NN I-NP O
10 330 332 9465301 of IN B-PP O
11 333 346 9465301 approximately RB B-NP O
12 347 348 9465301 2 CD I-NP O
13 348 349 9465301 . . I-NP O
14 350 351 9465301 6 CD I-NP O
15 352 354 9465301 kb NN I-NP O
16 355 358 9465301 and CC O O
17 359 360 9465301 a DT B-NP O
18 361 362 9465301 3 CD I-NP O
19 362 363 9465301 - HYPH I-NP O
20 363 375 9465301 untranslated JJ I-NP O
21 376 382 9465301 region NN I-NP O
22 383 384 9465301 ( ( O O
23 384 387 9465301 UTR NN B-NP O
24 387 388 9465301 ) ) O O
25 389 391 9465301 of IN B-PP O
26 392 393 9465301 < SYM B-NP O
27 394 396 9465301 50 CD I-NP O
28 397 399 9465301 bp NN I-NP O
29 399 400 9465301 , , O O
30 401 408 9465301 whereas IN O O
31 409 417 9465301 Northern NN B-NP O
32 418 426 9465301 analysis NN I-NP O
33 427 430 9465301 has VBZ B-VP O
34 431 440 9465301 indicated VBN I-VP O
35 441 445 9465301 mRNA NN B-NP O
36 446 451 9465301 sizes NNS I-NP O
37 452 454 9465301 of IN B-PP O
38 455 456 9465301 5 CD B-NP O
39 456 457 9465301 - HYPH I-NP O
40 457 458 9465301 8 CD I-NP O
41 459 461 9465301 kb NN I-NP O
42 461 462 9465301 . . O O

1 463 465 9465301 We PRP B-NP O
2 466 470 9465301 have VBP B-VP O
3 471 479 9465301 analyzed VBN I-VP O
4 480 490 9465301 additional JJ B-NP O
5 491 495 9465301 cDNA NN I-NP O
6 496 502 9465301 clones NNS I-NP O
7 503 506 9465301 and CC O O
8 507 514 9465301 provide VBP B-VP O
9 515 523 9465301 evidence NN B-NP O
10 524 527 9465301 for IN B-PP O
11 528 530 9465301 an DT B-NP O
12 531 541 9465301 additional JJ I-NP O
13 542 543 9465301 0 CD I-NP O
14 543 544 9465301 . . O O

1 545 546 9465301 5 CD B-NP O
2 547 549 9465301 kb NN I-NP O
3 550 552 9465301 of IN B-PP O
4 553 554 9465301 5 CD B-NP O
5 554 555 9465301 - HYPH I-NP O
6 555 558 9465301 UTR NN I-NP O
7 559 562 9465301 and CC O O
8 563 564 9465301 > JJR B-NP O
9 565 566 9465301 2 CD I-NP O
10 567 569 9465301 kb NN I-NP O
11 570 572 9465301 of IN B-PP O
12 573 574 9465301 3 CD B-NP O
13 574 575 9465301 - HYPH I-NP O
14 575 578 9465301 UTR NN I-NP O
15 578 579 9465301 . . O O

1 580 582 9465301 We PRP B-NP O
2 583 587 9465301 have VBP B-VP O
3 588 599 9465301 established VBN I-VP O
4 600 603 9465301 the DT B-NP O
5 604 611 9465301 genomic JJ I-NP O
6 612 624 9465301 organization NN I-NP O
7 625 627 9465301 of IN B-PP O
8 628 633 9465301 UBE3A NN B-NP O
9 634 637 9465301 and CC O O
10 638 641 9465301 the DT B-NP O
11 642 650 9465301 sequence NN I-NP O
12 651 653 9465301 of IN B-PP O
13 654 660 9465301 intron NN B-NP O
14 660 661 9465301 - HYPH B-NP O
15 661 665 9465301 exon NN I-NP O
16 666 673 9465301 borders NNS I-NP O
17 673 674 9465301 . . O O

1 675 677 9465301 We PRP B-NP O
2 678 682 9465301 have VBP B-VP O
3 683 687 9465301 also RB I-VP O
4 688 694 9465301 mapped VBN I-VP O
5 695 698 9465301 two CD B-NP O
6 699 705 9465301 highly RB I-NP O
7 706 716 9465301 homologous JJ I-NP O
8 717 726 9465301 processed VBN I-NP O
9 727 738 9465301 pseudogenes NNS I-NP O
10 738 739 9465301 , , I-NP O
11 740 747 9465301 UBE3AP1 NN I-NP O
12 748 751 9465301 and CC I-NP O
13 752 759 9465301 UBE3AP2 NN I-NP O
14 759 760 9465301 , , O O
15 761 763 9465301 to TO B-PP O
16 764 775 9465301 chromosomes NNS B-NP O
17 776 777 9465301 2 CD I-NP O
18 778 781 9465301 and CC I-NP O
19 782 784 9465301 21 CD I-NP O
20 784 785 9465301 , , O O
21 786 798 9465301 respectively RB B-ADVP O
22 798 799 9465301 , , O O
23 800 803 9465301 and CC O O
24 804 814 9465301 determined VBD B-VP O
25 815 820 9465301 their PRP$ B-NP O
26 821 828 9465301 genomic JJ I-NP O
27 829 841 9465301 organization NN I-NP O
28 841 842 9465301 . . O O

1 843 848 9465301 These DT B-NP O
2 849 856 9465301 results NNS I-NP O
3 857 861 9465301 will MD B-VP O
4 862 866 9465301 form VB I-VP O
5 867 870 9465301 the DT B-NP O
6 871 876 9465301 basis NN I-NP O
7 877 880 9465301 for IN B-PP O
8 881 888 9465301 studies NNS B-NP O
9 889 891 9465301 of IN B-PP O
10 892 900 9465301 mutation NN B-NP O
11 901 904 9465301 and CC I-NP O
12 905 915 9465301 imprinting NN I-NP O
13 916 918 9465301 of IN B-PP O
14 919 924 9465301 UBE3A NN B-NP O
15 924 925 9465301 . . O O

1 0 0 9427148 -DOCSTART- -X- -X- O

1 0 22 9427148 Aspartylglucosaminuria NN B-NP B-Disease
2 23 28 9427148 among IN B-PP O
3 29 40 9427148 Palestinian JJ B-NP O
4 41 46 9427148 Arabs NNS I-NP O
5 46 47 9427148 . . O O
6 48 70 9427148 Aspartylglucosaminuria NN B-NP B-Disease
7 71 72 9427148 ( ( O O
8 72 75 9427148 AGU NN B-NP B-Disease
9 75 76 9427148 ) ) O O
10 77 79 9427148 is VBZ B-VP O
11 80 81 9427148 a DT B-NP O
12 82 86 9427148 rare JJ I-NP O
13 87 95 9427148 disorder NN I-NP B-Disease
14 96 98 9427148 of IN B-PP I-Disease
15 99 111 9427148 glycoprotein NN B-NP I-Disease
16 112 122 9427148 metabolism NN I-NP I-Disease
17 123 129 9427148 caused VBN B-VP O
18 130 132 9427148 by IN B-PP O
19 133 136 9427148 the DT B-NP O
20 137 147 9427148 deficiency NN I-NP B-Disease
21 148 150 9427148 of IN B-PP I-Disease
22 151 154 9427148 the DT B-NP I-Disease
23 155 164 9427148 lysosomal JJ I-NP I-Disease
24 165 171 9427148 enzyme NN I-NP I-Disease
25 172 195 9427148 aspartylglucosaminidase NN I-NP I-Disease
26 196 197 9427148 ( ( O O
27 197 200 9427148 AGA NN B-NP O
28 200 201 9427148 ) ) O O
29 201 202 9427148 . . O O

1 203 206 9427148 AGU NN B-NP B-Disease
2 207 209 9427148 is VBZ B-VP O
3 210 219 9427148 inherited VBN I-VP O
4 220 222 9427148 as IN B-PP O
5 223 225 9427148 an DT B-NP O
6 226 235 9427148 autosomal JJ I-NP O
7 236 245 9427148 recessive JJ I-NP O
8 246 251 9427148 trait NN I-NP O
9 252 255 9427148 and CC O O
10 256 262 9427148 occurs VBZ B-VP O
11 263 267 9427148 with IN B-PP O
12 268 269 9427148 a DT B-NP O
13 270 274 9427148 high JJ I-NP O
14 275 284 9427148 frequency NN I-NP O
15 285 287 9427148 in IN B-PP O
16 288 295 9427148 Finland NNP B-NP O
17 296 303 9427148 because IN B-PP O
18 304 306 9427148 of IN I-PP O
19 307 308 9427148 a DT B-NP O
20 309 316 9427148 founder NN I-NP O
21 317 323 9427148 effect NN I-NP O
22 323 324 9427148 . . O O

1 325 330 9427148 While IN B-SBAR O
2 331 335 9427148 very RB B-NP O
3 336 339 9427148 few JJ I-NP O
4 340 348 9427148 patients NNS I-NP O
5 349 353 9427148 with IN B-PP O
6 354 357 9427148 AGU NN B-NP B-Disease
7 358 362 9427148 have VBP B-VP O
8 363 367 9427148 been VBN I-VP O
9 368 376 9427148 reported VBN I-VP O
10 377 381 9427148 from IN B-PP O
11 382 385 9427148 non AFX B-NP O
12 385 386 9427148 - HYPH I-NP O
13 386 393 9427148 Finnish JJ I-NP O
14 394 400 9427148 origin NN I-NP O
15 400 401 9427148 , , O O
16 402 404 9427148 we PRP B-NP O
17 405 414 9427148 diagnosed VBD B-VP O
18 415 418 9427148 the DT B-NP O
19 419 427 9427148 disorder NN I-NP O
20 428 430 9427148 in IN B-PP O
21 431 432 9427148 8 CD B-NP O
22 433 441 9427148 patients NNS I-NP O
23 442 453 9427148 originating VBG B-VP O
24 454 458 9427148 from IN B-PP O
25 459 460 9427148 3 CD B-NP O
26 461 470 9427148 unrelated JJ I-NP O
27 471 479 9427148 families NNS I-NP O
28 479 480 9427148 , , O O
29 481 484 9427148 all DT B-NP O
30 485 496 9427148 Palestinian JJ I-NP O
31 497 502 9427148 Arabs NNS I-NP O
32 503 507 9427148 from IN B-PP O
33 508 511 9427148 the DT B-NP O
34 512 518 9427148 region NN I-NP O
35 519 521 9427148 of IN B-PP O
36 522 531 9427148 Jerusalem NNP B-NP O
37 531 532 9427148 . . O O

1 533 536 9427148 The DT B-NP O
2 537 545 9427148 clinical JJ I-NP O
3 546 555 9427148 diagnosis NN I-NP O
4 556 558 9427148 of IN B-PP O
5 559 562 9427148 AGU NN B-NP B-Disease
6 563 565 9427148 is VBZ B-VP O
7 566 571 9427148 often RB B-ADVP O
8 572 581 9427148 difficult JJ B-ADJP O
9 581 582 9427148 , , O O
10 583 585 9427148 in IN B-PP O
11 586 596 9427148 particular JJ B-NP O
12 597 602 9427148 early JJ I-NP O
13 603 605 9427148 in IN B-PP O
14 606 609 9427148 the DT B-NP O
15 610 616 9427148 course NN I-NP O
16 617 619 9427148 of IN B-PP O
17 620 623 9427148 the DT B-NP O
18 624 631 9427148 disease NN I-NP O
19 631 632 9427148 , , O O
20 633 636 9427148 and CC O O
21 637 641 9427148 most JJS B-NP O
22 642 644 9427148 of IN B-PP O
23 645 648 9427148 the DT B-NP O
24 649 657 9427148 patients NNS I-NP O
25 658 661 9427148 are VBP B-VP O
26 662 671 9427148 diagnosed VBN I-VP O
27 672 677 9427148 after IN B-PP O
28 678 681 9427148 the DT B-NP O
29 682 685 9427148 age NN I-NP O
30 686 688 9427148 of IN B-PP O
31 689 690 9427148 5 CD B-NP O
32 691 696 9427148 years NNS I-NP O
33 696 697 9427148 . . O O

1 698 705 9427148 However RB B-ADVP O
2 705 706 9427148 , , O O
3 707 712 9427148 since IN B-SBAR O
4 713 718 9427148 these DT B-NP O
5 719 727 9427148 patients NNS I-NP O
6 728 735 9427148 excrete VBP B-VP O
7 736 741 9427148 early JJ B-NP O
8 742 747 9427148 large JJ I-NP O
9 748 755 9427148 amounts NNS I-NP O
10 756 758 9427148 of IN B-PP O
11 759 778 9427148 aspartylglucosamine NN B-NP O
12 779 781 9427148 in IN B-PP O
13 782 787 9427148 urine NN B-NP O
14 787 788 9427148 , , O O
15 789 800 9427148 biochemical JJ B-NP O
16 801 810 9427148 screening NN I-NP O
17 811 813 9427148 is VBZ B-VP O
18 814 818 9427148 easy JJ B-ADJP O
19 819 821 9427148 by IN B-PP O
20 822 827 9427148 urine NN B-NP O
21 828 842 9427148 chromatography NN I-NP O
22 842 843 9427148 . . O O
23 843 844 9427148 . . O O

1 0 0 9336417 -DOCSTART- -X- -X- O

1 0 14 9336417 Susceptibility NN B-NP O
2 15 17 9336417 to TO B-PP O
3 18 28 9336417 ankylosing VBG B-VP B-Disease
4 29 40 9336417 spondylitis NN B-NP I-Disease
5 41 43 9336417 in IN B-PP O
6 44 49 9336417 twins NNS B-NP O
7 49 50 9336417 : : O O
8 51 54 9336417 the DT B-NP O
9 55 59 9336417 role NN I-NP O
10 60 62 9336417 of IN B-PP O
11 63 68 9336417 genes NNS B-NP O
12 68 69 9336417 , , O O
13 70 73 9336417 HLA NN B-NP O
14 73 74 9336417 , , O O
15 75 78 9336417 and CC O O
16 79 82 9336417 the DT B-NP O
17 83 94 9336417 environment NN I-NP O
18 94 95 9336417 . . O O
19 96 105 9336417 OBJECTIVE NN B-NP O
20 107 109 9336417 To TO B-VP O
21 110 119 9336417 determine VB I-VP O
22 120 123 9336417 the DT B-NP O
23 124 132 9336417 relative JJ I-NP O
24 133 140 9336417 effects NNS I-NP O
25 141 143 9336417 of IN B-PP O
26 144 151 9336417 genetic JJ B-NP O
27 152 155 9336417 and CC I-NP O
28 156 169 9336417 environmental JJ I-NP O
29 170 177 9336417 factors NNS I-NP O
30 178 180 9336417 in IN B-PP O
31 181 195 9336417 susceptibility NN B-NP O
32 196 198 9336417 to TO B-PP O
33 199 209 9336417 ankylosing VBG B-VP B-Disease
34 210 221 9336417 spondylitis NN B-NP I-Disease
35 222 223 9336417 ( ( O O
36 223 225 9336417 AS NN B-NP B-Disease
37 225 226 9336417 ) ) O O
38 226 227 9336417 . . O O

1 228 235 9336417 METHODS NNS B-NP O
2 237 242 9336417 Twins NNS I-NP O
3 243 247 9336417 with IN B-PP O
4 248 250 9336417 AS NN B-NP B-Disease
5 251 255 9336417 were VBD B-VP O
6 256 266 9336417 identified VBN I-VP O
7 267 271 9336417 from IN B-PP O
8 272 275 9336417 the DT B-NP O
9 276 281 9336417 Royal NNP I-NP O
10 282 290 9336417 National NNP I-NP O
11 291 299 9336417 Hospital NNP I-NP O
12 300 303 9336417 for IN B-PP O
13 304 313 9336417 Rheumatic NNP B-NP B-Disease
14 314 322 9336417 Diseases NNP I-NP I-Disease
15 323 331 9336417 database NN I-NP O
16 331 332 9336417 . . O O

1 333 341 9336417 Clinical JJ B-NP O
2 342 345 9336417 and CC I-NP O
3 346 358 9336417 radiographic JJ I-NP O
4 359 371 9336417 examinations NNS I-NP O
5 372 376 9336417 were VBD B-VP O
6 377 386 9336417 performed VBN I-VP O
7 387 389 9336417 to TO I-VP O
8 390 399 9336417 establish VB I-VP O
9 400 409 9336417 diagnoses NNS B-NP O
10 409 410 9336417 , , O O
11 411 414 9336417 and CC O O
12 415 422 9336417 disease NN B-NP O
13 423 431 9336417 severity NN I-NP O
14 432 435 9336417 was VBD B-VP O
15 436 444 9336417 assessed VBN I-VP O
16 445 450 9336417 using VBG B-VP O
17 451 452 9336417 a DT B-NP O
18 453 464 9336417 combination NN I-NP O
19 465 467 9336417 of IN B-PP O
20 468 477 9336417 validated VBN B-NP O
21 478 485 9336417 scoring NN I-NP O
22 486 493 9336417 systems NNS I-NP O
23 493 494 9336417 . . O O

1 495 498 9336417 HLA NN B-NP O
2 499 505 9336417 typing NN I-NP O
3 506 509 9336417 for IN B-PP O
4 510 513 9336417 HLA NN B-NP O
5 513 514 9336417 - HYPH I-NP O
6 514 517 9336417 B27 NN I-NP O
7 517 518 9336417 , , O O
8 519 522 9336417 HLA NN B-NP O
9 522 523 9336417 - HYPH I-NP O
10 523 526 9336417 B60 NN I-NP O
11 526 527 9336417 , , O O
12 528 531 9336417 and CC O O
13 532 535 9336417 HLA NN B-NP O
14 535 536 9336417 - HYPH B-NP O
15 536 539 9336417 DR1 NN I-NP O
16 540 543 9336417 was VBD B-VP O
17 544 553 9336417 performed VBN I-VP O
18 554 556 9336417 by IN B-PP O
19 557 567 9336417 polymerase NN B-NP O
20 568 573 9336417 chain NN I-NP O
21 574 582 9336417 reaction NN I-NP O
22 583 587 9336417 with IN B-PP O
23 588 596 9336417 sequence NN B-NP O
24 596 597 9336417 - HYPH B-NP O
25 597 605 9336417 specific JJ I-NP O
26 606 613 9336417 primers NNS I-NP O
27 613 614 9336417 , , O O
28 615 618 9336417 and CC O O
29 619 627 9336417 zygosity NN B-NP O
30 628 631 9336417 was VBD B-VP O
31 632 640 9336417 assessed VBN I-VP O
32 641 646 9336417 using VBG B-VP O
33 647 661 9336417 microsatellite NN B-NP O
34 662 669 9336417 markers NNS I-NP O
35 669 670 9336417 . . O O

1 671 678 9336417 Genetic JJ B-NP O
2 679 682 9336417 and CC I-NP O
3 683 696 9336417 environmental JJ I-NP O
4 697 705 9336417 variance NN I-NP O
5 706 716 9336417 components NNS I-NP O
6 717 721 9336417 were VBD B-VP O
7 722 730 9336417 assessed VBN I-VP O
8 731 735 9336417 with IN B-PP O
9 736 739 9336417 the DT B-NP O
10 740 747 9336417 program NN I-NP O
11 748 750 9336417 Mx NN I-NP O
12 750 751 9336417 , , O O
13 752 757 9336417 using VBG B-VP O
14 758 762 9336417 data NNS B-NP O
15 763 767 9336417 from IN B-PP O
16 768 772 9336417 this DT B-NP O
17 773 776 9336417 and CC I-NP O
18 777 785 9336417 previous JJ I-NP O
19 786 793 9336417 studies NNS I-NP O
20 794 796 9336417 of IN B-PP O
21 797 802 9336417 twins NNS B-NP O
22 803 807 9336417 with IN B-PP O
23 808 810 9336417 AS NN B-NP B-Disease
24 810 811 9336417 . . O O

1 812 819 9336417 RESULTS NNS B-NP O
2 821 824 9336417 Six CD B-NP O
3 825 827 9336417 of IN B-PP O
4 828 829 9336417 8 CD B-NP O
5 830 841 9336417 monozygotic JJ I-NP O
6 842 843 9336417 ( ( O O
7 843 845 9336417 MZ JJ B-ADJP O
8 845 846 9336417 ) ) O O
9 847 851 9336417 twin NN B-NP O
10 852 857 9336417 pairs NNS I-NP O
11 858 862 9336417 were VBD B-VP O
12 863 870 9336417 disease NN B-ADJP O
13 871 881 9336417 concordant JJ I-ADJP O
14 881 882 9336417 , , O O
15 883 891 9336417 compared VBN B-PP O
16 892 896 9336417 with IN B-PP O
17 897 898 9336417 4 CD B-NP O
18 899 901 9336417 of IN B-PP O
19 902 904 9336417 15 CD B-NP O
20 905 908 9336417 B27 NN I-NP O
21 908 909 9336417 - HYPH B-NP O
22 909 917 9336417 positive JJ I-NP O
23 918 927 9336417 dizygotic JJ I-NP O
24 928 929 9336417 ( ( O O
25 929 931 9336417 DZ NN B-NP O
26 931 932 9336417 ) ) O O
27 933 937 9336417 twin NN B-NP O
28 938 943 9336417 pairs NNS I-NP O
29 944 945 9336417 ( ( O O
30 945 948 9336417 27% CD B-NP O
31 948 949 9336417 ) ) O O
32 950 953 9336417 and CC O O
33 954 955 9336417 4 CD B-NP O
34 956 958 9336417 of IN B-PP O
35 959 961 9336417 32 CD B-NP O
36 962 964 9336417 DZ NN I-NP O
37 965 969 9336417 twin NN I-NP O
38 970 975 9336417 pairs NNS I-NP O
39 976 983 9336417 overall JJ B-ADVP O
40 984 985 9336417 ( ( O O
41 985 987 9336417 12 CD B-NP O
42 987 988 9336417 . . O O

1 989 991 9336417 5% LS B-LST O
2 991 992 9336417 ) ) O O
3 992 993 9336417 . . O O

1 994 1008 9336417 Nonsignificant JJ B-NP O
2 1009 1018 9336417 increases NNS I-NP O
3 1019 1021 9336417 in IN B-PP O
4 1022 1032 9336417 similarity NN B-NP O
5 1033 1037 9336417 with IN B-PP O
6 1038 1044 9336417 regard NN B-NP O
7 1045 1047 9336417 to TO B-PP O
8 1048 1051 9336417 age NN B-NP O
9 1052 1054 9336417 at IN B-PP O
10 1055 1062 9336417 disease NN B-NP O
11 1063 1068 9336417 onset NN I-NP O
12 1069 1072 9336417 and CC O O
13 1073 1076 9336417 all DT B-NP O
14 1077 1079 9336417 of IN B-PP O
15 1080 1083 9336417 the DT B-NP O
16 1084 1091 9336417 disease NN I-NP O
17 1092 1100 9336417 severity NN I-NP O
18 1101 1107 9336417 scores NNS I-NP O
19 1108 1116 9336417 assessed VBN B-VP O
20 1117 1121 9336417 were VBD B-VP O
21 1122 1127 9336417 noted VBN I-VP O
22 1128 1130 9336417 in IN B-PP O
23 1131 1138 9336417 disease NN B-NP O
24 1138 1139 9336417 - HYPH B-NP O
25 1139 1149 9336417 concordant JJ I-NP O
26 1150 1152 9336417 MZ NN I-NP O
27 1153 1158 9336417 twins NNS I-NP O
28 1159 1167 9336417 compared VBN B-PP O
29 1168 1172 9336417 with IN B-PP O
30 1173 1183 9336417 concordant JJ B-NP O
31 1184 1186 9336417 DZ NN I-NP O
32 1187 1192 9336417 twins NNS I-NP O
33 1192 1193 9336417 . . O O

1 1194 1197 9336417 HLA NN B-NP O
2 1197 1198 9336417 - HYPH I-NP O
3 1198 1201 9336417 B27 NN I-NP O
4 1202 1205 9336417 and CC I-NP O
5 1206 1209 9336417 B60 NN I-NP O
6 1210 1214 9336417 were VBD B-VP O
7 1215 1225 9336417 associated VBN I-VP O
8 1226 1230 9336417 with IN B-PP O
9 1231 1234 9336417 the DT B-NP O
10 1235 1242 9336417 disease NN I-NP O
11 1243 1245 9336417 in IN B-PP O
12 1246 1254 9336417 probands NNS B-NP O
13 1254 1255 9336417 , , O O
14 1256 1259 9336417 and CC O O
15 1260 1263 9336417 the DT B-NP O
16 1264 1268 9336417 rate NN I-NP O
17 1269 1271 9336417 of IN B-PP O
18 1272 1279 9336417 disease NN B-NP O
19 1280 1291 9336417 concordance NN I-NP O
20 1292 1295 9336417 was VBD B-VP O
21 1296 1309 9336417 significantly RB I-VP O
22 1310 1319 9336417 increased VBN I-VP O
23 1320 1325 9336417 among IN B-PP O
24 1326 1328 9336417 DZ NN B-NP O
25 1329 1333 9336417 twin NN I-NP O
26 1334 1339 9336417 pairs NNS I-NP O
27 1340 1342 9336417 in IN B-PP O
28 1343 1348 9336417 which WDT B-NP O
29 1349 1352 9336417 the DT B-NP O
30 1353 1355 9336417 co AFX I-NP O
31 1355 1356 9336417 - HYPH I-NP O
32 1356 1360 9336417 twin NN I-NP O
33 1361 1364 9336417 was VBD B-VP O
34 1365 1373 9336417 positive JJ B-ADJP O
35 1374 1377 9336417 for IN B-PP O
36 1378 1382 9336417 both CC O O
37 1383 1386 9336417 B27 NN B-NP O
38 1387 1390 9336417 and CC I-NP O
39 1391 1394 9336417 DR1 NN I-NP O
40 1394 1395 9336417 . . O O

1 1396 1404 9336417 Additive JJ B-NP O
2 1405 1412 9336417 genetic JJ I-NP O
3 1413 1420 9336417 effects NNS I-NP O
4 1421 1425 9336417 were VBD B-VP O
5 1426 1435 9336417 estimated VBN I-VP O
6 1436 1438 9336417 to TO I-VP O
7 1439 1449 9336417 contribute VB I-VP O
8 1450 1453 9336417 97% CD B-NP O
9 1454 1456 9336417 of IN B-PP O
10 1457 1460 9336417 the DT B-NP O
11 1461 1471 9336417 population NN I-NP O
12 1472 1480 9336417 variance NN I-NP O
13 1480 1481 9336417 . . O O

1 1482 1492 9336417 CONCLUSION NN B-NP O
2 1494 1508 9336417 Susceptibility NN I-NP O
3 1509 1511 9336417 to TO B-PP O
4 1512 1514 9336417 AS NN B-NP B-Disease
5 1515 1517 9336417 is VBZ B-VP O
6 1518 1525 9336417 largely RB I-VP O
7 1526 1537 9336417 genetically RB I-VP O
8 1538 1548 9336417 determined VBN I-VP O
9 1548 1549 9336417 , , O O
10 1550 1553 9336417 and CC O O
11 1554 1557 9336417 the DT B-NP O
12 1558 1571 9336417 environmental JJ I-NP O
13 1572 1579 9336417 trigger NN I-NP O
14 1580 1583 9336417 for IN B-PP O
15 1584 1587 9336417 the DT B-NP O
16 1588 1595 9336417 disease NN I-NP O
17 1596 1598 9336417 is VBZ B-VP O
18 1599 1607 9336417 probably RB B-ADVP O
19 1608 1618 9336417 ubiquitous JJ B-ADJP O
20 1618 1619 9336417 . . O O

1 1620 1623 9336417 HLA NN B-NP O
2 1623 1624 9336417 - HYPH I-NP O
3 1624 1627 9336417 B27 NN I-NP O
4 1628 1636 9336417 accounts VBZ B-VP O
5 1637 1640 9336417 for IN B-PP O
6 1641 1642 9336417 a DT B-NP O
7 1643 1651 9336417 minority NN I-NP O
8 1652 1654 9336417 of IN B-PP O
9 1655 1658 9336417 the DT B-NP O
10 1659 1666 9336417 overall JJ I-NP O
11 1667 1674 9336417 genetic JJ I-NP O
12 1675 1689 9336417 susceptibility NN I-NP O
13 1690 1692 9336417 to TO B-PP O
14 1693 1695 9336417 AS NN B-NP B-Disease
15 1695 1696 9336417 . . O O

1 0 0 9620771 -DOCSTART- -X- -X- O

1 0 6 9620771 Severe JJ B-NP O
2 7 12 9620771 early JJ I-NP O
3 12 13 9620771 - HYPH I-NP O
4 13 18 9620771 onset NN I-NP O
5 19 26 9620771 obesity NN I-NP B-Disease
6 26 27 9620771 , , O O
7 28 35 9620771 adrenal JJ B-NP B-Disease
8 36 49 9620771 insufficiency NN I-NP I-Disease
9 50 53 9620771 and CC O O
10 54 57 9620771 red JJ B-NP O
11 58 62 9620771 hair NN I-NP O
12 63 75 9620771 pigmentation NN I-NP O
13 76 82 9620771 caused VBN B-VP O
14 83 85 9620771 by IN B-PP O
15 86 90 9620771 POMC NN B-NP O
16 91 100 9620771 mutations NNS I-NP O
17 101 103 9620771 in IN B-PP O
18 104 110 9620771 humans NNS B-NP O
19 110 111 9620771 . . O O
20 112 122 9620771 Sequential JJ B-NP O
21 123 131 9620771 cleavage NN I-NP O
22 132 134 9620771 of IN B-PP O
23 135 138 9620771 the DT B-NP O
24 139 148 9620771 precursor NN I-NP O
25 149 156 9620771 protein NN I-NP O
26 157 160 9620771 pre AFX O O
27 160 161 9620771 - HYPH O O
28 161 164 9620771 pro AFX O O
29 164 165 9620771 - HYPH O O
30 165 181 9620771 opiomelanocortin NN B-NP O
31 182 183 9620771 ( ( O O
32 183 187 9620771 POMC NN B-NP O
33 187 188 9620771 ) ) O O
34 189 198 9620771 generates VBZ B-VP O
35 199 202 9620771 the DT B-NP O
36 203 215 9620771 melanocortin NN I-NP O
37 216 224 9620771 peptides NNS I-NP O
38 225 245 9620771 adrenocorticotrophin NN I-NP O
39 246 247 9620771 ( ( O O
40 247 251 9620771 ACTH NN B-NP O
41 251 252 9620771 ) ) O O
42 252 253 9620771 , , O O
43 254 264 9620771 melanocyte NN B-NP O
44 264 265 9620771 - HYPH O O
45 265 276 9620771 stimulating VBG B-VP O
46 277 285 9620771 hormones NNS B-NP O
47 286 287 9620771 ( ( O O
48 287 290 9620771 MSH NN B-NP O
49 290 291 9620771 ) ) O O
50 292 297 9620771 alpha NN B-NP O
51 297 298 9620771 , , O O
52 299 303 9620771 beta NN B-NP O
53 304 307 9620771 and CC I-NP O
54 308 313 9620771 gamma NN I-NP O
55 314 316 9620771 as RB B-CONJP O
56 317 321 9620771 well RB I-CONJP O
57 322 324 9620771 as IN I-CONJP O
58 325 328 9620771 the DT B-NP O
59 329 335 9620771 opioid JJ I-NP O
60 335 336 9620771 - HYPH I-NP O
61 336 344 9620771 receptor NN I-NP O
62 345 351 9620771 ligand NN I-NP O
63 352 356 9620771 beta SYM B-VP O
64 356 357 9620771 - HYPH O O
65 357 366 9620771 endorphin NN B-NP O
66 366 367 9620771 . . O O

1 368 373 9620771 While IN B-SBAR O
2 374 375 9620771 a DT B-NP O
3 376 379 9620771 few JJ I-NP O
4 380 385 9620771 cases NNS I-NP O
5 386 388 9620771 of IN B-PP O
6 389 397 9620771 isolated VBN B-NP O
7 398 402 9620771 ACTH NN I-NP B-Disease
8 403 413 9620771 deficiency NN I-NP I-Disease
9 414 418 9620771 have VBP B-VP O
10 419 423 9620771 been VBN I-VP O
11 424 432 9620771 reported VBN I-VP O
12 433 434 9620771 ( ( O O
13 434 438 9620771 OMIM NN B-NP O
14 439 445 9620771 201400 CD I-NP O
15 445 446 9620771 ) ) O O
16 446 447 9620771 , , O O
17 448 450 9620771 an DT B-NP O
18 451 460 9620771 inherited VBN I-NP O
19 461 465 9620771 POMC NN I-NP O
20 466 472 9620771 defect NN I-NP O
21 473 476 9620771 has VBZ B-VP O
22 477 480 9620771 not RB I-VP O
23 481 485 9620771 been VBN I-VP O
24 486 495 9620771 described VBN I-VP O
25 496 498 9620771 so RB B-ADVP O
26 499 502 9620771 far RB I-ADVP O
27 502 503 9620771 . . O O

1 504 510 9620771 Recent JJ B-NP O
2 511 518 9620771 studies NNS I-NP O
3 519 521 9620771 in IN B-PP O
4 522 528 9620771 animal NN B-NP O
5 529 535 9620771 models NNS I-NP O
6 536 546 9620771 elucidated VBD B-VP O
7 547 548 9620771 a DT B-NP O
8 549 556 9620771 central JJ I-NP O
9 557 561 9620771 role NN I-NP O
10 562 564 9620771 of IN B-PP O
11 565 570 9620771 alpha SYM B-NP O
12 570 571 9620771 - HYPH B-VP O
13 571 574 9620771 MSH NN B-NP O
14 575 577 9620771 in IN B-PP O
15 578 581 9620771 the DT B-NP O
16 582 592 9620771 regulation NN I-NP O
17 593 595 9620771 of IN B-PP O
18 596 600 9620771 food NN B-NP O
19 601 607 9620771 intake NN I-NP O
20 608 610 9620771 by IN B-PP O
21 611 621 9620771 activation NN B-NP O
22 622 624 9620771 of IN B-PP O
23 625 628 9620771 the DT B-NP O
24 629 634 9620771 brain NN I-NP O
25 635 647 9620771 melanocortin NN I-NP O
26 647 648 9620771 - HYPH B-NP O
27 648 649 9620771 4 CD I-NP O
28 649 650 9620771 - HYPH I-NP O
29 650 658 9620771 receptor NN I-NP O
30 659 660 9620771 ( ( O O
31 660 663 9620771 MC4 NN B-NP O
32 663 664 9620771 - HYPH I-NP O
33 664 665 9620771 R NN I-NP O
34 665 666 9620771 ; : O O
35 667 671 9620771 refs NNS B-NP O
36 672 673 9620771 3 CD B-NP O
37 673 674 9620771 - HYPH I-NP O
38 674 675 9620771 5 CD I-NP O
39 675 676 9620771 ) ) O O
40 677 680 9620771 and CC O O
41 681 684 9620771 the DT B-NP O
42 685 692 9620771 linkage NN I-NP O
43 693 695 9620771 of IN B-PP O
44 696 701 9620771 human JJ B-NP O
45 702 709 9620771 obesity NN I-NP B-Disease
46 710 712 9620771 to TO B-PP O
47 713 723 9620771 chromosome NN B-NP O
48 724 725 9620771 2 CD I-NP O
49 726 728 9620771 in IN B-PP O
50 729 734 9620771 close JJ B-NP O
51 735 744 9620771 proximity NN I-NP O
52 745 747 9620771 to TO B-PP O
53 748 751 9620771 the DT B-NP O
54 752 756 9620771 POMC NN I-NP O
55 757 762 9620771 locus NN I-NP O
56 762 763 9620771 , , O O
57 764 767 9620771 led VBD B-VP O
58 768 770 9620771 to TO B-PP O
59 771 774 9620771 the DT B-NP O
60 775 783 9620771 proposal NN I-NP O
61 784 786 9620771 of IN B-PP O
62 787 789 9620771 an DT B-NP O
63 790 801 9620771 association NN I-NP O
64 802 804 9620771 of IN B-PP O
65 805 809 9620771 POMC NN B-NP O
66 810 814 9620771 with IN B-PP O
67 815 820 9620771 human JJ B-NP O
68 821 828 9620771 obesity NN I-NP B-Disease
69 828 829 9620771 . . O O

1 830 833 9620771 The DT B-NP O
2 834 838 9620771 dual JJ I-NP O
3 839 843 9620771 role NN I-NP O
4 844 846 9620771 of IN B-PP O
5 847 852 9620771 alpha SYM B-NP O
6 852 853 9620771 - HYPH B-VP O
7 853 856 9620771 MSH NN B-NP O
8 857 859 9620771 in IN B-PP O
9 860 870 9620771 regulating VBG B-VP O
10 871 875 9620771 food NN B-NP O
11 876 882 9620771 intake NN I-NP O
12 883 886 9620771 and CC O O
13 887 898 9620771 influencing VBG B-VP O
14 899 903 9620771 hair NN B-NP O
15 904 916 9620771 pigmentation NN I-NP O
16 917 925 9620771 predicts VBZ B-VP O
17 926 930 9620771 that IN B-SBAR O
18 931 934 9620771 the DT B-NP O
19 935 944 9620771 phenotype NN I-NP O
20 945 955 9620771 associated VBN B-VP O
21 956 960 9620771 with IN B-PP O
22 961 962 9620771 a DT B-NP O
23 963 969 9620771 defect NN I-NP O
24 970 972 9620771 in IN B-PP O
25 973 977 9620771 POMC NN B-NP O
26 978 986 9620771 function NN I-NP O
27 987 992 9620771 would MD B-VP O
28 993 1000 9620771 include VB I-VP O
29 1001 1008 9620771 obesity NN B-NP B-Disease
30 1008 1009 9620771 , , O O
31 1010 1020 9620771 alteration NN B-NP O
32 1021 1023 9620771 in IN B-PP O
33 1024 1036 9620771 pigmentation NN B-NP O
34 1037 1040 9620771 and CC O O
35 1041 1045 9620771 ACTH NN B-NP B-Disease
36 1046 1056 9620771 deficiency NN I-NP I-Disease
37 1056 1057 9620771 . . O O

1 1058 1061 9620771 The DT B-NP O
2 1062 1073 9620771 observation NN I-NP O
3 1074 1076 9620771 of IN B-PP O
4 1077 1082 9620771 these DT B-NP O
5 1083 1091 9620771 symptoms NNS I-NP O
6 1092 1094 9620771 in IN B-PP O
7 1095 1098 9620771 two CD B-NP O
8 1099 1107 9620771 probands NNS I-NP O
9 1108 1116 9620771 prompted VBD B-VP O
10 1117 1119 9620771 us PRP B-NP O
11 1120 1122 9620771 to TO B-VP O
12 1123 1129 9620771 search VB I-VP O
13 1130 1133 9620771 for IN B-PP O
14 1134 1143 9620771 mutations NNS B-NP O
15 1144 1150 9620771 within IN B-PP O
16 1151 1156 9620771 their PRP$ B-NP O
17 1157 1161 9620771 POMC NN I-NP O
18 1162 1167 9620771 genes NNS I-NP O
19 1167 1168 9620771 . . O O

1 1169 1176 9620771 Patient NN B-NP O
2 1177 1178 9620771 1 CD I-NP O
3 1179 1182 9620771 was VBD B-VP O
4 1183 1188 9620771 found VBN I-VP O
5 1189 1191 9620771 to TO I-VP O
6 1192 1194 9620771 be VB I-VP O
7 1195 1196 9620771 a DT B-NP O
8 1197 1205 9620771 compound NN I-NP O
9 1206 1218 9620771 heterozygote NN I-NP O
10 1219 1222 9620771 for IN B-PP O
11 1223 1226 9620771 two CD B-NP O
12 1227 1236 9620771 mutations NNS I-NP O
13 1237 1239 9620771 in IN B-PP O
14 1240 1244 9620771 exon NN B-NP O
15 1245 1246 9620771 3 CD I-NP O
16 1247 1248 9620771 ( ( O O
17 1248 1254 9620771 G7013T NN B-NP O
18 1254 1255 9620771 , , O O
19 1256 1266 9620771 C7133delta NN B-NP O
20 1266 1267 9620771 ) ) O O
21 1268 1273 9620771 which WDT B-NP O
22 1274 1283 9620771 interfere VBP B-VP O
23 1284 1288 9620771 with IN B-PP O
24 1289 1300 9620771 appropriate JJ B-NP O
25 1301 1310 9620771 synthesis NN I-NP O
26 1311 1313 9620771 of IN B-PP O
27 1314 1318 9620771 ACTH NN B-NP O
28 1319 1322 9620771 and CC O O
29 1323 1328 9620771 alpha SYM B-NP O
30 1328 1329 9620771 - HYPH O O
31 1329 1332 9620771 MSH NN B-NP O
32 1332 1333 9620771 . . O O

1 1334 1341 9620771 Patient NN B-NP O
2 1342 1343 9620771 2 CD I-NP O
3 1344 1347 9620771 was VBD B-VP O
4 1348 1358 9620771 homozygous JJ B-ADJP O
5 1359 1362 9620771 for IN B-PP O
6 1363 1364 9620771 a DT B-NP O
7 1365 1373 9620771 mutation NN I-NP O
8 1374 1376 9620771 in IN B-PP O
9 1377 1381 9620771 exon NN B-NP O
10 1382 1383 9620771 2 CD I-NP O
11 1384 1385 9620771 ( ( O O
12 1385 1391 9620771 C3804A NN B-NP O
13 1391 1392 9620771 ) ) O O
14 1393 1398 9620771 which WDT B-NP O
15 1399 1408 9620771 abolishes VBZ B-VP O
16 1409 1413 9620771 POMC NN B-NP O
17 1414 1425 9620771 translation NN I-NP O
18 1425 1426 9620771 . . O O

1 1427 1432 9620771 These DT B-NP O
2 1433 1441 9620771 findings NNS I-NP O
3 1442 1451 9620771 represent VBP B-VP O
4 1452 1455 9620771 the DT B-NP O
5 1456 1461 9620771 first JJ I-NP O
6 1462 1470 9620771 examples NNS I-NP O
7 1471 1473 9620771 of IN B-PP O
8 1474 1475 9620771 a DT B-NP O
9 1476 1483 9620771 genetic JJ I-NP B-Disease
10 1484 1490 9620771 defect NN I-NP I-Disease
11 1491 1497 9620771 within IN B-PP O
12 1498 1501 9620771 the DT B-NP O
13 1502 1506 9620771 POMC NN I-NP O
14 1507 1511 9620771 gene NN I-NP O
15 1512 1515 9620771 and CC O O
16 1516 1522 9620771 define VB B-VP O
17 1523 1524 9620771 a DT B-NP O
18 1525 1528 9620771 new JJ I-NP O
19 1529 1538 9620771 monogenic JJ I-NP B-Disease
20 1539 1548 9620771 endocrine JJ I-NP I-Disease
21 1549 1557 9620771 disorder NN I-NP I-Disease
22 1558 1567 9620771 resulting VBG B-VP O
23 1568 1570 9620771 in IN B-PP O
24 1571 1576 9620771 early JJ B-NP O
25 1576 1577 9620771 - HYPH I-NP O
26 1577 1582 9620771 onset NN I-NP O
27 1583 1590 9620771 obesity NN I-NP B-Disease
28 1590 1591 9620771 , , O O
29 1592 1599 9620771 adrenal JJ B-NP B-Disease
30 1600 1613 9620771 insufficiency NN I-NP I-Disease
31 1614 1617 9620771 and CC O O
32 1618 1621 9620771 red JJ B-NP O
33 1622 1626 9620771 hair NN I-NP O
34 1627 1639 9620771 pigmentation NN I-NP O
35 1639 1640 9620771 . . O O
36 1640 1641 9620771 . . O O

1 0 0 9618166 -DOCSTART- -X- -X- O

1 0 3 9618166 Two CD B-NP O
2 4 12 9618166 frequent JJ I-NP O
3 13 21 9618166 missense JJ I-NP O
4 22 31 9618166 mutations NNS I-NP O
5 32 34 9618166 in IN B-PP O
6 35 42 9618166 Pendred JJ B-NP B-Disease
7 43 51 9618166 syndrome NN I-NP I-Disease
8 51 52 9618166 . . O O
9 53 60 9618166 Pendred JJ B-NP B-Disease
10 61 69 9618166 syndrome NN I-NP I-Disease
11 70 72 9618166 is VBZ B-VP O
12 73 75 9618166 an DT B-NP O
13 76 85 9618166 autosomal JJ I-NP B-Disease
14 86 95 9618166 recessive JJ I-NP I-Disease
15 96 104 9618166 disorder NN I-NP I-Disease
16 105 118 9618166 characterized VBN B-VP O
17 119 121 9618166 by IN B-PP O
18 122 127 9618166 early JJ B-NP O
19 128 137 9618166 childhood NN I-NP O
20 138 146 9618166 deafness NN I-NP B-Disease
21 147 150 9618166 and CC I-NP O
22 151 157 9618166 goiter NN I-NP B-Disease
23 157 158 9618166 . . O O

1 159 160 9618166 A DT B-NP O
2 161 168 9618166 century NN I-NP O
3 169 174 9618166 after IN B-PP O
4 175 178 9618166 its PRP$ B-NP O
5 179 190 9618166 recognition NN I-NP O
6 191 193 9618166 as IN B-PP O
7 194 195 9618166 a DT B-NP O
8 196 204 9618166 syndrome NN I-NP O
9 205 207 9618166 by IN B-PP O
10 208 215 9618166 Vaughan NNP B-NP O
11 216 223 9618166 Pendred NNP I-NP O
12 223 224 9618166 , , O O
13 225 228 9618166 the DT B-NP O
14 229 236 9618166 disease NN I-NP O
15 237 241 9618166 gene NN I-NP O
16 242 243 9618166 ( ( O O
17 243 246 9618166 PDS NN B-NP O
18 246 247 9618166 ) ) O O
19 248 251 9618166 was VBD B-VP O
20 252 258 9618166 mapped VBN I-VP O
21 259 261 9618166 to TO B-PP O
22 262 272 9618166 chromosome NN B-NP O
23 273 277 9618166 7q22 NN I-NP O
24 277 278 9618166 - HYPH B-NP O
25 278 281 9618166 q31 NN I-NP O
26 281 282 9618166 . . O O

1 283 284 9618166 1 CD B-NP O
2 285 288 9618166 and CC O O
3 288 289 9618166 , , O O
4 290 298 9618166 recently RB B-ADVP O
5 298 299 9618166 , , O O
6 300 305 9618166 found VBN B-VP O
7 306 308 9618166 to TO I-VP O
8 309 315 9618166 encode VB I-VP O
9 316 317 9618166 a DT B-NP O
10 318 326 9618166 putative JJ I-NP O
11 327 334 9618166 sulfate NN I-NP O
12 335 346 9618166 transporter NN I-NP O
13 346 347 9618166 . . O O

1 348 350 9618166 We PRP B-NP O
2 351 360 9618166 performed VBD B-VP O
3 361 369 9618166 mutation NN B-NP O
4 370 378 9618166 analysis NN I-NP O
5 379 381 9618166 of IN B-PP O
6 382 385 9618166 the DT B-NP O
7 386 389 9618166 PDS NN I-NP B-Disease
8 390 394 9618166 gene NN I-NP O
9 395 397 9618166 in IN B-PP O
10 398 406 9618166 patients NNS B-NP O
11 407 411 9618166 from IN B-PP O
12 412 414 9618166 14 CD B-NP O
13 415 422 9618166 Pendred NNP I-NP B-Disease
14 423 431 9618166 families NNS I-NP O
15 432 443 9618166 originating VBG B-VP O
16 444 448 9618166 from IN B-PP O
17 449 454 9618166 seven CD B-NP O
18 455 464 9618166 countries NNS I-NP O
19 465 468 9618166 and CC O O
20 469 479 9618166 identified VBD B-VP O
21 480 483 9618166 all DT B-NP O
22 484 493 9618166 mutations NNS I-NP O
23 493 494 9618166 . . O O

1 495 498 9618166 The DT B-NP O
2 499 508 9618166 mutations NNS I-NP O
3 509 516 9618166 include VBP B-VP O
4 517 522 9618166 three CD B-NP O
5 523 529 9618166 single JJ I-NP O
6 530 534 9618166 base NN I-NP O
7 535 544 9618166 deletions NNS I-NP O
8 544 545 9618166 , , O O
9 546 549 9618166 one CD B-NP O
10 550 556 9618166 splice NN I-NP O
11 557 561 9618166 site NN I-NP O
12 562 570 9618166 mutation NN I-NP O
13 571 574 9618166 and CC O O
14 575 577 9618166 10 CD B-NP O
15 578 586 9618166 missense JJ I-NP O
16 587 596 9618166 mutations NNS I-NP O
17 596 597 9618166 . . O O

1 598 601 9618166 One CD B-NP O
2 602 610 9618166 missense JJ I-NP O
3 611 619 9618166 mutation NN I-NP O
4 620 621 9618166 ( ( O O
5 621 626 9618166 L236P NN B-NP O
6 626 627 9618166 ) ) O O
7 628 631 9618166 was VBD B-VP O
8 632 637 9618166 found VBN I-VP O
9 638 640 9618166 in IN B-PP O
10 641 642 9618166 a DT B-NP O
11 643 653 9618166 homozygous JJ I-NP O
12 654 659 9618166 state NN I-NP O
13 660 662 9618166 in IN B-PP O
14 663 666 9618166 two CD B-NP O
15 667 681 9618166 consanguineous JJ I-NP O
16 682 690 9618166 families NNS I-NP O
17 691 694 9618166 and CC B-PP O
18 695 697 9618166 in IN B-PP O
19 698 699 9618166 a DT B-NP O
20 700 712 9618166 heterozygous JJ I-NP O
21 713 718 9618166 state NN I-NP O
22 719 721 9618166 in IN B-PP O
23 722 726 9618166 five CD B-NP O
24 727 737 9618166 additional JJ I-NP O
25 738 741 9618166 non AFX I-NP O
26 741 742 9618166 - HYPH I-NP O
27 742 756 9618166 consanguineous JJ I-NP O
28 757 765 9618166 families NNS I-NP O
29 765 766 9618166 . . O O

1 767 774 9618166 Another DT B-NP O
2 775 783 9618166 missense JJ I-NP O
3 784 792 9618166 mutation NN I-NP O
4 793 794 9618166 ( ( O O
5 794 799 9618166 T416P NN B-NP O
6 799 800 9618166 ) ) O O
7 801 804 9618166 was VBD B-VP O
8 805 810 9618166 found VBN I-VP O
9 811 813 9618166 in IN B-PP O
10 814 815 9618166 a DT B-NP O
11 816 826 9618166 homozygous JJ I-NP O
12 827 832 9618166 state NN I-NP O
13 833 835 9618166 in IN B-PP O
14 836 839 9618166 one CD B-NP O
15 840 846 9618166 family NN I-NP O
16 847 850 9618166 and CC B-PP O
17 851 853 9618166 in IN B-PP O
18 854 855 9618166 a DT B-NP O
19 856 868 9618166 heterozygous JJ I-NP O
20 869 874 9618166 state NN I-NP O
21 875 877 9618166 in IN B-PP O
22 878 882 9618166 four CD B-NP O
23 883 891 9618166 families NNS I-NP O
24 891 892 9618166 . . O O

1 893 900 9618166 Pendred JJ B-NP B-Disease
2 901 909 9618166 patients NNS I-NP O
3 910 912 9618166 in IN B-PP O
4 913 918 9618166 three CD B-NP O
5 919 922 9618166 non AFX I-NP O
6 922 923 9618166 - HYPH I-NP O
7 923 937 9618166 consanguineous JJ I-NP O
8 938 946 9618166 families NNS I-NP O
9 947 951 9618166 were VBD B-VP O
10 952 957 9618166 shown VBN I-VP O
11 958 960 9618166 to TO I-VP O
12 961 963 9618166 be VB I-VP O
13 964 972 9618166 compound JJ B-NP O
14 973 986 9618166 heterozygotes NNS I-NP O
15 987 990 9618166 for IN B-PP O
16 991 996 9618166 L236P NN B-NP O
17 997 1000 9618166 and CC I-NP O
18 1001 1006 9618166 T416P NN I-NP O
19 1006 1007 9618166 . . O O

1 1008 1010 9618166 In IN B-PP O
2 1011 1016 9618166 total NN B-NP O
3 1016 1017 9618166 , , O O
4 1018 1021 9618166 one CD B-NP O
5 1022 1024 9618166 or CC O O
6 1025 1029 9618166 both DT B-NP O
7 1030 1032 9618166 of IN B-PP O
8 1033 1038 9618166 these DT B-NP O
9 1039 1048 9618166 mutations NNS I-NP O
10 1049 1053 9618166 were VBD B-VP O
11 1054 1059 9618166 found VBN I-VP O
12 1060 1062 9618166 in IN B-PP O
13 1063 1067 9618166 nine CD B-NP O
14 1068 1070 9618166 of IN B-PP O
15 1071 1074 9618166 the DT B-NP O
16 1075 1077 9618166 14 CD I-NP O
17 1078 1086 9618166 families NNS I-NP O
18 1087 1095 9618166 analyzed VBN B-VP O
19 1095 1096 9618166 . . O O

1 1097 1100 9618166 The DT B-NP O
2 1101 1115 9618166 identification NN I-NP O
3 1116 1118 9618166 of IN B-PP O
4 1119 1122 9618166 two CD B-NP O
5 1123 1131 9618166 frequent JJ I-NP O
6 1132 1135 9618166 PDS NN I-NP B-Disease
7 1136 1145 9618166 mutations NNS I-NP O
8 1146 1150 9618166 will MD B-VP O
9 1151 1161 9618166 facilitate VB I-VP O
10 1162 1165 9618166 the DT B-NP O
11 1166 1175 9618166 molecular JJ I-NP O
12 1176 1185 9618166 diagnosis NN I-NP O
13 1186 1188 9618166 of IN B-PP O
14 1189 1196 9618166 Pendred NNP B-NP B-Disease
15 1197 1205 9618166 syndrome NN I-NP I-Disease
16 1205 1206 9618166 . . O O

1 0 0 9950360 -DOCSTART- -X- -X- O

1 0 9 9950360 Molecular JJ B-NP O
2 10 18 9950360 analysis NN I-NP O
3 19 21 9950360 of IN B-PP O
4 22 25 9950360 the DT B-NP O
5 26 29 9950360 APC NN I-NP B-Disease
6 30 34 9950360 gene NN I-NP O
7 35 37 9950360 in IN B-PP O
8 38 41 9950360 205 CD B-NP O
9 42 50 9950360 families NNS I-NP O
10 50 51 9950360 : : O O
11 52 60 9950360 extended VBN B-NP O
12 61 69 9950360 genotype NN I-NP O
13 69 70 9950360 - HYPH B-NP O
14 70 79 9950360 phenotype NN I-NP O
15 80 92 9950360 correlations NNS I-NP O
16 93 95 9950360 in IN B-PP O
17 96 99 9950360 FAP NN B-NP B-Disease
18 100 103 9950360 and CC I-NP O
19 104 112 9950360 evidence NN I-NP O
20 113 116 9950360 for IN B-PP O
21 117 120 9950360 the DT B-NP O
22 121 125 9950360 role NN I-NP O
23 126 128 9950360 of IN B-PP O
24 129 132 9950360 APC NN B-NP B-Disease
25 133 138 9950360 amino JJ I-NP O
26 139 143 9950360 acid NN I-NP O
27 144 151 9950360 changes NNS I-NP O
28 152 154 9950360 in IN B-PP O
29 155 165 9950360 colorectal JJ B-NP B-Disease
30 166 172 9950360 cancer NN I-NP I-Disease
31 173 187 9950360 predisposition NN I-NP O
32 187 188 9950360 . SYM I-NP O
33 189 199 9950360 BACKGROUND NN I-NP O
34 199 200 9950360 / SYM B-NP O
35 200 204 9950360 AIMS NNS I-NP O
36 206 209 9950360 The DT B-NP O
37 210 221 9950360 development NN I-NP O
38 222 224 9950360 of IN B-PP O
39 225 235 9950360 colorectal JJ B-NP B-Disease
40 236 242 9950360 cancer NN I-NP I-Disease
41 243 246 9950360 and CC O O
42 247 248 9950360 a DT B-NP O
43 249 257 9950360 variable JJ I-NP O
44 258 263 9950360 range NN I-NP O
45 264 266 9950360 of IN B-PP O
46 267 279 9950360 extracolonic JJ B-NP O
47 280 294 9950360 manifestations NNS I-NP O
48 295 297 9950360 in IN B-PP O
49 298 306 9950360 familial JJ B-NP B-Disease
50 307 318 9950360 adenomatous JJ I-NP I-Disease
51 319 328 9950360 polyposis NN I-NP I-Disease
52 329 330 9950360 ( ( O O
53 330 333 9950360 FAP NN B-NP B-Disease
54 333 334 9950360 ) ) O O
55 335 337 9950360 is VBZ B-VP O
56 338 341 9950360 the DT B-NP O
57 342 348 9950360 result NN I-NP O
58 349 351 9950360 of IN B-PP O
59 352 355 9950360 the DT B-NP O
60 356 364 9950360 dominant JJ I-NP O
61 365 376 9950360 inheritance NN I-NP O
62 377 379 9950360 of IN B-PP O
63 380 391 9950360 adenomatous JJ B-NP B-Disease
64 392 401 9950360 polyposis NN I-NP I-Disease
65 402 406 9950360 coli NN I-NP I-Disease
66 407 408 9950360 ( ( O O
67 408 411 9950360 APC NN B-NP B-Disease
68 411 412 9950360 ) ) O O
69 413 417 9950360 gene NN B-NP O
70 418 427 9950360 mutations NNS I-NP O
71 427 428 9950360 . . O O

1 429 431 9950360 In IN B-PP O
2 432 436 9950360 this DT B-NP O
3 437 442 9950360 study NN I-NP O
4 442 443 9950360 , , O O
5 444 450 9950360 direct JJ B-NP O
6 451 459 9950360 mutation NN I-NP O
7 460 468 9950360 analysis NN I-NP O
8 469 471 9950360 of IN B-PP O
9 472 475 9950360 the DT B-NP O
10 476 479 9950360 APC NN I-NP B-Disease
11 480 484 9950360 gene NN I-NP O
12 485 488 9950360 was VBD B-VP O
13 489 498 9950360 performed VBN I-VP O
14 499 501 9950360 to TO B-VP O
15 502 511 9950360 determine VB I-VP O
16 512 520 9950360 genotype NN B-NP O
17 520 521 9950360 - HYPH B-NP O
18 521 530 9950360 phenotype NN I-NP O
19 531 543 9950360 correlations NNS I-NP O
20 544 547 9950360 for IN B-PP O
21 548 552 9950360 nine CD B-NP O
22 553 565 9950360 extracolonic JJ I-NP O
23 566 580 9950360 manifestations NNS I-NP O
24 581 584 9950360 and CC O O
25 585 587 9950360 to TO B-VP O
26 588 599 9950360 investigate VB I-VP O
27 600 603 9950360 the DT B-NP O
28 604 613 9950360 incidence NN I-NP O
29 614 616 9950360 of IN B-PP O
30 617 620 9950360 APC NN B-NP B-Disease
31 621 630 9950360 mutations NNS I-NP O
32 631 633 9950360 in IN B-PP O
33 634 637 9950360 non AFX B-NP O
34 637 638 9950360 - HYPH I-NP O
35 638 641 9950360 FAP NN I-NP O
36 642 652 9950360 colorectal JJ I-NP B-Disease
37 653 659 9950360 cancer NN I-NP I-Disease
38 659 660 9950360 . . O O

1 661 668 9950360 METHODS NNS B-NP O
2 670 673 9950360 The DT B-NP O
3 674 677 9950360 APC NN I-NP B-Disease
4 678 682 9950360 gene NN I-NP O
5 683 686 9950360 was VBD B-VP O
6 687 695 9950360 analysed VBN I-VP O
7 696 698 9950360 in IN B-PP O
8 699 702 9950360 190 CD B-NP O
9 703 712 9950360 unrelated JJ I-NP O
10 713 716 9950360 FAP NN I-NP B-Disease
11 717 720 9950360 and CC O O
12 721 723 9950360 15 CD B-NP O
13 724 727 9950360 non AFX I-NP O
14 727 728 9950360 - HYPH I-NP O
15 728 731 9950360 FAP NN I-NP O
16 732 742 9950360 colorectal JJ I-NP B-Disease
17 743 749 9950360 cancer NN I-NP I-Disease
18 750 758 9950360 patients NNS I-NP O
19 759 764 9950360 using VBG B-VP O
20 765 775 9950360 denaturing VBG B-VP O
21 776 784 9950360 gradient NN B-NP O
22 785 788 9950360 gel NN I-NP O
23 789 804 9950360 electrophoresis NN I-NP O
24 804 805 9950360 , , O O
25 806 809 9950360 the DT B-NP O
26 810 817 9950360 protein NN I-NP O
27 818 828 9950360 truncation NN I-NP O
28 829 833 9950360 test NN I-NP O
29 833 834 9950360 , , O O
30 835 838 9950360 and CC O O
31 839 845 9950360 direct JJ B-NP O
32 846 856 9950360 sequencing NN I-NP O
33 856 857 9950360 . . O O

1 858 865 9950360 RESULTS NNS B-NP O
2 867 872 9950360 Chain VBP B-VP O
3 873 884 9950360 terminating VBG B-NP O
4 885 892 9950360 signals NNS I-NP O
5 893 897 9950360 were VBD B-VP O
6 898 902 9950360 only RB I-VP O
7 903 913 9950360 identified VBN I-VP O
8 914 916 9950360 in IN B-PP O
9 917 925 9950360 patients NNS B-NP O
10 926 935 9950360 belonging VBG B-VP O
11 936 938 9950360 to TO B-PP O
12 939 942 9950360 the DT B-NP O
13 943 946 9950360 FAP NN I-NP B-Disease
14 947 952 9950360 group NN I-NP O
15 953 954 9950360 ( ( O O
16 954 957 9950360 105 CD B-NP O
17 958 966 9950360 patients NNS I-NP O
18 966 967 9950360 ) ) O O
19 967 968 9950360 . . O O

1 969 974 9950360 Amino NN B-NP O
2 975 979 9950360 acid NN I-NP O
3 980 987 9950360 changes NNS I-NP O
4 988 992 9950360 were VBD B-VP O
5 993 1003 9950360 identified VBN I-VP O
6 1004 1006 9950360 in IN B-PP O
7 1007 1011 9950360 four CD B-NP O
8 1012 1020 9950360 patients NNS I-NP O
9 1020 1021 9950360 , , O O
10 1022 1027 9950360 three CD B-NP O
11 1028 1030 9950360 of IN B-PP O
12 1031 1035 9950360 whom WP B-NP O
13 1036 1044 9950360 belonged VBD B-VP O
14 1045 1047 9950360 to TO B-PP O
15 1048 1051 9950360 the DT B-NP O
16 1052 1055 9950360 non AFX I-NP O
17 1055 1056 9950360 - HYPH I-NP O
18 1056 1059 9950360 FAP NN I-NP O
19 1060 1065 9950360 group NN I-NP O
20 1066 1068 9950360 of IN B-PP O
21 1069 1079 9950360 colorectal JJ B-NP B-Disease
22 1080 1086 9950360 cancer NN I-NP I-Disease
23 1087 1095 9950360 patients NNS I-NP O
24 1095 1096 9950360 . . O O

1 1097 1105 9950360 Genotype NN B-NP O
2 1105 1106 9950360 - HYPH I-NP O
3 1106 1115 9950360 phenotype NN I-NP O
4 1116 1128 9950360 correlations NNS I-NP O
5 1129 1139 9950360 identified VBD B-VP O
6 1140 1151 9950360 significant JJ B-NP O
7 1152 1163 9950360 differences NNS I-NP O
8 1164 1166 9950360 in IN B-PP O
9 1167 1170 9950360 the DT B-NP O
10 1171 1177 9950360 nature NN I-NP O
11 1178 1180 9950360 of IN B-PP O
12 1181 1188 9950360 certain JJ B-NP O
13 1189 1201 9950360 extracolonic JJ I-NP O
14 1202 1216 9950360 manifestations NNS I-NP O
15 1217 1219 9950360 in IN B-PP O
16 1220 1223 9950360 FAP NN B-NP B-Disease
17 1224 1232 9950360 patients NNS I-NP O
18 1233 1242 9950360 belonging VBG B-VP O
19 1243 1245 9950360 to TO B-PP O
20 1246 1251 9950360 three CD B-NP O
21 1252 1260 9950360 mutation NN I-NP O
22 1261 1270 9950360 subgroups NNS I-NP O
23 1270 1271 9950360 . . O O

1 1272 1283 9950360 CONCLUSIONS NNS B-NP O
2 1285 1293 9950360 Extended VBD B-VP O
3 1294 1302 9950360 genotype NN B-NP O
4 1302 1303 9950360 - HYPH O O
5 1303 1312 9950360 phenotype NN B-NP O
6 1313 1325 9950360 correlations NNS I-NP O
7 1326 1330 9950360 made VBN B-VP O
8 1331 1333 9950360 in IN B-PP O
9 1334 1338 9950360 this DT B-NP O
10 1339 1344 9950360 study NN I-NP O
11 1345 1348 9950360 may MD B-VP O
12 1349 1353 9950360 have VB I-VP O
13 1354 1357 9950360 the DT B-NP O
14 1358 1367 9950360 potential NN I-NP O
15 1368 1370 9950360 to TO B-VP O
16 1371 1380 9950360 determine VB I-VP O
17 1381 1384 9950360 the DT B-NP O
18 1385 1389 9950360 most RBS I-NP O
19 1390 1401 9950360 appropriate JJ I-NP O
20 1402 1414 9950360 surveillance NN I-NP O
21 1415 1418 9950360 and CC O O
22 1419 1431 9950360 prophylactic JJ B-NP O
23 1432 1441 9950360 treatment NN I-NP O
24 1442 1450 9950360 regimens NNS I-NP O
25 1451 1454 9950360 for IN B-PP O
26 1455 1460 9950360 those DT B-NP O
27 1461 1469 9950360 patients NNS I-NP O
28 1470 1474 9950360 with IN B-PP O
29 1475 1484 9950360 mutations NNS B-NP O
30 1485 1495 9950360 associated VBN B-VP O
31 1496 1500 9950360 with IN B-PP O
32 1501 1505 9950360 life NN B-NP O
33 1506 1517 9950360 threatening JJ I-NP O
34 1518 1528 9950360 conditions NNS I-NP O
35 1528 1529 9950360 . . O O

1 1530 1534 9950360 This DT B-NP O
2 1535 1540 9950360 study NN I-NP O
3 1541 1545 9950360 also RB B-ADVP O
4 1546 1554 9950360 provided VBD B-VP O
5 1555 1563 9950360 evidence NN B-NP O
6 1564 1567 9950360 for IN B-PP O
7 1568 1571 9950360 the DT B-NP O
8 1572 1584 9950360 pathological JJ I-NP O
9 1585 1591 9950360 nature NN I-NP O
10 1592 1594 9950360 of IN B-PP O
11 1595 1600 9950360 amino JJ B-NP O
12 1601 1605 9950360 acid NN I-NP O
13 1606 1613 9950360 changes NNS I-NP O
14 1614 1616 9950360 in IN B-PP O
15 1617 1620 9950360 APC NN B-NP O
16 1621 1631 9950360 associated VBN B-VP O
17 1632 1636 9950360 with IN B-PP O
18 1637 1641 9950360 both CC O O
19 1642 1645 9950360 FAP NN B-NP B-Disease
20 1646 1649 9950360 and CC O O
21 1650 1653 9950360 non AFX B-NP O
22 1653 1654 9950360 - HYPH I-NP O
23 1654 1657 9950360 FAP NN I-NP O
24 1658 1668 9950360 colorectal JJ I-NP B-Disease
25 1669 1675 9950360 cancer NN I-NP I-Disease
26 1676 1684 9950360 patients NNS I-NP O
27 1684 1685 9950360 . . O O
28 1685 1686 9950360 . . O O

1 0 0 9931324 -DOCSTART- -X- -X- O

1 0 8 9931324 Missense JJ B-NP O
2 9 18 9931324 mutations NNS I-NP O
3 19 21 9931324 in IN B-PP O
4 22 25 9931324 the DT B-NP O
5 26 30 9931324 most RBS I-NP O
6 31 38 9931324 ancient JJ I-NP O
7 39 47 9931324 residues NNS I-NP O
8 48 50 9931324 of IN B-PP O
9 51 54 9931324 the DT B-NP O
10 55 59 9931324 PAX6 NN I-NP O
11 60 66 9931324 paired JJ I-NP O
12 67 73 9931324 domain NN I-NP O
13 74 82 9931324 underlie VBP B-VP O
14 83 84 9931324 a DT B-NP O
15 85 93 9931324 spectrum NN I-NP O
16 94 96 9931324 of IN B-PP O
17 97 102 9931324 human JJ B-NP O
18 103 113 9931324 congenital JJ I-NP B-Disease
19 114 117 9931324 eye NN I-NP I-Disease
20 118 131 9931324 malformations NNS I-NP I-Disease
21 131 132 9931324 . . O O
22 133 142 9931324 Mutations NNS B-NP O
23 143 145 9931324 of IN B-PP O
24 146 149 9931324 the DT B-NP O
25 150 155 9931324 human JJ I-NP O
26 156 160 9931324 PAX6 NN I-NP O
27 161 165 9931324 gene NN I-NP O
28 166 174 9931324 underlie VBP B-VP O
29 175 183 9931324 aniridia NN B-NP B-Disease
30 184 185 9931324 ( ( O O
31 185 195 9931324 congenital JJ B-NP B-Disease
32 196 203 9931324 absence NN I-NP I-Disease
33 204 206 9931324 of IN B-PP I-Disease
34 207 210 9931324 the DT B-NP I-Disease
35 211 215 9931324 iris NN I-NP I-Disease
36 215 216 9931324 ) ) O O
37 216 217 9931324 , , O O
38 218 219 9931324 a DT B-NP O
39 220 224 9931324 rare JJ I-NP O
40 225 233 9931324 dominant JJ I-NP O
41 234 246 9931324 malformation NN I-NP B-Disease
42 247 249 9931324 of IN B-PP I-Disease
43 250 253 9931324 the DT B-NP I-Disease
44 254 257 9931324 eye NN I-NP I-Disease
45 257 258 9931324 . . O O

1 259 262 9931324 The DT B-NP O
2 263 271 9931324 spectrum NN I-NP O
3 272 274 9931324 of IN B-PP O
4 275 279 9931324 PAX6 NN B-NP O
5 280 289 9931324 mutations NNS I-NP O
6 290 292 9931324 in IN B-PP O
7 293 301 9931324 aniridia NN B-NP B-Disease
8 302 310 9931324 patients NNS I-NP O
9 311 313 9931324 is VBZ B-VP O
10 314 320 9931324 highly RB I-VP O
11 321 327 9931324 biased VBN I-VP O
12 327 328 9931324 , , O O
13 329 333 9931324 with IN B-PP O
14 334 337 9931324 92% CD B-NP O
15 338 340 9931324 of IN B-PP O
16 341 344 9931324 all DT B-NP O
17 345 353 9931324 reported VBN I-NP O
18 354 363 9931324 mutations NNS I-NP O
19 364 371 9931324 leading VBG B-VP O
20 372 374 9931324 to TO B-PP O
21 375 384 9931324 premature JJ B-NP O
22 385 395 9931324 truncation NN I-NP O
23 396 398 9931324 of IN B-PP O
24 399 402 9931324 the DT B-NP O
25 403 410 9931324 protein NN I-NP O
26 411 412 9931324 ( ( O O
27 412 420 9931324 nonsense NN B-NP O
28 420 421 9931324 , , O O
29 422 430 9931324 splicing NN B-NP O
30 430 431 9931324 , , O O
31 432 442 9931324 insertions NNS B-NP O
32 443 446 9931324 and CC I-NP O
33 447 456 9931324 deletions NNS I-NP O
34 456 457 9931324 ) ) O O
35 458 461 9931324 and CC O O
36 462 466 9931324 just RB B-NP O
37 467 469 9931324 2% CD I-NP O
38 470 477 9931324 leading VBG B-VP O
39 478 480 9931324 to TO B-PP O
40 481 493 9931324 substitution NN B-NP O
41 494 496 9931324 of IN B-PP O
42 497 500 9931324 one CD B-NP O
43 501 506 9931324 amino NN I-NP O
44 507 511 9931324 acid NN I-NP O
45 512 514 9931324 by IN B-PP O
46 515 522 9931324 another DT B-NP O
47 523 524 9931324 ( ( O O
48 524 532 9931324 missense JJ B-ADJP O
49 532 533 9931324 ) ) O O
50 533 534 9931324 . . O O

1 535 538 9931324 The DT B-NP O
2 539 552 9931324 extraordinary JJ I-NP O
3 553 565 9931324 conservation NN I-NP O
4 566 568 9931324 of IN B-PP O
5 569 572 9931324 the DT B-NP O
6 573 577 9931324 PAX6 NN I-NP O
7 578 585 9931324 protein NN I-NP O
8 586 588 9931324 at IN B-PP O
9 589 592 9931324 the DT B-NP O
10 593 598 9931324 amino JJ I-NP O
11 599 603 9931324 acid NN I-NP O
12 604 609 9931324 level NN I-NP O
13 610 617 9931324 amongst IN B-PP O
14 618 629 9931324 vertebrates NNS B-NP O
15 630 638 9931324 predicts VBZ B-VP O
16 639 643 9931324 that IN B-SBAR O
17 644 656 9931324 pathological JJ B-NP O
18 657 665 9931324 missense JJ I-NP O
19 666 675 9931324 mutations NNS I-NP O
20 676 682 9931324 should MD B-VP O
21 683 685 9931324 in IN B-PP O
22 686 690 9931324 fact NN B-NP O
23 691 693 9931324 be VB B-VP O
24 694 700 9931324 common JJ B-ADJP O
25 701 705 9931324 even RB B-SBAR O
26 706 712 9931324 though IN I-SBAR O
27 713 717 9931324 they PRP B-NP O
28 718 721 9931324 are VBP B-VP O
29 722 728 9931324 hardly RB I-VP O
30 729 733 9931324 ever RB I-VP O
31 734 738 9931324 seen VBN I-VP O
32 739 741 9931324 in IN B-PP O
33 742 750 9931324 aniridia NN B-NP B-Disease
34 751 759 9931324 patients NNS I-NP O
35 759 760 9931324 . . O O

1 761 765 9931324 This DT B-NP O
2 766 775 9931324 indicates VBZ B-VP O
3 776 780 9931324 that IN B-SBAR O
4 781 786 9931324 there EX B-NP O
5 787 789 9931324 is VBZ B-VP O
6 790 791 9931324 a DT B-NP O
7 792 797 9931324 heavy JJ I-NP O
8 798 811 9931324 ascertainment NN I-NP O
9 812 816 9931324 bias NN I-NP O
10 817 819 9931324 in IN B-PP O
11 820 823 9931324 the DT B-NP O
12 824 833 9931324 selection NN I-NP O
13 834 836 9931324 of IN B-PP O
14 837 845 9931324 patients NNS B-NP O
15 846 849 9931324 for IN B-PP O
16 850 854 9931324 PAX6 NN B-NP O
17 855 863 9931324 mutation NN I-NP O
18 864 872 9931324 analysis NN I-NP O
19 873 876 9931324 and CC O O
20 877 881 9931324 that IN B-SBAR O
21 882 885 9931324 the DT B-NP O
22 886 893 9931324 missing VBG I-NP O
23 894 898 9931324 PAX6 NN I-NP O
24 899 907 9931324 missense JJ I-NP O
25 908 917 9931324 mutations NNS I-NP O
26 918 928 9931324 frequently RB B-ADVP O
27 929 932 9931324 may MD B-VP O
28 933 941 9931324 underlie VB I-VP O
29 942 952 9931324 phenotypes NNS B-NP O
30 953 961 9931324 distinct JJ B-ADJP O
31 962 966 9931324 from IN B-PP O
32 967 975 9931324 textbook NN B-NP O
33 976 984 9931324 aniridia NN I-NP B-Disease
34 984 985 9931324 . . O O

1 986 990 9931324 Here RB B-ADVP O
2 991 993 9931324 we PRP B-NP O
3 994 1001 9931324 present VBP B-VP O
4 1002 1006 9931324 four CD B-NP O
5 1007 1012 9931324 novel JJ I-NP O
6 1013 1017 9931324 PAX6 NN I-NP O
7 1018 1026 9931324 missense JJ I-NP O
8 1027 1036 9931324 mutations NNS I-NP O
9 1036 1037 9931324 , , O O
10 1038 1041 9931324 two CD B-NP O
11 1042 1044 9931324 in IN B-PP O
12 1045 1056 9931324 association NN B-NP O
13 1057 1061 9931324 with IN B-PP O
14 1062 1070 9931324 atypical JJ B-NP O
15 1071 1081 9931324 phenotypes NNS I-NP O
16 1083 1090 9931324 ectopia NN I-NP B-Disease
17 1091 1099 9931324 pupillae NNS I-NP I-Disease
18 1100 1101 9931324 ( ( O O
19 1101 1110 9931324 displaced VBN B-NP B-Disease
20 1111 1117 9931324 pupils NNS I-NP I-Disease
21 1117 1118 9931324 ) ) O O
22 1119 1122 9931324 and CC O O
23 1123 1133 9931324 congenital JJ B-NP B-Disease
24 1134 1143 9931324 nystagmus NN I-NP I-Disease
25 1144 1145 9931324 ( ( O O
26 1145 1154 9931324 searching VBG B-VP B-Disease
27 1155 1159 9931324 gaze NN B-NP I-Disease
28 1159 1160 9931324 ) ) O O
29 1160 1161 9931324 , , O O
30 1162 1165 9931324 and CC O O
31 1166 1169 9931324 two CD B-NP O
32 1170 1172 9931324 in IN B-PP O
33 1173 1184 9931324 association NN B-NP O
34 1185 1189 9931324 with IN B-PP O
35 1190 1194 9931324 more RBR B-NP O
36 1195 1207 9931324 recognizable JJ I-NP O
37 1208 1216 9931324 aniridia NN I-NP B-Disease
38 1217 1227 9931324 phenotypes NNS I-NP O
39 1227 1228 9931324 . . O O

1 1229 1239 9931324 Strikingly RB B-ADVP O
2 1239 1240 9931324 , , O O
3 1241 1244 9931324 all DT B-NP O
4 1245 1249 9931324 four CD I-NP O
5 1250 1259 9931324 mutations NNS I-NP O
6 1260 1263 9931324 are VBP B-VP O
7 1264 1271 9931324 located JJ B-ADJP O
8 1272 1278 9931324 within IN B-PP O
9 1279 1282 9931324 the DT B-NP O
10 1283 1287 9931324 PAX6 NN I-NP O
11 1288 1294 9931324 paired JJ I-NP O
12 1295 1301 9931324 domain NN I-NP O
13 1302 1305 9931324 and CC O O
14 1306 1312 9931324 affect VB B-VP O
15 1313 1318 9931324 amino JJ B-NP O
16 1319 1324 9931324 acids NNS I-NP O
17 1325 1330 9931324 which WDT B-NP O
18 1331 1334 9931324 are VBP B-VP O
19 1335 1341 9931324 highly RB I-VP O
20 1342 1351 9931324 conserved VBN I-VP O
21 1352 1354 9931324 in IN B-PP O
22 1355 1358 9931324 all DT B-NP O
23 1359 1364 9931324 known VBN I-NP O
24 1365 1371 9931324 paired JJ I-NP O
25 1372 1378 9931324 domain NN I-NP O
26 1379 1387 9931324 proteins NNS I-NP O
27 1387 1388 9931324 . . O O

1 1389 1392 9931324 Our PRP$ B-NP O
2 1393 1400 9931324 results NNS I-NP O
3 1401 1408 9931324 support VBP B-VP O
4 1409 1412 9931324 the DT B-NP O
5 1413 1423 9931324 hypothesis NN I-NP O
6 1424 1428 9931324 that IN B-SBAR O
7 1429 1432 9931324 the DT B-NP O
8 1433 1438 9931324 under NN I-NP O
9 1438 1439 9931324 - HYPH I-NP O
10 1439 1453 9931324 representation NN I-NP O
11 1454 1456 9931324 of IN B-PP O
12 1457 1465 9931324 missense JJ B-NP O
13 1466 1475 9931324 mutations NNS I-NP O
14 1476 1478 9931324 is VBZ B-VP O
15 1479 1485 9931324 caused VBN I-VP O
16 1486 1488 9931324 by IN B-PP O
17 1489 1502 9931324 ascertainment NN B-NP O
18 1503 1507 9931324 bias NN I-NP O
19 1508 1511 9931324 and CC O O
20 1512 1519 9931324 suggest VBP B-VP O
21 1520 1524 9931324 that IN B-SBAR O
22 1525 1526 9931324 a DT B-NP O
23 1527 1538 9931324 substantial JJ I-NP O
24 1539 1545 9931324 burden NN I-NP O
25 1546 1548 9931324 of IN B-PP O
26 1549 1553 9931324 PAX6 NN B-NP B-Disease
27 1554 1555 9931324 - HYPH B-NP I-Disease
28 1555 1562 9931324 related VBN I-NP I-Disease
29 1563 1570 9931324 disease NN I-NP I-Disease
30 1571 1578 9931324 remains VBZ B-VP O
31 1579 1581 9931324 to TO I-VP O
32 1582 1584 9931324 be VB I-VP O
33 1585 1594 9931324 uncovered VBN I-VP O
34 1594 1595 9931324 . . O O
35 1595 1596 9931324 . . O O

1 0 0 9744473 -DOCSTART- -X- -X- O

1 0 3 9744473 The DT B-NP O
2 4 9 9744473 R496H NN I-NP O
3 10 18 9744473 mutation NN I-NP O
4 19 21 9744473 of IN B-PP O
5 22 35 9744473 arylsulfatase NN B-NP O
6 36 37 9744473 A NN I-NP O
7 38 42 9744473 does VBZ B-VP O
8 43 46 9744473 not RB I-VP O
9 47 52 9744473 cause VB I-VP O
10 53 66 9744473 metachromatic JJ B-NP B-Disease
11 67 81 9744473 leukodystrophy NN I-NP I-Disease
12 81 82 9744473 . . I-NP O
13 83 93 9744473 Deficiency NN I-NP B-Disease
14 94 96 9744473 of IN B-PP I-Disease
15 97 110 9744473 arylsulfatase NN B-NP I-Disease
16 111 112 9744473 A NN I-NP I-Disease
17 113 114 9744473 ( ( O O
18 114 118 9744473 ARSA NN B-NP O
19 118 119 9744473 ) ) O O
20 120 126 9744473 enzyme NN B-NP O
21 127 135 9744473 activity NN I-NP O
22 136 142 9744473 causes VBZ B-VP O
23 143 156 9744473 metachromatic JJ B-NP B-Disease
24 157 171 9744473 leukodystrophy NN I-NP I-Disease
25 172 173 9744473 ( ( O O
26 173 176 9744473 MLD NN B-NP B-Disease
27 176 177 9744473 ) ) O O
28 177 178 9744473 . . O O

1 179 180 9744473 A DT B-NP O
2 181 187 9744473 number NN I-NP O
3 188 190 9744473 of IN B-PP O
4 191 195 9744473 ARSA NN B-NP O
5 196 200 9744473 gene NN I-NP O
6 201 210 9744473 mutations NNS I-NP O
7 211 222 9744473 responsible JJ B-ADJP O
8 223 226 9744473 for IN B-PP O
9 227 230 9744473 MLD NN B-NP B-Disease
10 231 235 9744473 have VBP B-VP O
11 236 240 9744473 been VBN I-VP O
12 241 251 9744473 identified VBN I-VP O
13 251 252 9744473 . . O O

1 253 261 9744473 Recently RB B-ADVP O
2 261 262 9744473 , , O O
3 263 266 9744473 the DT B-NP O
4 267 272 9744473 R496H NN I-NP O
5 273 281 9744473 mutation NN I-NP O
6 282 284 9744473 of IN B-PP O
7 285 289 9744473 ARSA NN B-NP O
8 290 293 9744473 was VBD B-VP O
9 294 302 9744473 proposed VBN I-VP O
10 303 305 9744473 to TO I-VP O
11 306 308 9744473 be VB I-VP O
12 309 310 9744473 a DT B-NP O
13 311 316 9744473 cause NN I-NP O
14 317 319 9744473 of IN B-PP O
15 320 323 9744473 MLD NN B-NP B-Disease
16 324 325 9744473 ( ( O O
17 325 332 9744473 Draghia NNP B-NP O
18 333 335 9744473 et FW I-NP O
19 336 339 9744473 al. FW I-NP O
20 339 340 9744473 , , O O
21 341 345 9744473 1997 CD B-NP O
22 345 346 9744473 ) ) O O
23 346 347 9744473 . . O O

1 348 350 9744473 We PRP B-NP O
2 351 355 9744473 have VBP B-VP O
3 356 368 9744473 investigated VBN I-VP O
4 369 372 9744473 the DT B-NP O
5 373 378 9744473 R496H NN I-NP O
6 379 387 9744473 mutation NN I-NP O
7 388 391 9744473 and CC O O
8 392 397 9744473 found VBD B-VP O
9 398 402 9744473 this DT B-NP O
10 403 411 9744473 mutation NN I-NP O
11 412 414 9744473 at IN B-PP O
12 415 416 9744473 a DT B-NP O
13 417 427 9744473 relatively RB I-NP O
14 428 432 9744473 high JJ I-NP O
15 433 442 9744473 frequency NN I-NP O
16 443 445 9744473 in IN B-PP O
17 446 448 9744473 an DT B-NP O
18 449 456 9744473 African JJ I-NP O
19 457 465 9744473 American JJ I-NP O
20 466 476 9744473 population NN I-NP O
21 477 478 9744473 ( ( O O
22 478 479 9744473 f NN B-NP O
23 480 481 9744473 = SYM B-VP O
24 482 483 9744473 0 CD B-NP O
25 483 484 9744473 . . O O

1 485 487 9744473 09 CD B-NP O
2 487 488 9744473 , , O O
3 489 490 9744473 n NN B-NP O
4 491 492 9744473 = SYM B-VP O
5 493 495 9744473 61 CD B-NP O
6 496 504 9744473 subjects NNS I-NP O
7 504 505 9744473 ) ) O O
8 505 506 9744473 . . O O

1 507 510 9744473 The DT B-NP O
2 511 515 9744473 ARSA NN I-NP O
3 516 522 9744473 enzyme NN I-NP O
4 523 531 9744473 activity NN I-NP O
5 532 534 9744473 in IN B-PP O
6 535 543 9744473 subjects NNS B-NP O
7 544 548 9744473 with IN B-PP O
8 549 552 9744473 and CC I-PP O
9 553 560 9744473 without IN I-PP O
10 561 564 9744473 the DT B-NP O
11 565 570 9744473 R496H NN I-NP O
12 571 579 9744473 mutation NN I-NP O
13 580 583 9744473 was VBD B-VP O
14 584 594 9744473 determined VBN I-VP O
15 595 598 9744473 and CC O O
16 599 604 9744473 found VBN B-VP O
17 605 607 9744473 to TO I-VP O
18 608 610 9744473 be VB I-VP O
19 611 617 9744473 normal JJ B-ADJP O
20 617 618 9744473 . . O O

1 619 621 9744473 It PRP B-NP O
2 622 624 9744473 is VBZ B-VP O
3 625 634 9744473 therefore RB I-VP O
4 635 644 9744473 concluded VBN I-VP O
5 645 649 9744473 that IN B-SBAR O
6 650 653 9744473 the DT B-NP O
7 654 659 9744473 R496H NN I-NP O
8 660 668 9744473 mutation NN I-NP O
9 669 671 9744473 of IN B-PP O
10 672 676 9744473 ARSA NN B-NP O
11 677 681 9744473 does VBZ B-VP O
12 682 685 9744473 not RB I-VP O
13 686 696 9744473 negatively RB I-VP O
14 697 706 9744473 influence VB I-VP O
15 707 710 9744473 the DT B-NP O
16 711 719 9744473 activity NN I-NP O
17 720 722 9744473 of IN B-PP O
18 723 727 9744473 ARSA NN B-NP O
19 728 731 9744473 and CC O O
20 732 734 9744473 is VBZ B-VP O
21 735 738 9744473 not RB O O
22 739 740 9744473 a DT B-NP O
23 741 746 9744473 cause NN I-NP O
24 747 749 9744473 of IN B-PP O
25 750 753 9744473 MLD NN B-NP B-Disease

1 0 0 9342365 -DOCSTART- -X- -X- O

1 0 4 9342365 Cell NN B-NP O
2 5 10 9342365 cycle NN I-NP O
3 10 11 9342365 - HYPH B-NP O
4 11 20 9342365 dependent JJ I-NP O
5 21 35 9342365 colocalization NN I-NP O
6 36 38 9342365 of IN B-PP O
7 39 44 9342365 BARD1 NN B-NP O
8 45 48 9342365 and CC I-NP O
9 49 54 9342365 BRCA1 NN I-NP O
10 55 63 9342365 proteins NNS I-NP O
11 64 66 9342365 in IN B-PP O
12 67 75 9342365 discrete JJ B-NP O
13 76 83 9342365 nuclear JJ I-NP O
14 84 91 9342365 domains NNS I-NP O
15 91 92 9342365 . . O O
16 93 97 9342365 Germ NN B-NP O
17 97 98 9342365 - HYPH I-NP O
18 98 102 9342365 line NN I-NP O
19 103 112 9342365 mutations NNS I-NP O
20 113 115 9342365 of IN B-PP O
21 116 119 9342365 the DT B-NP O
22 120 125 9342365 BRCA1 NN I-NP O
23 126 130 9342365 gene NN I-NP O
24 131 141 9342365 predispose NN I-NP O
25 142 147 9342365 women NNS I-NP O
26 148 150 9342365 to TO B-PP O
27 151 156 9342365 early JJ B-NP O
28 156 157 9342365 - HYPH I-NP O
29 157 162 9342365 onset NN I-NP O
30 163 169 9342365 breast NN I-NP B-Disease
31 170 173 9342365 and CC O I-Disease
32 174 181 9342365 ovarian JJ B-NP I-Disease
33 182 188 9342365 cancer NN I-NP I-Disease
34 189 191 9342365 by IN B-PP O
35 192 204 9342365 compromising VBG B-VP O
36 205 208 9342365 the DT B-NP O
37 209 214 9342365 genes NNS I-NP O
38 215 226 9342365 presumptive JJ B-NP O
39 227 235 9342365 function NN I-NP O
40 236 238 9342365 as IN B-PP O
41 239 240 9342365 a DT B-NP O
42 241 246 9342365 tumor NN I-NP B-Disease
43 247 257 9342365 suppressor NN I-NP O
44 257 258 9342365 . . O O

1 259 267 9342365 Although IN B-SBAR O
2 268 271 9342365 the DT B-NP O
3 272 283 9342365 biochemical JJ I-NP O
4 284 294 9342365 properties NNS I-NP O
5 295 297 9342365 of IN B-PP O
6 298 303 9342365 BRCA1 NN B-NP O
7 304 316 9342365 polypeptides NNS I-NP O
8 317 320 9342365 are VBP B-VP O
9 321 324 9342365 not RB I-VP O
10 325 335 9342365 understood VBN I-VP O
11 335 336 9342365 , , O O
12 337 342 9342365 their PRP$ B-NP O
13 343 353 9342365 expression NN I-NP O
14 354 361 9342365 pattern NN I-NP O
15 362 365 9342365 and CC O O
16 366 377 9342365 subcellular JJ B-NP O
17 378 390 9342365 localization NN I-NP O
18 391 398 9342365 suggest VBP B-VP O
19 399 400 9342365 a DT B-NP O
20 401 405 9342365 role NN I-NP O
21 406 408 9342365 in IN B-PP O
22 409 413 9342365 cell NN B-NP O
23 413 414 9342365 - HYPH B-NP O
24 414 419 9342365 cycle NN I-NP O
25 420 430 9342365 regulation NN I-NP O
26 430 431 9342365 . . O O

1 432 436 9342365 When WRB B-ADVP O
2 437 444 9342365 resting VBG B-NP O
3 445 450 9342365 cells NNS I-NP O
4 451 454 9342365 are VBP B-VP O
5 455 462 9342365 induced VBN I-VP O
6 463 465 9342365 to TO I-VP O
7 466 477 9342365 proliferate VB I-VP O
8 477 478 9342365 , , O O
9 479 482 9342365 the DT B-NP O
10 483 489 9342365 steady JJ I-NP O
11 489 490 9342365 - HYPH I-NP O
12 490 495 9342365 state NN I-NP O
13 496 502 9342365 levels NNS I-NP O
14 503 505 9342365 of IN B-PP O
15 506 511 9342365 BRCA1 NN B-NP O
16 512 520 9342365 increase NN I-NP O
17 521 523 9342365 in IN B-PP O
18 524 528 9342365 late JJ B-NP O
19 529 531 9342365 G1 NN I-NP O
20 532 535 9342365 and CC O O
21 536 541 9342365 reach VB B-VP O
22 542 543 9342365 a DT B-NP O
23 544 551 9342365 maximum NN I-NP O
24 552 558 9342365 during IN B-PP O
25 559 560 9342365 S NN B-NP O
26 561 566 9342365 phase NN I-NP O
27 566 567 9342365 . . O O

1 568 576 9342365 Moreover RB B-ADVP O
2 576 577 9342365 , , O O
3 578 580 9342365 in IN B-PP O
4 581 582 9342365 S NN B-NP O
5 583 588 9342365 phase NN I-NP O
6 589 594 9342365 cells NNS I-NP O
7 594 595 9342365 , , O O
8 596 601 9342365 BRCA1 NN B-NP O
9 602 614 9342365 polypeptides NNS I-NP O
10 615 618 9342365 are VBP B-VP O
11 619 638 9342365 hyperphosphorylated VBN I-VP O
12 639 642 9342365 and CC O O
13 643 653 9342365 accumulate VBP B-VP O
14 654 658 9342365 into IN B-PP O
15 659 667 9342365 discrete JJ B-NP O
16 668 678 9342365 subnuclear JJ I-NP O
17 679 683 9342365 foci NNS I-NP O
18 684 690 9342365 termed VBN B-VP O
19 691 692 9342365 " `` B-NP O
20 693 698 9342365 BRCA1 NN I-NP O
21 699 706 9342365 nuclear JJ I-NP O
22 707 711 9342365 dots NNS I-NP O
23 711 712 9342365 . . O O

1 713 714 9342365 " `` O O
2 715 720 9342365 BRCA1 NN B-NP O
3 721 731 9342365 associates VBZ B-VP O
4 732 734 9342365 in FW B-ADVP O
5 735 739 9342365 vivo FW I-ADVP O
6 740 744 9342365 with IN B-PP O
7 745 746 9342365 a DT B-NP O
8 747 759 9342365 structurally RB I-NP O
9 760 767 9342365 related VBN I-NP O
10 768 775 9342365 protein NN I-NP O
11 776 782 9342365 termed VBN I-NP O
12 783 788 9342365 BARD1 NN I-NP O
13 788 789 9342365 . . O O

1 790 794 9342365 Here RB B-ADVP O
2 795 797 9342365 we PRP B-NP O
3 798 802 9342365 show VBP B-VP O
4 803 807 9342365 that IN B-SBAR O
5 808 811 9342365 the DT B-NP O
6 812 818 9342365 steady JJ I-NP O
7 818 819 9342365 - HYPH I-NP O
8 819 824 9342365 state NN I-NP O
9 825 831 9342365 levels NNS I-NP O
10 832 834 9342365 of IN B-PP O
11 835 840 9342365 BARD1 NN B-NP O
12 840 841 9342365 , , O O
13 842 848 9342365 unlike IN B-PP O
14 849 854 9342365 those DT B-NP O
15 855 857 9342365 of IN B-PP O
16 858 863 9342365 BRCA1 NN B-NP O
17 863 864 9342365 , , O O
18 865 871 9342365 remain VBP B-VP O
19 872 882 9342365 relatively RB B-ADJP O
20 883 891 9342365 constant JJ I-ADJP O
21 892 898 9342365 during IN B-PP O
22 899 903 9342365 cell NN B-NP O
23 904 909 9342365 cycle NN I-NP O
24 910 921 9342365 progression NN I-NP O
25 921 922 9342365 . . O O

1 923 930 9342365 However RB B-ADVP O
2 930 931 9342365 , , O O
3 932 946 9342365 immunostaining NN B-NP O
4 947 955 9342365 revealed VBD B-VP O
5 956 960 9342365 that IN B-SBAR O
6 961 966 9342365 BARD1 NN B-NP O
7 967 974 9342365 resides VBZ B-VP O
8 975 981 9342365 within IN B-PP O
9 982 987 9342365 BRCA1 NN B-NP O
10 988 995 9342365 nuclear JJ I-NP O
11 996 1000 9342365 dots NNS I-NP O
12 1001 1007 9342365 during IN B-PP O
13 1008 1009 9342365 S NN B-NP O
14 1010 1015 9342365 phase NN I-NP O
15 1016 1018 9342365 of IN B-PP O
16 1019 1022 9342365 the DT B-NP O
17 1023 1027 9342365 cell NN I-NP O
18 1028 1033 9342365 cycle NN I-NP O
19 1033 1034 9342365 , , B-PP O
20 1035 1038 9342365 but CC I-PP O
21 1039 1042 9342365 not RB B-PP O
22 1043 1049 9342365 during IN I-PP O
23 1050 1053 9342365 the DT B-NP O
24 1054 1056 9342365 G1 NN I-NP O
25 1057 1062 9342365 phase NN I-NP O
26 1062 1063 9342365 . . O O

1 1064 1076 9342365 Nevertheless RB B-ADVP O
2 1076 1077 9342365 , , O O
3 1078 1083 9342365 BARD1 NN B-NP O
4 1084 1096 9342365 polypeptides NNS I-NP O
5 1097 1100 9342365 are VBP B-VP O
6 1101 1106 9342365 found VBN I-VP O
7 1107 1118 9342365 exclusively RB B-ADVP O
8 1119 1121 9342365 in IN B-PP O
9 1122 1125 9342365 the DT B-NP O
10 1126 1133 9342365 nuclear JJ I-NP O
11 1134 1143 9342365 fractions NNS I-NP O
12 1144 1146 9342365 of IN B-PP O
13 1147 1151 9342365 both CC O O
14 1152 1154 9342365 G1 NN B-NP O
15 1154 1155 9342365 - HYPH I-NP O
16 1156 1159 9342365 and CC I-NP O
17 1160 1161 9342365 S NN I-NP O
18 1161 1162 9342365 - HYPH I-NP O
19 1162 1167 9342365 phase NN I-NP O
20 1168 1173 9342365 cells NNS I-NP O
21 1173 1174 9342365 . . O O

1 1175 1184 9342365 Therefore RB B-ADVP O
2 1184 1185 9342365 , , O O
3 1186 1197 9342365 progression NN B-NP O
4 1198 1200 9342365 to TO B-PP O
5 1201 1202 9342365 S NN B-NP O
6 1203 1208 9342365 phase NN I-NP O
7 1209 1211 9342365 is VBZ B-VP O
8 1212 1223 9342365 accompanied VBN I-VP O
9 1224 1226 9342365 by IN B-PP O
10 1227 1230 9342365 the DT B-NP O
11 1231 1242 9342365 aggregation NN I-NP O
12 1243 1245 9342365 of IN B-PP O
13 1246 1253 9342365 nuclear JJ B-NP O
14 1254 1259 9342365 BARD1 NN I-NP O
15 1260 1272 9342365 polypeptides NNS I-NP O
16 1273 1277 9342365 into IN B-PP O
17 1278 1283 9342365 BRCA1 NN B-NP O
18 1284 1291 9342365 nuclear JJ I-NP O
19 1292 1296 9342365 dots NNS I-NP O
20 1296 1297 9342365 . . O O

1 1298 1302 9342365 This DT B-NP O
2 1303 1307 9342365 cell NN I-NP O
3 1308 1313 9342365 cycle NN I-NP O
4 1313 1314 9342365 - HYPH B-NP O
5 1314 1323 9342365 dependent JJ I-NP O
6 1324 1338 9342365 colocalization NN I-NP O
7 1339 1341 9342365 of IN B-PP O
8 1342 1347 9342365 BARD1 NN B-NP O
9 1348 1351 9342365 and CC I-NP O
10 1352 1357 9342365 BRCA1 NN I-NP O
11 1358 1367 9342365 indicates VBZ B-VP O
12 1368 1369 9342365 a DT B-NP O
13 1370 1374 9342365 role NN I-NP O
14 1375 1378 9342365 for IN B-PP O
15 1379 1384 9342365 BARD1 NN B-NP O
16 1385 1387 9342365 in IN B-PP O
17 1388 1393 9342365 BRCA1 NN B-NP O
18 1393 1394 9342365 - HYPH B-NP O
19 1394 1402 9342365 mediated VBN I-NP O
20 1403 1408 9342365 tumor NN I-NP B-Disease
21 1409 1420 9342365 suppression NN I-NP O
22 1420 1421 9342365 . . O O

1 0 0 9385378 -DOCSTART- -X- -X- O

1 0 1 9385378 A DT B-NP O
2 2 7 9385378 novel JJ I-NP O
3 8 14 9385378 common JJ I-NP O
4 15 23 9385378 missense JJ I-NP O
5 24 32 9385378 mutation NN I-NP O
6 33 38 9385378 G301C NN I-NP O
7 39 41 9385378 in IN B-PP O
8 42 45 9385378 the DT B-NP O
9 46 47 9385378 N NN I-NP O
10 47 48 9385378 - HYPH B-NP O
11 48 67 9385378 acetylgalactosamine NN I-NP O
12 67 68 9385378 - HYPH B-NP O
13 68 69 9385378 6 CD I-NP O
14 69 70 9385378 - HYPH I-NP O
15 70 77 9385378 sulfate NN I-NP O
16 78 87 9385378 sulfatase NN I-NP O
17 88 92 9385378 gene NN I-NP O
18 93 95 9385378 in IN B-PP O
19 96 117 9385378 mucopolysaccharidosis NN B-NP B-Disease
20 118 121 9385378 IVA NN I-NP I-Disease
21 121 122 9385378 . . O O
22 123 144 9385378 Mucopolysaccharidosis NN B-NP B-Disease
23 145 148 9385378 IVA NN I-NP I-Disease
24 149 150 9385378 ( ( O O
25 150 153 9385378 MPS NN B-NP B-Disease
26 154 157 9385378 IVA NN I-NP I-Disease
27 157 158 9385378 ) ) O O
28 159 161 9385378 is VBZ B-VP O
29 162 164 9385378 an DT B-NP O
30 165 174 9385378 autosomal JJ I-NP B-Disease
31 175 184 9385378 recessive JJ I-NP I-Disease
32 185 194 9385378 lysosomal JJ I-NP I-Disease
33 195 202 9385378 storage NN I-NP I-Disease
34 203 211 9385378 disorder NN I-NP I-Disease
35 212 218 9385378 caused VBN B-VP O
36 219 221 9385378 by IN B-PP O
37 222 223 9385378 a DT B-NP O
38 224 231 9385378 genetic JJ I-NP B-Disease
39 232 238 9385378 defect NN I-NP I-Disease
40 239 241 9385378 in IN B-PP O
41 242 243 9385378 N NN B-NP O
42 243 244 9385378 - HYPH B-NP O
43 244 263 9385378 acetylgalactosamine NN I-NP O
44 263 264 9385378 - HYPH B-NP O
45 264 265 9385378 6 CD I-NP O
46 265 266 9385378 - HYPH I-NP O
47 266 273 9385378 sulfate NN I-NP O
48 274 283 9385378 sulfatase NN I-NP O
49 284 285 9385378 ( ( O O
50 285 290 9385378 GALNS NN B-NP O
51 290 291 9385378 ) ) O O
52 291 292 9385378 . . O O

1 293 295 9385378 In IN B-PP O
2 296 304 9385378 previous JJ B-NP O
3 305 312 9385378 studies NNS I-NP O
4 312 313 9385378 , , O O
5 314 316 9385378 we PRP B-NP O
6 317 321 9385378 have VBP B-VP O
7 322 327 9385378 found VBN I-VP O
8 328 331 9385378 two CD B-NP O
9 332 338 9385378 common JJ I-NP O
10 339 348 9385378 mutations NNS I-NP O
11 349 351 9385378 in IN B-PP O
12 352 362 9385378 Caucasians NNPS B-NP O
13 363 366 9385378 and CC I-NP O
14 367 375 9385378 Japanese NNPS I-NP O
15 375 376 9385378 , , O O
16 377 389 9385378 respectively RB B-ADVP O
17 389 390 9385378 . . O O

1 391 393 9385378 To TO B-VP O
2 394 406 9385378 characterize VB I-VP O
3 407 410 9385378 the DT B-NP O
4 411 421 9385378 mutational JJ I-NP O
5 422 430 9385378 spectrum NN I-NP O
6 431 433 9385378 in IN B-PP O
7 434 441 9385378 various JJ B-NP O
8 442 448 9385378 ethnic JJ I-NP O
9 449 455 9385378 groups NNS I-NP O
10 455 456 9385378 , , O O
11 457 466 9385378 mutations NNS B-NP O
12 467 469 9385378 in IN B-PP O
13 470 473 9385378 the DT B-NP O
14 474 479 9385378 GALNS NN I-NP O
15 480 484 9385378 gene NN I-NP O
16 485 487 9385378 in IN B-PP O
17 488 497 9385378 Colombian JJ B-NP O
18 498 501 9385378 MPS NN I-NP B-Disease
19 502 505 9385378 IVA NN I-NP I-Disease
20 506 514 9385378 patients NNS I-NP O
21 515 519 9385378 were VBD B-VP O
22 520 532 9385378 investigated VBN I-VP O
23 532 533 9385378 , , O O
24 534 537 9385378 and CC O O
25 538 545 9385378 genetic JJ B-NP O
26 546 557 9385378 backgrounds NNS I-NP O
27 558 562 9385378 were VBD B-VP O
28 563 574 9385378 extensively RB I-VP O
29 575 583 9385378 analyzed VBN I-VP O
30 584 586 9385378 to TO I-VP O
31 587 595 9385378 identify VB I-VP O
32 596 602 9385378 racial JJ B-NP O
33 603 609 9385378 origin NN I-NP O
34 609 610 9385378 , , O O
35 611 616 9385378 based VBN B-PP O
36 617 619 9385378 on IN B-PP O
37 620 633 9385378 mitochondrial JJ B-NP O
38 634 637 9385378 DNA NN I-NP O
39 638 639 9385378 ( ( O O
40 639 644 9385378 mtDNA NN B-NP O
41 644 645 9385378 ) ) O O
42 646 654 9385378 lineages NNS B-NP O
43 654 655 9385378 . . O O

1 656 661 9385378 Three CD B-NP O
2 662 667 9385378 novel JJ I-NP O
3 668 676 9385378 missense JJ I-NP O
4 677 686 9385378 mutations NNS I-NP O
5 687 692 9385378 never RB B-VP O
6 693 703 9385378 identified VBN I-VP O
7 704 714 9385378 previously RB B-ADVP O
8 715 717 9385378 in IN B-PP O
9 718 723 9385378 other JJ B-NP O
10 724 735 9385378 populations NNS I-NP O
11 736 739 9385378 and CC O O
12 740 745 9385378 found VBN B-VP O
13 746 748 9385378 in IN B-PP O
14 749 751 9385378 16 CD B-NP O
15 752 755 9385378 out IN B-PP O
16 756 758 9385378 of IN B-PP O
17 759 761 9385378 19 CD B-NP O
18 762 771 9385378 Colombian JJ I-NP O
19 772 775 9385378 MPS NN I-NP B-Disease
20 776 779 9385378 IVA NN I-NP I-Disease
21 780 789 9385378 unrelated JJ I-NP O
22 790 797 9385378 alleles NNS I-NP O
23 798 805 9385378 account VBP B-VP O
24 806 809 9385378 for IN B-PP O
25 810 812 9385378 84 CD B-NP O
26 812 813 9385378 . . O O

1 814 816 9385378 2% CD B-NP O
2 817 819 9385378 of IN B-PP O
3 820 823 9385378 the DT B-NP O
4 824 831 9385378 alleles NNS I-NP O
5 832 834 9385378 in IN B-PP O
6 835 839 9385378 this DT B-NP O
7 840 845 9385378 study NN I-NP O
8 845 846 9385378 . . O O

1 847 850 9385378 The DT B-NP O
2 851 856 9385378 G301C NN I-NP O
3 857 860 9385378 and CC I-NP O
4 861 866 9385378 S162F NN I-NP O
5 867 876 9385378 mutations NNS I-NP O
6 877 884 9385378 account VBP B-VP O
7 885 888 9385378 for IN B-PP O
8 889 891 9385378 68 CD B-NP O
9 891 892 9385378 . . O O

1 893 895 9385378 4% CD B-NP O
2 896 899 9385378 and CC I-NP O
3 900 902 9385378 10 CD I-NP O
4 902 903 9385378 . . O O

1 904 906 9385378 5% CD B-NP O
2 907 909 9385378 of IN B-PP O
3 910 919 9385378 mutations NNS B-NP O
4 919 920 9385378 , , O O
5 921 933 9385378 respectively RB B-ADVP O
6 933 934 9385378 , , O O
7 935 942 9385378 whereas IN O O
8 943 946 9385378 the DT B-NP O
9 947 956 9385378 remaining VBG I-NP O
10 957 961 9385378 F69V NN I-NP O
11 962 964 9385378 is VBZ B-VP O
12 965 972 9385378 limited VBN I-VP O
13 973 975 9385378 to TO B-PP O
14 976 977 9385378 a DT B-NP O
15 978 984 9385378 single JJ I-NP O
16 985 991 9385378 allele NN I-NP O
17 991 992 9385378 . . O O

1 993 996 9385378 The DT B-NP O
2 997 1003 9385378 skewed JJ I-NP O
3 1004 1014 9385378 prevalence NN I-NP O
4 1015 1017 9385378 of IN B-PP O
5 1018 1023 9385378 G301C NN B-NP O
6 1024 1026 9385378 in IN B-PP O
7 1027 1031 9385378 only JJ B-NP O
8 1032 1041 9385378 Colombian JJ I-NP O
9 1042 1050 9385378 patients NNS I-NP O
10 1051 1054 9385378 and CC O O
11 1055 1064 9385378 haplotype NN B-NP O
12 1065 1073 9385378 analysis NN I-NP O
13 1074 1076 9385378 by IN B-PP O
14 1077 1088 9385378 restriction NN B-NP O
15 1089 1097 9385378 fragment NN I-NP O
16 1098 1104 9385378 length NN I-NP O
17 1105 1118 9385378 polymorphisms NNS I-NP O
18 1119 1121 9385378 in IN B-PP O
19 1122 1125 9385378 the DT B-NP O
20 1126 1131 9385378 GALNS NN I-NP O
21 1132 1136 9385378 gene NN I-NP O
22 1137 1144 9385378 suggest VBP B-VP O
23 1145 1149 9385378 that IN B-SBAR O
24 1150 1155 9385378 G301C NN B-NP O
25 1156 1166 9385378 originated VBN B-VP O
26 1167 1171 9385378 from IN B-PP O
27 1172 1173 9385378 a DT B-NP O
28 1174 1180 9385378 common JJ I-NP O
29 1181 1189 9385378 ancestor NN I-NP O
30 1189 1190 9385378 . . O O

1 1191 1204 9385378 Investigation NN B-NP O
2 1205 1207 9385378 of IN B-PP O
3 1208 1211 9385378 the DT B-NP O
4 1212 1219 9385378 genetic JJ I-NP O
5 1220 1230 9385378 background NN I-NP O
6 1231 1233 9385378 by IN B-PP O
7 1234 1239 9385378 means NNS B-NP O
8 1240 1242 9385378 of IN B-PP O
9 1243 1248 9385378 mtDNA NN B-NP O
10 1249 1257 9385378 lineages NNS I-NP O
11 1258 1266 9385378 indicate VBP B-VP O
12 1267 1271 9385378 that IN B-SBAR O
13 1272 1275 9385378 all PDT B-NP O
14 1276 1279 9385378 our PRP$ I-NP O
15 1280 1288 9385378 patients NNS I-NP O
16 1289 1292 9385378 are VBP B-VP O
17 1293 1301 9385378 probably RB B-ADVP O
18 1302 1304 9385378 of IN B-PP O
19 1305 1311 9385378 native JJ B-NP O
20 1312 1320 9385378 American JJ I-NP O
21 1321 1328 9385378 descent NN I-NP O

1 0 0 9497246 -DOCSTART- -X- -X- O

1 0 7 9497246 Genetic JJ B-NP O
2 8 21 9497246 heterogeneity NN I-NP O
3 22 25 9497246 and CC I-NP O
4 26 36 9497246 penetrance NN I-NP O
5 37 45 9497246 analysis NN I-NP O
6 46 48 9497246 of IN B-PP O
7 49 52 9497246 the DT B-NP O
8 53 58 9497246 BRCA1 NN I-NP O
9 59 62 9497246 and CC I-NP O
10 63 68 9497246 BRCA2 NN I-NP O
11 69 74 9497246 genes NNS I-NP O
12 75 77 9497246 in IN B-PP O
13 78 84 9497246 breast NN B-NP B-Disease
14 85 91 9497246 cancer NN I-NP I-Disease
15 92 100 9497246 families NNS I-NP O
16 100 101 9497246 . . O O

1 102 105 9497246 The DT B-NP O
2 106 112 9497246 Breast NNP I-NP B-Disease
3 113 119 9497246 Cancer NNP I-NP I-Disease
4 120 127 9497246 Linkage NNP I-NP O
5 128 138 9497246 Consortium NNP I-NP O
6 138 139 9497246 . . O O
7 140 143 9497246 The DT B-NP O
8 144 156 9497246 contribution NN I-NP O
9 157 159 9497246 of IN B-PP O
10 160 165 9497246 BRCA1 NN B-NP O
11 166 169 9497246 and CC I-NP O
12 170 175 9497246 BRCA2 NN I-NP O
13 176 178 9497246 to TO B-PP O
14 179 188 9497246 inherited VBN B-NP B-Disease
15 189 195 9497246 breast NN I-NP I-Disease
16 196 202 9497246 cancer NN I-NP I-Disease
17 203 206 9497246 was VBD B-VP O
18 207 215 9497246 assessed VBN I-VP O
19 216 218 9497246 by IN B-PP O
20 219 226 9497246 linkage NN B-NP O
21 227 230 9497246 and CC I-NP O
22 231 239 9497246 mutation NN I-NP O
23 240 248 9497246 analysis NN I-NP O
24 249 251 9497246 in IN B-PP O
25 252 255 9497246 237 CD B-NP O
26 256 264 9497246 families NNS I-NP O
27 264 265 9497246 , , O O
28 266 270 9497246 each DT B-NP O
29 271 275 9497246 with IN B-PP O
30 276 278 9497246 at IN B-NP O
31 279 284 9497246 least JJS I-NP O
32 285 289 9497246 four CD I-NP O
33 290 295 9497246 cases NNS I-NP O
34 296 298 9497246 of IN B-PP O
35 299 305 9497246 breast NN B-NP B-Disease
36 306 312 9497246 cancer NN I-NP I-Disease
37 312 313 9497246 , , O O
38 314 323 9497246 collected VBN B-VP O
39 324 326 9497246 by IN B-PP O
40 327 330 9497246 the DT B-NP O
41 331 337 9497246 Breast NNP I-NP B-Disease
42 338 344 9497246 Cancer NNP I-NP I-Disease
43 345 352 9497246 Linkage NNP I-NP O
44 353 363 9497246 Consortium NNP I-NP O
45 363 364 9497246 . . O O

1 365 373 9497246 Families NNS B-NP O
2 374 378 9497246 were VBD B-VP O
3 379 387 9497246 included VBN I-VP O
4 388 395 9497246 without IN B-PP O
5 396 402 9497246 regard NN B-NP O
6 403 405 9497246 to TO B-PP O
7 406 409 9497246 the DT B-NP O
8 410 420 9497246 occurrence NN I-NP O
9 421 423 9497246 of IN B-PP O
10 424 431 9497246 ovarian JJ B-NP B-Disease
11 432 434 9497246 or CC I-NP I-Disease
12 435 440 9497246 other JJ I-NP I-Disease
13 441 448 9497246 cancers NNS I-NP I-Disease
14 448 449 9497246 . . O O

1 450 457 9497246 Overall RB B-ADVP O
2 457 458 9497246 , , O O
3 459 466 9497246 disease NN B-NP O
4 467 470 9497246 was VBD B-VP O
5 471 477 9497246 linked VBN I-VP O
6 478 480 9497246 to TO B-PP O
7 481 486 9497246 BRCA1 NN B-NP O
8 487 489 9497246 in IN B-PP O
9 490 492 9497246 an DT B-NP O
10 493 502 9497246 estimated VBN I-NP O
11 503 506 9497246 52% NN I-NP O
12 507 509 9497246 of IN B-PP O
13 510 518 9497246 families NNS B-NP O
14 518 519 9497246 , , O O
15 520 522 9497246 to TO B-PP O
16 523 528 9497246 BRCA2 NN B-NP O
17 529 531 9497246 in IN B-PP O
18 532 535 9497246 32% NN B-NP O
19 536 538 9497246 of IN B-PP O
20 539 547 9497246 families NNS B-NP O
21 547 548 9497246 , , B-PP O
22 549 552 9497246 and CC I-PP O
23 553 555 9497246 to TO B-PP O
24 556 563 9497246 neither CC O O
25 564 568 9497246 gene NN B-NP O
26 569 571 9497246 in IN B-PP O
27 572 575 9497246 16% NN B-NP O
28 576 577 9497246 ( ( O O
29 577 580 9497246 95% CD B-NP O
30 581 591 9497246 confidence NN I-NP O
31 592 600 9497246 interval NN I-NP O
32 601 602 9497246 [ ( O O
33 602 604 9497246 CI NN B-NP O
34 604 605 9497246 ] ) B-NP O
35 606 608 9497246 6% CD I-NP O
36 609 610 9497246 - HYPH B-NP O
37 610 613 9497246 28% CD I-NP O
38 613 614 9497246 ) ) O O
39 614 615 9497246 , , O O
40 616 626 9497246 suggesting VBG B-VP O
41 627 632 9497246 other JJ B-NP O
42 633 647 9497246 predisposition NN I-NP O
43 648 653 9497246 genes NNS I-NP O
44 653 654 9497246 . . O O

1 655 658 9497246 The DT B-NP O
2 659 667 9497246 majority NN I-NP O
3 668 669 9497246 ( ( O O
4 669 672 9497246 81% NN B-NP O
5 672 673 9497246 ) ) O O
6 674 676 9497246 of IN B-PP O
7 677 680 9497246 the DT B-NP O
8 681 687 9497246 breast NN I-NP B-Disease
9 687 688 9497246 - HYPH B-NP I-Disease
10 688 695 9497246 ovarian JJ I-NP I-Disease
11 696 702 9497246 cancer NN I-NP I-Disease
12 703 711 9497246 families NNS I-NP O
13 712 716 9497246 were VBD B-VP O
14 717 720 9497246 due IN B-PP O
15 721 723 9497246 to TO B-PP O
16 724 729 9497246 BRCA1 NN B-NP O
17 729 730 9497246 , , O O
18 731 735 9497246 with IN B-PP O
19 736 740 9497246 most JJS B-NP O
20 741 747 9497246 others NNS I-NP O
21 748 749 9497246 ( ( O O
22 749 752 9497246 14% NN B-NP O
23 752 753 9497246 ) ) O O
24 754 757 9497246 due IN B-PP O
25 758 760 9497246 to TO I-PP O
26 761 766 9497246 BRCA2 NN B-NP O
27 766 767 9497246 . . O O

1 768 778 9497246 Conversely RB B-ADVP O
2 778 779 9497246 , , O O
3 780 783 9497246 the DT B-NP O
4 784 792 9497246 majority NN I-NP O
5 793 795 9497246 of IN B-PP O
6 796 804 9497246 families NNS B-NP O
7 805 809 9497246 with IN B-PP O
8 810 814 9497246 male JJ B-NP B-Disease
9 815 818 9497246 and CC I-NP I-Disease
10 819 825 9497246 female JJ I-NP I-Disease
11 826 832 9497246 breast NN I-NP I-Disease
12 833 839 9497246 cancer NN I-NP I-Disease
13 840 844 9497246 were VBD B-VP O
14 845 848 9497246 due JJ B-ADJP O
15 849 851 9497246 to TO B-PP O
16 852 857 9497246 BRCA2 NN B-NP O
17 858 859 9497246 ( ( O O
18 859 862 9497246 76% CD B-NP O
19 862 863 9497246 ) ) O O
20 863 864 9497246 . . O O

1 865 868 9497246 The DT B-NP O
2 869 876 9497246 largest JJS I-NP O
3 877 887 9497246 proportion NN I-NP O
4 888 889 9497246 ( ( O O
5 889 892 9497246 67% CD B-NP O
6 892 893 9497246 ) ) O O
7 894 896 9497246 of IN B-PP O
8 897 905 9497246 families NNS B-NP O
9 906 909 9497246 due JJ B-PP O
10 910 912 9497246 to TO B-PP O
11 913 918 9497246 other JJ B-NP O
12 919 924 9497246 genes NNS I-NP O
13 925 928 9497246 was VBD B-VP O
14 929 934 9497246 found VBN I-VP O
15 935 937 9497246 in IN B-PP O
16 938 946 9497246 families NNS B-NP O
17 947 951 9497246 with IN B-PP O
18 952 956 9497246 four CD B-NP O
19 957 959 9497246 or CC I-NP O
20 960 964 9497246 five CD I-NP O
21 965 970 9497246 cases NNS I-NP O
22 971 973 9497246 of IN B-PP O
23 974 980 9497246 female JJ B-NP O
24 981 987 9497246 breast NN I-NP B-Disease
25 988 994 9497246 cancer NN I-NP I-Disease
26 995 999 9497246 only RB B-ADVP O
27 999 1000 9497246 . . O O

1 1001 1006 9497246 These DT B-NP O
2 1007 1016 9497246 estimates NNS I-NP O
3 1017 1021 9497246 were VBD B-VP O
4 1022 1025 9497246 not RB I-VP O
5 1026 1039 9497246 substantially RB I-VP O
6 1040 1048 9497246 affected VBN I-VP O
7 1049 1055 9497246 either CC O O
8 1056 1058 9497246 by IN B-PP O
9 1059 1067 9497246 changing VBG B-VP O
10 1068 1071 9497246 the DT B-NP O
11 1072 1079 9497246 assumed VBN I-NP O
12 1080 1090 9497246 penetrance NN I-NP O
13 1091 1096 9497246 model NN I-NP O
14 1097 1100 9497246 for IN B-PP O
15 1101 1106 9497246 BRCA1 NN B-NP O
16 1107 1109 9497246 or CC B-PP O
17 1110 1112 9497246 by IN B-PP O
18 1113 1122 9497246 including VBG B-VP O
19 1123 1125 9497246 or CC I-VP O
20 1126 1135 9497246 excluding VBG I-VP O
21 1136 1141 9497246 BRCA1 NN B-NP O
22 1142 1150 9497246 mutation NN I-NP O
23 1151 1155 9497246 data NNS I-NP O
24 1155 1156 9497246 . . O O

1 1157 1162 9497246 Among IN B-PP O
2 1163 1168 9497246 those DT B-NP O
3 1169 1177 9497246 families NNS I-NP O
4 1178 1182 9497246 with IN B-PP O
5 1183 1190 9497246 disease NN B-NP O
6 1191 1194 9497246 due JJ B-ADJP O
7 1195 1197 9497246 to TO B-PP O
8 1198 1203 9497246 BRCA1 NN B-NP O
9 1204 1208 9497246 that WDT B-NP O
10 1209 1213 9497246 were VBD B-VP O
11 1214 1220 9497246 tested VBN I-VP O
12 1221 1223 9497246 by IN B-PP O
13 1224 1227 9497246 one CD B-NP O
14 1228 1230 9497246 of IN B-PP O
15 1231 1234 9497246 the DT B-NP O
16 1235 1243 9497246 standard JJ I-NP O
17 1244 1253 9497246 screening NN I-NP O
18 1254 1261 9497246 methods NNS I-NP O
19 1261 1262 9497246 , , O O
20 1263 1272 9497246 mutations NNS B-NP O
21 1273 1277 9497246 were VBD B-VP O
22 1278 1286 9497246 detected VBN I-VP O
23 1287 1289 9497246 in IN B-PP O
24 1290 1293 9497246 the DT B-NP O
25 1294 1300 9497246 coding VBG I-NP O
26 1301 1309 9497246 sequence NN I-NP O
27 1310 1312 9497246 or CC I-NP O
28 1313 1319 9497246 splice NN I-NP O
29 1320 1325 9497246 sites NNS I-NP O
30 1326 1328 9497246 in IN B-PP O
31 1329 1331 9497246 an DT B-NP O
32 1332 1341 9497246 estimated VBN I-NP O
33 1342 1345 9497246 63% NN I-NP O
34 1346 1347 9497246 ( ( O O
35 1347 1350 9497246 95% CD B-NP O
36 1351 1353 9497246 CI NN I-NP O
37 1354 1357 9497246 51% CD B-NP O
38 1358 1359 9497246 - HYPH I-NP O
39 1359 1362 9497246 77% CD I-NP O
40 1362 1363 9497246 ) ) O O
41 1363 1364 9497246 . . O O

1 1365 1368 9497246 The DT B-NP O
2 1369 1378 9497246 estimated VBN I-NP O
3 1379 1390 9497246 sensitivity NN I-NP O
4 1391 1394 9497246 was VBD B-VP O
5 1395 1404 9497246 identical JJ B-ADJP O
6 1405 1408 9497246 for IN B-PP O
7 1409 1415 9497246 direct JJ B-NP O
8 1416 1426 9497246 sequencing NN I-NP O
9 1427 1430 9497246 and CC O O
10 1431 1436 9497246 other JJ B-NP O
11 1437 1447 9497246 techniques NNS I-NP O
12 1447 1448 9497246 . . O O

1 1449 1452 9497246 The DT B-NP O
2 1453 1463 9497246 penetrance NN I-NP O
3 1464 1466 9497246 of IN B-PP O
4 1467 1472 9497246 BRCA2 NN B-NP O
5 1473 1476 9497246 was VBD B-VP O
6 1477 1486 9497246 estimated VBN I-VP O
7 1487 1489 9497246 by IN B-PP O
8 1490 1500 9497246 maximizing VBG B-VP O
9 1501 1504 9497246 the DT B-NP O
10 1505 1508 9497246 LOD NN I-NP O
11 1509 1514 9497246 score NN I-NP O
12 1515 1517 9497246 in IN B-PP O
13 1518 1523 9497246 BRCA2 NN B-NP O
14 1523 1524 9497246 - HYPH B-NP O
15 1524 1532 9497246 mutation NN I-NP O
16 1533 1541 9497246 families NNS I-NP O
17 1541 1542 9497246 , , O O
18 1543 1547 9497246 over IN B-PP O
19 1548 1551 9497246 all DT B-NP O
20 1552 1560 9497246 possible JJ I-NP O
21 1561 1571 9497246 penetrance NN I-NP O
22 1572 1581 9497246 functions NNS I-NP O
23 1581 1582 9497246 . . O O

1 1583 1586 9497246 The DT B-NP O
2 1587 1596 9497246 estimated VBN I-NP O
3 1597 1607 9497246 cumulative JJ I-NP O
4 1608 1612 9497246 risk NN I-NP O
5 1613 1615 9497246 of IN B-PP O
6 1616 1622 9497246 breast NN B-NP B-Disease
7 1623 1629 9497246 cancer NN I-NP I-Disease
8 1630 1637 9497246 reached VBD B-VP O
9 1638 1641 9497246 28% CD B-NP O
10 1642 1643 9497246 ( ( O O
11 1643 1646 9497246 95% CD B-NP O
12 1647 1649 9497246 CI NN I-NP O
13 1650 1652 9497246 9% NN I-NP O
14 1653 1654 9497246 - HYPH B-NP O
15 1654 1657 9497246 44% NN I-NP O
16 1657 1658 9497246 ) ) O O
17 1659 1661 9497246 by IN B-PP O
18 1662 1665 9497246 age NN B-NP O
19 1666 1668 9497246 50 CD B-NP O
20 1669 1674 9497246 years NNS I-NP O
21 1675 1678 9497246 and CC O O
22 1679 1682 9497246 84% CD B-NP O
23 1683 1684 9497246 ( ( O O
24 1684 1687 9497246 95% CD B-NP O
25 1688 1690 9497246 CI NN I-NP O
26 1691 1694 9497246 43% CD B-NP O
27 1695 1696 9497246 - HYPH I-NP O
28 1696 1699 9497246 95% NN I-NP O
29 1699 1700 9497246 ) ) O O
30 1701 1703 9497246 by IN B-PP O
31 1704 1707 9497246 age NN B-NP O
32 1708 1710 9497246 70 CD B-NP O
33 1711 1716 9497246 years NNS I-NP O
34 1716 1717 9497246 . . O O

1 1718 1721 9497246 The DT B-NP O
2 1722 1735 9497246 corresponding VBG I-NP O
3 1736 1743 9497246 ovarian JJ I-NP B-Disease
4 1744 1750 9497246 cancer NN I-NP I-Disease
5 1751 1756 9497246 risks NNS I-NP O
6 1757 1761 9497246 were VBD B-VP O
7 1762 1763 9497246 0 CD B-NP O
8 1763 1764 9497246 . . O O

1 1765 1767 9497246 4% CD B-NP O
2 1768 1769 9497246 ( ( O O
3 1769 1772 9497246 95% CD B-NP O
4 1773 1775 9497246 CI NN I-NP O
5 1776 1778 9497246 0% NN I-NP O
6 1779 1780 9497246 - HYPH B-NP O
7 1780 1782 9497246 1% NN I-NP O
8 1782 1783 9497246 ) ) O O
9 1784 1786 9497246 by IN B-PP O
10 1787 1790 9497246 age NN B-NP O
11 1791 1793 9497246 50 CD B-NP O
12 1794 1799 9497246 years NNS I-NP O
13 1800 1803 9497246 and CC O O
14 1804 1807 9497246 27% CD B-NP O
15 1808 1809 9497246 ( ( O O
16 1809 1812 9497246 95% CD B-NP O
17 1813 1815 9497246 CI NN I-NP O
18 1816 1818 9497246 0% NN I-NP O
19 1819 1820 9497246 - HYPH B-NP O
20 1820 1823 9497246 47% NN I-NP O
21 1823 1824 9497246 ) ) O O
22 1825 1827 9497246 by IN B-PP O
23 1828 1831 9497246 age NN B-NP O
24 1832 1834 9497246 70 CD B-NP O
25 1835 1840 9497246 years NNS I-NP O
26 1840 1841 9497246 . . O O

1 1842 1845 9497246 The DT B-NP O
2 1846 1854 9497246 lifetime NN I-NP O
3 1855 1859 9497246 risk NN I-NP O
4 1860 1862 9497246 of IN B-PP O
5 1863 1869 9497246 breast NN B-NP B-Disease
6 1870 1876 9497246 cancer NN I-NP I-Disease
7 1877 1884 9497246 appears VBZ B-VP O
8 1885 1892 9497246 similar JJ B-ADJP O
9 1893 1895 9497246 to TO B-PP O
10 1896 1899 9497246 the DT B-NP O
11 1900 1904 9497246 risk NN I-NP O
12 1905 1907 9497246 in IN B-PP O
13 1908 1913 9497246 BRCA1 NN B-NP O
14 1914 1922 9497246 carriers NNS I-NP O
15 1922 1923 9497246 , , O O
16 1924 1927 9497246 but CC O O
17 1928 1933 9497246 there EX B-NP O
18 1934 1937 9497246 was VBD B-VP O
19 1938 1942 9497246 some DT B-NP O
20 1943 1953 9497246 suggestion NN I-NP O
21 1954 1956 9497246 of IN B-PP O
22 1957 1958 9497246 a DT B-NP O
23 1959 1964 9497246 lower JJR I-NP O
24 1965 1969 9497246 risk NN I-NP O
25 1970 1972 9497246 in IN B-PP O
26 1973 1978 9497246 BRCA2 NN B-NP O
27 1979 1987 9497246 carriers NNS I-NP O
28 1988 1989 9497246 < SYM B-VP O
29 1990 1992 9497246 50 CD B-NP O
30 1993 1998 9497246 years NNS I-NP O
31 1999 2001 9497246 of IN B-PP O
32 2002 2005 9497246 age NN B-NP O
33 2005 2006 9497246 . . O O

1 0 0 9465039 -DOCSTART- -X- -X- O

1 0 3 9465039 The DT B-NP O
2 4 19 9465039 hemochromatosis NN I-NP B-Disease
3 20 24 9465039 gene NN I-NP O
4 25 32 9465039 product NN I-NP O
5 33 42 9465039 complexes NNS I-NP O
6 43 47 9465039 with IN B-PP O
7 48 51 9465039 the DT B-NP O
8 52 63 9465039 transferrin NN I-NP O
9 64 72 9465039 receptor NN I-NP O
10 73 76 9465039 and CC O O
11 77 83 9465039 lowers VBZ B-VP O
12 84 87 9465039 its PRP$ B-NP O
13 88 96 9465039 affinity NN I-NP O
14 97 100 9465039 for IN B-PP O
15 101 107 9465039 ligand NN B-NP O
16 108 115 9465039 binding NN I-NP O
17 115 116 9465039 . . O O
18 117 119 9465039 We PRP B-NP O
19 120 128 9465039 recently RB B-ADVP O
20 129 137 9465039 reported VBD B-VP O
21 138 141 9465039 the DT B-NP O
22 142 152 9465039 positional JJ I-NP O
23 153 160 9465039 cloning NN I-NP O
24 161 163 9465039 of IN B-PP O
25 164 165 9465039 a DT B-NP O
26 166 175 9465039 candidate NN I-NP O
27 176 180 9465039 gene NN I-NP O
28 181 184 9465039 for IN B-PP O
29 185 195 9465039 hereditary JJ B-NP B-Disease
30 196 211 9465039 hemochromatosis NN I-NP I-Disease
31 212 218 9465039 called VBN B-VP O
32 219 222 9465039 HFE NN B-NP O
33 222 223 9465039 . . O O

1 224 227 9465039 The DT B-NP O
2 228 232 9465039 gene NN I-NP O
3 233 240 9465039 product NN I-NP O
4 240 241 9465039 , , O O
5 242 243 9465039 a DT B-NP O
6 244 250 9465039 member NN I-NP O
7 251 253 9465039 of IN B-PP O
8 254 257 9465039 the DT B-NP O
9 258 263 9465039 major JJ I-NP O
10 264 282 9465039 histocompatibility NN I-NP O
11 283 290 9465039 complex NN I-NP O
12 291 296 9465039 class NN I-NP O
13 297 298 9465039 I CD I-NP O
14 298 299 9465039 - HYPH B-NP O
15 299 303 9465039 like JJ I-NP O
16 304 310 9465039 family NN I-NP O
17 310 311 9465039 , , O O
18 312 315 9465039 was VBD B-VP O
19 316 321 9465039 found VBN I-VP O
20 322 324 9465039 to TO I-VP O
21 325 329 9465039 have VB I-VP O
22 330 331 9465039 a DT B-NP O
23 332 340 9465039 mutation NN I-NP O
24 340 341 9465039 , , O O
25 342 345 9465039 Cys NN B-NP O
26 345 346 9465039 - HYPH B-NP O
27 346 349 9465039 282 CD I-NP O
28 350 351 9465039 - HYPH O O
29 351 352 9465039 - HYPH O O
30 353 354 9465039 > SYM O O
31 355 358 9465039 Tyr NN B-NP O
32 359 360 9465039 ( ( O O
33 360 365 9465039 C282Y NN B-NP O
34 365 366 9465039 ) ) O O
35 366 367 9465039 , , O O
36 368 370 9465039 in IN B-PP O
37 371 374 9465039 85% NN B-NP O
38 375 377 9465039 of IN B-PP O
39 378 385 9465039 patient NN B-NP O
40 386 397 9465039 chromosomes NNS I-NP O
41 397 398 9465039 . . O O

1 399 403 9465039 This DT B-NP O
2 404 412 9465039 mutation NN I-NP O
3 413 423 9465039 eliminates VBZ B-VP O
4 424 427 9465039 the DT B-NP O
5 428 435 9465039 ability NN I-NP O
6 436 438 9465039 of IN B-PP O
7 439 442 9465039 HFE NN B-NP O
8 443 445 9465039 to TO B-VP O
9 446 455 9465039 associate VB I-VP O
10 456 460 9465039 with IN B-PP O
11 461 466 9465039 beta2 NN B-NP O
12 466 467 9465039 - HYPH O O
13 467 480 9465039 microglobulin NN B-NP O
14 481 482 9465039 ( ( O O
15 482 488 9465039 beta2m NN B-NP O
16 488 489 9465039 ) ) O O
17 490 493 9465039 and CC O O
18 494 502 9465039 prevents VBZ B-VP O
19 503 507 9465039 cell NN B-NP O
20 507 508 9465039 - HYPH B-NP O
21 508 515 9465039 surface NN I-NP O
22 516 526 9465039 expression NN I-NP O
23 526 527 9465039 . . O O

1 528 529 9465039 A DT B-NP O
2 530 536 9465039 second JJ I-NP O
3 537 545 9465039 mutation NN I-NP O
4 546 550 9465039 that WDT B-NP O
5 551 554 9465039 has VBZ B-VP O
6 555 557 9465039 no DT B-NP O
7 558 564 9465039 effect NN I-NP O
8 565 567 9465039 on IN B-PP O
9 568 574 9465039 beta2m NN B-NP O
10 575 586 9465039 association NN I-NP O
11 586 587 9465039 , , O O
12 588 592 9465039 H63D NN B-NP O
13 592 593 9465039 , , O O
14 594 597 9465039 was VBD B-VP O
15 598 603 9465039 found VBN I-VP O
16 604 606 9465039 in IN B-PP O
17 607 612 9465039 eight CD B-NP O
18 613 616 9465039 out IN B-PP O
19 617 619 9465039 of IN B-PP O
20 620 624 9465039 nine CD B-NP O
21 625 633 9465039 patients NNS I-NP O
22 634 646 9465039 heterozygous JJ B-ADJP O
23 647 650 9465039 for IN B-PP O
24 651 654 9465039 the DT B-NP O
25 655 660 9465039 C282Y NN I-NP O
26 661 667 9465039 mutant NN I-NP O
27 667 668 9465039 . . O O

1 669 671 9465039 In IN B-PP O
2 672 676 9465039 this DT B-NP O
3 677 683 9465039 report NN I-NP O
4 683 684 9465039 , , O O
5 685 687 9465039 we PRP B-NP O
6 688 699 9465039 demonstrate VBP B-VP O
7 700 702 9465039 in IN B-PP O
8 703 711 9465039 cultured VBN B-NP O
9 712 715 9465039 293 CD I-NP O
10 716 721 9465039 cells NNS I-NP O
11 722 736 9465039 overexpressing VBG B-VP O
12 737 741 9465039 wild JJ B-NP O
13 741 742 9465039 - HYPH I-NP O
14 742 746 9465039 type NN I-NP O
15 747 749 9465039 or CC I-NP O
16 750 756 9465039 mutant JJ I-NP O
17 757 760 9465039 HFE NN I-NP O
18 761 769 9465039 proteins NNS I-NP O
19 770 774 9465039 that WDT B-NP O
20 775 779 9465039 both CC O O
21 780 783 9465039 the DT B-NP O
22 784 788 9465039 wild JJ I-NP O
23 788 789 9465039 - HYPH I-NP O
24 789 793 9465039 type NN I-NP O
25 794 797 9465039 and CC I-NP O
26 798 802 9465039 H63D NN I-NP O
27 803 806 9465039 HFE NN I-NP O
28 807 815 9465039 proteins NNS I-NP O
29 816 820 9465039 form VBP B-VP O
30 821 827 9465039 stable JJ B-NP O
31 828 837 9465039 complexes NNS I-NP O
32 838 842 9465039 with IN B-PP O
33 843 846 9465039 the DT B-NP O
34 847 858 9465039 transferrin NN I-NP O
35 859 867 9465039 receptor NN I-NP O
36 868 869 9465039 ( ( O O
37 869 872 9465039 TfR NN B-NP O
38 872 873 9465039 ) ) O O
39 873 874 9465039 . . O O

1 875 878 9465039 The DT B-NP O
2 879 884 9465039 C282Y NN I-NP O
3 885 893 9465039 mutation NN I-NP O
4 894 900 9465039 nearly RB B-ADVP O
5 901 911 9465039 completely RB I-ADVP O
6 912 920 9465039 prevents VBZ B-VP O
7 921 924 9465039 the DT B-NP O
8 925 936 9465039 association NN I-NP O
9 937 939 9465039 of IN B-PP O
10 940 943 9465039 the DT B-NP O
11 944 950 9465039 mutant JJ I-NP O
12 951 954 9465039 HFE NN I-NP O
13 955 962 9465039 protein NN I-NP O
14 963 967 9465039 with IN B-PP O
15 968 971 9465039 the DT B-NP O
16 972 975 9465039 TfR NN I-NP O
17 975 976 9465039 . . O O

1 977 984 9465039 Studies NNS B-NP O
2 985 987 9465039 on IN B-PP O
3 988 992 9465039 cell NN B-NP O
4 992 993 9465039 - HYPH B-NP O
5 993 1003 9465039 associated VBN I-NP O
6 1004 1015 9465039 transferrin NN I-NP O
7 1016 1018 9465039 at IN B-PP O
8 1019 1021 9465039 37 CD B-NP O
9 1022 1029 9465039 degrees NNS I-NP O
10 1030 1031 9465039 C NN I-NP O
11 1032 1039 9465039 suggest VBP B-VP O
12 1040 1044 9465039 that IN B-SBAR O
13 1045 1048 9465039 the DT B-NP O
14 1049 1062 9465039 overexpressed VBN I-NP O
15 1063 1067 9465039 wild JJ I-NP O
16 1067 1068 9465039 - HYPH I-NP O
17 1068 1072 9465039 type NN I-NP O
18 1073 1076 9465039 HFE NN I-NP O
19 1077 1084 9465039 protein NN I-NP O
20 1085 1094 9465039 decreases VBZ B-VP O
21 1095 1098 9465039 the DT B-NP O
22 1099 1107 9465039 affinity NN I-NP O
23 1108 1110 9465039 of IN B-PP O
24 1111 1114 9465039 the DT B-NP O
25 1115 1118 9465039 TfR NN I-NP O
26 1119 1122 9465039 for IN B-PP O
27 1123 1134 9465039 transferrin NN B-NP O
28 1134 1135 9465039 . . O O

1 1136 1139 9465039 The DT B-NP O
2 1140 1153 9465039 overexpressed VBN I-NP O
3 1154 1158 9465039 H63D NN I-NP O
4 1159 1166 9465039 protein NN I-NP O
5 1167 1171 9465039 does VBZ B-VP O
6 1172 1175 9465039 not RB I-VP O
7 1176 1180 9465039 have VB I-VP O
8 1181 1185 9465039 this DT B-NP O
9 1186 1192 9465039 effect NN I-NP O
10 1192 1193 9465039 , , O O
11 1194 1203 9465039 providing VBG B-VP O
12 1204 1207 9465039 the DT B-NP O
13 1208 1213 9465039 first JJ I-NP O
14 1214 1220 9465039 direct JJ I-NP O
15 1221 1229 9465039 evidence NN I-NP O
16 1230 1233 9465039 for IN B-PP O
17 1234 1235 9465039 a DT B-NP O
18 1236 1246 9465039 functional JJ I-NP O
19 1247 1258 9465039 consequence NN I-NP O
20 1259 1261 9465039 of IN B-PP O
21 1262 1265 9465039 the DT B-NP O
22 1266 1270 9465039 H63D NN I-NP O
23 1271 1279 9465039 mutation NN I-NP O
24 1279 1280 9465039 . . O O

1 1281 1289 9465039 Addition NN B-NP O
2 1290 1292 9465039 of IN B-PP O
3 1293 1300 9465039 soluble JJ B-NP O
4 1301 1305 9465039 wild JJ I-NP O
5 1305 1306 9465039 - HYPH I-NP O
6 1306 1310 9465039 type NN I-NP O
7 1311 1314 9465039 HFE NN I-NP O
8 1314 1315 9465039 / SYM B-NP O
9 1315 1321 9465039 beta2m NN I-NP O
10 1322 1334 9465039 heterodimers NNS I-NP O
11 1335 1337 9465039 to TO B-PP O
12 1338 1346 9465039 cultured VBN B-NP O
13 1347 1352 9465039 cells NNS I-NP O
14 1353 1357 9465039 also RB B-ADVP O
15 1358 1367 9465039 decreased VBD B-VP O
16 1368 1371 9465039 the DT B-NP O
17 1372 1380 9465039 apparent JJ I-NP O
18 1381 1389 9465039 affinity NN I-NP O
19 1390 1392 9465039 of IN B-PP O
20 1393 1396 9465039 the DT B-NP O
21 1397 1400 9465039 TfR NN I-NP O
22 1401 1404 9465039 for IN B-PP O
23 1405 1408 9465039 its PRP$ B-NP O
24 1409 1415 9465039 ligand NN I-NP O
25 1416 1421 9465039 under IN B-PP O
26 1422 1428 9465039 steady JJ B-NP O
27 1428 1429 9465039 - HYPH I-NP O
28 1429 1434 9465039 state NN I-NP O
29 1435 1445 9465039 conditions NNS I-NP O
30 1445 1446 9465039 , , O O
31 1447 1451 9465039 both CC O O
32 1452 1454 9465039 in IN B-PP O
33 1455 1458 9465039 293 CD B-NP O
34 1459 1464 9465039 cells NNS I-NP O
35 1465 1468 9465039 and CC B-PP O
36 1469 1471 9465039 in IN B-PP O
37 1472 1476 9465039 HeLa NN B-NP O
38 1477 1482 9465039 cells NNS I-NP O
39 1482 1483 9465039 . . O O

1 1484 1495 9465039 Furthermore RB B-ADVP O
2 1495 1496 9465039 , , O O
3 1497 1499 9465039 at IN B-PP O
4 1500 1501 9465039 4 CD B-NP O
5 1502 1509 9465039 degrees NNS I-NP O
6 1510 1511 9465039 C JJ B-ADJP O
7 1511 1512 9465039 , , O O
8 1513 1516 9465039 the DT B-NP O
9 1517 1522 9465039 added VBN I-NP O
10 1523 1530 9465039 soluble JJ I-NP O
11 1531 1538 9465039 complex NN I-NP O
12 1539 1541 9465039 of IN B-PP O
13 1542 1545 9465039 HFE NN B-NP O
14 1545 1546 9465039 / SYM B-NP O
15 1546 1552 9465039 beta2m NN I-NP O
16 1553 1562 9465039 inhibited VBD B-VP O
17 1563 1570 9465039 binding NN B-NP O
18 1571 1573 9465039 of IN B-PP O
19 1574 1585 9465039 transferrin NN B-NP O
20 1586 1588 9465039 to TO B-PP O
21 1589 1593 9465039 HeLa NN B-NP O
22 1594 1598 9465039 cell NN I-NP O
23 1599 1602 9465039 TfR NN I-NP O
24 1603 1605 9465039 in IN B-PP O
25 1606 1607 9465039 a DT B-NP O
26 1608 1621 9465039 concentration NN I-NP O
27 1621 1622 9465039 - HYPH B-NP O
28 1622 1631 9465039 dependent JJ I-NP O
29 1632 1638 9465039 manner NN I-NP O
30 1638 1639 9465039 . . O O

1 1640 1649 9465039 Scatchard NNP B-NP O
2 1650 1655 9465039 plots NNS I-NP O
3 1656 1658 9465039 of IN B-PP O
4 1659 1664 9465039 these DT B-NP O
5 1665 1669 9465039 data NNS I-NP O
6 1670 1678 9465039 indicate VBP B-VP O
7 1679 1683 9465039 that IN B-SBAR O
8 1684 1687 9465039 the DT B-NP O
9 1688 1693 9465039 added VBN I-NP O
10 1694 1705 9465039 heterodimer NN I-NP O
11 1706 1719 9465039 substantially RB B-VP O
12 1720 1727 9465039 reduced VBD I-VP O
13 1728 1731 9465039 the DT B-NP O
14 1732 1740 9465039 affinity NN I-NP O
15 1741 1743 9465039 of IN B-PP O
16 1744 1747 9465039 TfR NN B-NP O
17 1748 1751 9465039 for IN B-PP O
18 1752 1763 9465039 transferrin NN B-NP O
19 1763 1764 9465039 . . O O

1 1765 1770 9465039 These DT B-NP O
2 1771 1778 9465039 results NNS I-NP O
3 1779 1788 9465039 establish VBP B-VP O
4 1789 1790 9465039 a DT B-NP O
5 1791 1800 9465039 molecular JJ I-NP O
6 1801 1805 9465039 link NN I-NP O
7 1806 1813 9465039 between IN B-PP O
8 1814 1817 9465039 HFE NN B-NP O
9 1818 1821 9465039 and CC O O
10 1822 1823 9465039 a DT B-NP O
11 1824 1827 9465039 key JJ I-NP O
12 1828 1835 9465039 protein NN I-NP O
13 1836 1844 9465039 involved VBN B-VP O
14 1845 1847 9465039 in IN B-PP O
15 1848 1852 9465039 iron NN B-NP O
16 1853 1862 9465039 transport NN I-NP O
17 1862 1863 9465039 , , O O
18 1864 1867 9465039 the DT B-NP O
19 1868 1871 9465039 TfR NN I-NP O
20 1871 1872 9465039 , , O O
21 1873 1876 9465039 and CC O O
22 1877 1882 9465039 raise VB B-VP O
23 1883 1886 9465039 the DT B-NP O
24 1887 1898 9465039 possibility NN I-NP O
25 1899 1903 9465039 that IN B-SBAR O
26 1904 1915 9465039 alterations NNS B-NP O
27 1916 1918 9465039 in IN B-PP O
28 1919 1923 9465039 this DT B-NP O
29 1924 1934 9465039 regulatory JJ I-NP O
30 1935 1944 9465039 mechanism NN I-NP O
31 1945 1948 9465039 may MD B-VP O
32 1949 1953 9465039 play VB I-VP O
33 1954 1955 9465039 a DT B-NP O
34 1956 1960 9465039 role NN I-NP O
35 1961 1963 9465039 in IN B-PP O
36 1964 1967 9465039 the DT B-NP O
37 1968 1980 9465039 pathogenesis NN I-NP O
38 1981 1983 9465039 of IN B-PP O
39 1984 1994 9465039 hereditary JJ B-NP B-Disease
40 1995 2010 9465039 hemochromatosis NN I-NP I-Disease
41 2010 2011 9465039 . . O O
42 2011 2012 9465039 . . O O

1 0 0 9443866 -DOCSTART- -X- -X- O

1 0 6 9443866 Ataxia NN B-NP B-Disease
2 6 7 9443866 - HYPH I-NP I-Disease
3 7 21 9443866 telangiectasia NN I-NP I-Disease
4 21 22 9443866 : : O O
5 23 37 9443866 identification NN B-NP O
6 38 41 9443866 and CC I-NP O
7 42 51 9443866 detection NN I-NP O
8 52 54 9443866 of IN B-PP O
9 55 62 9443866 founder NN B-NP O
10 62 63 9443866 - HYPH I-NP O
11 63 69 9443866 effect NN I-NP O
12 70 79 9443866 mutations NNS I-NP O
13 80 82 9443866 in IN B-PP O
14 83 86 9443866 the DT B-NP O
15 87 90 9443866 ATM NN I-NP O
16 91 95 9443866 gene NN I-NP O
17 96 98 9443866 in IN B-PP O
18 99 105 9443866 ethnic JJ B-NP O
19 106 117 9443866 populations NNS I-NP O
20 117 118 9443866 . . O O
21 119 121 9443866 To TO B-VP O
22 122 132 9443866 facilitate VB I-VP O
23 133 136 9443866 the DT B-NP O
24 137 147 9443866 evaluation NN I-NP O
25 148 150 9443866 of IN B-PP O
26 151 154 9443866 ATM NN B-NP O
27 155 168 9443866 heterozygotes NNS I-NP O
28 169 172 9443866 for IN B-PP O
29 173 187 9443866 susceptibility NN B-NP O
30 188 190 9443866 to TO B-PP O
31 191 196 9443866 other JJ B-NP O
32 197 205 9443866 diseases NNS I-NP O
33 205 206 9443866 , , O O
34 207 211 9443866 such JJ B-PP O
35 212 214 9443866 as IN I-PP O
36 215 221 9443866 breast NN B-NP B-Disease
37 222 228 9443866 cancer NN I-NP I-Disease
38 228 229 9443866 , , O O
39 230 232 9443866 we PRP B-NP O
40 233 237 9443866 have VBP B-VP O
41 238 247 9443866 attempted VBN I-VP O
42 248 250 9443866 to TO I-VP O
43 251 257 9443866 define VB I-VP O
44 258 261 9443866 the DT B-NP O
45 262 266 9443866 most RBS I-NP O
46 267 273 9443866 common JJ I-NP O
47 274 283 9443866 mutations NNS I-NP O
48 284 287 9443866 and CC O O
49 288 293 9443866 their PRP$ B-NP O
50 294 305 9443866 frequencies NNS I-NP O
51 306 308 9443866 in IN B-PP O
52 309 315 9443866 ataxia NN B-NP B-Disease
53 315 316 9443866 - HYPH B-NP I-Disease
54 316 330 9443866 telangiectasia NN I-NP I-Disease
55 331 332 9443866 ( ( O O
56 332 333 9443866 A NN B-NP B-Disease
57 333 334 9443866 - HYPH I-NP I-Disease
58 334 335 9443866 T NN I-NP I-Disease
59 335 336 9443866 ) ) O O
60 337 348 9443866 homozygotes NNS B-NP O
61 349 353 9443866 from IN B-PP O
62 354 356 9443866 10 CD B-NP O
63 357 363 9443866 ethnic JJ I-NP O
64 364 375 9443866 populations NNS I-NP O
65 375 376 9443866 . . O O

1 377 381 9443866 Both DT B-NP O
2 382 389 9443866 genomic JJ I-NP O
3 390 399 9443866 mutations NNS I-NP O
4 400 403 9443866 and CC O O
5 404 409 9443866 their PRP$ B-NP O
6 410 417 9443866 effects NNS I-NP O
7 418 420 9443866 on IN B-PP O
8 421 425 9443866 cDNA NN B-NP O
9 426 430 9443866 were VBD B-VP O
10 431 444 9443866 characterized VBN I-VP O
11 444 445 9443866 . . O O

1 446 453 9443866 Protein NN B-NP O
2 453 454 9443866 - HYPH I-NP O
3 454 464 9443866 truncation NN I-NP O
4 465 472 9443866 testing NN I-NP O
5 473 475 9443866 of IN B-PP O
6 476 479 9443866 the DT B-NP O
7 480 486 9443866 entire JJ I-NP O
8 487 490 9443866 ATM NN I-NP O
9 491 495 9443866 cDNA NN I-NP O
10 496 504 9443866 detected VBN B-VP O
11 505 507 9443866 92 CD B-NP O
12 508 509 9443866 ( ( O O
13 509 512 9443866 66% NN B-NP O
14 512 513 9443866 ) ) O O
15 514 524 9443866 truncating VBG B-VP O
16 525 534 9443866 mutations NNS B-NP O
17 535 537 9443866 in IN B-PP O
18 538 541 9443866 140 CD B-NP O
19 542 548 9443866 mutant JJ I-NP O
20 549 556 9443866 alleles NNS I-NP O
21 557 565 9443866 screened VBN B-VP O
22 565 566 9443866 . . O O

1 567 570 9443866 The DT B-NP O
2 571 582 9443866 haplotyping NN I-NP O
3 583 585 9443866 of IN B-PP O
4 586 594 9443866 patients NNS B-NP O
5 595 599 9443866 with IN B-PP O
6 600 609 9443866 identical JJ B-NP O
7 610 619 9443866 mutations NNS I-NP O
8 620 629 9443866 indicates VBZ B-VP O
9 630 634 9443866 that IN B-SBAR O
10 635 641 9443866 almost RB B-NP O
11 642 645 9443866 all DT I-NP O
12 646 648 9443866 of IN B-PP O
13 649 654 9443866 these DT B-NP O
14 655 664 9443866 represent JJ I-NP O
15 665 671 9443866 common JJ I-NP O
16 672 680 9443866 ancestry NN I-NP O
17 681 684 9443866 and CC O O
18 685 689 9443866 that IN B-SBAR O
19 690 694 9443866 very RB B-NP O
20 695 698 9443866 few JJ I-NP O
21 699 712 9443866 spontaneously RB B-VP O
22 713 722 9443866 recurring VBG I-VP O
23 723 726 9443866 ATM NN B-NP O
24 727 736 9443866 mutations NNS I-NP O
25 737 742 9443866 exist VBP B-VP O
26 742 743 9443866 . . O O

1 744 750 9443866 Assays NNS B-NP O
2 751 760 9443866 requiring VBG B-VP O
3 761 768 9443866 minimal JJ B-NP O
4 769 776 9443866 amounts NNS I-NP O
5 777 779 9443866 of IN B-PP O
6 780 787 9443866 genomic JJ B-NP O
7 788 791 9443866 DNA NN I-NP O
8 792 796 9443866 were VBD B-VP O
9 797 805 9443866 designed VBN I-VP O
10 806 808 9443866 to TO B-VP O
11 809 814 9443866 allow VB I-VP O
12 815 820 9443866 rapid JJ B-NP O
13 821 830 9443866 screening NN I-NP O
14 831 834 9443866 for IN B-PP O
15 835 841 9443866 common JJ B-NP O
16 842 848 9443866 ethnic JJ I-NP O
17 849 858 9443866 mutations NNS I-NP O
18 858 859 9443866 . . O O

1 860 865 9443866 These DT B-NP O
2 866 871 9443866 rapid JJ I-NP O
3 872 878 9443866 assays NNS I-NP O
4 879 887 9443866 detected VBD B-VP O
5 888 897 9443866 mutations NNS B-NP O
6 898 900 9443866 in IN B-PP O
7 901 904 9443866 76% CD B-NP O
8 905 907 9443866 of IN B-PP O
9 908 913 9443866 Costa JJ B-NP O
10 914 919 9443866 Rican JJ I-NP O
11 920 928 9443866 patients NNS I-NP O
12 929 930 9443866 ( ( O O
13 930 931 9443866 3 CD B-NP O
14 931 932 9443866 ) ) O O
15 932 933 9443866 , , O O
16 934 937 9443866 50% CD B-NP O
17 938 940 9443866 of IN B-PP O
18 941 950 9443866 Norwegian JJ B-NP O
19 951 959 9443866 patients NNS I-NP O
20 960 961 9443866 ( ( O O
21 961 962 9443866 1 CD B-NP O
22 962 963 9443866 ) ) O O
23 963 964 9443866 , , O O
24 965 968 9443866 25% CD B-NP O
25 969 971 9443866 of IN B-PP O
26 972 978 9443866 Polish JJ B-NP O
27 979 987 9443866 patients NNS I-NP O
28 988 989 9443866 ( ( O O
29 989 990 9443866 4 CD B-NP O
30 990 991 9443866 ) ) O O
31 991 992 9443866 , , O O
32 993 996 9443866 and CC O O
33 997 1000 9443866 14% CD B-NP O
34 1001 1003 9443866 of IN B-PP O
35 1004 1011 9443866 Italian JJ B-NP O
36 1012 1020 9443866 patients NNS I-NP O
37 1021 1022 9443866 ( ( O O
38 1022 1023 9443866 1 CD B-NP O
39 1023 1024 9443866 ) ) O O
40 1024 1025 9443866 , , O O
41 1026 1028 9443866 as RB B-CONJP O
42 1029 1033 9443866 well RB I-CONJP O
43 1034 1036 9443866 as IN I-CONJP O
44 1037 1039 9443866 in IN B-PP O
45 1040 1048 9443866 patients NNS B-NP O
46 1049 1051 9443866 of IN B-PP O
47 1052 1057 9443866 Amish NN B-NP O
48 1057 1058 9443866 / SYM B-NP O
49 1058 1067 9443866 Mennonite NN I-NP O
50 1068 1071 9443866 and CC O O
51 1072 1077 9443866 Irish JJ B-NP O
52 1078 1085 9443866 English JJ I-NP O
53 1086 1097 9443866 backgrounds NNS I-NP O
54 1097 1098 9443866 . . O O

1 1099 1109 9443866 Additional JJ B-NP O
2 1110 1119 9443866 mutations NNS I-NP O
3 1120 1124 9443866 were VBD B-VP O
4 1125 1133 9443866 observed VBN I-VP O
5 1134 1136 9443866 in IN B-PP O
6 1137 1145 9443866 Japanese NNP B-NP O
7 1145 1146 9443866 , , O O
8 1147 1151 9443866 Utah NNP B-NP O
9 1152 1158 9443866 Mormon NNP I-NP O
10 1158 1159 9443866 , , O O
11 1160 1163 9443866 and CC O O
12 1164 1171 9443866 African JJ B-NP O
13 1172 1180 9443866 American JJ I-NP O
14 1181 1189 9443866 patients NNS I-NP O
15 1189 1190 9443866 . . O O

1 1191 1196 9443866 These DT B-NP O
2 1197 1203 9443866 assays NNS I-NP O
3 1204 1210 9443866 should MD B-VP O
4 1211 1221 9443866 facilitate VB I-VP O
5 1222 1231 9443866 screening NN B-NP O
6 1232 1235 9443866 for IN B-PP O
7 1236 1237 9443866 A NN B-NP B-Disease
8 1237 1238 9443866 - HYPH I-NP I-Disease
9 1238 1239 9443866 T NN I-NP I-Disease
10 1240 1253 9443866 heterozygotes NNS I-NP O
11 1254 1256 9443866 in IN B-PP O
12 1257 1260 9443866 the DT B-NP O
13 1261 1272 9443866 populations NNS I-NP O
14 1273 1280 9443866 studied VBN B-VP O
15 1280 1281 9443866 . . O O
16 1281 1282 9443866 . . O O

1 0 0 9843038 -DOCSTART- -X- -X- O

1 0 14 9843038 Identification NN B-NP O
2 15 17 9843038 of IN B-PP O
3 18 19 9843038 a DT B-NP O
4 20 25 9843038 novel JJ I-NP O
5 26 34 9843038 mutation NN I-NP O
6 35 37 9843038 of IN B-PP O
7 38 41 9843038 the DT B-NP O
8 42 45 9843038 CPO NN I-NP O
9 46 50 9843038 gene NN I-NP O
10 51 53 9843038 in IN B-PP O
11 54 55 9843038 a DT B-NP O
12 56 64 9843038 Japanese JJ I-NP O
13 65 75 9843038 hereditary JJ I-NP B-Disease
14 76 90 9843038 coproporphyria NN I-NP I-Disease
15 91 97 9843038 family NN I-NP O
16 97 98 9843038 . . O O
17 99 109 9843038 Hereditary JJ B-NP B-Disease
18 110 124 9843038 coproporphyria NN I-NP I-Disease
19 125 126 9843038 ( ( O O
20 126 129 9843038 HCP NN B-NP B-Disease
21 129 130 9843038 ) ) O O
22 131 133 9843038 is VBZ B-VP O
23 134 136 9843038 an DT B-NP O
24 137 146 9843038 autosomal JJ I-NP B-Disease
25 147 155 9843038 dominant JJ I-NP I-Disease
26 156 163 9843038 disease NN I-NP I-Disease
27 164 177 9843038 characterized VBN B-VP O
28 178 180 9843038 by IN B-PP O
29 181 182 9843038 a DT B-NP O
30 183 193 9843038 deficiency NN I-NP B-Disease
31 194 196 9843038 of IN B-PP I-Disease
32 197 215 9843038 coproporphyrinogen NN B-NP I-Disease
33 216 223 9843038 oxidase NN I-NP I-Disease
34 224 225 9843038 ( ( O O
35 225 228 9843038 CPO NN B-NP O
36 228 229 9843038 ) ) O O
37 230 236 9843038 caused VBN B-VP O
38 237 239 9843038 by IN B-PP O
39 240 241 9843038 a DT B-NP O
40 242 250 9843038 mutation NN I-NP O
41 251 253 9843038 in IN B-PP O
42 254 257 9843038 the DT B-NP O
43 258 261 9843038 CPO NN I-NP O
44 262 266 9843038 gene NN I-NP O
45 266 267 9843038 . . O O

1 268 272 9843038 Only RB B-NP O
2 273 275 9843038 11 CD I-NP O
3 276 285 9843038 mutations NNS I-NP O
4 286 288 9843038 of IN B-PP O
5 289 292 9843038 the DT B-NP O
6 293 297 9843038 gene NN I-NP O
7 298 302 9843038 have VBP B-VP O
8 303 307 9843038 been VBN I-VP O
9 308 316 9843038 reported VBN I-VP O
10 317 319 9843038 in IN B-PP O
11 320 323 9843038 HCP NN B-NP B-Disease
12 324 332 9843038 patients NNS I-NP O
13 332 333 9843038 . . O O

1 334 336 9843038 We PRP B-NP O
2 337 343 9843038 report VBP B-VP O
3 344 351 9843038 another DT B-NP O
4 352 360 9843038 mutation NN I-NP O
5 361 363 9843038 in IN B-PP O
6 364 365 9843038 a DT B-NP O
7 366 374 9843038 Japanese JJ I-NP O
8 375 381 9843038 family NN I-NP O
9 381 382 9843038 . . O O

1 383 393 9843038 Polymerase NN B-NP O
2 394 399 9843038 chain NN I-NP O
3 400 408 9843038 reaction NN I-NP O
4 408 409 9843038 - HYPH B-NP O
5 409 415 9843038 single JJ I-NP O
6 416 422 9843038 strand NN I-NP O
7 423 437 9843038 conformational JJ I-NP O
8 438 450 9843038 polymorphism NN I-NP O
9 451 454 9843038 and CC O O
10 455 461 9843038 direct JJ B-NP O
11 462 470 9843038 sequence NN I-NP O
12 471 479 9843038 analyses NNS I-NP O
13 480 492 9843038 demonstrated VBD B-VP O
14 493 494 9843038 a DT B-NP O
15 495 496 9843038 C NN I-NP O
16 497 499 9843038 to TO B-PP O
17 500 501 9843038 T NN B-NP O
18 502 514 9843038 substitution NN I-NP O
19 515 517 9843038 in IN B-PP O
20 518 522 9843038 exon NN B-NP O
21 523 524 9843038 1 CD I-NP O
22 525 527 9843038 of IN B-PP O
23 528 531 9843038 the DT B-NP O
24 532 535 9843038 CPO NN I-NP O
25 536 540 9843038 gene NN I-NP O
26 541 543 9843038 at IN B-PP O
27 544 554 9843038 nucleotide NN B-NP O
28 555 563 9843038 position NN I-NP O
29 564 566 9843038 85 CD I-NP O
30 566 567 9843038 , , O O
31 568 573 9843038 which WDT B-NP O
32 574 578 9843038 lies VBZ B-VP O
33 579 581 9843038 in IN B-PP O
34 582 585 9843038 the DT B-NP O
35 586 594 9843038 putative JJ I-NP O
36 595 606 9843038 presequence NN I-NP O
37 607 610 9843038 for IN B-PP O
38 611 620 9843038 targeting VBG B-VP O
39 621 623 9843038 to TO B-PP O
40 624 636 9843038 mitochondria NNS B-NP O
41 636 637 9843038 . . O O

1 638 642 9843038 This DT B-NP O
2 643 651 9843038 mutation NN I-NP O
3 652 659 9843038 changes VBZ B-VP O
4 660 663 9843038 the DT B-NP O
5 664 669 9843038 codon NN I-NP O
6 670 673 9843038 for IN B-PP O
7 674 683 9843038 glutamine NN B-NP O
8 684 686 9843038 to TO B-PP O
9 687 688 9843038 a DT B-NP O
10 689 700 9843038 termination NN I-NP O
11 701 706 9843038 codon NN I-NP O
12 707 709 9843038 at IN B-PP O
13 710 715 9843038 amino JJ B-NP O
14 716 720 9843038 acid NN I-NP O
15 721 729 9843038 position NN I-NP O
16 730 732 9843038 29 CD I-NP O
17 732 733 9843038 . . O O

1 734 738 9843038 MaeI NN B-NP O
2 739 750 9843038 restriction NN I-NP O
3 751 759 9843038 analysis NN I-NP O
4 760 766 9843038 showed VBD B-VP O
5 767 770 9843038 two CD B-NP O
6 771 776 9843038 other JJ I-NP O
7 777 785 9843038 carriers NNS I-NP O
8 786 788 9843038 in IN B-PP O
9 789 792 9843038 the DT B-NP O
10 793 799 9843038 family NN I-NP O
11 799 800 9843038 . . O O

1 801 804 9843038 The DT B-NP O
2 805 806 9843038 C NN I-NP O
3 806 807 9843038 - HYPH I-NP O
4 807 808 9843038 T NN I-NP O
5 809 817 9843038 mutation NN I-NP O
6 818 820 9843038 is VBZ B-VP O
7 821 828 9843038 located JJ B-ADJP O
8 829 835 9843038 within IN B-PP O
9 836 837 9843038 a DT B-NP O
10 838 846 9843038 recently RB I-NP O
11 847 855 9843038 proposed VBN I-NP O
12 856 864 9843038 putative JJ I-NP O
13 865 876 9843038 alternative JJ I-NP O
14 877 888 9843038 translation NN I-NP O
15 889 899 9843038 initiation NN I-NP O
16 900 905 9843038 codon NN I-NP O
17 906 907 9843038 ( ( O O
18 907 910 9843038 TIC NN B-NP O
19 910 911 9843038 - HYPH B-NP O
20 911 912 9843038 1 CD I-NP O
21 912 913 9843038 ) ) O O
22 913 914 9843038 , , O O
23 915 925 9843038 supporting VBG B-VP O
24 926 930 9843038 that IN B-SBAR O
25 931 934 9843038 TIC NN B-NP O
26 934 935 9843038 - HYPH B-NP O
27 935 936 9843038 1 CD I-NP O
28 937 939 9843038 is VBZ B-VP O
29 940 943 9843038 the DT B-NP O
30 944 948 9843038 real JJ I-NP O
31 949 952 9843038 TIC NN I-NP O
32 953 959 9843038 rather RB B-CONJP O
33 960 964 9843038 than IN I-CONJP O
34 965 968 9843038 TIC NN B-NP O
35 968 969 9843038 - HYPH O O
36 969 970 9843038 2 CD B-NP O
37 970 971 9843038 . . O O
38 971 972 9843038 . . O O

1 0 0 9867744 -DOCSTART- -X- -X- O

1 0 9 9867744 Diagnosis NN B-NP O
2 10 12 9867744 of IN B-PP O
3 13 28 9867744 hemochromatosis NN B-NP B-Disease
4 28 29 9867744 . . O O
5 30 32 9867744 If IN B-SBAR O
6 33 42 9867744 untreated JJ B-NP O
7 42 43 9867744 , , I-NP O
8 44 59 9867744 hemochromatosis NN I-NP B-Disease
9 60 63 9867744 can MD B-VP O
10 64 69 9867744 cause VB I-VP O
11 70 77 9867744 serious JJ B-NP O
12 78 85 9867744 illness NN I-NP O
13 86 89 9867744 and CC O O
14 90 95 9867744 early JJ B-NP B-Disease
15 96 101 9867744 death NN I-NP I-Disease
16 101 102 9867744 , , O O
17 103 106 9867744 but CC O O
18 107 110 9867744 the DT B-NP O
19 111 118 9867744 disease NN I-NP O
20 119 121 9867744 is VBZ B-VP O
21 122 127 9867744 still RB B-ADVP O
22 128 141 9867744 substantially RB B-ADVP O
23 142 147 9867744 under IN B-PP O
24 147 148 9867744 - HYPH B-NP O
25 148 157 9867744 diagnosed VBN B-VP O
26 157 158 9867744 . . O O

1 159 162 9867744 The DT B-NP O
2 163 174 9867744 cornerstone NN I-NP O
3 175 177 9867744 of IN B-PP O
4 178 187 9867744 screening NN B-NP O
5 188 191 9867744 and CC I-NP O
6 192 196 9867744 case NN I-NP O
7 197 206 9867744 detection NN I-NP O
8 207 209 9867744 is VBZ B-VP O
9 210 213 9867744 the DT B-NP O
10 214 225 9867744 measurement NN I-NP O
11 226 228 9867744 of IN B-PP O
12 229 234 9867744 serum NN B-NP O
13 235 246 9867744 transferrin NN I-NP O
14 247 257 9867744 saturation NN I-NP O
15 258 261 9867744 and CC O O
16 262 265 9867744 the DT B-NP O
17 266 271 9867744 serum NN I-NP O
18 272 280 9867744 ferritin NN I-NP O
19 281 286 9867744 level NN I-NP O
20 286 287 9867744 . . O O

1 288 292 9867744 Once RB O O
2 293 296 9867744 the DT B-NP O
3 297 306 9867744 diagnosis NN I-NP O
4 307 309 9867744 is VBZ B-VP O
5 310 319 9867744 suspected VBN I-VP O
6 319 320 9867744 , , O O
7 321 331 9867744 physicians NNS B-NP O
8 332 336 9867744 must MD B-VP O
9 337 340 9867744 use VB I-VP O
10 341 346 9867744 serum NN B-NP O
11 347 355 9867744 ferritin NN I-NP O
12 356 362 9867744 levels NNS I-NP O
13 363 366 9867744 and CC O O
14 367 374 9867744 hepatic JJ B-NP O
15 375 379 9867744 iron NN I-NP O
16 380 386 9867744 stores NNS I-NP O
17 387 389 9867744 on IN B-PP O
18 390 395 9867744 liver NN B-NP O
19 396 402 9867744 biopsy NN I-NP O
20 403 412 9867744 specimens NNS I-NP O
21 413 415 9867744 to TO B-VP O
22 416 422 9867744 assess VB I-VP O
23 423 431 9867744 patients NNS B-NP O
24 432 435 9867744 for IN B-PP O
25 436 439 9867744 the DT B-NP O
26 440 448 9867744 presence NN I-NP O
27 449 451 9867744 of IN B-PP O
28 452 456 9867744 iron NN B-NP B-Disease
29 457 465 9867744 overload NN I-NP I-Disease
30 465 466 9867744 . . O O

1 467 472 9867744 Liver NN B-NP O
2 473 479 9867744 biopsy NN I-NP O
3 480 482 9867744 is VBZ B-VP O
4 483 487 9867744 also RB I-VP O
5 488 492 9867744 used VBN I-VP O
6 493 495 9867744 to TO B-VP O
7 496 505 9867744 establish VB I-VP O
8 506 509 9867744 the DT B-NP O
9 510 518 9867744 presence NN I-NP O
10 519 521 9867744 or CC I-NP O
11 522 529 9867744 absence NN I-NP O
12 530 532 9867744 of IN B-PP O
13 533 542 9867744 cirrhosis NN B-NP B-Disease
14 542 543 9867744 , , O O
15 544 549 9867744 which WDT B-NP O
16 550 553 9867744 can MD B-VP O
17 554 560 9867744 affect VB I-VP O
18 561 570 9867744 prognosis NN B-NP O
19 571 574 9867744 and CC I-NP O
20 575 585 9867744 management NN I-NP O
21 585 586 9867744 . . O O

1 587 588 9867744 A DT B-NP O
2 589 592 9867744 DNA NN I-NP O
3 592 593 9867744 - HYPH B-VP O
4 593 598 9867744 based VBN I-VP O
5 599 603 9867744 test NN B-NP O
6 604 607 9867744 for IN B-PP O
7 608 611 9867744 the DT B-NP O
8 612 615 9867744 HFE NN I-NP O
9 616 620 9867744 gene NN I-NP O
10 621 623 9867744 is VBZ B-VP O
11 624 636 9867744 commercially RB B-ADJP O
12 637 646 9867744 available JJ I-ADJP O
13 646 647 9867744 , , O O
14 648 651 9867744 but CC O O
15 652 655 9867744 its PRP$ B-NP O
16 656 661 9867744 place NN I-NP O
17 662 664 9867744 in IN B-PP O
18 665 668 9867744 the DT B-NP O
19 669 678 9867744 diagnosis NN I-NP O
20 679 681 9867744 of IN B-PP O
21 682 697 9867744 hemochromatosis NN B-NP B-Disease
22 698 700 9867744 is VBZ B-VP O
23 701 706 9867744 still RB I-VP O
24 707 712 9867744 being VBG I-VP O
25 713 722 9867744 evaluated VBN I-VP O
26 722 723 9867744 . . O O

1 724 733 9867744 Currently RB B-ADVP O
2 733 734 9867744 , , O O
3 735 738 9867744 the DT B-NP O
4 739 743 9867744 most RBS I-NP O
5 744 750 9867744 useful JJ I-NP O
6 751 755 9867744 role NN I-NP O
7 756 759 9867744 for IN B-PP O
8 760 764 9867744 this DT B-NP O
9 765 769 9867744 test NN I-NP O
10 770 772 9867744 is VBZ B-VP O
11 773 775 9867744 in IN B-PP O
12 776 779 9867744 the DT B-NP O
13 780 789 9867744 detection NN I-NP O
14 790 792 9867744 of IN B-PP O
15 793 808 9867744 hemochromatosis NN B-NP B-Disease
16 809 811 9867744 in IN B-PP O
17 812 815 9867744 the DT B-NP O
18 816 822 9867744 family NN I-NP O
19 823 830 9867744 members NNS I-NP O
20 831 833 9867744 of IN B-PP O
21 834 842 9867744 patients NNS B-NP O
22 843 847 9867744 with IN B-PP O
23 848 849 9867744 a DT B-NP O
24 850 856 9867744 proven JJ I-NP O
25 857 861 9867744 case NN I-NP O
26 862 864 9867744 of IN B-PP O
27 865 868 9867744 the DT B-NP O
28 869 876 9867744 disease NN I-NP O
29 876 877 9867744 . . O O

1 878 880 9867744 It PRP B-NP O
2 881 883 9867744 is VBZ B-VP O
3 884 891 9867744 crucial JJ B-ADJP O
4 892 894 9867744 to TO B-PP O
5 895 903 9867744 diagnose NN B-NP O
6 904 919 9867744 hemochromatosis NN I-NP B-Disease
7 920 926 9867744 before IN B-PP O
8 927 934 9867744 hepatic JJ B-NP B-Disease
9 935 944 9867744 cirrhosis NN I-NP I-Disease
10 945 953 9867744 develops VBZ B-VP O
11 954 961 9867744 because IN B-SBAR O
12 962 972 9867744 phlebotomy NN B-NP O
13 973 980 9867744 therapy NN I-NP O
14 981 984 9867744 can MD B-VP O
15 985 990 9867744 avert VB I-VP O
16 991 998 9867744 serious JJ B-NP O
17 999 1006 9867744 chronic JJ I-NP O
18 1007 1014 9867744 disease NN I-NP O
19 1015 1018 9867744 and CC O O
20 1019 1022 9867744 can MD B-VP O
21 1023 1027 9867744 even RB I-VP O
22 1028 1032 9867744 lead VB I-VP O
23 1033 1035 9867744 to TO B-PP O
24 1036 1042 9867744 normal JJ B-NP O
25 1043 1047 9867744 life NN I-NP O
26 1048 1058 9867744 expectancy NN I-NP O
27 1058 1059 9867744 . . O O
28 1059 1060 9867744 . . O O

1 0 0 9600235 -DOCSTART- -X- -X- O

1 0 9 9600235 Mutations NNS B-NP O
2 10 12 9600235 of IN B-PP O
3 13 16 9600235 the DT B-NP O
4 17 20 9600235 ATM NN I-NP O
5 21 25 9600235 gene NN I-NP O
6 26 34 9600235 detected VBN B-VP O
7 35 37 9600235 in IN B-PP O
8 38 46 9600235 Japanese JJ B-NP O
9 47 53 9600235 ataxia NN I-NP B-Disease
10 53 54 9600235 - HYPH O I-Disease
11 54 68 9600235 telangiectasia NN B-NP I-Disease
12 69 77 9600235 patients NNS I-NP O
13 77 78 9600235 : : O O
14 79 87 9600235 possible JJ B-NP O
15 88 101 9600235 preponderance NN I-NP O
16 102 104 9600235 of IN B-PP O
17 105 108 9600235 the DT B-NP O
18 109 112 9600235 two CD I-NP O
19 113 120 9600235 founder NN I-NP O
20 121 130 9600235 mutations NNS I-NP O
21 131 141 9600235 4612del165 CD B-NP O
22 142 145 9600235 and CC I-NP O
23 146 154 9600235 7883del5 CD I-NP O
24 154 155 9600235 . . O O
25 156 159 9600235 The DT B-NP O
26 160 163 9600235 ATM NN I-NP O
27 164 165 9600235 ( ( O O
28 165 166 9600235 A NN B-NP O
29 166 167 9600235 - HYPH I-NP O
30 167 168 9600235 T NN I-NP O
31 168 169 9600235 , , O O
32 170 177 9600235 mutated VBN B-VP O
33 177 178 9600235 ) ) O O
34 179 183 9600235 gene NN B-NP O
35 184 186 9600235 on IN B-PP O
36 187 192 9600235 human JJ B-NP O
37 193 203 9600235 chromosome NN I-NP O
38 204 209 9600235 11q22 NN I-NP O
39 209 210 9600235 . . O O

1 211 212 9600235 3 CD B-NP O
2 213 216 9600235 has VBZ B-VP O
3 217 225 9600235 recently RB I-VP O
4 226 230 9600235 been VBN I-VP O
5 231 241 9600235 identified VBN I-VP O
6 242 244 9600235 as IN B-PP O
7 245 248 9600235 the DT B-NP O
8 249 253 9600235 gene NN I-NP O
9 254 265 9600235 responsible JJ B-ADJP O
10 266 269 9600235 for IN B-PP O
11 270 273 9600235 the DT B-NP O
12 274 279 9600235 human JJ I-NP O
13 280 289 9600235 recessive JJ I-NP B-Disease
14 290 297 9600235 disease NN I-NP I-Disease
15 298 304 9600235 ataxia NN I-NP B-Disease
16 304 305 9600235 - HYPH B-NP I-Disease
17 305 319 9600235 telangiectasia NN I-NP I-Disease
18 320 321 9600235 ( ( O O
19 321 322 9600235 A NN B-NP B-Disease
20 322 323 9600235 - HYPH O I-Disease
21 323 324 9600235 T NN B-NP I-Disease
22 324 325 9600235 ) ) O O
23 325 326 9600235 . . O O

1 327 329 9600235 In IN B-SBAR O
2 330 335 9600235 order NN O O
3 336 338 9600235 to TO B-VP O
4 339 345 9600235 define VB I-VP O
5 346 349 9600235 the DT B-NP O
6 350 355 9600235 types NNS I-NP O
7 356 358 9600235 of IN B-PP O
8 359 366 9600235 disease NN B-NP O
9 366 367 9600235 - HYPH O O
10 367 374 9600235 causing VBG B-VP O
11 375 378 9600235 ATM NN B-NP O
12 379 388 9600235 mutations NNS I-NP O
13 389 391 9600235 in IN B-PP O
14 392 400 9600235 Japanese JJ B-NP O
15 401 402 9600235 A NN I-NP B-Disease
16 402 403 9600235 - HYPH I-NP I-Disease
17 403 404 9600235 T NN I-NP I-Disease
18 405 413 9600235 patients NNS I-NP O
19 414 416 9600235 as RB B-CONJP O
20 417 421 9600235 well RB I-CONJP O
21 422 424 9600235 as IN I-CONJP O
22 425 427 9600235 to TO B-VP O
23 428 432 9600235 look VB I-VP O
24 433 436 9600235 for IN B-PP O
25 437 445 9600235 possible JJ B-NP O
26 446 456 9600235 mutational JJ I-NP O
27 457 465 9600235 hotspots NNS I-NP O
28 465 466 9600235 , , O O
29 467 474 9600235 reverse NN B-NP O
30 474 475 9600235 - HYPH B-VP O
31 475 486 9600235 transcribed VBN B-NP O
32 487 490 9600235 RNA NN I-NP O
33 491 498 9600235 derived VBN B-VP O
34 499 503 9600235 from IN B-PP O
35 504 507 9600235 ten CD B-NP O
36 508 516 9600235 patients NNS I-NP O
37 517 526 9600235 belonging VBG B-VP O
38 527 529 9600235 to TO B-PP O
39 530 535 9600235 eight CD B-NP O
40 536 545 9600235 unrelated JJ I-NP O
41 546 554 9600235 Japanese JJ I-NP O
42 555 556 9600235 A NN I-NP B-Disease
43 556 557 9600235 - HYPH I-NP I-Disease
44 557 558 9600235 T NN I-NP I-Disease
45 559 567 9600235 families NNS I-NP O
46 568 571 9600235 was VBD B-VP O
47 572 580 9600235 analyzed VBN I-VP O
48 581 584 9600235 for IN B-PP O
49 585 594 9600235 mutations NNS B-NP O
50 595 597 9600235 by IN B-PP O
51 598 601 9600235 the DT B-NP O
52 602 613 9600235 restriction NN I-NP O
53 614 626 9600235 endonuclease NN I-NP O
54 627 641 9600235 fingerprinting NN I-NP O
55 642 648 9600235 method NN I-NP O
56 648 649 9600235 . . O O

1 650 652 9600235 As IN B-SBAR O
2 653 656 9600235 has VBZ B-VP O
3 657 661 9600235 been VBN I-VP O
4 662 670 9600235 reported VBN I-VP O
5 671 673 9600235 by IN B-PP O
6 674 680 9600235 others NNS B-NP O
7 680 681 9600235 , , O O
8 682 691 9600235 mutations NNS B-NP O
9 692 696 9600235 that WDT B-NP O
10 697 701 9600235 lead VBP B-VP O
11 702 704 9600235 to TO I-VP O
12 705 709 9600235 exon VB I-VP O
13 710 718 9600235 skipping NN B-NP O
14 719 721 9600235 or CC O O
15 722 731 9600235 premature JJ B-NP O
16 732 739 9600235 protein NN I-NP O
17 740 750 9600235 truncation NN I-NP O
18 751 755 9600235 were VBD B-VP O
19 756 760 9600235 also RB B-ADVP O
20 761 772 9600235 predominant JJ B-ADJP O
21 773 775 9600235 in IN B-PP O
22 776 779 9600235 our PRP$ B-NP O
23 780 787 9600235 mutants NNS I-NP O
24 787 788 9600235 . . O O

1 789 792 9600235 Six CD B-NP O
2 793 802 9600235 different JJ I-NP O
3 803 812 9600235 mutations NNS I-NP O
4 813 817 9600235 were VBD B-VP O
5 818 828 9600235 identified VBN I-VP O
6 829 831 9600235 on IN B-PP O
7 832 834 9600235 12 CD B-NP O
8 835 837 9600235 of IN B-PP O
9 838 841 9600235 the DT B-NP O
10 842 844 9600235 16 CD I-NP O
11 845 852 9600235 alleles NNS I-NP O
12 853 861 9600235 examined VBN B-VP O
13 861 862 9600235 . . O O

1 863 867 9600235 Four CD B-NP O
2 868 872 9600235 were VBD B-VP O
3 873 882 9600235 deletions NNS B-NP O
4 883 892 9600235 involving VBG B-VP O
5 893 894 9600235 a DT B-NP O
6 895 899 9600235 loss NN I-NP O
7 900 902 9600235 of IN B-PP O
8 903 904 9600235 a DT B-NP O
9 905 911 9600235 single JJ I-NP O
10 912 916 9600235 exon NN I-NP O
11 918 922 9600235 exon NN I-NP O
12 923 924 9600235 7 CD I-NP O
13 924 925 9600235 , , O O
14 926 930 9600235 exon NN B-NP O
15 931 933 9600235 16 CD I-NP O
16 933 934 9600235 , , O O
17 935 939 9600235 exon NN B-NP O
18 940 942 9600235 33 CD I-NP O
19 943 945 9600235 or CC O O
20 946 950 9600235 exon NN B-NP O
21 951 953 9600235 35 CD I-NP O
22 953 954 9600235 . . O O

1 955 958 9600235 The DT B-NP O
2 959 965 9600235 others NNS I-NP O
3 966 970 9600235 were VBD B-VP O
4 971 977 9600235 minute JJ B-NP O
5 978 987 9600235 deletions NNS I-NP O
6 987 988 9600235 , , O O
7 989 997 9600235 4649delA NN B-NP O
8 998 1000 9600235 in IN B-PP O
9 1001 1005 9600235 exon NN B-NP O
10 1006 1008 9600235 33 CD I-NP O
11 1009 1012 9600235 and CC I-NP O
12 1013 1021 9600235 7883del5 CD I-NP O
13 1022 1024 9600235 in IN B-PP O
14 1025 1029 9600235 exon NN B-NP O
15 1030 1032 9600235 55 CD I-NP O
16 1032 1033 9600235 . . O O

1 1034 1037 9600235 The DT B-NP O
2 1038 1047 9600235 mutations NNS I-NP O
3 1048 1058 9600235 4612del165 CD I-NP O
4 1059 1062 9600235 and CC I-NP O
5 1063 1071 9600235 7883del5 CD I-NP O
6 1072 1076 9600235 were VBD B-VP O
7 1077 1082 9600235 found VBN I-VP O
8 1083 1085 9600235 in IN B-PP O
9 1086 1090 9600235 more JJR B-NP O
10 1091 1095 9600235 than IN I-NP O
11 1096 1099 9600235 two CD I-NP O
12 1100 1109 9600235 unrelated JJ I-NP O
13 1110 1118 9600235 families NNS I-NP O
14 1118 1119 9600235 ; : O O
15 1120 1123 9600235 44% CD B-NP O
16 1124 1125 9600235 ( ( O O
17 1125 1126 9600235 7 CD B-NP O
18 1127 1129 9600235 of IN B-PP O
19 1130 1132 9600235 16 CD B-NP O
20 1132 1133 9600235 ) ) O O
21 1134 1136 9600235 of IN B-PP O
22 1137 1140 9600235 the DT B-NP O
23 1141 1147 9600235 mutant JJ I-NP O
24 1148 1155 9600235 alleles NNS I-NP O
25 1156 1159 9600235 had VBD B-VP O
26 1160 1163 9600235 one CD B-NP O
27 1164 1166 9600235 of IN B-PP O
28 1167 1170 9600235 the DT B-NP O
29 1171 1174 9600235 two CD I-NP O
30 1175 1184 9600235 mutations NNS I-NP O
31 1184 1185 9600235 . . O O

1 1186 1189 9600235 The DT B-NP O
2 1190 1200 9600235 4612del165 CD I-NP O
3 1201 1210 9600235 mutations NNS I-NP O
4 1211 1213 9600235 in IN B-PP O
5 1214 1219 9600235 three CD B-NP O
6 1220 1229 9600235 different JJ I-NP O
7 1230 1238 9600235 families NNS I-NP O
8 1239 1243 9600235 were VBD B-VP O
9 1244 1247 9600235 all DT O O
10 1248 1256 9600235 ascribed VBN B-VP O
11 1257 1259 9600235 to TO B-PP O
12 1260 1263 9600235 the DT B-NP O
13 1264 1268 9600235 same JJ I-NP O
14 1269 1270 9600235 T NN I-NP O
15 1270 1271 9600235 - SYM B-NP O
16 1271 1272 9600235 - SYM I-NP O
17 1273 1274 9600235 > SYM I-NP O
18 1275 1276 9600235 A NN I-NP O
19 1277 1289 9600235 substitution NN I-NP O
20 1290 1292 9600235 at IN B-PP O
21 1293 1296 9600235 the DT B-NP O
22 1297 1303 9600235 splice NN I-NP O
23 1304 1309 9600235 donor NN I-NP O
24 1310 1314 9600235 site NN I-NP O
25 1315 1317 9600235 in IN B-PP O
26 1318 1324 9600235 intron NN B-NP O
27 1325 1327 9600235 33 CD I-NP O
28 1327 1328 9600235 . . O O

1 1329 1343 9600235 Microsatellite NN B-NP O
2 1344 1354 9600235 genotyping NN I-NP O
3 1355 1361 9600235 around IN B-PP O
4 1362 1365 9600235 the DT B-NP O
5 1366 1369 9600235 ATM NN I-NP O
6 1370 1375 9600235 locus NN I-NP O
7 1376 1380 9600235 also RB B-ADVP O
8 1381 1390 9600235 indicated VBD B-VP O
9 1391 1395 9600235 that IN B-SBAR O
10 1396 1397 9600235 a DT B-NP O
11 1398 1404 9600235 common JJ I-NP O
12 1405 1414 9600235 haplotype NN I-NP O
13 1415 1418 9600235 was VBD B-VP O
14 1419 1425 9600235 shared VBN I-VP O
15 1426 1428 9600235 by IN B-PP O
16 1429 1432 9600235 the DT B-NP O
17 1433 1439 9600235 mutant JJ I-NP O
18 1440 1447 9600235 alleles NNS I-NP O
19 1448 1450 9600235 in IN B-PP O
20 1451 1455 9600235 both DT B-NP O
21 1456 1465 9600235 mutations NNS I-NP O
22 1465 1466 9600235 . . O O

1 1467 1471 9600235 This DT B-NP O
2 1472 1480 9600235 suggests VBZ B-VP O
3 1481 1485 9600235 that IN B-SBAR O
4 1486 1491 9600235 these DT B-NP O
5 1492 1495 9600235 two CD I-NP O
6 1496 1503 9600235 founder NN I-NP O
7 1504 1513 9600235 mutations NNS I-NP O
8 1514 1517 9600235 may MD B-VP O
9 1518 1520 9600235 be VB I-VP O
10 1521 1532 9600235 predominant JJ B-ADJP O
11 1533 1538 9600235 among IN B-PP O
12 1539 1547 9600235 Japanese JJ B-NP O
13 1548 1551 9600235 ATM NN I-NP O
14 1552 1558 9600235 mutant JJ I-NP O
15 1559 1566 9600235 alleles NNS I-NP O
16 1566 1567 9600235 . . O O

1 0 0 9949197 -DOCSTART- -X- -X- O

1 0 12 9949197 Distribution NN B-NP O
2 13 15 9949197 of IN B-PP O
3 16 22 9949197 emerin NN B-NP O
4 23 26 9949197 and CC I-NP O
5 27 33 9949197 lamins NNS I-NP O
6 34 36 9949197 in IN B-PP O
7 37 40 9949197 the DT B-NP O
8 41 46 9949197 heart NN I-NP O
9 47 50 9949197 and CC I-NP O
10 51 63 9949197 implications NNS I-NP O
11 64 67 9949197 for IN B-PP O
12 68 73 9949197 Emery NNP B-NP B-Disease
13 73 74 9949197 - HYPH B-NP I-Disease
14 74 82 9949197 Dreifuss NNP I-NP I-Disease
15 83 91 9949197 muscular JJ I-NP I-Disease
16 92 101 9949197 dystrophy NN I-NP I-Disease
17 101 102 9949197 . . I-NP O
18 103 109 9949197 Emerin NN I-NP O
19 110 112 9949197 is VBZ B-VP O
20 113 114 9949197 a DT B-NP O
21 115 122 9949197 nuclear JJ I-NP O
22 123 131 9949197 membrane NN I-NP O
23 132 139 9949197 protein NN I-NP O
24 140 145 9949197 which WDT B-NP O
25 146 148 9949197 is VBZ B-VP O
26 149 156 9949197 missing JJ B-ADJP O
27 157 159 9949197 or CC I-ADJP O
28 160 169 9949197 defective JJ I-ADJP O
29 170 172 9949197 in IN B-PP O
30 173 178 9949197 Emery NNP B-NP B-Disease
31 178 179 9949197 - HYPH B-NP I-Disease
32 179 187 9949197 Dreifuss NNP I-NP I-Disease
33 188 196 9949197 muscular JJ I-NP I-Disease
34 197 206 9949197 dystrophy NN I-NP I-Disease
35 207 208 9949197 ( ( O O
36 208 212 9949197 EDMD NN B-NP B-Disease
37 212 213 9949197 ) ) O O
38 213 214 9949197 . . O O

1 215 217 9949197 It PRP B-NP O
2 218 220 9949197 is VBZ B-VP O
3 221 224 9949197 one CD B-NP O
4 225 231 9949197 member NN I-NP O
5 232 234 9949197 of IN B-PP O
6 235 236 9949197 a DT B-NP O
7 237 243 9949197 family NN I-NP O
8 244 246 9949197 of IN B-PP O
9 247 253 9949197 lamina NN B-NP O
10 253 254 9949197 - HYPH B-NP O
11 254 264 9949197 associated VBN I-NP O
12 265 273 9949197 proteins NNS I-NP O
13 274 279 9949197 which WDT B-NP O
14 280 288 9949197 includes VBZ B-VP O
15 289 293 9949197 LAP1 NN B-NP O
16 293 294 9949197 , , I-NP O
17 295 299 9949197 LAP2 NN I-NP O
18 300 303 9949197 and CC I-NP O
19 304 309 9949197 lamin NN I-NP O
20 310 311 9949197 B NN I-NP O
21 312 320 9949197 receptor NN I-NP O
22 321 322 9949197 ( ( O O
23 322 325 9949197 LBR NN B-NP O
24 325 326 9949197 ) ) O O
25 326 327 9949197 . . O O

1 328 329 9949197 A DT B-NP O
2 330 335 9949197 panel NN I-NP O
3 336 338 9949197 of IN B-PP O
4 339 341 9949197 16 CD B-NP O
5 342 352 9949197 monoclonal JJ I-NP O
6 353 363 9949197 antibodies NNS I-NP O
7 364 365 9949197 ( ( O O
8 365 369 9949197 mAbs NNS B-NP O
9 369 370 9949197 ) ) O O
10 371 374 9949197 has VBZ B-VP O
11 375 379 9949197 been VBN I-VP O
12 380 386 9949197 mapped VBN I-VP O
13 387 389 9949197 to TO B-PP O
14 390 393 9949197 six CD B-NP O
15 394 402 9949197 specific JJ I-NP O
16 403 408 9949197 sites NNS I-NP O
17 409 419 9949197 throughout IN B-PP O
18 420 423 9949197 the DT B-NP O
19 424 430 9949197 emerin NN I-NP O
20 431 439 9949197 molecule NN I-NP O
21 440 445 9949197 using VBG B-VP O
22 446 451 9949197 phage NN B-NP O
23 451 452 9949197 - HYPH O O
24 452 461 9949197 displayed VBN B-NP O
25 462 469 9949197 peptide NN I-NP O
26 470 479 9949197 libraries NNS I-NP O
27 480 483 9949197 and CC O O
28 484 487 9949197 has VBZ B-VP O
29 488 492 9949197 been VBN I-VP O
30 493 497 9949197 used VBN I-VP O
31 498 500 9949197 to TO I-VP O
32 501 509 9949197 localize VB I-VP O
33 510 516 9949197 emerin NN B-NP O
34 517 519 9949197 in IN B-PP O
35 520 525 9949197 human JJ B-NP O
36 526 529 9949197 and CC I-NP O
37 530 536 9949197 rabbit NN I-NP O
38 537 542 9949197 heart NN I-NP O
39 542 543 9949197 . . O O

1 544 551 9949197 Several JJ B-NP O
2 552 556 9949197 mAbs NNS I-NP O
3 557 564 9949197 against IN B-PP O
4 565 574 9949197 different JJ B-NP O
5 575 581 9949197 emerin NN I-NP O
6 582 590 9949197 epitopes NNS I-NP O
7 591 594 9949197 did VBD B-VP O
8 595 598 9949197 not RB I-VP O
9 599 608 9949197 recognize VB I-VP O
10 609 621 9949197 intercalated VBN B-NP O
11 622 627 9949197 discs NNS I-NP O
12 628 630 9949197 in IN B-PP O
13 631 634 9949197 the DT B-NP O
14 635 640 9949197 heart NN I-NP O
15 640 641 9949197 , , O O
16 642 648 9949197 though IN B-SBAR O
17 649 653 9949197 they PRP B-NP O
18 654 664 9949197 recognized VBD B-VP O
19 665 678 9949197 cardiomyocyte NN B-NP O
20 679 685 9949197 nuclei NNS I-NP O
21 686 694 9949197 strongly RB B-ADVP O
22 694 695 9949197 , , O O
23 696 700 9949197 both DT B-NP O
24 701 703 9949197 at IN B-PP O
25 704 707 9949197 the DT B-NP O
26 708 711 9949197 rim NN I-NP O
27 712 715 9949197 and CC B-PP O
28 716 718 9949197 in IN B-PP O
29 719 731 9949197 intranuclear JJ B-NP O
30 732 737 9949197 spots NNS I-NP O
31 738 740 9949197 or CC I-NP O
32 741 749 9949197 channels NNS I-NP O
33 749 750 9949197 . . O O

1 751 752 9949197 A DT B-NP O
2 753 763 9949197 polyclonal JJ I-NP O
3 764 770 9949197 rabbit NN I-NP O
4 771 780 9949197 antiserum NN I-NP O
5 781 788 9949197 against IN B-PP O
6 789 795 9949197 emerin NN B-NP O
7 796 799 9949197 did VBD B-VP O
8 800 809 9949197 recognize VB I-VP O
9 810 814 9949197 both CC O O
10 815 822 9949197 nuclear JJ B-NP O
11 823 831 9949197 membrane NN I-NP O
12 832 835 9949197 and CC O O
13 836 848 9949197 intercalated JJ B-NP O
14 849 854 9949197 discs NNS I-NP O
15 855 858 9949197 but CC O O
16 858 859 9949197 , , O O
17 860 865 9949197 after IN B-PP O
18 866 874 9949197 affinity NN B-NP O
19 875 887 9949197 purification NN I-NP O
20 888 895 9949197 against IN B-PP O
21 896 897 9949197 a DT B-NP O
22 898 902 9949197 pure JJ I-NP O
23 902 903 9949197 - HYPH I-NP O
24 903 909 9949197 emerin NN I-NP O
25 910 914 9949197 band NN I-NP O
26 915 917 9949197 on IN B-PP O
27 918 919 9949197 a DT B-NP O
28 920 927 9949197 western JJ I-NP O
29 928 932 9949197 blot NN I-NP O
30 932 933 9949197 , , O O
31 934 936 9949197 it PRP B-NP O
32 937 944 9949197 stained VBD B-VP O
33 945 949 9949197 only RB B-NP O
34 950 953 9949197 the DT I-NP O
35 954 961 9949197 nuclear JJ I-NP O
36 962 970 9949197 membrane NN I-NP O
37 970 971 9949197 . . O O

1 972 977 9949197 These DT B-NP O
2 978 985 9949197 results NNS I-NP O
3 986 991 9949197 would MD B-VP O
4 992 995 9949197 not RB I-VP O
5 996 998 9949197 be VB I-VP O
6 999 1007 9949197 expected VBN I-VP O
7 1008 1010 9949197 if IN B-SBAR O
8 1011 1025 9949197 immunostaining NN B-NP O
9 1026 1028 9949197 at IN B-PP O
10 1029 1041 9949197 intercalated JJ B-NP O
11 1042 1047 9949197 discs NNS I-NP O
12 1048 1052 9949197 were VBD B-VP O
13 1053 1056 9949197 due JJ B-ADJP O
14 1057 1059 9949197 to TO B-PP O
15 1060 1061 9949197 a DT B-NP O
16 1062 1069 9949197 product NN I-NP O
17 1070 1072 9949197 of IN B-PP O
18 1073 1076 9949197 the DT B-NP O
19 1077 1083 9949197 emerin NN I-NP O
20 1084 1088 9949197 gene NN I-NP O
21 1089 1092 9949197 and CC O O
22 1092 1093 9949197 , , O O
23 1094 1103 9949197 therefore RB B-ADVP O
24 1103 1104 9949197 , , O O
25 1105 1109 9949197 cast VBD B-VP O
26 1110 1114 9949197 some DT B-NP O
27 1115 1120 9949197 doubt NN I-NP O
28 1121 1125 9949197 upon IN B-PP O
29 1126 1129 9949197 the DT B-NP O
30 1130 1140 9949197 hypothesis NN I-NP O
31 1141 1145 9949197 that IN B-SBAR O
32 1146 1153 9949197 cardiac JJ B-NP B-Disease
33 1154 1161 9949197 defects NNS I-NP I-Disease
34 1162 1164 9949197 in IN B-PP O
35 1165 1169 9949197 EDMD NN B-NP B-Disease
36 1170 1173 9949197 are VBP B-VP O
37 1174 1180 9949197 caused VBN I-VP O
38 1181 1183 9949197 by IN B-PP O
39 1184 1191 9949197 absence NN B-NP O
40 1192 1194 9949197 of IN B-PP O
41 1195 1201 9949197 emerin NN B-NP O
42 1202 1206 9949197 from IN B-PP O
43 1207 1219 9949197 intercalated VBN B-NP O
44 1220 1225 9949197 discs NNS I-NP O
45 1225 1226 9949197 . . O O

1 1227 1235 9949197 Although IN B-SBAR O
2 1236 1242 9949197 emerin NN B-NP O
3 1243 1246 9949197 was VBD B-VP O
4 1247 1255 9949197 abundant JJ B-ADJP O
5 1256 1258 9949197 in IN B-PP O
6 1259 1262 9949197 the DT B-NP O
7 1263 1272 9949197 membranes NNS I-NP O
8 1273 1275 9949197 of IN B-PP O
9 1276 1289 9949197 cardiomyocyte NN B-NP O
10 1290 1296 9949197 nuclei NNS I-NP O
11 1296 1297 9949197 , , O O
12 1298 1300 9949197 it PRP B-NP O
13 1301 1304 9949197 was VBD B-VP O
14 1305 1311 9949197 absent JJ B-ADJP O
15 1312 1316 9949197 from IN B-PP O
16 1317 1321 9949197 many JJ B-NP O
17 1322 1325 9949197 non AFX I-NP O
18 1325 1326 9949197 - HYPH I-NP O
19 1326 1333 9949197 myocyte NN I-NP O
20 1334 1339 9949197 cells NNS I-NP O
21 1340 1342 9949197 in IN B-PP O
22 1343 1346 9949197 the DT B-NP O
23 1347 1352 9949197 heart NN I-NP O
24 1352 1353 9949197 . . O O

1 1354 1358 9949197 This DT B-NP O
2 1359 1371 9949197 distribution NN I-NP O
3 1372 1374 9949197 of IN B-PP O
4 1375 1381 9949197 emerin NN B-NP O
5 1382 1385 9949197 was VBD B-VP O
6 1386 1393 9949197 similar JJ B-ADJP O
7 1394 1396 9949197 to TO B-PP O
8 1397 1401 9949197 that DT B-NP O
9 1402 1404 9949197 of IN B-PP O
10 1405 1410 9949197 lamin NN B-NP O
11 1411 1412 9949197 A NN I-NP O
12 1412 1413 9949197 , , O O
13 1414 1415 9949197 a DT B-NP O
14 1416 1425 9949197 candidate NN I-NP O
15 1426 1430 9949197 gene NN I-NP O
16 1431 1434 9949197 for IN B-PP O
17 1435 1437 9949197 an DT B-NP O
18 1438 1447 9949197 autosomal JJ I-NP O
19 1448 1452 9949197 form NN I-NP O
20 1453 1455 9949197 of IN B-PP O
21 1456 1460 9949197 EDMD NN B-NP B-Disease
22 1460 1461 9949197 . . O O

1 1462 1464 9949197 In IN B-PP O
2 1465 1473 9949197 contrast NN B-NP O
3 1473 1474 9949197 , , O O
4 1475 1480 9949197 lamin NN B-NP O
5 1481 1483 9949197 B1 NN I-NP O
6 1484 1487 9949197 was VBD B-VP O
7 1488 1494 9949197 absent JJ B-ADJP O
8 1495 1499 9949197 from IN B-PP O
9 1500 1513 9949197 cardiomyocyte NN B-NP O
10 1514 1520 9949197 nuclei NNS I-NP O
11 1520 1521 9949197 , , O O
12 1522 1529 9949197 showing VBG B-VP O
13 1530 1534 9949197 that IN B-SBAR O
14 1535 1540 9949197 lamin NN B-NP O
15 1541 1543 9949197 B1 NN I-NP O
16 1544 1546 9949197 is VBZ B-VP O
17 1547 1550 9949197 not RB O O
18 1551 1560 9949197 essential JJ B-ADJP O
19 1561 1564 9949197 for IN B-PP O
20 1565 1577 9949197 localization NN B-NP O
21 1578 1580 9949197 of IN B-PP O
22 1581 1587 9949197 emerin NN B-NP O
23 1588 1590 9949197 to TO B-PP O
24 1591 1594 9949197 the DT B-NP O
25 1595 1602 9949197 nuclear JJ I-NP O
26 1603 1609 9949197 lamina NN I-NP O
27 1609 1610 9949197 . . O O

1 1611 1616 9949197 Lamin NN B-NP O
2 1617 1619 9949197 B1 NN I-NP O
3 1620 1622 9949197 is VBZ B-VP O
4 1623 1627 9949197 also RB B-ADVP O
5 1628 1634 9949197 almost RB B-ADJP O
6 1635 1645 9949197 completely RB I-ADJP O
7 1646 1652 9949197 absent JJ I-ADJP O
8 1653 1657 9949197 from IN B-PP O
9 1658 1666 9949197 skeletal JJ B-NP O
10 1667 1673 9949197 muscle NN I-NP O
11 1674 1680 9949197 nuclei NNS I-NP O
12 1680 1681 9949197 . . O O

1 1682 1684 9949197 In IN B-PP O
2 1685 1689 9949197 EDMD NNP B-NP B-Disease
3 1689 1690 9949197 , , O O
4 1691 1694 9949197 the DT B-NP O
5 1695 1705 9949197 additional JJ I-NP O
6 1706 1713 9949197 absence NN I-NP O
7 1714 1716 9949197 of IN B-PP O
8 1717 1722 9949197 lamin NN B-NP O
9 1723 1725 9949197 B1 NN I-NP O
10 1726 1730 9949197 from IN B-PP O
11 1731 1736 9949197 heart NN B-NP O
12 1737 1740 9949197 and CC O O
13 1741 1749 9949197 skeletal JJ B-NP O
14 1750 1756 9949197 muscle NN I-NP O
15 1757 1763 9949197 nuclei NNS I-NP O
16 1764 1769 9949197 which WDT B-NP O
17 1770 1777 9949197 already RB B-ADVP O
18 1778 1782 9949197 lack VBP B-VP O
19 1783 1789 9949197 emerin NN B-NP O
20 1790 1793 9949197 may MD B-VP O
21 1794 1799 9949197 offer VB I-VP O
22 1800 1802 9949197 an DT B-NP O
23 1803 1814 9949197 alternative JJ I-NP O
24 1815 1826 9949197 explanation NN I-NP O
25 1827 1829 9949197 of IN B-PP O
26 1830 1833 9949197 why WRB B-ADVP O
27 1834 1839 9949197 these DT B-NP O
28 1840 1847 9949197 tissues NNS I-NP O
29 1848 1851 9949197 are VBP B-VP O
30 1852 1864 9949197 particularly RB I-VP O
31 1865 1873 9949197 affected VBN I-VP O
32 1873 1874 9949197 . . O O
33 1874 1875 9949197 . . O O

1 0 0 9861003 -DOCSTART- -X- -X- O

1 0 1 9861003 A DT B-NP O
2 2 8 9861003 genome NN I-NP O
3 8 9 9861003 - HYPH B-NP O
4 9 13 9861003 wide JJ I-NP O
5 14 20 9861003 search NN I-NP O
6 21 24 9861003 for IN B-PP O
7 25 36 9861003 chromosomal JJ B-NP O
8 37 41 9861003 loci NNS I-NP O
9 42 48 9861003 linked VBN B-VP O
10 49 51 9861003 to TO B-PP O
11 52 58 9861003 mental JJ B-NP O
12 59 65 9861003 health NN I-NP O
13 66 74 9861003 wellness NN I-NP O
14 75 77 9861003 in IN B-PP O
15 78 87 9861003 relatives NNS B-NP O
16 88 90 9861003 at IN B-PP O
17 91 95 9861003 high JJ B-NP O
18 96 100 9861003 risk NN I-NP O
19 101 104 9861003 for IN B-PP O
20 105 112 9861003 bipolar JJ B-NP B-Disease
21 113 122 9861003 affective JJ I-NP I-Disease
22 123 131 9861003 disorder NN I-NP I-Disease
23 132 137 9861003 among IN B-PP O
24 138 141 9861003 the DT B-NP O
25 142 145 9861003 Old NNP I-NP O
26 146 151 9861003 Order NNP I-NP O
27 152 157 9861003 Amish NNP I-NP O
28 157 158 9861003 . . I-NP O
29 159 166 9861003 Bipolar NNP I-NP B-Disease
30 167 176 9861003 affective JJ I-NP I-Disease
31 177 185 9861003 disorder NN I-NP I-Disease
32 186 187 9861003 ( ( O O
33 187 191 9861003 BPAD NN B-NP B-Disease
34 191 192 9861003 ; : O O
35 193 198 9861003 manic JJ B-NP B-Disease
36 198 199 9861003 - HYPH I-NP I-Disease
37 199 209 9861003 depressive JJ I-NP I-Disease
38 210 217 9861003 illness NN I-NP I-Disease
39 217 218 9861003 ) ) O O
40 219 221 9861003 is VBZ B-VP O
41 222 235 9861003 characterized VBN I-VP O
42 236 238 9861003 by IN B-PP O
43 239 247 9861003 episodes NNS B-NP O
44 248 250 9861003 of IN B-PP O
45 251 256 9861003 mania NN B-NP B-Disease
46 257 260 9861003 and CC O O
47 260 261 9861003 / SYM B-NP O
48 261 263 9861003 or CC O O
49 264 273 9861003 hypomania NN B-NP B-Disease
50 274 286 9861003 interspersed VBN B-VP O
51 287 291 9861003 with IN B-PP O
52 292 299 9861003 periods NNS B-NP O
53 300 302 9861003 of IN B-PP O
54 303 313 9861003 depression NN B-NP B-Disease
55 313 314 9861003 . . O O

1 315 325 9861003 Compelling NN B-NP O
2 326 334 9861003 evidence NN I-NP O
3 335 343 9861003 supports VBZ B-VP O
4 344 345 9861003 a DT B-NP O
5 346 357 9861003 significant JJ I-NP O
6 358 365 9861003 genetic JJ I-NP O
7 366 375 9861003 component NN I-NP O
8 376 378 9861003 in IN B-PP O
9 379 382 9861003 the DT B-NP O
10 383 397 9861003 susceptibility NN I-NP O
11 398 400 9861003 to TO B-VP O
12 401 408 9861003 develop VB I-VP O
13 409 413 9861003 BPAD NN B-NP B-Disease
14 413 414 9861003 . . O O

1 415 417 9861003 To TO B-PP O
2 418 422 9861003 date NN B-NP O
3 422 423 9861003 , , O O
4 424 431 9861003 however RB B-ADVP O
5 431 432 9861003 , , O O
6 433 440 9861003 linkage NN B-NP O
7 441 448 9861003 studies NNS I-NP O
8 449 453 9861003 have VBP B-VP O
9 454 463 9861003 attempted VBN I-VP O
10 464 468 9861003 only RB B-ADVP O
11 469 471 9861003 to TO B-VP O
12 472 480 9861003 identify VB I-VP O
13 481 492 9861003 chromosomal JJ B-NP O
14 493 497 9861003 loci NNS I-NP O
15 498 502 9861003 that WDT B-NP O
16 503 508 9861003 cause VBP B-VP O
17 509 511 9861003 or CC I-VP O
18 512 520 9861003 increase VBP I-VP O
19 521 524 9861003 the DT B-NP O
20 525 529 9861003 risk NN I-NP O
21 530 532 9861003 of IN B-PP O
22 533 543 9861003 developing VBG B-VP O
23 544 548 9861003 BPAD NN B-NP B-Disease
24 548 549 9861003 . . O O

1 550 552 9861003 To TO B-VP O
2 553 562 9861003 determine VB I-VP O
3 563 570 9861003 whether IN B-SBAR O
4 571 576 9861003 there EX B-NP O
5 577 582 9861003 could MD B-VP O
6 583 585 9861003 be VB I-VP O
7 586 596 9861003 protective JJ B-NP O
8 597 604 9861003 alleles NNS I-NP O
9 605 609 9861003 that WDT B-NP O
10 610 617 9861003 prevent VBP B-VP O
11 618 620 9861003 or CC I-VP O
12 621 627 9861003 reduce VBP I-VP O
13 628 631 9861003 the DT B-NP O
14 632 636 9861003 risk NN I-NP O
15 637 639 9861003 of IN B-PP O
16 640 650 9861003 developing VBG B-VP O
17 651 655 9861003 BPAD NN B-NP B-Disease
18 655 656 9861003 , , O O
19 657 664 9861003 similar JJ B-ADJP O
20 665 667 9861003 to TO B-PP O
21 668 672 9861003 what WP B-NP O
22 673 675 9861003 is VBZ B-VP O
23 676 684 9861003 observed VBN I-VP O
24 685 687 9861003 in IN B-PP O
25 688 693 9861003 other JJ B-NP O
26 694 701 9861003 genetic JJ I-NP B-Disease
27 702 711 9861003 disorders NNS I-NP I-Disease
28 711 712 9861003 , , O O
29 713 715 9861003 we PRP B-NP O
30 716 720 9861003 used VBD B-VP O
31 721 727 9861003 mental JJ B-NP O
32 728 734 9861003 health NN I-NP O
33 735 743 9861003 wellness NN I-NP O
34 744 745 9861003 ( ( O O
35 745 752 9861003 absence NN B-NP O
36 753 755 9861003 of IN B-PP O
37 756 759 9861003 any DT B-NP O
38 760 771 9861003 psychiatric JJ I-NP B-Disease
39 772 780 9861003 disorder NN I-NP I-Disease
40 780 781 9861003 ) ) O O
41 782 784 9861003 as IN B-PP O
42 785 788 9861003 the DT B-NP O
43 789 798 9861003 phenotype NN I-NP O
44 799 801 9861003 in IN B-PP O
45 802 805 9861003 our PRP$ B-NP O
46 806 812 9861003 genome NN I-NP O
47 812 813 9861003 - HYPH B-NP O
48 813 817 9861003 wide JJ I-NP O
49 818 825 9861003 linkage NN I-NP O
50 826 830 9861003 scan NN I-NP O
51 831 833 9861003 of IN B-PP O
52 834 841 9861003 several JJ B-NP O
53 842 847 9861003 large JJ I-NP O
54 848 863 9861003 multigeneration NN I-NP O
55 864 867 9861003 Old NNP I-NP O
56 868 873 9861003 Order NNP I-NP O
57 874 879 9861003 Amish NNP I-NP O
58 880 889 9861003 pedigrees NNS I-NP O
59 890 900 9861003 exhibiting VBG B-VP O
60 901 903 9861003 an DT B-NP O
61 904 913 9861003 extremely RB I-NP O
62 914 918 9861003 high JJ I-NP O
63 919 928 9861003 incidence NN I-NP O
64 929 931 9861003 of IN B-PP O
65 932 936 9861003 BPAD NN B-NP B-Disease
66 936 937 9861003 . . O O

1 938 940 9861003 We PRP B-NP O
2 941 945 9861003 have VBP B-VP O
3 946 951 9861003 found VBN I-VP O
4 952 958 9861003 strong JJ B-NP O
5 959 967 9861003 evidence NN I-NP O
6 968 971 9861003 for IN B-PP O
7 972 973 9861003 a DT B-NP O
8 974 979 9861003 locus NN I-NP O
9 980 982 9861003 on IN B-PP O
10 983 993 9861003 chromosome NN B-NP O
11 994 996 9861003 4p NN I-NP O
12 997 999 9861003 at IN B-PP O
13 1000 1007 9861003 D4S2949 NN B-NP O
14 1008 1009 9861003 ( ( O O
15 1009 1016 9861003 maximum NN B-NP O
16 1017 1027 9861003 GENEHUNTER NN I-NP O
17 1027 1028 9861003 - HYPH B-NP O
18 1028 1032 9861003 PLUS NN I-NP O
19 1033 1046 9861003 nonparametric JJ I-NP O
20 1047 1054 9861003 linkage NN I-NP O
21 1055 1060 9861003 score NN I-NP O
22 1061 1062 9861003 = SYM B-VP O
23 1063 1064 9861003 4 CD B-NP O
24 1064 1065 9861003 . SYM I-NP O
25 1066 1068 9861003 05 CD I-NP O
26 1068 1069 9861003 , , O O
27 1070 1071 9861003 P NN B-NP O
28 1072 1073 9861003 = SYM B-VP O
29 1074 1075 9861003 5 CD B-NP O
30 1075 1076 9861003 . SYM I-NP O
31 1077 1079 9861003 22 CD I-NP O
32 1080 1081 9861003 x SYM I-NP O
33 1082 1084 9861003 10 CD I-NP O
34 1085 1086 9861003 ( ( O O
35 1086 1087 9861003 - SYM O O
36 1087 1088 9861003 4 CD B-NP O
37 1088 1089 9861003 ) ) O O
38 1089 1090 9861003 ; : O O
39 1091 1097 9861003 SIBPAL JJ B-NP O
40 1098 1108 9861003 Pempirical JJ I-NP O
41 1109 1114 9861003 value NN I-NP O
42 1115 1116 9861003 < SYM B-NP O
43 1117 1118 9861003 3 CD B-NP O
44 1119 1120 9861003 x SYM I-NP O
45 1121 1123 9861003 10 CD I-NP O
46 1124 1125 9861003 ( ( O O
47 1125 1126 9861003 - SYM O O
48 1126 1127 9861003 5 CD B-NP O
49 1127 1128 9861003 ) ) O O
50 1128 1129 9861003 ) ) O O
51 1130 1133 9861003 and CC O O
52 1134 1144 9861003 suggestive JJ B-NP O
53 1145 1153 9861003 evidence NN I-NP O
54 1154 1157 9861003 for IN B-PP O
55 1158 1159 9861003 a DT B-NP O
56 1160 1165 9861003 locus NN I-NP O
57 1166 1168 9861003 on IN B-PP O
58 1169 1179 9861003 chromosome NN B-NP O
59 1180 1182 9861003 4q NN I-NP O
60 1183 1185 9861003 at IN B-PP O
61 1186 1192 9861003 D4S397 NN B-NP O
62 1193 1194 9861003 ( ( O O
63 1194 1201 9861003 maximum NN B-NP O
64 1202 1212 9861003 GENEHUNTER NN I-NP O
65 1212 1213 9861003 - HYPH B-NP O
66 1213 1217 9861003 PLUS NN I-NP O
67 1218 1231 9861003 nonparametric JJ I-NP O
68 1232 1239 9861003 linkage NN I-NP O
69 1240 1245 9861003 score NN I-NP O
70 1246 1247 9861003 = SYM B-VP O
71 1248 1249 9861003 3 CD B-NP O
72 1249 1250 9861003 . SYM I-NP O
73 1251 1253 9861003 29 CD I-NP O
74 1253 1254 9861003 , , O O
75 1255 1256 9861003 P NN B-NP O
76 1257 1258 9861003 = SYM B-VP O
77 1259 1260 9861003 2 CD B-NP O
78 1260 1261 9861003 . . O O
79 1262 1264 9861003 57 CD B-NP O
80 1265 1266 9861003 x CC I-NP O
81 1267 1269 9861003 10 CD I-NP O
82 1270 1271 9861003 ( ( O O
83 1271 1272 9861003 - SYM B-NP O
84 1272 1273 9861003 3 CD I-NP O
85 1273 1274 9861003 ) ) O O
86 1274 1275 9861003 ; : O O
87 1276 1282 9861003 SIBPAL JJ B-NP O
88 1283 1293 9861003 Pempirical JJ I-NP O
89 1294 1299 9861003 value NN I-NP O
90 1300 1301 9861003 < SYM B-NP O
91 1302 1303 9861003 1 CD I-NP O
92 1304 1305 9861003 x SYM I-NP O
93 1306 1308 9861003 10 CD I-NP O
94 1309 1310 9861003 ( ( O O
95 1310 1311 9861003 - SYM B-NP O
96 1311 1312 9861003 3 CD I-NP O
97 1312 1313 9861003 ) ) O O
98 1313 1314 9861003 ) ) O O
99 1315 1319 9861003 that WDT B-NP O
100 1320 1323 9861003 are VBP B-VP O
101 1324 1330 9861003 linked VBN I-VP O
102 1331 1333 9861003 to TO B-PP O
103 1334 1340 9861003 mental JJ B-NP O
104 1341 1347 9861003 health NN I-NP O
105 1348 1356 9861003 wellness NN I-NP O
106 1356 1357 9861003 . . O O

1 1358 1363 9861003 These DT B-NP O
2 1364 1372 9861003 findings NNS I-NP O
3 1373 1376 9861003 are VBP B-VP O
4 1377 1387 9861003 consistent JJ B-ADJP O
5 1388 1392 9861003 with IN B-PP O
6 1393 1396 9861003 the DT B-NP O
7 1397 1407 9861003 hypothesis NN I-NP O
8 1408 1412 9861003 that IN B-SBAR O
9 1413 1420 9861003 certain JJ B-NP O
10 1421 1428 9861003 alleles NNS I-NP O
11 1429 1434 9861003 could MD B-VP O
12 1435 1442 9861003 prevent VB I-VP O
13 1443 1445 9861003 or CC I-VP O
14 1446 1452 9861003 modify VB I-VP O
15 1453 1456 9861003 the DT B-NP O
16 1457 1465 9861003 clinical JJ I-NP O
17 1466 1480 9861003 manifestations NNS I-NP O
18 1481 1483 9861003 of IN B-PP O
19 1484 1488 9861003 BPAD NN B-NP B-Disease
20 1489 1492 9861003 and CC O O
21 1493 1500 9861003 perhaps RB B-ADVP O
22 1501 1506 9861003 other JJ B-NP O
23 1507 1514 9861003 related JJ I-NP O
24 1515 1524 9861003 affective JJ I-NP B-Disease
25 1525 1534 9861003 disorders NNS I-NP I-Disease
26 1534 1535 9861003 . . O O

1 0 0 9714764 -DOCSTART- -X- -X- O

1 0 7 9714764 Cloning NN B-NP O
2 8 10 9714764 of IN B-PP O
3 11 12 9714764 a DT B-NP O
4 13 18 9714764 novel JJ I-NP O
5 19 25 9714764 member NN I-NP O
6 26 28 9714764 of IN B-PP O
7 29 32 9714764 the DT B-NP O
8 33 36 9714764 low JJ I-NP O
9 36 37 9714764 - HYPH I-NP O
10 37 44 9714764 density NN I-NP O
11 45 56 9714764 lipoprotein NN I-NP O
12 57 65 9714764 receptor NN I-NP O
13 66 72 9714764 family NN I-NP O
14 72 73 9714764 . . I-NP O
15 74 75 9714764 A NN I-NP O
16 76 80 9714764 gene NN I-NP O
17 81 89 9714764 encoding VBG B-VP O
18 90 91 9714764 a DT B-NP O
19 92 97 9714764 novel JJ I-NP O
20 98 111 9714764 transmembrane JJ I-NP O
21 112 119 9714764 protein NN I-NP O
22 120 123 9714764 was VBD B-VP O
23 124 134 9714764 identified VBN I-VP O
24 135 137 9714764 by IN B-PP O
25 138 141 9714764 DNA NN B-NP O
26 142 150 9714764 sequence NN I-NP O
27 151 159 9714764 analysis NN I-NP O
28 160 166 9714764 within IN B-PP O
29 167 170 9714764 the DT B-NP O
30 171 178 9714764 insulin NN I-NP B-Disease
31 178 179 9714764 - HYPH B-NP I-Disease
32 179 188 9714764 dependent JJ I-NP I-Disease
33 189 197 9714764 diabetes NN I-NP I-Disease
34 198 206 9714764 mellitus NN I-NP I-Disease
35 207 208 9714764 ( ( O O
36 208 212 9714764 IDDM NN B-NP B-Disease
37 212 213 9714764 ) ) O O
38 214 219 9714764 locus NN B-NP O
39 220 225 9714764 IDDM4 NN I-NP O
40 226 228 9714764 on IN B-PP O
41 229 239 9714764 chromosome NN B-NP O
42 240 245 9714764 11q13 NN I-NP O
43 245 246 9714764 . . O O

1 247 252 9714764 Based VBN B-PP O
2 253 255 9714764 on IN B-PP O
3 256 259 9714764 its PRP$ B-NP O
4 260 271 9714764 chromosomal JJ I-NP O
5 272 280 9714764 position NN I-NP O
6 280 281 9714764 , , O O
7 282 286 9714764 this DT B-NP O
8 287 291 9714764 gene NN I-NP O
9 292 294 9714764 is VBZ B-VP O
10 295 296 9714764 a DT B-NP O
11 297 306 9714764 candidate NN I-NP O
12 307 310 9714764 for IN B-PP O
13 311 321 9714764 conferring VBG B-VP O
14 322 336 9714764 susceptibility NN B-NP O
15 337 339 9714764 to TO B-PP O
16 340 348 9714764 diabetes NNS B-NP B-Disease
17 348 349 9714764 . . O O

1 350 353 9714764 The DT B-NP O
2 354 358 9714764 gene NN I-NP O
3 358 359 9714764 , , O O
4 360 366 9714764 termed VBN B-VP O
5 367 370 9714764 low JJ B-NP O
6 370 371 9714764 - HYPH I-NP O
7 371 378 9714764 density NN I-NP O
8 379 390 9714764 lipoprotein NN I-NP O
9 391 399 9714764 receptor NN I-NP O
10 400 407 9714764 related JJ I-NP O
11 408 415 9714764 protein NN I-NP O
12 416 417 9714764 5 CD I-NP O
13 418 419 9714764 ( ( O O
14 419 423 9714764 LRP5 NN B-NP O
15 423 424 9714764 ) ) O O
16 424 425 9714764 , , O O
17 426 433 9714764 encodes VBZ B-VP O
18 434 435 9714764 a DT B-NP O
19 436 443 9714764 protein NN I-NP O
20 444 446 9714764 of IN B-PP O
21 447 451 9714764 1615 CD B-NP O
22 452 457 9714764 amino NN I-NP O
23 458 463 9714764 acids NNS I-NP O
24 464 468 9714764 that WDT B-NP O
25 469 477 9714764 contains VBZ B-VP O
26 478 487 9714764 conserved VBN B-NP O
27 488 495 9714764 modules NNS I-NP O
28 496 501 9714764 which WDT B-NP O
29 502 505 9714764 are VBP B-VP O
30 506 520 9714764 characteristic JJ B-ADJP O
31 521 523 9714764 of IN B-PP O
32 524 527 9714764 the DT B-NP O
33 528 531 9714764 low JJ I-NP O
34 531 532 9714764 - HYPH I-NP O
35 532 539 9714764 density NN I-NP O
36 540 551 9714764 lipoprotein NN I-NP O
37 552 553 9714764 ( ( O O
38 553 556 9714764 LDL NN B-NP O
39 556 557 9714764 ) ) O O
40 558 566 9714764 receptor NN B-NP O
41 567 573 9714764 family NN I-NP O
42 573 574 9714764 . . O O

1 575 580 9714764 These DT B-NP O
2 581 588 9714764 modules NNS I-NP O
3 589 596 9714764 include VBP B-VP O
4 597 598 9714764 a DT B-NP O
5 599 607 9714764 putative JJ I-NP O
6 608 614 9714764 signal NN I-NP O
7 615 622 9714764 peptide NN I-NP O
8 623 626 9714764 for IN B-PP O
9 627 634 9714764 protein NN B-NP O
10 635 641 9714764 export NN I-NP O
11 641 642 9714764 , , O O
12 643 647 9714764 four CD B-NP O
13 648 657 9714764 epidermal JJ I-NP O
14 658 664 9714764 growth NN I-NP O
15 665 671 9714764 factor NN I-NP O
16 672 673 9714764 ( ( O O
17 673 676 9714764 EGF NN B-NP O
18 676 677 9714764 ) ) O O
19 678 685 9714764 repeats NNS B-NP O
20 686 690 9714764 with IN B-PP O
21 691 701 9714764 associated VBN B-NP O
22 702 708 9714764 spacer NN I-NP O
23 709 716 9714764 domains NNS I-NP O
24 716 717 9714764 , , O O
25 718 723 9714764 three CD B-NP O
26 724 727 9714764 LDL NN I-NP O
27 727 728 9714764 - HYPH I-NP O
28 728 736 9714764 receptor NN I-NP O
29 737 738 9714764 ( ( O O
30 738 742 9714764 LDLR NN B-NP O
31 742 743 9714764 ) ) O O
32 744 751 9714764 repeats NNS B-NP O
33 751 752 9714764 , , O O
34 753 754 9714764 a DT B-NP O
35 755 761 9714764 single JJ I-NP O
36 762 775 9714764 transmembrane NN I-NP O
37 776 784 9714764 spanning VBG I-NP O
38 785 791 9714764 domain NN I-NP O
39 791 792 9714764 , , O O
40 793 796 9714764 and CC O O
41 797 798 9714764 a DT B-NP O
42 799 810 9714764 cytoplasmic JJ I-NP O
43 811 817 9714764 domain NN I-NP O
44 817 818 9714764 . . O O

1 819 822 9714764 The DT B-NP O
2 823 830 9714764 encoded VBN I-NP O
3 831 838 9714764 protein NN I-NP O
4 839 842 9714764 has VBZ B-VP O
5 843 844 9714764 a DT B-NP O
6 845 851 9714764 unique JJ I-NP O
7 852 864 9714764 organization NN I-NP O
8 865 867 9714764 of IN B-PP O
9 868 871 9714764 EGF NN B-NP O
10 872 875 9714764 and CC I-NP O
11 876 880 9714764 LDLR NN I-NP O
12 881 888 9714764 repeats NNS I-NP O
13 888 889 9714764 ; : O O
14 890 899 9714764 therefore RB B-ADVP O
15 899 900 9714764 , , O O
16 901 905 9714764 LRP5 NN B-NP O
17 906 912 9714764 likely RB B-VP O
18 913 923 9714764 represents VBZ I-VP O
19 924 925 9714764 a DT B-NP O
20 926 929 9714764 new JJ I-NP O
21 930 938 9714764 category NN I-NP O
22 939 941 9714764 of IN B-PP O
23 942 945 9714764 the DT B-NP O
24 946 950 9714764 LDLR NN I-NP O
25 951 957 9714764 family NN I-NP O
26 957 958 9714764 . . O O

1 959 963 9714764 Both CC O O
2 964 969 9714764 human JJ O O
3 970 973 9714764 and CC O O
4 974 979 9714764 mouse NN B-NP O
5 980 984 9714764 LRP5 NN I-NP O
6 985 990 9714764 cDNAs NNS I-NP O
7 991 995 9714764 have VBP B-VP O
8 996 1000 9714764 been VBN I-VP O
9 1001 1009 9714764 isolated VBN I-VP O
10 1010 1013 9714764 and CC O O
11 1014 1017 9714764 the DT B-NP O
12 1018 1025 9714764 encoded VBN I-NP O
13 1026 1032 9714764 mature JJ I-NP O
14 1033 1041 9714764 proteins NNS I-NP O
15 1042 1045 9714764 are VBP B-VP O
16 1046 1049 9714764 95% CD B-NP O
17 1050 1059 9714764 identical JJ I-NP O
18 1059 1060 9714764 , , O O
19 1061 1071 9714764 indicating VBG B-VP O
20 1072 1073 9714764 a DT B-NP O
21 1074 1078 9714764 high JJ I-NP O
22 1079 1085 9714764 degree NN I-NP O
23 1086 1088 9714764 of IN B-PP O
24 1089 1101 9714764 evolutionary JJ B-NP O
25 1102 1114 9714764 conservation NN I-NP O
26 1114 1115 9714764 . . O O
27 1115 1116 9714764 . . O O

1 0 0 9988281 -DOCSTART- -X- -X- O

1 0 12 9988281 Localization NN B-NP O
2 13 15 9988281 of IN B-PP O
3 16 21 9988281 human JJ B-NP O
4 22 27 9988281 BRCA1 NN I-NP O
5 28 31 9988281 and CC O O
6 32 35 9988281 its PRP$ B-NP O
7 36 40 9988281 loss NN I-NP O
8 41 43 9988281 in IN B-PP O
9 44 48 9988281 high JJ B-NP O
10 48 49 9988281 - HYPH I-NP O
11 49 54 9988281 grade NN I-NP O
12 54 55 9988281 , , O O
13 56 59 9988281 non AFX O B-Disease
14 59 60 9988281 - HYPH O I-Disease
15 60 69 9988281 inherited VBN B-NP I-Disease
16 70 76 9988281 breast NN I-NP I-Disease
17 77 87 9988281 carcinomas NNS I-NP I-Disease
18 87 88 9988281 . . O O
19 89 97 9988281 Although IN B-SBAR O
20 98 101 9988281 the DT B-NP O
21 102 106 9988281 link NN I-NP O
22 107 114 9988281 between IN B-PP O
23 115 118 9988281 the DT B-NP O
24 119 124 9988281 BRCA1 NN I-NP O
25 125 131 9988281 tumour NN I-NP B-Disease
26 131 132 9988281 - HYPH B-NP O
27 132 142 9988281 suppressor NN I-NP O
28 143 147 9988281 gene NN I-NP O
29 148 151 9988281 and CC O O
30 152 162 9988281 hereditary JJ B-NP B-Disease
31 163 169 9988281 breast NN I-NP I-Disease
32 170 173 9988281 and CC O I-Disease
33 174 181 9988281 ovarian JJ B-NP I-Disease
34 182 188 9988281 cancer NN I-NP I-Disease
35 189 191 9988281 is VBZ B-VP O
36 192 203 9988281 established VBN I-VP O
37 203 204 9988281 , , O O
38 205 208 9988281 the DT B-NP O
39 209 213 9988281 role NN I-NP O
40 213 214 9988281 , , O O
41 215 217 9988281 if IN B-SBAR O
42 218 221 9988281 any DT B-NP O
43 221 222 9988281 , , O O
44 223 225 9988281 of IN B-PP O
45 226 231 9988281 BRCA1 NN B-NP O
46 232 234 9988281 in IN B-PP O
47 235 238 9988281 non AFX B-NP B-Disease
48 238 239 9988281 - HYPH I-NP I-Disease
49 239 247 9988281 familial JJ I-NP I-Disease
50 248 255 9988281 cancers NNS I-NP I-Disease
51 256 258 9988281 is VBZ B-VP O
52 259 266 9988281 unclear JJ B-ADJP O
53 266 267 9988281 . . O O

1 268 273 9988281 BRCA1 NN B-NP O
2 274 283 9988281 mutations NNS I-NP O
3 284 287 9988281 are VBP B-VP O
4 288 292 9988281 rare JJ B-ADJP O
5 293 295 9988281 in IN B-PP O
6 296 304 9988281 sporadic JJ B-NP B-Disease
7 305 312 9988281 cancers NNS I-NP I-Disease
8 312 313 9988281 , , O O
9 314 317 9988281 but CC O O
10 318 322 9988281 loss NN B-NP O
11 323 325 9988281 of IN B-PP O
12 326 331 9988281 BRCA1 NN B-NP O
13 332 341 9988281 resulting VBG B-VP O
14 342 346 9988281 from IN B-PP O
15 347 354 9988281 reduced VBN B-NP O
16 355 365 9988281 expression NN I-NP O
17 366 368 9988281 or CC O O
18 369 378 9988281 incorrect JJ B-NP O
19 379 390 9988281 subcellular JJ I-NP O
20 391 403 9988281 localization NN I-NP O
21 404 406 9988281 is VBZ B-VP O
22 407 417 9988281 postulated VBN I-VP O
23 418 420 9988281 to TO I-VP O
24 421 423 9988281 be VB I-VP O
25 424 433 9988281 important JJ B-ADJP O
26 434 436 9988281 in IN B-PP O
27 437 440 9988281 non AFX B-NP B-Disease
28 440 441 9988281 - HYPH I-NP I-Disease
29 441 449 9988281 familial JJ I-NP I-Disease
30 450 456 9988281 breast NN I-NP I-Disease
31 457 460 9988281 and CC O I-Disease
32 461 468 9988281 ovarian JJ B-NP I-Disease
33 469 476 9988281 cancers NNS I-NP I-Disease
34 476 477 9988281 . . O O

1 478 488 9988281 Epigenetic JJ B-NP O
2 489 493 9988281 loss NN I-NP O
3 493 494 9988281 , , O O
4 495 502 9988281 however RB B-ADVP O
5 502 503 9988281 , , O O
6 504 507 9988281 has VBZ B-VP O
7 508 511 9988281 not RB I-VP O
8 512 520 9988281 received VBN I-VP O
9 521 528 9988281 general JJ B-NP O
10 529 539 9988281 acceptance NN I-NP O
11 540 543 9988281 due JJ B-ADJP O
12 544 546 9988281 to TO B-VP O
13 547 558 9988281 controversy VB I-VP O
14 559 568 9988281 regarding VBG I-VP O
15 569 572 9988281 the DT B-NP O
16 573 584 9988281 subcellular JJ I-NP O
17 585 597 9988281 localization NN I-NP O
18 598 600 9988281 of IN B-PP O
19 601 606 9988281 BRCA1 NN B-NP O
20 607 615 9988281 proteins NNS I-NP O
21 615 616 9988281 , , O O
22 617 624 9988281 reports NNS B-NP O
23 625 627 9988281 of IN B-PP O
24 628 633 9988281 which WDT B-NP O
25 634 638 9988281 have VBP B-VP O
26 639 645 9988281 ranged VBN I-VP O
27 646 650 9988281 from IN B-PP O
28 651 662 9988281 exclusively RB B-ADJP O
29 663 670 9988281 nuclear JJ I-ADJP O
30 670 671 9988281 , , O O
31 672 674 9988281 to TO B-PP O
32 675 688 9988281 conditionally RB B-NP O
33 689 696 9988281 nuclear JJ I-NP O
34 696 697 9988281 , , O O
35 698 700 9988281 to TO B-PP O
36 701 704 9988281 the DT B-NP O
37 705 707 9988281 ER NN I-NP O
38 707 708 9988281 / SYM B-NP O
39 708 713 9988281 golgi NN I-NP O
40 713 714 9988281 , , O O
41 715 717 9988281 to TO B-PP O
42 718 729 9988281 cytoplasmic JJ B-NP O
43 730 743 9988281 invaginations NNS I-NP O
44 744 748 9988281 into IN B-PP O
45 749 752 9988281 the DT B-NP O
46 753 760 9988281 nucleus NN I-NP O
47 760 761 9988281 . . O O

1 762 764 9988281 In IN B-PP O
2 765 767 9988281 an DT B-NP O
3 768 775 9988281 attempt NN I-NP O
4 776 778 9988281 to TO B-VP O
5 779 786 9988281 resolve VB I-VP O
6 787 791 9988281 this DT B-NP O
7 792 797 9988281 issue NN I-NP O
8 797 798 9988281 , , O O
9 799 801 9988281 we PRP B-NP O
10 802 806 9988281 have VBP B-VP O
11 807 822 9988281 comprehensively RB I-VP O
12 823 836 9988281 characterized VBN I-VP O
13 837 839 9988281 19 CD B-NP O
14 840 844 9988281 anti AFX B-NP O
15 844 845 9988281 - HYPH I-NP O
16 845 850 9988281 BRCA1 NN I-NP O
17 851 861 9988281 antibodies NNS I-NP O
18 861 862 9988281 . . O O

1 863 868 9988281 These DT B-NP O
2 869 877 9988281 reagents NNS I-NP O
3 878 884 9988281 detect VBP B-VP O
4 885 886 9988281 a DT B-NP O
5 887 890 9988281 220 CD I-NP O
6 890 891 9988281 - HYPH I-NP O
7 891 893 9988281 kD NN I-NP O
8 894 901 9988281 protein NN I-NP O
9 902 911 9988281 localized VBN B-VP O
10 912 914 9988281 in IN B-PP O
11 915 923 9988281 discrete JJ B-NP O
12 924 931 9988281 nuclear JJ I-NP O
13 932 936 9988281 foci NNS I-NP O
14 937 939 9988281 in IN B-PP O
15 940 943 9988281 all DT B-NP O
16 944 954 9988281 epithelial JJ I-NP O
17 955 959 9988281 cell NN I-NP O
18 960 965 9988281 lines NNS I-NP O
19 965 966 9988281 , , O O
20 967 976 9988281 including VBG B-PP O
21 977 982 9988281 those DT B-NP O
22 983 990 9988281 derived VBN B-VP O
23 991 995 9988281 from IN B-PP O
24 996 1002 9988281 breast NN B-NP B-Disease
25 1003 1015 9988281 malignancies NNS I-NP I-Disease
26 1015 1016 9988281 . . O O

1 1017 1036 9988281 Immunohistochemical JJ B-NP O
2 1037 1045 9988281 staining NN I-NP O
3 1046 1048 9988281 of IN B-PP O
4 1049 1054 9988281 human JJ B-NP O
5 1055 1061 9988281 breast NN I-NP O
6 1062 1071 9988281 specimens NNS I-NP O
7 1072 1076 9988281 also RB B-ADVP O
8 1077 1085 9988281 revealed VBD B-VP O
9 1086 1091 9988281 BRCA1 NN B-NP O
10 1092 1099 9988281 nuclear JJ I-NP O
11 1100 1104 9988281 foci NNS I-NP O
12 1105 1107 9988281 in IN B-PP O
13 1108 1114 9988281 benign JJ B-NP O
14 1115 1121 9988281 breast NN I-NP O
15 1121 1122 9988281 , , O O
16 1123 1131 9988281 invasive JJ B-NP B-Disease
17 1132 1139 9988281 lobular JJ I-NP I-Disease
18 1140 1147 9988281 cancers NNS I-NP I-Disease
19 1148 1151 9988281 and CC O O
20 1152 1155 9988281 low JJ B-NP B-Disease
21 1155 1156 9988281 - HYPH I-NP I-Disease
22 1156 1161 9988281 grade NN I-NP I-Disease
23 1162 1168 9988281 ductal JJ I-NP I-Disease
24 1169 1179 9988281 carcinomas NNS I-NP I-Disease
25 1179 1180 9988281 . . O O

1 1181 1191 9988281 Conversely RB B-ADVP O
2 1191 1192 9988281 , , O O
3 1193 1198 9988281 BRCA1 NN B-NP O
4 1199 1209 9988281 expression NN I-NP O
5 1210 1213 9988281 was VBD B-VP O
6 1214 1221 9988281 reduced VBN I-VP O
7 1222 1224 9988281 or CC O O
8 1225 1237 9988281 undetectable JJ B-ADJP O
9 1238 1240 9988281 in IN B-PP O
10 1241 1244 9988281 the DT B-NP O
11 1245 1253 9988281 majority NN I-NP O
12 1254 1256 9988281 of IN B-PP O
13 1257 1261 9988281 high JJ B-NP O
14 1261 1262 9988281 - HYPH I-NP O
15 1262 1267 9988281 grade NN I-NP O
16 1267 1268 9988281 , , O O
17 1269 1275 9988281 ductal JJ B-NP B-Disease
18 1276 1286 9988281 carcinomas NNS I-NP I-Disease
19 1286 1287 9988281 , , O O
20 1288 1298 9988281 suggesting VBG B-VP O
21 1299 1303 9988281 that IN B-SBAR O
22 1304 1311 9988281 absence NN B-NP O
23 1312 1314 9988281 of IN B-PP O
24 1315 1320 9988281 BRCA1 NN B-NP O
25 1321 1324 9988281 may MD B-VP O
26 1325 1335 9988281 contribute VB I-VP O
27 1336 1338 9988281 to TO B-PP O
28 1339 1342 9988281 the DT B-NP O
29 1343 1355 9988281 pathogenesis NN I-NP O
30 1356 1358 9988281 of IN B-PP O
31 1359 1360 9988281 a DT B-NP O
32 1361 1372 9988281 significant JJ I-NP O
33 1373 1383 9988281 percentage NN I-NP O
34 1384 1386 9988281 of IN B-PP O
35 1387 1395 9988281 sporadic JJ B-NP B-Disease
36 1396 1402 9988281 breast NN I-NP I-Disease
37 1403 1410 9988281 cancers NNS I-NP I-Disease
38 1410 1411 9988281 . . O O
39 1411 1412 9988281 . . O O

1 0 0 9771706 -DOCSTART- -X- -X- O

1 0 1 9771706 A DT B-NP O
2 2 6 9771706 gene NN I-NP O
3 7 15 9771706 encoding VBG B-VP O
4 16 17 9771706 a DT B-NP O
5 18 31 9771706 transmembrane JJ I-NP O
6 32 39 9771706 protein NN I-NP O
7 40 42 9771706 is VBZ B-VP O
8 43 50 9771706 mutated VBN I-VP O
9 51 53 9771706 in IN B-PP O
10 54 62 9771706 patients NNS B-NP O
11 63 67 9771706 with IN B-PP O
12 68 76 9771706 diabetes NN B-NP B-Disease
13 77 85 9771706 mellitus NN I-NP I-Disease
14 86 89 9771706 and CC O O
15 90 95 9771706 optic JJ B-NP B-Disease
16 96 103 9771706 atrophy NN I-NP I-Disease
17 104 105 9771706 ( ( O O
18 105 112 9771706 Wolfram NN B-NP B-Disease
19 113 121 9771706 syndrome NN I-NP I-Disease
20 121 122 9771706 ) ) O O
21 122 123 9771706 . . O O
22 124 131 9771706 Wolfram NN B-NP B-Disease
23 132 140 9771706 syndrome NN I-NP I-Disease
24 141 142 9771706 ( ( O O
25 142 145 9771706 WFS NN B-NP B-Disease
26 145 146 9771706 ; : O O
27 147 151 9771706 OMIM NN B-NP O
28 152 158 9771706 222300 CD I-NP O
29 158 159 9771706 ) ) O O
30 160 162 9771706 is VBZ B-VP O
31 163 165 9771706 an DT B-NP O
32 166 175 9771706 autosomal JJ I-NP B-Disease
33 176 185 9771706 recessive JJ I-NP I-Disease
34 186 203 9771706 neurodegenerative JJ I-NP I-Disease
35 204 212 9771706 disorder NN I-NP I-Disease
36 213 220 9771706 defined VBN B-VP O
37 221 223 9771706 by IN B-PP O
38 224 229 9771706 young JJ B-NP O
39 229 230 9771706 - HYPH I-NP O
40 230 235 9771706 onset NN I-NP O
41 236 239 9771706 non AFX O O
42 239 240 9771706 - HYPH O O
43 240 246 9771706 immune JJ B-NP O
44 247 254 9771706 insulin NN I-NP B-Disease
45 254 255 9771706 - HYPH B-NP I-Disease
46 255 264 9771706 dependent JJ I-NP I-Disease
47 265 273 9771706 diabetes NNS I-NP I-Disease
48 274 282 9771706 mellitus NN I-NP I-Disease
49 283 286 9771706 and CC O O
50 287 298 9771706 progressive JJ B-NP O
51 299 304 9771706 optic JJ I-NP B-Disease
52 305 312 9771706 atrophy NN I-NP I-Disease
53 312 313 9771706 . . O O

1 314 321 9771706 Linkage NN B-NP O
2 322 324 9771706 to TO B-PP O
3 325 332 9771706 markers NNS B-NP O
4 333 335 9771706 on IN B-PP O
5 336 346 9771706 chromosome NN B-NP O
6 347 349 9771706 4p NN I-NP O
7 350 353 9771706 was VBD B-VP O
8 354 363 9771706 confirmed VBN I-VP O
9 364 366 9771706 in IN B-PP O
10 367 371 9771706 five CD B-NP O
11 372 380 9771706 families NNS I-NP O
12 380 381 9771706 . . O O

1 382 384 9771706 On IN B-PP O
2 385 388 9771706 the DT B-NP O
3 389 394 9771706 basis NN I-NP O
4 395 397 9771706 of IN B-PP O
5 398 405 9771706 meiotic JJ B-NP O
6 406 418 9771706 recombinants NNS I-NP O
7 419 422 9771706 and CC I-NP O
8 423 430 9771706 disease NN I-NP O
9 430 431 9771706 - HYPH B-NP O
10 431 441 9771706 associated VBN I-NP O
11 442 452 9771706 haplotypes NNS I-NP O
12 452 453 9771706 , , O O
13 454 457 9771706 the DT B-NP O
14 458 461 9771706 WFS NN I-NP B-Disease
15 462 466 9771706 gene NN I-NP O
16 467 470 9771706 was VBD B-VP O
17 471 480 9771706 localized JJ B-ADJP O
18 481 483 9771706 to TO B-PP O
19 484 485 9771706 a DT B-NP O
20 486 489 9771706 BAC NN I-NP O
21 489 490 9771706 / SYM B-NP O
22 490 492 9771706 P1 NN I-NP O
23 493 499 9771706 contig NN I-NP O
24 500 502 9771706 of IN B-PP O
25 503 507 9771706 less JJR B-NP O
26 508 512 9771706 than IN I-NP O
27 513 516 9771706 250 CD I-NP O
28 517 519 9771706 kb NN I-NP O
29 519 520 9771706 . . O O

1 521 530 9771706 Mutations NNS B-NP O
2 531 533 9771706 in IN B-PP O
3 534 535 9771706 a DT B-NP O
4 536 541 9771706 novel JJ I-NP O
5 542 546 9771706 gene NN I-NP O
6 547 548 9771706 ( ( O O
7 548 552 9771706 WFS1 NN B-NP O
8 552 553 9771706 ) ) O O
9 554 562 9771706 encoding VBG B-VP O
10 563 564 9771706 a DT B-NP O
11 565 573 9771706 putative JJ I-NP O
12 574 587 9771706 transmembrane JJ I-NP O
13 588 595 9771706 protein NN I-NP O
14 596 600 9771706 were VBD B-VP O
15 601 606 9771706 found VBN I-VP O
16 607 609 9771706 in IN B-PP O
17 610 613 9771706 all DT B-NP O
18 614 622 9771706 affected VBN I-NP O
19 623 634 9771706 individuals NNS I-NP O
20 635 637 9771706 in IN B-PP O
21 638 641 9771706 six CD B-NP O
22 642 645 9771706 WFS NN I-NP B-Disease
23 646 654 9771706 families NNS I-NP O
24 654 655 9771706 , , O O
25 656 659 9771706 and CC O O
26 660 665 9771706 these DT B-NP O
27 666 675 9771706 mutations NNS I-NP O
28 676 680 9771706 were VBD B-VP O
29 681 691 9771706 associated VBN I-VP O
30 692 696 9771706 with IN B-PP O
31 697 700 9771706 the DT B-NP O
32 701 708 9771706 disease NN I-NP O
33 709 718 9771706 phenotype NN I-NP O
34 718 719 9771706 . . O O

1 720 724 9771706 WFS1 NN B-NP O
2 725 732 9771706 appears VBZ B-VP O
3 733 735 9771706 to TO I-VP O
4 736 744 9771706 function VB I-VP O
5 745 747 9771706 in IN B-PP O
6 748 756 9771706 survival NN B-NP O
7 757 759 9771706 of IN B-PP O
8 760 765 9771706 islet NN B-NP O
9 766 770 9771706 beta SYM B-NP O
10 770 771 9771706 - HYPH B-NP O
11 771 776 9771706 cells NNS I-NP O
12 777 780 9771706 and CC I-NP O
13 781 788 9771706 neurons NNS I-NP O
14 788 789 9771706 . . O O
15 789 790 9771706 . . O O

1 0 0 9371490 -DOCSTART- -X- -X- O

1 0 8 9371490 Frequent JJ B-NP O
2 9 21 9371490 inactivation NN I-NP O
3 22 24 9371490 of IN B-PP O
4 25 29 9371490 PTEN NN B-NP O
5 29 30 9371490 / SYM B-VP O
6 30 35 9371490 MMAC1 NN B-NP O
7 36 38 9371490 in IN B-PP O
8 39 46 9371490 primary JJ B-NP O
9 47 55 9371490 prostate NN I-NP B-Disease
10 56 62 9371490 cancer NN I-NP I-Disease
11 62 63 9371490 . . O O
12 64 72 9371490 Sporadic JJ B-NP B-Disease
13 73 81 9371490 prostate NN I-NP I-Disease
14 82 91 9371490 carcinoma NN I-NP I-Disease
15 92 94 9371490 is VBZ B-VP O
16 95 98 9371490 the DT B-NP O
17 99 103 9371490 most RBS I-NP O
18 104 110 9371490 common JJ I-NP O
19 111 115 9371490 male JJ I-NP B-Disease
20 116 122 9371490 cancer NN I-NP I-Disease
21 123 125 9371490 in IN B-PP O
22 126 129 9371490 the DT B-NP O
23 130 137 9371490 Western JJ I-NP O
24 138 143 9371490 world NN I-NP O
25 143 144 9371490 , , O O
26 145 148 9371490 yet RB O O
27 149 153 9371490 many JJ B-NP O
28 154 156 9371490 of IN B-PP O
29 157 160 9371490 the DT B-NP O
30 161 166 9371490 major JJ I-NP O
31 167 174 9371490 genetic JJ I-NP O
32 175 181 9371490 events NNS I-NP O
33 182 190 9371490 involved VBN B-VP O
34 191 193 9371490 in IN B-PP O
35 194 197 9371490 the DT B-NP O
36 198 209 9371490 progression NN I-NP O
37 210 212 9371490 of IN B-PP O
38 213 217 9371490 this DT B-NP O
39 218 223 9371490 often RB I-NP O
40 224 229 9371490 fatal JJ I-NP O
41 230 236 9371490 cancer NN I-NP B-Disease
42 237 243 9371490 remain VBP B-VP O
43 244 246 9371490 to TO I-VP O
44 247 249 9371490 be VB I-VP O
45 250 260 9371490 elucidated VBN I-VP O
46 260 261 9371490 . . O O

1 262 270 9371490 Numerous JJ B-NP O
2 271 282 9371490 cytogenetic JJ I-NP O
3 283 286 9371490 and CC I-NP O
4 287 297 9371490 allelotype NN I-NP O
5 298 305 9371490 studies NNS I-NP O
6 306 310 9371490 have VBP B-VP O
7 311 319 9371490 reported VBN I-VP O
8 320 328 9371490 frequent JJ B-NP O
9 329 333 9371490 loss NN I-NP O
10 334 336 9371490 of IN B-PP O
11 337 351 9371490 heterozygosity NN B-NP O
12 352 354 9371490 on IN B-PP O
13 355 366 9371490 chromosomal JJ B-NP O
14 367 370 9371490 arm NN I-NP O
15 371 374 9371490 10q NN I-NP O
16 375 377 9371490 in IN B-PP O
17 378 386 9371490 sporadic JJ B-NP B-Disease
18 387 395 9371490 prostate NN I-NP I-Disease
19 396 402 9371490 cancer NN I-NP I-Disease
20 402 403 9371490 . . O O

1 404 412 9371490 Deletion NN B-NP O
2 413 420 9371490 mapping NN I-NP O
3 421 428 9371490 studies NNS I-NP O
4 429 433 9371490 have VBP B-VP O
5 434 447 9371490 unambiguously RB I-VP O
6 448 458 9371490 identified VBN I-VP O
7 459 460 9371490 a DT B-NP O
8 461 467 9371490 region NN I-NP O
9 468 470 9371490 of IN B-PP O
10 471 481 9371490 chromosome NN B-NP O
11 482 487 9371490 10q23 CD I-NP O
12 488 490 9371490 to TO B-VP O
13 491 493 9371490 be VB I-VP O
14 494 497 9371490 the DT B-NP O
15 498 505 9371490 minimal JJ I-NP O
16 506 510 9371490 area NN I-NP O
17 511 513 9371490 of IN B-PP O
18 514 518 9371490 loss NN B-NP O
19 518 519 9371490 . . O O

1 520 521 9371490 A DT B-NP O
2 522 525 9371490 new JJ I-NP O
3 526 531 9371490 tumor NN I-NP B-Disease
4 532 542 9371490 suppressor NN I-NP O
5 543 547 9371490 gene NN I-NP O
6 547 548 9371490 , , O O
7 549 553 9371490 PTEN NN B-NP O
8 553 554 9371490 / SYM B-NP O
9 554 559 9371490 MMAC1 NN I-NP O
10 559 560 9371490 , , O O
11 561 564 9371490 was VBD B-VP O
12 565 573 9371490 isolated VBN I-VP O
13 574 582 9371490 recently RB B-ADVP O
14 583 585 9371490 at IN B-PP O
15 586 590 9371490 this DT B-NP O
16 591 597 9371490 region NN I-NP O
17 598 600 9371490 of IN B-PP O
18 601 611 9371490 chromosome NN B-NP O
19 612 617 9371490 10q23 CD I-NP O
20 618 621 9371490 and CC O O
21 622 627 9371490 found VBN B-VP O
22 628 630 9371490 to TO I-VP O
23 631 633 9371490 be VB I-VP O
24 634 645 9371490 inactivated VBN I-VP O
25 646 648 9371490 by IN B-PP O
26 649 657 9371490 mutation NN B-NP O
27 658 660 9371490 in IN B-PP O
28 661 666 9371490 three CD B-NP O
29 667 675 9371490 prostate NN I-NP B-Disease
30 676 682 9371490 cancer NN I-NP I-Disease
31 683 687 9371490 cell NN I-NP O
32 688 693 9371490 lines NNS I-NP O
33 693 694 9371490 . . O O

1 695 697 9371490 We PRP B-NP O
2 698 706 9371490 screened VBD B-VP O
3 707 709 9371490 80 CD B-NP O
4 710 718 9371490 prostate NN I-NP B-Disease
5 719 725 9371490 tumors NNS I-NP I-Disease
6 726 728 9371490 by IN B-PP O
7 729 743 9371490 microsatellite NN B-NP O
8 744 752 9371490 analysis NN I-NP O
9 753 756 9371490 and CC O O
10 757 762 9371490 found VBN B-VP O
11 763 773 9371490 chromosome NN B-NP O
12 774 779 9371490 10q23 CD I-NP O
13 780 782 9371490 to TO B-VP O
14 783 785 9371490 be VB I-VP O
15 786 793 9371490 deleted VBN I-VP O
16 794 796 9371490 in IN B-PP O
17 797 799 9371490 23 CD B-NP O
18 800 805 9371490 cases NNS I-NP O
19 805 806 9371490 . . O O

1 807 809 9371490 We PRP B-NP O
2 810 814 9371490 then RB B-ADVP O
3 815 824 9371490 proceeded VBD B-VP O
4 825 829 9371490 with IN B-PP O
5 830 838 9371490 sequence NN B-NP O
6 839 847 9371490 analysis NN I-NP O
7 848 850 9371490 of IN B-PP O
8 851 854 9371490 the DT B-NP O
9 855 861 9371490 entire JJ I-NP O
10 862 866 9371490 PTEN NN I-NP O
11 866 867 9371490 / SYM B-NP O
12 867 872 9371490 MMAC1 NN I-NP O
13 873 879 9371490 coding NN I-NP O
14 880 886 9371490 region NN I-NP O
15 887 890 9371490 and CC O O
16 891 897 9371490 tested VBN B-VP O
17 898 901 9371490 for IN B-PP O
18 902 912 9371490 homozygous JJ B-NP O
19 913 921 9371490 deletion NN I-NP O
20 922 926 9371490 with IN B-PP O
21 927 930 9371490 new JJ B-NP O
22 931 941 9371490 intragenic JJ I-NP O
23 942 949 9371490 markers NNS I-NP O
24 950 952 9371490 in IN B-PP O
25 953 958 9371490 these DT B-NP O
26 959 961 9371490 23 CD I-NP O
27 962 967 9371490 cases NNS I-NP O
28 968 972 9371490 with IN B-PP O
29 973 978 9371490 10q23 CD B-NP O
30 979 983 9371490 loss NN I-NP O
31 984 986 9371490 of IN B-PP O
32 987 1001 9371490 heterozygosity NN B-NP O
33 1001 1002 9371490 . . O O

1 1003 1006 9371490 The DT B-NP O
2 1007 1021 9371490 identification NN I-NP O
3 1022 1024 9371490 of IN B-PP O
4 1025 1028 9371490 the DT B-NP O
5 1029 1035 9371490 second JJ I-NP O
6 1036 1046 9371490 mutational JJ I-NP O
7 1047 1052 9371490 event NN I-NP O
8 1053 1055 9371490 in IN B-PP O
9 1056 1058 9371490 10 CD B-NP O
10 1059 1060 9371490 ( ( O O
11 1060 1063 9371490 43% CD B-NP O
12 1063 1064 9371490 ) ) O O
13 1065 1071 9371490 tumors NNS B-NP B-Disease
14 1072 1083 9371490 establishes VBZ B-VP O
15 1084 1088 9371490 PTEN NN B-NP O
16 1088 1089 9371490 / SYM B-NP O
17 1089 1094 9371490 MMAC1 NN I-NP O
18 1095 1097 9371490 as IN B-PP O
19 1098 1099 9371490 a DT B-NP O
20 1100 1104 9371490 main JJ I-NP O
21 1105 1117 9371490 inactivation NN I-NP O
22 1118 1124 9371490 target NN I-NP O
23 1125 1127 9371490 of IN B-PP O
24 1128 1131 9371490 10q NN B-NP O
25 1132 1136 9371490 loss NN I-NP O
26 1137 1139 9371490 in IN B-PP O
27 1140 1148 9371490 sporadic JJ B-NP B-Disease
28 1149 1157 9371490 prostate NN I-NP I-Disease
29 1158 1164 9371490 cancer NN I-NP I-Disease
30 1164 1165 9371490 . . O O
31 1165 1166 9371490 . . O O

1 0 0 9425228 -DOCSTART- -X- -X- O

1 0 10 9425228 Prevalence NN B-NP O
2 11 13 9425228 of IN B-PP O
3 14 17 9425228 p16 NN B-NP O
4 18 21 9425228 and CC I-NP O
5 22 26 9425228 CDK4 NN I-NP O
6 27 35 9425228 germline NN I-NP O
7 36 45 9425228 mutations NNS I-NP O
8 46 48 9425228 in IN B-PP O
9 49 51 9425228 48 CD B-NP O
10 52 60 9425228 melanoma NN I-NP B-Disease
11 60 61 9425228 - HYPH B-NP O
12 61 66 9425228 prone JJ I-NP O
13 67 75 9425228 families NNS I-NP O
14 76 78 9425228 in IN B-PP O
15 79 85 9425228 France NNP B-NP O
16 85 86 9425228 . . O O

1 87 90 9425228 The DT B-NP O
2 91 97 9425228 French NNP I-NP O
3 98 106 9425228 Familial NNP I-NP B-Disease
4 107 115 9425228 Melanoma NNP I-NP I-Disease
5 116 121 9425228 Study NNP I-NP O
6 122 127 9425228 Group NNP I-NP O
7 127 128 9425228 . . I-NP O
8 129 137 9425228 Germline NNP I-NP O
9 138 147 9425228 mutations NNS I-NP O
10 148 150 9425228 in IN B-PP O
11 151 154 9425228 the DT B-NP O
12 155 158 9425228 p16 NN I-NP O
13 159 162 9425228 and CC I-NP O
14 163 167 9425228 CDK4 NN I-NP O
15 168 173 9425228 genes NNS I-NP O
16 174 178 9425228 have VBP B-VP O
17 179 183 9425228 been VBN I-VP O
18 184 192 9425228 reported VBN I-VP O
19 193 195 9425228 in IN B-PP O
20 196 197 9425228 a DT B-NP O
21 198 204 9425228 subset NN I-NP O
22 205 207 9425228 of IN B-PP O
23 208 216 9425228 melanoma NN B-NP B-Disease
24 217 226 9425228 pedigrees NNS I-NP O
25 226 227 9425228 , , O O
26 228 231 9425228 but CC O O
27 232 237 9425228 their PRP$ B-NP O
28 238 248 9425228 prevalence NN I-NP O
29 249 251 9425228 is VBZ B-VP O
30 252 255 9425228 not RB I-VP O
31 256 260 9425228 well RB I-VP O
32 261 266 9425228 known VBN I-VP O
33 266 267 9425228 . . O O

1 268 270 9425228 We PRP B-NP O
2 271 279 9425228 searched VBD B-VP O
3 280 283 9425228 for IN B-PP O
4 284 288 9425228 such JJ B-NP O
5 289 297 9425228 germline NN I-NP O
6 298 307 9425228 mutations NNS I-NP O
7 308 310 9425228 in IN B-PP O
8 311 313 9425228 48 CD B-NP O
9 314 320 9425228 French JJ I-NP O
10 321 329 9425228 melanoma NN I-NP B-Disease
11 329 330 9425228 - HYPH I-NP O
12 330 335 9425228 prone JJ I-NP O
13 336 344 9425228 families NNS I-NP O
14 345 353 9425228 selected VBN B-VP O
15 354 363 9425228 according VBG B-PP O
16 364 366 9425228 to TO B-PP O
17 367 370 9425228 two CD B-NP O
18 371 376 9425228 major JJ I-NP O
19 377 385 9425228 criteria NNS I-NP O
20 387 395 9425228 families NNS I-NP O
21 396 400 9425228 with IN B-PP O
22 401 403 9425228 at IN B-NP O
23 404 409 9425228 least JJS I-NP O
24 410 415 9425228 three CD I-NP O
25 416 424 9425228 affected VBN I-NP O
26 425 432 9425228 members NNS I-NP O
27 433 434 9425228 ( ( O O
28 434 435 9425228 n NN B-NP O
29 436 437 9425228 = SYM B-VP O
30 438 440 9425228 20 CD B-NP O
31 440 441 9425228 ) ) O O
32 442 444 9425228 or CC O O
33 445 453 9425228 families NNS B-NP O
34 454 458 9425228 with IN B-PP O
35 459 462 9425228 two CD B-NP O
36 463 471 9425228 affected VBN I-NP O
37 472 479 9425228 members NNS I-NP O
38 479 480 9425228 , , O O
39 481 484 9425228 one CD B-NP O
40 485 487 9425228 of IN B-PP O
41 488 492 9425228 them PRP B-NP O
42 493 501 9425228 affected VBD B-VP O
43 502 508 9425228 before IN B-PP O
44 509 512 9425228 the DT B-NP O
45 513 516 9425228 age NN I-NP O
46 517 519 9425228 of IN B-PP O
47 520 522 9425228 50 CD B-NP O
48 523 524 9425228 ( ( O O
49 524 525 9425228 n NN B-NP O
50 526 527 9425228 = SYM B-VP O
51 528 530 9425228 28 CD B-NP O
52 530 531 9425228 ) ) O O
53 531 532 9425228 , , O O
54 533 536 9425228 and CC O O
55 537 540 9425228 one CD B-NP O
56 541 551 9425228 additional JJ I-NP O
57 552 557 9425228 minor JJ I-NP O
58 558 567 9425228 criterion NN I-NP O
59 567 568 9425228 . . O O

1 569 576 9425228 Sixteen CD B-NP O
2 577 586 9425228 different JJ I-NP O
3 587 590 9425228 p16 NN I-NP O
4 591 599 9425228 germline NN I-NP O
5 600 609 9425228 mutations NNS I-NP O
6 610 614 9425228 were VBD B-VP O
7 615 620 9425228 found VBN I-VP O
8 621 623 9425228 in IN B-PP O
9 624 626 9425228 21 CD B-NP O
10 627 635 9425228 families NNS I-NP O
11 635 636 9425228 , , O O
12 637 642 9425228 while IN B-SBAR O
13 643 646 9425228 one CD B-NP O
14 647 655 9425228 germline NN I-NP O
15 656 664 9425228 mutation NN I-NP O
16 664 665 9425228 , , O O
17 666 674 9425228 Arg24His NN B-NP O
18 674 675 9425228 , , O O
19 676 679 9425228 was VBD B-VP O
20 680 688 9425228 detected VBN I-VP O
21 689 691 9425228 in IN B-PP O
22 692 695 9425228 the DT B-NP O
23 696 700 9425228 CDK4 NN I-NP O
24 701 705 9425228 gene NN I-NP O
25 705 706 9425228 . . O O

1 707 710 9425228 The DT B-NP O
2 711 720 9425228 frequency NN I-NP O
3 721 723 9425228 of IN B-PP O
4 724 727 9425228 p16 NN B-NP O
5 728 732 9425228 gene NN I-NP O
6 733 741 9425228 mutation NN I-NP O
7 742 744 9425228 in IN B-PP O
8 745 748 9425228 our PRP$ B-NP O
9 749 755 9425228 sample NN I-NP O
10 756 757 9425228 ( ( O O
11 757 760 9425228 44% NN B-NP O
12 760 761 9425228 ) ) O O
13 762 764 9425228 is VBZ B-VP O
14 765 770 9425228 among IN B-PP O
15 771 774 9425228 the DT B-NP O
16 775 782 9425228 highest JJS I-NP O
17 783 788 9425228 rates NNS I-NP O
18 789 792 9425228 yet RB B-VP O
19 793 801 9425228 reported VBN I-VP O
20 802 805 9425228 and CC O O
21 806 809 9425228 the DT B-NP O
22 810 814 9425228 CDK4 NN I-NP O
23 815 823 9425228 mutation NN I-NP O
24 824 826 9425228 is VBZ B-VP O
25 827 830 9425228 the DT B-NP O
26 831 837 9425228 second JJ I-NP O
27 838 846 9425228 mutation NN I-NP O
28 847 855 9425228 detected VBN B-VP O
29 856 858 9425228 in IN B-PP O
30 859 863 9425228 this DT B-NP O
31 864 868 9425228 gene NN I-NP O
32 869 878 9425228 worldwide RB B-ADVP O
33 878 879 9425228 . . O O

1 880 882 9425228 In IN B-PP O
2 883 890 9425228 summary NN B-NP O
3 890 891 9425228 , , O O
4 892 895 9425228 our PRP$ B-NP O
5 896 903 9425228 results NNS I-NP O
6 904 908 9425228 show VBP B-VP O
7 909 917 9425228 frequent JJ B-NP O
8 918 929 9425228 involvement NN I-NP O
9 930 932 9425228 of IN B-PP O
10 933 936 9425228 the DT B-NP O
11 937 940 9425228 p16 NN I-NP O
12 941 945 9425228 gene NN I-NP O
13 946 948 9425228 in IN B-PP O
14 949 957 9425228 familial JJ B-NP B-Disease
15 958 966 9425228 melanoma NN I-NP I-Disease
16 967 970 9425228 and CC O O
17 971 978 9425228 confirm VBP B-VP O
18 979 982 9425228 the DT B-NP O
19 983 987 9425228 role NN I-NP O
20 988 990 9425228 of IN B-PP O
21 991 994 9425228 the DT B-NP O
22 995 999 9425228 CDK4 NN I-NP O
23 1000 1004 9425228 gene NN I-NP O
24 1005 1007 9425228 as IN B-PP O
25 1008 1009 9425228 a DT B-NP O
26 1010 1018 9425228 melanoma NN I-NP B-Disease
27 1018 1019 9425228 - HYPH O O
28 1019 1031 9425228 predisposing VBG B-VP O
29 1032 1036 9425228 gene NN B-NP O
30 1036 1037 9425228 . . O O
31 1037 1038 9425228 . . O O

1 0 0 9450866 -DOCSTART- -X- -X- O

1 0 10 9450866 Piebaldism NN B-NP B-Disease
2 11 15 9450866 with IN B-PP O
3 16 24 9450866 deafness NN B-NP B-Disease
4 24 25 9450866 : : O O
5 26 35 9450866 molecular JJ B-NP O
6 36 44 9450866 evidence NN I-NP O
7 45 48 9450866 for IN B-PP O
8 49 51 9450866 an DT B-NP O
9 52 60 9450866 expanded VBN I-NP O
10 61 69 9450866 syndrome NN I-NP O
11 69 70 9450866 . . O O
12 71 73 9450866 In IN B-PP O
13 74 75 9450866 a DT B-NP O
14 76 81 9450866 South JJ I-NP O
15 82 89 9450866 African JJ I-NP O
16 90 94 9450866 girl NN I-NP O
17 95 97 9450866 of IN B-PP O
18 98 103 9450866 Xhosa NNP B-NP O
19 104 109 9450866 stock NN I-NP O
20 110 114 9450866 with IN B-PP O
21 115 121 9450866 severe JJ B-NP O
22 122 132 9450866 piebaldism NN I-NP B-Disease
23 133 136 9450866 and CC O O
24 137 145 9450866 profound JJ B-NP O
25 146 156 9450866 congenital JJ I-NP O
26 157 170 9450866 sensorineural JJ I-NP B-Disease
27 171 179 9450866 deafness NN I-NP I-Disease
28 180 182 9450866 we PRP B-NP O
29 183 193 9450866 identified VBD B-VP O
30 194 195 9450866 a DT B-NP O
31 196 201 9450866 novel JJ I-NP O
32 202 210 9450866 missense JJ I-NP O
33 211 223 9450866 substitution NN I-NP O
34 224 226 9450866 at IN B-PP O
35 227 228 9450866 a DT B-NP O
36 229 235 9450866 highly RB I-NP O
37 236 245 9450866 conserved VBN I-NP O
38 246 253 9450866 residue NN I-NP O
39 254 256 9450866 in IN B-PP O
40 257 260 9450866 the DT B-NP O
41 261 274 9450866 intracellular JJ I-NP O
42 275 281 9450866 kinase NN I-NP O
43 282 288 9450866 domain NN I-NP O
44 289 291 9450866 of IN B-PP O
45 292 295 9450866 the DT B-NP O
46 296 299 9450866 KIT NN I-NP O
47 300 305 9450866 proto AFX O O
48 305 306 9450866 - HYPH O O
49 306 314 9450866 oncogene NN B-NP O
50 314 315 9450866 , , O O
51 316 321 9450866 R796G NN B-NP O
52 321 322 9450866 . . O O

1 323 329 9450866 Though IN B-SBAR O
2 330 338 9450866 auditory JJ B-NP B-Disease
3 339 348 9450866 anomalies NNS I-NP I-Disease
4 349 353 9450866 have VBP B-VP O
5 354 358 9450866 been VBN I-VP O
6 359 367 9450866 observed VBN I-VP O
7 368 370 9450866 in IN B-PP O
8 371 375 9450866 mice NNS B-NP O
9 376 380 9450866 with IN B-PP O
10 381 389 9450866 dominant JJ B-NP O
11 390 395 9450866 white JJ I-NP O
12 396 404 9450866 spotting NN I-NP O
13 405 406 9450866 ( ( O O
14 406 407 9450866 W NN B-NP O
15 407 408 9450866 ) ) O O
16 409 412 9450866 due IN B-PP O
17 413 415 9450866 to TO B-PP O
18 416 419 9450866 KIT NN B-NP O
19 420 429 9450866 mutations NNS I-NP O
20 429 430 9450866 , , O O
21 431 439 9450866 deafness NN B-NP B-Disease
22 440 442 9450866 is VBZ B-VP O
23 443 446 9450866 not RB O O
24 447 454 9450866 typical JJ B-ADJP O
25 455 457 9450866 in IN B-PP O
26 458 463 9450866 human JJ B-NP O
27 464 474 9450866 piebaldism NN I-NP B-Disease
28 474 475 9450866 . . O O

1 476 480 9450866 Thus RB B-ADVP O
2 480 481 9450866 , , O O
3 482 485 9450866 the DT B-NP O
4 486 496 9450866 occurrence NN I-NP O
5 497 499 9450866 of IN B-PP O
6 500 513 9450866 sensorineural JJ B-NP B-Disease
7 514 522 9450866 deafness NN I-NP I-Disease
8 523 525 9450866 in IN B-PP O
9 526 530 9450866 this DT B-NP O
10 531 538 9450866 patient NN I-NP O
11 539 546 9450866 extends VBZ B-VP O
12 547 559 9450866 considerably RB B-ADVP O
13 560 563 9450866 the DT B-NP O
14 564 574 9450866 phenotypic JJ I-NP O
15 575 580 9450866 range NN I-NP O
16 581 583 9450866 of IN B-PP O
17 584 594 9450866 piebaldism NN B-NP B-Disease
18 595 598 9450866 due JJ B-ADJP O
19 599 601 9450866 to TO B-PP O
20 602 605 9450866 KIT NN B-NP O
21 606 610 9450866 gene NN I-NP O
22 611 619 9450866 mutation NN I-NP O
23 620 622 9450866 in IN B-PP O
24 623 629 9450866 humans NNS B-NP O
25 630 633 9450866 and CC O O
26 634 642 9450866 tightens VBZ B-VP O
27 643 646 9450866 the DT B-NP O
28 647 655 9450866 clinical JJ I-NP O
29 656 666 9450866 similarity NN I-NP O
30 667 674 9450866 between IN B-PP O
31 675 685 9450866 piebaldism NN B-NP B-Disease
32 686 689 9450866 and CC O O
33 690 693 9450866 the DT B-NP O
34 694 701 9450866 various JJ I-NP O
35 702 707 9450866 forms NNS I-NP O
36 708 710 9450866 of IN B-PP O
37 711 722 9450866 Waardenburg NNP B-NP B-Disease
38 723 731 9450866 syndrome NN I-NP I-Disease
39 731 732 9450866 . . O O
40 732 733 9450866 . . O O

1 0 0 9770531 -DOCSTART- -X- -X- O

1 0 4 9770531 Down RB B-ADVP O
2 4 5 9770531 - HYPH O O
3 5 15 9770531 regulation NN B-NP O
4 16 18 9770531 of IN B-PP O
5 19 32 9770531 transmembrane NN B-NP O
6 33 41 9770531 carbonic JJ I-NP O
7 42 52 9770531 anhydrases NNS I-NP O
8 53 55 9770531 in IN B-PP O
9 56 61 9770531 renal JJ B-NP B-Disease
10 62 66 9770531 cell NN I-NP I-Disease
11 67 76 9770531 carcinoma NN I-NP I-Disease
12 77 81 9770531 cell NN I-NP O
13 82 87 9770531 lines NNS I-NP O
14 88 90 9770531 by IN B-PP O
15 91 95 9770531 wild JJ B-NP O
16 95 96 9770531 - HYPH I-NP O
17 96 100 9770531 type NN I-NP O
18 101 104 9770531 von NN I-NP B-Disease
19 105 111 9770531 Hippel NNP I-NP I-Disease
20 111 112 9770531 - HYPH I-NP I-Disease
21 112 118 9770531 Lindau NNP I-NP I-Disease
22 119 129 9770531 transgenes NNS I-NP O
23 129 130 9770531 . . O O
24 131 133 9770531 To TO B-VP O
25 134 142 9770531 discover VB I-VP O
26 143 148 9770531 genes NNS B-NP O
27 149 157 9770531 involved VBN B-VP O
28 158 160 9770531 in IN B-PP O
29 161 164 9770531 von NNP B-NP B-Disease
30 165 171 9770531 Hippel NNP I-NP I-Disease
31 171 172 9770531 - HYPH I-NP I-Disease
32 172 178 9770531 Lindau NNP I-NP I-Disease
33 179 180 9770531 ( ( O O
34 180 183 9770531 VHL NNP B-NP B-Disease
35 183 184 9770531 ) ) O O
36 185 186 9770531 - HYPH B-NP O
37 186 194 9770531 mediated VBN I-NP O
38 195 209 9770531 carcinogenesis NN I-NP O
39 209 210 9770531 , , O O
40 211 213 9770531 we PRP B-NP O
41 214 218 9770531 used VBD B-VP O
42 219 224 9770531 renal JJ B-NP B-Disease
43 225 229 9770531 cell NN I-NP I-Disease
44 230 239 9770531 carcinoma NN I-NP I-Disease
45 240 244 9770531 cell NN I-NP O
46 245 250 9770531 lines NNS I-NP O
47 251 257 9770531 stably RB B-VP O
48 258 269 9770531 transfected VBN I-VP O
49 270 274 9770531 with IN B-PP O
50 275 279 9770531 wild JJ B-NP O
51 279 280 9770531 - HYPH I-NP O
52 280 284 9770531 type NN I-NP O
53 285 288 9770531 VHL NN I-NP O
54 288 289 9770531 - HYPH O O
55 289 299 9770531 expressing VBG B-VP O
56 300 310 9770531 transgenes NNS B-NP O
57 310 311 9770531 . . O O

1 312 317 9770531 Large JJ B-NP O
2 317 318 9770531 - HYPH I-NP O
3 318 323 9770531 scale NN I-NP O
4 324 327 9770531 RNA NN I-NP O
5 328 340 9770531 differential JJ I-NP O
6 341 348 9770531 display NN I-NP O
7 349 359 9770531 technology NN I-NP O
8 360 367 9770531 applied VBN B-VP O
9 368 370 9770531 to TO B-PP O
10 371 376 9770531 these DT B-NP O
11 377 381 9770531 cell NN I-NP O
12 382 387 9770531 lines NNS I-NP O
13 388 398 9770531 identified VBD B-VP O
14 399 406 9770531 several JJ B-NP O
15 407 421 9770531 differentially RB I-NP O
16 422 431 9770531 expressed VBN I-NP O
17 432 437 9770531 genes NNS I-NP O
18 437 438 9770531 , , O O
19 439 448 9770531 including VBG B-PP O
20 449 451 9770531 an DT B-NP O
21 452 457 9770531 alpha NN I-NP O
22 458 466 9770531 carbonic JJ I-NP O
23 467 476 9770531 anhydrase NN I-NP O
24 477 481 9770531 gene NN I-NP O
25 481 482 9770531 , , O O
26 483 489 9770531 termed VBN B-NP O
27 490 494 9770531 CA12 NN I-NP O
28 494 495 9770531 . . O O

1 496 499 9770531 The DT B-NP O
2 500 507 9770531 deduced VBN I-NP O
3 508 515 9770531 protein NN I-NP O
4 516 524 9770531 sequence NN I-NP O
5 525 528 9770531 was VBD B-VP O
6 529 539 9770531 classified VBN I-VP O
7 540 542 9770531 as IN B-PP O
8 543 544 9770531 a DT B-NP O
9 545 548 9770531 one CD I-NP O
10 548 549 9770531 - HYPH I-NP O
11 549 553 9770531 pass NN I-NP O
12 554 567 9770531 transmembrane JJ I-NP O
13 568 570 9770531 CA NN I-NP O
14 571 581 9770531 possessing VBG B-VP O
15 582 584 9770531 an DT B-NP O
16 585 595 9770531 apparently RB I-NP O
17 596 602 9770531 intact JJ I-NP O
18 603 612 9770531 catalytic JJ I-NP O
19 613 619 9770531 domain NN I-NP O
20 620 622 9770531 in IN B-PP O
21 623 626 9770531 the DT B-NP O
22 627 640 9770531 extracellular JJ I-NP O
23 641 643 9770531 CA NN I-NP O
24 644 650 9770531 module NN I-NP O
25 650 651 9770531 . . O O

1 652 664 9770531 Reintroduced VBN B-NP O
2 665 669 9770531 wild JJ I-NP O
3 669 670 9770531 - HYPH I-NP O
4 670 674 9770531 type NN I-NP O
5 675 678 9770531 VHL NN I-NP B-Disease
6 679 687 9770531 strongly RB B-ADVP O
7 688 697 9770531 inhibited VBD B-VP O
8 698 701 9770531 the DT B-NP O
9 702 716 9770531 overexpression NN I-NP O
10 717 719 9770531 of IN B-PP O
11 720 723 9770531 the DT B-NP O
12 724 728 9770531 CA12 NN I-NP O
13 729 733 9770531 gene NN I-NP O
14 734 736 9770531 in IN B-PP O
15 737 740 9770531 the DT B-NP O
16 741 749 9770531 parental JJ I-NP O
17 750 755 9770531 renal JJ I-NP B-Disease
18 756 760 9770531 cell NN I-NP I-Disease
19 761 770 9770531 carcinoma NN I-NP I-Disease
20 771 775 9770531 cell NN I-NP O
21 776 781 9770531 lines NNS I-NP O
22 781 782 9770531 . . O O

1 783 790 9770531 Similar JJ B-NP O
2 791 798 9770531 results NNS I-NP O
3 799 803 9770531 were VBD B-VP O
4 804 812 9770531 obtained VBN I-VP O
5 813 817 9770531 with IN B-PP O
6 818 821 9770531 CA9 NN B-NP O
7 821 822 9770531 , , O O
8 823 831 9770531 encoding VBG B-VP O
9 832 839 9770531 another DT B-NP O
10 840 853 9770531 transmembrane JJ I-NP O
11 854 856 9770531 CA NN I-NP O
12 857 861 9770531 with IN B-PP O
13 862 864 9770531 an DT B-NP O
14 865 871 9770531 intact JJ I-NP O
15 872 881 9770531 catalytic JJ I-NP O
16 882 888 9770531 domain NN I-NP O
17 888 889 9770531 . . O O

1 890 898 9770531 Although IN B-SBAR O
2 899 903 9770531 both DT B-NP O
3 904 911 9770531 domains NNS I-NP O
4 912 914 9770531 of IN B-PP O
5 915 918 9770531 the DT B-NP O
6 919 922 9770531 VHL NN I-NP B-Disease
7 923 930 9770531 protein NN I-NP O
8 931 941 9770531 contribute VBP B-VP O
9 942 944 9770531 to TO B-PP O
10 945 955 9770531 regulation NN B-NP O
11 956 958 9770531 of IN B-PP O
12 959 963 9770531 CA12 NN B-NP O
13 964 974 9770531 expression NN I-NP O
14 974 975 9770531 , , O O
15 976 979 9770531 the DT B-NP O
16 980 987 9770531 elongin NN I-NP O
17 988 995 9770531 binding NN I-NP O
18 996 1002 9770531 domain NN I-NP O
19 1003 1008 9770531 alone RB B-ADVP O
20 1009 1014 9770531 could MD B-VP O
21 1015 1026 9770531 effectively RB I-VP O
22 1027 1035 9770531 regulate VB I-VP O
23 1036 1039 9770531 CA9 NN B-NP O
24 1040 1050 9770531 expression NN I-NP O
25 1050 1051 9770531 . . O O

1 1052 1054 9770531 We PRP B-NP O
2 1055 1061 9770531 mapped VBD B-VP O
3 1062 1066 9770531 CA12 NN B-NP O
4 1067 1070 9770531 and CC I-NP O
5 1071 1074 9770531 CA9 NN I-NP O
6 1075 1079 9770531 loci NNS I-NP O
7 1080 1082 9770531 to TO B-PP O
8 1083 1093 9770531 chromosome NN B-NP O
9 1094 1099 9770531 bands NNS I-NP O
10 1100 1105 9770531 15q22 NN I-NP O
11 1106 1109 9770531 and CC I-NP O
12 1110 1115 9770531 17q21 NN I-NP O
13 1115 1116 9770531 . . O O

1 1117 1118 9770531 2 CD B-NP O
2 1119 1131 9770531 respectively RB I-NP O
3 1131 1132 9770531 , , O O
4 1133 1140 9770531 regions NNS B-NP O
5 1141 1146 9770531 prone JJ B-ADJP O
6 1147 1149 9770531 to TO B-PP O
7 1150 1163 9770531 amplification NN B-NP O
8 1164 1166 9770531 in IN B-PP O
9 1167 1171 9770531 some DT B-NP O
10 1172 1177 9770531 human JJ I-NP O
11 1178 1185 9770531 cancers NNS I-NP B-Disease
12 1185 1186 9770531 . . O O

1 1187 1197 9770531 Additional JJ B-NP O
2 1198 1209 9770531 experiments NNS I-NP O
3 1210 1213 9770531 are VBP B-VP O
4 1214 1220 9770531 needed VBN I-VP O
5 1221 1223 9770531 to TO B-VP O
6 1224 1230 9770531 define VB I-VP O
7 1231 1234 9770531 the DT B-NP O
8 1235 1239 9770531 role NN I-NP O
9 1240 1242 9770531 of IN B-PP O
10 1243 1245 9770531 CA NN B-NP O
11 1246 1248 9770531 IX CD I-NP O
12 1249 1252 9770531 and CC O O
13 1253 1255 9770531 CA NN B-NP O
14 1256 1259 9770531 XII NN I-NP O
15 1260 1267 9770531 enzymes NNS I-NP O
16 1268 1270 9770531 in IN B-PP O
17 1271 1274 9770531 the DT B-NP O
18 1275 1285 9770531 regulation NN I-NP O
19 1286 1288 9770531 of IN B-PP O
20 1289 1291 9770531 pH NN B-NP O
21 1292 1294 9770531 in IN B-PP O
22 1295 1298 9770531 the DT B-NP O
23 1299 1312 9770531 extracellular JJ I-NP O
24 1313 1329 9770531 microenvironment NN I-NP O
25 1330 1333 9770531 and CC O O
26 1334 1337 9770531 its PRP$ B-NP O
27 1338 1347 9770531 potential JJ I-NP O
28 1348 1354 9770531 impact NN I-NP O
29 1355 1357 9770531 on IN B-PP O
30 1358 1364 9770531 cancer NN B-NP B-Disease
31 1365 1369 9770531 cell NN I-NP O
32 1370 1376 9770531 growth NN I-NP O
33 1376 1377 9770531 . . O O

1 0 0 9774970 -DOCSTART- -X- -X- O

1 0 6 9774970 Stable JJ B-NP O
2 7 18 9774970 interaction NN I-NP O
3 19 26 9774970 between IN B-PP O
4 27 30 9774970 the DT B-NP O
5 31 39 9774970 products NNS I-NP O
6 40 42 9774970 of IN B-PP O
7 43 46 9774970 the DT B-NP O
8 47 52 9774970 BRCA1 NN I-NP O
9 53 56 9774970 and CC I-NP O
10 57 62 9774970 BRCA2 NN I-NP O
11 63 68 9774970 tumor NN I-NP B-Disease
12 69 79 9774970 suppressor NN I-NP O
13 80 85 9774970 genes NNS I-NP O
14 86 88 9774970 in IN B-PP O
15 89 96 9774970 mitotic JJ B-NP O
16 97 100 9774970 and CC I-NP O
17 101 108 9774970 meiotic JJ I-NP O
18 109 114 9774970 cells NNS I-NP O
19 114 115 9774970 . . O O
20 116 121 9774970 BRCA1 NN B-NP O
21 122 125 9774970 and CC I-NP O
22 126 131 9774970 BRCA2 NN I-NP O
23 132 139 9774970 account VBP B-VP O
24 140 143 9774970 for IN B-PP O
25 144 148 9774970 most JJS B-NP O
26 149 154 9774970 cases NNS I-NP O
27 155 157 9774970 of IN B-PP O
28 158 166 9774970 familial JJ B-NP O
29 166 167 9774970 , , I-NP O
30 168 173 9774970 early JJ I-NP O
31 174 179 9774970 onset NN I-NP O
32 180 186 9774970 breast NN I-NP B-Disease
33 187 190 9774970 and CC O I-Disease
34 190 191 9774970 / SYM B-NP I-Disease
35 191 193 9774970 or CC O I-Disease
36 194 201 9774970 ovarian JJ B-NP I-Disease
37 202 208 9774970 cancer NN I-NP I-Disease
38 209 212 9774970 and CC O O
39 213 219 9774970 encode VBP B-VP O
40 220 228 9774970 products NNS B-NP O
41 229 233 9774970 that IN B-SBAR O
42 234 238 9774970 each DT B-NP O
43 239 247 9774970 interact NN I-NP O
44 248 252 9774970 with IN B-PP O
45 253 259 9774970 hRAD51 NN B-NP O
46 259 260 9774970 . . O O

1 261 268 9774970 Results NNS B-NP O
2 269 278 9774970 presented VBN B-VP O
3 279 283 9774970 here RB B-ADVP O
4 284 288 9774970 show VBP B-VP O
5 289 293 9774970 that IN B-SBAR O
6 294 299 9774970 BRCA1 NN B-NP O
7 300 303 9774970 and CC I-NP O
8 304 309 9774970 BRCA2 NN I-NP O
9 310 317 9774970 coexist NN I-NP O
10 318 320 9774970 in IN B-PP O
11 321 322 9774970 a DT B-NP O
12 323 334 9774970 biochemical JJ I-NP O
13 335 342 9774970 complex NN I-NP O
14 343 346 9774970 and CC I-NP O
15 347 357 9774970 colocalize NN I-NP O
16 358 360 9774970 in IN B-PP O
17 361 371 9774970 subnuclear JJ B-NP O
18 372 376 9774970 foci NNS I-NP O
19 377 379 9774970 in IN B-PP O
20 380 387 9774970 somatic JJ B-NP O
21 388 393 9774970 cells NNS I-NP O
22 394 397 9774970 and CC B-PP O
23 398 400 9774970 on IN B-PP O
24 401 404 9774970 the DT B-NP O
25 405 410 9774970 axial JJ I-NP O
26 411 419 9774970 elements NNS I-NP O
27 420 422 9774970 of IN B-PP O
28 423 433 9774970 developing VBG B-VP O
29 434 446 9774970 synaptonemal JJ B-NP O
30 447 456 9774970 complexes NNS I-NP O
31 456 457 9774970 . . O O

1 458 462 9774970 Like IN B-PP O
2 463 468 9774970 BRCA1 NN B-NP O
3 469 472 9774970 and CC I-NP O
4 473 478 9774970 RAD51 NN I-NP O
5 478 479 9774970 , , O O
6 480 485 9774970 BRCA2 NN B-NP O
7 486 495 9774970 relocates VBZ B-VP O
8 496 498 9774970 to TO B-PP O
9 499 503 9774970 PCNA NN B-NP O
10 504 505 9774970 + SYM O O
11 506 517 9774970 replication NN B-NP O
12 518 523 9774970 sites NNS I-NP O
13 524 533 9774970 following VBG B-PP O
14 534 542 9774970 exposure NN B-NP O
15 543 545 9774970 of IN B-PP O
16 546 547 9774970 S NN B-NP O
17 548 553 9774970 phase NN I-NP O
18 554 559 9774970 cells NNS I-NP O
19 560 562 9774970 to TO B-PP O
20 563 574 9774970 hydroxyurea NN B-NP O
21 575 577 9774970 or CC I-NP O
22 578 580 9774970 UV NN I-NP O
23 581 592 9774970 irradiation NN I-NP O
24 592 593 9774970 . . O O

1 594 598 9774970 Thus RB B-ADVP O
2 598 599 9774970 , , O O
3 600 605 9774970 BRCA1 NN B-NP O
4 606 609 9774970 and CC I-NP O
5 610 615 9774970 BRCA2 NN I-NP O
6 616 627 9774970 participate VBP B-VP O
7 627 628 9774970 , , O O
8 629 637 9774970 together RB B-ADVP O
9 637 638 9774970 , , O O
10 639 641 9774970 in IN B-PP O
11 642 643 9774970 a DT B-NP O
12 644 651 9774970 pathway NN I-NP O
13 652 653 9774970 ( ( I-NP O
14 653 654 9774970 s NNS I-NP O
15 654 655 9774970 ) ) O O
16 656 666 9774970 associated VBN B-VP O
17 667 671 9774970 with IN B-PP O
18 672 675 9774970 the DT B-NP O
19 676 686 9774970 activation NN I-NP O
20 687 689 9774970 of IN B-PP O
21 690 696 9774970 double JJ B-NP O
22 696 697 9774970 - HYPH I-NP O
23 697 703 9774970 strand NN I-NP O
24 704 709 9774970 break NN I-NP O
25 710 716 9774970 repair NN I-NP O
26 717 720 9774970 and CC O O
27 720 721 9774970 / SYM B-NP O
28 721 723 9774970 or CC O O
29 724 734 9774970 homologous JJ B-NP O
30 735 748 9774970 recombination NN I-NP O
31 748 749 9774970 . . O O

1 750 761 9774970 Dysfunction NN B-NP O
2 762 764 9774970 of IN B-PP O
3 765 769 9774970 this DT B-NP O
4 770 777 9774970 pathway NN I-NP O
5 778 781 9774970 may MD B-VP O
6 782 784 9774970 be VB I-VP O
7 785 786 9774970 a DT B-NP O
8 787 794 9774970 general JJ I-NP O
9 795 805 9774970 phenomenon NN I-NP O
10 806 808 9774970 in IN B-PP O
11 809 812 9774970 the DT B-NP O
12 813 821 9774970 majority NN I-NP O
13 822 824 9774970 of IN B-PP O
14 825 830 9774970 cases NNS B-NP O
15 831 833 9774970 of IN B-PP O
16 834 844 9774970 hereditary JJ B-NP B-Disease
17 845 851 9774970 breast NN I-NP I-Disease
18 852 855 9774970 and CC O I-Disease
19 855 856 9774970 / SYM B-NP I-Disease
20 856 858 9774970 or CC O I-Disease
21 859 866 9774970 ovarian JJ B-NP I-Disease
22 867 873 9774970 cancer NN I-NP I-Disease
23 873 874 9774970 . . O O
24 874 875 9774970 . . O O

1 0 0 9420335 -DOCSTART- -X- -X- O

1 0 3 9420335 The DT B-NP O
2 4 9 9420335 tumor NN I-NP B-Disease
3 10 20 9420335 suppressor NN I-NP O
4 21 25 9420335 gene NN I-NP O
5 26 31 9420335 Smad4 NN I-NP O
6 31 32 9420335 / SYM B-NP O
7 32 36 9420335 Dpc4 NN I-NP O
8 37 39 9420335 is VBZ B-VP O
9 40 48 9420335 required VBN I-VP O
10 49 52 9420335 for IN B-PP O
11 53 65 9420335 gastrulation NN B-NP O
12 66 69 9420335 and CC B-PP O
13 70 75 9420335 later RB B-ADVP O
14 76 79 9420335 for IN B-PP O
15 80 88 9420335 anterior JJ B-NP O
16 89 100 9420335 development NN I-NP O
17 101 103 9420335 of IN B-PP O
18 104 107 9420335 the DT B-NP O
19 108 113 9420335 mouse NN I-NP O
20 114 120 9420335 embryo NN I-NP O
21 120 121 9420335 . . O O
22 122 131 9420335 Mutations NNS B-NP O
23 132 134 9420335 in IN B-PP O
24 135 138 9420335 the DT B-NP O
25 139 144 9420335 SMAD4 NN I-NP O
26 144 145 9420335 / SYM B-NP O
27 145 149 9420335 DPC4 NN I-NP O
28 150 155 9420335 tumor NN I-NP B-Disease
29 156 166 9420335 suppressor NN I-NP O
30 167 171 9420335 gene NN I-NP O
31 171 172 9420335 , , O O
32 173 174 9420335 a DT B-NP O
33 175 178 9420335 key JJ I-NP O
34 179 185 9420335 signal NN I-NP O
35 186 196 9420335 transducer NN I-NP O
36 197 199 9420335 in IN B-PP O
37 200 204 9420335 most JJS B-NP O
38 205 212 9420335 TGFbeta NN I-NP O
39 212 213 9420335 - HYPH B-NP O
40 213 220 9420335 related VBN I-NP O
41 221 229 9420335 pathways NNS I-NP O
42 229 230 9420335 , , O O
43 231 234 9420335 are VBP B-VP O
44 235 243 9420335 involved VBN I-VP O
45 244 246 9420335 in IN B-PP O
46 247 250 9420335 50% CD B-NP O
47 251 253 9420335 of IN B-PP O
48 254 264 9420335 pancreatic JJ B-NP B-Disease
49 265 272 9420335 cancers NNS I-NP I-Disease
50 272 273 9420335 . . O O

1 274 284 9420335 Homozygous JJ B-NP O
2 285 290 9420335 Smad4 NN I-NP O
3 291 297 9420335 mutant JJ I-NP O
4 298 302 9420335 mice NNS I-NP O
5 303 306 9420335 die VBP B-VP O
6 307 313 9420335 before IN B-SBAR O
7 314 317 9420335 day NN B-NP O
8 318 319 9420335 7 CD I-NP O
9 319 320 9420335 . . O O

1 321 322 9420335 5 CD B-NP O
2 323 325 9420335 of IN B-PP O
3 326 339 9420335 embryogenesis NN B-NP O
4 339 340 9420335 . . O O

1 341 347 9420335 Mutant JJ B-NP O
2 348 355 9420335 embryos NNS I-NP O
3 356 360 9420335 have VBP B-VP O
4 361 368 9420335 reduced VBN I-VP O
5 369 373 9420335 size NN B-NP O
6 373 374 9420335 , , O O
7 375 379 9420335 fail VBP B-VP O
8 380 382 9420335 to TO I-VP O
9 383 393 9420335 gastrulate VB I-VP O
10 394 396 9420335 or CC I-VP O
11 397 404 9420335 express VB I-VP O
12 405 406 9420335 a DT B-NP O
13 407 417 9420335 mesodermal JJ I-NP O
14 418 424 9420335 marker NN I-NP O
15 424 425 9420335 , , O O
16 426 429 9420335 and CC O O
17 430 434 9420335 show VBP B-VP O
18 435 443 9420335 abnormal JJ B-NP O
19 444 452 9420335 visceral JJ I-NP O
20 453 461 9420335 endoderm NN I-NP O
21 462 473 9420335 development NN I-NP O
22 473 474 9420335 . . O O

1 475 481 9420335 Growth NN B-NP B-Disease
2 482 493 9420335 retardation NN I-NP I-Disease
3 494 496 9420335 of IN B-PP O
4 497 500 9420335 the DT B-NP O
5 501 506 9420335 Smad4 NN I-NP O
6 506 507 9420335 - HYPH B-NP O
7 507 516 9420335 deficient JJ I-NP O
8 517 524 9420335 embryos NNS I-NP O
9 525 532 9420335 results VBZ B-VP O
10 533 537 9420335 from IN B-PP O
11 538 545 9420335 reduced VBN B-NP O
12 546 550 9420335 cell NN I-NP O
13 551 564 9420335 proliferation NN I-NP O
14 565 571 9420335 rather RB B-CONJP O
15 572 576 9420335 than IN I-CONJP O
16 577 586 9420335 increased VBN B-NP O
17 587 596 9420335 apoptosis NN I-NP O
18 596 597 9420335 . . O O

1 598 609 9420335 Aggregation NN B-NP O
2 610 612 9420335 of IN B-PP O
3 613 619 9420335 mutant JJ B-NP O
4 620 625 9420335 Smad4 NN I-NP O
5 626 628 9420335 ES NN I-NP O
6 629 634 9420335 cells NNS I-NP O
7 635 639 9420335 with IN B-PP O
8 640 644 9420335 wild JJ B-NP O
9 644 645 9420335 - HYPH I-NP O
10 645 649 9420335 type NN I-NP O
11 650 660 9420335 tetraploid JJ I-NP O
12 661 668 9420335 morulae NNS I-NP O
13 669 676 9420335 rescues VBZ B-VP O
14 677 680 9420335 the DT B-NP O
15 681 693 9420335 gastrulation NN I-NP B-Disease
16 694 700 9420335 defect NN I-NP I-Disease
17 700 701 9420335 . . O O

1 702 707 9420335 These DT B-NP O
2 708 715 9420335 results NNS I-NP O
3 716 724 9420335 indicate VBP B-VP O
4 725 729 9420335 that IN B-SBAR O
5 730 735 9420335 Smad4 NN B-NP O
6 736 738 9420335 is VBZ B-VP O
7 739 748 9420335 initially RB I-VP O
8 749 757 9420335 required VBN I-VP O
9 758 761 9420335 for IN B-PP O
10 762 765 9420335 the DT B-NP O
11 766 781 9420335 differentiation NN I-NP O
12 782 784 9420335 of IN B-PP O
13 785 788 9420335 the DT B-NP O
14 789 797 9420335 visceral JJ I-NP O
15 798 806 9420335 endoderm NN I-NP O
16 807 810 9420335 and CC O O
17 811 815 9420335 that IN B-SBAR O
18 816 819 9420335 the DT B-NP O
19 820 832 9420335 gastrulation NN I-NP B-Disease
20 833 839 9420335 defect NN I-NP I-Disease
21 840 842 9420335 in IN B-PP O
22 843 846 9420335 the DT B-NP O
23 847 855 9420335 epiblast NN I-NP O
24 856 858 9420335 is VBZ B-VP O
25 859 868 9420335 secondary JJ B-ADJP O
26 869 872 9420335 and CC O O
27 873 876 9420335 non AFX O O
28 876 877 9420335 - HYPH O O
29 877 881 9420335 cell NN B-NP O
30 882 892 9420335 autonomous JJ B-ADJP O
31 892 893 9420335 . . O O

1 894 901 9420335 Rescued VBN B-NP O
2 902 909 9420335 embryos NNS I-NP O
3 910 914 9420335 show VBP B-VP O
4 915 921 9420335 severe JJ B-NP O
5 922 930 9420335 anterior JJ I-NP O
6 931 942 9420335 truncations NNS I-NP O
7 942 943 9420335 , , O O
8 944 954 9420335 indicating VBG B-VP O
9 955 956 9420335 a DT B-NP O
10 957 963 9420335 second JJ I-NP O
11 964 973 9420335 important JJ I-NP O
12 974 978 9420335 role NN I-NP O
13 979 982 9420335 for IN B-PP O
14 983 988 9420335 Smad4 NN B-NP O
15 989 991 9420335 in IN B-PP O
16 992 1000 9420335 anterior JJ B-NP O
17 1001 1011 9420335 patterning NN I-NP O
18 1012 1018 9420335 during IN B-PP O
19 1019 1032 9420335 embryogenesis NN B-NP O
20 1032 1033 9420335 . . O O

1 0 0 9634518 -DOCSTART- -X- -X- O

1 0 1 9634518 A DT B-NP O
2 2 10 9634518 European JJ I-NP O
3 11 22 9634518 multicenter JJ I-NP O
4 23 28 9634518 study NN I-NP O
5 29 31 9634518 of IN B-PP O
6 32 45 9634518 phenylalanine NN B-NP B-Disease
7 46 57 9634518 hydroxylase NN I-NP I-Disease
8 58 68 9634518 deficiency NN I-NP I-Disease
9 68 69 9634518 : : O O
10 70 84 9634518 classification NN B-NP O
11 85 87 9634518 of IN B-PP O
12 88 91 9634518 105 CD B-NP O
13 92 101 9634518 mutations NNS I-NP O
14 102 105 9634518 and CC O O
15 106 107 9634518 a DT B-NP O
16 108 115 9634518 general JJ I-NP O
17 116 122 9634518 system NN I-NP O
18 123 126 9634518 for IN B-PP O
19 127 135 9634518 genotype NN B-NP O
20 135 136 9634518 - HYPH O O
21 136 141 9634518 based VBN B-NP O
22 142 152 9634518 prediction NN I-NP O
23 153 155 9634518 of IN B-PP O
24 156 165 9634518 metabolic JJ B-NP O
25 166 175 9634518 phenotype NN I-NP O
26 175 176 9634518 . . O O
27 177 192 9634518 Phenylketonuria NN B-NP B-Disease
28 193 194 9634518 ( ( O O
29 194 197 9634518 PKU NN B-NP B-Disease
30 197 198 9634518 ) ) O O
31 199 202 9634518 and CC O O
32 203 207 9634518 mild JJ B-NP B-Disease
33 208 229 9634518 hyperphenylalaninemia NN I-NP I-Disease
34 230 231 9634518 ( ( O O
35 231 234 9634518 MHP NN B-NP B-Disease
36 234 235 9634518 ) ) O O
37 236 239 9634518 are VBP B-VP O
38 240 247 9634518 allelic JJ B-NP B-Disease
39 248 257 9634518 disorders NNS I-NP I-Disease
40 258 264 9634518 caused VBN B-VP O
41 265 267 9634518 by IN B-PP O
42 268 277 9634518 mutations NNS B-NP O
43 278 280 9634518 in IN B-PP O
44 281 284 9634518 the DT B-NP O
45 285 289 9634518 gene NN I-NP O
46 290 298 9634518 encoding VBG B-VP O
47 299 312 9634518 phenylalanine NN B-NP O
48 313 324 9634518 hydroxylase NN I-NP O
49 325 326 9634518 ( ( O O
50 326 329 9634518 PAH NN B-NP O
51 329 330 9634518 ) ) O O
52 330 331 9634518 . . O O

1 332 340 9634518 Previous JJ B-NP O
2 341 348 9634518 studies NNS I-NP O
3 349 353 9634518 have VBP B-VP O
4 354 363 9634518 suggested VBN I-VP O
5 364 368 9634518 that IN B-SBAR O
6 369 372 9634518 the DT B-NP O
7 373 379 9634518 highly RB I-NP O
8 380 388 9634518 variable JJ I-NP O
9 389 398 9634518 metabolic JJ I-NP O
10 399 409 9634518 phenotypes NNS I-NP O
11 410 412 9634518 of IN B-PP O
12 413 416 9634518 PAH NN B-NP B-Disease
13 417 427 9634518 deficiency NN I-NP I-Disease
14 428 437 9634518 correlate VBP B-VP O
15 438 442 9634518 with IN B-PP O
16 443 446 9634518 PAH NN B-NP O
17 447 456 9634518 genotypes NNS I-NP O
18 456 457 9634518 . . O O

1 458 460 9634518 We PRP B-NP O
2 461 471 9634518 identified VBD B-VP O
3 472 476 9634518 both CC O O
4 477 486 9634518 causative JJ B-NP O
5 487 496 9634518 mutations NNS I-NP O
6 497 499 9634518 in IN B-PP O
7 500 503 9634518 686 CD B-NP O
8 504 512 9634518 patients NNS I-NP O
9 513 517 9634518 from IN B-PP O
10 518 523 9634518 seven CD B-NP O
11 524 532 9634518 European JJ I-NP O
12 533 540 9634518 centers NNS I-NP O
13 540 541 9634518 . . O O

1 542 544 9634518 On IN B-PP O
2 545 548 9634518 the DT B-NP O
3 549 554 9634518 basis NN I-NP O
4 555 557 9634518 of IN B-PP O
5 558 561 9634518 the DT B-NP O
6 562 572 9634518 phenotypic JJ I-NP O
7 573 588 9634518 characteristics NNS I-NP O
8 589 591 9634518 of IN B-PP O
9 592 595 9634518 297 CD B-NP O
10 596 608 9634518 functionally RB I-NP O
11 609 619 9634518 hemizygous JJ I-NP O
12 620 628 9634518 patients NNS I-NP O
13 628 629 9634518 , , O O
14 630 633 9634518 105 CD B-NP O
15 634 636 9634518 of IN B-PP O
16 637 640 9634518 the DT B-NP O
17 641 650 9634518 mutations NNS I-NP O
18 651 655 9634518 were VBD B-VP O
19 656 664 9634518 assigned VBN I-VP O
20 665 667 9634518 to TO B-PP O
21 668 671 9634518 one CD B-NP O
22 672 674 9634518 of IN B-PP O
23 675 679 9634518 four CD B-NP O
24 680 689 9634518 arbitrary JJ I-NP O
25 690 699 9634518 phenotype NN I-NP O
26 700 710 9634518 categories NNS I-NP O
27 710 711 9634518 . . O O

1 712 714 9634518 We PRP B-NP O
2 715 723 9634518 proposed VBD B-VP O
3 724 727 9634518 and CC I-VP O
4 728 734 9634518 tested VBD I-VP O
5 735 736 9634518 a DT B-NP O
6 737 743 9634518 simple JJ I-NP O
7 744 749 9634518 model NN I-NP O
8 750 753 9634518 for IN B-PP O
9 754 765 9634518 correlation NN B-NP O
10 766 773 9634518 between IN B-PP O
11 774 782 9634518 genotype NN B-NP O
12 783 786 9634518 and CC O O
13 787 797 9634518 phenotypic JJ B-NP O
14 798 805 9634518 outcome NN I-NP O
15 805 806 9634518 . . O O

1 807 810 9634518 The DT B-NP O
2 811 819 9634518 observed VBN I-NP O
3 820 829 9634518 phenotype NN I-NP O
4 830 837 9634518 matched VBD B-VP O
5 838 841 9634518 the DT B-NP O
6 842 851 9634518 predicted VBN I-NP O
7 852 861 9634518 phenotype NN I-NP O
8 862 864 9634518 in IN B-PP O
9 865 868 9634518 79% NN B-NP O
10 869 871 9634518 of IN B-PP O
11 872 875 9634518 the DT B-NP O
12 876 881 9634518 cases NNS I-NP O
13 881 882 9634518 , , O O
14 883 886 9634518 and CC O O
15 887 889 9634518 in IN B-PP O
16 890 894 9634518 only RB B-NP O
17 895 896 9634518 5 CD I-NP O
18 897 899 9634518 of IN B-PP O
19 900 903 9634518 184 CD B-NP O
20 904 912 9634518 patients NNS I-NP O
21 913 916 9634518 was VBD B-VP O
22 917 920 9634518 the DT B-NP O
23 921 929 9634518 observed VBN I-NP O
24 930 939 9634518 phenotype NN I-NP O
25 940 944 9634518 more JJR B-NP O
26 945 949 9634518 than IN I-NP O
27 950 953 9634518 one CD I-NP O
28 954 962 9634518 category NN I-NP O
29 963 967 9634518 away RB B-ADVP O
30 968 972 9634518 from IN B-PP O
31 973 977 9634518 that DT B-NP O
32 978 986 9634518 expected VBN B-VP O
33 986 987 9634518 . . O O

1 988 993 9634518 Among IN B-PP O
2 994 997 9634518 the DT B-NP O
3 998 1003 9634518 seven CD I-NP O
4 1004 1016 9634518 contributing VBG I-NP O
5 1017 1024 9634518 centers NNS I-NP O
6 1024 1025 9634518 , , O O
7 1026 1029 9634518 the DT B-NP O
8 1030 1040 9634518 proportion NN I-NP O
9 1041 1043 9634518 of IN B-PP O
10 1044 1052 9634518 patients NNS B-NP O
11 1053 1056 9634518 for IN B-PP O
12 1057 1061 9634518 whom WP B-NP O
13 1062 1065 9634518 the DT B-NP O
14 1066 1074 9634518 observed VBN I-NP O
15 1075 1084 9634518 phenotype NN I-NP O
16 1085 1088 9634518 did VBD B-VP O
17 1089 1092 9634518 not RB I-VP O
18 1093 1098 9634518 match VB I-VP O
19 1099 1102 9634518 the DT B-NP O
20 1103 1112 9634518 predicted VBN I-NP O
21 1113 1122 9634518 phenotype NN I-NP O
22 1123 1126 9634518 was VBD B-VP O
23 1127 1129 9634518 4% CD B-NP O
24 1130 1131 9634518 - HYPH O O
25 1131 1134 9634518 23% CD B-NP O
26 1135 1136 9634518 ( ( O O
27 1136 1137 9634518 P NN B-NP O
28 1138 1139 9634518 < SYM B-ADJP O
29 1139 1140 9634518 . . O O

1 1141 1145 9634518 0001 CD B-NP O
2 1145 1146 9634518 ) ) O O
3 1146 1147 9634518 , , O O
4 1148 1158 9634518 suggesting VBG B-VP O
5 1159 1163 9634518 that IN B-SBAR O
6 1164 1175 9634518 differences NNS B-NP O
7 1176 1178 9634518 in IN B-PP O
8 1179 1186 9634518 methods NNS B-NP O
9 1187 1191 9634518 used VBN B-VP O
10 1192 1195 9634518 for IN B-PP O
11 1196 1204 9634518 mutation NN B-NP O
12 1205 1214 9634518 detection NN I-NP O
13 1215 1217 9634518 or CC O O
14 1218 1227 9634518 phenotype NN B-NP O
15 1228 1242 9634518 classification NN I-NP O
16 1243 1246 9634518 may MD B-VP O
17 1247 1254 9634518 account VB I-VP O
18 1255 1258 9634518 for IN B-PP O
19 1259 1260 9634518 a DT B-NP O
20 1261 1273 9634518 considerable JJ I-NP O
21 1274 1284 9634518 proportion NN I-NP O
22 1285 1287 9634518 of IN B-PP O
23 1288 1296 9634518 genotype NN B-NP O
24 1296 1297 9634518 - HYPH B-NP O
25 1297 1306 9634518 phenotype NN I-NP O
26 1307 1322 9634518 inconsistencies NNS I-NP O
27 1322 1323 9634518 . . O O

1 1324 1327 9634518 Our PRP$ B-NP O
2 1328 1332 9634518 data NNS I-NP O
3 1333 1341 9634518 indicate VBP B-VP O
4 1342 1346 9634518 that IN B-SBAR O
5 1347 1350 9634518 the DT B-NP O
6 1351 1354 9634518 PAH NN I-NP O
7 1354 1355 9634518 - HYPH B-NP O
8 1355 1363 9634518 mutation NN I-NP O
9 1364 1372 9634518 genotype NN I-NP O
10 1373 1375 9634518 is VBZ B-VP O
11 1376 1379 9634518 the DT B-NP O
12 1380 1384 9634518 main JJ I-NP O
13 1385 1396 9634518 determinant NN I-NP O
14 1397 1399 9634518 of IN B-PP O
15 1400 1409 9634518 metabolic JJ B-NP O
16 1410 1419 9634518 phenotype NN I-NP O
17 1420 1422 9634518 in IN B-PP O
18 1423 1427 9634518 most JJS B-NP O
19 1428 1436 9634518 patients NNS I-NP O
20 1437 1441 9634518 with IN B-PP O
21 1442 1445 9634518 PAH NN B-NP B-Disease
22 1446 1456 9634518 deficiency NN I-NP I-Disease
23 1456 1457 9634518 . . O O

1 1458 1460 9634518 In IN B-PP O
2 1461 1464 9634518 the DT B-NP O
3 1465 1472 9634518 present JJ I-NP O
4 1473 1478 9634518 study NN I-NP O
5 1478 1479 9634518 , , O O
6 1480 1483 9634518 the DT B-NP O
7 1484 1498 9634518 classification NN I-NP O
8 1499 1501 9634518 of IN B-PP O
9 1502 1505 9634518 105 CD B-NP O
10 1506 1509 9634518 PAH NN I-NP O
11 1510 1519 9634518 mutations NNS I-NP O
12 1520 1523 9634518 may MD B-VP O
13 1524 1529 9634518 allow VB I-VP O
14 1530 1533 9634518 the DT B-NP O
15 1534 1544 9634518 prediction NN I-NP O
16 1545 1547 9634518 of IN B-PP O
17 1548 1551 9634518 the DT B-NP O
18 1552 1563 9634518 biochemical JJ I-NP O
19 1564 1573 9634518 phenotype NN I-NP O
20 1574 1576 9634518 in IN B-PP O
21 1577 1578 9634518 > JJR B-NP O
22 1579 1581 9634518 10 CD I-NP O
23 1581 1582 9634518 , , I-NP O
24 1583 1586 9634518 000 CD I-NP O
25 1587 1596 9634518 genotypes NNS I-NP O
26 1596 1597 9634518 , , O O
27 1598 1603 9634518 which WDT B-NP O
28 1604 1607 9634518 may MD B-VP O
29 1608 1610 9634518 be VB I-VP O
30 1611 1617 9634518 useful JJ B-ADJP O
31 1618 1621 9634518 for IN B-PP O
32 1622 1625 9634518 the DT B-NP O
33 1626 1636 9634518 management NN I-NP O
34 1637 1639 9634518 of IN B-PP O
35 1640 1661 9634518 hyperphenylalaninemia NN B-NP B-Disease
36 1662 1664 9634518 in IN B-PP O
37 1665 1673 9634518 newborns NNS B-NP O
38 1673 1674 9634518 . . O O

1 0 0 9709714 -DOCSTART- -X- -X- O

1 0 8 9709714 Reversal NN B-NP O
2 9 11 9709714 of IN B-PP O
3 12 18 9709714 severe JJ B-NP O
4 19 31 9709714 hypertrophic JJ I-NP B-Disease
5 32 46 9709714 cardiomyopathy NN I-NP I-Disease
6 47 50 9709714 and CC O O
7 51 60 9709714 excellent JJ B-NP O
8 61 77 9709714 neuropsychologic JJ I-NP O
9 78 85 9709714 outcome NN I-NP O
10 86 88 9709714 in IN B-PP O
11 89 93 9709714 very RB B-NP B-Disease
12 93 94 9709714 - HYPH I-NP I-Disease
13 94 98 9709714 long JJ I-NP I-Disease
14 98 99 9709714 - HYPH I-NP I-Disease
15 99 104 9709714 chain NN I-NP I-Disease
16 105 109 9709714 acyl NN I-NP I-Disease
17 109 110 9709714 - HYPH B-NP I-Disease
18 110 118 9709714 coenzyme NN I-NP I-Disease
19 119 120 9709714 A NN I-NP I-Disease
20 121 134 9709714 dehydrogenase NN I-NP I-Disease
21 135 145 9709714 deficiency NN I-NP I-Disease
22 145 146 9709714 . . B-NP O
23 147 151 9709714 Very NN I-NP B-Disease
24 151 152 9709714 - HYPH B-NP I-Disease
25 152 156 9709714 long JJ I-NP I-Disease
26 156 157 9709714 - HYPH I-NP I-Disease
27 157 162 9709714 chain NN I-NP I-Disease
28 163 167 9709714 acyl NN I-NP I-Disease
29 167 168 9709714 - HYPH B-NP I-Disease
30 168 176 9709714 coenzyme NN I-NP I-Disease
31 177 178 9709714 A NN I-NP I-Disease
32 179 192 9709714 dehydrogenase NN I-NP I-Disease
33 193 194 9709714 ( ( O I-Disease
34 194 199 9709714 VLCAD NN B-NP I-Disease
35 199 200 9709714 ) ) O I-Disease
36 201 211 9709714 deficiency NN B-NP I-Disease
37 212 214 9709714 is VBZ B-VP O
38 215 216 9709714 a DT B-NP O
39 217 225 9709714 disorder NN I-NP O
40 226 228 9709714 of IN B-PP O
41 229 234 9709714 fatty JJ B-NP O
42 235 239 9709714 acid NN I-NP O
43 240 244 9709714 beta NN I-NP O
44 245 254 9709714 oxidation NN I-NP O
45 255 259 9709714 that WDT B-NP O
46 260 270 9709714 reportedly RB B-ADVP O
47 271 274 9709714 has VBZ B-VP O
48 275 279 9709714 high JJ B-NP O
49 280 285 9709714 rates NNS I-NP O
50 286 288 9709714 of IN B-PP O
51 289 298 9709714 morbidity NN B-NP O
52 299 302 9709714 and CC I-NP O
53 303 312 9709714 mortality NN I-NP O
54 312 313 9709714 . . O O

1 314 316 9709714 We PRP B-NP O
2 317 325 9709714 describe VBP B-VP O
3 326 329 9709714 the DT B-NP O
4 330 337 9709714 outcome NN I-NP O
5 338 340 9709714 of IN B-PP O
6 341 342 9709714 a DT B-NP O
7 343 344 9709714 5 CD I-NP O
8 344 345 9709714 - HYPH I-NP O
9 345 349 9709714 year NN I-NP O
10 349 350 9709714 - HYPH O O
11 350 353 9709714 old JJ B-NP O
12 354 358 9709714 girl NN I-NP O
13 359 363 9709714 with IN B-PP O
14 364 369 9709714 VLCAD NN B-NP B-Disease
15 370 380 9709714 deficiency NN I-NP I-Disease
16 381 384 9709714 who WP B-NP O
17 385 388 9709714 was VBD B-VP O
18 389 394 9709714 first RB I-VP O
19 395 399 9709714 seen VBN I-VP O
20 400 402 9709714 at IN B-PP O
21 403 404 9709714 5 CD B-NP O
22 405 411 9709714 months NNS I-NP O
23 412 414 9709714 of IN B-PP O
24 415 418 9709714 age NN B-NP O
25 419 423 9709714 with IN B-PP O
26 424 430 9709714 severe JJ B-NP O
27 431 443 9709714 hypertrophic JJ I-NP B-Disease
28 444 458 9709714 cardiomyopathy NN I-NP I-Disease
29 458 459 9709714 , , O O
30 460 472 9709714 hepatomegaly NN B-NP B-Disease
31 472 473 9709714 , , O O
32 474 488 9709714 encephalopathy NN B-NP B-Disease
33 488 489 9709714 , , O O
34 490 493 9709714 and CC O O
35 494 503 9709714 hypotonia NN B-NP B-Disease
36 503 504 9709714 . . O O

1 505 516 9709714 Biochemical JJ B-NP O
2 517 524 9709714 studies NNS I-NP O
3 525 534 9709714 indicated VBD B-VP O
4 535 540 9709714 VLCAD NN B-NP B-Disease
5 541 551 9709714 deficiency NN I-NP I-Disease
6 552 558 9709714 caused VBN B-VP O
7 559 561 9709714 by IN B-PP O
8 562 563 9709714 a DT B-NP O
9 564 570 9709714 stable JJ I-NP O
10 571 574 9709714 yet RB I-NP O
11 575 583 9709714 inactive JJ I-NP O
12 584 590 9709714 enzyme NN I-NP O
13 590 591 9709714 . . O O

1 592 601 9709714 Molecular JJ B-NP O
2 602 609 9709714 genetic JJ I-NP O
3 610 618 9709714 analysis NN I-NP O
4 619 621 9709714 of IN B-PP O
5 622 625 9709714 her PRP$ B-NP O
6 626 631 9709714 VLCAD NN I-NP O
7 632 636 9709714 gene NN I-NP O
8 637 645 9709714 revealed VBD B-VP O
9 646 647 9709714 a DT B-NP O
10 648 654 9709714 T1372C NN I-NP O
11 655 656 9709714 ( ( O O
12 656 661 9709714 F458L NN B-NP O
13 661 662 9709714 ) ) O O
14 663 671 9709714 missense JJ B-NP O
15 672 680 9709714 mutation NN I-NP O
16 681 684 9709714 and CC O O
17 685 686 9709714 a DT B-NP O
18 687 691 9709714 1668 CD I-NP O
19 692 696 9709714 ACAG NN I-NP O
20 697 701 9709714 1669 CD B-NP O
21 702 708 9709714 splice NN I-NP O
22 709 713 9709714 site NN I-NP O
23 714 722 9709714 mutation NN I-NP O
24 722 723 9709714 . . O O

1 724 729 9709714 After IN B-PP O
2 730 737 9709714 initial JJ B-NP O
3 738 747 9709714 treatment NN I-NP O
4 748 752 9709714 with IN B-PP O
5 753 764 9709714 intravenous JJ B-NP O
6 765 772 9709714 glucose NN I-NP O
7 773 776 9709714 and CC I-NP O
8 777 786 9709714 carnitine NN I-NP O
9 786 787 9709714 , , O O
10 788 791 9709714 the DT B-NP O
11 792 799 9709714 patient NN I-NP O
12 800 803 9709714 has VBZ B-VP O
13 804 811 9709714 thrived VBN I-VP O
14 812 814 9709714 on IN B-PP O
15 815 816 9709714 a DT B-NP O
16 817 820 9709714 low JJ I-NP O
17 820 821 9709714 - HYPH I-NP O
18 821 824 9709714 fat NN I-NP O
19 825 829 9709714 diet NN I-NP O
20 830 842 9709714 supplemented VBN B-VP O
21 843 847 9709714 with IN B-PP O
22 848 854 9709714 medium JJ B-NP O
23 854 855 9709714 - HYPH I-NP O
24 855 860 9709714 chain NN I-NP O
25 861 873 9709714 triglyceride NN I-NP O
26 874 877 9709714 oil NN I-NP O
27 878 881 9709714 and CC I-NP O
28 882 891 9709714 carnitine NN I-NP O
29 892 895 9709714 and CC I-NP O
30 896 905 9709714 avoidance NN I-NP O
31 906 908 9709714 of IN B-PP O
32 909 916 9709714 fasting VBG B-NP O
33 916 917 9709714 . . O O

1 918 921 9709714 Her PRP$ B-NP O
2 922 933 9709714 ventricular JJ I-NP O
3 934 945 9709714 hypertrophy NN I-NP O
4 946 954 9709714 resolved VBN B-VP O
5 955 968 9709714 significantly RB B-NP O
6 969 973 9709714 over IN I-NP O
7 974 975 9709714 1 CD I-NP O
8 976 980 9709714 year NN I-NP O
9 980 981 9709714 , , O O
10 982 985 9709714 and CC O O
11 986 997 9709714 cognitively RB B-ADVP O
12 997 998 9709714 , , O O
13 999 1002 9709714 she PRP B-NP O
14 1003 1005 9709714 is VBZ B-VP O
15 1006 1008 9709714 in IN B-PP O
16 1009 1012 9709714 the DT B-NP O
17 1013 1021 9709714 superior JJ I-NP O
18 1022 1027 9709714 range NN I-NP O
19 1028 1031 9709714 for IN B-PP O
20 1032 1035 9709714 age NN B-NP O
21 1035 1036 9709714 . . O O

1 1037 1045 9709714 Clinical JJ B-NP O
2 1046 1057 9709714 recognition NN I-NP O
3 1058 1060 9709714 of IN B-PP O
4 1061 1066 9709714 VLCAD NN B-NP B-Disease
5 1067 1077 9709714 deficiency NN I-NP I-Disease
6 1078 1080 9709714 is VBZ B-VP O
7 1081 1090 9709714 important JJ B-ADJP O
8 1091 1098 9709714 because IN B-SBAR O
9 1099 1101 9709714 it PRP B-NP O
10 1102 1104 9709714 is VBZ B-VP O
11 1105 1108 9709714 one CD B-NP O
12 1109 1111 9709714 of IN B-PP O
13 1112 1115 9709714 the DT B-NP O
14 1116 1119 9709714 few JJ I-NP O
15 1120 1128 9709714 directly RB I-NP O
16 1129 1138 9709714 treatable JJ I-NP O
17 1139 1145 9709714 causes NNS I-NP O
18 1146 1148 9709714 of IN B-PP O
19 1149 1163 9709714 cardiomyopathy NN B-NP B-Disease
20 1164 1166 9709714 in IN B-PP O
21 1167 1175 9709714 children NNS B-NP O
22 1175 1176 9709714 . . O O
23 1176 1177 9709714 . . O O

1 0 0 9590178 -DOCSTART- -X- -X- O

1 0 6 9590178 Wilms' IN B-PP B-Disease
2 7 12 9590178 tumor NN B-NP I-Disease
3 13 14 9590178 1 CD I-NP O
4 15 18 9590178 and CC I-NP O
5 19 22 9590178 Dax NN I-NP O
6 22 23 9590178 - HYPH B-NP O
7 23 24 9590178 1 CD I-NP O
8 25 33 9590178 modulate VBP B-VP O
9 34 37 9590178 the DT B-NP O
10 38 44 9590178 orphan NN I-NP O
11 45 52 9590178 nuclear JJ I-NP O
12 53 61 9590178 receptor NN I-NP O
13 62 64 9590178 SF NN I-NP O
14 64 65 9590178 - HYPH B-NP O
15 65 66 9590178 1 CD I-NP O
16 67 69 9590178 in IN B-PP O
17 70 73 9590178 sex NN B-NP O
18 73 74 9590178 - HYPH I-NP O
19 74 82 9590178 specific JJ I-NP O
20 83 87 9590178 gene NN I-NP O
21 88 98 9590178 expression NN I-NP O
22 98 99 9590178 . . O O
23 100 108 9590178 Products NNS B-NP O
24 109 111 9590178 of IN B-PP O
25 112 125 9590178 steroidogenic JJ B-NP O
26 126 132 9590178 factor NN I-NP O
27 133 134 9590178 1 CD I-NP O
28 135 136 9590178 ( ( O O
29 136 138 9590178 SF NN B-NP O
30 138 139 9590178 - HYPH B-NP O
31 139 140 9590178 1 CD I-NP O
32 140 141 9590178 ) ) O O
33 142 145 9590178 and CC O O
34 146 151 9590178 Wilms NNP B-NP B-Disease
35 152 157 9590178 tumor NN I-NP I-Disease
36 158 159 9590178 1 CD I-NP O
37 160 161 9590178 ( ( O O
38 161 164 9590178 WT1 NN B-NP O
39 164 165 9590178 ) ) O O
40 166 171 9590178 genes NNS B-NP O
41 172 175 9590178 are VBP B-VP O
42 176 185 9590178 essential JJ B-ADJP O
43 186 189 9590178 for IN B-PP O
44 190 199 9590178 mammalian JJ B-NP O
45 200 213 9590178 gonadogenesis NN I-NP O
46 214 219 9590178 prior JJ B-ADJP O
47 220 222 9590178 to TO B-PP O
48 223 229 9590178 sexual JJ B-NP O
49 230 245 9590178 differentiation NN I-NP O
50 245 246 9590178 . . O O

1 247 249 9590178 In IN B-PP O
2 250 255 9590178 males NNS B-NP O
3 255 256 9590178 , , O O
4 257 259 9590178 SF NN B-NP O
5 259 260 9590178 - HYPH B-NP O
6 260 261 9590178 1 CD I-NP O
7 262 274 9590178 participates NNS I-NP O
8 275 277 9590178 in IN B-PP O
9 278 284 9590178 sexual JJ B-NP O
10 285 296 9590178 development NN I-NP O
11 297 299 9590178 by IN B-PP O
12 300 310 9590178 regulating VBG B-VP O
13 311 321 9590178 expression NN B-NP O
14 322 324 9590178 of IN B-PP O
15 325 328 9590178 the DT B-NP O
16 329 340 9590178 polypeptide NN I-NP O
17 341 348 9590178 hormone NN I-NP O
18 349 358 9590178 Mullerian JJ I-NP O
19 359 369 9590178 inhibiting VBG I-NP O
20 370 379 9590178 substance NN I-NP O
21 380 381 9590178 ( ( O O
22 381 384 9590178 MIS NN B-NP O
23 384 385 9590178 ) ) O O
24 385 386 9590178 . . O O

1 387 391 9590178 Here RB B-ADVP O
2 391 392 9590178 , , O O
3 393 395 9590178 we PRP B-NP O
4 396 400 9590178 show VBP B-VP O
5 401 405 9590178 that IN B-SBAR O
6 406 409 9590178 WT1 NN B-NP O
7 410 411 9590178 - HYPH B-NP O
8 411 414 9590178 KTS NN I-NP O
9 415 423 9590178 isoforms NNS I-NP O
10 424 433 9590178 associate VBP B-VP O
11 434 437 9590178 and CC I-VP O
12 438 447 9590178 synergize VBP I-VP O
13 448 452 9590178 with IN B-PP O
14 453 455 9590178 SF NN B-NP O
15 455 456 9590178 - HYPH B-NP O
16 456 457 9590178 1 CD I-NP O
17 458 460 9590178 to TO B-VP O
18 461 468 9590178 promote VB I-VP O
19 469 472 9590178 MIS NN B-NP O
20 473 483 9590178 expression NN I-NP O
21 483 484 9590178 . . O O

1 485 487 9590178 In IN B-PP O
2 488 496 9590178 contrast NN B-NP O
3 496 497 9590178 , , O O
4 498 501 9590178 WT1 NN B-NP O
5 502 510 9590178 missense JJ I-NP O
6 511 520 9590178 mutations NNS I-NP O
7 520 521 9590178 , , O O
8 522 532 9590178 associated VBN B-VP O
9 533 537 9590178 with IN B-PP O
10 538 542 9590178 male JJ B-NP B-Disease
11 543 564 9590178 pseudohermaphroditism NN I-NP I-Disease
12 565 567 9590178 in IN B-PP O
13 568 573 9590178 Denys NNP B-NP B-Disease
14 573 574 9590178 - HYPH B-NP I-Disease
15 574 579 9590178 Drash NNP I-NP I-Disease
16 580 588 9590178 syndrome NN I-NP I-Disease
17 588 589 9590178 , , O O
18 590 594 9590178 fail VBP B-VP O
19 595 597 9590178 to TO I-VP O
20 598 607 9590178 synergize VB I-VP O
21 608 612 9590178 with IN B-PP O
22 613 615 9590178 SF NN B-NP O
23 615 616 9590178 - HYPH B-NP O
24 616 617 9590178 1 CD I-NP O
25 617 618 9590178 . . O O

1 619 631 9590178 Additionally RB B-ADVP O
2 631 632 9590178 , , O O
3 633 636 9590178 the DT B-NP O
4 637 638 9590178 X NN I-NP O
5 638 639 9590178 - HYPH B-VP O
6 639 645 9590178 linked VBN I-VP O
7 645 646 9590178 , , O O
8 647 656 9590178 candidate NN B-NP O
9 657 663 9590178 dosage NN I-NP O
10 663 664 9590178 - HYPH B-NP O
11 664 673 9590178 sensitive JJ I-NP O
12 674 677 9590178 sex NN I-NP O
13 677 678 9590178 - HYPH B-NP O
14 678 686 9590178 reversal NN I-NP O
15 687 691 9590178 gene NN I-NP O
16 691 692 9590178 , , O O
17 693 696 9590178 Dax NN B-NP O
18 696 697 9590178 - HYPH B-NP O
19 697 698 9590178 1 CD I-NP O
20 698 699 9590178 , , O O
21 700 711 9590178 antagonizes VBZ B-VP O
22 712 719 9590178 synergy NN B-NP O
23 720 727 9590178 between IN B-PP O
24 728 730 9590178 SF NN B-NP O
25 730 731 9590178 - HYPH B-NP O
26 731 732 9590178 1 CD I-NP O
27 733 736 9590178 and CC I-NP O
28 737 740 9590178 WT1 NN I-NP O
29 740 741 9590178 , , O O
30 742 746 9590178 most RBS B-ADVP O
31 747 753 9590178 likely RB I-ADVP O
32 754 761 9590178 through IN B-PP O
33 762 763 9590178 a DT B-NP O
34 764 770 9590178 direct JJ I-NP O
35 771 782 9590178 interaction NN I-NP O
36 783 787 9590178 with IN B-PP O
37 788 790 9590178 SF NN B-NP O
38 790 791 9590178 - HYPH B-NP O
39 791 792 9590178 1 CD I-NP O
40 792 793 9590178 . . O O

1 794 796 9590178 We PRP B-NP O
2 797 804 9590178 propose VBP B-VP O
3 805 809 9590178 that IN B-SBAR O
4 810 813 9590178 WT1 NN B-NP O
5 814 817 9590178 and CC I-NP O
6 818 821 9590178 Dax NN I-NP O
7 821 822 9590178 - HYPH B-NP O
8 822 823 9590178 1 CD I-NP O
9 824 836 9590178 functionally RB B-ADVP O
10 837 843 9590178 oppose VBP B-VP O
11 844 848 9590178 each DT B-NP O
12 849 854 9590178 other JJ I-NP O
13 855 857 9590178 in IN B-PP O
14 858 864 9590178 testis NN B-NP O
15 865 876 9590178 development NN I-NP O
16 877 879 9590178 by IN B-PP O
17 880 890 9590178 modulating VBG B-VP O
18 891 893 9590178 SF NN B-NP O
19 893 894 9590178 - HYPH B-NP O
20 894 895 9590178 1 CD I-NP O
21 895 896 9590178 - HYPH I-NP O
22 896 904 9590178 mediated VBN I-NP O
23 905 920 9590178 transactivation NN I-NP O
24 920 921 9590178 . . O O
25 921 922 9590178 . . O O

1 0 0 9294109 -DOCSTART- -X- -X- O

1 0 8 9294109 Myotonic JJ B-NP B-Disease
2 9 18 9294109 dystrophy NN I-NP I-Disease
3 19 26 9294109 protein NN I-NP O
4 27 33 9294109 kinase NN I-NP O
5 34 36 9294109 is VBZ B-VP O
6 37 45 9294109 involved VBN I-VP O
7 46 48 9294109 in IN B-PP O
8 49 52 9294109 the DT B-NP O
9 53 63 9294109 modulation NN I-NP O
10 64 66 9294109 of IN B-PP O
11 67 70 9294109 the DT B-NP O
12 71 75 9294109 Ca2+ NN I-NP O
13 76 87 9294109 homeostasis NN I-NP O
14 88 90 9294109 in IN B-PP O
15 91 99 9294109 skeletal JJ B-NP O
16 100 106 9294109 muscle NN I-NP O
17 107 112 9294109 cells NNS I-NP O
18 112 113 9294109 . . O O
19 114 122 9294109 Myotonic JJ B-NP B-Disease
20 123 132 9294109 dystrophy NN I-NP I-Disease
21 133 134 9294109 ( ( O O
22 134 136 9294109 DM NN B-NP B-Disease
23 136 137 9294109 ) ) O O
24 137 138 9294109 , , O O
25 139 142 9294109 the DT B-NP O
26 143 147 9294109 most RBS I-NP O
27 148 157 9294109 prevalent JJ I-NP O
28 158 166 9294109 muscular JJ I-NP B-Disease
29 167 175 9294109 disorder NN I-NP I-Disease
30 176 178 9294109 in IN B-PP O
31 179 185 9294109 adults NNS B-NP O
32 185 186 9294109 , , O O
33 187 189 9294109 is VBZ B-VP O
34 190 196 9294109 caused VBN I-VP O
35 197 199 9294109 by IN B-PP O
36 200 201 9294109 ( ( O O
37 201 204 9294109 CTG NN B-NP O
38 204 205 9294109 ) ) O O
39 206 207 9294109 n NN B-NP O
40 207 208 9294109 - HYPH B-NP O
41 208 214 9294109 repeat NN I-NP O
42 215 224 9294109 expansion NN I-NP O
43 225 227 9294109 in IN B-PP O
44 228 229 9294109 a DT B-NP O
45 230 234 9294109 gene NN I-NP O
46 235 243 9294109 encoding VBG B-VP O
47 244 245 9294109 a DT B-NP O
48 246 253 9294109 protein NN I-NP O
49 254 260 9294109 kinase NN I-NP O
50 261 262 9294109 ( ( O O
51 262 264 9294109 DM NN B-NP B-Disease
52 265 272 9294109 protein NN I-NP O
53 273 279 9294109 kinase NN I-NP O
54 279 280 9294109 ; : O O
55 281 285 9294109 DMPK NN B-NP O
56 285 286 9294109 ) ) O O
57 287 290 9294109 and CC O O
58 291 299 9294109 involves VBZ B-VP O
59 300 307 9294109 changes NNS B-NP O
60 308 310 9294109 in IN B-PP O
61 311 327 9294109 cytoarchitecture NN B-NP O
62 328 331 9294109 and CC I-NP O
63 332 335 9294109 ion NN I-NP O
64 336 347 9294109 homeostasis NN I-NP O
65 347 348 9294109 . . O O

1 349 351 9294109 To TO B-VP O
2 352 358 9294109 obtain VB I-VP O
3 359 364 9294109 clues NNS B-NP O
4 365 367 9294109 to TO B-PP O
5 368 371 9294109 the DT B-NP O
6 372 378 9294109 normal JJ I-NP O
7 379 389 9294109 biological JJ I-NP O
8 390 394 9294109 role NN I-NP O
9 395 397 9294109 of IN B-PP O
10 398 402 9294109 DMPK NN B-NP O
11 403 405 9294109 in IN B-PP O
12 406 414 9294109 cellular JJ B-NP O
13 415 418 9294109 ion NN I-NP O
14 419 430 9294109 homeostasis NN I-NP O
15 430 431 9294109 , , O O
16 432 434 9294109 we PRP B-NP O
17 435 439 9294109 have VBP B-VP O
18 440 448 9294109 compared VBN I-VP O
19 449 452 9294109 the DT B-NP O
20 453 460 9294109 resting NN I-NP O
21 461 462 9294109 [ ( O O
22 462 465 9294109 Ca2 NN B-NP O
23 466 467 9294109 + SYM O O
24 467 468 9294109 ] ) O O
25 469 470 9294109 i NN B-NP O
26 470 471 9294109 , , O O
27 472 475 9294109 the DT B-NP O
28 476 485 9294109 amplitude NN I-NP O
29 486 489 9294109 and CC I-NP O
30 490 495 9294109 shape NN I-NP O
31 496 498 9294109 of IN B-PP O
32 499 513 9294109 depolarization NN B-NP O
33 513 514 9294109 - HYPH B-NP O
34 514 521 9294109 induced VBN I-NP O
35 522 525 9294109 Ca2 NN I-NP O
36 526 527 9294109 + SYM B-NP O
37 528 538 9294109 transients NNS I-NP O
38 538 539 9294109 , , O O
39 540 543 9294109 and CC O O
40 544 547 9294109 the DT B-NP O
41 548 555 9294109 content NN I-NP O
42 556 558 9294109 of IN B-PP O
43 559 562 9294109 ATP NN B-NP O
44 562 563 9294109 - HYPH O O
45 563 569 9294109 driven VBN B-NP O
46 570 573 9294109 ion NN I-NP O
47 574 579 9294109 pumps NNS I-NP O
48 580 582 9294109 in IN B-PP O
49 583 591 9294109 cultured VBN B-NP O
50 592 600 9294109 skeletal JJ I-NP O
51 601 607 9294109 muscle NN I-NP O
52 608 613 9294109 cells NNS I-NP O
53 614 616 9294109 of IN B-PP O
54 617 621 9294109 wild JJ B-NP O
55 621 622 9294109 - HYPH I-NP O
56 622 626 9294109 type NN I-NP O
57 627 630 9294109 and CC I-NP O
58 631 635 9294109 DMPK NN I-NP O
59 636 637 9294109 [ ( O O
60 637 638 9294109 - HYPH B-NP O
61 638 639 9294109 / SYM I-NP O
62 639 640 9294109 - HYPH I-NP O
63 640 641 9294109 ] ) I-NP O
64 642 650 9294109 knockout NN I-NP O
65 651 655 9294109 mice NNS I-NP O
66 655 656 9294109 . . O O

1 657 659 9294109 In FW B-NP O
2 660 665 9294109 vitro FW I-NP O
3 665 666 9294109 - HYPH B-VP O
4 666 680 9294109 differentiated VBN B-NP O
5 681 685 9294109 DMPK NN I-NP O
6 686 687 9294109 [ ( O O
7 687 688 9294109 - HYPH O O
8 688 689 9294109 / SYM O O
9 689 690 9294109 - HYPH O O
10 690 691 9294109 ] ) O O
11 692 700 9294109 myotubes NNS B-NP O
12 701 708 9294109 exhibit VBP B-VP O
13 709 710 9294109 a DT B-NP O
14 711 717 9294109 higher JJR I-NP O
15 718 725 9294109 resting VBG I-NP O
16 726 727 9294109 [ ( O O
17 727 730 9294109 Ca2 NN O O
18 731 732 9294109 + SYM O O
19 732 733 9294109 ] ) O O
20 734 735 9294109 i NN B-NP O
21 736 740 9294109 than IN B-SBAR O
22 741 743 9294109 do VBP B-VP O
23 744 748 9294109 wild JJ B-NP O
24 748 749 9294109 - HYPH I-NP O
25 749 753 9294109 type NN I-NP O
26 754 762 9294109 myotubes NNS I-NP O
27 763 770 9294109 because IN B-PP O
28 771 773 9294109 of IN I-PP O
29 774 776 9294109 an DT B-NP O
30 777 784 9294109 altered JJ I-NP O
31 785 789 9294109 open JJ I-NP O
32 790 801 9294109 probability NN I-NP O
33 802 804 9294109 of IN B-PP O
34 805 812 9294109 voltage NN B-NP O
35 812 813 9294109 - HYPH B-NP O
36 813 822 9294109 dependent JJ I-NP O
37 823 824 9294109 l NN I-NP O
38 824 825 9294109 - HYPH I-NP O
39 825 829 9294109 type NN I-NP O
40 830 833 9294109 Ca2 NN I-NP O
41 834 835 9294109 + SYM B-NP O
42 836 839 9294109 and CC O O
43 840 842 9294109 Na NN B-NP O
44 843 844 9294109 + SYM I-NP O
45 845 853 9294109 channels NNS I-NP O
46 853 854 9294109 . . O O

1 855 858 9294109 The DT B-NP O
2 859 865 9294109 mutant JJ I-NP O
3 866 874 9294109 myotubes NNS I-NP O
4 875 882 9294109 exhibit VBP B-VP O
5 883 890 9294109 smaller JJR B-NP O
6 891 894 9294109 and CC I-NP O
7 895 901 9294109 slower JJR I-NP O
8 902 905 9294109 Ca2 NN I-NP O
9 906 907 9294109 + SYM I-NP O
10 908 917 9294109 responses NNS I-NP O
11 918 922 9294109 upon IN B-PP O
12 923 933 9294109 triggering NN B-NP O
13 934 936 9294109 by IN B-PP O
14 937 950 9294109 acetylcholine NN B-NP O
15 951 953 9294109 or CC O O
16 954 958 9294109 high JJ B-NP O
17 959 967 9294109 external JJ I-NP O
18 968 969 9294109 K NN I-NP O
19 970 971 9294109 + SYM B-NP O
20 971 972 9294109 . . O O

1 973 975 9294109 In IN B-PP O
2 976 984 9294109 addition NN B-NP O
3 984 985 9294109 , , O O
4 986 988 9294109 we PRP B-NP O
5 989 997 9294109 observed VBD B-VP O
6 998 1002 9294109 that IN B-SBAR O
7 1003 1008 9294109 these DT B-NP O
8 1009 1012 9294109 Ca2 NN I-NP O
9 1013 1014 9294109 + SYM O O
10 1015 1025 9294109 transients NNS B-NP O
11 1026 1035 9294109 partially RB B-ADVP O
12 1036 1042 9294109 result VBP B-VP O
13 1043 1047 9294109 from IN B-PP O
14 1048 1050 9294109 an DT B-NP O
15 1051 1057 9294109 influx NN I-NP O
16 1058 1060 9294109 of IN B-PP O
17 1061 1074 9294109 extracellular JJ B-NP O
18 1075 1078 9294109 Ca2 NN I-NP O
19 1079 1080 9294109 + SYM B-ADVP O
20 1081 1088 9294109 through IN B-PP O
21 1089 1092 9294109 the DT B-NP O
22 1093 1094 9294109 l NN I-NP O
23 1094 1095 9294109 - HYPH I-NP O
24 1095 1099 9294109 type NN I-NP O
25 1100 1103 9294109 Ca2 NN I-NP O
26 1104 1105 9294109 + SYM B-NP O
27 1106 1113 9294109 channel NN I-NP O
28 1113 1114 9294109 . . O O

1 1115 1122 9294109 Neither CC O O
2 1123 1126 9294109 the DT B-NP O
3 1127 1134 9294109 content NN I-NP O
4 1135 1138 9294109 nor CC O O
5 1139 1142 9294109 the DT B-NP O
6 1143 1151 9294109 activity NN I-NP O
7 1152 1154 9294109 of IN B-PP O
8 1155 1157 9294109 Na NN B-NP O
9 1158 1159 9294109 + SYM O O
10 1159 1160 9294109 / SYM O O
11 1160 1161 9294109 K NN B-NP O
12 1162 1163 9294109 + SYM I-NP O
13 1164 1170 9294109 ATPase NN I-NP O
14 1171 1174 9294109 and CC O O
15 1175 1187 9294109 sarcoplasmic JJ B-NP O
16 1188 1197 9294109 reticulum NN I-NP O
17 1198 1201 9294109 Ca2 NN I-NP O
18 1202 1203 9294109 + SYM O O
19 1204 1205 9294109 - HYPH O O
20 1205 1211 9294109 ATPase NN B-NP O
21 1212 1215 9294109 are VBP B-VP O
22 1216 1224 9294109 affected VBN I-VP O
23 1225 1227 9294109 by IN B-PP O
24 1228 1232 9294109 DMPK NN B-NP O
25 1233 1240 9294109 absence NN I-NP O
26 1240 1241 9294109 . . O O

1 1242 1244 9294109 In IN B-PP O
2 1245 1255 9294109 conclusion NN B-NP O
3 1255 1256 9294109 , , O O
4 1257 1260 9294109 our PRP$ B-NP O
5 1261 1265 9294109 data NNS I-NP O
6 1266 1273 9294109 suggest VBP B-VP O
7 1274 1278 9294109 that IN B-SBAR O
8 1279 1283 9294109 DMPK NN B-NP O
9 1284 1286 9294109 is VBZ B-VP O
10 1287 1295 9294109 involved VBN I-VP O
11 1296 1298 9294109 in IN B-PP O
12 1299 1309 9294109 modulating VBG B-VP O
13 1310 1313 9294109 the DT B-NP O
14 1314 1321 9294109 initial JJ I-NP O
15 1322 1328 9294109 events NNS I-NP O
16 1329 1331 9294109 of IN B-PP O
17 1332 1342 9294109 excitation NN B-NP O
18 1342 1343 9294109 - HYPH I-NP O
19 1343 1354 9294109 contraction NN I-NP O
20 1355 1363 9294109 coupling NN I-NP O
21 1364 1366 9294109 in IN B-PP O
22 1367 1375 9294109 skeletal JJ B-NP O
23 1376 1382 9294109 muscle NN I-NP O
24 1382 1383 9294109 . . O O
25 1383 1384 9294109 . . O O

1 0 0 9529364 -DOCSTART- -X- -X- O

1 0 14 9529364 Identification NN B-NP O
2 15 17 9529364 of IN B-PP O
3 18 32 9529364 constitutional JJ B-NP O
4 33 36 9529364 WT1 NN I-NP O
5 37 46 9529364 mutations NNS I-NP O
6 46 47 9529364 , , O O
7 48 50 9529364 in IN B-PP O
8 51 59 9529364 patients NNS B-NP O
9 60 64 9529364 with IN B-PP O
10 65 73 9529364 isolated VBN B-NP O
11 74 81 9529364 diffuse JJ I-NP B-Disease
12 82 91 9529364 mesangial JJ I-NP I-Disease
13 92 101 9529364 sclerosis NN I-NP I-Disease
14 101 102 9529364 , , O O
15 103 106 9529364 and CC O O
16 107 115 9529364 analysis NN B-NP O
17 116 118 9529364 of IN B-PP O
18 119 127 9529364 genotype NN B-NP O
19 127 128 9529364 / SYM B-NP O
20 128 137 9529364 phenotype NN I-NP O
21 138 150 9529364 correlations NNS I-NP O
22 151 153 9529364 by IN B-PP O
23 154 157 9529364 use NN B-NP O
24 158 160 9529364 of IN B-PP O
25 161 162 9529364 a DT B-NP O
26 163 175 9529364 computerized JJ I-NP O
27 176 184 9529364 mutation NN I-NP O
28 185 193 9529364 database NN I-NP O
29 193 194 9529364 . . O O
30 195 209 9529364 Constitutional JJ B-NP O
31 210 219 9529364 mutations NNS I-NP O
32 220 222 9529364 of IN B-PP O
33 223 226 9529364 the DT B-NP O
34 227 230 9529364 WT1 NN I-NP O
35 231 235 9529364 gene NN I-NP O
36 235 236 9529364 , , O O
37 237 245 9529364 encoding VBG B-VP O
38 246 247 9529364 a DT B-NP O
39 248 252 9529364 zinc NN I-NP O
40 252 253 9529364 - HYPH B-NP O
41 253 259 9529364 finger NN I-NP O
42 260 273 9529364 transcription NN I-NP O
43 274 280 9529364 factor NN I-NP O
44 281 289 9529364 involved VBN B-VP O
45 290 292 9529364 in IN B-PP O
46 293 298 9529364 renal JJ B-NP O
47 299 302 9529364 and CC I-NP O
48 303 310 9529364 gonadal JJ I-NP O
49 311 322 9529364 development NN I-NP O
50 322 323 9529364 , , O O
51 324 327 9529364 are VBP B-VP O
52 328 333 9529364 found VBN I-VP O
53 334 336 9529364 in IN B-PP O
54 337 341 9529364 most JJS B-NP O
55 342 350 9529364 patients NNS I-NP O
56 351 355 9529364 with IN B-PP O
57 356 361 9529364 Denys NNPS B-NP B-Disease
58 361 362 9529364 - HYPH B-NP I-Disease
59 362 367 9529364 Drash NN I-NP I-Disease
60 368 376 9529364 syndrome NN I-NP I-Disease
61 377 378 9529364 ( ( O O
62 378 381 9529364 DDS NN B-NP B-Disease
63 381 382 9529364 ) ) O O
64 382 383 9529364 , , O O
65 384 386 9529364 or CC O O
66 387 394 9529364 diffuse JJ B-NP B-Disease
67 395 404 9529364 mesangial JJ I-NP I-Disease
68 405 414 9529364 sclerosis NN I-NP I-Disease
69 415 416 9529364 ( ( O O
70 416 419 9529364 DMS NN B-NP B-Disease
71 419 420 9529364 ) ) O O
72 421 431 9529364 associated VBN B-VP O
73 432 436 9529364 with IN B-PP O
74 437 458 9529364 pseudohermaphroditism NN B-NP B-Disease
75 459 462 9529364 and CC O O
76 462 463 9529364 / SYM B-NP O
77 463 465 9529364 or CC O O
78 466 471 9529364 Wilms NNP B-NP B-Disease
79 472 477 9529364 tumor NN I-NP I-Disease
80 478 479 9529364 ( ( O O
81 479 481 9529364 WT NN B-NP B-Disease
82 481 482 9529364 ) ) O O
83 482 483 9529364 . . O O

1 484 488 9529364 Most JJS B-NP O
2 489 498 9529364 mutations NNS I-NP O
3 499 501 9529364 in IN B-PP O
4 502 505 9529364 DDS NN B-NP B-Disease
5 506 514 9529364 patients NNS I-NP O
6 515 518 9529364 lie VBP B-VP O
7 519 521 9529364 in IN B-PP O
8 522 526 9529364 exon NN B-NP O
9 527 528 9529364 8 CD I-NP O
10 529 531 9529364 or CC O O
11 532 536 9529364 exon NN B-NP O
12 537 538 9529364 9 CD I-NP O
13 538 539 9529364 , , O O
14 540 548 9529364 encoding VBG B-VP O
15 549 553 9529364 zinc NN B-NP O
16 554 560 9529364 finger NN I-NP O
17 561 562 9529364 2 CD I-NP O
18 563 565 9529364 or CC I-NP O
19 566 570 9529364 zinc NN I-NP O
20 571 577 9529364 finger NN I-NP O
21 578 579 9529364 3 CD I-NP O
22 579 580 9529364 , , O O
23 581 593 9529364 respectively RB B-ADVP O
24 593 594 9529364 , , O O
25 595 599 9529364 with IN B-PP O
26 600 601 9529364 a DT B-NP O
27 602 605 9529364 hot JJ I-NP O
28 606 610 9529364 spot NN I-NP O
29 611 612 9529364 ( ( O O
30 612 617 9529364 R394W NN B-NP O
31 617 618 9529364 ) ) O O
32 619 621 9529364 in IN B-PP O
33 622 626 9529364 exon NN B-NP O
34 627 628 9529364 9 CD I-NP O
35 628 629 9529364 . . O O

1 630 632 9529364 We PRP B-NP O
2 633 641 9529364 analyzed VBD B-VP O
3 642 643 9529364 a DT B-NP O
4 644 650 9529364 series NN I-NP O
5 651 653 9529364 of IN B-PP O
6 654 656 9529364 24 CD B-NP O
7 657 665 9529364 patients NNS I-NP O
8 665 666 9529364 , , O O
9 667 669 9529364 10 CD B-NP O
10 670 674 9529364 with IN B-PP O
11 675 683 9529364 isolated VBN B-NP B-Disease
12 684 687 9529364 DMS NN I-NP I-Disease
13 688 689 9529364 ( ( O O
14 689 693 9529364 IDMS NN B-NP B-Disease
15 693 694 9529364 ) ) O O
16 694 695 9529364 , , O O
17 696 698 9529364 10 CD B-NP O
18 699 703 9529364 with IN B-PP O
19 704 707 9529364 DDS NN B-NP B-Disease
20 707 708 9529364 , , O O
21 709 712 9529364 and CC O O
22 713 714 9529364 4 CD B-NP O
23 715 719 9529364 with IN B-PP O
24 720 730 9529364 urogenital JJ B-NP B-Disease
25 731 744 9529364 abnormalities NNS I-NP I-Disease
26 745 748 9529364 and CC O O
27 748 749 9529364 / SYM B-NP O
28 749 751 9529364 or CC O O
29 752 755 9529364 WT. NNP B-NP B-Disease

1 756 758 9529364 We PRP B-NP O
2 759 765 9529364 report VBP B-VP O
3 766 769 9529364 WT1 NN B-NP O
4 770 782 9529364 heterozygous JJ I-NP O
5 783 792 9529364 mutations NNS I-NP O
6 793 795 9529364 in IN B-PP O
7 796 798 9529364 16 CD B-NP O
8 799 807 9529364 patients NNS I-NP O
9 807 808 9529364 , , O O
10 809 810 9529364 4 CD B-NP O
11 811 813 9529364 of IN B-PP O
12 814 818 9529364 whom WP B-NP O
13 819 828 9529364 presented VBD B-VP O
14 829 833 9529364 with IN B-PP O
15 834 838 9529364 IDMS NN B-NP B-Disease
16 838 839 9529364 . . O O

1 840 843 9529364 One CD B-NP O
2 844 848 9529364 male JJ I-NP O
3 849 852 9529364 and CC O O
4 853 856 9529364 two CD B-NP O
5 857 863 9529364 female JJ I-NP O
6 864 868 9529364 IDMS NN I-NP B-Disease
7 869 877 9529364 patients NNS I-NP O
8 878 882 9529364 with IN B-PP O
9 883 886 9529364 WT1 NN B-NP O
10 887 896 9529364 mutations NNS I-NP O
11 897 906 9529364 underwent VBD B-VP O
12 907 913 9529364 normal JJ B-NP O
13 914 921 9529364 puberty NN I-NP O
14 921 922 9529364 . . O O

1 923 926 9529364 Two CD B-NP O
2 927 936 9529364 mutations NNS I-NP O
3 937 947 9529364 associated VBN B-VP O
4 948 952 9529364 with IN B-PP O
5 953 957 9529364 IDMS NN B-NP B-Disease
6 958 961 9529364 are VBP B-VP O
7 962 971 9529364 different JJ B-ADJP O
8 972 976 9529364 from IN B-PP O
9 977 982 9529364 those DT B-NP O
10 983 992 9529364 described VBN B-VP O
11 993 995 9529364 in IN B-PP O
12 996 999 9529364 DDS NN B-NP B-Disease
13 1000 1008 9529364 patients NNS I-NP O
14 1008 1009 9529364 . . O O

1 1010 1012 9529364 No DT B-NP O
2 1013 1016 9529364 WT1 NN I-NP O
3 1017 1026 9529364 mutations NNS I-NP O
4 1027 1031 9529364 were VBD B-VP O
5 1032 1040 9529364 detected VBN I-VP O
6 1041 1043 9529364 in IN B-PP O
7 1044 1047 9529364 the DT B-NP O
8 1048 1051 9529364 six CD I-NP O
9 1052 1057 9529364 other JJ I-NP O
10 1058 1062 9529364 IDMS NN I-NP B-Disease
11 1063 1071 9529364 patients NNS I-NP O
12 1071 1072 9529364 , , O O
13 1073 1083 9529364 suggesting VBG B-VP O
14 1084 1091 9529364 genetic JJ B-NP O
15 1092 1105 9529364 heterogeneity NN I-NP O
16 1106 1108 9529364 of IN B-PP O
17 1109 1113 9529364 this DT B-NP O
18 1114 1121 9529364 disease NN I-NP O
19 1121 1122 9529364 . . O O

1 1123 1125 9529364 We PRP B-NP O
2 1126 1134 9529364 analyzed VBD B-VP O
3 1135 1143 9529364 genotype NN B-NP O
4 1143 1144 9529364 / SYM B-NP O
5 1144 1153 9529364 phenotype NN I-NP O
6 1154 1166 9529364 correlations NNS I-NP O
7 1166 1167 9529364 , , O O
8 1168 1170 9529364 on IN B-PP O
9 1171 1174 9529364 the DT B-NP O
10 1175 1180 9529364 basis NN I-NP O
11 1181 1183 9529364 of IN B-PP O
12 1184 1187 9529364 the DT B-NP O
13 1188 1200 9529364 constitution NN I-NP O
14 1201 1203 9529364 of IN B-PP O
15 1204 1205 9529364 a DT B-NP O
16 1206 1209 9529364 WT1 NN I-NP O
17 1210 1218 9529364 mutation NN I-NP O
18 1219 1227 9529364 database NN I-NP O
19 1228 1230 9529364 of IN B-PP O
20 1231 1233 9529364 84 CD B-NP O
21 1234 1238 9529364 germ NN I-NP O
22 1238 1239 9529364 - HYPH B-NP O
23 1239 1243 9529364 line NN I-NP O
24 1244 1253 9529364 mutations NNS I-NP O
25 1253 1254 9529364 , , O O
26 1255 1257 9529364 to TO B-VP O
27 1258 1265 9529364 compare VB I-VP O
28 1266 1269 9529364 the DT B-NP O
29 1270 1282 9529364 distribution NN I-NP O
30 1283 1286 9529364 and CC I-NP O
31 1287 1291 9529364 type NN I-NP O
32 1292 1294 9529364 of IN B-PP O
33 1295 1304 9529364 mutations NNS B-NP O
34 1304 1305 9529364 , , O O
35 1306 1315 9529364 according VBG B-PP O
36 1316 1318 9529364 to TO B-PP O
37 1319 1322 9529364 the DT B-NP O
38 1323 1332 9529364 different JJ I-NP O
39 1333 1341 9529364 symptoms NNS I-NP O
40 1341 1342 9529364 . . O O

1 1343 1347 9529364 This DT B-NP O
2 1348 1360 9529364 demonstrated VBD B-VP O
3 1361 1362 9529364 ( ( B-LST O
4 1362 1363 9529364 1 LS I-LST O
5 1363 1364 9529364 ) ) O O
6 1365 1368 9529364 the DT B-NP O
7 1369 1380 9529364 association NN I-NP O
8 1381 1388 9529364 between IN B-PP O
9 1389 1398 9529364 mutations NNS B-NP O
10 1399 1401 9529364 in IN B-PP O
11 1402 1407 9529364 exons NNS B-NP O
12 1408 1409 9529364 8 CD B-NP O
13 1410 1413 9529364 and CC I-NP O
14 1414 1415 9529364 9 CD I-NP O
15 1416 1419 9529364 and CC O O
16 1420 1423 9529364 DMS NN B-NP B-Disease
17 1423 1424 9529364 ; : O O
18 1425 1426 9529364 ( ( B-LST O
19 1426 1427 9529364 2 LS I-LST O
20 1427 1428 9529364 ) ) O O
21 1429 1434 9529364 among IN B-PP O
22 1435 1443 9529364 patients NNS B-NP O
23 1444 1448 9529364 with IN B-PP O
24 1449 1452 9529364 DMS NN B-NP B-Disease
25 1452 1453 9529364 , , O O
26 1454 1455 9529364 a DT B-NP O
27 1456 1462 9529364 higher JJR I-NP O
28 1463 1472 9529364 frequency NN I-NP O
29 1473 1475 9529364 of IN B-PP O
30 1476 1480 9529364 exon NN B-NP O
31 1481 1482 9529364 8 CD B-NP O
32 1483 1492 9529364 mutations NNS I-NP O
33 1493 1498 9529364 among IN B-PP O
34 1499 1501 9529364 46 CD B-NP O
35 1501 1502 9529364 , , O O
36 1503 1505 9529364 XY NN B-NP O
37 1506 1514 9529364 patients NNS I-NP O
38 1515 1519 9529364 with IN B-PP O
39 1520 1526 9529364 female JJ B-NP O
40 1527 1536 9529364 phenotype NN I-NP O
41 1537 1541 9529364 than IN B-PP O
42 1542 1547 9529364 among IN B-PP O
43 1548 1550 9529364 46 CD B-NP O
44 1550 1551 9529364 , , O O
45 1552 1554 9529364 XY NN B-NP O
46 1555 1563 9529364 patients NNS I-NP O
47 1564 1568 9529364 with IN B-PP O
48 1569 1575 9529364 sexual JJ B-NP O
49 1576 1585 9529364 ambiguity NN I-NP O
50 1586 1588 9529364 or CC O O
51 1589 1593 9529364 male JJ B-NP O
52 1594 1603 9529364 phenotype NN I-NP O
53 1603 1604 9529364 ; : O O
54 1605 1608 9529364 and CC O O
55 1609 1610 9529364 ( ( B-LST O
56 1610 1611 9529364 3 LS I-LST O
57 1611 1612 9529364 ) ) O O
58 1613 1626 9529364 statistically RB B-NP O
59 1627 1638 9529364 significant JJ I-NP O
60 1639 1647 9529364 evidence NN I-NP O
61 1648 1652 9529364 that IN B-SBAR O
62 1653 1662 9529364 mutations NNS B-NP O
63 1663 1665 9529364 in IN B-PP O
64 1666 1671 9529364 exons NNS B-NP O
65 1672 1673 9529364 8 CD B-NP O
66 1674 1677 9529364 and CC I-NP O
67 1678 1679 9529364 9 CD I-NP O
68 1680 1694 9529364 preferentially RB B-VP O
69 1695 1701 9529364 affect VB I-VP O
70 1702 1707 9529364 amino NN B-NP O
71 1708 1713 9529364 acids NNS I-NP O
72 1714 1718 9529364 with IN B-PP O
73 1719 1728 9529364 different JJ B-NP O
74 1729 1738 9529364 functions NNS I-NP O
75 1738 1739 9529364 . . O O
76 1739 1740 9529364 . . O O

1 0 0 9425239 -DOCSTART- -X- -X- O

1 0 11 9425239 Progression NN B-NP O
2 12 14 9425239 of IN B-PP O
3 15 22 9425239 somatic JJ B-NP O
4 23 26 9425239 CTG NN I-NP O
5 27 33 9425239 repeat NN I-NP O
6 34 40 9425239 length NN I-NP O
7 41 54 9425239 heterogeneity NN I-NP O
8 55 57 9425239 in IN B-PP O
9 58 61 9425239 the DT B-NP O
10 62 67 9425239 blood NN I-NP O
11 68 73 9425239 cells NNS I-NP O
12 74 76 9425239 of IN B-PP O
13 77 85 9425239 myotonic JJ B-NP B-Disease
14 86 95 9425239 dystrophy NN I-NP I-Disease
15 96 104 9425239 patients NNS I-NP O
16 104 105 9425239 . . O O
17 106 109 9425239 The DT B-NP O
18 110 117 9425239 genetic JJ I-NP O
19 118 123 9425239 basis NN I-NP O
20 124 126 9425239 of IN B-PP O
21 127 135 9425239 myotonic JJ B-NP B-Disease
22 136 145 9425239 dystrophy NN I-NP I-Disease
23 146 147 9425239 ( ( O O
24 147 149 9425239 DM NN B-NP B-Disease
25 149 150 9425239 ) ) O O
26 151 153 9425239 is VBZ B-VP O
27 154 157 9425239 the DT B-NP O
28 158 167 9425239 expansion NN I-NP O
29 168 170 9425239 of IN B-PP O
30 171 173 9425239 an DT B-NP O
31 174 182 9425239 unstable JJ I-NP O
32 183 186 9425239 CTG NN I-NP O
33 187 193 9425239 repeat NN I-NP O
34 194 196 9425239 in IN B-PP O
35 197 200 9425239 the DT B-NP O
36 201 203 9425239 34 CD I-NP O
37 204 207 9425239 UTR NN I-NP O
38 208 210 9425239 of IN B-PP O
39 211 214 9425239 the DT B-NP O
40 215 217 9425239 DM NN I-NP B-Disease
41 218 225 9425239 protein NN I-NP O
42 226 232 9425239 kinase NN I-NP O
43 233 237 9425239 gene NN I-NP O
44 238 240 9425239 on IN B-PP O
45 241 251 9425239 chromosome NN B-NP O
46 252 254 9425239 19 CD I-NP O
47 254 255 9425239 . . O O

1 256 259 9425239 One CD B-NP O
2 260 262 9425239 of IN B-PP O
3 263 266 9425239 the DT B-NP O
4 267 276 9425239 principal JJ I-NP O
5 277 285 9425239 features NNS I-NP O
6 286 288 9425239 of IN B-PP O
7 289 292 9425239 the DT B-NP O
8 293 295 9425239 DM NN I-NP B-Disease
9 296 304 9425239 mutation NN I-NP O
10 305 307 9425239 is VBZ B-VP O
11 308 310 9425239 an DT B-NP O
12 311 326 9425239 extraordinarily RB I-NP O
13 327 331 9425239 high JJ I-NP O
14 332 337 9425239 level NN I-NP O
15 338 340 9425239 of IN B-PP O
16 341 348 9425239 somatic JJ B-NP O
17 349 358 9425239 mosaicism NN I-NP O
18 358 359 9425239 , , O O
19 360 363 9425239 due IN B-PP O
20 364 366 9425239 to TO B-PP O
21 367 369 9425239 an DT B-NP O
22 370 379 9425239 extremely RB I-NP O
23 380 384 9425239 high JJ I-NP O
24 385 391 9425239 degree NN I-NP O
25 392 394 9425239 of IN B-PP O
26 395 402 9425239 somatic JJ B-NP O
27 403 414 9425239 instability NN I-NP O
28 415 419 9425239 both CC B-PP O
29 420 426 9425239 within IN B-PP O
30 427 430 9425239 and CC I-PP O
31 431 438 9425239 between IN I-PP O
32 439 448 9425239 different JJ B-NP O
33 449 456 9425239 tissues NNS I-NP O
34 456 457 9425239 . . O O

1 458 462 9425239 This DT B-NP O
2 463 474 9425239 instability NN I-NP O
3 475 482 9425239 appears VBZ B-VP O
4 483 485 9425239 to TO I-VP O
5 486 488 9425239 be VB I-VP O
6 489 495 9425239 biased VBN I-VP O
7 496 503 9425239 towards IN B-PP O
8 504 511 9425239 further JJ B-NP O
9 512 521 9425239 expansion NN I-NP O
10 522 525 9425239 and CC O O
11 526 536 9425239 continuous JJ B-ADJP O
12 537 547 9425239 throughout IN B-PP O
13 548 551 9425239 the DT B-NP O
14 552 556 9425239 life NN I-NP O
15 557 559 9425239 of IN B-PP O
16 560 562 9425239 an DT B-NP O
17 563 573 9425239 individual NN I-NP O
18 573 574 9425239 , , O O
19 575 583 9425239 features NNS B-NP O
20 584 588 9425239 that WDT B-NP O
21 589 594 9425239 could MD B-VP O
22 595 597 9425239 be VB I-VP O
23 598 608 9425239 associated VBN I-VP O
24 609 613 9425239 with IN B-PP O
25 614 617 9425239 the DT B-NP O
26 618 629 9425239 progressive JJ I-NP O
27 630 636 9425239 nature NN I-NP O
28 637 639 9425239 of IN B-PP O
29 640 643 9425239 the DT B-NP O
30 644 651 9425239 disease NN I-NP O
31 651 652 9425239 . . O O

1 653 661 9425239 Although IN B-SBAR O
2 662 672 9425239 increasing VBG B-VP O
3 673 681 9425239 measured VBN B-NP O
4 682 688 9425239 allele NN I-NP O
5 689 693 9425239 size NN I-NP O
6 694 701 9425239 between IN B-PP O
7 702 710 9425239 patients NNS B-NP O
8 711 718 9425239 clearly RB B-ADVP O
9 719 729 9425239 correlates VBZ B-VP O
10 730 734 9425239 with IN B-PP O
11 735 737 9425239 an DT B-NP O
12 738 747 9425239 increased VBN I-NP O
13 748 756 9425239 severity NN I-NP O
14 757 759 9425239 of IN B-PP O
15 760 768 9425239 symptoms NNS B-NP O
16 769 772 9425239 and CC O O
17 773 775 9425239 an DT B-NP O
18 776 783 9425239 earlier JJR I-NP O
19 784 787 9425239 age NN I-NP O
20 788 790 9425239 of IN B-PP O
21 791 796 9425239 onset NN B-NP O
22 796 797 9425239 , , O O
23 798 802 9425239 this DT B-NP O
24 803 814 9425239 correlation NN I-NP O
25 815 817 9425239 is VBZ B-VP O
26 818 821 9425239 not RB O O
27 822 829 9425239 precise JJ B-NP O
28 830 833 9425239 and CC I-NP O
29 834 842 9425239 measured VBN I-NP O
30 843 849 9425239 allele NN I-NP O
31 850 856 9425239 length NN I-NP O
32 857 863 9425239 cannot MD B-VP O
33 864 866 9425239 be VB I-VP O
34 867 871 9425239 used VBN I-VP O
35 872 874 9425239 as IN B-PP O
36 875 877 9425239 an DT B-NP O
37 878 886 9425239 accurate JJ I-NP O
38 887 896 9425239 predictor NN I-NP O
39 897 899 9425239 of IN B-PP O
40 900 903 9425239 age NN B-NP O
41 904 906 9425239 of IN B-PP O
42 907 912 9425239 onset NN B-NP O
43 912 913 9425239 . . O O

1 914 916 9425239 In IN B-SBAR O
2 917 922 9425239 order NN O O
3 923 925 9425239 to TO B-VP O
4 926 933 9425239 further RB I-VP O
5 934 946 9425239 characterize VB I-VP O
6 947 950 9425239 the DT B-NP O
7 951 959 9425239 dynamics NNS I-NP O
8 960 962 9425239 of IN B-PP O
9 963 965 9425239 DM NN B-NP B-Disease
10 966 969 9425239 CTG NN I-NP O
11 970 976 9425239 repeat NN I-NP O
12 977 984 9425239 somatic JJ I-NP O
13 985 996 9425239 instability NN I-NP O
14 996 997 9425239 , , O O
15 998 1000 9425239 we PRP B-NP O
16 1001 1005 9425239 have VBP B-VP O
17 1006 1013 9425239 studied VBN I-VP O
18 1014 1020 9425239 repeat NN B-NP O
19 1021 1027 9425239 length NN I-NP O
20 1028 1035 9425239 changes VBZ B-VP O
21 1036 1040 9425239 over IN B-PP O
22 1041 1045 9425239 time NN B-NP O
23 1046 1048 9425239 in IN B-PP O
24 1049 1052 9425239 111 CD B-NP O
25 1053 1061 9425239 myotonic JJ I-NP B-Disease
26 1062 1071 9425239 dystrophy NN I-NP I-Disease
27 1072 1080 9425239 patients NNS I-NP O
28 1081 1085 9425239 with IN B-PP O
29 1086 1093 9425239 varying VBG B-VP O
30 1094 1102 9425239 clinical JJ B-NP O
31 1103 1111 9425239 severity NN I-NP O
32 1112 1115 9425239 and CC I-NP O
33 1116 1119 9425239 CTG NN I-NP O
34 1120 1126 9425239 repeat NN I-NP O
35 1127 1131 9425239 size NN I-NP O
36 1132 1136 9425239 over IN B-PP O
37 1137 1141 9425239 time NN B-NP O
38 1142 1151 9425239 intervals NNS I-NP O
39 1152 1154 9425239 of IN B-PP O
40 1155 1156 9425239 1 CD B-NP O
41 1156 1157 9425239 - HYPH I-NP O
42 1157 1158 9425239 7 CD I-NP O
43 1159 1164 9425239 years NNS I-NP O
44 1164 1165 9425239 . . O O

1 1166 1168 9425239 We PRP B-NP O
2 1169 1173 9425239 have VBP B-VP O
3 1174 1179 9425239 found VBN I-VP O
4 1180 1181 9425239 a DT B-NP O
5 1182 1188 9425239 direct JJ I-NP O
6 1189 1200 9425239 progression NN I-NP O
7 1201 1203 9425239 of IN B-PP O
8 1204 1207 9425239 the DT B-NP O
9 1208 1212 9425239 size NN I-NP O
10 1213 1226 9425239 heterogeneity NN I-NP O
11 1227 1231 9425239 over IN B-PP O
12 1232 1236 9425239 time NN B-NP O
13 1237 1244 9425239 related VBN B-VP O
14 1245 1247 9425239 to TO B-PP O
15 1248 1255 9425239 initial JJ B-NP O
16 1256 1259 9425239 CTG NN I-NP O
17 1260 1266 9425239 repeat NN I-NP O
18 1267 1271 9425239 size NN I-NP O
19 1272 1275 9425239 and CC O O
20 1276 1279 9425239 the DT B-NP O
21 1280 1284 9425239 time NN I-NP O
22 1285 1293 9425239 interval NN I-NP O
23 1294 1297 9425239 and CC O O
24 1298 1304 9425239 always RB B-VP O
25 1305 1311 9425239 biased VBN I-VP O
26 1312 1319 9425239 towards IN B-PP O
27 1320 1327 9425239 further JJ B-NP O
28 1328 1337 9425239 expansion NN I-NP O
29 1337 1338 9425239 . . O O

1 1339 1347 9425239 Attempts NNS B-NP O
2 1348 1350 9425239 to TO B-VP O
3 1351 1365 9425239 mathematically RB I-VP O
4 1366 1371 9425239 model VB I-VP O
5 1372 1375 9425239 the DT B-NP O
6 1376 1384 9425239 dynamics NNS I-NP O
7 1385 1389 9425239 have VBP B-VP O
8 1390 1396 9425239 proved VBN I-VP O
9 1397 1401 9425239 only RB B-ADJP O
10 1402 1411 9425239 partially RB I-ADJP O
11 1412 1422 9425239 successful JJ I-ADJP O
12 1423 1433 9425239 suggesting VBG B-VP O
13 1434 1438 9425239 that IN B-SBAR O
14 1439 1449 9425239 individual JJ B-NP O
15 1450 1458 9425239 specific JJ I-NP O
16 1459 1466 9425239 genetic JJ I-NP O
17 1467 1470 9425239 and CC I-NP O
18 1470 1471 9425239 / SYM I-NP O
19 1471 1473 9425239 or CC O O
20 1474 1487 9425239 environmental JJ B-NP O
21 1488 1495 9425239 factors NNS I-NP O
22 1496 1500 9425239 also RB B-ADVP O
23 1501 1505 9425239 play VBP B-VP O
24 1506 1507 9425239 a DT B-NP O
25 1508 1512 9425239 role NN I-NP O
26 1513 1515 9425239 in IN B-PP O
27 1516 1523 9425239 somatic JJ B-NP O
28 1524 1533 9425239 mosaicism NN I-NP O
29 1533 1534 9425239 . . O O
30 1534 1535 9425239 . . O O

1 0 0 9580132 -DOCSTART- -X- -X- O

1 0 14 9580132 Identification NN B-NP O
2 15 17 9580132 of IN B-PP O
3 18 19 9580132 a DT B-NP O
4 20 25 9580132 novel JJ I-NP O
5 26 34 9580132 nonsense JJ I-NP O
6 35 43 9580132 mutation NN I-NP O
7 44 47 9580132 and CC O O
8 48 49 9580132 a DT B-NP O
9 50 58 9580132 missense JJ I-NP O
10 59 71 9580132 substitution NN I-NP O
11 72 74 9580132 in IN B-PP O
12 75 78 9580132 the DT B-NP O
13 79 90 9580132 vasopressin NN I-NP O
14 90 91 9580132 - HYPH O O
15 91 102 9580132 neurophysin NN B-NP O
16 103 105 9580132 II CD I-NP O
17 106 110 9580132 gene NN I-NP O
18 111 113 9580132 in IN B-PP O
19 114 117 9580132 two CD B-NP O
20 118 125 9580132 Spanish JJ I-NP O
21 126 134 9580132 kindreds NNS I-NP O
22 135 139 9580132 with IN B-PP O
23 140 148 9580132 familial JJ B-NP B-Disease
24 149 165 9580132 neurohypophyseal JJ I-NP I-Disease
25 166 174 9580132 diabetes NN I-NP I-Disease
26 175 184 9580132 insipidus NN I-NP I-Disease
27 184 185 9580132 . . O O
28 186 194 9580132 Familial JJ B-NP B-Disease
29 195 211 9580132 neurohypophyseal JJ I-NP I-Disease
30 212 220 9580132 diabetes NN I-NP I-Disease
31 221 230 9580132 insipidus NN I-NP I-Disease
32 231 232 9580132 ( ( O O
33 232 236 9580132 FNDI NN B-NP B-Disease
34 236 237 9580132 ) ) O O
35 238 240 9580132 is VBZ B-VP O
36 241 243 9580132 an DT B-NP O
37 244 253 9580132 autosomal JJ I-NP B-Disease
38 254 262 9580132 dominant JJ I-NP I-Disease
39 263 270 9580132 disease NN I-NP I-Disease
40 271 277 9580132 caused VBN B-VP O
41 278 280 9580132 by IN B-PP O
42 281 291 9580132 deficiency NN B-NP O
43 292 294 9580132 in IN B-PP O
44 295 298 9580132 the DT B-NP O
45 299 311 9580132 antidiuretic JJ I-NP O
46 312 319 9580132 hormone NN I-NP O
47 320 328 9580132 arginine NN I-NP O
48 329 340 9580132 vasopressin NN I-NP O
49 341 342 9580132 ( ( O O
50 342 345 9580132 AVP NN B-NP O
51 345 346 9580132 ) ) O O
52 347 354 9580132 encoded VBN B-VP O
53 355 357 9580132 by IN B-PP O
54 358 361 9580132 the DT B-NP O
55 362 365 9580132 AVP NN I-NP O
56 365 366 9580132 - HYPH O O
57 366 377 9580132 neurophysin NN B-NP O
58 378 380 9580132 II CD I-NP O
59 381 382 9580132 ( ( O O
60 382 385 9580132 AVP NN B-NP O
61 385 386 9580132 - HYPH B-NP O
62 386 390 9580132 NPII NN I-NP O
63 390 391 9580132 ) ) O O
64 392 396 9580132 gene NN B-NP O
65 397 399 9580132 on IN B-PP O
66 400 410 9580132 chromosome NN B-NP O
67 411 416 9580132 20p13 CD I-NP O
68 416 417 9580132 . . O O

1 418 420 9580132 In IN B-PP O
2 421 425 9580132 this DT B-NP O
3 426 431 9580132 study NN I-NP O
4 431 432 9580132 , , O O
5 433 435 9580132 we PRP B-NP O
6 436 444 9580132 analyzed VBD B-VP O
7 445 448 9580132 two CD B-NP O
8 449 457 9580132 families NNS I-NP O
9 458 462 9580132 with IN B-PP O
10 463 467 9580132 FNDI NN B-NP B-Disease
11 468 473 9580132 using VBG B-VP O
12 474 480 9580132 direct JJ B-NP O
13 481 490 9580132 automated VBN I-NP O
14 491 502 9580132 fluorescent JJ I-NP O
15 502 503 9580132 , , I-NP O
16 504 509 9580132 solid JJ I-NP O
17 510 515 9580132 phase NN I-NP O
18 515 516 9580132 , , O O
19 517 523 9580132 single JJ B-NP O
20 523 524 9580132 - HYPH I-NP O
21 524 532 9580132 stranded JJ I-NP O
22 533 536 9580132 DNA NN I-NP O
23 537 547 9580132 sequencing NN I-NP O
24 548 550 9580132 of IN B-PP O
25 551 554 9580132 PCR NN B-NP O
26 554 555 9580132 - HYPH O O
27 555 564 9580132 amplified VBN B-NP O
28 565 568 9580132 AVP NN I-NP O
29 568 569 9580132 - HYPH B-NP O
30 569 573 9580132 NPII NN I-NP O
31 574 577 9580132 DNA NN I-NP O
32 577 578 9580132 . . O O

1 579 581 9580132 In IN B-PP O
2 582 585 9580132 one CD B-NP O
3 586 588 9580132 of IN B-PP O
4 589 592 9580132 the DT B-NP O
5 593 601 9580132 families NNS I-NP O
6 601 602 9580132 , , O O
7 603 611 9580132 affected VBN B-NP O
8 612 623 9580132 individuals NNS I-NP O
9 624 633 9580132 presented VBD B-VP O
10 634 635 9580132 a DT B-NP O
11 636 641 9580132 novel JJ I-NP O
12 642 650 9580132 nonsense JJ I-NP O
13 651 659 9580132 mutation NN I-NP O
14 660 662 9580132 in IN B-PP O
15 663 667 9580132 exon NN B-NP O
16 668 669 9580132 3 CD I-NP O
17 670 672 9580132 of IN B-PP O
18 673 676 9580132 the DT B-NP O
19 677 681 9580132 gene NN I-NP O
20 681 682 9580132 , , O O
21 683 693 9580132 consisting VBG B-VP O
22 694 696 9580132 in IN B-PP O
23 697 698 9580132 a DT B-NP O
24 699 700 9580132 G NN I-NP O
25 701 703 9580132 to TO B-PP O
26 704 705 9580132 T NN B-NP O
27 706 716 9580132 transition NN I-NP O
28 717 719 9580132 at IN B-PP O
29 720 730 9580132 nucleotide NN B-NP O
30 731 735 9580132 2101 CD I-NP O
31 735 736 9580132 , , O O
32 737 742 9580132 which WDT B-NP O
33 743 751 9580132 produces VBZ B-VP O
34 752 753 9580132 a DT B-NP O
35 754 758 9580132 stop NN I-NP O
36 759 765 9580132 signal NN I-NP O
37 766 768 9580132 in IN B-PP O
38 769 774 9580132 codon NN B-NP O
39 775 777 9580132 82 CD I-NP O
40 778 779 9580132 ( ( O O
41 779 782 9580132 Glu NN B-NP O
42 782 783 9580132 ) ) O O
43 784 786 9580132 of IN B-PP O
44 787 791 9580132 NPII NN B-NP O
45 791 792 9580132 . . O O

1 793 796 9580132 The DT B-NP O
2 797 806 9580132 premature JJ I-NP O
3 807 818 9580132 termination NN I-NP O
4 819 829 9580132 eliminates VBZ B-VP O
5 830 834 9580132 part NN B-NP O
6 835 837 9580132 of IN B-PP O
7 838 841 9580132 the DT B-NP O
8 842 843 9580132 C NN I-NP O
9 843 844 9580132 - HYPH B-NP O
10 844 852 9580132 terminal JJ I-NP O
11 853 859 9580132 domain NN I-NP O
12 860 862 9580132 of IN B-PP O
13 863 867 9580132 NPII NN B-NP O
14 867 868 9580132 , , O O
15 869 878 9580132 including VBG B-PP O
16 879 880 9580132 a DT B-NP O
17 881 889 9580132 cysteine NN I-NP O
18 890 897 9580132 residue NN I-NP O
19 898 900 9580132 in IN B-PP O
20 901 909 9580132 position NN B-NP O
21 910 912 9580132 85 CD I-NP O
22 912 913 9580132 , , O O
23 914 919 9580132 which WDT B-NP O
24 920 925 9580132 could MD B-VP O
25 926 928 9580132 be VB I-VP O
26 929 937 9580132 involved VBN I-VP O
27 938 940 9580132 in IN B-PP O
28 941 944 9580132 the DT B-NP O
29 945 952 9580132 correct JJ I-NP O
30 953 960 9580132 folding NN I-NP O
31 961 963 9580132 of IN B-PP O
32 964 967 9580132 the DT B-NP O
33 968 978 9580132 prohormone NN I-NP O
34 978 979 9580132 . . O O

1 980 982 9580132 In IN B-PP O
2 983 986 9580132 the DT B-NP O
3 987 993 9580132 second JJ I-NP O
4 994 1000 9580132 family NN I-NP O
5 1000 1001 9580132 , , O O
6 1002 1003 9580132 a DT B-NP O
7 1004 1009 9580132 G279A NN I-NP O
8 1010 1022 9580132 substitution NN I-NP O
9 1023 1025 9580132 at IN B-PP O
10 1026 1034 9580132 position NN B-NP O
11 1035 1036 9580132 - HYPH B-NP O
12 1036 1037 9580132 1 CD I-NP O
13 1038 1040 9580132 of IN B-PP O
14 1041 1044 9580132 the DT B-NP O
15 1045 1051 9580132 signal NN I-NP O
16 1052 1059 9580132 peptide NN I-NP O
17 1060 1063 9580132 was VBD B-VP O
18 1064 1072 9580132 observed VBN I-VP O
19 1073 1075 9580132 in IN B-PP O
20 1076 1079 9580132 all DT B-NP O
21 1080 1088 9580132 affected VBN I-NP O
22 1089 1100 9580132 individuals NNS I-NP O
23 1100 1101 9580132 . . O O

1 1102 1106 9580132 This DT B-NP O
2 1107 1115 9580132 missense JJ I-NP O
3 1116 1124 9580132 mutation NN I-NP O
4 1124 1125 9580132 , , O O
5 1126 1131 9580132 which WDT B-NP O
6 1132 1140 9580132 replaces VBZ B-VP O
7 1141 1144 9580132 Ala NN B-NP O
8 1145 1149 9580132 with IN B-PP O
9 1150 1153 9580132 Thr NN B-NP O
10 1153 1154 9580132 , , O O
11 1155 1157 9580132 is VBZ B-VP O
12 1158 1166 9580132 frequent JJ B-ADJP O
13 1167 1172 9580132 among IN B-PP O
14 1173 1177 9580132 FNDI NNP B-NP B-Disease
15 1178 1186 9580132 patients NNS I-NP O
16 1187 1190 9580132 and CC O O
17 1191 1193 9580132 is VBZ B-VP O
18 1194 1201 9580132 thought VBN I-VP O
19 1202 1204 9580132 to TO I-VP O
20 1205 1211 9580132 reduce VB I-VP O
21 1212 1215 9580132 the DT B-NP O
22 1216 1226 9580132 efficiency NN I-NP O
23 1227 1229 9580132 of IN B-PP O
24 1230 1238 9580132 cleavage NN B-NP O
25 1239 1241 9580132 by IN B-PP O
26 1242 1248 9580132 signal NN B-NP O
27 1249 1259 9580132 peptidases NNS I-NP O
28 1259 1260 9580132 . . O O
29 1260 1261 9580132 . . O O

1 0 0 9506545 -DOCSTART- -X- -X- O

1 0 3 9506545 Eye NN B-NP B-Disease
2 4 12 9506545 movement NN I-NP I-Disease
3 13 26 9506545 abnormalities NNS I-NP I-Disease
4 27 36 9506545 correlate VBP B-VP O
5 37 41 9506545 with IN B-PP O
6 42 50 9506545 genotype NN B-NP O
7 51 53 9506545 in IN B-PP O
8 54 63 9506545 autosomal JJ B-NP O
9 64 72 9506545 dominant JJ I-NP O
10 73 83 9506545 cerebellar JJ I-NP B-Disease
11 84 90 9506545 ataxia NN I-NP I-Disease
12 91 95 9506545 type NN I-NP I-Disease
13 96 97 9506545 I CD I-NP I-Disease
14 97 98 9506545 . . O O
15 99 101 9506545 We PRP B-NP O
16 102 110 9506545 compared VBD B-VP O
17 111 121 9506545 horizontal JJ B-NP O
18 122 125 9506545 eye NN I-NP O
19 126 135 9506545 movements NNS I-NP O
20 136 137 9506545 ( ( O O
21 137 145 9506545 visually RB B-NP O
22 146 152 9506545 guided VBN I-NP O
23 153 161 9506545 saccades NNS I-NP O
24 161 162 9506545 , , O O
25 163 175 9506545 antisaccades NNS B-NP O
26 175 176 9506545 , , O O
27 177 180 9506545 and CC O O
28 181 187 9506545 smooth JJ B-NP O
29 188 195 9506545 pursuit NN I-NP O
30 195 196 9506545 ) ) O O
31 197 199 9506545 in IN B-PP O
32 200 207 9506545 control JJ B-NP O
33 208 216 9506545 subjects NNS I-NP O
34 217 218 9506545 ( ( O O
35 218 219 9506545 n NN B-NP O
36 220 221 9506545 = SYM B-VP O
37 222 224 9506545 14 CD B-NP O
38 224 225 9506545 ) ) O O
39 226 229 9506545 and CC O O
40 230 238 9506545 patients NNS B-NP O
41 239 243 9506545 with IN B-PP O
42 244 249 9506545 three CD B-NP O
43 250 255 9506545 forms NNS I-NP O
44 256 258 9506545 of IN B-PP O
45 259 268 9506545 autosomal JJ B-NP O
46 269 277 9506545 dominant JJ I-NP O
47 278 288 9506545 cerebellar JJ I-NP B-Disease
48 289 296 9506545 ataxias NN I-NP I-Disease
49 297 301 9506545 type NN I-NP I-Disease
50 302 303 9506545 I CD I-NP I-Disease
51 304 319 9506545 spinocerebellar NN I-NP B-Disease
52 320 327 9506545 ataxias NNS I-NP I-Disease
53 328 329 9506545 1 CD B-NP I-Disease
54 330 333 9506545 and CC I-NP I-Disease
55 334 335 9506545 2 CD I-NP I-Disease
56 336 337 9506545 ( ( O O
57 337 341 9506545 SCA1 NN B-NP B-Disease
58 341 342 9506545 , , O O
59 343 344 9506545 n NN B-NP O
60 345 346 9506545 = SYM B-VP O
61 347 349 9506545 11 CD B-NP O
62 349 350 9506545 ; : O O
63 351 355 9506545 SCA2 NN B-NP B-Disease
64 355 356 9506545 , , O O
65 357 358 9506545 n NN B-NP O
66 359 360 9506545 = SYM B-VP O
67 361 363 9506545 10 CD B-NP O
68 363 364 9506545 ) ) O O
69 365 368 9506545 and CC O O
70 369 373 9506545 SCA3 NN B-NP B-Disease
71 373 374 9506545 / SYM O O
72 374 381 9506545 Machado NNP B-NP B-Disease
73 381 382 9506545 - HYPH I-NP I-Disease
74 382 388 9506545 Joseph NNP I-NP I-Disease
75 389 396 9506545 disease NN I-NP I-Disease
76 397 398 9506545 ( ( O O
77 398 401 9506545 MJD NN B-NP B-Disease
78 401 402 9506545 ) ) O O
79 403 404 9506545 ( ( O O
80 404 405 9506545 n NN B-NP O
81 406 407 9506545 = SYM B-VP O
82 408 410 9506545 16 CD B-NP O
83 410 411 9506545 ) ) O O
84 411 412 9506545 . . O O

1 413 415 9506545 In IN B-PP O
2 416 420 9506545 SCA1 NN B-NP B-Disease
3 420 421 9506545 , , O O
4 422 429 9506545 saccade NN B-NP O
5 430 439 9506545 amplitude NN I-NP O
6 440 443 9506545 was VBD B-VP O
7 444 457 9506545 significantly RB I-VP O
8 458 467 9506545 increased VBN I-VP O
9 467 468 9506545 , , O O
10 469 478 9506545 resulting VBG B-VP O
11 479 481 9506545 in IN B-PP O
12 482 493 9506545 hypermetria NN B-NP B-Disease
13 493 494 9506545 . . O O

1 495 498 9506545 The DT B-NP O
2 499 505 9506545 smooth JJ I-NP O
3 506 513 9506545 pursuit NN I-NP O
4 514 518 9506545 gain NN I-NP O
5 519 522 9506545 was VBD B-VP O
6 523 532 9506545 decreased VBN I-VP O
7 532 533 9506545 . . O O

1 534 536 9506545 In IN B-PP O
2 537 541 9506545 SCA2 NN B-NP B-Disease
3 541 542 9506545 , , O O
4 543 550 9506545 saccade NN B-NP O
5 551 559 9506545 velocity NN I-NP O
6 560 563 9506545 was VBD B-VP O
7 564 572 9506545 markedly RB I-VP O
8 573 582 9506545 decreased VBN I-VP O
9 582 583 9506545 . . O O

1 584 587 9506545 The DT B-NP O
2 588 598 9506545 percentage NN I-NP O
3 599 601 9506545 of IN B-PP O
4 602 608 9506545 errors NNS B-NP O
5 609 611 9506545 in IN B-PP O
6 612 624 9506545 antisaccades NNS B-NP O
7 625 628 9506545 was VBD B-VP O
8 629 636 9506545 greatly RB I-VP O
9 637 646 9506545 increased VBN I-VP O
10 647 650 9506545 and CC O O
11 651 654 9506545 was VBD B-VP O
12 655 668 9506545 significantly RB I-VP O
13 669 679 9506545 correlated VBN I-VP O
14 680 684 9506545 with IN B-PP O
15 685 688 9506545 age NN B-NP O
16 689 691 9506545 at IN B-PP O
17 692 699 9506545 disease NN B-NP O
18 700 705 9506545 onset NN I-NP O
19 705 706 9506545 . . O O

1 707 709 9506545 In IN B-PP O
2 710 718 9506545 addition NN B-NP O
3 718 719 9506545 , , O O
4 720 721 9506545 a DT B-NP O
5 722 733 9506545 correlation NN I-NP O
6 734 741 9506545 between IN B-PP O
7 742 748 9506545 smooth JJ B-NP O
8 749 756 9506545 pursuit NN I-NP O
9 757 761 9506545 gain NN I-NP O
10 762 765 9506545 and CC O O
11 766 769 9506545 the DT B-NP O
12 770 776 9506545 number NN I-NP O
13 777 779 9506545 of IN B-PP O
14 780 793 9506545 trinucleotide NN B-NP O
15 794 801 9506545 repeats NNS I-NP O
16 802 805 9506545 was VBD B-VP O
17 806 811 9506545 found VBN I-VP O
18 811 812 9506545 . . O O

1 813 815 9506545 In IN B-PP O
2 816 820 9506545 SCA3 NN B-NP B-Disease
3 820 821 9506545 , , O O
4 822 826 9506545 gaze NN B-NP B-Disease
5 826 827 9506545 - HYPH B-VP I-Disease
6 827 833 9506545 evoked VBN B-NP I-Disease
7 834 843 9506545 nystagmus NN I-NP I-Disease
8 844 847 9506545 was VBD B-VP O
9 848 853 9506545 often RB B-ADVP O
10 854 861 9506545 present JJ B-ADJP O
11 862 864 9506545 as IN B-SBAR O
12 865 868 9506545 was VBD B-VP O
13 869 876 9506545 saccade NN B-NP O
14 877 887 9506545 hypometria NN I-NP O
15 888 891 9506545 and CC O O
16 892 898 9506545 smooth JJ B-NP O
17 899 906 9506545 pursuit NN I-NP O
18 907 911 9506545 gain NN I-NP O
19 912 915 9506545 was VBD B-VP O
20 916 924 9506545 markedly RB I-VP O
21 925 934 9506545 decreased VBN I-VP O
22 934 935 9506545 . . O O

1 936 941 9506545 Three CD B-NP O
2 942 947 9506545 major JJ I-NP O
3 948 956 9506545 criteria NNS I-NP O
4 956 957 9506545 , , O O
5 958 965 9506545 saccade NN B-NP O
6 966 975 9506545 amplitude NN I-NP O
7 975 976 9506545 , , O O
8 977 984 9506545 saccade NN B-NP O
9 985 993 9506545 velocity NN I-NP O
10 993 994 9506545 , , O O
11 995 998 9506545 and CC O O
12 999 1007 9506545 presence NN B-NP O
13 1008 1010 9506545 of IN B-PP O
14 1011 1015 9506545 gaze NN B-NP B-Disease
15 1015 1016 9506545 - HYPH B-NP I-Disease
16 1016 1022 9506545 evoked VBN I-NP I-Disease
17 1023 1032 9506545 nystagmus NN I-NP I-Disease
18 1032 1033 9506545 , , O O
19 1034 1043 9506545 permitted VBD B-VP O
20 1044 1047 9506545 the DT B-NP O
21 1048 1055 9506545 correct JJ I-NP O
22 1056 1066 9506545 assignment NN I-NP O
23 1067 1069 9506545 of IN B-PP O
24 1070 1073 9506545 90% NN B-NP O
25 1074 1076 9506545 of IN B-PP O
26 1077 1080 9506545 the DT B-NP O
27 1081 1085 9506545 SCA1 NN I-NP B-Disease
28 1085 1086 9506545 , , O O
29 1087 1090 9506545 90% CD B-NP O
30 1091 1093 9506545 of IN B-PP O
31 1094 1097 9506545 the DT B-NP O
32 1098 1102 9506545 SCA2 NN I-NP B-Disease
33 1102 1103 9506545 , , O O
34 1104 1107 9506545 and CC O O
35 1108 1111 9506545 93% CD B-NP O
36 1112 1114 9506545 of IN B-PP O
37 1115 1118 9506545 the DT B-NP O
38 1119 1127 9506545 patients NNS I-NP O
39 1128 1132 9506545 with IN B-PP O
40 1133 1137 9506545 SCA3 NN B-NP B-Disease
41 1138 1140 9506545 to TO B-PP O
42 1141 1146 9506545 their PRP$ B-NP O
43 1147 1158 9506545 genetically RB I-NP O
44 1159 1168 9506545 confirmed VBN I-NP O
45 1169 1176 9506545 patient NN I-NP O
46 1177 1182 9506545 group NN I-NP O
47 1183 1186 9506545 and CC O O
48 1186 1187 9506545 , , O O
49 1188 1197 9506545 therefore RB B-ADVP O
50 1197 1198 9506545 , , O O
51 1199 1202 9506545 may MD B-VP O
52 1203 1207 9506545 help VB I-VP O
53 1208 1214 9506545 orient JJ B-NP O
54 1215 1224 9506545 diagnoses NNS I-NP O
55 1225 1227 9506545 of IN B-PP O
56 1228 1232 9506545 SCA1 NN B-NP B-Disease
57 1232 1233 9506545 , , O O
58 1234 1238 9506545 SCA2 NN B-NP B-Disease
59 1238 1239 9506545 , , O O
60 1240 1243 9506545 and CC O O
61 1244 1248 9506545 SCA3 NN B-NP B-Disease
62 1249 1251 9506545 at IN B-PP O
63 1252 1257 9506545 early JJ B-NP O
64 1258 1266 9506545 clinical JJ I-NP O
65 1267 1273 9506545 stages NNS I-NP O
66 1274 1276 9506545 of IN B-PP O
67 1277 1280 9506545 the DT B-NP O
68 1281 1289 9506545 diseases NNS I-NP O
69 1289 1290 9506545 . . O O
70 1290 1291 9506545 . . O O

1 0 0 9927033 -DOCSTART- -X- -X- O

1 0 5 9927033 Human JJ B-NP O
2 6 10 9927033 MLH1 NN I-NP O
3 11 21 9927033 deficiency NN I-NP O
4 22 33 9927033 predisposes VBZ B-VP O
5 34 36 9927033 to TO B-PP O
6 37 50 9927033 hematological JJ B-NP B-Disease
7 51 61 9927033 malignancy NN I-NP I-Disease
8 62 65 9927033 and CC I-NP O
9 66 83 9927033 neurofibromatosis NN I-NP B-Disease
10 84 88 9927033 type NN I-NP I-Disease
11 89 90 9927033 1 CD I-NP I-Disease
12 90 91 9927033 . . I-NP O
13 92 104 9927033 Heterozygous JJ I-NP O
14 105 109 9927033 germ NN I-NP O
15 109 110 9927033 - HYPH I-NP O
16 110 114 9927033 line NN I-NP O
17 115 124 9927033 mutations NNS I-NP O
18 125 127 9927033 in IN B-PP O
19 128 131 9927033 the DT B-NP O
20 132 135 9927033 DNA NN I-NP O
21 136 144 9927033 mismatch NN I-NP O
22 145 151 9927033 repair NN I-NP O
23 152 157 9927033 genes NNS I-NP O
24 158 162 9927033 lead VBP B-VP O
25 163 165 9927033 to TO B-PP O
26 166 176 9927033 hereditary JJ B-NP B-Disease
27 177 189 9927033 nonpolyposis JJ I-NP I-Disease
28 190 200 9927033 colorectal JJ I-NP I-Disease
29 201 207 9927033 cancer NN I-NP I-Disease
30 207 208 9927033 . . O O

1 209 212 9927033 The DT B-NP O
2 213 220 9927033 disease NN I-NP O
3 221 235 9927033 susceptibility NN I-NP O
4 236 238 9927033 of IN B-PP O
5 239 250 9927033 individuals NNS B-NP O
6 251 254 9927033 who WP B-NP O
7 255 271 9927033 constitutionally RB B-ADVP O
8 272 276 9927033 lack VBP B-VP O
9 277 281 9927033 both CC O O
10 282 286 9927033 wild JJ B-NP O
11 286 287 9927033 - HYPH I-NP O
12 287 291 9927033 type NN I-NP O
13 292 299 9927033 alleles NNS I-NP O
14 300 302 9927033 is VBZ B-VP O
15 303 310 9927033 unknown JJ B-ADJP O
16 310 311 9927033 . . O O

1 312 314 9927033 We PRP B-NP O
2 315 319 9927033 have VBP B-VP O
3 320 330 9927033 identified VBN I-VP O
4 331 336 9927033 three CD B-NP O
5 337 346 9927033 offspring NN I-NP O
6 347 349 9927033 in IN B-PP O
7 350 351 9927033 a DT B-NP O
8 352 362 9927033 hereditary JJ I-NP B-Disease
9 363 375 9927033 nonpolyposis NN I-NP I-Disease
10 376 386 9927033 colorectal JJ I-NP I-Disease
11 387 393 9927033 cancer NN I-NP I-Disease
12 394 400 9927033 family NN I-NP O
13 401 404 9927033 who WP B-NP O
14 405 414 9927033 developed VBD B-VP O
15 415 428 9927033 hematological JJ B-NP B-Disease
16 429 439 9927033 malignancy NN I-NP I-Disease
17 440 442 9927033 at IN B-PP O
18 443 444 9927033 a DT B-NP O
19 445 449 9927033 very RB I-NP O
20 450 455 9927033 early JJ I-NP O
21 456 459 9927033 age NN I-NP O
22 459 460 9927033 , , O O
23 461 464 9927033 and CC O O
24 465 467 9927033 at IN B-NP O
25 468 473 9927033 least JJS I-NP O
26 474 477 9927033 two CD I-NP O
27 478 480 9927033 of IN B-PP O
28 481 485 9927033 them PRP B-NP O
29 486 495 9927033 displayed VBD B-VP O
30 496 501 9927033 signs NNS B-NP O
31 502 504 9927033 of IN B-PP O
32 505 522 9927033 neurofibromatosis NN B-NP B-Disease
33 523 527 9927033 type NN I-NP I-Disease
34 528 529 9927033 1 CD I-NP I-Disease
35 530 531 9927033 ( ( O O
36 531 534 9927033 NF1 NN B-NP B-Disease
37 534 535 9927033 ) ) O O
38 535 536 9927033 . . O O

1 537 540 9927033 DNA NN B-NP O
2 541 549 9927033 sequence NN I-NP O
3 550 558 9927033 analysis NN I-NP O
4 559 562 9927033 and CC I-NP O
5 563 569 9927033 allele NN I-NP O
6 569 570 9927033 - HYPH B-NP O
7 570 578 9927033 specific JJ I-NP O
8 579 592 9927033 amplification NN I-NP O
9 593 595 9927033 in IN B-PP O
10 596 599 9927033 two CD B-NP O
11 600 608 9927033 siblings NNS I-NP O
12 609 617 9927033 revealed VBD B-VP O
13 618 619 9927033 a DT B-NP O
14 620 630 9927033 homozygous JJ I-NP O
15 631 635 9927033 MLH1 NN I-NP O
16 636 644 9927033 mutation NN I-NP O
17 645 646 9927033 ( ( O O
18 646 651 9927033 C676T NN B-NP O
19 651 652 9927033 - SYM O O
20 652 653 9927033 - HYPH B-NP O
21 654 655 9927033 > SYM I-NP O
22 656 666 9927033 Arg226Stop NN I-NP O
23 666 667 9927033 ) ) O O
24 667 668 9927033 . . O O

1 669 673 9927033 Thus RB B-ADVP O
2 673 674 9927033 , , O O
3 675 676 9927033 a DT B-NP O
4 677 687 9927033 homozygous JJ I-NP O
5 688 692 9927033 germ NN I-NP O
6 692 693 9927033 - HYPH I-NP O
7 693 697 9927033 line NN I-NP O
8 698 702 9927033 MLH1 NN I-NP O
9 703 711 9927033 mutation NN I-NP O
10 712 715 9927033 and CC O O
11 716 726 9927033 consequent JJ B-NP O
12 727 735 9927033 mismatch NN I-NP O
13 736 742 9927033 repair NN I-NP O
14 743 753 9927033 deficiency NN I-NP O
15 754 761 9927033 results VBZ B-VP O
16 762 764 9927033 in IN B-PP O
17 765 766 9927033 a DT B-NP O
18 767 774 9927033 mutator NN I-NP O
19 775 784 9927033 phenotype NN I-NP O
20 785 798 9927033 characterized VBN B-VP O
21 799 801 9927033 by IN B-PP O
22 802 810 9927033 leukemia NN B-NP B-Disease
23 811 814 9927033 and CC O O
24 814 815 9927033 / SYM B-NP O
25 815 817 9927033 or CC O O
26 818 826 9927033 lymphoma NN B-NP B-Disease
27 827 837 9927033 associated VBN B-VP O
28 838 842 9927033 with IN B-PP O
29 843 860 9927033 neurofibromatosis NN B-NP B-Disease
30 861 865 9927033 type NN I-NP I-Disease
31 866 867 9927033 1 CD I-NP I-Disease
32 867 868 9927033 . . O O
33 868 869 9927033 . . O O

1 0 0 9463314 -DOCSTART- -X- -X- O

1 0 3 9463314 ATM NN B-NP O
2 4 13 9463314 mutations NNS I-NP O
3 14 17 9463314 and CC I-NP O
4 18 28 9463314 phenotypes NNS I-NP O
5 29 31 9463314 in IN B-PP O
6 32 38 9463314 ataxia NN B-NP B-Disease
7 38 39 9463314 - HYPH B-NP I-Disease
8 39 53 9463314 telangiectasia NN I-NP I-Disease
9 54 62 9463314 families NNS I-NP O
10 63 65 9463314 in IN B-PP O
11 66 69 9463314 the DT B-NP O
12 70 77 9463314 British JJ I-NP O
13 78 83 9463314 Isles NNPS I-NP O
14 83 84 9463314 : : O O
15 85 95 9463314 expression NN B-NP O
16 96 98 9463314 of IN B-PP O
17 99 105 9463314 mutant JJ B-NP O
18 106 109 9463314 ATM NN I-NP O
19 110 113 9463314 and CC O O
20 114 117 9463314 the DT B-NP O
21 118 122 9463314 risk NN I-NP O
22 123 125 9463314 of IN B-PP O
23 126 134 9463314 leukemia NN B-NP B-Disease
24 134 135 9463314 , , O O
25 136 144 9463314 lymphoma NN B-NP B-Disease
26 144 145 9463314 , , O O
27 146 149 9463314 and CC O O
28 150 156 9463314 breast NN B-NP B-Disease
29 157 163 9463314 cancer NN I-NP I-Disease
30 163 164 9463314 . . O O
31 165 167 9463314 We PRP B-NP O
32 168 174 9463314 report VBP B-VP O
33 175 178 9463314 the DT B-NP O
34 179 187 9463314 spectrum NN I-NP O
35 188 190 9463314 of IN B-PP O
36 191 193 9463314 59 CD B-NP O
37 194 197 9463314 ATM NN I-NP O
38 198 207 9463314 mutations NNS I-NP O
39 208 216 9463314 observed VBN B-VP O
40 217 219 9463314 in IN B-PP O
41 220 226 9463314 ataxia NN B-NP B-Disease
42 226 227 9463314 - HYPH B-NP I-Disease
43 227 241 9463314 telangiectasia NN I-NP I-Disease
44 242 243 9463314 ( ( O O
45 243 244 9463314 A NN B-NP B-Disease
46 244 245 9463314 - HYPH I-NP I-Disease
47 245 246 9463314 T NN I-NP I-Disease
48 246 247 9463314 ) ) O O
49 248 256 9463314 patients NNS B-NP O
50 257 259 9463314 in IN B-PP O
51 260 263 9463314 the DT B-NP O
52 264 271 9463314 British JJ I-NP O
53 272 277 9463314 Isles NNPS I-NP O
54 277 278 9463314 . . O O

1 279 281 9463314 Of IN B-PP O
2 282 284 9463314 51 CD B-NP O
3 285 288 9463314 ATM NN I-NP O
4 289 298 9463314 mutations NNS I-NP O
5 299 309 9463314 identified VBN B-VP O
6 310 312 9463314 in IN B-PP O
7 313 321 9463314 families NNS B-NP O
8 322 328 9463314 native JJ B-ADJP O
9 329 331 9463314 to TO B-PP O
10 332 335 9463314 the DT B-NP O
11 336 343 9463314 British JJ I-NP O
12 344 349 9463314 Isles NNPS I-NP O
13 349 350 9463314 , , O O
14 351 353 9463314 11 CD B-NP O
15 354 358 9463314 were VBD B-VP O
16 359 366 9463314 founder NN B-NP O
17 367 376 9463314 mutations NNS I-NP O
18 376 377 9463314 , , O O
19 378 381 9463314 and CC O O
20 382 383 9463314 2 CD B-NP O
21 384 386 9463314 of IN B-PP O
22 387 392 9463314 these DT B-NP O
23 393 395 9463314 11 CD I-NP O
24 396 405 9463314 conferred VBD B-VP O
25 406 407 9463314 a DT B-NP O
26 408 414 9463314 milder JJR I-NP O
27 415 423 9463314 clinical JJ I-NP O
28 424 433 9463314 phenotype NN I-NP O
29 434 438 9463314 with IN B-PP O
30 439 446 9463314 respect NN B-NP O
31 447 449 9463314 to TO B-PP O
32 450 454 9463314 both CC O O
33 455 465 9463314 cerebellar JJ B-NP B-Disease
34 466 478 9463314 degeneration NN I-NP I-Disease
35 479 482 9463314 and CC O O
36 483 491 9463314 cellular JJ B-NP O
37 492 500 9463314 features NNS I-NP O
38 500 501 9463314 . . O O

1 502 504 9463314 We PRP B-NP O
2 505 511 9463314 report VBP B-VP O
3 511 512 9463314 , , O O
4 513 515 9463314 in IN B-PP O
5 516 519 9463314 two CD B-NP O
6 520 521 9463314 A NN I-NP B-Disease
7 521 522 9463314 - HYPH I-NP I-Disease
8 522 523 9463314 T NN I-NP I-Disease
9 524 532 9463314 families NNS I-NP O
10 532 533 9463314 , , O O
11 534 536 9463314 an DT B-NP O
12 537 540 9463314 ATM NN I-NP O
13 541 549 9463314 mutation NN I-NP O
14 550 551 9463314 ( ( O O
15 551 556 9463314 7271T NN B-NP O
16 556 557 9463314 - SYM O O
17 557 558 9463314 - HYPH B-NP O
18 559 560 9463314 > SYM I-NP O
19 561 562 9463314 G NN I-NP O
20 562 563 9463314 ) ) O O
21 564 568 9463314 that WDT B-NP O
22 569 572 9463314 may MD B-VP O
23 573 575 9463314 be VB I-VP O
24 576 586 9463314 associated VBN I-VP O
25 587 591 9463314 with IN B-PP O
26 592 594 9463314 an DT B-NP O
27 595 604 9463314 increased VBN I-NP O
28 605 609 9463314 risk NN I-NP O
29 610 612 9463314 of IN B-PP O
30 613 619 9463314 breast NN B-NP B-Disease
31 620 626 9463314 cancer NN I-NP I-Disease
32 627 629 9463314 in IN B-PP O
33 630 634 9463314 both CC B-NP O
34 635 646 9463314 homozygotes NNS I-NP O
35 647 650 9463314 and CC I-NP O
36 651 664 9463314 heterozygotes NNS I-NP O
37 665 666 9463314 ( ( O O
38 666 674 9463314 relative JJ B-NP O
39 675 679 9463314 risk NN I-NP O
40 680 682 9463314 12 CD I-NP O
41 682 683 9463314 . . O O

1 684 685 9463314 7 CD B-NP O
2 685 686 9463314 ; : O O
3 687 688 9463314 P NN B-NP O
4 689 690 9463314 = JJ B-ADJP O
5 690 691 9463314 . . O O

1 692 696 9463314 0025 CD B-NP O
2 696 697 9463314 ) ) O O
3 697 698 9463314 , , O O
4 699 707 9463314 although IN B-SBAR O
5 708 713 9463314 there EX B-NP O
6 714 716 9463314 is VBZ B-VP O
7 717 718 9463314 a DT B-NP O
8 719 723 9463314 less RBR I-NP O
9 724 730 9463314 severe JJ I-NP O
10 731 732 9463314 A NN I-NP B-Disease
11 732 733 9463314 - HYPH I-NP I-Disease
12 733 734 9463314 T NN I-NP I-Disease
13 735 744 9463314 phenotype NN I-NP O
14 745 747 9463314 in IN B-PP O
15 748 753 9463314 terms NNS B-NP O
16 754 756 9463314 of IN B-PP O
17 757 760 9463314 the DT B-NP O
18 761 767 9463314 degree NN I-NP O
19 768 770 9463314 of IN B-PP O
20 771 781 9463314 cerebellar JJ B-NP B-Disease
21 782 794 9463314 degeneration NN I-NP I-Disease
22 794 795 9463314 . . O O

1 796 800 9463314 This DT B-NP O
2 801 809 9463314 mutation NN I-NP O
3 810 811 9463314 ( ( O O
4 811 816 9463314 7271T NN B-NP O
5 816 817 9463314 - SYM O O
6 817 818 9463314 - HYPH B-NP O
7 819 820 9463314 > SYM I-NP O
8 821 822 9463314 G NN I-NP O
9 822 823 9463314 ) ) O O
10 824 828 9463314 also RB B-ADVP O
11 829 835 9463314 allows VBZ B-VP O
12 836 846 9463314 expression NN B-NP O
13 847 849 9463314 of IN B-PP O
14 850 854 9463314 full JJ B-NP O
15 854 855 9463314 - HYPH I-NP O
16 855 861 9463314 length NN I-NP O
17 862 865 9463314 ATM NN I-NP O
18 866 873 9463314 protein NN I-NP O
19 874 876 9463314 at IN B-PP O
20 877 878 9463314 a DT B-NP O
21 879 884 9463314 level NN I-NP O
22 885 895 9463314 comparable JJ B-ADJP O
23 896 900 9463314 with IN B-PP O
24 901 905 9463314 that DT B-NP O
25 906 908 9463314 in IN B-PP O
26 909 919 9463314 unaffected JJ B-NP O
27 920 931 9463314 individuals NNS I-NP O
28 931 932 9463314 . . O O

1 933 935 9463314 In IN B-PP O
2 936 944 9463314 addition NN B-NP O
3 944 945 9463314 , , O O
4 946 948 9463314 we PRP B-NP O
5 949 953 9463314 have VBP B-VP O
6 954 961 9463314 studied VBN I-VP O
7 962 964 9463314 18 CD B-NP O
8 965 966 9463314 A NN I-NP B-Disease
9 966 967 9463314 - HYPH B-NP I-Disease
10 967 968 9463314 T NN I-NP I-Disease
11 969 977 9463314 patients NNS I-NP O
12 977 978 9463314 , , O O
13 979 981 9463314 in IN B-PP O
14 982 984 9463314 15 CD B-NP O
15 985 993 9463314 families NNS I-NP O
16 993 994 9463314 , , O O
17 995 998 9463314 who WP B-NP O
18 999 1008 9463314 developed VBD B-VP O
19 1009 1017 9463314 leukemia NN B-NP B-Disease
20 1017 1018 9463314 , , O O
21 1019 1027 9463314 lymphoma NN B-NP B-Disease
22 1027 1028 9463314 , , O O
23 1029 1040 9463314 preleukemic JJ B-NP O
24 1041 1042 9463314 T NN I-NP O
25 1042 1043 9463314 - HYPH B-NP O
26 1043 1047 9463314 cell NN I-NP O
27 1048 1061 9463314 proliferation NN I-NP O
28 1061 1062 9463314 , , O O
29 1063 1065 9463314 or CC O O
30 1066 1073 9463314 Hodgkin NN B-NP B-Disease
31 1074 1082 9463314 lymphoma NN I-NP I-Disease
32 1082 1083 9463314 , , O O
33 1084 1090 9463314 mostly RB B-ADVP O
34 1091 1093 9463314 in IN B-PP O
35 1094 1103 9463314 childhood NN B-NP O
36 1103 1104 9463314 . . O O

1 1105 1106 9463314 A DT B-NP O
2 1107 1111 9463314 wide JJ I-NP O
3 1112 1119 9463314 variety NN I-NP O
4 1120 1122 9463314 of IN B-PP O
5 1123 1126 9463314 ATM NN B-NP O
6 1127 1135 9463314 mutation NN I-NP O
7 1136 1141 9463314 types NNS I-NP O
8 1141 1142 9463314 , , O O
9 1143 1152 9463314 including VBG B-PP O
10 1153 1161 9463314 missense JJ B-NP O
11 1162 1171 9463314 mutations NNS I-NP O
12 1172 1175 9463314 and CC B-PP O
13 1176 1178 9463314 in IN B-PP O
14 1178 1179 9463314 - HYPH B-NP O
15 1179 1184 9463314 frame NN I-NP O
16 1185 1194 9463314 deletions NNS I-NP O
17 1194 1195 9463314 , , O O
18 1196 1200 9463314 were VBD B-VP O
19 1201 1205 9463314 seen VBN I-VP O
20 1206 1208 9463314 in IN B-PP O
21 1209 1214 9463314 these DT B-NP O
22 1215 1223 9463314 patients NNS I-NP O
23 1223 1224 9463314 . . O O

1 1225 1227 9463314 We PRP B-NP O
2 1228 1232 9463314 also RB B-ADVP O
3 1233 1237 9463314 show VBP B-VP O
4 1238 1242 9463314 that IN B-SBAR O
5 1243 1246 9463314 25% NN B-NP O
6 1247 1249 9463314 of IN B-PP O
7 1250 1253 9463314 all DT B-NP O
8 1254 1255 9463314 A NN I-NP B-Disease
9 1255 1256 9463314 - HYPH I-NP I-Disease
10 1256 1257 9463314 T NN I-NP I-Disease
11 1258 1266 9463314 patients NNS I-NP O
12 1267 1274 9463314 carried VBD B-VP O
13 1275 1277 9463314 in IN B-PP O
14 1277 1278 9463314 - HYPH B-NP O
15 1278 1283 9463314 frame NN I-NP O
16 1284 1293 9463314 deletions NNS I-NP O
17 1294 1296 9463314 or CC O O
18 1297 1305 9463314 missense JJ B-NP O
19 1306 1315 9463314 mutations NNS I-NP O
20 1315 1316 9463314 , , O O
21 1317 1321 9463314 many JJ B-NP O
22 1322 1324 9463314 of IN B-PP O
23 1325 1330 9463314 which WDT B-NP O
24 1331 1335 9463314 were VBD B-VP O
25 1336 1340 9463314 also RB I-VP O
26 1341 1351 9463314 associated VBN I-VP O
27 1352 1356 9463314 with IN B-PP O
28 1357 1367 9463314 expression NN B-NP O
29 1368 1370 9463314 of IN B-PP O
30 1371 1377 9463314 mutant JJ B-NP O
31 1378 1381 9463314 ATM NN I-NP O
32 1382 1389 9463314 protein NN I-NP O
33 1389 1390 9463314 . . O O

1 0 0 9703501 -DOCSTART- -X- -X- O

1 0 5 9703501 BRCA1 NN B-NP O
2 6 14 9703501 required VBN B-VP O
3 15 18 9703501 for IN B-PP O
4 19 32 9703501 transcription NN B-NP O
5 32 33 9703501 - HYPH O O
6 33 40 9703501 coupled VBN B-NP O
7 41 47 9703501 repair NN I-NP O
8 48 50 9703501 of IN B-PP O
9 51 60 9703501 oxidative JJ B-NP O
10 61 64 9703501 DNA NN I-NP O
11 65 71 9703501 damage NN I-NP O
12 71 72 9703501 . . O O
13 73 76 9703501 The DT B-NP O
14 77 83 9703501 breast NN I-NP B-Disease
15 84 87 9703501 and CC O I-Disease
16 88 95 9703501 ovarian JJ B-NP I-Disease
17 96 102 9703501 cancer NN I-NP I-Disease
18 103 117 9703501 susceptibility NN I-NP O
19 118 122 9703501 gene NN I-NP O
20 123 128 9703501 BRCA1 NN I-NP O
21 129 136 9703501 encodes VBZ B-VP O
22 137 138 9703501 a DT B-NP O
23 139 143 9703501 zinc NN I-NP O
24 144 150 9703501 finger NN I-NP O
25 151 158 9703501 protein NN I-NP O
26 159 161 9703501 of IN B-PP O
27 162 169 9703501 unknown JJ B-NP O
28 170 178 9703501 function NN I-NP O
29 178 179 9703501 . . O O

1 180 191 9703501 Association NN B-NP O
2 192 194 9703501 of IN B-PP O
3 195 198 9703501 the DT B-NP O
4 199 204 9703501 BRCA1 NN I-NP O
5 205 212 9703501 protein NN I-NP O
6 213 217 9703501 with IN B-PP O
7 218 221 9703501 the DT B-NP O
8 222 225 9703501 DNA NN I-NP O
9 226 232 9703501 repair NN I-NP O
10 233 240 9703501 protein NN I-NP O
11 241 246 9703501 Rad51 NN I-NP O
12 247 250 9703501 and CC O O
13 251 258 9703501 changes NNS B-NP O
14 259 261 9703501 in IN B-PP O
15 262 265 9703501 the DT B-NP O
16 266 281 9703501 phosphorylation NN I-NP O
17 282 285 9703501 and CC I-NP O
18 286 294 9703501 cellular JJ I-NP O
19 295 307 9703501 localization NN I-NP O
20 308 310 9703501 of IN B-PP O
21 311 314 9703501 the DT B-NP O
22 315 322 9703501 protein NN I-NP O
23 323 328 9703501 after IN B-PP O
24 329 337 9703501 exposure NN B-NP O
25 338 340 9703501 to TO B-PP O
26 341 344 9703501 DNA NN B-NP O
27 344 345 9703501 - HYPH O O
28 345 353 9703501 damaging VBG B-NP O
29 354 360 9703501 agents NNS I-NP O
30 361 364 9703501 are VBP B-VP O
31 365 375 9703501 consistent JJ B-ADJP O
32 376 380 9703501 with IN B-PP O
33 381 382 9703501 a DT B-NP O
34 383 387 9703501 role NN I-NP O
35 388 391 9703501 for IN B-PP O
36 392 397 9703501 BRCA1 NN B-NP O
37 398 400 9703501 in IN B-PP O
38 401 404 9703501 DNA NN B-NP O
39 405 411 9703501 repair NN I-NP O
40 411 412 9703501 . . O O

1 413 417 9703501 Here RB B-ADVP O
2 417 418 9703501 , , O O
3 419 421 9703501 it PRP B-NP O
4 422 424 9703501 is VBZ B-VP O
5 425 430 9703501 shown VBN I-VP O
6 431 435 9703501 that IN B-SBAR O
7 436 441 9703501 mouse NN B-NP O
8 442 451 9703501 embryonic JJ I-NP O
9 452 456 9703501 stem NN I-NP O
10 457 462 9703501 cells NNS I-NP O
11 463 472 9703501 deficient JJ B-ADJP B-Disease
12 473 475 9703501 in IN B-PP I-Disease
13 476 481 9703501 BRCA1 NN B-NP I-Disease
14 482 485 9703501 are VBP B-VP O
15 486 495 9703501 defective JJ B-ADJP O
16 496 498 9703501 in IN B-PP O
17 499 502 9703501 the DT B-NP O
18 503 510 9703501 ability NN I-NP O
19 511 513 9703501 to TO B-VP O
20 514 519 9703501 carry VB I-VP O
21 520 523 9703501 out RP B-PRT O
22 524 537 9703501 transcription NN B-NP O
23 537 538 9703501 - HYPH B-VP O
24 538 545 9703501 coupled VBN B-NP O
25 546 552 9703501 repair NN I-NP O
26 553 555 9703501 of IN B-PP O
27 556 565 9703501 oxidative JJ B-NP O
28 566 569 9703501 DNA NN I-NP O
29 570 576 9703501 damage NN I-NP O
30 576 577 9703501 , , O O
31 578 581 9703501 and CC O O
32 582 585 9703501 are VBP B-VP O
33 586 600 9703501 hypersensitive JJ B-ADJP O
34 601 603 9703501 to TO B-PP O
35 604 612 9703501 ionizing VBG B-VP O
36 613 622 9703501 radiation NN B-NP O
37 623 626 9703501 and CC I-NP O
38 627 635 9703501 hydrogen NN I-NP O
39 636 644 9703501 peroxide NN I-NP O
40 644 645 9703501 . . O O

1 646 651 9703501 These DT B-NP O
2 652 659 9703501 results NNS I-NP O
3 660 667 9703501 suggest VBP B-VP O
4 668 672 9703501 that IN B-SBAR O
5 673 678 9703501 BRCA1 NN B-NP O
6 679 691 9703501 participates VBZ B-VP O
7 691 692 9703501 , , O O
8 693 701 9703501 directly RB B-ADVP O
9 702 704 9703501 or CC I-ADVP O
10 705 715 9703501 indirectly RB I-ADVP O
11 715 716 9703501 , , O O
12 717 719 9703501 in IN B-PP O
13 720 733 9703501 transcription NN B-NP O
14 733 734 9703501 - HYPH O O
15 734 741 9703501 coupled VBN B-NP O
16 742 748 9703501 repair NN I-NP O
17 749 751 9703501 of IN B-PP O
18 752 761 9703501 oxidative JJ B-NP O
19 762 765 9703501 DNA NN I-NP O
20 766 772 9703501 damage NN I-NP O
21 772 773 9703501 . . O O
22 773 774 9703501 . . O O

1 0 0 9482572 -DOCSTART- -X- -X- O

1 0 4 9482572 PAX6 NN B-NP O
2 5 14 9482572 mutations NNS I-NP O
3 15 23 9482572 reviewed VBN B-VP O
4 23 24 9482572 . . O O
5 25 34 9482572 Mutations NNS B-NP O
6 35 37 9482572 in IN B-PP O
7 38 42 9482572 PAX6 NN B-NP O
8 43 46 9482572 are VBP B-VP O
9 47 58 9482572 responsible JJ B-ADJP O
10 59 62 9482572 for IN B-PP O
11 63 68 9482572 human JJ B-NP O
12 69 77 9482572 aniridia NN I-NP B-Disease
13 78 81 9482572 and CC O O
14 82 86 9482572 have VBP B-VP O
15 87 91 9482572 also RB I-VP O
16 92 96 9482572 been VBN I-VP O
17 97 102 9482572 found VBN I-VP O
18 103 105 9482572 in IN B-PP O
19 106 114 9482572 patients NNS B-NP O
20 115 119 9482572 with IN B-PP O
21 120 126 9482572 Peters NNP B-NP B-Disease
22 127 134 9482572 anomaly RB B-ADVP I-Disease
23 134 135 9482572 , , O O
24 136 140 9482572 with IN B-PP O
25 141 151 9482572 congenital JJ B-NP B-Disease
26 152 161 9482572 cataracts NNS I-NP I-Disease
27 161 162 9482572 , , O O
28 163 167 9482572 with IN B-PP O
29 168 177 9482572 autosomal JJ B-NP B-Disease
30 178 186 9482572 dominant JJ I-NP I-Disease
31 187 196 9482572 keratitis NN I-NP I-Disease
32 196 197 9482572 , , O O
33 198 201 9482572 and CC O O
34 202 206 9482572 with IN B-PP O
35 207 215 9482572 isolated VBN B-NP B-Disease
36 216 222 9482572 foveal JJ I-NP I-Disease
37 223 233 9482572 hypoplasia NN I-NP I-Disease
38 233 234 9482572 . . O O

1 235 237 9482572 No DT B-NP O
2 238 243 9482572 locus NN I-NP O
3 244 249 9482572 other JJ B-ADJP O
4 250 254 9482572 than IN B-PP O
5 255 265 9482572 chromosome NN B-NP O
6 266 271 9482572 11p13 NN I-NP O
7 272 275 9482572 has VBZ B-VP O
8 276 280 9482572 been VBN I-VP O
9 281 291 9482572 implicated VBN I-VP O
10 292 294 9482572 in IN B-PP O
11 295 303 9482572 aniridia NN B-NP B-Disease
12 303 304 9482572 , , O O
13 305 308 9482572 and CC O O
14 309 313 9482572 PAX6 NN B-NP O
15 314 316 9482572 is VBZ B-VP O
16 317 324 9482572 clearly RB B-ADVP O
17 325 328 9482572 the DT B-NP O
18 329 334 9482572 major JJ I-NP O
19 334 335 9482572 , , O O
20 336 338 9482572 if IN B-SBAR O
21 339 342 9482572 not RB B-CONJP O
22 343 347 9482572 only RB I-CONJP O
23 347 348 9482572 , , O O
24 349 353 9482572 gene NN B-NP O
25 354 365 9482572 responsible JJ B-ADJP O
26 365 366 9482572 . . O O

1 367 373 9482572 Twenty CD B-NP O
2 373 374 9482572 - HYPH I-NP O
3 374 379 9482572 eight CD I-NP O
4 380 387 9482572 percent NN I-NP O
5 388 390 9482572 of IN B-PP O
6 391 401 9482572 identified VBN B-NP O
7 402 406 9482572 PAX6 NN I-NP O
8 407 416 9482572 mutations NNS I-NP O
9 417 420 9482572 are VBP B-VP O
10 421 422 9482572 C NN B-NP O
11 422 423 9482572 - HYPH B-NP O
12 423 424 9482572 T NN I-NP O
13 425 432 9482572 changes NNS I-NP O
14 433 435 9482572 at IN B-PP O
15 436 439 9482572 CpG NN B-NP O
16 440 453 9482572 dinucleotides NNS I-NP O
17 453 454 9482572 , , O O
18 455 458 9482572 20% CD B-NP O
19 459 462 9482572 are VBP B-VP O
20 463 471 9482572 splicing VBG I-VP O
21 472 478 9482572 errors NNS B-NP O
22 478 479 9482572 , , O O
23 480 483 9482572 and CC O O
24 484 488 9482572 more JJR B-NP O
25 489 493 9482572 than IN I-NP O
26 494 497 9482572 30% CD I-NP O
27 498 501 9482572 are VBP B-VP O
28 502 510 9482572 deletion NN B-NP O
29 511 513 9482572 or CC I-NP O
30 514 523 9482572 insertion NN I-NP O
31 524 530 9482572 events NNS I-NP O
32 530 531 9482572 . . O O

1 532 537 9482572 There EX B-NP O
2 538 540 9482572 is VBZ B-VP O
3 541 542 9482572 a DT B-NP O
4 543 553 9482572 noticeably RB I-NP O
5 554 562 9482572 elevated JJ I-NP O
6 563 568 9482572 level NN I-NP O
7 569 571 9482572 of IN B-PP O
8 572 580 9482572 mutation NN B-NP O
9 581 583 9482572 in IN B-PP O
10 584 587 9482572 the DT B-NP O
11 588 594 9482572 paired JJ I-NP O
12 595 601 9482572 domain NN I-NP O
13 602 610 9482572 compared VBN B-PP O
14 611 615 9482572 with IN B-PP O
15 616 619 9482572 the DT B-NP O
16 620 624 9482572 rest NN I-NP O
17 625 627 9482572 of IN B-PP O
18 628 631 9482572 the DT B-NP O
19 632 636 9482572 gene NN I-NP O
20 636 637 9482572 . . O O

1 638 647 9482572 Increased VBN B-NP O
2 648 656 9482572 mutation NN I-NP O
3 657 659 9482572 in IN B-PP O
4 660 663 9482572 the DT B-NP O
5 664 675 9482572 homeodomain NN I-NP O
6 676 678 9482572 is VBZ B-VP O
7 679 688 9482572 accounted VBN I-VP O
8 689 692 9482572 for IN B-PP O
9 693 695 9482572 by IN B-PP O
10 696 699 9482572 the DT B-NP O
11 700 712 9482572 hypermutable JJ I-NP O
12 713 716 9482572 CpG NN I-NP O
13 717 729 9482572 dinucleotide NN I-NP O
14 730 732 9482572 in IN B-PP O
15 733 738 9482572 codon NN B-NP O
16 739 742 9482572 240 CD I-NP O
17 742 743 9482572 . . O O

1 744 748 9482572 Very RB B-ADVP O
2 749 755 9482572 nearly RB B-NP O
3 756 759 9482572 all DT I-NP O
4 760 769 9482572 mutations NNS I-NP O
5 770 776 9482572 appear VBP B-VP O
6 777 779 9482572 to TO I-VP O
7 780 785 9482572 cause VB I-VP O
8 786 790 9482572 loss NN B-NP O
9 791 793 9482572 of IN B-PP O
10 794 802 9482572 function NN B-NP O
11 803 805 9482572 of IN B-PP O
12 806 809 9482572 the DT B-NP O
13 810 816 9482572 mutant JJ I-NP O
14 817 823 9482572 allele NN I-NP O
15 823 824 9482572 , , O O
16 825 828 9482572 and CC O O
17 829 833 9482572 more JJR B-NP O
18 834 838 9482572 than IN I-NP O
19 839 842 9482572 80% CD I-NP O
20 843 845 9482572 of IN B-PP O
21 846 852 9482572 exonic JJ B-NP O
22 853 866 9482572 substitutions NNS I-NP O
23 867 873 9482572 result VBP B-VP O
24 874 876 9482572 in IN B-PP O
25 877 885 9482572 nonsense JJ B-NP O
26 886 892 9482572 codons NNS I-NP O
27 892 893 9482572 . . O O

1 894 896 9482572 In IN B-PP O
2 897 898 9482572 a DT B-NP O
3 899 903 9482572 gene NN I-NP O
4 904 908 9482572 with IN B-PP O
5 909 913 9482572 such JJ B-NP O
6 914 929 9482572 extraordinarily RB I-NP O
7 930 934 9482572 high JJ I-NP O
8 935 943 9482572 sequence NN I-NP O
9 944 956 9482572 conservation NN I-NP O
10 957 967 9482572 throughout IN B-PP O
11 968 977 9482572 evolution NN B-NP O
12 977 978 9482572 , , O O
13 979 984 9482572 there EX B-NP O
14 985 988 9482572 are VBP B-VP O
15 989 997 9482572 presumed VBN I-VP O
16 998 1010 9482572 undiscovered JJ B-NP O
17 1011 1019 9482572 missense JJ I-NP O
18 1020 1029 9482572 mutations NNS I-NP O
19 1029 1030 9482572 , , O O
20 1031 1036 9482572 these DT B-NP O
21 1037 1040 9482572 are VBP B-VP O
22 1041 1053 9482572 hypothesized VBN I-VP O
23 1054 1056 9482572 to TO I-VP O
24 1057 1062 9482572 exist VB I-VP O
25 1063 1065 9482572 in IN B-PP O
26 1066 1068 9482572 as RB O O
27 1068 1069 9482572 - HYPH B-ADJP O
28 1069 1072 9482572 yet RB B-NP O
29 1073 1085 9482572 unidentified JJ I-NP O
30 1086 1096 9482572 phenotypes NNS I-NP O
31 1096 1097 9482572 . . O O
32 1097 1098 9482572 . . O O

1 0 0 9618170 -DOCSTART- -X- -X- O

1 0 11 9618170 Insertional JJ B-NP O
2 12 20 9618170 mutation NN I-NP O
3 21 23 9618170 by IN B-PP O
4 24 36 9618170 transposable JJ B-NP O
5 37 44 9618170 element NN I-NP O
6 44 45 9618170 , , O O
7 46 48 9618170 L1 NN B-NP O
8 48 49 9618170 , , O O
9 50 52 9618170 in IN B-PP O
10 53 56 9618170 the DT B-NP O
11 57 60 9618170 DMD NN I-NP B-Disease
12 61 65 9618170 gene NN I-NP O
13 66 73 9618170 results VBZ B-VP O
14 74 76 9618170 in IN B-PP O
15 77 78 9618170 X NN B-NP B-Disease
16 78 79 9618170 - HYPH O I-Disease
17 79 85 9618170 linked VBN B-VP I-Disease
18 86 93 9618170 dilated VBN B-NP I-Disease
19 94 108 9618170 cardiomyopathy NN I-NP I-Disease
20 108 109 9618170 . . I-NP O
21 110 111 9618170 X NN I-NP B-Disease
22 111 112 9618170 - HYPH B-VP I-Disease
23 112 118 9618170 linked VBN I-VP I-Disease
24 119 126 9618170 dilated VBN B-NP I-Disease
25 127 141 9618170 cardiomyopathy NN I-NP I-Disease
26 142 143 9618170 ( ( O O
27 143 148 9618170 XLDCM NN B-NP B-Disease
28 148 149 9618170 ) ) O O
29 150 152 9618170 is VBZ B-VP O
30 153 154 9618170 a DT B-NP O
31 155 163 9618170 clinical JJ I-NP O
32 164 173 9618170 phenotype NN I-NP O
33 174 176 9618170 of IN B-PP O
34 177 193 9618170 dystrophinopathy NN B-NP B-Disease
35 194 199 9618170 which WDT B-NP O
36 200 202 9618170 is VBZ B-VP O
37 203 216 9618170 characterized VBN I-VP O
38 217 219 9618170 by IN B-PP O
39 220 232 9618170 preferential JJ B-NP O
40 233 243 9618170 myocardial JJ I-NP B-Disease
41 244 255 9618170 involvement NN I-NP I-Disease
42 256 263 9618170 without IN B-PP O
43 264 267 9618170 any DT B-NP O
44 268 273 9618170 overt JJ I-NP O
45 274 282 9618170 clinical JJ I-NP O
46 283 288 9618170 signs NNS I-NP O
47 289 291 9618170 of IN B-PP O
48 292 300 9618170 skeletal JJ B-NP B-Disease
49 301 309 9618170 myopathy NN I-NP I-Disease
50 309 310 9618170 . . O O

1 311 313 9618170 To TO B-PP O
2 314 318 9618170 date NN B-NP O
3 318 319 9618170 , , O O
4 320 327 9618170 several JJ B-NP O
5 328 337 9618170 mutations NNS I-NP O
6 338 340 9618170 in IN B-PP O
7 341 344 9618170 the DT B-NP O
8 345 353 9618170 Duchenne NNP I-NP B-Disease
9 354 362 9618170 muscular JJ I-NP I-Disease
10 363 372 9618170 dystrophy NN I-NP I-Disease
11 373 377 9618170 gene NN I-NP O
12 377 378 9618170 , , O O
13 379 382 9618170 DMD NN B-NP O
14 382 383 9618170 , , O O
15 384 388 9618170 have VBP B-VP O
16 389 393 9618170 been VBN I-VP O
17 394 404 9618170 identified VBN I-VP O
18 405 407 9618170 in IN B-PP O
19 408 416 9618170 patients NNS B-NP O
20 417 421 9618170 with IN B-PP O
21 422 427 9618170 XLDCM NN B-NP B-Disease
22 427 428 9618170 , , O O
23 429 432 9618170 but CC O O
24 433 434 9618170 a DT B-NP O
25 435 445 9618170 pathogenic JJ I-NP O
26 446 457 9618170 correlation NN I-NP O
27 458 460 9618170 of IN B-PP O
28 461 466 9618170 these DT B-NP O
29 467 481 9618170 cardiospecific JJ I-NP O
30 482 491 9618170 mutations NNS I-NP O
31 492 494 9618170 in IN B-PP O
32 495 498 9618170 DMD NN B-NP O
33 499 503 9618170 with IN B-PP O
34 504 507 9618170 the DT B-NP O
35 508 513 9618170 XLDCM NN I-NP B-Disease
36 514 523 9618170 phenotype NN I-NP O
37 524 527 9618170 has VBZ B-VP O
38 528 536 9618170 remained VBN I-VP O
39 537 539 9618170 to TO I-VP O
40 540 542 9618170 be VB I-VP O
41 543 553 9618170 elucidated VBN I-VP O
42 553 554 9618170 . . O O

1 555 557 9618170 We PRP B-NP O
2 558 564 9618170 report VBP B-VP O
3 565 569 9618170 here RB B-ADVP O
4 570 573 9618170 the DT B-NP O
5 574 588 9618170 identification NN I-NP O
6 589 591 9618170 of IN B-PP O
7 592 593 9618170 a DT B-NP O
8 594 600 9618170 unique JJ I-NP O
9 601 603 9618170 de FW I-NP O
10 604 608 9618170 novo FW I-NP O
11 609 611 9618170 L1 NN I-NP O
12 612 621 9618170 insertion NN I-NP O
13 622 624 9618170 in IN B-PP O
14 625 628 9618170 the DT B-NP O
15 629 635 9618170 muscle NN I-NP O
16 636 640 9618170 exon NN I-NP O
17 641 642 9618170 1 CD I-NP O
18 643 645 9618170 in IN B-PP O
19 646 649 9618170 DMD NN B-NP O
20 650 652 9618170 in IN B-PP O
21 653 658 9618170 three CD B-NP O
22 659 664 9618170 XLDCM NN I-NP B-Disease
23 665 673 9618170 patients NNS I-NP O
24 674 678 9618170 from IN B-PP O
25 679 682 9618170 two CD B-NP O
26 683 692 9618170 unrelated JJ I-NP O
27 693 701 9618170 Japanese JJ I-NP O
28 702 710 9618170 families NNS I-NP O
29 710 711 9618170 . . O O

1 712 715 9618170 The DT B-NP O
2 716 725 9618170 insertion NN I-NP O
3 726 729 9618170 was VBD B-VP O
4 730 731 9618170 a DT B-NP O
5 732 733 9618170 5 CD I-NP O
6 733 734 9618170 - HYPH I-NP O
7 734 743 9618170 truncated VBN I-NP O
8 744 748 9618170 form NN I-NP O
9 749 751 9618170 of IN B-PP O
10 752 757 9618170 human JJ B-NP O
11 758 760 9618170 L1 NN I-NP O
12 761 770 9618170 inversely RB B-VP O
13 771 781 9618170 integrated VBN I-VP O
14 782 784 9618170 in IN B-PP O
15 785 788 9618170 the DT B-NP O
16 789 790 9618170 5 CD I-NP O
17 790 791 9618170 - HYPH I-NP O
18 791 803 9618170 untranslated JJ I-NP O
19 804 810 9618170 region NN I-NP O
20 811 813 9618170 in IN B-PP O
21 814 817 9618170 the DT B-NP O
22 818 824 9618170 muscle NN I-NP O
23 825 829 9618170 exon NN I-NP O
24 830 831 9618170 1 CD I-NP O
25 831 832 9618170 , , O O
26 833 838 9618170 which WDT B-NP O
27 839 847 9618170 affected VBD B-VP O
28 848 851 9618170 the DT B-NP O
29 852 865 9618170 transcription NN I-NP O
30 866 868 9618170 or CC O O
31 869 872 9618170 the DT B-NP O
32 873 882 9618170 stability NN I-NP O
33 883 885 9618170 of IN B-PP O
34 886 889 9618170 the DT B-NP O
35 890 896 9618170 muscle NN I-NP O
36 897 901 9618170 form NN I-NP O
37 902 904 9618170 of IN B-PP O
38 905 915 9618170 dystrophin NN B-NP O
39 916 927 9618170 transcripts NNS I-NP O
40 928 931 9618170 but CC B-NP O
41 932 935 9618170 not RB I-NP O
42 936 940 9618170 that DT B-NP O
43 941 943 9618170 of IN B-PP O
44 944 947 9618170 the DT B-NP O
45 948 953 9618170 brain NN I-NP O
46 954 956 9618170 or CC I-NP O
47 957 965 9618170 Purkinje NN I-NP O
48 966 970 9618170 cell NN I-NP O
49 971 975 9618170 form NN I-NP O
50 975 976 9618170 , , O O
51 977 985 9618170 probably RB B-ADVP O
52 986 989 9618170 due IN B-PP O
53 990 992 9618170 to TO B-PP O
54 993 996 9618170 its PRP$ B-NP O
55 997 1003 9618170 unique JJ I-NP O
56 1004 1008 9618170 site NN I-NP O
57 1009 1011 9618170 of IN B-PP O
58 1012 1023 9618170 integration NN B-NP O
59 1023 1024 9618170 . . O O

1 1025 1027 9618170 We PRP B-NP O
2 1028 1037 9618170 speculate VBP B-VP O
3 1038 1042 9618170 that IN B-SBAR O
4 1043 1047 9618170 this DT B-NP O
5 1048 1057 9618170 insertion NN I-NP O
6 1058 1060 9618170 of IN B-PP O
7 1061 1063 9618170 an DT B-NP O
8 1064 1066 9618170 L1 NN I-NP O
9 1067 1075 9618170 sequence NN I-NP O
10 1076 1078 9618170 in IN B-PP O
11 1079 1082 9618170 DMD NN B-NP O
12 1083 1085 9618170 is VBZ B-VP O
13 1086 1097 9618170 responsible JJ B-ADJP O
14 1098 1101 9618170 for IN B-PP O
15 1102 1106 9618170 some DT B-NP O
16 1107 1109 9618170 of IN B-PP O
17 1110 1113 9618170 the DT B-NP O
18 1114 1124 9618170 population NN I-NP O
19 1125 1127 9618170 of IN B-PP O
20 1128 1136 9618170 Japanese JJ B-NP O
21 1137 1145 9618170 patients NNS I-NP O
22 1146 1150 9618170 with IN B-PP O
23 1151 1156 9618170 XLDCM NN B-NP B-Disease
24 1156 1157 9618170 . . O O
25 1157 1158 9618170 . . O O

1 0 0 9463309 -DOCSTART- -X- -X- O

1 0 3 9463309 The DT B-NP O
2 4 15 9463309 haptoglobin NN I-NP O
3 15 16 9463309 - HYPH I-NP O
4 16 20 9463309 gene NN I-NP O
5 21 29 9463309 deletion NN I-NP O
6 30 41 9463309 responsible JJ B-ADJP O
7 42 45 9463309 for IN B-PP O
8 46 63 9463309 anhaptoglobinemia NN B-NP B-Disease
9 63 64 9463309 . . O O
10 65 67 9463309 We PRP B-NP O
11 68 72 9463309 have VBP B-VP O
12 73 78 9463309 found VBN I-VP O
13 79 81 9463309 an DT B-NP O
14 82 89 9463309 allelic JJ I-NP O
15 90 98 9463309 deletion NN I-NP O
16 99 101 9463309 of IN B-PP O
17 102 105 9463309 the DT B-NP O
18 106 117 9463309 haptoglobin NN I-NP O
19 118 119 9463309 ( ( O O
20 119 121 9463309 Hp NN B-NP O
21 121 122 9463309 ) ) O O
22 123 127 9463309 gene NN B-NP O
23 128 132 9463309 from IN B-PP O
24 133 135 9463309 an DT B-NP O
25 136 146 9463309 individual NN I-NP O
26 147 151 9463309 with IN B-PP O
27 152 169 9463309 anhaptoglobinemia NN B-NP B-Disease
28 169 170 9463309 . . O O

1 171 174 9463309 The DT B-NP O
2 175 177 9463309 Hp NN I-NP O
3 178 182 9463309 gene NN I-NP O
4 183 190 9463309 cluster NN I-NP O
5 191 199 9463309 consists VBZ B-VP O
6 200 202 9463309 of IN B-PP O
7 203 209 9463309 coding VBG B-VP O
8 210 217 9463309 regions NNS B-NP O
9 218 220 9463309 of IN B-PP O
10 221 224 9463309 the DT B-NP O
11 225 230 9463309 alpha NN I-NP O
12 231 236 9463309 chain NN I-NP O
13 237 240 9463309 and CC O O
14 241 245 9463309 beta NN B-NP O
15 246 251 9463309 chain NN I-NP O
16 252 254 9463309 of IN B-PP O
17 255 258 9463309 the DT B-NP O
18 259 270 9463309 haptoglobin NN I-NP O
19 271 275 9463309 gene NN I-NP O
20 276 277 9463309 ( ( O O
21 277 279 9463309 Hp NN B-NP O
22 279 280 9463309 ) ) O O
23 281 284 9463309 and CC O O
24 285 287 9463309 of IN B-PP O
25 288 291 9463309 the DT B-NP O
26 292 297 9463309 alpha NN I-NP O
27 298 303 9463309 chain NN I-NP O
28 304 307 9463309 and CC O O
29 308 312 9463309 beta NN B-NP O
30 313 318 9463309 chain NN I-NP O
31 319 321 9463309 of IN B-PP O
32 322 325 9463309 the DT B-NP O
33 326 337 9463309 haptoglobin NN I-NP O
34 337 338 9463309 - HYPH B-NP O
35 338 345 9463309 related VBN I-NP O
36 346 350 9463309 gene NN B-NP O
37 351 352 9463309 ( ( O O
38 352 355 9463309 Hpr NN B-NP O
39 355 356 9463309 ) ) O O
40 356 357 9463309 , , O O
41 358 360 9463309 in IN B-PP O
42 361 367 9463309 tandem NN B-NP O
43 368 372 9463309 from IN B-PP O
44 373 376 9463309 the DT B-NP O
45 377 378 9463309 5 CD I-NP O
46 379 383 9463309 side NN I-NP O
47 383 384 9463309 . . O O

1 385 393 9463309 Southern NN B-NP O
2 394 398 9463309 blot NN I-NP O
3 399 402 9463309 and CC I-NP O
4 403 406 9463309 PCR NN I-NP O
5 407 415 9463309 analyses NNS I-NP O
6 416 420 9463309 have VBP B-VP O
7 421 430 9463309 indicated VBN I-VP O
8 431 435 9463309 that IN B-SBAR O
9 436 439 9463309 the DT B-NP O
10 440 450 9463309 individual NN I-NP O
11 451 455 9463309 with IN B-PP O
12 456 473 9463309 anhaptoglobinemia NN B-NP B-Disease
13 474 477 9463309 was VBD B-VP O
14 478 488 9463309 homozygous JJ B-ADJP O
15 489 492 9463309 for IN B-PP O
16 493 496 9463309 the DT B-NP O
17 497 501 9463309 gene NN I-NP O
18 502 510 9463309 deletion NN I-NP O
19 511 514 9463309 and CC O O
20 515 519 9463309 that IN B-SBAR O
21 520 523 9463309 the DT B-NP O
22 524 528 9463309 gene NN I-NP O
23 529 537 9463309 deletion NN I-NP O
24 538 541 9463309 was VBD B-VP O
25 542 550 9463309 included VBN I-VP O
26 551 553 9463309 at IN B-ADVP O
27 554 559 9463309 least JJS I-ADVP O
28 560 564 9463309 from IN B-PP O
29 565 568 9463309 the DT B-NP O
30 569 577 9463309 promoter NN I-NP O
31 578 584 9463309 region NN I-NP O
32 585 587 9463309 of IN B-PP O
33 588 590 9463309 Hp NN B-NP O
34 591 593 9463309 to TO B-PP O
35 594 597 9463309 Hpr NN B-NP O
36 598 603 9463309 alpha NN I-NP O
37 604 607 9463309 but CC B-PP O
38 608 611 9463309 not RB B-PP O
39 612 614 9463309 to TO I-PP O
40 615 618 9463309 Hpr NN B-NP O
41 619 623 9463309 beta NN I-NP O
42 624 625 9463309 ( ( O O
43 625 630 9463309 Hpdel NN B-NP O
44 630 631 9463309 ) ) O O
45 631 632 9463309 . . O O

1 633 635 9463309 In IN B-PP O
2 636 644 9463309 addition NN B-NP O
3 644 645 9463309 , , O O
4 646 648 9463309 we PRP B-NP O
5 649 654 9463309 found VBD B-VP O
6 655 660 9463309 seven CD B-NP O
7 661 672 9463309 individuals NNS I-NP O
8 673 677 9463309 with IN B-PP O
9 678 697 9463309 hypohaptoglobinemia NN B-NP B-Disease
10 698 700 9463309 in IN B-PP O
11 701 706 9463309 three CD B-NP O
12 707 715 9463309 families NNS I-NP O
13 715 716 9463309 , , O O
14 717 720 9463309 and CC O O
15 721 724 9463309 the DT B-NP O
16 725 734 9463309 genotypes NNS I-NP O
17 735 737 9463309 of IN B-PP O
18 738 741 9463309 six CD B-NP O
19 742 744 9463309 of IN B-PP O
20 745 748 9463309 the DT B-NP O
21 749 754 9463309 seven CD I-NP O
22 755 766 9463309 individuals NNS I-NP O
23 767 771 9463309 were VBD B-VP O
24 772 777 9463309 found VBN I-VP O
25 778 780 9463309 to TO I-VP O
26 781 783 9463309 be VB I-VP O
27 784 787 9463309 Hp2 NN B-NP O
28 787 788 9463309 / SYM B-NP O
29 788 793 9463309 Hpdel NN I-NP O
30 793 794 9463309 . . O O

1 795 798 9463309 The DT B-NP O
2 799 809 9463309 phenotypes NNS I-NP O
3 810 813 9463309 and CC I-NP O
4 814 823 9463309 genotypes NNS I-NP O
5 824 826 9463309 in IN B-PP O
6 827 830 9463309 one CD B-NP O
7 831 833 9463309 of IN B-PP O
8 834 839 9463309 these DT B-NP O
9 840 845 9463309 three CD I-NP O
10 846 854 9463309 families NNS I-NP O
11 855 861 9463309 showed VBD B-VP O
12 862 865 9463309 the DT B-NP O
13 866 872 9463309 father NN I-NP O
14 873 875 9463309 to TO B-VP O
15 876 878 9463309 be VB I-VP O
16 879 898 9463309 hypohaptoglobinemic JJ B-ADJP B-Disease
17 899 900 9463309 ( ( O O
18 900 903 9463309 Hp2 NN B-NP O
19 903 904 9463309 ) ) O O
20 905 908 9463309 and CC O O
21 909 912 9463309 Hp2 NN B-NP O
22 912 913 9463309 / SYM B-NP O
23 913 918 9463309 Hpdel NN I-NP O
24 918 919 9463309 , , O O
25 920 923 9463309 the DT B-NP O
26 924 930 9463309 mother NN I-NP O
27 931 933 9463309 to TO B-VP O
28 934 936 9463309 be VB I-VP O
29 937 940 9463309 Hp2 NN B-NP O
30 940 941 9463309 - HYPH B-NP O
31 941 942 9463309 1 CD I-NP O
32 943 946 9463309 and CC I-NP O
33 947 950 9463309 Hp1 NN I-NP O
34 950 951 9463309 / SYM I-NP O
35 951 954 9463309 Hp2 NN I-NP O
36 954 955 9463309 , , O O
37 956 959 9463309 one CD B-NP O
38 960 962 9463309 of IN B-PP O
39 963 966 9463309 the DT B-NP O
40 967 970 9463309 two CD I-NP O
41 971 979 9463309 children NNS I-NP O
42 980 982 9463309 to TO B-VP O
43 983 985 9463309 be VB I-VP O
44 986 1005 9463309 hypohaptoglobinemic JJ B-ADJP B-Disease
45 1006 1007 9463309 ( ( O O
46 1007 1010 9463309 Hp2 NN B-NP O
47 1010 1011 9463309 ) ) O O
48 1012 1015 9463309 and CC O O
49 1016 1019 9463309 Hp2 NN B-NP O
50 1019 1020 9463309 / SYM O O
51 1020 1025 9463309 Hpdel NN B-NP O
52 1025 1026 9463309 , , O O
53 1027 1030 9463309 and CC O O
54 1031 1034 9463309 the DT B-NP O
55 1035 1040 9463309 other JJ I-NP O
56 1041 1046 9463309 child NN I-NP O
57 1047 1049 9463309 to TO B-VP O
58 1050 1052 9463309 be VB I-VP O
59 1053 1056 9463309 Hp1 NN B-NP O
60 1057 1060 9463309 and CC I-NP O
61 1061 1064 9463309 Hp1 NN I-NP O
62 1064 1065 9463309 / SYM B-NP O
63 1065 1070 9463309 Hpdel NN I-NP O
64 1070 1071 9463309 , , O O
65 1072 1079 9463309 showing VBG B-VP O
66 1080 1082 9463309 an DT B-NP O
67 1083 1092 9463309 anomalous JJ I-NP O
68 1093 1104 9463309 inheritance NN I-NP O
69 1105 1107 9463309 of IN B-PP O
70 1108 1110 9463309 Hp NN B-NP O
71 1111 1121 9463309 phenotypes NNS I-NP O
72 1122 1124 9463309 in IN B-PP O
73 1125 1128 9463309 the DT B-NP O
74 1129 1134 9463309 child NN I-NP O
75 1135 1139 9463309 with IN B-PP O
76 1140 1143 9463309 Hp1 NN B-NP O
77 1143 1144 9463309 . . O O

1 1145 1148 9463309 The DT B-NP O
2 1149 1152 9463309 Hp2 NN I-NP O
3 1152 1153 9463309 / SYM B-VP O
4 1153 1158 9463309 Hpdel NN B-NP O
5 1159 1170 9463309 individuals NNS I-NP O
6 1171 1174 9463309 had VBD B-VP O
7 1175 1177 9463309 an DT B-NP O
8 1178 1187 9463309 extremely RB I-NP O
9 1188 1191 9463309 low JJ I-NP O
10 1192 1197 9463309 level NN I-NP O
11 1198 1200 9463309 of IN B-PP O
12 1201 1203 9463309 Hp NN B-NP O
13 1204 1205 9463309 ( ( O O
14 1205 1209 9463309 mean NN B-NP O
15 1210 1211 9463309 + SYM O O
16 1211 1212 9463309 / SYM O O
17 1212 1213 9463309 - SYM O O
18 1213 1215 9463309 SD NN B-NP O
19 1216 1217 9463309 = SYM B-VP O
20 1218 1219 9463309 0 CD B-NP O
21 1219 1220 9463309 . . O O

1 1221 1224 9463309 049 CD B-NP O
2 1225 1226 9463309 + SYM O O
3 1226 1227 9463309 / SYM O O
4 1227 1228 9463309 - SYM B-NP O
5 1228 1229 9463309 0 CD B-NP O
6 1229 1230 9463309 . . O O

1 1231 1234 9463309 043 CD B-NP O
2 1235 1237 9463309 mg NN I-NP O
3 1237 1238 9463309 / SYM B-NP O
4 1238 1240 9463309 ml NN I-NP O
5 1240 1241 9463309 ; : O O
6 1242 1243 9463309 n NN B-NP O
7 1244 1245 9463309 = JJ B-VP O
8 1246 1247 9463309 6 CD B-NP O
9 1247 1248 9463309 ) ) O O
10 1248 1249 9463309 , , O O
11 1250 1258 9463309 compared VBN B-PP O
12 1259 1263 9463309 with IN B-PP O
13 1264 1267 9463309 the DT B-NP O
14 1268 1273 9463309 level NN I-NP O
15 1274 1275 9463309 ( ( O O
16 1275 1276 9463309 1 CD B-NP O
17 1276 1277 9463309 . . O O

1 1278 1280 9463309 64 CD B-NP O
2 1281 1282 9463309 + SYM O O
3 1282 1283 9463309 / SYM B-NP O
4 1283 1284 9463309 - SYM B-NP O
5 1284 1285 9463309 1 CD I-NP O
6 1285 1286 9463309 . . O O

1 1287 1289 9463309 07 CD B-NP O
2 1290 1292 9463309 mg NN I-NP O
3 1292 1293 9463309 / SYM B-NP O
4 1293 1295 9463309 ml NN I-NP O
5 1295 1296 9463309 ) ) O O
6 1297 1305 9463309 obtained VBN B-VP O
7 1306 1310 9463309 from IN B-PP O
8 1311 1313 9463309 52 CD B-NP O
9 1314 1321 9463309 healthy JJ I-NP O
10 1322 1332 9463309 volunteers NNS I-NP O
11 1333 1339 9463309 having VBG B-VP O
12 1340 1349 9463309 phenotype NN B-NP O
13 1350 1353 9463309 Hp2 NN I-NP O
14 1353 1354 9463309 , , O O
15 1355 1362 9463309 whereas IN O O
16 1363 1366 9463309 the DT B-NP O
17 1367 1372 9463309 serum NN I-NP O
18 1373 1375 9463309 Hp NN I-NP O
19 1376 1381 9463309 level NN I-NP O
20 1382 1384 9463309 of IN B-PP O
21 1385 1387 9463309 an DT B-NP O
22 1388 1398 9463309 individual NN I-NP O
23 1399 1403 9463309 with IN B-PP O
24 1404 1407 9463309 Hp1 NN B-NP O
25 1407 1408 9463309 / SYM B-NP O
26 1408 1413 9463309 Hpdel NN I-NP O
27 1414 1417 9463309 was VBD B-VP O
28 1418 1419 9463309 0 CD B-NP O
29 1419 1420 9463309 . . O O

1 1421 1423 9463309 50 CD B-NP O
2 1424 1426 9463309 mg NN I-NP O
3 1426 1427 9463309 / SYM B-NP O
4 1427 1429 9463309 ml NN I-NP O
5 1429 1430 9463309 , , O O
6 1431 1436 9463309 which WDT B-NP O
7 1437 1440 9463309 was VBD B-VP O
8 1441 1454 9463309 approximately RB B-NP O
9 1455 1459 9463309 half PDT I-NP O
10 1460 1463 9463309 the DT I-NP O
11 1464 1469 9463309 level NN I-NP O
12 1470 1472 9463309 of IN B-PP O
13 1473 1475 9463309 Hp NN B-NP O
14 1476 1478 9463309 in IN B-PP O
15 1479 1486 9463309 control NN B-NP O
16 1487 1491 9463309 sera NNS I-NP O
17 1492 1496 9463309 from IN B-PP O
18 1497 1500 9463309 the DT B-NP O
19 1501 1504 9463309 Hp1 NN I-NP O
20 1505 1514 9463309 phenotype NN I-NP O
21 1515 1516 9463309 ( ( O O
22 1516 1517 9463309 1 CD B-NP O
23 1517 1518 9463309 . . O O

1 1519 1521 9463309 26 CD B-NP O
2 1522 1523 9463309 + SYM O O
3 1523 1524 9463309 / SYM O O
4 1524 1525 9463309 - SYM B-NP O
5 1525 1526 9463309 0 CD B-NP O
6 1526 1527 9463309 . . O O

1 1528 1530 9463309 33 CD B-NP O
2 1531 1533 9463309 mg NN I-NP O
3 1533 1534 9463309 / SYM B-NP O
4 1534 1536 9463309 ml NN I-NP O
5 1536 1537 9463309 ; : O O
6 1538 1539 9463309 n NN B-NP O
7 1540 1541 9463309 = SYM B-VP O
8 1542 1543 9463309 9 CD B-NP O
9 1543 1544 9463309 ) ) O O
10 1544 1545 9463309 , , O O
11 1546 1553 9463309 showing VBG B-VP O
12 1554 1555 9463309 a DT B-NP O
13 1556 1560 9463309 gene NN I-NP O
14 1560 1561 9463309 - HYPH B-NP O
15 1561 1567 9463309 dosage NN I-NP O
16 1568 1574 9463309 effect NN I-NP O
17 1574 1575 9463309 . . O O

1 1576 1579 9463309 The DT B-NP O
2 1580 1585 9463309 other JJ I-NP O
3 1586 1592 9463309 allele NN I-NP O
4 1593 1594 9463309 ( ( O O
5 1594 1597 9463309 Hp2 NN B-NP O
6 1597 1598 9463309 ) ) O O
7 1599 1601 9463309 of IN B-PP O
8 1602 1613 9463309 individuals NNS B-NP O
9 1614 1618 9463309 with IN B-PP O
10 1619 1622 9463309 Hp2 NN B-NP O
11 1622 1623 9463309 / SYM B-NP O
12 1623 1628 9463309 Hpdel NN I-NP O
13 1629 1632 9463309 was VBD B-VP O
14 1633 1638 9463309 found VBN I-VP O
15 1639 1641 9463309 to TO I-VP O
16 1642 1646 9463309 have VB I-VP O
17 1646 1647 9463309 , , O O
18 1648 1650 9463309 in IN B-PP O
19 1651 1654 9463309 all DT B-NP O
20 1655 1660 9463309 exons NNS I-NP O
21 1660 1661 9463309 , , O O
22 1662 1664 9463309 no DT B-NP O
23 1665 1673 9463309 mutation NN I-NP O
24 1673 1674 9463309 , , O O
25 1675 1677 9463309 by IN B-PP O
26 1678 1681 9463309 DNA NN B-NP O
27 1682 1692 9463309 sequencing NN I-NP O
28 1692 1693 9463309 . . O O

1 1694 1696 9463309 On IN B-PP O
2 1697 1700 9463309 the DT B-NP O
3 1701 1706 9463309 basis NN I-NP O
4 1707 1709 9463309 of IN B-PP O
5 1710 1713 9463309 the DT B-NP O
6 1714 1721 9463309 present JJ I-NP O
7 1722 1727 9463309 study NN I-NP O
8 1727 1728 9463309 , , O O
9 1729 1732 9463309 the DT B-NP O
10 1733 1742 9463309 mechanism NN I-NP O
11 1743 1745 9463309 of IN B-PP O
12 1746 1763 9463309 anhaptoglobinemia NN B-NP B-Disease
13 1764 1767 9463309 and CC O O
14 1768 1771 9463309 the DT B-NP O
15 1772 1781 9463309 mechanism NN I-NP O
16 1782 1784 9463309 of IN B-PP O
17 1785 1794 9463309 anomalous JJ B-NP O
18 1795 1806 9463309 inheritance NN I-NP O
19 1807 1809 9463309 of IN B-PP O
20 1810 1812 9463309 Hp NN B-NP O
21 1813 1823 9463309 phenotypes NNS I-NP O
22 1824 1828 9463309 were VBD B-VP O
23 1829 1833 9463309 well RB I-VP O
24 1834 1843 9463309 explained VBN I-VP O
25 1843 1844 9463309 . . O O

1 1845 1852 9463309 However RB B-ADVP O
2 1852 1853 9463309 , , O O
3 1854 1857 9463309 the DT B-NP O
4 1858 1867 9463309 mechanism NN I-NP O
5 1868 1870 9463309 of IN B-PP O
6 1871 1890 9463309 hypohaptoglobinemia NN B-NP B-Disease
7 1891 1898 9463309 remains VBZ B-VP O
8 1899 1906 9463309 unknown JJ B-ADJP O

1 0 0 9590284 -DOCSTART- -X- -X- O

1 0 1 9590284 A DT B-NP O
2 2 7 9590284 mouse NN I-NP O
3 8 13 9590284 model NN I-NP O
4 14 17 9590284 for IN B-PP O
5 18 24 9590284 Prader NNP B-NP B-Disease
6 24 25 9590284 - HYPH I-NP I-Disease
7 25 30 9590284 Willi NNP I-NP I-Disease
8 31 39 9590284 syndrome NN I-NP I-Disease
9 40 50 9590284 imprinting NN I-NP O
10 50 51 9590284 - HYPH B-NP O
11 51 57 9590284 centre NN I-NP O
12 58 67 9590284 mutations NNS I-NP O
13 67 68 9590284 . . B-NP O
14 69 79 9590284 Imprinting NN I-NP O
15 80 82 9590284 in IN B-PP O
16 83 86 9590284 the DT B-NP O
17 87 92 9590284 15q11 CD I-NP O
18 92 93 9590284 - HYPH I-NP O
19 93 96 9590284 q13 NN I-NP O
20 97 103 9590284 region NN I-NP O
21 104 112 9590284 involves VBZ B-VP O
22 113 115 9590284 an DT B-NP O
23 116 126 9590284 imprinting NN I-NP O
24 127 133 9590284 centre NN I-NP O
25 134 135 9590284 ( ( O O
26 135 137 9590284 IC NN B-NP O
27 137 138 9590284 ) ) O O
28 138 139 9590284 , , O O
29 140 147 9590284 mapping VBG B-VP O
30 148 150 9590284 in IN B-PP O
31 151 155 9590284 part NN B-NP O
32 156 158 9590284 to TO B-PP O
33 159 162 9590284 the DT B-NP O
34 163 171 9590284 promoter NN I-NP O
35 172 175 9590284 and CC I-NP O
36 176 181 9590284 first JJ I-NP O
37 182 186 9590284 exon NN I-NP O
38 187 189 9590284 of IN B-PP O
39 190 195 9590284 SNRPN NN B-NP O
40 195 196 9590284 . . O O

1 197 205 9590284 Deletion NN B-NP O
2 206 208 9590284 of IN B-PP O
3 209 213 9590284 this DT B-NP O
4 214 216 9590284 IC NN I-NP O
5 217 226 9590284 abolishes VBZ B-VP O
6 227 232 9590284 local JJ B-NP O
7 233 243 9590284 paternally RB I-NP O
8 244 251 9590284 derived VBN I-NP O
9 252 256 9590284 gene NN I-NP O
10 257 267 9590284 expression NN I-NP O
11 268 271 9590284 and CC O O
12 272 279 9590284 results VBZ B-VP O
13 280 282 9590284 in IN B-PP O
14 283 289 9590284 Prader NNP B-NP B-Disease
15 289 290 9590284 - HYPH B-NP I-Disease
16 290 295 9590284 Willi NNP I-NP I-Disease
17 296 304 9590284 syndrome NN I-NP I-Disease
18 305 306 9590284 ( ( O O
19 306 309 9590284 PWS NN B-NP B-Disease
20 309 310 9590284 ) ) O O
21 310 311 9590284 . . O O

1 312 314 9590284 We PRP B-NP O
2 315 319 9590284 have VBP B-VP O
3 320 327 9590284 created VBN I-VP O
4 328 331 9590284 two CD B-NP O
5 332 340 9590284 deletion NN I-NP O
6 341 350 9590284 mutations NNS I-NP O
7 351 353 9590284 in IN B-PP O
8 354 358 9590284 mice NNS B-NP O
9 359 361 9590284 to TO B-VP O
10 362 372 9590284 understand VB I-VP O
11 373 376 9590284 PWS NN B-NP B-Disease
12 377 380 9590284 and CC O O
13 381 384 9590284 the DT B-NP O
14 385 394 9590284 mechanism NN I-NP O
15 395 397 9590284 of IN B-PP O
16 398 402 9590284 this DT B-NP O
17 403 405 9590284 IC NN I-NP O
18 405 406 9590284 . . O O

1 407 411 9590284 Mice NNS B-NP O
2 412 422 9590284 harbouring VBG B-VP O
3 423 425 9590284 an DT B-NP O
4 426 436 9590284 intragenic JJ I-NP O
5 437 445 9590284 deletion NN I-NP O
6 446 448 9590284 in IN B-PP O
7 449 454 9590284 Snrpn NN B-NP O
8 455 458 9590284 are VBP B-VP O
9 459 473 9590284 phenotypically RB B-ADJP O
10 474 480 9590284 normal JJ I-ADJP O
11 480 481 9590284 , , O O
12 482 492 9590284 suggesting VBG B-VP O
13 493 497 9590284 that IN B-SBAR O
14 498 507 9590284 mutations NNS B-NP O
15 508 510 9590284 of IN B-PP O
16 511 516 9590284 SNRPN NN B-NP O
17 517 520 9590284 are VBP B-VP O
18 521 524 9590284 not RB O O
19 525 535 9590284 sufficient JJ B-ADJP O
20 536 538 9590284 to TO B-VP O
21 539 545 9590284 induce VB I-VP O
22 546 549 9590284 PWS NN B-NP B-Disease
23 549 550 9590284 . . O O

1 551 555 9590284 Mice NNS B-NP O
2 556 560 9590284 with IN B-PP O
3 561 562 9590284 a DT B-NP O
4 563 569 9590284 larger JJR I-NP O
5 570 578 9590284 deletion NN I-NP O
6 579 588 9590284 involving VBG B-VP O
7 589 593 9590284 both CC O O
8 594 599 9590284 Snrpn NN B-NP O
9 600 603 9590284 and CC O O
10 604 607 9590284 the DT B-NP O
11 608 616 9590284 putative JJ I-NP O
12 617 620 9590284 PWS NN I-NP O
13 620 621 9590284 - HYPH B-NP O
14 621 623 9590284 IC NN I-NP O
15 624 628 9590284 lack NN I-NP O
16 629 639 9590284 expression NN I-NP O
17 640 642 9590284 of IN B-PP O
18 643 646 9590284 the DT B-NP O
19 647 656 9590284 imprinted VBN I-NP O
20 657 662 9590284 genes NNS I-NP O
21 663 669 9590284 Zfp127 NN I-NP O
22 670 671 9590284 ( ( O O
23 671 676 9590284 mouse NN B-NP O
24 677 686 9590284 homologue NN I-NP O
25 687 689 9590284 of IN B-PP O
26 690 696 9590284 ZNF127 NN B-NP O
27 696 697 9590284 ) ) O O
28 697 698 9590284 , , O O
29 699 702 9590284 Ndn NN B-NP O
30 703 706 9590284 and CC I-NP O
31 707 710 9590284 Ipw NN I-NP O
32 710 711 9590284 , , O O
33 712 715 9590284 and CC O O
34 716 724 9590284 manifest JJS B-NP O
35 725 732 9590284 several JJ I-NP O
36 733 743 9590284 phenotypes NNS I-NP O
37 744 750 9590284 common JJ B-ADJP O
38 751 753 9590284 to TO B-PP O
39 754 757 9590284 PWS NN B-NP B-Disease
40 758 765 9590284 infants NNS I-NP O
41 765 766 9590284 . . O O

1 767 772 9590284 These DT B-NP O
2 773 777 9590284 data NNS I-NP O
3 778 789 9590284 demonstrate VBP B-VP O
4 790 794 9590284 that IN B-SBAR O
5 795 799 9590284 both CC O O
6 800 803 9590284 the DT B-NP O
7 804 812 9590284 position NN I-NP O
8 813 815 9590284 of IN B-PP O
9 816 819 9590284 the DT B-NP O
10 820 822 9590284 IC NN I-NP O
11 823 826 9590284 and CC O O
12 827 830 9590284 its PRP$ B-NP O
13 831 835 9590284 role NN I-NP O
14 836 838 9590284 in IN B-PP O
15 839 842 9590284 the DT B-NP O
16 843 853 9590284 coordinate JJ I-NP O
17 854 864 9590284 expression NN I-NP O
18 865 867 9590284 of IN B-PP O
19 868 873 9590284 genes NNS B-NP O
20 874 876 9590284 is VBZ B-VP O
21 877 886 9590284 conserved VBN I-VP O
22 887 894 9590284 between IN B-PP O
23 895 900 9590284 mouse NN B-NP O
24 901 904 9590284 and CC O O
25 905 910 9590284 human JJ B-ADJP O
26 910 911 9590284 , , O O
27 912 915 9590284 and CC O O
28 916 924 9590284 indicate VBP B-VP O
29 925 929 9590284 that IN B-SBAR O
30 930 933 9590284 the DT B-NP O
31 934 939 9590284 mouse NN I-NP O
32 940 942 9590284 is VBZ B-VP O
33 943 944 9590284 a DT B-NP O
34 945 953 9590284 suitable JJ I-NP O
35 954 959 9590284 model NN I-NP O
36 960 966 9590284 system NN I-NP O
37 967 969 9590284 in IN B-PP O
38 970 975 9590284 which WDT B-NP O
39 976 978 9590284 to TO B-VP O
40 979 990 9590284 investigate VB I-VP O
41 991 994 9590284 the DT B-NP O
42 995 1004 9590284 molecular JJ I-NP O
43 1005 1015 9590284 mechanisms NNS I-NP O
44 1016 1018 9590284 of IN B-PP O
45 1019 1029 9590284 imprinting NN B-NP O
46 1030 1032 9590284 in IN B-PP O
47 1033 1037 9590284 this DT B-NP O
48 1038 1044 9590284 region NN I-NP O
49 1045 1047 9590284 of IN B-PP O
50 1048 1051 9590284 the DT B-NP O
51 1052 1058 9590284 genome NN I-NP O
52 1058 1059 9590284 . . O O
53 1059 1060 9590284 . . O O

1 0 0 9848786 -DOCSTART- -X- -X- O

1 0 5 9848786 Human JJ B-NP B-Disease
2 6 16 9848786 complement NN I-NP I-Disease
3 17 23 9848786 factor NN I-NP I-Disease
4 24 25 9848786 H NN I-NP I-Disease
5 26 36 9848786 deficiency NN I-NP I-Disease
6 37 47 9848786 associated VBN B-VP O
7 48 52 9848786 with IN B-PP O
8 53 62 9848786 hemolytic JJ B-NP B-Disease
9 63 69 9848786 uremic JJ I-NP I-Disease
10 70 78 9848786 syndrome NN I-NP I-Disease
11 78 79 9848786 . . O O
12 80 84 9848786 This DT B-NP O
13 85 90 9848786 study NN I-NP O
14 91 98 9848786 reports VBZ B-VP O
15 99 101 9848786 on IN B-PP O
16 102 105 9848786 six CD B-NP O
17 106 111 9848786 cases NNS I-NP O
18 112 114 9848786 of IN B-PP O
19 115 125 9848786 deficiency NN B-NP B-Disease
20 126 128 9848786 in IN B-PP I-Disease
21 129 132 9848786 the DT B-NP I-Disease
22 133 138 9848786 human JJ I-NP I-Disease
23 139 149 9848786 complement NN I-NP I-Disease
24 150 160 9848786 regulatory JJ I-NP I-Disease
25 161 168 9848786 protein NN I-NP I-Disease
26 169 175 9848786 Factor NN I-NP I-Disease
27 176 177 9848786 H NN I-NP I-Disease
28 178 179 9848786 ( ( O O
29 179 181 9848786 FH NN B-NP O
30 181 182 9848786 ) ) O O
31 183 185 9848786 in IN B-PP O
32 186 189 9848786 the DT B-NP O
33 190 197 9848786 context NN I-NP O
34 198 200 9848786 of IN B-PP O
35 201 203 9848786 an DT B-NP O
36 204 209 9848786 acute JJ I-NP B-Disease
37 210 215 9848786 renal JJ I-NP I-Disease
38 216 223 9848786 disease NN I-NP I-Disease
39 223 224 9848786 . . O O

1 225 229 9848786 Five CD B-NP O
2 230 232 9848786 of IN B-PP O
3 233 236 9848786 the DT B-NP O
4 237 242 9848786 cases NNS I-NP O
5 243 247 9848786 were VBD B-VP O
6 248 256 9848786 observed VBN I-VP O
7 257 259 9848786 in IN B-PP O
8 260 268 9848786 children NNS B-NP O
9 269 279 9848786 presenting VBG B-VP O
10 280 284 9848786 with IN B-PP O
11 285 295 9848786 idiopathic JJ B-NP O
12 296 305 9848786 hemolytic JJ I-NP B-Disease
13 306 312 9848786 uremic JJ I-NP I-Disease
14 313 321 9848786 syndrome NN I-NP I-Disease
15 322 323 9848786 ( ( O O
16 323 326 9848786 HUS NN B-NP B-Disease
17 326 327 9848786 ) ) O O
18 327 328 9848786 . . O O

1 329 332 9848786 Two CD B-NP O
2 333 335 9848786 of IN B-PP O
3 336 339 9848786 the DT B-NP O
4 340 348 9848786 children NNS I-NP O
5 349 358 9848786 exhibited VBD B-VP O
6 359 360 9848786 a DT B-NP O
7 361 371 9848786 homozygous JJ I-NP O
8 372 382 9848786 deficiency NN I-NP O
9 383 396 9848786 characterized VBN B-VP O
10 397 399 9848786 by IN B-PP O
11 400 403 9848786 the DT B-NP O
12 404 411 9848786 absence NN I-NP O
13 412 414 9848786 of IN B-PP O
14 415 418 9848786 the DT B-NP O
15 419 422 9848786 150 CD I-NP O
16 422 423 9848786 - HYPH I-NP O
17 423 425 9848786 kD NN I-NP O
18 426 430 9848786 form NN I-NP O
19 431 433 9848786 of IN B-PP O
20 434 440 9848786 Factor NN B-NP O
21 441 442 9848786 H NN I-NP O
22 443 446 9848786 and CC O O
23 447 450 9848786 the DT B-NP O
24 451 459 9848786 presence NN I-NP O
25 459 460 9848786 , , O O
26 461 465 9848786 upon IN B-PP O
27 466 480 9848786 immunoblotting NN B-NP O
28 480 481 9848786 , , O O
29 482 484 9848786 of IN B-PP O
30 485 488 9848786 the DT B-NP O
31 489 491 9848786 42 CD I-NP O
32 491 492 9848786 - HYPH I-NP O
33 492 494 9848786 kD NN I-NP O
34 495 501 9848786 Factor NN I-NP O
35 502 503 9848786 H NN I-NP O
36 503 504 9848786 - HYPH B-NP O
37 504 508 9848786 like JJ I-NP O
38 509 516 9848786 protein NN I-NP O
39 517 518 9848786 1 CD I-NP O
40 519 520 9848786 ( ( O O
41 520 523 9848786 FHL NN B-NP O
42 523 524 9848786 - HYPH B-NP O
43 524 525 9848786 1 CD I-NP O
44 525 526 9848786 ) ) O O
45 527 530 9848786 and CC O O
46 531 536 9848786 other JJ B-NP O
47 537 539 9848786 FH NN I-NP O
48 539 540 9848786 - HYPH B-VP O
49 540 547 9848786 related VBN B-NP O
50 548 555 9848786 protein NN I-NP O
51 556 557 9848786 ( ( O O
52 557 560 9848786 FHR NN B-NP O
53 560 561 9848786 ) ) O O
54 562 567 9848786 bands NNS B-NP O
55 567 568 9848786 . . O O

1 569 577 9848786 Southern NN B-NP O
2 578 582 9848786 blot NN I-NP O
3 583 586 9848786 and CC O O
4 587 590 9848786 PCR NN B-NP O
5 591 599 9848786 analysis NN I-NP O
6 600 602 9848786 of IN B-PP O
7 603 606 9848786 DNA NN B-NP O
8 607 609 9848786 of IN B-PP O
9 610 613 9848786 one CD B-NP O
10 614 621 9848786 patient NN I-NP O
11 622 626 9848786 with IN B-PP O
12 627 637 9848786 homozygous JJ B-NP O
13 638 648 9848786 deficiency NN I-NP O
14 649 654 9848786 ruled VBD B-VP O
15 655 658 9848786 out RP B-PRT O
16 659 662 9848786 the DT B-NP O
17 663 671 9848786 presence NN I-NP O
18 672 674 9848786 of IN B-PP O
19 675 676 9848786 a DT B-NP O
20 677 682 9848786 large JJ I-NP O
21 683 691 9848786 deletion NN I-NP O
22 692 694 9848786 of IN B-PP O
23 695 698 9848786 the DT B-NP O
24 699 701 9848786 FH NN I-NP O
25 702 706 9848786 gene NN I-NP O
26 707 709 9848786 as IN B-PP O
27 710 713 9848786 the DT B-NP O
28 714 724 9848786 underlying VBG I-NP O
29 725 731 9848786 defect NN I-NP O
30 732 735 9848786 for IN B-PP O
31 736 739 9848786 the DT B-NP O
32 740 750 9848786 deficiency NN I-NP O
33 750 751 9848786 . . O O

1 752 755 9848786 The DT B-NP O
2 756 761 9848786 other JJ I-NP O
3 762 766 9848786 four CD I-NP O
4 767 775 9848786 children NNS I-NP O
5 776 785 9848786 presented VBD B-VP O
6 786 790 9848786 with IN B-PP O
7 791 803 9848786 heterozygous JJ B-NP O
8 804 814 9848786 deficiency NN I-NP O
9 815 818 9848786 and CC O O
10 819 828 9848786 exhibited VBD B-VP O
11 829 830 9848786 a DT B-NP O
12 831 837 9848786 normal JJ I-NP O
13 838 852 9848786 immunoblotting NN I-NP O
14 853 860 9848786 pattern NN I-NP O
15 861 863 9848786 of IN B-PP O
16 864 872 9848786 proteins NNS B-NP O
17 873 875 9848786 of IN B-PP O
18 876 879 9848786 the DT B-NP O
19 880 882 9848786 FH NN I-NP O
20 883 889 9848786 family NN I-NP O
21 889 890 9848786 . . O O

1 891 897 9848786 Factor NN B-NP B-Disease
2 898 899 9848786 H NN I-NP I-Disease
3 900 910 9848786 deficiency NN I-NP I-Disease
4 911 913 9848786 is VBZ B-VP O
5 914 917 9848786 the DT B-NP O
6 918 922 9848786 only JJ I-NP O
7 923 933 9848786 complement NN I-NP B-Disease
8 934 944 9848786 deficiency NN I-NP I-Disease
9 945 955 9848786 associated VBN B-VP O
10 956 960 9848786 with IN B-PP O
11 961 964 9848786 HUS NN B-NP B-Disease
12 964 965 9848786 . . O O

1 966 971 9848786 These DT B-NP O
2 972 984 9848786 observations NNS I-NP O
3 985 992 9848786 suggest VBP B-VP O
4 993 994 9848786 a DT B-NP O
5 995 999 9848786 role NN I-NP O
6 1000 1003 9848786 for IN B-PP O
7 1004 1006 9848786 FH NN B-NP O
8 1007 1010 9848786 and CC O O
9 1010 1011 9848786 / SYM B-NP O
10 1011 1013 9848786 or CC O O
11 1014 1016 9848786 FH NN B-NP O
12 1017 1026 9848786 receptors NNS I-NP O
13 1027 1029 9848786 in IN B-PP O
14 1030 1033 9848786 the DT B-NP O
15 1034 1046 9848786 pathogenesis NN I-NP O
16 1047 1049 9848786 of IN B-PP O
17 1050 1060 9848786 idiopathic JJ B-NP O
18 1061 1064 9848786 HUS NN I-NP B-Disease
19 1064 1065 9848786 . . O O
20 1065 1066 9848786 . . O O

1 0 0 9792409 -DOCSTART- -X- -X- O

1 0 3 9792409 ATM NN B-NP O
2 4 12 9792409 germline NN I-NP O
3 13 22 9792409 mutations NNS I-NP O
4 23 25 9792409 in IN B-PP O
5 26 35 9792409 classical JJ B-NP O
6 36 42 9792409 ataxia NN I-NP B-Disease
7 42 43 9792409 - HYPH B-NP I-Disease
8 43 57 9792409 telangiectasia NN I-NP I-Disease
9 58 66 9792409 patients NNS I-NP O
10 67 69 9792409 in IN B-PP O
11 70 73 9792409 the DT B-NP O
12 74 79 9792409 Dutch JJ I-NP O
13 80 90 9792409 population NN I-NP O
14 90 91 9792409 . . O O
15 92 100 9792409 Germline NN B-NP O
16 101 110 9792409 mutations NNS I-NP O
17 111 113 9792409 in IN B-PP O
18 114 117 9792409 the DT B-NP O
19 118 121 9792409 ATM NN I-NP O
20 122 126 9792409 gene NN I-NP O
21 127 130 9792409 are VBP B-VP O
22 131 142 9792409 responsible JJ B-ADJP O
23 143 146 9792409 for IN B-PP O
24 147 150 9792409 the DT B-NP O
25 151 160 9792409 autosomal JJ I-NP B-Disease
26 161 170 9792409 recessive JJ I-NP I-Disease
27 171 179 9792409 disorder NN I-NP I-Disease
28 180 186 9792409 ataxia NN I-NP B-Disease
29 186 187 9792409 - HYPH B-NP I-Disease
30 187 201 9792409 telangiectasia NN I-NP I-Disease
31 202 203 9792409 ( ( O O
32 203 204 9792409 A NN B-NP B-Disease
33 204 205 9792409 - HYPH O I-Disease
34 205 206 9792409 T NN B-NP I-Disease
35 206 207 9792409 ) ) O O
36 207 208 9792409 . . O O

1 209 211 9792409 In IN B-PP O
2 212 215 9792409 our PRP$ B-NP O
3 216 221 9792409 study NN I-NP O
4 221 222 9792409 , , O O
5 223 225 9792409 we PRP B-NP O
6 226 230 9792409 have VBP B-VP O
7 231 241 9792409 determined VBN I-VP O
8 242 245 9792409 the DT B-NP O
9 246 249 9792409 ATM NN I-NP O
10 250 258 9792409 mutation NN I-NP O
11 259 267 9792409 spectrum NN I-NP O
12 268 270 9792409 in IN B-PP O
13 271 273 9792409 19 CD B-NP O
14 274 283 9792409 classical JJ I-NP O
15 284 285 9792409 A NN I-NP B-Disease
16 285 286 9792409 - HYPH I-NP I-Disease
17 286 287 9792409 T NN I-NP I-Disease
18 288 296 9792409 patients NNS I-NP O
19 296 297 9792409 , , O O
20 298 307 9792409 including VBG B-PP O
21 308 312 9792409 some DT B-NP O
22 313 322 9792409 immigrant JJ I-NP O
23 323 334 9792409 populations NNS I-NP O
24 334 335 9792409 , , O O
25 336 338 9792409 as RB B-CONJP O
26 339 343 9792409 well RB I-CONJP O
27 344 346 9792409 as IN I-CONJP O
28 347 349 9792409 12 CD B-NP O
29 350 352 9792409 of IN B-PP O
30 353 358 9792409 Dutch JJ B-NP O
31 359 365 9792409 ethnic JJ I-NP O
32 366 372 9792409 origin NN I-NP O
33 372 373 9792409 . . O O

1 374 378 9792409 Both CC O O
2 379 382 9792409 the DT B-NP O
3 383 390 9792409 protein NN I-NP O
4 391 401 9792409 truncation NN I-NP O
5 402 406 9792409 test NN I-NP O
6 407 408 9792409 ( ( O O
7 408 411 9792409 PTT NN B-NP O
8 411 412 9792409 ) ) O O
9 413 416 9792409 and CC O O
10 417 420 9792409 the DT B-NP O
11 421 432 9792409 restriction NN I-NP O
12 433 445 9792409 endonuclease NN I-NP O
13 446 460 9792409 fingerprinting NN I-NP O
14 461 462 9792409 ( ( O O
15 462 465 9792409 REF NN B-NP O
16 465 466 9792409 ) ) O O
17 467 473 9792409 method NN B-NP O
18 474 478 9792409 were VBD B-VP O
19 479 483 9792409 used VBN I-VP O
20 484 487 9792409 and CC O O
21 488 496 9792409 compared VBN B-VP O
22 497 500 9792409 for IN B-PP O
23 501 506 9792409 their PRP$ B-NP O
24 507 516 9792409 detection NN I-NP O
25 517 527 9792409 efficiency NN I-NP O
26 527 528 9792409 , , O O
27 529 540 9792409 identifying VBG B-VP O
28 541 544 9792409 76% NN B-NP O
29 545 548 9792409 and CC I-NP O
30 549 552 9792409 60% NN I-NP O
31 553 555 9792409 of IN B-PP O
32 556 559 9792409 the DT B-NP O
33 560 569 9792409 mutations NNS I-NP O
34 569 570 9792409 , , O O
35 571 583 9792409 respectively RB B-ADVP O
36 583 584 9792409 . . O O

1 585 589 9792409 Most JJS B-NP O
2 590 598 9792409 patients NNS I-NP O
3 599 603 9792409 were VBD B-VP O
4 604 609 9792409 found VBN I-VP O
5 610 612 9792409 to TO I-VP O
6 613 615 9792409 be VB I-VP O
7 616 624 9792409 compound JJ B-NP O
8 625 637 9792409 heterozygote NN I-NP O
9 637 638 9792409 . . O O

1 639 648 9792409 Seventeen CD B-NP O
2 649 658 9792409 mutations NNS I-NP O
3 659 663 9792409 were VBD B-VP O
4 664 672 9792409 distinct JJ B-ADJP O
5 672 673 9792409 , , O O
6 674 676 9792409 of IN B-PP O
7 677 682 9792409 which WDT B-NP O
8 683 685 9792409 10 CD B-NP O
9 686 690 9792409 were VBD B-VP O
10 691 694 9792409 not RB I-VP O
11 695 703 9792409 reported VBN I-VP O
12 704 714 9792409 previously RB B-ADVP O
13 714 715 9792409 . . O O

1 716 725 9792409 Mutations NNS B-NP O
2 726 729 9792409 are VBP B-VP O
3 730 735 9792409 small JJ B-NP O
4 736 745 9792409 deletions NNS I-NP O
5 746 748 9792409 or CC O O
6 749 754 9792409 point NN B-NP O
7 755 764 9792409 mutations NNS I-NP O
8 765 775 9792409 frequently RB B-VP O
9 776 785 9792409 affecting VBG I-VP O
10 786 792 9792409 splice NN B-NP O
11 793 798 9792409 sites NNS I-NP O
12 798 799 9792409 . . O O

1 800 808 9792409 Moreover RB B-ADVP O
2 808 809 9792409 , , O O
3 810 811 9792409 a DT B-NP O
4 812 814 9792409 16 CD I-NP O
5 814 815 9792409 . . O O

1 816 817 9792409 7 CD B-NP O
2 817 818 9792409 - HYPH I-NP O
3 818 820 9792409 kb NN I-NP O
4 821 828 9792409 genomic JJ I-NP O
5 829 837 9792409 deletion NN I-NP O
6 838 840 9792409 of IN B-PP O
7 841 844 9792409 the DT B-NP O
8 845 846 9792409 3 CD I-NP O
9 847 850 9792409 end NN I-NP O
10 851 853 9792409 of IN B-PP O
11 854 857 9792409 the DT B-NP O
12 858 862 9792409 gene NN I-NP O
13 862 863 9792409 , , O O
14 864 868 9792409 most RBS B-ADVP O
15 869 875 9792409 likely RB I-ADVP O
16 876 877 9792409 a DT B-NP O
17 878 884 9792409 result NN I-NP O
18 885 887 9792409 of IN B-PP O
19 888 901 9792409 recombination NN B-NP O
20 902 909 9792409 between IN B-PP O
21 910 913 9792409 two CD B-NP O
22 914 918 9792409 LINE NNP I-NP O
23 919 927 9792409 elements NNS I-NP O
24 927 928 9792409 , , O O
25 929 932 9792409 was VBD B-VP O
26 933 943 9792409 identified VBN I-VP O
27 943 944 9792409 . . O O

1 945 948 9792409 The DT B-NP O
2 949 953 9792409 most RBS I-NP O
3 954 964 9792409 frequently RB I-NP O
4 965 970 9792409 found VBN I-NP O
5 971 979 9792409 mutation NN I-NP O
6 979 980 9792409 , , O O
7 981 991 9792409 identified VBN B-VP O
8 992 994 9792409 in IN B-PP O
9 995 1000 9792409 three CD B-NP O
10 1001 1010 9792409 unrelated JJ I-NP O
11 1011 1018 9792409 Turkish JJ I-NP O
12 1019 1020 9792409 A NN I-NP B-Disease
13 1020 1021 9792409 - HYPH I-NP I-Disease
14 1021 1022 9792409 T NN I-NP I-Disease
15 1023 1034 9792409 individuals NNS I-NP O
16 1034 1035 9792409 , , O O
17 1036 1039 9792409 was VBD B-VP O
18 1040 1050 9792409 previously RB I-VP O
19 1051 1060 9792409 described VBN I-VP O
20 1061 1063 9792409 to TO I-VP O
21 1064 1066 9792409 be VB I-VP O
22 1067 1068 9792409 a DT B-NP O
23 1069 1076 9792409 Turkish JJ I-NP O
24 1077 1078 9792409 A NN I-NP B-Disease
25 1078 1079 9792409 - HYPH I-NP I-Disease
26 1079 1080 9792409 T NN I-NP I-Disease
27 1081 1088 9792409 founder NN I-NP O
28 1089 1097 9792409 mutation NN I-NP O
29 1097 1098 9792409 . . O O

1 1099 1102 9792409 The DT B-NP O
2 1103 1111 9792409 presence NN I-NP O
3 1112 1114 9792409 of IN B-PP O
4 1115 1116 9792409 a DT B-NP O
5 1117 1124 9792409 founder NN I-NP O
6 1125 1133 9792409 mutation NN I-NP O
7 1134 1139 9792409 among IN B-PP O
8 1140 1150 9792409 relatively RB B-NP O
9 1151 1156 9792409 small JJ I-NP O
10 1157 1163 9792409 ethnic JJ I-NP O
11 1164 1174 9792409 population NN I-NP O
12 1175 1181 9792409 groups NNS I-NP O
13 1182 1184 9792409 in IN B-PP O
14 1185 1192 9792409 Western NNP B-NP O
15 1193 1199 9792409 Europe NNP I-NP O
16 1200 1205 9792409 could MD B-VP O
17 1206 1214 9792409 indicate VB I-VP O
18 1215 1216 9792409 a DT B-NP O
19 1217 1221 9792409 high JJ I-NP O
20 1222 1229 9792409 carrier NN I-NP O
21 1230 1239 9792409 frequency NN I-NP O
22 1240 1242 9792409 in IN B-PP O
23 1243 1247 9792409 such JJ B-NP O
24 1248 1259 9792409 communities NNS I-NP O
25 1259 1260 9792409 . . O O

1 1261 1263 9792409 In IN B-PP O
2 1264 1272 9792409 patients NNS B-NP O
3 1273 1275 9792409 of IN B-PP O
4 1276 1281 9792409 Dutch JJ B-NP O
5 1282 1288 9792409 ethnic JJ I-NP O
6 1289 1295 9792409 origin NN I-NP O
7 1295 1296 9792409 , , O O
8 1297 1304 9792409 however RB B-ADVP O
9 1304 1305 9792409 , , O O
10 1306 1308 9792409 no DT B-NP O
11 1309 1320 9792409 significant JJ I-NP O
12 1321 1328 9792409 founder NN I-NP O
13 1329 1335 9792409 effect NN I-NP O
14 1336 1341 9792409 could MD B-VP O
15 1342 1344 9792409 be VB I-VP O
16 1345 1355 9792409 identified VBN I-VP O
17 1355 1356 9792409 . . O O

1 1357 1360 9792409 The DT B-NP O
2 1361 1369 9792409 observed VBN I-NP O
3 1370 1377 9792409 genetic JJ I-NP O
4 1378 1391 9792409 heterogeneity NN I-NP O
5 1392 1401 9792409 including VBG B-PP O
6 1402 1405 9792409 the DT B-NP O
7 1406 1414 9792409 relative JJ I-NP O
8 1415 1419 9792409 high JJ I-NP O
9 1420 1430 9792409 percentage NN I-NP O
10 1431 1433 9792409 of IN B-PP O
11 1434 1440 9792409 splice NN B-NP O
12 1440 1441 9792409 - HYPH B-NP O
13 1441 1445 9792409 site NN I-NP O
14 1446 1455 9792409 mutations NNS I-NP O
15 1456 1459 9792409 had VBD B-VP O
16 1460 1462 9792409 no DT B-NP O
17 1463 1473 9792409 reflection NN I-NP O
18 1474 1476 9792409 on IN B-PP O
19 1477 1480 9792409 the DT B-NP O
20 1481 1490 9792409 phenotype NN I-NP O
21 1490 1491 9792409 . . O O

1 1492 1495 9792409 All DT B-NP O
2 1496 1504 9792409 patients NNS I-NP O
3 1505 1515 9792409 manifested VBD B-VP O
4 1516 1525 9792409 classical JJ B-NP O
5 1526 1527 9792409 A NN I-NP B-Disease
6 1527 1528 9792409 - HYPH I-NP I-Disease
7 1528 1529 9792409 T NN I-NP I-Disease
8 1530 1533 9792409 and CC O O
9 1534 1543 9792409 increased VBD B-VP O
10 1544 1552 9792409 cellular JJ B-NP O
11 1553 1567 9792409 radioresistant JJ I-NP O
12 1568 1571 9792409 DNA NN I-NP O
13 1572 1581 9792409 synthesis NN I-NP O
14 1581 1582 9792409 . . O O

1 0 0 993342 -DOCSTART- -X- -X- O

1 0 3 993342 The DT B-NP O
2 4 15 993342 chromosomal JJ I-NP O
3 16 21 993342 order NN I-NP O
4 22 24 993342 of IN B-PP O
5 25 30 993342 genes NNS B-NP O
6 31 42 993342 controlling VBG B-VP O
7 43 46 993342 the DT B-NP O
8 47 52 993342 major JJ I-NP O
9 53 71 993342 histocompatibility NN I-NP O
10 72 79 993342 complex NN I-NP O
11 79 80 993342 , , O O
12 81 90 993342 properdin NN B-NP O
13 91 97 993342 factor NN I-NP O
14 98 99 993342 B NN I-NP O
15 99 100 993342 , , O O
16 101 104 993342 and CC O O
17 105 115 993342 deficiency NN B-NP B-Disease
18 116 118 993342 of IN B-PP I-Disease
19 119 122 993342 the DT B-NP I-Disease
20 123 129 993342 second JJ I-NP I-Disease
21 130 139 993342 component NN I-NP I-Disease
22 140 142 993342 of IN B-PP I-Disease
23 143 153 993342 complement NN B-NP I-Disease
24 153 154 993342 . . O O
25 155 158 993342 The DT B-NP O
26 159 171 993342 relationship NN I-NP O
27 172 174 993342 of IN B-PP O
28 175 178 993342 the DT B-NP O
29 179 184 993342 genes NNS I-NP O
30 185 191 993342 coding VBG B-VP O
31 192 195 993342 for IN B-PP O
32 196 199 993342 HLA NN B-NP O
33 200 202 993342 to TO B-PP O
34 203 208 993342 those DT B-NP O
35 209 215 993342 coding VBG B-VP O
36 216 219 993342 for IN B-PP O
37 220 229 993342 properdin NN B-NP O
38 230 236 993342 Factor NN I-NP O
39 237 238 993342 B NN I-NP O
40 239 248 993342 allotypes NNS I-NP O
41 249 252 993342 and CC B-PP O
42 253 256 993342 for IN B-PP O
43 257 267 993342 deficiency NN B-NP B-Disease
44 268 270 993342 of IN B-PP I-Disease
45 271 274 993342 the DT B-NP I-Disease
46 275 281 993342 second JJ I-NP I-Disease
47 282 291 993342 component NN I-NP I-Disease
48 292 294 993342 of IN B-PP I-Disease
49 295 305 993342 complement NN B-NP I-Disease
50 306 307 993342 ( ( O O
51 307 309 993342 C2 NN B-NP O
52 309 310 993342 ) ) O O
53 311 314 993342 was VBD B-VP O
54 315 322 993342 studied VBN I-VP O
55 323 325 993342 in IN B-PP O
56 326 334 993342 families NNS B-NP O
57 335 337 993342 of IN B-PP O
58 338 346 993342 patients NNS B-NP O
59 347 351 993342 with IN B-PP O
60 352 362 993342 connective JJ B-NP O
61 363 369 993342 tissue NN I-NP O
62 370 379 993342 disorders NNS I-NP O
63 379 380 993342 . . O O

1 381 389 993342 Patients NNS B-NP O
2 390 394 993342 were VBD B-VP O
3 395 403 993342 selected VBN I-VP O
4 404 411 993342 because IN B-SBAR O
5 412 416 993342 they PRP B-NP O
6 417 421 993342 were VBD B-VP O
7 422 434 993342 heterozygous JJ B-ADJP O
8 435 437 993342 or CC I-ADJP O
9 438 448 993342 homozygous JJ I-ADJP O
10 449 452 993342 for IN B-PP O
11 453 455 993342 C2 NN B-NP B-Disease
12 456 466 993342 deficiency NN I-NP I-Disease
13 466 467 993342 . . O O

1 468 470 993342 12 CD B-NP O
2 471 479 993342 families NNS I-NP O
3 480 484 993342 with IN B-PP O
4 485 487 993342 15 CD B-NP O
5 488 495 993342 matings NNS I-NP O
6 496 507 993342 informative JJ B-ADJP O
7 508 511 993342 for IN B-PP O
8 512 514 993342 C2 NN B-NP B-Disease
9 515 525 993342 deficiency NN I-NP I-Disease
10 526 530 993342 were VBD B-VP O
11 531 536 993342 found VBN I-VP O
12 536 537 993342 . . O O

1 538 540 993342 Of IN B-PP O
2 541 543 993342 57 CD B-NP O
3 544 555 993342 informative JJ I-NP O
4 556 563 993342 meioses NNS I-NP O
5 563 564 993342 , , O O
6 565 568 993342 two CD B-NP O
7 569 579 993342 crossovers NNS I-NP O
8 580 584 993342 were VBD B-VP O
9 585 590 993342 noted VBN I-VP O
10 591 598 993342 between IN B-PP O
11 599 602 993342 the DT B-NP O
12 603 605 993342 C2 NN I-NP B-Disease
13 606 616 993342 deficiency NN I-NP I-Disease
14 617 621 993342 gene NN I-NP O
15 622 625 993342 and CC O O
16 626 629 993342 the DT B-NP O
17 630 633 993342 HLA NN I-NP O
18 633 634 993342 - HYPH B-NP O
19 634 635 993342 B NN I-NP O
20 636 640 993342 gene NN I-NP O
21 640 641 993342 , , O O
22 642 646 993342 with IN B-PP O
23 647 648 993342 a DT B-NP O
24 649 660 993342 recombinant JJ I-NP O
25 661 669 993342 fraction NN I-NP O
26 670 672 993342 of IN B-PP O
27 673 674 993342 0 CD B-NP O
28 674 675 993342 . . O O

1 676 679 993342 035 CD B-NP O
2 679 680 993342 . . O O

1 681 682 993342 A DT B-NP O
2 683 686 993342 lod NN I-NP O
3 687 692 993342 score NN I-NP O
4 693 695 993342 of IN B-PP O
5 696 698 993342 13 CD B-NP O
6 699 702 993342 was VBD B-VP O
7 703 713 993342 calculated VBN I-VP O
8 714 717 993342 for IN B-PP O
9 718 725 993342 linkage NN B-NP O
10 726 733 993342 between IN B-PP O
11 734 736 993342 C2 NN B-NP B-Disease
12 737 747 993342 deficiency NN I-NP I-Disease
13 748 751 993342 and CC I-NP O
14 752 755 993342 HLA NN I-NP O
15 755 756 993342 - HYPH O O
16 756 757 993342 B NN B-NP O
17 758 760 993342 at IN B-PP O
18 761 762 993342 a DT B-NP O
19 763 770 993342 maximum NN I-NP O
20 771 781 993342 likelihood NN I-NP O
21 782 787 993342 value NN I-NP O
22 788 790 993342 of IN B-PP O
23 791 794 993342 the DT B-NP O
24 795 806 993342 recombinant JJ I-NP O
25 807 815 993342 fraction NN I-NP O
26 816 818 993342 of IN B-PP O
27 819 820 993342 0 CD B-NP O
28 820 821 993342 . . O O

1 822 824 993342 04 CD B-NP O
2 824 825 993342 . . O O

1 826 828 993342 18 CD B-NP O
2 829 837 993342 families NNS I-NP O
3 838 842 993342 with IN B-PP O
4 843 845 993342 21 CD B-NP O
5 846 857 993342 informative JJ I-NP O
6 858 865 993342 matings NNS I-NP O
7 866 869 993342 for IN B-PP O
8 870 874 993342 both CC O O
9 875 884 993342 properdin NN B-NP O
10 885 891 993342 Factor NN I-NP O
11 892 893 993342 B NN I-NP O
12 894 902 993342 allotype NN I-NP O
13 903 906 993342 and CC I-NP O
14 907 910 993342 HLA NN I-NP O
15 910 911 993342 - HYPH O O
16 911 912 993342 B NN B-NP O
17 913 917 993342 were VBD B-VP O
18 918 923 993342 found VBN I-VP O
19 923 924 993342 . . O O

1 925 927 993342 Of IN B-PP O
2 928 930 993342 72 CD B-NP O
3 931 942 993342 informative JJ I-NP O
4 943 950 993342 meioses NNS I-NP O
5 950 951 993342 , , O O
6 952 957 993342 three CD B-NP O
7 958 970 993342 recombinants NNS I-NP O
8 971 975 993342 were VBD B-VP O
9 976 981 993342 found VBN I-VP O
10 981 982 993342 , , O O
11 983 989 993342 giving VBG B-VP O
12 990 991 993342 a DT B-NP O
13 992 1003 993342 recombinant JJ I-NP O
14 1004 1012 993342 fraction NN I-NP O
15 1013 1015 993342 of IN B-PP O
16 1016 1017 993342 0 CD B-NP O
17 1017 1018 993342 . . O O

1 1019 1022 993342 042 CD B-NP O
2 1022 1023 993342 . . O O

1 1024 1025 993342 A DT B-NP O
2 1026 1029 993342 lod NN I-NP O
3 1030 1035 993342 score NN I-NP O
4 1036 1038 993342 of IN B-PP O
5 1039 1041 993342 16 CD B-NP O
6 1042 1049 993342 between IN B-PP O
7 1050 1053 993342 HLA NN B-NP O
8 1053 1054 993342 - HYPH I-NP O
9 1054 1055 993342 B NN I-NP O
10 1056 1059 993342 and CC I-NP O
11 1060 1066 993342 Factor NN I-NP O
12 1067 1068 993342 B NN I-NP O
13 1069 1078 993342 allotypes NNS I-NP O
14 1079 1082 993342 was VBD B-VP O
15 1083 1093 993342 calculated VBN I-VP O
16 1094 1096 993342 at IN B-PP O
17 1097 1098 993342 a DT B-NP O
18 1099 1106 993342 maximum NN I-NP O
19 1107 1117 993342 likelihood NN I-NP O
20 1118 1123 993342 value NN I-NP O
21 1124 1126 993342 of IN B-PP O
22 1127 1130 993342 the DT B-NP O
23 1131 1142 993342 recombinant JJ I-NP O
24 1143 1151 993342 fraction NN I-NP O
25 1152 1154 993342 of IN B-PP O
26 1155 1156 993342 0 CD B-NP O
27 1156 1157 993342 . . O O

1 1158 1160 993342 04 CD B-NP O
2 1160 1161 993342 . . O O

1 1162 1163 993342 A DT B-NP O
2 1164 1173 993342 crossover NN I-NP O
3 1174 1177 993342 was VBD B-VP O
4 1178 1183 993342 shown VBN I-VP O
5 1184 1186 993342 to TO I-VP O
6 1187 1191 993342 have VB I-VP O
7 1192 1200 993342 occurred VBN I-VP O
8 1201 1208 993342 between IN B-PP O
9 1209 1214 993342 genes NNS B-NP O
10 1215 1218 993342 for IN B-PP O
11 1219 1225 993342 Factor NN B-NP O
12 1226 1227 993342 B NN I-NP O
13 1228 1231 993342 and CC O O
14 1232 1235 993342 HLA NN B-NP O
15 1235 1236 993342 - HYPH O O
16 1236 1237 993342 D NN B-NP O
17 1237 1238 993342 , , O O
18 1239 1241 993342 in IN B-PP O
19 1242 1247 993342 which WDT B-NP O
20 1248 1251 993342 HLA NN B-NP O
21 1251 1252 993342 - HYPH I-NP O
22 1252 1253 993342 D NN I-NP O
23 1254 1264 993342 segregared VBN B-VP O
24 1265 1269 993342 with IN B-PP O
25 1270 1273 993342 HLA NN B-NP O
26 1273 1274 993342 - HYPH I-NP O
27 1274 1275 993342 A NN I-NP O
28 1276 1279 993342 and CC I-NP O
29 1280 1281 993342 B NN I-NP O
30 1281 1282 993342 . . O O

1 1283 1288 993342 These DT B-NP O
2 1289 1296 993342 studies NNS I-NP O
3 1297 1304 993342 suggest VBP B-VP O
4 1305 1309 993342 that IN B-SBAR O
5 1310 1313 993342 the DT B-NP O
6 1314 1319 993342 genes NNS I-NP O
7 1320 1323 993342 for IN B-PP O
8 1324 1330 993342 Factor NN B-NP O
9 1331 1332 993342 B NN I-NP O
10 1333 1336 993342 and CC O O
11 1337 1339 993342 C2 NN B-NP B-Disease
12 1340 1350 993342 deficiency NN I-NP I-Disease
13 1351 1354 993342 are VBP B-VP O
14 1355 1362 993342 located JJ B-ADJP O
15 1363 1370 993342 outside IN B-PP O
16 1371 1376 993342 those DT B-NP O
17 1377 1380 993342 for IN B-PP O
18 1381 1384 993342 HLA NN B-NP O
19 1384 1385 993342 , , O O
20 1386 1390 993342 that IN B-SBAR O
21 1391 1394 993342 the DT B-NP O
22 1395 1400 993342 order NN I-NP O
23 1401 1403 993342 of IN B-PP O
24 1404 1410 993342 genese NN B-NP O
25 1411 1413 993342 is VBZ B-VP O
26 1414 1417 993342 HLA NN B-NP O
27 1417 1418 993342 - HYPH I-NP O
28 1418 1419 993342 A NN I-NP O
29 1419 1420 993342 , , O O
30 1421 1422 993342 - HYPH B-NP O
31 1422 1423 993342 B NN I-NP O
32 1423 1424 993342 , , O O
33 1425 1426 993342 - HYPH B-NP O
34 1426 1427 993342 D NN I-NP O
35 1427 1428 993342 , , O O
36 1429 1435 993342 Factor NN B-NP O
37 1436 1437 993342 B NN I-NP O
38 1438 1446 993342 allotype NN I-NP O
39 1446 1447 993342 , , O O
40 1448 1450 993342 C2 NN B-NP B-Disease
41 1451 1461 993342 deficiency NN I-NP I-Disease
42 1461 1462 993342 , , O O
43 1463 1467 993342 that IN B-SBAR O
44 1468 1471 993342 the DT B-NP O
45 1472 1477 993342 genes NNS I-NP O
46 1478 1484 993342 coding VBG B-VP O
47 1485 1488 993342 for IN B-PP O
48 1489 1491 993342 C2 NN B-NP B-Disease
49 1492 1502 993342 deficiency NN I-NP I-Disease
50 1503 1506 993342 and CC O O
51 1507 1513 993342 Factor NN B-NP O
52 1514 1515 993342 B NN I-NP O
53 1516 1525 993342 allotypes NNS I-NP O
54 1526 1529 993342 are VBP B-VP O
55 1530 1543 993342 approximately RB B-NP O
56 1544 1545 993342 3 CD I-NP O
57 1545 1546 993342 - HYPH I-NP O
58 1546 1547 993342 - SYM I-NP O
59 1547 1548 993342 5 CD I-NP O
60 1549 1561 993342 centimorgans NNS I-NP O
61 1562 1566 993342 from IN B-PP O
62 1567 1570 993342 the DT B-NP O
63 1571 1574 993342 HLA NN I-NP O
64 1574 1575 993342 - HYPH I-NP O
65 1575 1576 993342 A NN I-NP O
66 1577 1580 993342 and CC I-NP O
67 1581 1584 993342 HLA NN I-NP O
68 1584 1585 993342 - HYPH B-NP O
69 1585 1586 993342 B NN I-NP O
70 1587 1591 993342 loci NNS I-NP O
71 1591 1592 993342 , , O O
72 1593 1596 993342 and CC O O
73 1597 1601 993342 that IN B-SBAR O
74 1602 1605 993342 the DT B-NP O
75 1606 1614 993342 apparent JJ I-NP O
76 1615 1619 993342 lack NN I-NP O
77 1620 1622 993342 of IN B-PP O
78 1623 1635 993342 recombinants NNS B-NP O
79 1636 1643 993342 between IN B-PP O
80 1644 1647 993342 the DT B-NP O
81 1648 1654 993342 Factor NN I-NP O
82 1655 1656 993342 B NN I-NP O
83 1657 1661 993342 gene NN I-NP O
84 1662 1665 993342 and CC O O
85 1666 1668 993342 C2 NN B-NP B-Disease
86 1669 1679 993342 deficiency NN I-NP I-Disease
87 1680 1684 993342 gene NN I-NP O
88 1685 1693 993342 suggests VBZ B-VP O
89 1694 1698 993342 that IN B-SBAR O
90 1699 1704 993342 these DT B-NP O
91 1705 1708 993342 two CD I-NP O
92 1709 1714 993342 genes NNS I-NP O
93 1715 1718 993342 lie VBP B-VP O
94 1719 1721 993342 in IN B-PP O
95 1722 1727 993342 close JJ B-NP O
96 1728 1737 993342 proximity NN I-NP O
97 1738 1740 993342 to TO B-PP O
98 1741 1744 993342 one CD B-NP O
99 1745 1752 993342 another DT I-NP O
100 1752 1753 993342 . . O O

1 0 0 9856499 -DOCSTART- -X- -X- O

1 0 10 9856499 Complement NN B-NP B-Disease
2 11 13 9856499 C7 NN I-NP I-Disease
3 14 24 9856499 deficiency NN I-NP I-Disease
4 24 25 9856499 : : O O
5 26 31 9856499 seven CD B-NP O
6 32 39 9856499 further JJ I-NP O
7 40 49 9856499 molecular JJ I-NP O
8 50 57 9856499 defects NNS I-NP O
9 58 61 9856499 and CC O O
10 62 67 9856499 their PRP$ B-NP O
11 68 78 9856499 associated VBN I-NP O
12 79 85 9856499 marker NN I-NP O
13 86 96 9856499 haplotypes NNS I-NP O
14 96 97 9856499 . . O O
15 98 103 9856499 Seven CD B-NP O
16 104 111 9856499 further JJ I-NP O
17 112 121 9856499 molecular JJ I-NP O
18 122 127 9856499 bases NNS I-NP O
19 128 130 9856499 of IN B-PP O
20 131 133 9856499 C7 NN B-NP B-Disease
21 134 144 9856499 deficiency NN I-NP I-Disease
22 145 148 9856499 are VBP B-VP O
23 149 158 9856499 described VBN I-VP O
24 158 159 9856499 . . O O

1 160 163 9856499 All PDT B-NP O
2 164 169 9856499 these DT I-NP O
3 170 173 9856499 new JJ I-NP O
4 174 183 9856499 molecular JJ I-NP O
5 184 191 9856499 defects NNS I-NP O
6 192 199 9856499 involve VBP B-VP O
7 200 206 9856499 single JJ B-NP O
8 206 207 9856499 - HYPH I-NP O
9 207 217 9856499 nucleotide NN I-NP O
10 218 224 9856499 events NNS I-NP O
11 224 225 9856499 , , I-NP O
12 226 235 9856499 deletions NNS I-NP O
13 236 239 9856499 and CC I-NP O
14 240 253 9856499 substitutions NNS I-NP O
15 253 254 9856499 , , O O
16 255 259 9856499 some DT B-NP O
17 260 262 9856499 of IN B-PP O
18 263 268 9856499 which WDT B-NP O
19 269 274 9856499 alter VBP B-VP O
20 275 281 9856499 splice NN B-NP O
21 282 287 9856499 sites NNS I-NP O
22 287 288 9856499 , , O O
23 289 292 9856499 and CC O O
24 293 299 9856499 others NNS B-NP O
25 300 306 9856499 codons NNS I-NP O
26 306 307 9856499 . . O O

1 308 312 9856499 They PRP B-NP O
2 313 316 9856499 are VBP B-VP O
3 317 328 9856499 distributed VBN I-VP O
4 329 334 9856499 along IN B-PP O
5 335 338 9856499 the DT B-NP O
6 339 341 9856499 C7 NN I-NP O
7 342 346 9856499 gene NN I-NP O
8 346 347 9856499 , , O O
9 348 351 9856499 but CC O O
10 352 365 9856499 predominantly RB B-ADVP O
11 366 373 9856499 towards IN B-PP O
12 374 377 9856499 the DT B-NP O
13 378 379 9856499 3 CD I-NP O
14 380 383 9856499 end NN I-NP O
15 383 384 9856499 . . O O

1 385 388 9856499 All DT B-NP O
2 389 393 9856499 were VBD B-VP O
3 394 399 9856499 found VBN I-VP O
4 400 402 9856499 in IN B-PP O
5 403 411 9856499 compound NN B-NP O
6 412 424 9856499 heterozygous JJ I-NP O
7 425 436 9856499 individuals NNS I-NP O
8 436 437 9856499 . . O O

1 438 441 9856499 The DT B-NP O
2 442 444 9856499 C6 NN I-NP O
3 444 445 9856499 / SYM B-VP O
4 445 447 9856499 C7 NN B-NP O
5 448 454 9856499 marker NN I-NP O
6 455 465 9856499 haplotypes NNS I-NP O
7 466 476 9856499 associated VBN B-VP O
8 477 481 9856499 with IN B-PP O
9 482 486 9856499 most JJS B-NP O
10 487 489 9856499 C7 NN I-NP B-Disease
11 490 497 9856499 defects NNS I-NP I-Disease
12 498 501 9856499 are VBP B-VP O
13 502 511 9856499 tabulated VBN I-VP O
14 511 512 9856499 . . O O
15 512 513 9856499 . . O O

1 0 0 9792860 -DOCSTART- -X- -X- O

1 0 13 9792860 Determination NN B-NP O
2 14 16 9792860 of IN B-PP O
3 17 20 9792860 the DT B-NP O
4 21 28 9792860 genomic JJ I-NP O
5 29 38 9792860 structure NN I-NP O
6 39 41 9792860 of IN B-PP O
7 42 45 9792860 the DT B-NP O
8 46 52 9792860 COL4A4 NN I-NP O
9 53 57 9792860 gene NN I-NP O
10 58 61 9792860 and CC B-PP O
11 62 64 9792860 of IN B-PP O
12 65 70 9792860 novel JJ B-NP O
13 71 80 9792860 mutations NNS I-NP O
14 81 88 9792860 causing VBG B-VP O
15 89 98 9792860 autosomal JJ B-NP B-Disease
16 99 108 9792860 recessive JJ I-NP I-Disease
17 109 115 9792860 Alport NN I-NP I-Disease
18 116 124 9792860 syndrome NN I-NP I-Disease
19 124 125 9792860 . . O O
20 126 135 9792860 Autosomal JJ B-NP B-Disease
21 136 145 9792860 recessive JJ I-NP I-Disease
22 146 152 9792860 Alport NN I-NP I-Disease
23 153 161 9792860 syndrome NN I-NP I-Disease
24 162 164 9792860 is VBZ B-VP O
25 165 166 9792860 a DT B-NP O
26 167 178 9792860 progressive JJ I-NP O
27 179 188 9792860 hematuric JJ I-NP B-Disease
28 189 207 9792860 glomerulonephritis NN I-NP I-Disease
29 208 221 9792860 characterized VBN B-VP O
30 222 224 9792860 by IN B-PP O
31 225 235 9792860 glomerular JJ B-NP B-Disease
32 236 244 9792860 basement NN I-NP I-Disease
33 245 253 9792860 membrane NN I-NP I-Disease
34 254 267 9792860 abnormalities NNS I-NP I-Disease
35 268 271 9792860 and CC O O
36 272 282 9792860 associated VBN B-VP O
37 283 287 9792860 with IN B-PP O
38 288 297 9792860 mutations NNS B-NP O
39 298 300 9792860 in IN B-PP O
40 301 307 9792860 either CC O O
41 308 311 9792860 the DT B-NP O
42 312 318 9792860 COL4A3 NN I-NP O
43 319 321 9792860 or CC O O
44 322 325 9792860 the DT B-NP O
45 326 332 9792860 COL4A4 NN I-NP O
46 333 337 9792860 gene NN I-NP O
47 337 338 9792860 , , O O
48 339 344 9792860 which WDT B-NP O
49 345 351 9792860 encode VBP B-VP O
50 352 355 9792860 the DT B-NP O
51 356 362 9792860 alpha3 NN I-NP O
52 363 366 9792860 and CC I-NP O
53 367 373 9792860 alpha4 NN I-NP O
54 374 378 9792860 type NN I-NP O
55 379 381 9792860 IV CD I-NP O
56 382 390 9792860 collagen NN I-NP O
57 391 397 9792860 chains NNS I-NP O
58 397 398 9792860 , , O O
59 399 411 9792860 respectively RB B-ADVP O
60 411 412 9792860 . . O O

1 413 415 9792860 To TO B-PP O
2 416 420 9792860 date NN B-NP O
3 420 421 9792860 , , O O
4 422 430 9792860 mutation NN B-NP O
5 431 440 9792860 screening NN I-NP O
6 441 443 9792860 in IN B-PP O
7 444 447 9792860 the DT B-NP O
8 448 451 9792860 two CD I-NP O
9 452 457 9792860 genes NNS I-NP O
10 458 461 9792860 has VBZ B-VP O
11 462 466 9792860 been VBN I-VP O
12 467 475 9792860 hampered VBN I-VP O
13 476 478 9792860 by IN B-PP O
14 479 482 9792860 the DT B-NP O
15 483 487 9792860 lack NN I-NP O
16 488 490 9792860 of IN B-PP O
17 491 498 9792860 genomic JJ B-NP O
18 499 508 9792860 structure NN I-NP O
19 509 520 9792860 information NN I-NP O
20 520 521 9792860 . . O O

1 522 524 9792860 We PRP B-NP O
2 525 531 9792860 report VBP B-VP O
3 532 536 9792860 here RB B-ADVP O
4 537 540 9792860 the DT B-NP O
5 541 549 9792860 complete JJ I-NP O
6 550 566 9792860 characterization NN I-NP O
7 567 569 9792860 of IN B-PP O
8 570 573 9792860 the DT B-NP O
9 574 576 9792860 48 CD I-NP O
10 577 582 9792860 exons NNS I-NP O
11 583 585 9792860 of IN B-PP O
12 586 589 9792860 the DT B-NP O
13 590 596 9792860 COL4A4 NN I-NP O
14 597 601 9792860 gene NN I-NP O
15 601 602 9792860 , , O O
16 603 604 9792860 a DT B-NP O
17 605 618 9792860 comprehensive JJ I-NP O
18 619 623 9792860 gene NN I-NP O
19 624 630 9792860 screen NN I-NP O
20 630 631 9792860 , , O O
21 632 635 9792860 and CC O O
22 636 639 9792860 the DT B-NP O
23 640 650 9792860 subsequent JJ I-NP O
24 651 660 9792860 detection NN I-NP O
25 661 663 9792860 of IN B-PP O
26 664 666 9792860 10 CD B-NP O
27 667 672 9792860 novel JJ I-NP O
28 673 682 9792860 mutations NNS I-NP O
29 683 685 9792860 in IN B-PP O
30 686 691 9792860 eight CD B-NP O
31 692 700 9792860 patients NNS I-NP O
32 701 710 9792860 diagnosed VBN B-VP O
33 711 715 9792860 with IN B-PP O
34 716 725 9792860 autosomal JJ B-NP B-Disease
35 726 735 9792860 recessive JJ I-NP I-Disease
36 736 742 9792860 Alport NN I-NP I-Disease
37 743 751 9792860 syndrome NN I-NP I-Disease
38 751 752 9792860 . . O O

1 753 764 9792860 Furthermore RB B-ADVP O
2 764 765 9792860 , , O O
3 766 768 9792860 we PRP B-NP O
4 769 779 9792860 identified VBD B-VP O
5 780 781 9792860 a DT B-NP O
6 782 789 9792860 glycine NN I-NP O
7 790 792 9792860 to TO B-PP O
8 793 800 9792860 alanine NN B-NP O
9 801 813 9792860 substitution NN I-NP O
10 814 816 9792860 in IN B-PP O
11 817 820 9792860 the DT B-NP O
12 821 832 9792860 collagenous JJ I-NP O
13 833 839 9792860 domain NN I-NP O
14 840 844 9792860 that WDT B-NP O
15 845 847 9792860 is VBZ B-VP O
16 848 858 9792860 apparently RB B-ADJP O
17 859 865 9792860 silent JJ I-ADJP O
18 866 868 9792860 in IN B-PP O
19 869 872 9792860 the DT B-NP O
20 873 885 9792860 heterozygous JJ I-NP O
21 886 894 9792860 carriers NNS I-NP O
22 894 895 9792860 , , O O
23 896 898 9792860 in IN B-PP O
24 899 901 9792860 11 CD B-NP O
25 901 902 9792860 . . O O

1 903 905 9792860 5% CD B-NP O
2 906 908 9792860 of IN B-PP O
3 909 912 9792860 all DT B-NP O
4 913 920 9792860 control NN I-NP O
5 921 932 9792860 individuals NNS I-NP O
6 932 933 9792860 , , O O
7 934 937 9792860 and CC O O
8 938 940 9792860 in IN B-PP O
9 941 944 9792860 one CD B-NP O
10 945 952 9792860 control NN I-NP O
11 953 963 9792860 individual JJ B-VP O
12 964 974 9792860 homozygous JJ B-ADJP O
13 975 978 9792860 for IN B-PP O
14 979 983 9792860 this DT B-NP O
15 984 991 9792860 glycine NN I-NP O
16 992 1004 9792860 substitution NN I-NP O
17 1004 1005 9792860 . . O O

1 1006 1011 9792860 There EX B-NP O
2 1012 1015 9792860 has VBZ B-VP O
3 1016 1020 9792860 been VBN I-VP O
4 1021 1023 9792860 no DT B-NP O
5 1024 1032 9792860 previous JJ I-NP O
6 1033 1040 9792860 finding NN I-NP O
7 1041 1043 9792860 of IN B-PP O
8 1044 1045 9792860 a DT B-NP O
9 1046 1053 9792860 glycine NN I-NP O
10 1054 1066 9792860 substitution NN I-NP O
11 1067 1071 9792860 that WDT B-NP O
12 1072 1074 9792860 is VBZ B-VP O
13 1075 1078 9792860 not RB I-VP O
14 1079 1089 9792860 associated VBN I-VP O
15 1090 1094 9792860 with IN B-PP O
16 1095 1098 9792860 any DT B-NP O
17 1099 1106 9792860 obvious JJ I-NP O
18 1107 1116 9792860 phenotype NN I-NP O
19 1117 1119 9792860 in IN B-PP O
20 1120 1130 9792860 homozygous JJ B-NP O
21 1131 1142 9792860 individuals NNS I-NP O
22 1142 1143 9792860 . . O O

1 0 0 9792861 -DOCSTART- -X- -X- O

1 0 7 9792861 Founder NN B-NP O
2 8 13 9792861 BRCA1 NN I-NP O
3 14 17 9792861 and CC I-NP O
4 18 23 9792861 BRCA2 NN I-NP O
5 24 33 9792861 mutations NNS I-NP O
6 34 36 9792861 in IN B-PP O
7 37 43 9792861 French JJ B-NP O
8 44 52 9792861 Canadian JJ I-NP O
9 53 59 9792861 breast NN I-NP B-Disease
10 60 63 9792861 and CC O I-Disease
11 64 71 9792861 ovarian JJ B-NP I-Disease
12 72 78 9792861 cancer NN I-NP I-Disease
13 79 87 9792861 families NNS I-NP O
14 87 88 9792861 . . O O
15 89 91 9792861 We PRP B-NP O
16 92 96 9792861 have VBP B-VP O
17 97 107 9792861 identified VBN I-VP O
18 108 112 9792861 four CD B-NP O
19 113 122 9792861 mutations NNS I-NP O
20 123 125 9792861 in IN B-PP O
21 126 130 9792861 each DT B-NP O
22 131 133 9792861 of IN B-PP O
23 134 137 9792861 the DT B-NP O
24 138 144 9792861 breast NN I-NP B-Disease
25 145 151 9792861 cancer NN I-NP I-Disease
26 151 152 9792861 - HYPH B-NP O
27 152 166 9792861 susceptibility NN I-NP O
28 167 172 9792861 genes NNS I-NP O
29 172 173 9792861 , , O O
30 174 179 9792861 BRCA1 NN B-NP O
31 180 183 9792861 and CC O O
32 184 189 9792861 BRCA2 NN B-NP O
33 189 190 9792861 , , O O
34 191 193 9792861 in IN B-PP O
35 194 200 9792861 French JJ B-NP O
36 201 209 9792861 Canadian JJ I-NP O
37 210 216 9792861 breast NN I-NP B-Disease
38 217 223 9792861 cancer NN I-NP I-Disease
39 224 227 9792861 and CC I-NP O
40 228 234 9792861 breast NN I-NP B-Disease
41 234 235 9792861 / SYM B-NP I-Disease
42 235 242 9792861 ovarian JJ B-NP I-Disease
43 243 249 9792861 cancer NN I-NP I-Disease
44 250 258 9792861 families NNS I-NP O
45 259 263 9792861 from IN B-PP O
46 264 270 9792861 Quebec NNP B-NP O
47 270 271 9792861 . . O O

1 272 274 9792861 To TO B-VP O
2 275 283 9792861 identify VB I-VP O
3 284 291 9792861 founder NN B-NP O
4 292 299 9792861 effects NNS I-NP O
5 299 300 9792861 , , O O
6 301 303 9792861 we PRP B-NP O
7 304 312 9792861 examined VBD B-VP O
8 313 326 9792861 independently RB I-VP O
9 327 338 9792861 ascertained VBN I-VP O
10 339 345 9792861 French JJ B-NP O
11 346 354 9792861 Canadian JJ I-NP O
12 355 361 9792861 cancer NN I-NP B-Disease
13 362 370 9792861 families NNS I-NP O
14 371 374 9792861 for IN B-PP O
15 375 378 9792861 the DT B-NP O
16 379 391 9792861 distribution NN I-NP O
17 392 394 9792861 of IN B-PP O
18 395 400 9792861 these DT B-NP O
19 401 406 9792861 eight CD I-NP O
20 407 416 9792861 mutations NNS I-NP O
21 416 417 9792861 . . O O

1 418 427 9792861 Mutations NNS B-NP O
2 428 432 9792861 were VBD B-VP O
3 433 438 9792861 found VBN I-VP O
4 439 441 9792861 in IN B-PP O
5 442 444 9792861 41 CD B-NP O
6 445 447 9792861 of IN B-PP O
7 448 450 9792861 97 CD B-NP O
8 451 459 9792861 families NNS I-NP O
9 459 460 9792861 . . O O

1 461 464 9792861 Six CD B-NP O
2 465 467 9792861 of IN B-PP O
3 468 473 9792861 eight CD B-NP O
4 474 483 9792861 mutations NNS I-NP O
5 484 488 9792861 were VBD B-VP O
6 489 497 9792861 observed VBN I-VP O
7 498 500 9792861 at IN B-ADVP O
8 501 506 9792861 least JJS I-ADVP O
9 507 512 9792861 twice RB B-ADVP O
10 512 513 9792861 . . O O

1 514 517 9792861 The DT B-NP O
2 518 523 9792861 BRCA1 NN I-NP O
3 524 530 9792861 C4446T NN I-NP O
4 531 539 9792861 mutation NN I-NP O
5 540 543 9792861 was VBD B-VP O
6 544 547 9792861 the DT B-NP O
7 548 552 9792861 most RBS I-NP O
8 553 559 9792861 common JJ I-NP O
9 560 568 9792861 mutation NN I-NP O
10 569 574 9792861 found VBN B-VP O
11 574 575 9792861 , , O O
12 576 584 9792861 followed VBN B-VP O
13 585 587 9792861 by IN B-PP O
14 588 591 9792861 the DT B-NP O
15 592 597 9792861 BRCA2 NN I-NP O
16 598 607 9792861 8765delAG NN I-NP O
17 608 616 9792861 mutation NN I-NP O
18 616 617 9792861 . . O O

1 618 626 9792861 Together RB B-ADVP O
2 626 627 9792861 , , O O
3 628 633 9792861 these DT B-NP O
4 634 643 9792861 mutations NNS I-NP O
5 644 648 9792861 were VBD B-VP O
6 649 654 9792861 found VBN I-VP O
7 655 657 9792861 in IN B-PP O
8 658 660 9792861 28 CD B-NP O
9 661 663 9792861 of IN B-PP O
10 664 666 9792861 41 CD B-NP O
11 667 675 9792861 families NNS I-NP O
12 676 686 9792861 identified VBN B-VP O
13 687 689 9792861 to TO I-VP O
14 690 694 9792861 have VB I-VP O
15 695 696 9792861 a DT B-NP O
16 697 705 9792861 mutation NN I-NP O
17 705 706 9792861 . . O O

1 707 710 9792861 The DT B-NP O
2 711 715 9792861 odds NNS I-NP O
3 716 718 9792861 of IN B-PP O
4 719 728 9792861 detection NN B-NP O
5 729 731 9792861 of IN B-PP O
6 732 735 9792861 any DT B-NP O
7 736 738 9792861 of IN B-PP O
8 739 742 9792861 the DT B-NP O
9 743 747 9792861 four CD I-NP O
10 748 753 9792861 BRCA1 NN I-NP O
11 754 763 9792861 mutations NNS I-NP O
12 764 767 9792861 was VBD B-VP O
13 768 770 9792861 18 CD B-NP O
14 770 771 9792861 . . O O

1 772 774 9792861 7x LS B-LST O
2 775 782 9792861 greater JJR B-NP O
3 783 785 9792861 if IN I-NP O
4 786 789 9792861 one CD I-NP O
5 790 792 9792861 or CC I-NP O
6 793 797 9792861 more JJR I-NP O
7 798 803 9792861 cases NNS I-NP O
8 804 806 9792861 of IN B-PP O
9 807 814 9792861 ovarian JJ B-NP B-Disease
10 815 821 9792861 cancer NN I-NP I-Disease
11 822 826 9792861 were VBD B-VP O
12 827 831 9792861 also RB B-ADVP O
13 832 839 9792861 present JJ B-ADJP O
14 840 842 9792861 in IN B-PP O
15 843 846 9792861 the DT B-NP O
16 847 853 9792861 family NN I-NP O
17 853 854 9792861 . . O O

1 855 858 9792861 The DT B-NP O
2 859 863 9792861 odds NNS I-NP O
3 864 866 9792861 of IN B-PP O
4 867 876 9792861 detection NN B-NP O
5 877 879 9792861 of IN B-PP O
6 880 883 9792861 any DT B-NP O
7 884 886 9792861 of IN B-PP O
8 887 890 9792861 the DT B-NP O
9 891 895 9792861 four CD I-NP O
10 896 901 9792861 BRCA2 NN I-NP O
11 902 911 9792861 mutations NNS I-NP O
12 912 915 9792861 was VBD B-VP O
13 916 917 9792861 5 CD B-NP O
14 917 918 9792861 . . O O
15 919 921 9792861 3x CD B-NP O
16 922 929 9792861 greater JJR B-ADJP O
17 930 932 9792861 if IN B-SBAR O
18 933 938 9792861 there EX B-NP O
19 939 943 9792861 were VBD B-VP O
20 944 946 9792861 at IN B-NP O
21 947 952 9792861 least JJS I-NP O
22 953 957 9792861 five CD I-NP O
23 958 963 9792861 cases NNS I-NP O
24 964 966 9792861 of IN B-PP O
25 967 973 9792861 breast NN B-NP B-Disease
26 974 980 9792861 cancer NN I-NP I-Disease
27 981 983 9792861 in IN B-PP O
28 984 987 9792861 the DT B-NP O
29 988 994 9792861 family NN I-NP O
30 994 995 9792861 . . O O

1 996 1009 9792861 Interestingly RB B-ADVP O
2 1009 1010 9792861 , , O O
3 1011 1014 9792861 the DT B-NP O
4 1015 1023 9792861 presence NN I-NP O
5 1024 1026 9792861 of IN B-PP O
6 1027 1028 9792861 a DT B-NP O
7 1029 1035 9792861 breast NN I-NP B-Disease
8 1036 1042 9792861 cancer NN I-NP I-Disease
9 1043 1047 9792861 case NN I-NP O
10 1048 1049 9792861 < SYM O O
11 1050 1052 9792861 36 CD B-NP O
12 1053 1058 9792861 years NNS I-NP O
13 1059 1061 9792861 of IN B-PP O
14 1062 1065 9792861 age NN B-NP O
15 1066 1069 9792861 was VBD B-VP O
16 1070 1078 9792861 strongly RB B-ADJP O
17 1079 1089 9792861 predictive JJ I-ADJP O
18 1090 1092 9792861 of IN B-PP O
19 1093 1096 9792861 the DT B-NP O
20 1097 1105 9792861 presence NN I-NP O
21 1106 1108 9792861 of IN B-PP O
22 1109 1112 9792861 any DT B-NP O
23 1113 1115 9792861 of IN B-PP O
24 1116 1119 9792861 the DT B-NP O
25 1120 1125 9792861 eight CD I-NP O
26 1126 1135 9792861 mutations NNS I-NP O
27 1136 1144 9792861 screened VBN B-VP O
28 1144 1145 9792861 . . O O

1 1146 1154 9792861 Carriers NNS B-NP O
2 1155 1157 9792861 of IN B-PP O
3 1158 1161 9792861 the DT B-NP O
4 1162 1166 9792861 same JJ I-NP O
5 1167 1175 9792861 mutation NN I-NP O
6 1175 1176 9792861 , , O O
7 1177 1181 9792861 from IN B-PP O
8 1182 1191 9792861 different JJ B-NP O
9 1192 1200 9792861 families NNS I-NP O
10 1200 1201 9792861 , , O O
11 1202 1208 9792861 shared VBD B-VP O
12 1209 1216 9792861 similar JJ B-NP O
13 1217 1227 9792861 haplotypes NNS I-NP O
14 1227 1228 9792861 , , O O
15 1229 1239 9792861 indicating VBG B-VP O
16 1240 1244 9792861 that IN B-SBAR O
17 1245 1248 9792861 the DT B-NP O
18 1249 1255 9792861 mutant JJ I-NP O
19 1256 1263 9792861 alleles NNS I-NP O
20 1264 1268 9792861 were VBD B-VP O
21 1269 1275 9792861 likely JJ B-ADJP O
22 1276 1278 9792861 to TO B-VP O
23 1279 1281 9792861 be VB I-VP O
24 1282 1291 9792861 identical JJ B-ADJP O
25 1292 1294 9792861 by IN B-PP O
26 1295 1302 9792861 descent NN B-NP O
27 1303 1306 9792861 for IN B-PP O
28 1307 1308 9792861 a DT B-NP O
29 1309 1317 9792861 mutation NN I-NP O
30 1318 1320 9792861 in IN B-PP O
31 1321 1324 9792861 the DT B-NP O
32 1325 1332 9792861 founder NN I-NP O
33 1333 1343 9792861 population NN I-NP O
34 1343 1344 9792861 . . O O

1 1345 1348 9792861 The DT B-NP O
2 1349 1363 9792861 identification NN I-NP O
3 1364 1366 9792861 of IN B-PP O
4 1367 1373 9792861 common JJ B-NP O
5 1374 1379 9792861 BRCA1 NN I-NP O
6 1380 1383 9792861 and CC I-NP O
7 1384 1389 9792861 BRCA2 NN I-NP O
8 1390 1399 9792861 mutations NNS I-NP O
9 1400 1404 9792861 will MD B-VP O
10 1405 1415 9792861 facilitate VB I-VP O
11 1416 1423 9792861 carrier NN B-NP O
12 1424 1433 9792861 detection NN I-NP O
13 1434 1436 9792861 in IN B-PP O
14 1437 1443 9792861 French JJ B-NP O
15 1444 1452 9792861 Canadian JJ I-NP O
16 1453 1459 9792861 breast NN I-NP B-Disease
17 1460 1466 9792861 cancer NN I-NP I-Disease
18 1467 1470 9792861 and CC I-NP O
19 1471 1477 9792861 breast NN I-NP B-Disease
20 1477 1478 9792861 / SYM B-NP I-Disease
21 1478 1485 9792861 ovarian JJ B-NP I-Disease
22 1486 1492 9792861 cancer NN I-NP I-Disease
23 1493 1501 9792861 families NNS I-NP O
24 1501 1502 9792861 . . O O

1 0 0 9856498 -DOCSTART- -X- -X- O

1 0 3 9856498 The DT B-NP O
2 4 13 9856498 molecular JJ I-NP O
3 14 19 9856498 basis NN I-NP O
4 20 22 9856498 of IN B-PP O
5 23 25 9856498 C6 NN B-NP B-Disease
6 26 36 9856498 deficiency NN I-NP I-Disease
7 37 39 9856498 in IN B-PP O
8 40 43 9856498 the DT B-NP O
9 44 51 9856498 western JJ I-NP O
10 52 56 9856498 Cape NNP I-NP O
11 56 57 9856498 , , O O
12 58 63 9856498 South NNP B-NP O
13 64 70 9856498 Africa NNP I-NP O
14 70 71 9856498 . . I-NP O
15 72 82 9856498 Deficiency NNP I-NP B-Disease
16 83 85 9856498 of IN B-PP I-Disease
17 86 89 9856498 the DT B-NP I-Disease
18 90 95 9856498 sixth JJ I-NP I-Disease
19 96 105 9856498 component NN I-NP I-Disease
20 106 108 9856498 of IN B-PP I-Disease
21 109 114 9856498 human JJ B-NP I-Disease
22 115 125 9856498 complement NN I-NP I-Disease
23 126 127 9856498 ( ( O O
24 127 129 9856498 C6 NN B-NP O
25 129 130 9856498 ) ) O O
26 131 134 9856498 has VBZ B-VP O
27 135 139 9856498 been VBN I-VP O
28 140 148 9856498 reported VBN I-VP O
29 149 151 9856498 in IN B-PP O
30 152 153 9856498 a DT B-NP O
31 154 160 9856498 number NN I-NP O
32 161 163 9856498 of IN B-PP O
33 164 172 9856498 families NNS B-NP O
34 173 177 9856498 from IN B-PP O
35 178 181 9856498 the DT B-NP O
36 182 189 9856498 western JJ I-NP O
37 190 194 9856498 Cape NNP I-NP O
38 194 195 9856498 , , O O
39 196 201 9856498 South NNP B-NP O
40 202 208 9856498 Africa NNP I-NP O
41 208 209 9856498 . . O O

1 210 223 9856498 Meningococcal JJ B-NP B-Disease
2 224 231 9856498 disease NN I-NP I-Disease
3 232 234 9856498 is VBZ B-VP O
4 235 242 9856498 endemic JJ B-ADJP O
5 243 245 9856498 in IN B-PP O
6 246 249 9856498 the DT B-NP O
7 250 254 9856498 Cape NNP I-NP O
8 255 258 9856498 and CC O O
9 259 265 9856498 almost RB B-NP O
10 266 269 9856498 all DT I-NP O
11 270 279 9856498 pedigrees NNS I-NP O
12 280 282 9856498 of IN B-PP O
13 283 288 9856498 total JJ B-NP O
14 289 291 9856498 C6 NN I-NP B-Disease
15 292 302 9856498 deficiency NN I-NP I-Disease
16 303 304 9856498 ( ( O O
17 304 308 9856498 C6Q0 NN B-NP O
18 308 309 9856498 ) ) O O
19 310 314 9856498 have VBP B-VP O
20 315 319 9856498 been VBN I-VP O
21 320 331 9856498 ascertained VBN I-VP O
22 332 339 9856498 because IN B-PP O
23 340 342 9856498 of IN I-PP O
24 343 352 9856498 recurrent JJ B-NP O
25 353 360 9856498 disease NN I-NP O
26 360 361 9856498 . . O O

1 362 364 9856498 We PRP B-NP O
2 365 369 9856498 have VBP B-VP O
3 370 379 9856498 sequenced VBN I-VP O
4 380 383 9856498 the DT B-NP O
5 384 393 9856498 expressed VBN I-NP O
6 394 399 9856498 exons NNS I-NP O
7 400 402 9856498 of IN B-PP O
8 403 406 9856498 the DT B-NP O
9 407 409 9856498 C6 NN I-NP O
10 410 414 9856498 gene NN I-NP O
11 415 419 9856498 from IN B-PP O
12 420 428 9856498 selected VBN B-NP O
13 429 434 9856498 cases NNS I-NP O
14 435 438 9856498 and CC O O
15 439 443 9856498 have VBP B-VP O
16 444 449 9856498 found VBN I-VP O
17 450 455 9856498 three CD B-NP O
18 456 465 9856498 molecular JJ I-NP O
19 466 473 9856498 defects NNS I-NP O
20 474 481 9856498 leading VBG B-VP O
21 482 484 9856498 to TO B-PP O
22 485 490 9856498 total JJ B-NP O
23 491 501 9856498 deficiency NN I-NP O
24 503 510 9856498 879delG NN I-NP O
25 510 511 9856498 , , O O
26 512 517 9856498 which WDT B-NP O
27 518 520 9856498 is VBZ B-VP O
28 521 524 9856498 the DT B-NP O
29 525 531 9856498 common JJ I-NP O
30 532 538 9856498 defect NN I-NP O
31 539 541 9856498 in IN B-PP O
32 542 545 9856498 the DT B-NP O
33 546 550 9856498 Cape NNP I-NP O
34 551 554 9856498 and CC O O
35 555 563 9856498 hitherto RB B-ADJP O
36 564 574 9856498 unreported JJ I-ADJP O
37 574 575 9856498 , , O O
38 576 579 9856498 and CC O O
39 580 588 9856498 1195delC NN B-NP O
40 589 592 9856498 and CC I-NP O
41 593 601 9856498 1936delG NN I-NP O
42 601 602 9856498 , , O O
43 603 608 9856498 which WDT B-NP O
44 609 613 9856498 have VBP B-VP O
45 614 618 9856498 been VBN I-VP O
46 619 629 9856498 previously RB I-VP O
47 630 638 9856498 reported VBN I-VP O
48 639 641 9856498 in IN B-PP O
49 642 649 9856498 African JJ B-NP O
50 649 650 9856498 - HYPH I-NP O
51 650 659 9856498 Americans NNPS I-NP O
52 659 660 9856498 . . O O

1 661 663 9856498 We PRP B-NP O
2 664 668 9856498 also RB B-ADVP O
3 669 673 9856498 show VBP B-VP O
4 674 678 9856498 that IN B-SBAR O
5 679 682 9856498 the DT B-NP O
6 683 690 9856498 879delG NN I-NP O
7 691 694 9856498 and CC I-NP O
8 695 703 9856498 1195delC NN I-NP O
9 704 711 9856498 defects NNS I-NP O
10 712 715 9856498 are VBP B-VP O
11 716 726 9856498 associated VBN I-VP O
12 727 731 9856498 with IN B-PP O
13 732 746 9856498 characteristic JJ B-NP O
14 747 749 9856498 C6 NN I-NP O
15 749 750 9856498 / SYM B-NP O
16 750 752 9856498 C7 NN I-NP O
17 753 759 9856498 region NN I-NP O
18 760 763 9856498 DNA NN I-NP O
19 764 770 9856498 marker NN I-NP O
20 771 781 9856498 haplotypes NNS I-NP O
21 781 782 9856498 , , O O
22 783 791 9856498 although IN B-SBAR O
23 792 797 9856498 small JJ B-NP O
24 798 808 9856498 variations NNS I-NP O
25 809 813 9856498 were VBD B-VP O
26 814 822 9856498 observed VBN I-VP O
27 822 823 9856498 . . O O

1 824 827 9856498 The DT B-NP O
2 828 836 9856498 1936delG NN I-NP O
3 837 843 9856498 defect NN I-NP O
4 844 847 9856498 was VBD B-VP O
5 848 856 9856498 observed VBN I-VP O
6 857 861 9856498 only RB B-ADVP O
7 862 866 9856498 once RB I-ADVP O
8 867 869 9856498 in IN B-PP O
9 870 873 9856498 the DT B-NP O
10 874 878 9856498 Cape NNP I-NP O
11 878 879 9856498 , , O O
12 880 883 9856498 but CC O O
13 884 887 9856498 its PRP$ B-NP O
14 888 898 9856498 associated VBN I-NP O
15 899 908 9856498 haplotype NN I-NP O
16 909 914 9856498 could MD B-VP O
17 915 917 9856498 be VB I-VP O
18 918 925 9856498 deduced VBN I-VP O
19 925 926 9856498 . . O O

1 927 930 9856498 The DT B-NP O
2 931 935 9856498 data NNS I-NP O
3 936 940 9856498 from IN B-PP O
4 941 944 9856498 the DT B-NP O
5 945 955 9856498 haplotypes NNS I-NP O
6 956 964 9856498 indicate VBP B-VP O
7 965 969 9856498 that IN B-SBAR O
8 970 975 9856498 these DT B-NP O
9 976 981 9856498 three CD I-NP O
10 982 991 9856498 molecular JJ I-NP O
11 992 999 9856498 defects NNS I-NP O
12 1000 1007 9856498 account VBP B-VP O
13 1008 1011 9856498 for IN B-PP O
14 1012 1015 9856498 the DT B-NP O
15 1016 1023 9856498 defects NNS I-NP O
16 1024 1026 9856498 in IN B-PP O
17 1027 1030 9856498 all PDT B-NP O
18 1031 1034 9856498 the DT I-NP O
19 1035 1037 9856498 38 CD I-NP O
20 1038 1047 9856498 unrelated JJ I-NP O
21 1048 1052 9856498 C6Q0 NN I-NP O
22 1053 1064 9856498 individuals NNS I-NP O
23 1065 1067 9856498 we PRP B-NP O
24 1068 1072 9856498 have VBP B-VP O
25 1073 1080 9856498 studied VBN I-VP O
26 1081 1085 9856498 from IN B-PP O
27 1086 1089 9856498 the DT B-NP O
28 1090 1094 9856498 Cape NNP I-NP O
29 1094 1095 9856498 . . O O

1 1096 1098 9856498 We PRP B-NP O
2 1099 1103 9856498 have VBP B-VP O
3 1104 1108 9856498 also RB I-VP O
4 1109 1117 9856498 observed VBN I-VP O
5 1118 1121 9856498 the DT B-NP O
6 1122 1129 9856498 879delG NN I-NP O
7 1130 1136 9856498 defect NN I-NP O
8 1137 1139 9856498 in IN B-PP O
9 1140 1143 9856498 two CD B-NP O
10 1144 1149 9856498 Dutch JJ I-NP O
11 1150 1152 9856498 C6 NN I-NP B-Disease
12 1152 1153 9856498 - HYPH B-NP I-Disease
13 1153 1162 9856498 deficient JJ I-NP I-Disease
14 1163 1171 9856498 kindreds NNS I-NP O
15 1171 1172 9856498 , , O O
16 1173 1176 9856498 but CC O O
17 1177 1180 9856498 the DT B-NP O
18 1181 1188 9856498 879delG NN I-NP O
19 1189 1195 9856498 defect NN I-NP O
20 1196 1198 9856498 in IN B-PP O
21 1199 1202 9856498 the DT B-NP O
22 1203 1207 9856498 Cape NNP I-NP O
23 1208 1216 9856498 probably RB B-ADVP O
24 1217 1220 9856498 did VBD B-VP O
25 1221 1224 9856498 not RB I-VP O
26 1225 1229 9856498 come VB I-VP O
27 1230 1234 9856498 from IN B-PP O
28 1235 1238 9856498 The DT B-NP O
29 1239 1250 9856498 Netherlands NNP I-NP O
30 1250 1251 9856498 . . O O
31 1251 1252 9856498 . . O O

1 0 0 9724771 -DOCSTART- -X- -X- O

1 0 3 9724771 The DT B-NP O
2 4 7 9724771 APC NN I-NP B-Disease
3 8 16 9724771 variants NNS I-NP O
4 17 23 9724771 I1307K NN I-NP O
5 24 27 9724771 and CC I-NP O
6 28 34 9724771 E1317Q NN I-NP O
7 35 38 9724771 are VBP B-VP O
8 39 49 9724771 associated VBN I-VP O
9 50 54 9724771 with IN B-PP O
10 55 65 9724771 colorectal JJ B-NP B-Disease
11 66 72 9724771 tumors NNS I-NP I-Disease
12 72 73 9724771 , , O O
13 74 77 9724771 but CC O O
14 78 81 9724771 not RB B-ADVP O
15 82 88 9724771 always RB I-ADVP O
16 89 93 9724771 with IN B-PP O
17 94 95 9724771 a DT B-NP O
18 96 102 9724771 family NN I-NP O
19 103 110 9724771 history NN I-NP O
20 110 111 9724771 . . I-NP O
21 112 121 9724771 Classical JJ I-NP O
22 122 130 9724771 familial JJ I-NP B-Disease
23 131 142 9724771 adenomatous JJ I-NP I-Disease
24 143 152 9724771 polyposis NN I-NP I-Disease
25 153 154 9724771 ( ( O O
26 154 157 9724771 FAP NN B-NP B-Disease
27 157 158 9724771 ) ) O O
28 159 161 9724771 is VBZ B-VP O
29 162 163 9724771 a DT B-NP O
30 164 168 9724771 high JJ I-NP O
31 168 169 9724771 - HYPH I-NP O
32 169 179 9724771 penetrance NN I-NP O
33 180 189 9724771 autosomal JJ I-NP B-Disease
34 190 198 9724771 dominant JJ I-NP I-Disease
35 199 206 9724771 disease NN I-NP I-Disease
36 207 211 9724771 that WDT B-NP O
37 212 223 9724771 predisposes VBZ B-VP O
38 224 226 9724771 to TO B-PP O
39 227 235 9724771 hundreds NNS B-NP O
40 236 238 9724771 or CC I-NP O
41 239 248 9724771 thousands NNS I-NP O
42 249 251 9724771 of IN B-PP O
43 252 262 9724771 colorectal JJ B-NP B-Disease
44 263 271 9724771 adenomas NNS I-NP I-Disease
45 272 275 9724771 and CC O I-Disease
46 276 285 9724771 carcinoma NN B-NP I-Disease
47 286 289 9724771 and CC O O
48 290 294 9724771 that DT B-NP O
49 295 302 9724771 results VBZ B-VP O
50 303 307 9724771 from IN B-PP O
51 308 318 9724771 truncating VBG B-VP O
52 319 328 9724771 mutations NNS B-NP O
53 329 331 9724771 in IN B-PP O
54 332 335 9724771 the DT B-NP O
55 336 339 9724771 APC NN I-NP B-Disease
56 340 344 9724771 gene NN I-NP O
57 344 345 9724771 . . O O

1 346 347 9724771 A DT B-NP O
2 348 355 9724771 variant NN I-NP O
3 356 358 9724771 of IN B-PP O
4 359 362 9724771 FAP NN B-NP B-Disease
5 363 365 9724771 is VBZ B-VP O
6 366 376 9724771 attenuated VBN I-VP B-Disease
7 377 388 9724771 adenomatous JJ B-NP I-Disease
8 389 398 9724771 polyposis NN I-NP I-Disease
9 399 403 9724771 coli NN I-NP I-Disease
10 403 404 9724771 , , O O
11 405 410 9724771 which WDT B-NP O
12 411 418 9724771 results VBZ B-VP O
13 419 423 9724771 from IN B-PP O
14 424 428 9724771 germ NN B-NP O
15 428 429 9724771 - HYPH B-NP O
16 429 433 9724771 line NN I-NP O
17 434 443 9724771 mutations NNS I-NP O
18 444 446 9724771 in IN B-PP O
19 447 450 9724771 the DT B-NP O
20 451 452 9724771 5 CD I-NP O
21 453 456 9724771 and CC I-NP O
22 457 458 9724771 3 CD I-NP O
23 459 466 9724771 regions NNS I-NP O
24 467 469 9724771 of IN B-PP O
25 470 473 9724771 the DT B-NP O
26 474 477 9724771 APC NN I-NP B-Disease
27 478 482 9724771 gene NN I-NP O
28 482 483 9724771 . . O O

1 484 494 9724771 Attenuated VBN B-NP B-Disease
2 495 506 9724771 adenomatous JJ I-NP I-Disease
3 507 516 9724771 polyposis NN I-NP I-Disease
4 517 521 9724771 coli NN I-NP I-Disease
5 522 530 9724771 patients NNS I-NP O
6 531 535 9724771 have VBP B-VP O
7 536 537 9724771 " `` B-NP O
8 538 546 9724771 multiple JJ I-NP O
9 547 548 9724771 " '' I-NP O
10 549 559 9724771 colorectal JJ I-NP B-Disease
11 560 568 9724771 adenomas NNS I-NP I-Disease
12 569 570 9724771 ( ( O O
13 570 579 9724771 typically RB B-NP O
14 580 585 9724771 fewer JJR I-NP O
15 586 590 9724771 than IN I-NP O
16 591 594 9724771 100 CD I-NP O
17 594 595 9724771 ) ) O O
18 596 603 9724771 without IN B-PP O
19 604 607 9724771 the DT B-NP O
20 608 614 9724771 florid JJ I-NP O
21 615 624 9724771 phenotype NN I-NP O
22 625 627 9724771 of IN B-PP O
23 628 637 9724771 classical JJ B-NP O
24 638 641 9724771 FAP NN I-NP B-Disease
25 641 642 9724771 . . O O

1 643 650 9724771 Another DT B-NP O
2 651 656 9724771 group NN I-NP O
3 657 659 9724771 of IN B-PP O
4 660 668 9724771 patients NNS B-NP O
5 669 673 9724771 with IN B-PP O
6 674 682 9724771 multiple JJ B-NP O
7 683 691 9724771 adenomas NNS I-NP B-Disease
8 692 695 9724771 has VBZ B-VP O
9 696 698 9724771 no DT B-NP O
10 699 708 9724771 mutations NNS I-NP O
11 709 711 9724771 in IN B-PP O
12 712 715 9724771 the DT B-NP O
13 716 719 9724771 APC NN I-NP B-Disease
14 720 724 9724771 gene NN I-NP O
15 724 725 9724771 , , O O
16 726 729 9724771 and CC O O
17 730 735 9724771 their PRP$ B-NP O
18 736 745 9724771 phenotype NN I-NP O
19 746 754 9724771 probably RB B-ADVP O
20 755 762 9724771 results VBZ B-VP O
21 763 767 9724771 from IN B-PP O
22 768 777 9724771 variation NN B-NP O
23 778 780 9724771 at IN B-PP O
24 781 782 9724771 a DT B-NP O
25 783 788 9724771 locus NN I-NP O
26 788 789 9724771 , , O O
27 790 792 9724771 or CC O O
28 793 797 9724771 loci NNS B-NP O
29 797 798 9724771 , , O O
30 799 808 9724771 elsewhere RB B-ADVP O
31 809 811 9724771 in IN B-PP O
32 812 815 9724771 the DT B-NP O
33 816 822 9724771 genome NN I-NP O
34 822 823 9724771 . . O O

1 824 832 9724771 Recently RB B-ADVP O
2 832 833 9724771 , , O O
3 834 841 9724771 however RB B-ADVP O
4 841 842 9724771 , , O O
5 843 844 9724771 a DT B-NP O
6 845 853 9724771 missense JJ I-NP O
7 854 861 9724771 variant NN I-NP O
8 862 864 9724771 of IN B-PP O
9 865 868 9724771 APC NN B-NP B-Disease
10 869 870 9724771 ( ( O O
11 870 876 9724771 I1307K NN B-NP O
12 876 877 9724771 ) ) O O
13 878 881 9724771 was VBD B-VP O
14 882 891 9724771 described VBN I-VP O
15 892 896 9724771 that WDT B-NP O
16 897 904 9724771 confers VBZ B-VP O
17 905 907 9724771 an DT B-NP O
18 908 917 9724771 increased VBN I-NP O
19 918 922 9724771 risk NN I-NP O
20 923 925 9724771 of IN B-PP O
21 926 936 9724771 colorectal JJ B-NP B-Disease
22 937 943 9724771 tumors NNS I-NP I-Disease
23 943 944 9724771 , , O O
24 945 954 9724771 including VBG B-PP O
25 955 963 9724771 multiple JJ B-NP O
26 964 972 9724771 adenomas NNS I-NP B-Disease
27 972 973 9724771 , , O O
28 974 976 9724771 in IN B-PP O
29 977 987 9724771 Ashkenazim NNP B-NP O
30 987 988 9724771 . . O O

1 989 991 9724771 We PRP B-NP O
2 992 996 9724771 have VBP B-VP O
3 997 1004 9724771 studied VBN I-VP O
4 1005 1006 9724771 a DT B-NP O
5 1007 1010 9724771 set NN I-NP O
6 1011 1013 9724771 of IN B-PP O
7 1014 1017 9724771 164 CD B-NP O
8 1018 1026 9724771 patients NNS I-NP O
9 1027 1031 9724771 with IN B-PP O
10 1032 1040 9724771 multiple JJ B-NP O
11 1041 1051 9724771 colorectal JJ I-NP B-Disease
12 1052 1060 9724771 adenomas NNS I-NP I-Disease
13 1061 1064 9724771 and CC O I-Disease
14 1064 1065 9724771 / SYM B-NP I-Disease
15 1065 1067 9724771 or CC O I-Disease
16 1068 1077 9724771 carcinoma NN B-NP I-Disease
17 1078 1081 9724771 and CC O O
18 1082 1090 9724771 analyzed VBN B-NP O
19 1091 1097 9724771 codons NNS I-NP O
20 1098 1102 9724771 1263 CD B-NP O
21 1102 1103 9724771 - HYPH I-NP O
22 1103 1107 9724771 1377 CD I-NP O
23 1108 1109 9724771 ( ( O O
24 1109 1113 9724771 exon NN B-NP O
25 1114 1117 9724771 15G NN I-NP O
26 1117 1118 9724771 ) ) O O
27 1119 1121 9724771 of IN B-PP O
28 1122 1125 9724771 the DT B-NP O
29 1126 1129 9724771 APC NN I-NP B-Disease
30 1130 1134 9724771 gene NN I-NP O
31 1135 1138 9724771 for IN B-PP O
32 1139 1143 9724771 germ NN B-NP O
33 1143 1144 9724771 - HYPH I-NP O
34 1144 1148 9724771 line NN I-NP O
35 1149 1157 9724771 variants NNS I-NP O
36 1157 1158 9724771 . . O O

1 1159 1164 9724771 Three CD B-NP O
2 1165 1173 9724771 patients NNS I-NP O
3 1174 1178 9724771 with IN B-PP O
4 1179 1182 9724771 the DT B-NP O
5 1183 1189 9724771 I1307K NN I-NP O
6 1190 1196 9724771 allele NN I-NP O
7 1197 1201 9724771 were VBD B-VP O
8 1202 1210 9724771 detected VBN I-VP O
9 1210 1211 9724771 , , O O
10 1212 1216 9724771 each DT B-NP O
11 1217 1219 9724771 of IN B-PP O
12 1220 1229 9724771 Ashkenazi NNP B-NP O
13 1230 1237 9724771 descent NNP I-NP O
14 1237 1238 9724771 . . O O

1 1239 1243 9724771 Four CD B-NP O
2 1244 1252 9724771 patients NNS I-NP O
3 1253 1256 9724771 had VBD B-VP O
4 1257 1258 9724771 a DT B-NP O
5 1259 1263 9724771 germ NN I-NP O
6 1263 1264 9724771 - HYPH I-NP O
7 1264 1268 9724771 line NN I-NP O
8 1269 1275 9724771 E1317Q NN I-NP O
9 1276 1284 9724771 missense JJ I-NP O
10 1285 1292 9724771 variant NN I-NP O
11 1293 1295 9724771 of IN B-PP O
12 1296 1299 9724771 APC NN B-NP O
13 1300 1304 9724771 that WDT B-NP O
14 1305 1308 9724771 was VBD B-VP O
15 1309 1312 9724771 not RB O O
16 1313 1320 9724771 present JJ B-ADJP O
17 1321 1323 9724771 in IN B-PP O
18 1324 1332 9724771 controls NNS B-NP O
19 1332 1333 9724771 ; : O O
20 1334 1337 9724771 one CD B-NP O
21 1338 1340 9724771 of IN B-PP O
22 1341 1346 9724771 these DT B-NP O
23 1347 1358 9724771 individuals NNS I-NP O
24 1359 1362 9724771 had VBD B-VP O
25 1363 1365 9724771 an DT B-NP O
26 1366 1375 9724771 unusually RB I-NP O
27 1376 1381 9724771 large JJ I-NP O
28 1382 1388 9724771 number NN I-NP O
29 1389 1391 9724771 of IN B-PP O
30 1392 1403 9724771 metaplastic JJ B-NP B-Disease
31 1404 1410 9724771 polyps NNS I-NP I-Disease
32 1411 1413 9724771 of IN B-PP I-Disease
33 1414 1417 9724771 the DT B-NP I-Disease
34 1418 1428 9724771 colorectum NN I-NP I-Disease
35 1428 1429 9724771 . . O O

1 1430 1435 9724771 There EX B-NP O
2 1436 1438 9724771 is VBZ B-VP O
3 1439 1449 9724771 increasing VBG I-VP O
4 1450 1458 9724771 evidence NN B-NP O
5 1459 1463 9724771 that IN B-SBAR O
6 1464 1469 9724771 there EX B-NP O
7 1470 1475 9724771 exist VBP B-VP O
8 1476 1480 9724771 germ NN B-NP O
9 1480 1481 9724771 - HYPH B-NP O
10 1481 1485 9724771 line NN I-NP O
11 1486 1494 9724771 variants NNS I-NP O
12 1495 1497 9724771 of IN B-PP O
13 1498 1501 9724771 the DT B-NP O
14 1502 1505 9724771 APC NN I-NP B-Disease
15 1506 1510 9724771 gene NN I-NP O
16 1511 1515 9724771 that WDT B-NP O
17 1516 1526 9724771 predispose VBP B-VP O
18 1527 1529 9724771 to TO B-PP O
19 1530 1533 9724771 the DT B-NP O
20 1534 1545 9724771 development NN I-NP O
21 1546 1548 9724771 of IN B-PP O
22 1549 1557 9724771 multiple JJ B-NP O
23 1558 1568 9724771 colorectal JJ I-NP B-Disease
24 1569 1577 9724771 adenomas NNS I-NP I-Disease
25 1578 1581 9724771 and CC I-NP I-Disease
26 1582 1591 9724771 carcinoma NN I-NP I-Disease
27 1591 1592 9724771 , , O O
28 1593 1596 9724771 but CC O O
29 1597 1604 9724771 without IN B-PP O
30 1605 1608 9724771 the DT B-NP O
31 1609 1615 9724771 florid JJ I-NP O
32 1616 1625 9724771 phenotype NN I-NP O
33 1626 1628 9724771 of IN B-PP O
34 1629 1638 9724771 classical JJ B-NP O
35 1639 1642 9724771 FAP NN I-NP B-Disease
36 1642 1643 9724771 , , O O
37 1644 1647 9724771 and CC O O
38 1648 1656 9724771 possibly RB B-ADVP O
39 1657 1661 9724771 with IN B-PP O
40 1662 1672 9724771 importance NN B-NP O
41 1673 1676 9724771 for IN B-PP O
42 1677 1687 9724771 colorectal JJ B-NP B-Disease
43 1688 1694 9724771 cancer NN I-NP I-Disease
44 1695 1699 9724771 risk NN I-NP O
45 1700 1702 9724771 in IN B-PP O
46 1703 1706 9724771 the DT B-NP O
47 1707 1714 9724771 general JJ I-NP O
48 1715 1725 9724771 population NN I-NP O
49 1725 1726 9724771 . . O O
50 1726 1727 9724771 . . O O

1 0 0 9949209 -DOCSTART- -X- -X- O

1 0 7 9949209 Genetic JJ B-NP O
2 8 15 9949209 mapping NN I-NP O
3 16 18 9949209 of IN B-PP O
4 19 22 9949209 the DT B-NP O
5 23 29 9949209 copper NN I-NP B-Disease
6 30 39 9949209 toxicosis NN I-NP I-Disease
7 40 45 9949209 locus NN I-NP O
8 46 48 9949209 in IN B-PP O
9 49 59 9949209 Bedlington NNP B-NP O
10 60 68 9949209 terriers NNS I-NP O
11 69 71 9949209 to TO B-PP O
12 72 75 9949209 dog NN B-NP O
13 76 86 9949209 chromosome NN I-NP O
14 87 89 9949209 10 CD I-NP O
15 89 90 9949209 , , O O
16 91 93 9949209 in IN B-PP O
17 94 95 9949209 a DT B-NP O
18 96 102 9949209 region NN I-NP O
19 103 111 9949209 syntenic JJ B-ADJP O
20 112 114 9949209 to TO B-PP O
21 115 120 9949209 human JJ B-NP O
22 121 131 9949209 chromosome NN I-NP O
23 132 138 9949209 region NN I-NP O
24 139 143 9949209 2p13 NN I-NP O
25 143 144 9949209 - HYPH B-NP O
26 144 147 9949209 p16 NN I-NP O
27 147 148 9949209 . . O O
28 149 157 9949209 Abnormal JJ B-NP O
29 158 165 9949209 hepatic JJ I-NP B-Disease
30 166 172 9949209 copper NN I-NP I-Disease
31 173 185 9949209 accumulation NN I-NP I-Disease
32 186 188 9949209 is VBZ B-VP O
33 189 199 9949209 recognized VBN I-VP O
34 200 202 9949209 as IN B-PP O
35 203 205 9949209 an DT B-NP O
36 206 215 9949209 inherited VBN I-NP B-Disease
37 216 224 9949209 disorder NN I-NP I-Disease
38 225 227 9949209 in IN B-PP O
39 228 231 9949209 man NN B-NP O
40 231 232 9949209 , , O O
41 233 238 9949209 mouse NN B-NP O
42 238 239 9949209 , , O O
43 240 243 9949209 rat NN B-NP O
44 244 247 9949209 and CC I-NP O
45 248 251 9949209 dog NN I-NP O
46 251 252 9949209 . . O O

1 253 256 9949209 The DT B-NP O
2 257 262 9949209 major JJ I-NP O
3 263 268 9949209 cause NN I-NP O
4 269 271 9949209 of IN B-PP O
5 272 279 9949209 hepatic JJ B-NP B-Disease
6 280 286 9949209 copper NN I-NP I-Disease
7 287 299 9949209 accumulation NN I-NP I-Disease
8 300 302 9949209 in IN B-PP O
9 303 306 9949209 man NN B-NP O
10 307 309 9949209 is VBZ B-VP O
11 310 311 9949209 a DT B-NP O
12 312 325 9949209 dysfunctional JJ I-NP O
13 326 331 9949209 ATP7B NN I-NP O
14 332 336 9949209 gene NN I-NP O
15 336 337 9949209 , , O O
16 338 345 9949209 causing VBG B-VP O
17 346 352 9949209 Wilson NNP B-NP B-Disease
18 353 360 9949209 disease NN I-NP I-Disease
19 361 362 9949209 ( ( O O
20 362 364 9949209 WD NN B-NP B-Disease
21 364 365 9949209 ) ) O O
22 365 366 9949209 . . O O

1 367 376 9949209 Mutations NNS B-NP O
2 377 379 9949209 in IN B-PP O
3 380 383 9949209 the DT B-NP O
4 384 389 9949209 ATP7B NN I-NP O
5 390 395 9949209 genes NNS I-NP O
6 396 400 9949209 have VBP B-VP O
7 401 405 9949209 also RB I-VP O
8 406 410 9949209 been VBN I-VP O
9 411 423 9949209 demonstrated VBN I-VP O
10 424 426 9949209 in IN B-PP O
11 427 432 9949209 mouse NN B-NP O
12 433 436 9949209 and CC O O
13 437 440 9949209 rat NN B-NP O
14 440 441 9949209 . . O O

1 442 445 9949209 The DT B-NP O
2 446 451 9949209 ATP7B NN I-NP O
3 452 456 9949209 gene NN I-NP O
4 457 460 9949209 has VBZ B-VP O
5 461 465 9949209 been VBN I-VP O
6 466 474 9949209 excluded VBN I-VP O
7 475 477 9949209 in IN B-PP O
8 478 481 9949209 the DT B-NP O
9 482 486 9949209 much JJ I-NP O
10 487 492 9949209 rarer NN I-NP O
11 493 498 9949209 human JJ I-NP O
12 499 505 9949209 copper NN I-NP B-Disease
13 506 514 9949209 overload NN I-NP I-Disease
14 515 522 9949209 disease NN I-NP O
15 523 526 9949209 non AFX O B-Disease
16 526 527 9949209 - HYPH B-NP I-Disease
17 527 533 9949209 Indian JJ I-NP I-Disease
18 534 543 9949209 childhood NN I-NP I-Disease
19 544 553 9949209 cirrhosis NN I-NP I-Disease
20 553 554 9949209 , , O O
21 555 565 9949209 indicating VBG B-VP O
22 566 573 9949209 genetic JJ B-NP O
23 574 587 9949209 heterogeneity NN I-NP O
24 587 588 9949209 . . O O

1 589 591 9949209 By IN B-PP O
2 592 605 9949209 investigating VBG B-VP O
3 606 609 9949209 the DT B-NP O
4 610 616 9949209 common JJ I-NP O
5 617 626 9949209 autosomal JJ I-NP O
6 627 636 9949209 recessive JJ I-NP O
7 637 643 9949209 copper NN I-NP B-Disease
8 644 653 9949209 toxicosis NN I-NP I-Disease
9 654 655 9949209 ( ( O O
10 655 657 9949209 CT NN B-NP B-Disease
11 657 658 9949209 ) ) O O
12 659 661 9949209 in IN B-PP O
13 662 672 9949209 Bedlington NNP B-NP O
14 673 681 9949209 terriers NNS I-NP O
15 681 682 9949209 , , O O
16 683 685 9949209 we PRP B-NP O
17 686 690 9949209 have VBP B-VP O
18 691 701 9949209 identified VBN I-VP O
19 702 703 9949209 a DT B-NP O
20 704 707 9949209 new JJ I-NP O
21 708 713 9949209 locus NN I-NP O
22 714 722 9949209 involved VBN B-VP O
23 723 725 9949209 in IN B-PP O
24 726 737 9949209 progressive JJ B-NP O
25 738 743 9949209 liver NN I-NP B-Disease
26 744 751 9949209 disease NN I-NP I-Disease
27 751 752 9949209 . . O O

1 753 755 9949209 We PRP B-NP O
2 756 764 9949209 examined VBD B-VP O
3 765 772 9949209 whether IN B-SBAR O
4 773 776 9949209 the DT B-NP O
5 777 779 9949209 WD JJ I-NP B-Disease
6 780 784 9949209 gene NN I-NP O
7 785 790 9949209 ATP7B NN I-NP O
8 791 794 9949209 was VBD B-VP O
9 795 799 9949209 also RB B-ADVP O
10 800 809 9949209 causative JJ B-ADJP O
11 810 813 9949209 for IN B-PP O
12 814 816 9949209 CT NN B-NP B-Disease
13 817 819 9949209 by IN B-PP O
14 820 833 9949209 investigating VBG B-VP O
15 834 837 9949209 the DT B-NP O
16 838 849 9949209 chromosomal JJ I-NP O
17 850 852 9949209 co AFX I-NP O
18 852 853 9949209 - HYPH I-NP O
19 853 865 9949209 localization NN I-NP O
20 866 868 9949209 of IN B-PP O
21 869 874 9949209 ATP7B NN B-NP O
22 875 878 9949209 and CC I-NP O
23 879 885 9949209 C04107 NN I-NP O
24 885 886 9949209 , , O O
25 887 892 9949209 using VBG B-VP O
26 893 905 9949209 fluorescence NN B-NP O
27 906 908 9949209 in FW B-NP O
28 909 913 9949209 situ FW I-NP O
29 914 927 9949209 hybridization NN I-NP O
30 928 929 9949209 ( ( O O
31 929 933 9949209 FISH NN B-NP O
32 933 934 9949209 ) ) O O
33 934 935 9949209 . . O O

1 936 942 9949209 C04107 NN B-NP O
2 943 945 9949209 is VBZ B-VP O
3 946 948 9949209 an DT B-NP O
4 949 958 9949209 anonymous JJ I-NP O
5 959 973 9949209 microsatellite NN I-NP O
6 974 980 9949209 marker NN I-NP O
7 981 988 9949209 closely RB B-VP O
8 989 995 9949209 linked VBN I-VP O
9 996 998 9949209 to TO B-PP O
10 999 1001 9949209 CT NN B-NP B-Disease
11 1001 1002 9949209 . . O O

1 1003 1010 9949209 However RB B-ADVP O
2 1010 1011 9949209 , , O O
3 1012 1015 9949209 BAC NN B-NP O
4 1016 1022 9949209 clones NNS I-NP O
5 1023 1033 9949209 containing VBG B-VP O
6 1034 1039 9949209 ATP7B NN B-NP O
7 1040 1043 9949209 and CC I-NP O
8 1044 1050 9949209 C04107 NN I-NP O
9 1051 1057 9949209 mapped VBD B-VP O
10 1058 1060 9949209 to TO B-PP O
11 1061 1064 9949209 the DT B-NP O
12 1065 1071 9949209 canine JJ I-NP O
13 1072 1082 9949209 chromosome NN I-NP O
14 1083 1090 9949209 regions NNS I-NP O
15 1091 1099 9949209 CFA22q11 NN I-NP O
16 1100 1103 9949209 and CC I-NP O
17 1104 1112 9949209 CFA10q26 NN I-NP O
18 1112 1113 9949209 , , O O
19 1114 1126 9949209 respectively RB B-ADVP O
20 1126 1127 9949209 , , O O
21 1128 1141 9949209 demonstrating VBG B-VP O
22 1142 1146 9949209 that IN B-SBAR O
23 1147 1149 9949209 WD NN B-NP B-Disease
24 1150 1156 9949209 cannot MD B-VP O
25 1157 1159 9949209 be VB I-VP O
26 1160 1170 9949209 homologous JJ B-ADJP O
27 1171 1173 9949209 to TO B-PP O
28 1174 1176 9949209 CT NN B-NP B-Disease
29 1176 1177 9949209 . . O O

1 1178 1181 9949209 The DT B-NP O
2 1182 1188 9949209 copper NN I-NP O
3 1189 1198 9949209 transport NN I-NP O
4 1199 1204 9949209 genes NNS I-NP O
5 1205 1209 9949209 CTR1 NN I-NP O
6 1210 1213 9949209 and CC I-NP O
7 1214 1218 9949209 CTR2 NN I-NP O
8 1219 1223 9949209 were VBD B-VP O
9 1224 1228 9949209 also RB I-VP O
10 1229 1237 9949209 excluded VBN I-VP O
11 1238 1240 9949209 as IN B-PP O
12 1241 1250 9949209 candidate NN B-NP O
13 1251 1256 9949209 genes NNS I-NP O
14 1257 1260 9949209 for IN B-PP O
15 1261 1263 9949209 CT NN B-NP B-Disease
16 1264 1269 9949209 since IN B-SBAR O
17 1270 1274 9949209 they PRP B-NP O
18 1275 1279 9949209 both DT B-NP O
19 1280 1286 9949209 mapped VBD B-VP O
20 1287 1289 9949209 to TO B-PP O
21 1290 1296 9949209 canine JJ B-NP O
22 1297 1307 9949209 chromosome NN I-NP O
23 1308 1314 9949209 region NN I-NP O
24 1315 1323 9949209 CFA11q22 NN I-NP O
25 1323 1324 9949209 . . O O
26 1325 1326 9949209 2 CD B-NP O
27 1326 1327 9949209 - HYPH I-NP O
28 1327 1329 9949209 22 CD I-NP O
29 1329 1330 9949209 . . O O

1 1331 1332 9949209 5 LS B-LST O
2 1332 1333 9949209 . . O O

1 1334 1335 9949209 A DT B-NP O
2 1336 1347 9949209 transcribed VBN I-NP O
3 1348 1356 9949209 sequence NN I-NP O
4 1357 1367 9949209 identified VBN B-VP O
5 1368 1372 9949209 from IN B-PP O
6 1373 1376 9949209 the DT B-NP O
7 1377 1383 9949209 C04107 NN I-NP O
8 1383 1384 9949209 - HYPH O O
9 1384 1394 9949209 containing VBG B-VP O
10 1395 1398 9949209 BAC NN B-NP O
11 1399 1402 9949209 was VBD B-VP O
12 1403 1408 9949209 found VBN I-VP O
13 1409 1411 9949209 to TO I-VP O
14 1412 1414 9949209 be VB I-VP O
15 1415 1425 9949209 homologous JJ B-ADJP O
16 1426 1428 9949209 to TO B-PP O
17 1429 1430 9949209 a DT B-NP O
18 1431 1435 9949209 gene NN I-NP O
19 1436 1445 9949209 expressed VBN B-VP O
20 1446 1450 9949209 from IN B-PP O
21 1451 1456 9949209 human JJ B-NP O
22 1457 1467 9949209 chromosome NN I-NP O
23 1468 1472 9949209 2p13 NN I-NP O
24 1472 1473 9949209 - HYPH B-NP O
25 1473 1476 9949209 p16 NN I-NP O
26 1476 1477 9949209 , , O O
27 1478 1479 9949209 a DT B-NP O
28 1480 1486 9949209 region NN I-NP O
29 1487 1493 9949209 devoid JJ B-ADJP O
30 1494 1496 9949209 of IN B-PP O
31 1497 1500 9949209 any DT B-NP O
32 1501 1511 9949209 positional JJ I-NP O
33 1512 1521 9949209 candidate NN I-NP O
34 1522 1527 9949209 genes NNS I-NP O
35 1527 1528 9949209 . . O O

1 0 0 9674903 -DOCSTART- -X- -X- O

1 0 8 9674903 Maternal JJ B-NP B-Disease
2 9 15 9674903 disomy NN I-NP I-Disease
3 16 19 9674903 and CC O O
4 20 26 9674903 Prader NNP B-NP B-Disease
5 26 27 9674903 - HYPH I-NP I-Disease
6 27 32 9674903 Willi NNP I-NP I-Disease
7 33 41 9674903 syndrome NN I-NP I-Disease
8 42 52 9674903 consistent JJ B-ADJP O
9 53 57 9674903 with IN B-PP O
10 58 64 9674903 gamete NN B-NP O
11 65 80 9674903 complementation NN I-NP O
12 81 83 9674903 in IN B-PP O
13 84 85 9674903 a DT B-NP O
14 86 90 9674903 case NN I-NP O
15 91 93 9674903 of IN B-PP O
16 94 102 9674903 familial JJ B-NP O
17 103 116 9674903 translocation NN I-NP O
18 117 118 9674903 ( ( O O
19 118 122 9674903 3;15 CD B-NP O
20 122 123 9674903 ) ) O O
21 124 125 9674903 ( ( O O
22 125 134 9674903 p25;q11.2 NN B-NP O
23 134 135 9674903 ) ) O O
24 135 136 9674903 . . O O
25 137 145 9674903 Maternal JJ B-NP B-Disease
26 146 157 9674903 uniparental JJ I-NP I-Disease
27 158 164 9674903 disomy NN I-NP I-Disease
28 165 166 9674903 ( ( O I-Disease
29 166 169 9674903 UPD NN B-NP I-Disease
30 169 170 9674903 ) ) O I-Disease
31 171 174 9674903 for IN B-PP I-Disease
32 175 185 9674903 chromosome NN B-NP I-Disease
33 186 188 9674903 15 CD I-NP I-Disease
34 189 191 9674903 is VBZ B-VP O
35 192 203 9674903 responsible JJ B-ADJP O
36 204 207 9674903 for IN B-PP O
37 208 210 9674903 an DT B-NP O
38 211 220 9674903 estimated VBN I-NP O
39 221 224 9674903 30% CD I-NP O
40 225 227 9674903 of IN B-PP O
41 228 233 9674903 cases NNS B-NP O
42 234 236 9674903 of IN B-PP O
43 237 243 9674903 Prader NNP B-NP B-Disease
44 243 244 9674903 - HYPH I-NP I-Disease
45 244 249 9674903 Willi NNP I-NP I-Disease
46 250 258 9674903 syndrome NN I-NP I-Disease
47 259 260 9674903 ( ( O O
48 260 263 9674903 PWS NN B-NP B-Disease
49 263 264 9674903 ) ) O O
50 264 265 9674903 . . O O

1 266 268 9674903 We PRP B-NP O
2 269 275 9674903 report VBP B-VP O
3 276 278 9674903 on IN B-PP O
4 279 281 9674903 an DT B-NP O
5 282 289 9674903 unusual JJ I-NP O
6 290 294 9674903 case NN I-NP O
7 295 297 9674903 of IN B-PP O
8 298 306 9674903 maternal JJ B-NP B-Disease
9 307 313 9674903 disomy NN I-NP I-Disease
10 314 316 9674903 15 CD I-NP I-Disease
11 317 319 9674903 in IN B-PP O
12 320 323 9674903 PWS NN B-NP B-Disease
13 324 328 9674903 that WDT B-NP O
14 329 331 9674903 is VBZ B-VP O
15 332 336 9674903 most RBS B-ADJP O
16 337 347 9674903 consistent JJ I-ADJP O
17 348 352 9674903 with IN B-PP O
18 353 361 9674903 adjacent JJ B-NP O
19 361 362 9674903 - HYPH I-NP O
20 362 363 9674903 1 CD I-NP O
21 364 375 9674903 segregation NN I-NP O
22 376 378 9674903 of IN B-PP O
23 379 380 9674903 a DT B-NP O
24 381 389 9674903 paternal JJ I-NP O
25 390 391 9674903 t NN I-NP O
26 392 393 9674903 ( ( O O
27 393 394 9674903 3 CD B-NP O
28 394 395 9674903 ; : O O
29 396 398 9674903 15 CD B-NP O
30 398 399 9674903 ) ) O O
31 400 401 9674903 ( ( O O
32 401 404 9674903 p25 NN B-NP O
33 404 405 9674903 ; : O O
34 406 409 9674903 q11 NN B-NP O
35 409 410 9674903 . . O O

1 411 412 9674903 2 LS B-LST O
2 412 413 9674903 ) ) O O
3 414 418 9674903 with IN B-PP O
4 419 431 9674903 simultaneous JJ B-NP O
5 432 440 9674903 maternal JJ I-NP O
6 441 448 9674903 meiotic JJ I-NP O
7 449 463 9674903 nondisjunction NN I-NP O
8 464 467 9674903 for IN B-PP O
9 468 478 9674903 chromosome NN B-NP O
10 479 481 9674903 15 CD I-NP O
11 481 482 9674903 . . O O

1 483 486 9674903 The DT B-NP O
2 487 494 9674903 patient NN I-NP O
3 495 496 9674903 ( ( O O
4 496 497 9674903 J NN B-NP O
5 497 498 9674903 . . O O

1 499 500 9674903 B NN B-NP O
2 500 501 9674903 . . O O
3 501 502 9674903 ) ) O O
4 502 503 9674903 , , O O
5 504 505 9674903 a DT B-NP O
6 506 508 9674903 17 CD I-NP O
7 508 509 9674903 - HYPH I-NP O
8 509 513 9674903 year NN I-NP O
9 513 514 9674903 - HYPH B-NP O
10 514 517 9674903 old JJ I-NP O
11 518 523 9674903 white JJ I-NP O
12 524 528 9674903 male NN I-NP O
13 529 533 9674903 with IN B-PP O
14 534 537 9674903 PWS NN B-NP B-Disease
15 537 538 9674903 , , O O
16 539 542 9674903 was VBD B-VP O
17 543 548 9674903 found VBN I-VP O
18 549 551 9674903 to TO I-VP O
19 552 556 9674903 have VB I-VP O
20 557 559 9674903 47 CD B-NP O
21 560 571 9674903 chromosomes NNS I-NP O
22 572 576 9674903 with IN B-PP O
23 577 578 9674903 a DT B-NP O
24 579 592 9674903 supernumerary JJ I-NP O
25 592 593 9674903 , , I-NP O
26 594 602 9674903 paternal JJ I-NP O
27 603 606 9674903 der NN I-NP O
28 607 608 9674903 ( ( O O
29 608 610 9674903 15 CD B-NP O
30 610 611 9674903 ) ) O O
31 612 622 9674903 consisting VBG B-VP O
32 623 625 9674903 of IN B-PP O
33 626 629 9674903 the DT B-NP O
34 630 635 9674903 short JJ I-NP O
35 636 639 9674903 arm NN I-NP O
36 640 643 9674903 and CC O O
37 644 647 9674903 the DT B-NP O
38 648 656 9674903 proximal JJ I-NP O
39 657 661 9674903 long JJ I-NP O
40 662 665 9674903 arm NN I-NP O
41 666 668 9674903 of IN B-PP O
42 669 679 9674903 chromosome NN B-NP O
43 680 682 9674903 15 CD I-NP O
44 682 683 9674903 , , O O
45 684 687 9674903 and CC O O
46 688 694 9674903 distal JJ B-NP O
47 695 705 9674903 chromosome NN I-NP O
48 706 709 9674903 arm NN I-NP O
49 710 712 9674903 3p NN I-NP O
50 712 713 9674903 . . O O

1 714 717 9674903 The DT B-NP O
2 718 719 9674903 t NN I-NP O
3 720 721 9674903 ( ( O O
4 721 722 9674903 3 CD B-NP O
5 722 723 9674903 ; : O O
6 724 726 9674903 15 CD B-NP O
7 726 727 9674903 ) ) O O
8 728 731 9674903 was VBD B-VP O
9 732 739 9674903 present JJ B-ADJP O
10 740 742 9674903 in IN B-PP O
11 743 746 9674903 the DT B-NP O
12 747 755 9674903 balanced JJ I-NP O
13 756 761 9674903 state NN I-NP O
14 762 764 9674903 in IN B-PP O
15 765 768 9674903 the DT B-NP O
16 769 777 9674903 patients NNS I-NP O
17 778 784 9674903 father NN I-NP O
18 785 788 9674903 and CC O O
19 789 790 9674903 a DT B-NP O
20 791 797 9674903 sister NN I-NP O
21 797 798 9674903 . . O O

1 799 810 9674903 Fluorescent JJ B-NP O
2 811 813 9674903 in FW I-NP O
3 814 818 9674903 situ FW I-NP O
4 819 832 9674903 hybridization NN I-NP O
5 833 841 9674903 analysis NN I-NP O
6 842 854 9674903 demonstrated VBD B-VP O
7 855 859 9674903 that IN B-SBAR O
8 860 863 9674903 the DT B-NP O
9 864 867 9674903 PWS NN I-NP B-Disease
10 868 876 9674903 critical JJ I-NP O
11 877 883 9674903 region NN I-NP O
12 884 891 9674903 resided VBD B-VP O
13 892 894 9674903 on IN B-PP O
14 895 898 9674903 the DT B-NP O
15 899 909 9674903 derivative JJ I-NP O
16 910 920 9674903 chromosome NN I-NP O
17 921 922 9674903 3 CD I-NP O
18 923 926 9674903 and CC O O
19 927 931 9674903 that IN B-SBAR O
20 932 937 9674903 there EX B-NP O
21 938 941 9674903 was VBD B-VP O
22 942 944 9674903 no DT B-NP O
23 945 953 9674903 deletion NN I-NP O
24 954 956 9674903 of IN B-PP O
25 957 960 9674903 the DT B-NP O
26 961 964 9674903 PWS NN I-NP B-Disease
27 965 971 9674903 region NN I-NP O
28 972 974 9674903 on IN B-PP O
29 975 978 9674903 the DT B-NP O
30 979 985 9674903 normal JJ I-NP O
31 986 990 9674903 pair NN I-NP O
32 991 993 9674903 of IN B-PP O
33 994 997 9674903 15s NNS B-NP O
34 998 1005 9674903 present JJ B-ADJP O
35 1006 1008 9674903 in IN B-PP O
36 1009 1010 9674903 J NNP B-NP O
37 1010 1011 9674903 . . I-NP O
38 1012 1013 9674903 B NNP I-NP O
39 1013 1014 9674903 . . O O

1 1015 1026 9674903 Methylation NN B-NP O
2 1027 1035 9674903 analysis NN I-NP O
3 1036 1038 9674903 at IN B-PP O
4 1039 1043 9674903 exon NN B-NP O
5 1044 1049 9674903 alpha NN I-NP O
6 1050 1052 9674903 of IN B-PP O
7 1053 1056 9674903 the DT B-NP O
8 1057 1062 9674903 small JJ I-NP O
9 1063 1070 9674903 nuclear JJ I-NP O
10 1071 1088 9674903 ribonucleoprotein NN I-NP O
11 1088 1089 9674903 - HYPH O O
12 1089 1099 9674903 associated VBN B-NP O
13 1100 1111 9674903 polypeptide NN I-NP O
14 1112 1113 9674903 N NN I-NP O
15 1114 1115 9674903 ( ( O O
16 1115 1120 9674903 SNRPN NN B-NP O
17 1120 1121 9674903 ) ) O O
18 1122 1126 9674903 gene NN B-NP O
19 1127 1133 9674903 showed VBD B-VP O
20 1134 1135 9674903 a DT B-NP O
21 1136 1143 9674903 pattern NN I-NP O
22 1144 1158 9674903 characteristic JJ B-ADJP O
23 1159 1161 9674903 of IN B-PP O
24 1162 1166 9674903 only RB B-NP O
25 1167 1170 9674903 the DT I-NP O
26 1171 1179 9674903 maternal JJ I-NP O
27 1180 1190 9674903 chromosome NN I-NP O
28 1191 1193 9674903 15 CD I-NP O
29 1194 1196 9674903 in IN B-PP O
30 1197 1198 9674903 J NNP B-NP O
31 1198 1199 9674903 . . I-NP O
32 1200 1201 9674903 B NNP I-NP O
33 1201 1202 9674903 . . O O

1 1203 1211 9674903 Maternal JJ B-NP B-Disease
2 1212 1218 9674903 disomy NN I-NP I-Disease
3 1219 1222 9674903 was VBD B-VP O
4 1223 1232 9674903 confirmed VBN I-VP O
5 1233 1235 9674903 by IN B-PP O
6 1236 1246 9674903 polymerase NN B-NP O
7 1247 1252 9674903 chain NN I-NP O
8 1253 1261 9674903 reaction NN I-NP O
9 1262 1270 9674903 analysis NN I-NP O
10 1271 1273 9674903 of IN B-PP O
11 1274 1288 9674903 microsatellite NN B-NP O
12 1289 1296 9674903 repeats NNS I-NP O
13 1297 1299 9674903 at IN B-PP O
14 1300 1303 9674903 the DT B-NP O
15 1304 1309 9674903 gamma SYM I-NP O
16 1309 1310 9674903 - HYPH I-NP O
17 1310 1322 9674903 aminobutyric JJ I-NP O
18 1323 1327 9674903 acid NN I-NP O
19 1328 1336 9674903 receptor NN I-NP O
20 1337 1342 9674903 beta3 NN I-NP O
21 1343 1350 9674903 subunit NN I-NP O
22 1351 1352 9674903 ( ( O O
23 1352 1358 9674903 GABRB3 NN B-NP O
24 1358 1359 9674903 ) ) O O
25 1360 1365 9674903 locus NN B-NP O
26 1365 1366 9674903 . . O O

1 1367 1368 9674903 A DT B-NP O
2 1369 1374 9674903 niece NN I-NP O
3 1375 1376 9674903 ( ( O O
4 1376 1377 9674903 B NN B-NP O
5 1377 1378 9674903 . . O O

1 1379 1380 9674903 B NN B-NP O
2 1380 1381 9674903 . . O O
3 1381 1382 9674903 ) ) O O
4 1383 1387 9674903 with IN B-PP O
5 1388 1390 9674903 45 CD B-NP O
6 1391 1402 9674903 chromosomes NNS I-NP O
7 1403 1406 9674903 and CC O O
8 1407 1410 9674903 the DT B-NP O
9 1411 1421 9674903 derivative JJ I-NP O
10 1422 1423 9674903 3 CD I-NP O
11 1424 1427 9674903 but CC O O
12 1428 1435 9674903 without IN B-PP O
13 1436 1439 9674903 the DT B-NP O
14 1440 1443 9674903 der NN I-NP O
15 1444 1445 9674903 ( ( O O
16 1445 1447 9674903 15 CD B-NP O
17 1447 1448 9674903 ) ) O O
18 1449 1461 9674903 demonstrated VBD B-VP O
19 1462 1463 9674903 a DT B-NP O
20 1464 1473 9674903 phenotype NN I-NP O
21 1474 1484 9674903 consistent JJ B-ADJP O
22 1485 1489 9674903 with IN B-PP O
23 1490 1494 9674903 that DT B-NP O
24 1495 1503 9674903 reported VBN B-VP O
25 1504 1507 9674903 for IN B-PP O
26 1508 1526 9674903 haploinsufficiency NN B-NP O
27 1527 1529 9674903 of IN B-PP O
28 1530 1536 9674903 distal JJ B-NP O
29 1537 1538 9674903 3 CD I-NP O
30 1539 1540 9674903 p NN I-NP O
31 1540 1541 9674903 . . O O

1 1542 1553 9674903 Uniparental JJ B-NP B-Disease
2 1554 1560 9674903 disomy NN I-NP I-Disease
3 1561 1571 9674903 associated VBN B-VP O
4 1572 1576 9674903 with IN B-PP O
5 1577 1587 9674903 unbalanced JJ B-NP O
6 1588 1599 9674903 segregation NN I-NP O
7 1600 1602 9674903 of IN B-PP O
8 1603 1606 9674903 non AFX B-NP O
9 1606 1607 9674903 - HYPH I-NP O
10 1607 1619 9674903 Robertsonian JJ I-NP O
11 1620 1634 9674903 translocations NNS I-NP O
12 1635 1638 9674903 has VBZ B-VP O
13 1639 1643 9674903 been VBN I-VP O
14 1644 1652 9674903 reported VBN I-VP O
15 1653 1663 9674903 previously RB B-ADVP O
16 1664 1667 9674903 but CC O O
17 1668 1671 9674903 has VBZ B-VP O
18 1672 1675 9674903 not RB O O
19 1675 1676 9674903 , , O O
20 1677 1679 9674903 to TO B-PP O
21 1680 1683 9674903 our PRP$ B-NP O
22 1684 1693 9674903 knowledge NN I-NP O
23 1693 1694 9674903 , , O O
24 1695 1699 9674903 been VBN B-VP O
25 1700 1708 9674903 observed VBN I-VP O
26 1709 1711 9674903 in IN B-PP O
27 1712 1713 9674903 a DT B-NP O
28 1714 1718 9674903 case NN I-NP O
29 1719 1721 9674903 of IN B-PP O
30 1722 1725 9674903 PWS NN B-NP B-Disease
31 1725 1726 9674903 . . O O

1 1727 1738 9674903 Furthermore RB B-ADVP O
2 1738 1739 9674903 , , O O
3 1740 1743 9674903 our PRP$ B-NP O
4 1744 1752 9674903 findings NNS I-NP O
5 1753 1756 9674903 are VBP B-VP O
6 1757 1761 9674903 best RB I-VP O
7 1762 1773 9674903 interpreted VBN I-VP O
8 1774 1776 9674903 as IN B-PP O
9 1777 1781 9674903 true JJ B-NP O
10 1782 1788 9674903 gamete NN I-NP O
11 1789 1804 9674903 complementation NN I-NP O
12 1805 1814 9674903 resulting VBG B-VP O
13 1815 1817 9674903 in IN B-PP O
14 1818 1826 9674903 maternal JJ B-NP B-Disease
15 1827 1830 9674903 UPD NNP I-NP I-Disease
16 1831 1833 9674903 15 CD I-NP I-Disease
17 1834 1837 9674903 and CC O O
18 1838 1841 9674903 PWS NN B-NP B-Disease

1 0 0 9674906 -DOCSTART- -X- -X- O

1 0 8 9674906 Schwartz NNP B-NP B-Disease
2 8 9 9674906 - HYPH I-NP I-Disease
3 9 15 9674906 Jampel NNP I-NP I-Disease
4 16 24 9674906 syndrome NN I-NP I-Disease
5 25 29 9674906 type NN I-NP I-Disease
6 30 31 9674906 2 CD I-NP I-Disease
7 32 35 9674906 and CC O O
8 36 41 9674906 Stuve NNP B-NP B-Disease
9 41 42 9674906 - HYPH I-NP I-Disease
10 42 51 9674906 Wiedemann NNP I-NP I-Disease
11 52 60 9674906 syndrome NN I-NP I-Disease
12 60 61 9674906 : : O O
13 62 63 9674906 a DT B-NP O
14 64 68 9674906 case NN I-NP O
15 69 72 9674906 for IN B-PP O
16 73 74 9674906 " `` O O
17 74 81 9674906 lumping VBG B-VP O
18 81 82 9674906 " '' O O
19 82 83 9674906 . . O O
20 84 90 9674906 Recent JJ B-NP O
21 91 98 9674906 studies NNS I-NP O
22 99 111 9674906 demonstrated VBD B-VP O
23 112 115 9674906 the DT B-NP O
24 116 125 9674906 existence NN I-NP O
25 126 128 9674906 of IN B-PP O
26 129 130 9674906 a DT B-NP O
27 131 142 9674906 genetically RB I-NP O
28 143 151 9674906 distinct JJ I-NP O
29 151 152 9674906 , , I-NP O
30 153 160 9674906 usually RB I-NP O
31 161 167 9674906 lethal JJ I-NP O
32 168 172 9674906 form NN I-NP O
33 173 175 9674906 of IN B-PP O
34 176 179 9674906 the DT B-NP O
35 180 188 9674906 Schwartz NNP I-NP B-Disease
36 188 189 9674906 - HYPH I-NP I-Disease
37 189 195 9674906 Jampel NNP I-NP I-Disease
38 196 204 9674906 syndrome NN I-NP I-Disease
39 205 206 9674906 ( ( O O
40 206 209 9674906 SJS NN B-NP B-Disease
41 209 210 9674906 ) ) O O
42 211 213 9674906 of IN B-PP O
43 214 222 9674906 myotonia NN B-NP B-Disease
44 223 226 9674906 and CC O O
45 227 235 9674906 skeletal JJ B-NP B-Disease
46 236 245 9674906 dysplasia NN I-NP I-Disease
47 245 246 9674906 , , O O
48 247 252 9674906 which WDT B-NP O
49 253 255 9674906 we PRP B-NP O
50 256 262 9674906 called VBD B-VP O
51 263 266 9674906 SJS NN B-NP B-Disease
52 267 271 9674906 type NN I-NP I-Disease
53 272 273 9674906 2 CD I-NP I-Disease
54 273 274 9674906 . . O O

1 275 279 9674906 This DT B-NP O
2 280 288 9674906 disorder NN I-NP O
3 289 291 9674906 is VBZ B-VP O
4 292 303 9674906 reminiscent JJ B-ADJP O
5 304 306 9674906 of IN B-PP O
6 307 314 9674906 another DT B-NP O
7 315 319 9674906 rare JJ I-NP O
8 320 329 9674906 condition NN I-NP O
9 329 330 9674906 , , O O
10 331 334 9674906 the DT B-NP O
11 335 340 9674906 Stuve NNP I-NP B-Disease
12 340 341 9674906 - HYPH I-NP I-Disease
13 341 350 9674906 Wiedemann NNP I-NP I-Disease
14 351 359 9674906 syndrome NN I-NP I-Disease
15 360 361 9674906 ( ( O O
16 361 364 9674906 SWS NN B-NP B-Disease
17 364 365 9674906 ) ) O O
18 365 366 9674906 , , O O
19 367 372 9674906 which WDT B-NP O
20 373 382 9674906 comprises VBZ B-VP O
21 383 393 9674906 campomelia NN B-NP B-Disease
22 394 396 9674906 at IN B-PP O
23 397 402 9674906 birth NN B-NP O
24 403 407 9674906 with IN B-PP O
25 408 416 9674906 skeletal JJ B-NP B-Disease
26 417 426 9674906 dysplasia NN I-NP I-Disease
27 426 427 9674906 , , O O
28 428 440 9674906 contractures NNS B-NP B-Disease
29 440 441 9674906 , , O O
30 442 445 9674906 and CC O O
31 446 451 9674906 early JJ B-NP B-Disease
32 452 457 9674906 death NN I-NP I-Disease
33 457 458 9674906 . . O O

1 459 461 9674906 To TO B-VP O
2 462 466 9674906 test VB I-VP O
3 467 470 9674906 for IN B-PP O
4 471 479 9674906 possible JJ B-NP O
5 480 489 9674906 nosologic JJ I-NP O
6 490 498 9674906 identity NN I-NP O
7 499 506 9674906 between IN B-PP O
8 507 512 9674906 these DT B-NP O
9 513 522 9674906 disorders NNS I-NP O
10 522 523 9674906 , , O O
11 524 526 9674906 we PRP B-NP O
12 527 535 9674906 reviewed VBD B-VP O
13 536 539 9674906 the DT B-NP O
14 540 550 9674906 literature NN I-NP O
15 551 554 9674906 and CC O O
16 555 563 9674906 obtained VBD B-VP O
17 564 565 9674906 a DT B-NP O
18 566 572 9674906 follow VB I-NP O
19 572 573 9674906 - HYPH O O
20 573 575 9674906 up RP B-PRT O
21 576 578 9674906 of IN B-PP O
22 579 582 9674906 the DT B-NP O
23 583 587 9674906 only JJ I-NP O
24 588 591 9674906 two CD I-NP O
25 592 601 9674906 surviving VBG I-NP O
26 602 610 9674906 patients NNS I-NP O
27 610 611 9674906 , , O O
28 612 615 9674906 one CD B-NP O
29 616 620 9674906 with IN B-PP O
30 621 624 9674906 SJS NN B-NP B-Disease
31 625 629 9674906 type NN I-NP I-Disease
32 630 631 9674906 2 CD I-NP I-Disease
33 632 634 9674906 at IN B-PP O
34 635 638 9674906 age NN B-NP O
35 639 641 9674906 10 CD B-NP O
36 642 647 9674906 years NNS I-NP O
37 648 651 9674906 and CC O O
38 652 659 9674906 another DT B-NP O
39 660 664 9674906 with IN B-PP O
40 665 668 9674906 SWS NN B-NP B-Disease
41 669 671 9674906 at IN B-PP O
42 672 675 9674906 age NN B-NP O
43 676 677 9674906 7 CD B-NP O
44 678 683 9674906 years NNS I-NP O
45 683 684 9674906 . . O O

1 685 693 9674906 Patients NNS B-NP O
2 694 702 9674906 reported VBN B-VP O
3 703 705 9674906 as IN B-PP O
4 706 712 9674906 having VBG B-VP O
5 713 719 9674906 either CC B-NP O
6 720 728 9674906 neonatal JJ I-NP O
7 729 732 9674906 SJS NN I-NP B-Disease
8 733 735 9674906 or CC I-NP O
9 736 739 9674906 SWS NN I-NP B-Disease
10 740 749 9674906 presented VBD B-VP O
11 750 751 9674906 a DT B-NP O
12 752 763 9674906 combination NN I-NP O
13 764 766 9674906 of IN B-PP O
14 767 768 9674906 a DT B-NP O
15 769 775 9674906 severe JJ I-NP O
16 775 776 9674906 , , I-NP O
17 777 785 9674906 prenatal JJ I-NP O
18 785 786 9674906 - HYPH I-NP O
19 786 791 9674906 onset NN I-NP O
20 792 805 9674906 neuromuscular JJ I-NP B-Disease
21 806 814 9674906 disorder NN I-NP I-Disease
22 815 816 9674906 ( ( O O
23 816 820 9674906 with IN B-PP O
24 821 831 9674906 congenital JJ B-NP B-Disease
25 832 837 9674906 joint JJ I-NP I-Disease
26 838 850 9674906 contractures NNS I-NP I-Disease
27 850 851 9674906 , , O O
28 852 863 9674906 respiratory JJ B-NP O
29 864 867 9674906 and CC I-NP O
30 868 875 9674906 feeding NN I-NP O
31 876 888 9674906 difficulties NNS I-NP O
32 888 889 9674906 , , O O
33 890 898 9674906 tendency NN B-NP O
34 899 901 9674906 to TO B-PP O
35 902 914 9674906 hyperthermia NN B-NP B-Disease
36 914 915 9674906 , , O O
37 916 919 9674906 and CC O O
38 920 928 9674906 frequent JJ B-NP O
39 929 934 9674906 death NN I-NP O
40 935 937 9674906 in IN B-PP O
41 938 945 9674906 infancy NN B-NP O
42 945 946 9674906 ) ) O O
43 947 951 9674906 with IN B-PP O
44 952 953 9674906 a DT B-NP O
45 954 962 9674906 distinct JJ I-NP O
46 963 973 9674906 campomelic JJ I-NP B-Disease
47 973 974 9674906 - HYPH I-NP I-Disease
48 974 985 9674906 metaphyseal JJ I-NP I-Disease
49 986 994 9674906 skeletal JJ I-NP I-Disease
50 995 1004 9674906 dysplasia NN I-NP I-Disease
51 1004 1005 9674906 . . O O

1 1006 1009 9674906 The DT B-NP O
2 1010 1020 9674906 similarity NN I-NP O
3 1021 1023 9674906 of IN B-PP O
4 1024 1027 9674906 the DT B-NP O
5 1028 1036 9674906 clinical JJ I-NP O
6 1037 1040 9674906 and CC I-NP O
7 1041 1053 9674906 radiographic JJ I-NP O
8 1054 1062 9674906 findings NNS I-NP O
9 1063 1065 9674906 is VBZ B-VP O
10 1066 1068 9674906 so RB B-ADJP O
11 1069 1078 9674906 extensive JJ I-ADJP O
12 1079 1083 9674906 that IN B-SBAR O
13 1084 1089 9674906 these DT B-NP O
14 1090 1099 9674906 disorders NNS I-NP O
15 1100 1106 9674906 appear VBP B-VP O
16 1107 1109 9674906 to TO I-VP O
17 1110 1112 9674906 be VB I-VP O
18 1113 1114 9674906 a DT B-NP O
19 1115 1121 9674906 single JJ I-NP O
20 1122 1128 9674906 entity NN I-NP O
21 1128 1129 9674906 . . O O

1 1130 1133 9674906 The DT B-NP O
2 1134 1140 9674906 follow VB I-NP O
3 1140 1141 9674906 - HYPH B-VP O
4 1141 1143 9674906 up RP B-PRT O
5 1144 1155 9674906 observation NN B-NP O
6 1156 1158 9674906 of IN B-PP O
7 1159 1161 9674906 an DT B-NP O
8 1162 1171 9674906 identical JJ I-NP O
9 1172 1175 9674906 and CC I-NP O
10 1176 1182 9674906 unique JJ I-NP O
11 1183 1190 9674906 pattern NN I-NP O
12 1191 1193 9674906 of IN B-PP O
13 1194 1205 9674906 progressive JJ B-NP O
14 1206 1210 9674906 bone NN I-NP B-Disease
15 1211 1220 9674906 dysplasia NN I-NP I-Disease
16 1221 1223 9674906 in IN B-PP O
17 1224 1227 9674906 the DT B-NP O
18 1228 1231 9674906 two CD I-NP O
19 1232 1240 9674906 patients NNS I-NP O
20 1241 1242 9674906 ( ( O O
21 1242 1245 9674906 one CD B-NP O
22 1246 1250 9674906 with IN B-PP O
23 1251 1254 9674906 SJS NN B-NP B-Disease
24 1255 1259 9674906 type NN I-NP I-Disease
25 1260 1261 9674906 2 CD I-NP I-Disease
26 1261 1262 9674906 , , O O
27 1263 1266 9674906 one CD B-NP O
28 1267 1271 9674906 with IN B-PP O
29 1272 1275 9674906 SWS NN B-NP B-Disease
30 1275 1276 9674906 ) ) O O
31 1277 1286 9674906 surviving VBG B-VP O
32 1287 1293 9674906 beyond IN B-PP O
33 1294 1301 9674906 infancy NN B-NP O
34 1302 1306 9674906 adds VBZ B-VP O
35 1307 1309 9674906 to TO B-PP O
36 1310 1313 9674906 the DT B-NP O
37 1314 1322 9674906 evidence NN I-NP O
38 1323 1325 9674906 in IN B-PP O
39 1326 1331 9674906 favor NN B-NP O
40 1332 1334 9674906 of IN B-PP O
41 1335 1343 9674906 identity NN B-NP O
42 1343 1344 9674906 . . O O

1 1345 1348 9674906 The DT B-NP O
2 1349 1359 9674906 hypothesis NN I-NP O
3 1360 1364 9674906 that IN B-SBAR O
4 1365 1368 9674906 SWS NN B-NP B-Disease
5 1369 1372 9674906 and CC I-NP O
6 1373 1376 9674906 SJS NN I-NP B-Disease
7 1377 1381 9674906 type NN I-NP I-Disease
8 1382 1383 9674906 2 CD I-NP I-Disease
9 1384 1387 9674906 are VBP B-VP O
10 1388 1391 9674906 the DT B-NP O
11 1392 1396 9674906 same JJ I-NP O
12 1397 1405 9674906 disorder NN I-NP O
13 1406 1412 9674906 should MD B-VP O
14 1413 1415 9674906 be VB I-VP O
15 1416 1424 9674906 testable JJ B-ADJP O
16 1425 1427 9674906 by IN B-PP O
17 1428 1437 9674906 molecular JJ B-NP O
18 1438 1445 9674906 methods NNS I-NP O
19 1445 1446 9674906 . . O O
20 1446 1447 9674906 . . O O

1 0 0 9831355 -DOCSTART- -X- -X- O

1 0 6 9831355 I1307K NN B-NP O
2 7 10 9831355 APC NN I-NP O
3 11 14 9831355 and CC I-NP O
4 15 20 9831355 hMLH1 NN I-NP O
5 21 30 9831355 mutations NNS I-NP O
6 31 33 9831355 in IN B-PP O
7 34 35 9831355 a DT B-NP O
8 36 39 9831355 non AFX I-NP O
9 39 40 9831355 - HYPH I-NP O
10 40 46 9831355 Jewish JJ I-NP O
11 47 53 9831355 family NN I-NP O
12 54 58 9831355 with IN B-PP O
13 59 69 9831355 hereditary JJ B-NP B-Disease
14 70 73 9831355 non AFX I-NP I-Disease
15 73 74 9831355 - HYPH I-NP I-Disease
16 74 83 9831355 polyposis NN I-NP I-Disease
17 84 94 9831355 colorectal JJ I-NP I-Disease
18 95 101 9831355 cancer NN I-NP I-Disease
19 101 102 9831355 . . O O
20 103 105 9831355 We PRP B-NP O
21 106 114 9831355 describe VBP B-VP O
22 115 116 9831355 a DT B-NP O
23 117 123 9831355 French JJ I-NP O
24 124 132 9831355 Canadian JJ I-NP O
25 133 143 9831355 hereditary JJ I-NP B-Disease
26 144 147 9831355 non AFX I-NP I-Disease
27 147 148 9831355 - HYPH I-NP I-Disease
28 148 157 9831355 polyposis NN I-NP I-Disease
29 158 168 9831355 colorectal JJ I-NP I-Disease
30 169 175 9831355 cancer NN I-NP I-Disease
31 176 177 9831355 ( ( O O
32 177 182 9831355 HNPCC NN B-NP B-Disease
33 182 183 9831355 ) ) O O
34 184 191 9831355 kindred NN B-NP O
35 192 197 9831355 which WDT B-NP O
36 198 205 9831355 carries VBZ B-VP O
37 206 207 9831355 a DT B-NP O
38 208 213 9831355 novel JJ I-NP O
39 214 224 9831355 truncating VBG I-NP O
40 225 233 9831355 mutation NN I-NP O
41 234 236 9831355 in IN B-PP O
42 237 242 9831355 hMLH1 NN B-NP O
43 242 243 9831355 . . O O

1 244 257 9831355 Interestingly RB B-ADVP O
2 257 258 9831355 , , O O
3 259 262 9831355 the DT B-NP O
4 263 269 9831355 I1307K NN I-NP O
5 270 273 9831355 APC NN I-NP O
6 274 286 9831355 polymorphism NN I-NP O
7 286 287 9831355 , , O O
8 288 298 9831355 associated VBN B-VP O
9 299 303 9831355 with IN B-PP O
10 304 306 9831355 an DT B-NP O
11 307 316 9831355 increased VBN I-NP O
12 317 321 9831355 risk NN I-NP O
13 322 324 9831355 of IN B-PP O
14 325 335 9831355 colorectal JJ B-NP B-Disease
15 336 342 9831355 cancer NN I-NP I-Disease
16 342 343 9831355 , , O O
17 344 346 9831355 is VBZ B-VP O
18 347 351 9831355 also RB B-ADVP O
19 352 359 9831355 present JJ B-ADJP O
20 360 362 9831355 in IN B-PP O
21 363 367 9831355 this DT B-NP O
22 368 374 9831355 family NN I-NP O
23 374 375 9831355 . . O O

1 376 379 9831355 The DT B-NP O
2 380 386 9831355 I1307K NN I-NP O
3 387 399 9831355 polymorphism NN I-NP O
4 400 403 9831355 has VBZ B-VP O
5 404 414 9831355 previously RB I-VP O
6 415 419 9831355 only RB I-VP O
7 420 424 9831355 been VBN I-VP O
8 425 435 9831355 identified VBN I-VP O
9 436 438 9831355 in IN B-PP O
10 439 450 9831355 individuals NNS B-NP O
11 451 453 9831355 of IN B-PP O
12 454 458 9831355 self NN B-NP O
13 458 459 9831355 - HYPH B-NP O
14 459 467 9831355 reported VBN I-NP O
15 468 477 9831355 Ashkenazi NN I-NP O
16 478 484 9831355 Jewish JJ I-NP O
17 485 492 9831355 origins NNS I-NP O
18 492 493 9831355 . . O O

1 494 496 9831355 In IN B-PP O
2 497 505 9831355 addition NN B-NP O
3 505 506 9831355 , , O O
4 507 509 9831355 in IN B-PP O
5 510 514 9831355 this DT B-NP O
6 515 521 9831355 family NN I-NP O
7 521 522 9831355 , , O O
8 523 528 9831355 there EX B-NP O
9 529 536 9831355 appears VBZ B-VP O
10 537 539 9831355 to TO I-VP O
11 540 542 9831355 be VB I-VP O
12 543 545 9831355 no DT B-NP O
13 546 558 9831355 relationship NN I-NP O
14 559 566 9831355 between IN B-PP O
15 567 570 9831355 the DT B-NP O
16 571 577 9831355 I1307K NN I-NP O
17 578 590 9831355 polymorphism NN I-NP O
18 591 594 9831355 and CC O O
19 595 598 9831355 the DT B-NP O
20 599 607 9831355 presence NN I-NP O
21 608 610 9831355 or CC I-NP O
22 611 618 9831355 absence NN I-NP O
23 619 621 9831355 of IN B-PP O
24 622 628 9831355 cancer NN B-NP B-Disease
25 628 629 9831355 . . O O
26 629 630 9831355 . . O O

1 0 0 9463318 -DOCSTART- -X- -X- O

1 0 3 9463318 The DT B-NP O
2 4 8 9463318 DMPK NN I-NP O
3 9 13 9463318 gene NN I-NP O
4 14 16 9463318 of IN B-PP O
5 17 25 9463318 severely RB B-NP O
6 26 34 9463318 affected VBN I-NP O
7 35 43 9463318 myotonic JJ I-NP B-Disease
8 44 53 9463318 dystrophy NN I-NP I-Disease
9 54 62 9463318 patients NNS I-NP O
10 63 65 9463318 is VBZ B-VP O
11 66 81 9463318 hypermethylated VBN I-VP O
12 82 90 9463318 proximal JJ B-ADJP O
13 91 93 9463318 to TO B-PP O
14 94 97 9463318 the DT B-NP O
15 98 105 9463318 largely RB I-NP O
16 106 114 9463318 expanded VBN I-NP O
17 115 118 9463318 CTG NN I-NP O
18 119 125 9463318 repeat NN I-NP O
19 125 126 9463318 . . O O
20 127 132 9463318 Using VBG B-VP O
21 133 144 9463318 methylation NN B-NP O
22 144 145 9463318 - HYPH B-NP O
23 145 154 9463318 sensitive JJ I-NP O
24 155 166 9463318 restriction NN I-NP O
25 167 174 9463318 enzymes NNS I-NP O
26 174 175 9463318 , , O O
27 176 178 9463318 we PRP B-NP O
28 179 192 9463318 characterized VBD B-VP O
29 193 196 9463318 the DT B-NP O
30 197 208 9463318 methylation NN I-NP O
31 209 216 9463318 pattern NN I-NP O
32 217 219 9463318 on IN B-PP O
33 220 223 9463318 the DT B-NP O
34 224 225 9463318 5 CD I-NP O
35 226 230 9463318 side NN I-NP O
36 231 233 9463318 of IN B-PP O
37 234 237 9463318 the DT B-NP O
38 238 241 9463318 CTG NN I-NP O
39 242 248 9463318 repeat NN I-NP O
40 249 251 9463318 in IN B-PP O
41 252 255 9463318 the DT B-NP O
42 256 260 9463318 DMPK NN I-NP O
43 261 265 9463318 gene NN I-NP O
44 266 268 9463318 of IN B-PP O
45 269 275 9463318 normal JJ B-NP O
46 276 287 9463318 individuals NNS I-NP O
47 288 291 9463318 and CC B-PP O
48 292 294 9463318 of IN B-PP O
49 295 303 9463318 patients NNS B-NP O
50 304 312 9463318 affected VBN B-VP O
51 313 317 9463318 with IN B-PP O
52 318 326 9463318 myotonic JJ B-NP B-Disease
53 327 336 9463318 dystrophy NN I-NP I-Disease
54 336 337 9463318 , , O O
55 338 345 9463318 showing VBG B-VP O
56 346 356 9463318 expansions NNS B-NP O
57 357 359 9463318 of IN B-PP O
58 360 363 9463318 the DT B-NP O
59 364 374 9463318 repetitive JJ I-NP O
60 375 383 9463318 sequence NN I-NP O
61 383 384 9463318 . . O O

1 385 388 9463318 The DT B-NP O
2 389 393 9463318 gene NN I-NP O
3 394 401 9463318 segment NN I-NP O
4 402 410 9463318 analyzed VBN B-VP O
5 411 422 9463318 corresponds VBZ B-VP O
6 423 425 9463318 to TO B-PP O
7 426 429 9463318 the DT B-NP O
8 430 437 9463318 genomic JJ I-NP O
9 438 442 9463318 SacI NN I-NP O
10 442 443 9463318 - HYPH B-NP O
11 443 450 9463318 HindIII NN I-NP O
12 451 459 9463318 fragment NN I-NP O
13 460 468 9463318 carrying VBG B-VP O
14 469 474 9463318 exons NNS B-NP O
15 475 477 9463318 11 CD B-NP O
16 477 478 9463318 - : O O
17 478 480 9463318 15 CD B-NP O
18 480 481 9463318 . . O O

1 482 487 9463318 There EX B-NP O
2 488 490 9463318 is VBZ B-VP O
3 491 503 9463318 constitutive JJ B-NP O
4 504 515 9463318 methylation NN I-NP O
5 516 518 9463318 in IN B-PP O
6 519 525 9463318 intron NN B-NP O
7 526 528 9463318 12 CD I-NP O
8 529 531 9463318 at IN B-PP O
9 532 543 9463318 restriction NN B-NP O
10 544 549 9463318 sites NNS I-NP O
11 550 552 9463318 of IN B-PP O
12 553 558 9463318 SacII NN B-NP O
13 559 562 9463318 and CC I-NP O
14 563 567 9463318 HhaI NN I-NP O
15 567 568 9463318 , , O O
16 569 578 9463318 localized VBD B-VP O
17 579 580 9463318 1 CD B-NP O
18 580 581 9463318 , , I-NP O
19 582 585 9463318 159 CD I-NP O
20 585 586 9463318 - HYPH B-NP O
21 586 587 9463318 1 CD I-NP O
22 587 588 9463318 , , I-NP O
23 589 592 9463318 232 CD I-NP O
24 593 595 9463318 bp NN I-NP O
25 596 604 9463318 upstream RB B-ADVP O
26 605 607 9463318 of IN B-PP O
27 608 611 9463318 the DT B-NP O
28 612 615 9463318 CTG NN I-NP O
29 616 622 9463318 repeat NN I-NP O
30 622 623 9463318 , , O O
31 624 631 9463318 whereas IN O O
32 632 636 9463318 most JJS O O
33 636 637 9463318 , , O O
34 638 640 9463318 if IN B-SBAR O
35 641 644 9463318 not RB B-NP O
36 645 648 9463318 all DT I-NP O
37 648 649 9463318 , , O O
38 650 652 9463318 of IN B-PP O
39 653 656 9463318 the DT B-NP O
40 657 662 9463318 other JJ I-NP O
41 663 668 9463318 sites NNS I-NP O
42 669 671 9463318 of IN B-PP O
43 672 677 9463318 SacII NN B-NP O
44 677 678 9463318 , , O O
45 679 683 9463318 HhaI NN B-NP O
46 683 684 9463318 , , O O
47 685 688 9463318 and CC O O
48 689 694 9463318 HpaII NN B-NP O
49 695 697 9463318 in IN B-PP O
50 698 702 9463318 this DT B-NP O
51 703 709 9463318 region NN I-NP O
52 710 713 9463318 are VBP B-VP O
53 714 726 9463318 unmethylated VBN I-VP O
54 726 727 9463318 , , O O
55 728 730 9463318 in IN B-PP O
56 731 737 9463318 normal JJ B-NP O
57 738 749 9463318 individuals NNS I-NP O
58 750 753 9463318 and CC O O
59 754 758 9463318 most JJS B-NP O
60 759 761 9463318 of IN B-PP O
61 762 765 9463318 the DT B-NP O
62 766 774 9463318 patients NNS I-NP O
63 774 775 9463318 . . O O

1 776 778 9463318 In IN B-PP O
2 779 780 9463318 a DT B-NP O
3 781 787 9463318 number NN I-NP O
4 788 790 9463318 of IN B-PP O
5 791 796 9463318 young JJ O O
6 797 800 9463318 and CC O O
7 801 809 9463318 severely RB B-VP O
8 810 818 9463318 affected VBN I-VP O
9 819 827 9463318 patients NNS B-NP O
10 827 828 9463318 , , O O
11 829 836 9463318 however RB B-ADVP O
12 836 837 9463318 , , O O
13 838 846 9463318 complete JJ B-NP O
14 847 858 9463318 methylation NN I-NP O
15 859 861 9463318 of IN B-PP O
16 862 867 9463318 these DT B-NP O
17 868 879 9463318 restriction NN I-NP O
18 880 885 9463318 sites NNS I-NP O
19 886 889 9463318 was VBD B-VP O
20 890 895 9463318 found VBN I-VP O
21 896 898 9463318 in IN B-PP O
22 899 902 9463318 the DT B-NP O
23 903 910 9463318 mutated VBN I-NP O
24 911 917 9463318 allele NN I-NP O
25 917 918 9463318 . . O O

1 919 921 9463318 In IN B-PP O
2 922 926 9463318 most JJS B-NP O
3 927 929 9463318 of IN B-PP O
4 930 935 9463318 these DT B-NP O
5 936 944 9463318 patients NNS I-NP O
6 944 945 9463318 , , O O
7 946 949 9463318 the DT B-NP O
8 950 955 9463318 onset NN I-NP O
9 956 958 9463318 of IN B-PP O
10 959 962 9463318 the DT B-NP O
11 963 970 9463318 disease NN I-NP O
12 971 974 9463318 was VBD B-VP O
13 975 985 9463318 congenital JJ B-ADJP O
14 985 986 9463318 . . O O

1 987 998 9463318 Preliminary JJ B-NP O
2 999 1001 9463318 in FW I-NP O
3 1002 1006 9463318 vivo FW I-NP O
4 1007 1019 9463318 footprinting NN I-NP O
5 1020 1024 9463318 data NNS I-NP O
6 1025 1029 9463318 gave VBD B-VP O
7 1030 1038 9463318 evidence NN B-NP O
8 1039 1042 9463318 for IN B-PP O
9 1043 1050 9463318 protein NN B-NP O
10 1050 1051 9463318 - HYPH B-NP O
11 1051 1054 9463318 DNA NN I-NP O
12 1055 1062 9463318 contact NN I-NP O
13 1063 1065 9463318 in IN B-PP O
14 1066 1072 9463318 normal JJ B-NP O
15 1073 1078 9463318 genes NNS I-NP O
16 1079 1081 9463318 at IN B-PP O
17 1082 1084 9463318 an DT B-NP O
18 1085 1088 9463318 Sp1 NN I-NP O
19 1089 1098 9463318 consensus NN I-NP O
20 1099 1106 9463318 binding NN I-NP O
21 1107 1111 9463318 site NN I-NP O
22 1112 1120 9463318 upstream JJ B-ADJP O
23 1121 1123 9463318 of IN B-PP O
24 1124 1127 9463318 the DT B-NP O
25 1128 1131 9463318 CTG NN I-NP O
26 1132 1138 9463318 repeat NN I-NP O
27 1139 1142 9463318 and CC B-PP O
28 1143 1146 9463318 for IN B-PP O
29 1147 1148 9463318 a DT B-NP O
30 1149 1160 9463318 significant JJ I-NP O
31 1161 1170 9463318 reduction NN I-NP O
32 1171 1173 9463318 of IN B-PP O
33 1174 1178 9463318 this DT B-NP O
34 1179 1190 9463318 interaction NN I-NP O
35 1191 1193 9463318 in IN B-PP O
36 1194 1199 9463318 cells NNS B-NP O
37 1200 1204 9463318 with IN B-PP O
38 1205 1206 9463318 a DT B-NP O
39 1207 1222 9463318 hypermethylated VBN I-NP O
40 1223 1227 9463318 DMPK NN I-NP O
41 1228 1232 9463318 gene NN I-NP O
42 1232 1233 9463318 . . O O
43 1233 1234 9463318 . . O O

1 0 0 9382108 -DOCSTART- -X- -X- O

1 0 4 9382108 Risk NN B-NP O
2 5 14 9382108 reversals NNS I-NP O
3 15 17 9382108 in IN B-PP O
4 18 28 9382108 predictive JJ B-NP O
5 29 36 9382108 testing NN I-NP O
6 37 40 9382108 for IN B-PP O
7 41 51 9382108 Huntington NNP B-NP B-Disease
8 52 59 9382108 disease NN I-NP I-Disease
9 59 60 9382108 . . O O
10 61 64 9382108 The DT B-NP O
11 65 70 9382108 first JJ I-NP O
12 71 81 9382108 predictive JJ I-NP O
13 82 89 9382108 testing NN I-NP O
14 90 93 9382108 for IN B-PP O
15 94 104 9382108 Huntington NNP B-NP B-Disease
16 105 112 9382108 disease NN I-NP I-Disease
17 113 114 9382108 ( ( O O
18 114 116 9382108 HD NN B-NP B-Disease
19 116 117 9382108 ) ) O O
20 118 121 9382108 was VBD B-VP O
21 122 127 9382108 based VBN I-VP O
22 128 130 9382108 on IN B-PP O
23 131 139 9382108 analysis NN B-NP O
24 140 142 9382108 of IN B-PP O
25 143 149 9382108 linked VBN B-NP O
26 150 161 9382108 polymorphic JJ I-NP O
27 162 165 9382108 DNA NN I-NP O
28 166 173 9382108 markers NNS I-NP O
29 174 176 9382108 to TO B-VP O
30 177 185 9382108 estimate VB I-VP O
31 186 189 9382108 the DT B-NP O
32 190 200 9382108 likelihood NN I-NP O
33 201 203 9382108 of IN B-PP O
34 204 214 9382108 inheriting VBG B-VP O
35 215 218 9382108 the DT B-NP O
36 219 227 9382108 mutation NN I-NP O
37 228 231 9382108 for IN B-PP O
38 232 234 9382108 HD NN B-NP B-Disease
39 234 235 9382108 . . O O

1 236 242 9382108 Limits NNS B-NP O
2 243 245 9382108 to TO B-PP O
3 246 254 9382108 accuracy NN B-NP O
4 255 263 9382108 included VBD B-VP O
5 264 277 9382108 recombination NN B-NP O
6 278 285 9382108 between IN B-PP O
7 286 289 9382108 the DT B-NP O
8 290 293 9382108 DNA NN I-NP O
9 294 301 9382108 markers NNS I-NP O
10 302 305 9382108 and CC O O
11 306 309 9382108 the DT B-NP O
12 310 318 9382108 mutation NN I-NP O
13 318 319 9382108 , , O O
14 320 328 9382108 pedigree NN B-NP O
15 329 338 9382108 structure NN I-NP O
16 338 339 9382108 , , O O
17 340 343 9382108 and CC O O
18 344 351 9382108 whether IN B-SBAR O
19 352 355 9382108 DNA NN B-NP O
20 356 363 9382108 samples NNS I-NP O
21 364 368 9382108 were VBD B-VP O
22 369 378 9382108 available JJ B-ADJP O
23 379 383 9382108 from IN B-PP O
24 384 390 9382108 family NN B-NP O
25 391 398 9382108 members NNS I-NP O
26 398 399 9382108 . . O O

1 400 404 9382108 With IN B-PP O
2 405 411 9382108 direct JJ B-NP O
3 412 417 9382108 tests NNS I-NP O
4 418 421 9382108 for IN B-PP O
5 422 425 9382108 the DT B-NP O
6 426 428 9382108 HD NN I-NP B-Disease
7 429 437 9382108 mutation NN I-NP O
8 437 438 9382108 , , O O
9 439 441 9382108 we PRP B-NP O
10 442 446 9382108 have VBP B-VP O
11 447 455 9382108 assessed VBN I-VP O
12 456 459 9382108 the DT B-NP O
13 460 468 9382108 accuracy NN I-NP O
14 469 471 9382108 of IN B-PP O
15 472 479 9382108 results NNS B-NP O
16 480 488 9382108 obtained VBN B-VP O
17 489 491 9382108 by IN B-PP O
18 492 499 9382108 linkage NN B-NP O
19 500 510 9382108 approaches NNS I-NP O
20 511 515 9382108 when WRB B-ADVP O
21 516 525 9382108 requested VBN B-VP O
22 526 528 9382108 to TO B-VP O
23 529 531 9382108 do VB I-VP O
24 532 534 9382108 so RB B-ADVP O
25 535 537 9382108 by IN B-PP O
26 538 541 9382108 the DT B-NP O
27 542 546 9382108 test NN I-NP O
28 547 558 9382108 individuals NNS I-NP O
29 558 559 9382108 . . O O

1 560 563 9382108 For IN B-PP O
2 564 567 9382108 six CD B-NP O
3 568 572 9382108 such JJ I-NP O
4 573 584 9382108 individuals NNS I-NP O
5 584 585 9382108 , , O O
6 586 591 9382108 there EX B-NP O
7 592 595 9382108 was VBD B-VP O
8 596 607 9382108 significant JJ B-NP O
9 608 617 9382108 disparity NN I-NP O
10 618 625 9382108 between IN B-PP O
11 626 629 9382108 the DT B-NP O
12 630 635 9382108 tests NNS I-NP O
13 635 636 9382108 . . O O

1 637 642 9382108 Three CD B-NP O
2 643 647 9382108 went VBD B-VP O
3 648 652 9382108 from IN B-PP O
4 653 654 9382108 a DT B-NP O
5 655 664 9382108 decreased VBN I-NP O
6 665 669 9382108 risk NN I-NP O
7 670 672 9382108 to TO B-PP O
8 673 675 9382108 an DT B-NP O
9 676 685 9382108 increased VBN I-NP O
10 686 690 9382108 risk NN I-NP O
11 690 691 9382108 , , O O
12 692 697 9382108 while IN B-SBAR O
13 698 700 9382108 in IN B-PP O
14 701 708 9382108 another DT B-NP O
15 709 714 9382108 three CD I-NP O
16 715 718 9382108 the DT B-NP O
17 719 723 9382108 risk NN I-NP O
18 724 727 9382108 was VBD B-VP O
19 728 737 9382108 decreased VBN I-VP O
20 737 738 9382108 . . O O

1 739 748 9382108 Knowledge NN B-NP O
2 749 751 9382108 of IN B-PP O
3 752 755 9382108 the DT B-NP O
4 756 765 9382108 potential JJ I-NP O
5 766 773 9382108 reasons NNS I-NP O
6 774 777 9382108 for IN B-PP O
7 778 783 9382108 these DT B-NP O
8 784 791 9382108 changes NNS I-NP O
9 792 794 9382108 in IN B-PP O
10 795 802 9382108 results NNS B-NP O
11 803 806 9382108 and CC I-NP O
12 807 813 9382108 impact NN I-NP O
13 814 816 9382108 of IN B-PP O
14 817 822 9382108 these DT B-NP O
15 823 827 9382108 risk NN I-NP O
16 828 837 9382108 reversals NNS I-NP O
17 838 840 9382108 on IN B-PP O
18 841 845 9382108 both DT B-NP O
19 846 854 9382108 patients NNS I-NP O
20 855 858 9382108 and CC O O
21 859 862 9382108 the DT B-NP O
22 863 873 9382108 counseling NN I-NP O
23 874 878 9382108 team NN I-NP O
24 879 882 9382108 can MD B-VP O
25 883 889 9382108 assist VB I-VP O
26 890 892 9382108 in IN B-PP O
27 893 896 9382108 the DT B-NP O
28 897 908 9382108 development NN I-NP O
29 909 911 9382108 of IN B-PP O
30 912 922 9382108 strategies NNS B-NP O
31 923 926 9382108 for IN B-PP O
32 927 930 9382108 the DT B-NP O
33 931 941 9382108 prevention NN I-NP O
34 942 945 9382108 and CC O O
35 945 946 9382108 , , O O
36 947 952 9382108 where WRB B-ADVP O
37 953 962 9382108 necessary JJ B-ADJP O
38 962 963 9382108 , , O O
39 964 974 9382108 management NN B-NP O
40 975 977 9382108 of IN B-PP O
41 978 979 9382108 a DT B-NP O
42 980 984 9382108 risk NN I-NP O
43 985 993 9382108 reversal NN I-NP O
44 994 996 9382108 in IN B-PP O
45 997 1000 9382108 any DT B-NP O
46 1001 1011 9382108 predictive JJ I-NP O
47 1012 1019 9382108 testing NN I-NP O
48 1020 1027 9382108 program NN I-NP O
49 1027 1028 9382108 . . O O
50 1028 1029 9382108 . . O O

1 0 0 9603435 -DOCSTART- -X- -X- O

1 0 5 9603435 W474C NN B-NP O
2 6 11 9603435 amino JJ I-NP O
3 12 16 9603435 acid NN I-NP O
4 17 29 9603435 substitution NN I-NP O
5 30 37 9603435 affects VBZ B-VP O
6 38 43 9603435 early JJ B-NP O
7 44 54 9603435 processing NN I-NP O
8 55 57 9603435 of IN B-PP O
9 58 61 9603435 the DT B-NP O
10 62 67 9603435 alpha SYM I-NP O
11 67 68 9603435 - HYPH I-NP O
12 68 75 9603435 subunit NN I-NP O
13 76 78 9603435 of IN B-PP O
14 79 83 9603435 beta SYM B-NP O
15 83 84 9603435 - HYPH I-NP O
16 84 98 9603435 hexosaminidase NN I-NP O
17 99 100 9603435 A NN I-NP O
18 101 104 9603435 and CC O O
19 105 107 9603435 is VBZ B-VP O
20 108 118 9603435 associated VBN I-VP O
21 119 123 9603435 with IN B-PP O
22 124 132 9603435 subacute JJ B-NP O
23 133 138 9603435 G(M2) NN I-NP B-Disease
24 139 153 9603435 gangliosidosis NN I-NP I-Disease
25 153 154 9603435 . . O O
26 155 164 9603435 Mutations NNS B-NP O
27 165 167 9603435 in IN B-PP O
28 168 171 9603435 the DT B-NP O
29 172 176 9603435 HEXA NN I-NP O
30 177 181 9603435 gene NN I-NP O
31 181 182 9603435 , , O O
32 183 191 9603435 encoding VBG B-VP O
33 192 195 9603435 the DT B-NP O
34 196 201 9603435 alpha SYM I-NP O
35 201 202 9603435 - HYPH I-NP O
36 202 209 9603435 subunit NN I-NP O
37 210 212 9603435 of IN B-PP O
38 213 217 9603435 beta SYM B-NP O
39 217 218 9603435 - HYPH O O
40 218 232 9603435 hexosaminidase NN B-NP O
41 233 234 9603435 A NN I-NP O
42 235 236 9603435 ( ( O O
43 236 239 9603435 Hex NN B-NP O
44 240 241 9603435 A NN I-NP O
45 241 242 9603435 ) ) O O
46 242 243 9603435 , , O O
47 244 248 9603435 that WDT B-NP O
48 249 256 9603435 abolish VBP B-VP O
49 257 260 9603435 Hex NNP B-NP O
50 261 262 9603435 A NNP I-NP O
51 263 269 9603435 enzyme NN I-NP O
52 270 278 9603435 activity NN I-NP O
53 279 284 9603435 cause VBP B-VP O
54 285 288 9603435 Tay NNP B-NP B-Disease
55 288 289 9603435 - HYPH I-NP I-Disease
56 289 294 9603435 Sachs NNP I-NP I-Disease
57 295 302 9603435 disease NN I-NP I-Disease
58 303 304 9603435 ( ( O O
59 304 307 9603435 TSD NN B-NP B-Disease
60 307 308 9603435 ) ) O O
61 308 309 9603435 , , O O
62 310 313 9603435 the DT B-NP O
63 314 319 9603435 fatal JJ I-NP O
64 320 329 9603435 infantile JJ I-NP B-Disease
65 330 334 9603435 form NN I-NP I-Disease
66 335 337 9603435 of IN B-PP I-Disease
67 338 339 9603435 G NN B-NP I-Disease
68 340 341 9603435 ( ( O I-Disease
69 341 343 9603435 M2 NN B-NP I-Disease
70 343 344 9603435 ) ) O I-Disease
71 345 359 9603435 gangliosidosis NN B-NP I-Disease
72 359 360 9603435 , , O I-Disease
73 361 365 9603435 Type NN B-NP I-Disease
74 366 367 9603435 1 CD I-NP I-Disease
75 367 368 9603435 . . O O

1 369 373 9603435 Less RBR B-ADJP O
2 374 380 9603435 severe JJ I-ADJP O
3 380 381 9603435 , , O O
4 382 390 9603435 subacute JJ O O
5 391 392 9603435 ( ( O O
6 392 400 9603435 juvenile JJ B-NP O
7 400 401 9603435 - HYPH I-NP O
8 401 406 9603435 onset NN I-NP O
9 406 407 9603435 ) ) O O
10 408 411 9603435 and CC O O
11 412 419 9603435 chronic JJ O O
12 420 421 9603435 ( ( O O
13 421 426 9603435 adult JJ B-NP O
14 426 427 9603435 - HYPH I-NP O
15 427 432 9603435 onset NN I-NP O
16 432 433 9603435 ) ) O O
17 434 442 9603435 variants NNS B-NP O
18 443 446 9603435 are VBP B-VP O
19 447 460 9603435 characterized VBN I-VP O
20 461 463 9603435 by IN B-PP O
21 464 465 9603435 a DT B-NP O
22 466 471 9603435 broad JJ I-NP O
23 472 480 9603435 spectrum NN I-NP O
24 481 483 9603435 of IN B-PP O
25 484 492 9603435 clinical JJ B-NP O
26 493 507 9603435 manifestations NNS I-NP O
27 508 511 9603435 and CC O O
28 512 515 9603435 are VBP B-VP O
29 516 526 9603435 associated VBN I-VP O
30 527 531 9603435 with IN B-PP O
31 532 540 9603435 residual JJ B-NP O
32 541 547 9603435 levels NNS I-NP O
33 548 550 9603435 of IN B-PP O
34 551 554 9603435 Hex NNP B-NP O
35 555 556 9603435 A NNP I-NP O
36 557 563 9603435 enzyme NN I-NP O
37 564 572 9603435 activity NN I-NP O
38 572 573 9603435 . . O O

1 574 576 9603435 We PRP B-NP O
2 577 587 9603435 identified VBD B-VP O
3 588 589 9603435 a DT B-NP O
4 590 594 9603435 1422 CD I-NP O
5 595 596 9603435 G NN I-NP O
6 596 597 9603435 - SYM O O
7 597 598 9603435 - HYPH O O
8 599 600 9603435 > SYM O O
9 601 602 9603435 C NN B-NP O
10 603 604 9603435 ( ( O O
11 604 609 9603435 amino NN B-NP O
12 610 614 9603435 acid NN I-NP O
13 615 620 9603435 W474C NN I-NP O
14 620 621 9603435 ) ) O O
15 622 634 9603435 substitution NN B-NP O
16 635 637 9603435 in IN B-PP O
17 638 641 9603435 the DT B-NP O
18 642 647 9603435 first JJ I-NP O
19 648 656 9603435 position NN I-NP O
20 657 659 9603435 of IN B-PP O
21 660 664 9603435 exon NN B-NP O
22 665 667 9603435 13 CD I-NP O
23 668 670 9603435 of IN B-PP O
24 671 675 9603435 HEXA NN B-NP O
25 676 678 9603435 of IN B-PP O
26 679 680 9603435 a DT B-NP O
27 681 684 9603435 non AFX I-NP O
28 684 685 9603435 - HYPH I-NP O
29 685 691 9603435 Jewish JJ I-NP O
30 692 699 9603435 proband NN I-NP O
31 700 703 9603435 who WP B-NP O
32 704 714 9603435 manifested VBD B-VP O
33 715 716 9603435 a DT B-NP O
34 717 725 9603435 subacute JJ I-NP O
35 726 733 9603435 variant NN I-NP O
36 734 736 9603435 of IN B-PP O
37 737 738 9603435 G NN B-NP B-Disease
38 739 740 9603435 ( ( O I-Disease
39 740 742 9603435 M2 NN B-NP I-Disease
40 742 743 9603435 ) ) O I-Disease
41 744 758 9603435 gangliosidosis NN B-NP I-Disease
42 758 759 9603435 . . O O

1 760 762 9603435 On IN B-PP O
2 763 766 9603435 the DT B-NP O
3 767 773 9603435 second JJ I-NP O
4 774 784 9603435 maternally RB I-NP O
5 785 794 9603435 inherited VBN I-NP O
6 795 801 9603435 allele NN I-NP O
7 801 802 9603435 , , O O
8 803 805 9603435 we PRP B-NP O
9 806 816 9603435 identified VBD B-VP O
10 817 820 9603435 the DT B-NP O
11 821 827 9603435 common JJ I-NP O
12 828 837 9603435 infantile JJ I-NP O
13 838 845 9603435 disease NN I-NP O
14 845 846 9603435 - HYPH O O
15 846 853 9603435 causing VBG B-VP O
16 854 855 9603435 4 CD B-NP O
17 855 856 9603435 - HYPH I-NP O
18 856 858 9603435 bp NN I-NP O
19 859 868 9603435 insertion NN I-NP O
20 868 869 9603435 , , O O
21 870 871 9603435 + SYM O O
22 872 876 9603435 TATC NN B-NP O
23 877 881 9603435 1278 CD I-NP O
24 881 882 9603435 , , O O
25 883 885 9603435 in IN B-PP O
26 886 890 9603435 exon NN B-NP O
27 891 893 9603435 11 CD I-NP O
28 893 894 9603435 . . O O

1 895 900 9603435 Pulse NN B-NP O
2 900 901 9603435 - HYPH I-NP O
3 901 906 9603435 chase NN I-NP O
4 907 915 9603435 analysis NN I-NP O
5 916 921 9603435 using VBG B-VP O
6 922 929 9603435 proband NN B-NP O
7 930 941 9603435 fibroblasts NNS I-NP O
8 942 950 9603435 revealed VBD B-VP O
9 951 955 9603435 that IN B-SBAR O
10 956 959 9603435 the DT B-NP O
11 960 965 9603435 W474C NN I-NP O
12 965 966 9603435 - HYPH O O
13 966 976 9603435 containing VBG B-VP O
14 977 982 9603435 alpha SYM B-NP O
15 982 983 9603435 - HYPH B-NP O
16 983 990 9603435 subunit NN I-NP O
17 991 1000 9603435 precursor NN I-NP O
18 1001 1004 9603435 was VBD B-VP O
19 1005 1013 9603435 normally RB I-VP O
20 1014 1025 9603435 synthesized VBN I-VP O
21 1025 1026 9603435 , , O O
22 1027 1030 9603435 but CC O O
23 1031 1034 9603435 not RB B-VP O
24 1035 1049 9603435 phosphorylated VBN I-VP O
25 1050 1052 9603435 or CC I-VP O
26 1053 1061 9603435 secreted VBN I-VP O
27 1061 1062 9603435 , , O O
28 1063 1066 9603435 and CC O O
29 1067 1070 9603435 the DT B-NP O
30 1071 1077 9603435 mature JJ I-NP O
31 1078 1087 9603435 lysosomal JJ I-NP O
32 1088 1093 9603435 alpha SYM I-NP O
33 1093 1094 9603435 - HYPH I-NP O
34 1094 1101 9603435 subunit NN B-NP O
35 1102 1105 9603435 was VBD B-VP O
36 1106 1109 9603435 not RB I-VP O
37 1110 1118 9603435 detected VBN I-VP O
38 1118 1119 9603435 . . O O

1 1120 1124 9603435 When WRB B-ADVP O
2 1125 1128 9603435 the DT B-NP O
3 1129 1134 9603435 W474C NN I-NP O
4 1134 1135 9603435 - HYPH O O
5 1135 1145 9603435 containing VBG B-VP O
6 1146 1151 9603435 alpha SYM B-NP O
7 1151 1152 9603435 - HYPH O O
8 1152 1159 9603435 subunit NN B-NP O
9 1160 1163 9603435 was VBD B-VP O
10 1164 1175 9603435 transiently RB B-ADVP O
11 1176 1178 9603435 co AFX B-ADJP O
12 1178 1179 9603435 - HYPH O O
13 1179 1188 9603435 expressed VBN B-VP O
14 1189 1193 9603435 with IN B-PP O
15 1194 1197 9603435 the DT B-NP O
16 1198 1202 9603435 beta SYM I-NP O
17 1202 1203 9603435 - HYPH I-NP O
18 1203 1210 9603435 subunit NN I-NP O
19 1211 1213 9603435 to TO B-VP O
20 1214 1221 9603435 produce VB I-VP O
21 1222 1225 9603435 Hex NN B-NP O
22 1226 1227 9603435 A NN I-NP O
23 1228 1229 9603435 ( ( O O
24 1229 1238 9603435 alphabeta NN B-NP O
25 1238 1239 9603435 ) ) O O
26 1240 1242 9603435 in IN B-PP O
27 1243 1246 9603435 COS NN B-NP O
28 1246 1247 9603435 - HYPH B-NP O
29 1247 1248 9603435 7 CD I-NP O
30 1249 1254 9603435 cells NNS I-NP O
31 1254 1255 9603435 , , O O
32 1256 1259 9603435 the DT B-NP O
33 1260 1266 9603435 mature JJ I-NP O
34 1267 1272 9603435 alpha SYM I-NP O
35 1272 1273 9603435 - HYPH I-NP O
36 1273 1280 9603435 subunit NN B-NP O
37 1281 1284 9603435 was VBD B-VP O
38 1285 1292 9603435 present JJ B-ADJP O
39 1292 1293 9603435 , , O O
40 1294 1297 9603435 but CC O O
41 1298 1301 9603435 its PRP$ B-NP O
42 1302 1307 9603435 level NN I-NP O
43 1308 1311 9603435 was VBD B-VP O
44 1312 1316 9603435 much RB B-ADJP O
45 1317 1322 9603435 lower JJR I-ADJP O
46 1323 1327 9603435 than IN B-PP O
47 1328 1332 9603435 that DT B-NP O
48 1333 1337 9603435 from IN B-PP O
49 1338 1344 9603435 normal JJ B-NP O
50 1345 1350 9603435 alpha SYM I-NP O
51 1350 1351 9603435 - HYPH I-NP O
52 1351 1358 9603435 subunit NN I-NP O
53 1359 1372 9603435 transfections NNS I-NP O
54 1372 1373 9603435 , , O O
55 1374 1382 9603435 although IN B-SBAR O
56 1383 1389 9603435 higher JJR B-ADJP O
57 1390 1394 9603435 than IN B-PP O
58 1395 1397 9603435 in IN B-PP O
59 1398 1403 9603435 those DT B-NP O
60 1404 1409 9603435 cells NNS I-NP O
61 1410 1421 9603435 transfected VBN B-VP O
62 1422 1426 9603435 with IN B-PP O
63 1427 1429 9603435 an DT B-NP O
64 1430 1435 9603435 alpha SYM I-NP O
65 1435 1436 9603435 - HYPH I-NP O
66 1436 1443 9603435 subunit NN I-NP O
67 1444 1454 9603435 associated VBN B-VP O
68 1455 1459 9603435 with IN B-PP O
69 1460 1469 9603435 infantile JJ B-NP O
70 1470 1473 9603435 TSD NN I-NP B-Disease
71 1473 1474 9603435 . . O O

1 1475 1486 9603435 Furthermore RB B-ADVP O
2 1486 1487 9603435 , , O O
3 1488 1491 9603435 the DT B-NP O
4 1492 1501 9603435 precursor NN I-NP O
5 1502 1507 9603435 level NN I-NP O
6 1508 1510 9603435 of IN B-PP O
7 1511 1514 9603435 the DT B-NP O
8 1515 1520 9603435 W474C NN I-NP O
9 1521 1526 9603435 alpha SYM O O
10 1526 1527 9603435 - HYPH O O
11 1527 1534 9603435 subunit NN B-NP O
12 1535 1538 9603435 was VBD B-VP O
13 1539 1544 9603435 found VBN I-VP O
14 1545 1547 9603435 to TO I-VP O
15 1548 1558 9603435 accumulate VB I-VP O
16 1559 1561 9603435 in IN B-PP O
17 1562 1572 9603435 comparison NN B-NP O
18 1573 1575 9603435 to TO B-PP O
19 1576 1579 9603435 the DT B-NP O
20 1580 1586 9603435 normal JJ I-NP O
21 1587 1592 9603435 alpha SYM I-NP O
22 1592 1593 9603435 - HYPH I-NP O
23 1593 1600 9603435 subunit NN I-NP O
24 1601 1610 9603435 precursor NN I-NP O
25 1611 1617 9603435 levels NNS I-NP O
26 1617 1618 9603435 . . O O

1 1619 1621 9603435 We PRP B-NP O
2 1622 1630 9603435 conclude VBP B-VP O
3 1631 1635 9603435 that IN B-SBAR O
4 1636 1639 9603435 the DT B-NP O
5 1640 1644 9603435 1422 CD I-NP O
6 1645 1646 9603435 G NN I-NP O
7 1646 1647 9603435 - SYM B-NP O
8 1647 1648 9603435 - HYPH B-NP O
9 1649 1650 9603435 > SYM I-NP O
10 1651 1652 9603435 C NN I-NP O
11 1653 1661 9603435 mutation NN I-NP O
12 1662 1664 9603435 is VBZ B-VP O
13 1665 1668 9603435 the DT B-NP O
14 1669 1674 9603435 cause NN I-NP O
15 1675 1677 9603435 of IN B-PP O
16 1678 1681 9603435 Hex NNP B-NP B-Disease
17 1682 1683 9603435 A NNP I-NP I-Disease
18 1684 1690 9603435 enzyme NN I-NP I-Disease
19 1691 1701 9603435 deficiency NN I-NP I-Disease
20 1702 1704 9603435 in IN B-PP O
21 1705 1708 9603435 the DT B-NP O
22 1709 1716 9603435 proband NN I-NP O
23 1716 1717 9603435 . . O O

1 1718 1721 9603435 The DT B-NP O
2 1722 1731 9603435 resulting VBG I-NP O
3 1732 1737 9603435 W474C NN I-NP O
4 1738 1750 9603435 substitution NN I-NP O
5 1751 1758 9603435 clearly RB B-ADVP O
6 1759 1769 9603435 interferes VBZ B-VP O
7 1770 1774 9603435 with IN B-PP O
8 1775 1780 9603435 alpha SYM B-NP O
9 1780 1781 9603435 - HYPH I-NP O
10 1781 1788 9603435 subunit NN I-NP O
11 1789 1799 9603435 processing NN I-NP O
12 1799 1800 9603435 , , O O
13 1801 1804 9603435 but CC O O
14 1805 1812 9603435 because IN B-SBAR O
15 1813 1816 9603435 the DT B-NP O
16 1817 1821 9603435 base NN I-NP O
17 1822 1834 9603435 substitution NN I-NP O
18 1835 1840 9603435 falls VBZ B-VP O
19 1841 1843 9603435 at IN B-PP O
20 1844 1847 9603435 the DT B-NP O
21 1848 1853 9603435 first JJ I-NP O
22 1854 1862 9603435 position NN I-NP O
23 1863 1865 9603435 of IN B-PP O
24 1866 1870 9603435 exon NN B-NP O
25 1871 1873 9603435 13 CD I-NP O
26 1873 1874 9603435 , , O O
27 1875 1883 9603435 aberrant JJ B-NP O
28 1884 1892 9603435 splicing NN I-NP O
29 1893 1896 9603435 may MD B-VP O
30 1897 1901 9603435 also RB I-VP O
31 1902 1912 9603435 contribute VB I-VP O
32 1913 1915 9603435 to TO B-PP O
33 1916 1919 9603435 Hex NNP B-NP B-Disease
34 1920 1921 9603435 A NNP I-NP I-Disease
35 1922 1932 9603435 deficiency NN I-NP I-Disease
36 1933 1935 9603435 in IN B-PP O
37 1936 1940 9603435 this DT B-NP O
38 1941 1948 9603435 proband NN I-NP O
39 1948 1949 9603435 . . O O
40 1949 1950 9603435 . . O O

1 0 0 9671401 -DOCSTART- -X- -X- O

1 0 1 9671401 A DT B-NP O
2 2 7 9671401 novel JJ I-NP O
3 8 16 9671401 missense JJ I-NP O
4 17 25 9671401 mutation NN I-NP O
5 26 28 9671401 in IN B-PP O
6 29 37 9671401 patients NNS B-NP O
7 38 42 9671401 from IN B-PP O
8 43 44 9671401 a DT B-NP O
9 45 59 9671401 retinoblastoma NN I-NP B-Disease
10 60 68 9671401 pedigree NN I-NP O
11 69 76 9671401 showing VBG B-VP O
12 77 81 9671401 only RB B-NP O
13 82 86 9671401 mild JJ I-NP O
14 87 97 9671401 expression NN I-NP O
15 98 100 9671401 of IN B-PP O
16 101 104 9671401 the DT B-NP O
17 105 110 9671401 tumor NN I-NP B-Disease
18 111 120 9671401 phenotype NN I-NP O
19 120 121 9671401 . . O O
20 122 124 9671401 We PRP B-NP O
21 125 129 9671401 have VBP B-VP O
22 130 134 9671401 used VBN I-VP O
23 135 141 9671401 single JJ B-NP O
24 142 148 9671401 strand NN I-NP O
25 149 161 9671401 conformation NN I-NP O
26 162 174 9671401 polymorphism NN I-NP O
27 175 183 9671401 analysis NN I-NP O
28 184 186 9671401 to TO B-VP O
29 187 192 9671401 study VB I-VP O
30 193 196 9671401 the DT B-NP O
31 197 199 9671401 27 CD I-NP O
32 200 205 9671401 exons NNS I-NP O
33 206 208 9671401 of IN B-PP O
34 209 212 9671401 the DT B-NP O
35 213 216 9671401 RB1 NN I-NP O
36 217 221 9671401 gene NN I-NP O
37 222 224 9671401 in IN B-PP O
38 225 236 9671401 individuals NNS B-NP O
39 237 241 9671401 from IN B-PP O
40 242 243 9671401 a DT B-NP O
41 244 250 9671401 family NN I-NP O
42 251 258 9671401 showing VBG B-VP O
43 259 263 9671401 mild JJ B-NP O
44 264 274 9671401 expression NN I-NP O
45 275 277 9671401 of IN B-PP O
46 278 281 9671401 the DT B-NP O
47 282 296 9671401 retinoblastoma NN I-NP B-Disease
48 297 306 9671401 phenotype NN I-NP O
49 306 307 9671401 . . O O

1 308 310 9671401 In IN B-PP O
2 311 315 9671401 this DT B-NP O
3 316 322 9671401 family NN I-NP O
4 323 331 9671401 affected VBD B-VP O
5 332 343 9671401 individuals NNS B-NP O
6 344 353 9671401 developed VBD B-VP O
7 354 364 9671401 unilateral JJ B-NP B-Disease
8 365 371 9671401 tumors NNS I-NP I-Disease
9 372 375 9671401 and CC O O
10 375 376 9671401 , , O O
11 377 379 9671401 as IN B-PP O
12 380 381 9671401 a DT B-NP O
13 382 388 9671401 result NN I-NP O
14 389 391 9671401 of IN B-PP O
15 392 399 9671401 linkage NN B-NP O
16 400 408 9671401 analysis NN I-NP O
17 408 409 9671401 , , O O
18 410 420 9671401 unaffected JJ B-NP O
19 421 429 9671401 mutation NN I-NP O
20 430 438 9671401 carriers NNS I-NP O
21 439 443 9671401 were VBD B-VP O
22 444 448 9671401 also RB I-VP O
23 449 459 9671401 identified VBN I-VP O
24 460 466 9671401 within IN B-PP O
25 467 470 9671401 the DT B-NP O
26 471 479 9671401 pedigree NN I-NP O
27 479 480 9671401 . . O O

1 481 482 9671401 A DT B-NP O
2 483 489 9671401 single JJ I-NP O
3 490 494 9671401 band NN I-NP O
4 495 500 9671401 shift NN I-NP O
5 501 506 9671401 using VBG B-VP O
6 507 511 9671401 SSCP NN B-NP O
7 512 515 9671401 was VBD B-VP O
8 516 526 9671401 identified VBN I-VP O
9 527 529 9671401 in IN B-PP O
10 530 534 9671401 exon NN B-NP O
11 535 537 9671401 21 CD I-NP O
12 538 543 9671401 which WDT B-NP O
13 544 552 9671401 resulted VBD B-VP O
14 553 555 9671401 in IN B-PP O
15 556 557 9671401 a DT B-NP O
16 558 566 9671401 missense JJ I-NP O
17 567 575 9671401 mutation NN I-NP O
18 576 586 9671401 converting VBG B-VP O
19 587 588 9671401 a DT B-NP O
20 589 592 9671401 cys NNS I-NP O
21 592 593 9671401 - SYM B-NP O
22 593 594 9671401 - HYPH B-NP O
23 595 596 9671401 > SYM I-NP O
24 597 600 9671401 arg NN I-NP O
25 601 603 9671401 at IN B-PP O
26 604 614 9671401 nucleotide NN B-NP O
27 615 623 9671401 position NN I-NP O
28 624 626 9671401 28 CD I-NP O
29 627 629 9671401 in IN B-PP O
30 630 633 9671401 the DT B-NP O
31 634 638 9671401 exon NN I-NP O
32 638 639 9671401 . . O O

1 640 643 9671401 The DT B-NP O
2 644 652 9671401 mutation NN I-NP O
3 653 662 9671401 destroyed VBD B-VP O
4 663 665 9671401 an DT B-NP O
5 666 670 9671401 NdeI NN I-NP O
6 671 682 9671401 restriction NN I-NP O
7 683 689 9671401 enzyme NN I-NP O
8 690 694 9671401 site NN I-NP O
9 694 695 9671401 . . O O

1 696 704 9671401 Analysis NN B-NP O
2 705 707 9671401 of IN B-PP O
3 708 711 9671401 all DT B-NP O
4 712 718 9671401 family NN I-NP O
5 719 726 9671401 members NNS I-NP O
6 727 739 9671401 demonstrated VBD B-VP O
7 740 744 9671401 that IN B-SBAR O
8 745 748 9671401 the DT B-NP O
9 749 757 9671401 missense JJ I-NP O
10 758 766 9671401 mutation NN I-NP O
11 767 769 9671401 co AFX O O
12 769 770 9671401 - HYPH O O
13 770 780 9671401 segregated VBN B-VP O
14 781 785 9671401 with IN B-PP O
15 786 794 9671401 patients NNS B-NP O
16 795 799 9671401 with IN B-PP O
17 800 806 9671401 tumors NNS B-NP B-Disease
18 807 809 9671401 or CC O O
19 810 813 9671401 who WP B-NP O
20 813 814 9671401 , , O O
21 815 817 9671401 as IN B-PP O
22 818 819 9671401 a DT B-NP O
23 820 826 9671401 result NN I-NP O
24 827 829 9671401 of IN B-PP O
25 830 837 9671401 linkage NN B-NP O
26 838 846 9671401 analysis NN I-NP O
27 847 850 9671401 had VBD B-VP O
28 851 855 9671401 been VBN I-VP O
29 856 865 9671401 predicted VBN I-VP O
30 866 868 9671401 to TO I-VP O
31 869 874 9671401 carry VB I-VP O
32 875 878 9671401 the DT B-NP O
33 879 891 9671401 predisposing VBG I-NP O
34 892 900 9671401 mutation NN I-NP O
35 900 901 9671401 . . O O

1 902 907 9671401 These DT B-NP O
2 908 920 9671401 observations NNS I-NP O
3 921 926 9671401 point VBP B-VP O
4 927 929 9671401 to TO B-PP O
5 930 937 9671401 another DT B-NP O
6 938 944 9671401 region NN I-NP O
7 945 947 9671401 of IN B-PP O
8 948 951 9671401 the DT B-NP O
9 952 955 9671401 RB1 NN I-NP O
10 956 960 9671401 gene NN I-NP O
11 961 966 9671401 where WRB B-ADVP O
12 967 976 9671401 mutations NNS B-NP O
13 977 981 9671401 only RB B-ADVP O
14 982 988 9671401 modify VBP B-VP O
15 989 992 9671401 the DT B-NP O
16 993 1001 9671401 function NN I-NP O
17 1002 1004 9671401 of IN B-PP O
18 1005 1008 9671401 the DT B-NP O
19 1009 1013 9671401 gene NN I-NP O
20 1014 1017 9671401 and CC O O
21 1018 1023 9671401 raise VB B-VP O
22 1024 1033 9671401 important JJ B-NP O
23 1034 1043 9671401 questions NNS I-NP O
24 1044 1047 9671401 for IN B-PP O
25 1048 1055 9671401 genetic JJ B-NP O
26 1056 1066 9671401 counseling NN I-NP O
27 1067 1069 9671401 in IN B-PP O
28 1070 1078 9671401 families NNS B-NP O
29 1079 1083 9671401 with IN B-PP O
30 1084 1089 9671401 these DT B-NP O
31 1090 1101 9671401 distinctive JJ I-NP O
32 1102 1112 9671401 phenotypes NNS I-NP O
33 1112 1113 9671401 . . O O
34 1113 1114 9671401 . . O O

1 0 0 9546397 -DOCSTART- -X- -X- O

1 0 7 9546397 Crystal JJ B-NP O
2 8 17 9546397 structure NN I-NP O
3 18 20 9546397 of IN B-PP O
4 21 24 9546397 the DT B-NP O
5 25 40 9546397 hemochromatosis NN I-NP B-Disease
6 41 48 9546397 protein NN I-NP O
7 49 52 9546397 HFE NN I-NP O
8 53 56 9546397 and CC O O
9 57 73 9546397 characterization NN B-NP O
10 74 76 9546397 of IN B-PP O
11 77 80 9546397 its PRP$ B-NP O
12 81 92 9546397 interaction NN I-NP O
13 93 97 9546397 with IN B-PP O
14 98 109 9546397 transferrin NN B-NP O
15 110 118 9546397 receptor NN I-NP O
16 118 119 9546397 . . O O
17 120 123 9546397 HFE NN B-NP O
18 124 126 9546397 is VBZ B-VP O
19 127 129 9546397 an DT B-NP O
20 130 133 9546397 MHC NN I-NP O
21 133 134 9546397 - HYPH B-NP O
22 134 141 9546397 related VBN I-NP O
23 142 149 9546397 protein NN I-NP O
24 150 154 9546397 that WDT B-NP O
25 155 157 9546397 is VBZ B-VP O
26 158 165 9546397 mutated VBN I-VP O
27 166 168 9546397 in IN B-PP O
28 169 172 9546397 the DT B-NP O
29 173 177 9546397 iron NN I-NP B-Disease
30 177 178 9546397 - HYPH B-NP I-Disease
31 178 186 9546397 overload NN I-NP I-Disease
32 187 194 9546397 disease NN I-NP I-Disease
33 195 205 9546397 hereditary JJ I-NP B-Disease
34 206 221 9546397 hemochromatosis NN I-NP I-Disease
35 221 222 9546397 . . O O

1 223 226 9546397 HFE NN B-NP O
2 227 232 9546397 binds VBZ B-VP O
3 233 235 9546397 to TO B-PP O
4 236 247 9546397 transferrin NN B-NP O
5 248 256 9546397 receptor NN I-NP O
6 257 258 9546397 ( ( O O
7 258 261 9546397 TfR NN B-NP O
8 261 262 9546397 ) ) O O
9 263 266 9546397 and CC O O
10 267 274 9546397 reduces VBZ B-VP O
11 275 278 9546397 its PRP$ B-NP O
12 279 287 9546397 affinity NN I-NP O
13 288 291 9546397 for IN B-PP O
14 292 296 9546397 iron NN B-NP O
15 296 297 9546397 - HYPH B-NP O
16 297 303 9546397 loaded VBN I-NP O
17 304 315 9546397 transferrin NN I-NP O
18 315 316 9546397 , , O O
19 317 328 9546397 implicating VBG B-VP O
20 329 332 9546397 HFE NN B-NP O
21 333 335 9546397 in IN B-PP O
22 336 340 9546397 iron NN B-NP O
23 341 351 9546397 metabolism NN I-NP O
24 351 352 9546397 . . O O

1 353 356 9546397 The DT B-NP O
2 357 358 9546397 2 CD I-NP O
3 358 359 9546397 . . I-NP O
4 360 361 9546397 6 CD I-NP O
5 362 363 9546397 A NN I-NP O
6 364 371 9546397 crystal NN I-NP O
7 372 381 9546397 structure NN I-NP O
8 382 384 9546397 of IN B-PP O
9 385 388 9546397 HFE NN B-NP O
10 389 396 9546397 reveals VBZ B-VP O
11 397 400 9546397 the DT B-NP O
12 401 410 9546397 locations NNS I-NP O
13 411 413 9546397 of IN B-PP O
14 414 429 9546397 hemochromatosis NN B-NP B-Disease
15 430 439 9546397 mutations NNS I-NP O
16 440 443 9546397 and CC O O
17 444 445 9546397 a DT B-NP O
18 446 451 9546397 patch NN I-NP O
19 452 454 9546397 of IN B-PP O
20 455 465 9546397 histidines NNS B-NP O
21 466 470 9546397 that WDT B-NP O
22 471 476 9546397 could MD B-VP O
23 477 479 9546397 be VB I-VP O
24 480 488 9546397 involved VBN I-VP O
25 489 491 9546397 in IN B-PP O
26 492 494 9546397 pH NN B-NP O
27 494 495 9546397 - HYPH B-NP O
28 495 504 9546397 dependent JJ I-NP O
29 505 517 9546397 interactions NNS I-NP O
30 517 518 9546397 . . O O

1 519 521 9546397 We PRP B-NP O
2 522 526 9546397 also RB B-ADVP O
3 527 538 9546397 demonstrate VBP B-VP O
4 539 543 9546397 that IN B-SBAR O
5 544 551 9546397 soluble JJ B-NP O
6 552 555 9546397 TfR NN I-NP O
7 556 559 9546397 and CC I-NP O
8 560 563 9546397 HFE NN I-NP O
9 564 568 9546397 bind VBP B-VP O
10 569 576 9546397 tightly RB B-ADVP O
11 577 579 9546397 at IN B-PP O
12 580 583 9546397 the DT B-NP O
13 584 589 9546397 basic JJ I-NP O
14 590 592 9546397 pH NN I-NP O
15 593 595 9546397 of IN B-PP O
16 596 599 9546397 the DT B-NP O
17 600 604 9546397 cell NN I-NP O
18 605 612 9546397 surface NN I-NP O
19 612 613 9546397 , , O O
20 614 617 9546397 but CC O O
21 618 621 9546397 not RB O O
22 622 624 9546397 at IN B-PP O
23 625 628 9546397 the DT B-NP O
24 629 635 9546397 acidic JJ I-NP O
25 636 638 9546397 pH NN I-NP O
26 639 641 9546397 of IN B-PP O
27 642 655 9546397 intracellular JJ B-NP O
28 656 664 9546397 vesicles NNS I-NP O
29 664 665 9546397 . . O O

1 666 669 9546397 TfR NN B-NP O
2 671 674 9546397 HFE NN I-NP O
3 675 688 9546397 stoichiometry NN I-NP O
4 689 690 9546397 ( ( O O
5 690 691 9546397 2 CD B-NP O
6 693 694 9546397 1 CD I-NP O
7 694 695 9546397 ) ) O O
8 696 703 9546397 differs VBZ B-VP O
9 704 708 9546397 from IN B-PP O
10 709 712 9546397 TfR NN B-NP O
11 714 725 9546397 transferrin NN I-NP O
12 726 739 9546397 stoichiometry NN I-NP O
13 740 741 9546397 ( ( O O
14 741 742 9546397 2 CD B-NP O
15 744 745 9546397 2 CD I-NP O
16 745 746 9546397 ) ) O O
17 746 747 9546397 , , O O
18 748 756 9546397 implying VBG B-VP O
19 757 758 9546397 a DT B-NP O
20 759 768 9546397 different JJ I-NP O
21 769 773 9546397 mode NN I-NP O
22 774 776 9546397 of IN B-PP O
23 777 784 9546397 binding NN B-NP O
24 785 788 9546397 for IN B-PP O
25 789 792 9546397 HFE NN B-NP O
26 793 796 9546397 and CC I-NP O
27 797 808 9546397 transferrin NN I-NP O
28 809 811 9546397 to TO B-PP O
29 812 815 9546397 TfR NN B-NP O
30 815 816 9546397 , , O O
31 817 827 9546397 consistent JJ B-ADJP O
32 828 832 9546397 with IN B-PP O
33 833 836 9546397 our PRP$ B-NP O
34 837 850 9546397 demonstration NN I-NP O
35 851 855 9546397 that IN B-SBAR O
36 856 859 9546397 HFE NN B-NP O
37 859 860 9546397 , , O O
38 861 872 9546397 transferrin NN B-NP O
39 872 873 9546397 , , O O
40 874 877 9546397 and CC O O
41 878 881 9546397 TfR NN B-NP O
42 882 886 9546397 form VBP B-VP O
43 887 888 9546397 a DT B-NP O
44 889 896 9546397 ternary JJ I-NP O
45 897 904 9546397 complex NN I-NP O
46 904 905 9546397 . . O O

1 0 0 9472666 -DOCSTART- -X- -X- O

1 0 9 9472666 Molecular JJ B-NP O
2 10 17 9472666 defects NNS I-NP O
3 18 25 9472666 leading VBG B-VP O
4 26 28 9472666 to TO B-PP O
5 29 34 9472666 human JJ B-NP O
6 35 45 9472666 complement NN I-NP B-Disease
7 46 55 9472666 component NN I-NP I-Disease
8 56 58 9472666 C6 NN I-NP I-Disease
9 59 69 9472666 deficiency NN I-NP I-Disease
10 70 72 9472666 in IN B-PP O
11 73 75 9472666 an DT B-NP O
12 76 83 9472666 African JJ I-NP O
13 83 84 9472666 - HYPH I-NP O
14 84 92 9472666 American JJ I-NP O
15 93 99 9472666 family NN I-NP O
16 99 100 9472666 . . I-NP O
17 101 111 9472666 Complement NN I-NP B-Disease
18 112 121 9472666 component NN I-NP I-Disease
19 122 124 9472666 C6 NN I-NP I-Disease
20 125 135 9472666 deficiency NN I-NP I-Disease
21 136 137 9472666 ( ( O O
22 137 140 9472666 C6D NN B-NP B-Disease
23 140 141 9472666 ) ) O O
24 142 145 9472666 was VBD B-VP O
25 146 155 9472666 diagnosed VBN I-VP O
26 156 158 9472666 in IN B-PP O
27 159 160 9472666 a DT B-NP O
28 161 163 9472666 16 CD I-NP O
29 163 164 9472666 - HYPH I-NP O
30 164 168 9472666 year NN I-NP O
31 168 169 9472666 - HYPH O O
32 169 172 9472666 old JJ B-NP O
33 173 180 9472666 African JJ I-NP O
34 180 181 9472666 - HYPH I-NP O
35 181 189 9472666 American JJ I-NP O
36 190 194 9472666 male NN I-NP O
37 195 199 9472666 with IN B-PP O
38 200 213 9472666 meningococcal JJ B-NP B-Disease
39 214 224 9472666 meningitis NN I-NP I-Disease
40 224 225 9472666 . . O O

1 226 229 9472666 The DT B-NP O
2 230 238 9472666 patients NNS I-NP O
3 239 245 9472666 father NN I-NP O
4 246 249 9472666 and CC O O
5 250 253 9472666 two CD B-NP O
6 254 262 9472666 brothers NNS I-NP O
7 263 267 9472666 also RB B-ADVP O
8 268 271 9472666 had VBD B-VP O
9 272 275 9472666 C6D NN B-NP B-Disease
10 275 276 9472666 , , O O
11 277 280 9472666 but CC O O
12 281 285 9472666 gave VBD B-VP O
13 286 288 9472666 no DT B-NP O
14 289 296 9472666 history NN I-NP O
15 297 299 9472666 of IN B-PP O
16 300 310 9472666 meningitis NN B-NP B-Disease
17 311 313 9472666 or CC O O
18 314 319 9472666 other JJ B-NP O
19 320 330 9472666 neisserial JJ I-NP B-Disease
20 331 340 9472666 infection NN I-NP I-Disease
21 340 341 9472666 . . O O

1 342 344 9472666 By IN B-PP O
2 345 350 9472666 using VBG B-VP O
3 351 355 9472666 exon NN B-NP O
4 355 356 9472666 - HYPH B-NP O
5 356 364 9472666 specific JJ I-NP O
6 365 375 9472666 polymerase NN I-NP O
7 376 381 9472666 chain NN I-NP O
8 382 390 9472666 reaction NN I-NP O
9 391 392 9472666 ( ( O O
10 392 395 9472666 PCR NN B-NP O
11 395 396 9472666 ) ) O O
12 396 397 9472666 / SYM B-NP O
13 397 403 9472666 single JJ I-NP O
14 403 404 9472666 - HYPH I-NP O
15 404 410 9472666 strand NN I-NP O
16 411 423 9472666 conformation NN I-NP O
17 424 436 9472666 polymorphism NN I-NP O
18 437 439 9472666 as IN B-PP O
19 440 441 9472666 a DT B-NP O
20 442 451 9472666 screening NN I-NP O
21 452 456 9472666 step NN I-NP O
22 457 460 9472666 and CC I-NP O
23 461 471 9472666 nucleotide NN I-NP O
24 472 482 9472666 sequencing NN I-NP O
25 483 485 9472666 of IN B-PP O
26 486 492 9472666 target NN B-NP O
27 493 498 9472666 exons NNS I-NP O
28 498 499 9472666 , , O O
29 500 502 9472666 we PRP B-NP O
30 503 513 9472666 determined VBD B-VP O
31 514 518 9472666 that IN B-SBAR O
32 519 522 9472666 the DT B-NP O
33 523 530 9472666 proband NN I-NP O
34 531 534 9472666 was VBD B-VP O
35 535 536 9472666 a DT B-NP O
36 537 545 9472666 compound NN I-NP O
37 546 558 9472666 heterozygote NN I-NP O
38 559 562 9472666 for IN B-PP O
39 563 566 9472666 two CD B-NP O
40 567 569 9472666 C6 NN I-NP O
41 570 574 9472666 gene NN I-NP O
42 575 584 9472666 mutations NNS I-NP O
43 584 585 9472666 . . O O

1 586 589 9472666 The DT B-NP O
2 590 595 9472666 first JJ I-NP O
3 595 596 9472666 , , I-NP O
4 597 605 9472666 1195delC NN I-NP O
5 606 613 9472666 located JJ I-NP O
6 614 616 9472666 in IN B-PP O
7 617 621 9472666 exon NN B-NP O
8 622 623 9472666 7 CD I-NP O
9 623 624 9472666 , , O O
10 625 627 9472666 is VBZ B-VP O
11 628 629 9472666 a DT B-NP O
12 630 635 9472666 novel JJ I-NP O
13 636 644 9472666 mutation NN I-NP O
14 644 645 9472666 , , O O
15 646 651 9472666 while IN B-SBAR O
16 652 655 9472666 the DT B-NP O
17 656 662 9472666 second JJ I-NP O
18 662 663 9472666 , , I-NP O
19 664 672 9472666 1936delG NN I-NP O
20 673 675 9472666 in IN B-PP O
21 676 680 9472666 exon NN B-NP O
22 681 683 9472666 12 CD I-NP O
23 683 684 9472666 , , O O
24 685 688 9472666 has VBZ B-VP O
25 689 693 9472666 been VBN I-VP O
26 694 703 9472666 described VBN I-VP O
27 704 710 9472666 before RB B-ADVP O
28 711 713 9472666 to TO B-VP O
29 714 719 9472666 cause VB I-VP O
30 720 723 9472666 C6D NN B-NP B-Disease
31 724 726 9472666 in IN B-PP O
32 727 729 9472666 an DT B-NP O
33 730 739 9472666 unrelated JJ I-NP O
34 740 747 9472666 African JJ I-NP O
35 747 748 9472666 - HYPH I-NP O
36 748 756 9472666 American JJ I-NP O
37 757 767 9472666 individual NN I-NP O
38 767 768 9472666 . . O O

1 769 773 9472666 Both DT B-NP O
2 774 783 9472666 mutations NNS I-NP O
3 784 790 9472666 result VBP B-VP O
4 791 793 9472666 in IN B-PP O
5 794 803 9472666 premature JJ B-NP O
6 804 815 9472666 termination NN I-NP O
7 816 822 9472666 codons NNS I-NP O
8 823 826 9472666 and CC O O
9 827 829 9472666 C6 NN B-NP O
10 830 834 9472666 null JJ I-NP O
11 835 842 9472666 alleles NNS I-NP O
12 842 843 9472666 . . O O

1 844 850 9472666 Allele NN B-NP O
2 850 851 9472666 - HYPH I-NP O
3 851 859 9472666 specific JJ I-NP O
4 860 863 9472666 PCR NN I-NP O
5 864 873 9472666 indicated VBD B-VP O
6 874 878 9472666 that IN B-SBAR O
7 879 882 9472666 the DT B-NP O
8 883 891 9472666 probands NNS I-NP O
9 892 895 9472666 two CD B-NP O
10 896 904 9472666 brothers NNS I-NP O
11 905 909 9472666 also RB B-ADVP O
12 910 919 9472666 inherited VBD B-VP O
13 920 923 9472666 the DT B-NP O
14 924 932 9472666 1195delC NN I-NP O
15 933 941 9472666 mutation NN I-NP O
16 942 946 9472666 from IN B-PP O
17 947 952 9472666 their PRP$ B-NP O
18 953 965 9472666 heterozygous JJ I-NP O
19 966 972 9472666 mother NN I-NP O
20 973 976 9472666 and CC O O
21 977 980 9472666 the DT B-NP O
22 981 989 9472666 1936delG NN I-NP O
23 990 998 9472666 mutation NN I-NP O
24 999 1003 9472666 from IN B-PP O
25 1004 1009 9472666 their PRP$ B-NP O
26 1010 1020 9472666 homozygous JJ I-NP O
27 1021 1027 9472666 father NN I-NP O
28 1027 1028 9472666 . . O O
29 1028 1029 9472666 . . O O

1 0 0 932197 -DOCSTART- -X- -X- O

1 0 10 932197 Hereditary JJ B-NP B-Disease
2 11 21 932197 deficiency NN I-NP I-Disease
3 22 24 932197 of IN B-PP I-Disease
4 25 28 932197 the DT B-NP I-Disease
5 29 34 932197 fifth JJ I-NP I-Disease
6 35 44 932197 component NN I-NP I-Disease
7 45 47 932197 of IN B-PP I-Disease
8 48 58 932197 complement NN B-NP I-Disease
9 59 61 932197 in IN B-PP O
10 62 65 932197 man NN B-NP O
11 65 66 932197 . . O O

1 67 68 932197 I PRP B-NP O
2 68 69 932197 . . O O

1 70 78 932197 Clinical JJ B-NP O
2 78 79 932197 , , I-NP O
3 80 94 932197 immunochemical JJ I-NP O
4 94 95 932197 , , O O
5 96 99 932197 and CC O O
6 100 106 932197 family NN B-NP O
7 107 114 932197 studies NNS I-NP O
8 114 115 932197 . . O O
9 116 119 932197 The DT B-NP O
10 120 125 932197 first JJ I-NP O
11 126 136 932197 recognized VBN I-NP O
12 137 142 932197 human JJ I-NP O
13 143 150 932197 kindred NN I-NP O
14 151 155 932197 with IN B-PP O
15 156 166 932197 hereditary JJ B-NP B-Disease
16 167 177 932197 deficiency NN I-NP I-Disease
17 178 180 932197 of IN B-PP I-Disease
18 181 184 932197 the DT B-NP I-Disease
19 185 190 932197 fifth JJ I-NP I-Disease
20 191 200 932197 component NN I-NP I-Disease
21 201 203 932197 of IN B-PP I-Disease
22 204 214 932197 complement NN B-NP I-Disease
23 215 216 932197 ( ( O O
24 216 218 932197 C5 NN B-NP O
25 218 219 932197 ) ) O O
26 220 222 932197 is VBZ B-VP O
27 223 232 932197 described VBN I-VP O
28 232 233 932197 . . O O

1 234 237 932197 The DT B-NP O
2 238 245 932197 proband NN I-NP O
3 245 246 932197 , , O O
4 247 248 932197 a DT B-NP O
5 249 251 932197 20 CD I-NP O
6 251 252 932197 - HYPH I-NP O
7 252 256 932197 year NN I-NP O
8 256 257 932197 - HYPH B-NP O
9 257 260 932197 old JJ I-NP O
10 261 266 932197 black JJ I-NP O
11 267 273 932197 female NN I-NP O
12 274 278 932197 with IN B-PP O
13 279 287 932197 systemic JJ B-NP B-Disease
14 288 293 932197 lupus NN I-NP I-Disease
15 294 307 932197 erythematosus NN I-NP I-Disease
16 308 313 932197 since IN B-PP O
17 314 317 932197 age NN B-NP O
18 318 320 932197 11 CD I-NP O
19 320 321 932197 , , O O
20 322 328 932197 lacked VBD B-VP O
21 329 334 932197 serum NN B-NP O
22 335 344 932197 hemolytic JJ I-NP O
23 345 355 932197 complement NN I-NP O
24 356 364 932197 activity NN I-NP O
25 364 365 932197 , , O O
26 366 370 932197 even RB B-ADVP O
27 371 377 932197 during IN B-PP O
28 378 387 932197 remission NN B-NP O
29 387 388 932197 . . O O

1 389 391 932197 C5 NN B-NP O
2 392 395 932197 was VBD B-VP O
3 396 408 932197 undetectable JJ B-ADJP O
4 409 411 932197 in IN B-PP O
5 412 415 932197 her PRP$ B-NP O
6 416 421 932197 serum NN I-NP O
7 422 424 932197 by IN B-PP O
8 425 429 932197 both CC O O
9 430 445 932197 immunodiffusion NN B-NP O
10 446 449 932197 and CC O O
11 450 459 932197 hemolytic JJ B-NP O
12 460 466 932197 assays NNS I-NP O
13 466 467 932197 . . O O

1 468 473 932197 Other JJ B-NP O
2 474 484 932197 complement NN I-NP O
3 485 495 932197 components NNS I-NP O
4 496 500 932197 were VBD B-VP O
5 501 507 932197 normal JJ B-ADJP O
6 508 514 932197 during IN B-PP O
7 515 524 932197 remission NN B-NP O
8 525 527 932197 of IN B-PP O
9 528 533 932197 lupus NN B-NP O
10 533 534 932197 , , O O
11 535 538 932197 but CC O O
12 539 541 932197 C1 NN B-NP O
13 541 542 932197 , , O O
14 543 545 932197 C4 NN B-NP O
15 545 546 932197 , , O O
16 547 549 932197 C2 NN B-NP O
17 549 550 932197 , , O O
18 551 554 932197 and CC O O
19 555 557 932197 C3 NN B-NP O
20 558 564 932197 levels NNS I-NP O
21 565 569 932197 fell VBD B-VP O
22 570 576 932197 during IN B-PP O
23 577 590 932197 exacerbations NNS B-NP O
24 590 591 932197 . . O O

1 592 593 932197 A DT B-NP O
2 594 601 932197 younger JJR I-NP O
3 602 606 932197 half NN I-NP O
4 606 607 932197 - HYPH I-NP O
5 607 613 932197 sister NN I-NP O
6 613 614 932197 , , O O
7 615 618 932197 who WP B-NP O
8 619 622 932197 had VBD B-VP O
9 623 625 932197 no DT B-NP O
10 626 636 932197 underlying VBG I-NP O
11 637 644 932197 disease NN I-NP O
12 644 645 932197 , , O O
13 646 649 932197 was VBD B-VP O
14 650 654 932197 also RB I-VP O
15 655 660 932197 found VBN I-VP O
16 661 663 932197 to TO I-VP O
17 664 668 932197 lack VB I-VP O
18 669 685 932197 immunochemically RB B-NP O
19 686 696 932197 detectable JJ I-NP O
20 697 699 932197 C5 NN I-NP O
21 699 700 932197 . . O O

1 701 703 932197 By IN B-PP O
2 704 713 932197 hemolytic JJ B-NP O
3 714 719 932197 assay NN I-NP O
4 719 720 932197 , , O O
5 721 724 932197 she PRP B-NP O
6 725 734 932197 exhibited VBD B-VP O
7 735 736 932197 1 CD B-NP O
8 736 737 932197 - HYPH I-NP O
9 737 739 932197 2% CD I-NP O
10 740 742 932197 of IN B-PP O
11 743 746 932197 the DT B-NP O
12 747 753 932197 normal JJ I-NP O
13 754 759 932197 serum NN I-NP O
14 760 762 932197 C5 NN I-NP O
15 763 768 932197 level NN I-NP O
16 769 772 932197 and CC O O
17 773 779 932197 normal JJ B-NP O
18 780 794 932197 concentrations NNS I-NP O
19 795 797 932197 of IN B-PP O
20 798 803 932197 other JJ B-NP O
21 804 814 932197 complement NN I-NP O
22 815 825 932197 components NNS I-NP O
23 825 826 932197 . . O O

1 827 829 932197 C5 NN B-NP O
2 830 836 932197 levels NNS I-NP O
3 837 839 932197 of IN B-PP O
4 840 845 932197 other JJ B-NP O
5 846 852 932197 family NN I-NP O
6 853 860 932197 members NNS I-NP O
7 861 865 932197 were VBD B-VP O
8 866 872 932197 either CC O O
9 873 879 932197 normal JJ B-ADJP O
10 880 882 932197 or CC O O
11 883 896 932197 approximately RB B-ADVP O
12 897 901 932197 half RB B-ADJP O
13 901 902 932197 - HYPH I-ADJP O
14 902 908 932197 normal JJ B-ADJP O
15 908 909 932197 , , O O
16 910 920 932197 consistent JJ B-ADJP O
17 921 925 932197 with IN B-PP O
18 926 935 932197 autosomal JJ B-NP O
19 936 946 932197 codominant JJ I-NP O
20 947 958 932197 inheritance NN I-NP O
21 959 961 932197 of IN B-PP O
22 962 965 932197 the DT B-NP O
23 966 970 932197 gene NN I-NP O
24 971 982 932197 determining VBG B-VP O
25 983 985 932197 C5 NN B-NP B-Disease
26 986 996 932197 deficiency NN I-NP I-Disease
27 996 997 932197 . . O O

1 998 1004 932197 Normal JJ B-NP O
2 1005 1014 932197 hemolytic JJ I-NP O
3 1015 1021 932197 titers NNS I-NP O
4 1022 1026 932197 were VBD B-VP O
5 1027 1035 932197 restored VBN I-VP O
6 1036 1038 932197 to TO B-PP O
7 1039 1043 932197 both CC O O
8 1044 1054 932197 homozygous JJ B-NP O
9 1055 1057 932197 C5 NN I-NP B-Disease
10 1057 1058 932197 - HYPH B-NP I-Disease
11 1058 1067 932197 deficient JJ I-NP I-Disease
12 1068 1069 932197 ( ( O O
13 1069 1072 932197 C5D NN B-NP B-Disease
14 1072 1073 932197 ) ) O O
15 1074 1078 932197 sera NNS B-NP O
16 1079 1081 932197 by IN B-PP O
17 1082 1090 932197 addition NN B-NP O
18 1091 1093 932197 of IN B-PP O
19 1094 1100 932197 highly RB B-NP O
20 1101 1109 932197 purified VBN I-NP O
21 1110 1115 932197 human JJ I-NP O
22 1116 1118 932197 C5 NN I-NP O
23 1118 1119 932197 . . O O

1 1120 1122 932197 In IN B-PP O
2 1123 1131 932197 specific JJ B-NP O
3 1132 1134 932197 C5 NN I-NP O
4 1135 1145 932197 titrations NNS I-NP O
5 1145 1146 932197 , , O O
6 1147 1154 932197 however RB B-ADVP O
7 1154 1155 932197 , , O O
8 1156 1158 932197 it PRP B-NP O
9 1159 1162 932197 was VBD B-VP O
10 1163 1168 932197 noted VBN I-VP O
11 1169 1173 932197 that IN B-SBAR O
12 1174 1178 932197 when WRB B-ADVP O
13 1179 1186 932197 limited JJ B-NP O
14 1187 1194 932197 amounts NNS I-NP O
15 1195 1197 932197 of IN B-PP O
16 1198 1200 932197 C5 NN B-NP O
17 1201 1205 932197 were VBD B-VP O
18 1206 1213 932197 assayed VBN I-VP O
19 1214 1216 932197 in IN B-PP O
20 1217 1220 932197 the DT B-NP O
21 1221 1229 932197 presence NN I-NP O
22 1230 1232 932197 of IN B-PP O
23 1233 1236 932197 low JJ B-NP O
24 1237 1246 932197 dilutions NNS I-NP O
25 1247 1249 932197 of IN B-PP O
26 1250 1256 932197 either CC O O
27 1257 1260 932197 C5D NN B-NP B-Disease
28 1261 1266 932197 serum NN I-NP O
29 1266 1267 932197 , , O O
30 1268 1275 932197 curving VBG B-VP O
31 1276 1282 932197 rather RB B-PP O
32 1283 1287 932197 than IN I-PP O
33 1288 1294 932197 linear JJ B-NP O
34 1295 1299 932197 dose NN I-NP O
35 1299 1300 932197 - HYPH B-NP O
36 1300 1308 932197 response NN I-NP O
37 1309 1314 932197 plots NNS I-NP O
38 1315 1319 932197 were VBD B-VP O
39 1320 1332 932197 consistently RB I-VP O
40 1333 1341 932197 obtained VBN I-VP O
41 1341 1342 932197 , , O O
42 1343 1353 932197 suggesting VBG B-VP O
43 1354 1358 932197 some DT B-NP O
44 1359 1369 932197 inhibitory JJ I-NP O
45 1370 1376 932197 effect NN I-NP O
46 1376 1377 932197 . . O O

1 1378 1385 932197 Further JJ B-NP O
2 1386 1393 932197 studies NNS I-NP O
3 1394 1403 932197 suggested VBD B-VP O
4 1404 1408 932197 that IN B-SBAR O
5 1409 1412 932197 low JJ B-NP O
6 1413 1422 932197 dilutions NNS I-NP O
7 1423 1425 932197 of IN B-PP O
8 1426 1429 932197 C5D NN B-NP B-Disease
9 1430 1435 932197 serum NN I-NP O
10 1436 1443 932197 contain VBP B-VP O
11 1444 1445 932197 a DT B-NP O
12 1446 1452 932197 factor NN I-NP O
13 1453 1454 932197 ( ( O O
14 1454 1456 932197 or CC O O
15 1457 1464 932197 factors NNS B-NP O
16 1464 1465 932197 ) ) O O
17 1466 1477 932197 interfering VBG B-VP O
18 1478 1480 932197 at IN B-PP O
19 1481 1485 932197 some DT B-NP O
20 1486 1490 932197 step NN I-NP O
21 1491 1493 932197 in IN B-PP O
22 1494 1497 932197 the DT B-NP O
23 1498 1507 932197 hemolytic JJ I-NP O
24 1508 1513 932197 assay NN I-NP O
25 1514 1516 932197 of IN B-PP O
26 1517 1519 932197 C5 NN B-NP O
27 1519 1520 932197 , , O O
28 1521 1527 932197 rather RB B-CONJP O
29 1528 1532 932197 than IN I-CONJP O
30 1533 1534 932197 a DT B-NP O
31 1535 1539 932197 true JJ I-NP O
32 1540 1542 932197 C5 NN I-NP O
33 1543 1552 932197 inhibitor NN I-NP O
34 1553 1555 932197 or CC I-NP O
35 1556 1567 932197 inactivator NN I-NP O
36 1567 1568 932197 . . O O

1 1569 1571 932197 Of IN B-PP O
2 1572 1580 932197 clinical JJ B-NP O
3 1581 1589 932197 interest NN I-NP O
4 1590 1593 932197 are VBP B-VP O
5 1594 1595 932197 ( ( B-LST O
6 1595 1596 932197 a LS I-LST O
7 1596 1597 932197 ) ) O O
8 1598 1601 932197 the DT B-NP O
9 1602 1615 932197 documentation NN I-NP O
10 1616 1618 932197 of IN B-PP O
11 1619 1629 932197 membranous JJ B-NP O
12 1630 1648 932197 glomerulonephritis NN I-NP B-Disease
13 1648 1649 932197 , , O O
14 1650 1660 932197 vasculitis NN B-NP B-Disease
15 1660 1661 932197 , , O O
16 1662 1665 932197 and CC O O
17 1666 1675 932197 arthritis NN B-NP B-Disease
18 1676 1678 932197 in IN B-PP O
19 1679 1681 932197 an DT B-NP O
20 1682 1692 932197 individual JJ I-NP O
21 1693 1700 932197 lacking VBG I-NP O
22 1701 1703 932197 C5 NN I-NP O
23 1704 1705 932197 ( ( O O
24 1705 1708 932197 and CC O O
25 1709 1712 932197 its PRP$ B-NP O
26 1713 1721 932197 biologic JJ I-NP O
27 1722 1731 932197 functions NNS I-NP O
28 1731 1732 932197 ) ) O O
29 1732 1733 932197 , , O O
30 1734 1737 932197 and CC O O
31 1738 1739 932197 ( ( B-LST O
32 1739 1740 932197 b LS I-LST O
33 1740 1741 932197 ) ) O O
34 1742 1743 932197 a DT B-NP O
35 1744 1754 932197 remarkable JJ I-NP O
36 1755 1765 932197 propensity NN I-NP O
37 1766 1768 932197 to TO B-PP O
38 1769 1778 932197 bacterial JJ B-NP B-Disease
39 1779 1789 932197 infections NNS I-NP I-Disease
40 1790 1792 932197 in IN B-PP O
41 1793 1796 932197 the DT B-NP O
42 1797 1804 932197 proband NN I-NP O
43 1804 1805 932197 , , O O
44 1806 1810 932197 even RB B-ADVP O
45 1811 1817 932197 during IN B-PP O
46 1818 1825 932197 periods NNS B-NP O
47 1826 1828 932197 of IN B-PP O
48 1829 1832 932197 low JJ B-NP O
49 1832 1833 932197 - HYPH I-NP O
50 1833 1837 932197 dose NN I-NP O
51 1838 1840 932197 or CC I-NP O
52 1841 1850 932197 alternate JJ I-NP O
53 1850 1851 932197 - HYPH I-NP O
54 1851 1854 932197 day NN I-NP O
55 1855 1869 932197 corticosteroid NN I-NP O
56 1870 1877 932197 therapy NN I-NP O
57 1877 1878 932197 . . O O

1 1879 1884 932197 Other JJ B-NP O
2 1885 1897 932197 observations NNS I-NP O
3 1898 1906 932197 indicate VBP B-VP O
4 1907 1911 932197 that IN B-SBAR O
5 1912 1915 932197 the DT B-NP O
6 1916 1919 932197 C5D NN I-NP B-Disease
7 1920 1925 932197 state NN I-NP O
8 1926 1928 932197 is VBZ B-VP O
9 1929 1939 932197 compatible JJ B-ADJP O
10 1940 1944 932197 with IN B-PP O
11 1945 1951 932197 normal JJ B-NP O
12 1952 1963 932197 coagulation NN I-NP O
13 1964 1972 932197 function NN I-NP O
14 1973 1976 932197 and CC O O
15 1977 1980 932197 the DT B-NP O
16 1981 1989 932197 capacity NN I-NP O
17 1990 1992 932197 to TO B-VP O
18 1993 1998 932197 mount VB I-VP O
19 1999 2000 932197 a DT B-NP O
20 2001 2013 932197 neutrophilic JJ I-NP O
21 2014 2026 932197 leukocytosis NN I-NP O
22 2027 2033 932197 during IN B-PP O
23 2034 2042 932197 pyogenic JJ B-NP B-Disease
24 2043 2052 932197 infection NN I-NP I-Disease
25 2052 2053 932197 . . O O
26 2053 2054 932197 . . O O

1 0 0 9400934 -DOCSTART- -X- -X- O

1 0 3 9400934 The DT B-NP O
2 4 7 9400934 RB1 NN I-NP O
3 8 12 9400934 gene NN I-NP O
4 13 21 9400934 mutation NN I-NP O
5 22 24 9400934 in IN B-PP O
6 25 26 9400934 a DT B-NP O
7 27 32 9400934 child NN I-NP O
8 33 37 9400934 with IN B-PP O
9 38 45 9400934 ectopic JJ B-NP B-Disease
10 46 58 9400934 intracranial JJ I-NP I-Disease
11 59 73 9400934 retinoblastoma NN I-NP I-Disease
12 73 74 9400934 . . O O
13 75 78 9400934 The DT B-NP O
14 79 82 9400934 RB1 NN I-NP O
15 83 87 9400934 gene NN I-NP O
16 88 96 9400934 mutation NN I-NP O
17 97 100 9400934 was VBD B-VP O
18 101 113 9400934 investigated VBN I-VP O
19 114 116 9400934 in IN B-PP O
20 117 118 9400934 a DT B-NP O
21 119 124 9400934 child NN I-NP O
22 125 129 9400934 with IN B-PP O
23 130 137 9400934 ectopic JJ B-NP B-Disease
24 138 150 9400934 intracranial JJ I-NP I-Disease
25 151 165 9400934 retinoblastoma NN I-NP I-Disease
26 166 171 9400934 using VBG B-VP O
27 172 175 9400934 DNA NN B-NP O
28 176 184 9400934 obtained VBN B-VP O
29 185 189 9400934 from IN B-PP O
30 190 194 9400934 both CC O O
31 195 198 9400934 the DT B-NP O
32 199 205 9400934 pineal JJ I-NP B-Disease
33 206 209 9400934 and CC I-NP I-Disease
34 210 217 9400934 retinal JJ I-NP I-Disease
35 218 225 9400934 tumours NNS I-NP I-Disease
36 226 228 9400934 of IN B-PP O
37 229 232 9400934 the DT B-NP O
38 233 240 9400934 patient NN I-NP O
39 240 241 9400934 . . O O

1 242 243 9400934 A DT B-NP O
2 244 252 9400934 nonsense JJ I-NP O
3 253 261 9400934 mutation NN I-NP O
4 262 264 9400934 in IN B-PP O
5 265 269 9400934 exon NN B-NP O
6 270 272 9400934 17 CD I-NP O
7 273 274 9400934 ( ( O O
8 274 279 9400934 codon NN B-NP O
9 280 283 9400934 556 CD I-NP O
10 283 284 9400934 ) ) O O
11 285 287 9400934 of IN B-PP O
12 288 291 9400934 the DT B-NP O
13 292 295 9400934 RB1 NN I-NP O
14 296 300 9400934 gene NN I-NP O
15 301 304 9400934 was VBD B-VP O
16 305 310 9400934 found VBN I-VP O
17 311 313 9400934 to TO I-VP O
18 314 316 9400934 be VB I-VP O
19 317 324 9400934 present JJ B-ADJP O
20 325 337 9400934 homozygously RB B-ADVP O
21 338 340 9400934 in IN B-PP O
22 341 345 9400934 both CC O O
23 346 349 9400934 the DT B-NP O
24 350 357 9400934 retinal NN I-NP B-Disease
25 358 361 9400934 and CC O I-Disease
26 362 365 9400934 the DT B-NP I-Disease
27 366 372 9400934 pineal JJ I-NP I-Disease
28 373 380 9400934 tumours NNS I-NP I-Disease
29 380 381 9400934 . . O O

1 382 385 9400934 The DT B-NP O
2 386 390 9400934 same JJ I-NP O
3 391 399 9400934 mutation NN I-NP O
4 400 403 9400934 was VBD B-VP O
5 404 411 9400934 present JJ B-ADJP O
6 412 426 9400934 heterozygously RB B-ADVP O
7 427 429 9400934 in IN B-PP O
8 430 433 9400934 the DT B-NP O
9 434 437 9400934 DNA NN I-NP O
10 438 442 9400934 from IN B-PP O
11 443 446 9400934 the DT B-NP O
12 447 461 9400934 constitutional JJ I-NP O
13 462 467 9400934 cells NNS I-NP O
14 468 470 9400934 of IN B-PP O
15 471 474 9400934 the DT B-NP O
16 475 482 9400934 patient NN I-NP O
17 482 483 9400934 , , O O
18 484 491 9400934 proving VBG B-VP O
19 492 494 9400934 it PRP B-NP O
20 495 497 9400934 to TO B-VP O
21 498 500 9400934 be VB I-VP O
22 501 503 9400934 of IN B-PP O
23 504 512 9400934 germline NN B-NP O
24 513 519 9400934 origin NN I-NP O
25 519 520 9400934 . . O O

1 521 524 9400934 The DT B-NP O
2 525 532 9400934 initial JJ I-NP O
3 533 541 9400934 mutation NN I-NP O
4 542 545 9400934 was VBD B-VP O
5 546 551 9400934 shown VBN I-VP O
6 552 554 9400934 to TO I-VP O
7 555 559 9400934 have VB I-VP O
8 560 568 9400934 occurred VBN I-VP O
9 569 571 9400934 in IN B-PP O
10 572 575 9400934 the DT B-NP O
11 576 586 9400934 paternally RB I-NP O
12 587 594 9400934 derived VBN I-NP O
13 595 598 9400934 RB1 NN I-NP O
14 599 605 9400934 allele NN I-NP O
15 605 606 9400934 . . O O

1 607 610 9400934 The DT B-NP O
2 611 619 9400934 mutation NN I-NP O
3 620 622 9400934 is VBZ B-VP O
4 623 625 9400934 in IN B-PP O
5 626 628 9400934 an DT B-NP O
6 629 633 9400934 area NN I-NP O
7 634 636 9400934 of IN B-PP O
8 637 640 9400934 the DT B-NP O
9 641 645 9400934 gene NN I-NP O
10 646 650 9400934 that WDT B-NP O
11 651 658 9400934 encodes VBZ B-VP O
12 659 662 9400934 the DT B-NP O
13 663 670 9400934 protein NN I-NP O
14 670 671 9400934 - HYPH B-PP O
15 671 678 9400934 binding VBG B-NP O
16 679 685 9400934 region NN I-NP O
17 686 691 9400934 known VBN B-VP O
18 692 694 9400934 as IN B-PP O
19 695 698 9400934 the DT B-NP O
20 699 705 9400934 pocket NN I-NP O
21 706 712 9400934 region NN I-NP O
22 713 716 9400934 and CC O O
23 717 720 9400934 has VBZ B-VP O
24 721 725 9400934 been VBN I-VP O
25 726 734 9400934 detected VBN I-VP O
26 735 737 9400934 in IN B-PP O
27 738 743 9400934 other JJ B-NP O
28 744 749 9400934 cases NNS I-NP O
29 750 752 9400934 of IN B-PP O
30 753 767 9400934 retinoblastoma NN B-NP B-Disease
31 767 768 9400934 . . O O
32 768 769 9400934 . . O O

1 0 0 9467011 -DOCSTART- -X- -X- O

1 0 8 9467011 Mutation NN B-NP O
2 9 17 9467011 spectrum NN I-NP O
3 18 21 9467011 and CC I-NP O
4 22 30 9467011 genotype NN I-NP O
5 30 31 9467011 - HYPH B-NP O
6 31 40 9467011 phenotype NN I-NP O
7 41 49 9467011 analyses NNS I-NP O
8 50 52 9467011 in IN B-PP O
9 53 59 9467011 Cowden NNP B-NP B-Disease
10 60 67 9467011 disease NN I-NP I-Disease
11 68 71 9467011 and CC O O
12 72 80 9467011 Bannayan NNP B-NP B-Disease
13 80 81 9467011 - HYPH B-NP I-Disease
14 81 87 9467011 Zonana NNP I-NP I-Disease
15 88 96 9467011 syndrome NN I-NP I-Disease
16 96 97 9467011 , , O O
17 98 101 9467011 two CD B-NP O
18 102 111 9467011 hamartoma NN I-NP B-Disease
19 112 121 9467011 syndromes NNS I-NP I-Disease
20 122 126 9467011 with IN B-PP O
21 127 135 9467011 germline NN B-NP O
22 136 140 9467011 PTEN NN I-NP O
23 141 149 9467011 mutation NN I-NP O
24 149 150 9467011 . . O O
25 151 154 9467011 The DT B-NP O
26 155 161 9467011 tumour NN I-NP B-Disease
27 162 172 9467011 suppressor NN I-NP O
28 173 177 9467011 gene NN I-NP O
29 178 182 9467011 PTEN NN I-NP O
30 182 183 9467011 , , O O
31 184 189 9467011 which WDT B-NP O
32 190 194 9467011 maps VBZ B-VP O
33 195 197 9467011 to TO B-PP O
34 198 203 9467011 10q23 CD B-NP O
35 203 204 9467011 . . O O

1 205 206 9467011 3 CD B-NP O
2 207 210 9467011 and CC O O
3 211 218 9467011 encodes VBZ B-VP O
4 219 220 9467011 a DT B-NP O
5 221 224 9467011 403 CD I-NP O
6 225 230 9467011 amino NN I-NP O
7 231 235 9467011 acid NN I-NP O
8 236 240 9467011 dual JJ I-NP O
9 241 252 9467011 specificity NN I-NP O
10 253 264 9467011 phosphatase NN I-NP O
11 265 266 9467011 ( ( O O
12 266 273 9467011 protein NN B-NP O
13 274 282 9467011 tyrosine NN I-NP O
14 283 294 9467011 phosphatase NN I-NP O
15 294 295 9467011 ; : O O
16 296 302 9467011 PTPase NN B-NP O
17 302 303 9467011 ) ) O O
18 303 304 9467011 , , O O
19 305 308 9467011 was VBD B-VP O
20 309 314 9467011 shown VBN I-VP O
21 315 323 9467011 recently RB B-ADVP O
22 324 326 9467011 to TO B-VP O
23 327 331 9467011 play VB I-VP O
24 332 333 9467011 a DT B-NP O
25 334 339 9467011 broad JJ I-NP O
26 340 344 9467011 role NN I-NP O
27 345 347 9467011 in IN B-PP O
28 348 353 9467011 human JJ B-NP O
29 354 364 9467011 malignancy NN I-NP B-Disease
30 364 365 9467011 . . O O

1 366 373 9467011 Somatic JJ B-NP O
2 374 378 9467011 PTEN NN I-NP O
3 379 388 9467011 deletions NNS I-NP O
4 389 392 9467011 and CC I-NP O
5 393 402 9467011 mutations NNS I-NP O
6 403 407 9467011 were VBD B-VP O
7 408 416 9467011 observed VBN I-VP O
8 417 419 9467011 in IN B-PP O
9 420 428 9467011 sporadic JJ B-NP B-Disease
10 429 435 9467011 breast NN I-NP I-Disease
11 435 436 9467011 , , I-NP I-Disease
12 437 442 9467011 brain NN I-NP I-Disease
13 442 443 9467011 , , I-NP I-Disease
14 444 452 9467011 prostate NN I-NP I-Disease
15 453 456 9467011 and CC I-NP I-Disease
16 457 463 9467011 kidney NN I-NP I-Disease
17 464 470 9467011 cancer NN I-NP I-Disease
18 471 475 9467011 cell NN I-NP O
19 476 481 9467011 lines NNS I-NP O
20 482 485 9467011 and CC B-PP O
21 486 488 9467011 in IN B-PP O
22 489 496 9467011 several JJ B-NP O
23 497 504 9467011 primary JJ I-NP O
24 505 512 9467011 tumours NNS I-NP B-Disease
25 513 517 9467011 such JJ B-PP O
26 518 520 9467011 as IN I-PP O
27 521 532 9467011 endometrial JJ B-NP B-Disease
28 533 543 9467011 carcinomas NNS I-NP I-Disease
29 543 544 9467011 , , O O
30 545 554 9467011 malignant JJ B-NP B-Disease
31 555 563 9467011 melanoma NN I-NP I-Disease
32 564 567 9467011 and CC O O
33 568 575 9467011 thyroid JJ B-NP B-Disease
34 576 583 9467011 tumours NNS I-NP I-Disease
35 583 584 9467011 . . O O

1 585 587 9467011 In IN B-PP O
2 588 596 9467011 addition NN B-NP O
3 596 597 9467011 , , O O
4 598 602 9467011 PTEN NN B-NP O
5 603 606 9467011 was VBD B-VP O
6 607 617 9467011 identified VBN I-VP O
7 618 620 9467011 as IN B-PP O
8 621 624 9467011 the DT B-NP O
9 625 639 9467011 susceptibility NN I-NP O
10 640 644 9467011 gene NN I-NP O
11 645 648 9467011 for IN B-PP O
12 649 652 9467011 two CD B-NP O
13 653 662 9467011 hamartoma NN I-NP B-Disease
14 663 672 9467011 syndromes NNS I-NP I-Disease
15 674 680 9467011 Cowden NN I-NP B-Disease
16 681 688 9467011 disease NN I-NP I-Disease
17 689 690 9467011 ( ( O O
18 690 692 9467011 CD NN B-NP B-Disease
19 692 693 9467011 ; : O O
20 694 697 9467011 MIM NN B-NP O
21 698 704 9467011 158350 CD I-NP O
22 704 705 9467011 ) ) O O
23 706 709 9467011 and CC O O
24 710 718 9467011 Bannayan NNP B-NP B-Disease
25 718 719 9467011 - HYPH I-NP I-Disease
26 719 725 9467011 Zonana NNP I-NP I-Disease
27 726 727 9467011 ( ( O I-Disease
28 727 730 9467011 BZS NNP B-NP I-Disease
29 730 731 9467011 ) ) O I-Disease
30 732 734 9467011 or CC O I-Disease
31 735 744 9467011 Ruvalcaba NNP B-NP I-Disease
32 744 745 9467011 - HYPH B-NP I-Disease
33 745 750 9467011 Riley NNP I-NP I-Disease
34 750 751 9467011 - HYPH I-NP I-Disease
35 751 756 9467011 Smith NNP I-NP I-Disease
36 757 765 9467011 syndrome NN I-NP I-Disease
37 766 767 9467011 ( ( O O
38 767 770 9467011 MIM NN B-NP O
39 771 777 9467011 153480 CD I-NP O
40 777 778 9467011 ) ) O O
41 778 779 9467011 . . O O

1 780 792 9467011 Constitutive JJ B-NP O
2 793 796 9467011 DNA NN I-NP O
3 797 801 9467011 from IN B-PP O
4 802 804 9467011 37 CD B-NP O
5 805 807 9467011 CD NN I-NP B-Disease
6 808 816 9467011 families NNS I-NP O
7 817 820 9467011 and CC O O
8 821 826 9467011 seven CD B-NP O
9 827 830 9467011 BZS NN I-NP B-Disease
10 831 839 9467011 families NNS I-NP O
11 840 843 9467011 was VBD B-VP O
12 844 852 9467011 screened VBN I-VP O
13 853 856 9467011 for IN B-PP O
14 857 865 9467011 germline NN B-NP O
15 866 870 9467011 PTEN NN I-NP O
16 871 880 9467011 mutations NNS I-NP O
17 880 881 9467011 . . O O

1 882 886 9467011 PTEN NN B-NP O
2 887 896 9467011 mutations NNS I-NP O
3 897 901 9467011 were VBD B-VP O
4 902 912 9467011 identified VBN I-VP O
5 913 915 9467011 in IN B-PP O
6 916 918 9467011 30 CD B-NP O
7 919 921 9467011 of IN B-PP O
8 922 924 9467011 37 CD B-NP O
9 925 926 9467011 ( ( O O
10 926 929 9467011 81% CD B-NP O
11 929 930 9467011 ) ) O O
12 931 933 9467011 CD NN B-NP B-Disease
13 934 942 9467011 families NNS I-NP O
14 942 943 9467011 , , O O
15 944 953 9467011 including VBG B-PP O
16 954 962 9467011 missense JJ B-NP O
17 963 966 9467011 and CC I-NP O
18 967 975 9467011 nonsense JJ I-NP O
19 976 981 9467011 point NN I-NP O
20 982 991 9467011 mutations NNS I-NP O
21 991 992 9467011 , , O O
22 993 1002 9467011 deletions NNS B-NP O
23 1002 1003 9467011 , , O O
24 1004 1014 9467011 insertions NNS B-NP O
25 1014 1015 9467011 , , O O
26 1016 1017 9467011 a DT B-NP O
27 1018 1026 9467011 deletion NN I-NP O
28 1026 1027 9467011 / SYM B-NP O
29 1027 1036 9467011 insertion NN B-NP O
30 1037 1040 9467011 and CC I-NP O
31 1041 1047 9467011 splice NN I-NP O
32 1048 1052 9467011 site NN I-NP O
33 1053 1062 9467011 mutations NNS I-NP O
34 1062 1063 9467011 . . O O

1 1064 1069 9467011 These DT B-NP O
2 1070 1079 9467011 mutations NNS I-NP O
3 1080 1084 9467011 were VBD B-VP O
4 1085 1094 9467011 scattered VBN I-VP O
5 1095 1099 9467011 over IN B-PP O
6 1100 1103 9467011 the DT B-NP O
7 1104 1110 9467011 entire JJ I-NP O
8 1111 1117 9467011 length NN I-NP O
9 1118 1120 9467011 of IN B-PP O
10 1121 1125 9467011 PTEN NN B-NP O
11 1125 1126 9467011 , , O O
12 1127 1131 9467011 with IN B-PP O
13 1132 1135 9467011 the DT B-NP O
14 1136 1145 9467011 exception NN I-NP O
15 1146 1148 9467011 of IN B-PP O
16 1149 1152 9467011 the DT B-NP O
17 1153 1158 9467011 first JJ I-NP O
18 1158 1159 9467011 , , I-NP O
19 1160 1166 9467011 fourth JJ I-NP O
20 1167 1170 9467011 and CC I-NP O
21 1171 1175 9467011 last JJ I-NP O
22 1176 1181 9467011 exons NNS I-NP O
23 1181 1182 9467011 . . O O

1 1183 1184 9467011 A DT B-NP O
2 1185 1188 9467011 hot JJ I-NP O
3 1189 1193 9467011 spot NN I-NP O
4 1194 1197 9467011 for IN B-PP O
5 1198 1202 9467011 PTEN NN B-NP O
6 1203 1211 9467011 mutation NN I-NP O
7 1212 1214 9467011 in IN B-PP O
8 1215 1217 9467011 CD NN B-NP B-Disease
9 1218 1221 9467011 was VBD B-VP O
10 1222 1232 9467011 identified VBN I-VP O
11 1233 1235 9467011 in IN B-PP O
12 1236 1240 9467011 exon NN B-NP O
13 1241 1242 9467011 5 CD I-NP O
14 1243 1247 9467011 that WDT B-NP O
15 1248 1256 9467011 contains VBZ B-VP O
16 1257 1260 9467011 the DT B-NP O
17 1261 1267 9467011 PTPase NN I-NP O
18 1268 1272 9467011 core NN I-NP O
19 1273 1278 9467011 motif NN I-NP O
20 1278 1279 9467011 , , O O
21 1280 1284 9467011 with IN B-PP O
22 1285 1287 9467011 13 CD B-NP O
23 1288 1290 9467011 of IN B-PP O
24 1291 1293 9467011 30 CD B-NP O
25 1294 1295 9467011 ( ( O O
26 1295 1298 9467011 43% CD B-NP O
27 1298 1299 9467011 ) ) O O
28 1300 1302 9467011 CD NN B-NP B-Disease
29 1303 1312 9467011 mutations NNS I-NP O
30 1313 1323 9467011 identified VBN B-VP O
31 1324 1326 9467011 in IN B-PP O
32 1327 1331 9467011 this DT B-NP O
33 1332 1336 9467011 exon NN I-NP O
34 1336 1337 9467011 . . O O

1 1338 1343 9467011 Seven CD B-NP O
2 1344 1346 9467011 of IN B-PP O
3 1347 1349 9467011 30 CD B-NP O
4 1350 1351 9467011 ( ( O O
5 1351 1354 9467011 23% NN B-NP O
6 1354 1355 9467011 ) ) O O
7 1356 1360 9467011 were VBD B-VP O
8 1361 1367 9467011 within IN B-PP O
9 1368 1371 9467011 the DT B-NP O
10 1372 1376 9467011 core NN I-NP O
11 1377 1382 9467011 motif NN I-NP O
12 1382 1383 9467011 , , O O
13 1384 1387 9467011 the DT B-NP O
14 1388 1396 9467011 majority NN I-NP O
15 1397 1398 9467011 ( ( O O
16 1398 1402 9467011 five CD B-NP O
17 1403 1405 9467011 of IN B-PP O
18 1406 1411 9467011 seven CD B-NP O
19 1411 1412 9467011 ) ) O O
20 1413 1415 9467011 of IN B-PP O
21 1416 1421 9467011 which WDT B-NP O
22 1422 1426 9467011 were VBD B-VP O
23 1427 1435 9467011 missense JJ B-NP O
24 1436 1445 9467011 mutations NNS I-NP O
25 1445 1446 9467011 , , O O
26 1447 1455 9467011 possibly RB B-VP O
27 1456 1464 9467011 pointing VBG I-VP O
28 1465 1467 9467011 to TO B-PP O
29 1468 1471 9467011 the DT B-NP O
30 1472 1482 9467011 functional JJ I-NP O
31 1483 1495 9467011 significance NN I-NP O
32 1496 1498 9467011 of IN B-PP O
33 1499 1503 9467011 this DT B-NP O
34 1504 1510 9467011 region NN I-NP O
35 1510 1511 9467011 . . O O

1 1512 1520 9467011 Germline NN B-NP O
2 1521 1525 9467011 PTEN NN I-NP O
3 1526 1535 9467011 mutations NNS I-NP O
4 1536 1540 9467011 were VBD B-VP O
5 1541 1551 9467011 identified VBN I-VP O
6 1552 1554 9467011 in IN B-PP O
7 1555 1559 9467011 four CD B-NP O
8 1560 1562 9467011 of IN B-PP O
9 1563 1568 9467011 seven CD B-NP O
10 1569 1570 9467011 ( ( O O
11 1570 1573 9467011 57% CD B-NP O
12 1573 1574 9467011 ) ) O O
13 1575 1578 9467011 BZS NN B-NP B-Disease
14 1579 1587 9467011 families NNS I-NP O
15 1588 1595 9467011 studied VBN B-VP O
16 1595 1596 9467011 . . O O

1 1597 1610 9467011 Interestingly RB B-ADVP O
2 1610 1611 9467011 , , O O
3 1612 1616 9467011 none NN B-NP O
4 1617 1619 9467011 of IN B-PP O
5 1620 1625 9467011 these DT B-NP O
6 1626 1635 9467011 mutations NNS I-NP O
7 1636 1639 9467011 was VBD B-VP O
8 1640 1648 9467011 observed VBN I-VP O
9 1649 1651 9467011 in IN B-PP O
10 1652 1655 9467011 the DT B-NP O
11 1656 1662 9467011 PTPase NN I-NP O
12 1663 1667 9467011 core NN I-NP O
13 1668 1673 9467011 motif NN I-NP O
14 1673 1674 9467011 . . O O

1 1675 1677 9467011 It PRP B-NP O
2 1678 1680 9467011 is VBZ B-VP O
3 1681 1685 9467011 also RB B-ADVP O
4 1686 1692 9467011 worthy JJ B-ADJP O
5 1693 1695 9467011 of IN B-PP O
6 1696 1700 9467011 note NN B-NP O
7 1701 1705 9467011 that IN B-SBAR O
8 1706 1707 9467011 a DT B-NP O
9 1708 1714 9467011 single JJ I-NP O
10 1715 1723 9467011 nonsense JJ I-NP O
11 1724 1729 9467011 point NN I-NP O
12 1730 1738 9467011 mutation NN I-NP O
13 1738 1739 9467011 , , O O
14 1740 1745 9467011 R233X NN B-NP O
15 1745 1746 9467011 , , O O
16 1747 1750 9467011 was VBD B-VP O
17 1751 1759 9467011 observed VBN I-VP O
18 1760 1762 9467011 in IN B-PP O
19 1763 1766 9467011 the DT B-NP O
20 1767 1775 9467011 germline NN I-NP O
21 1776 1779 9467011 DNA NN I-NP O
22 1780 1784 9467011 from IN B-PP O
23 1785 1788 9467011 two CD B-NP O
24 1789 1798 9467011 unrelated JJ I-NP O
25 1799 1801 9467011 CD NN I-NP B-Disease
26 1802 1810 9467011 families NNS I-NP O
27 1811 1814 9467011 and CC O O
28 1815 1818 9467011 one CD B-NP O
29 1819 1822 9467011 BZS NN I-NP B-Disease
30 1823 1829 9467011 family NN I-NP O
31 1829 1830 9467011 . . O O

1 1831 1839 9467011 Genotype NN B-NP O
2 1839 1840 9467011 - HYPH I-NP O
3 1840 1849 9467011 phenotype NN I-NP O
4 1850 1857 9467011 studies NNS I-NP O
5 1858 1862 9467011 were VBD B-VP O
6 1863 1866 9467011 not RB I-VP O
7 1867 1876 9467011 performed VBN I-VP O
8 1877 1879 9467011 on IN B-PP O
9 1880 1884 9467011 this DT B-NP O
10 1885 1890 9467011 small JJ I-NP O
11 1891 1896 9467011 group NN I-NP O
12 1897 1899 9467011 of IN B-PP O
13 1900 1903 9467011 BZS NN B-NP B-Disease
14 1904 1912 9467011 families NNS I-NP O
15 1912 1913 9467011 . . O O

1 1914 1921 9467011 However RB B-ADVP O
2 1921 1922 9467011 , , O O
3 1923 1931 9467011 genotype NN B-NP O
4 1931 1932 9467011 - HYPH I-NP O
5 1932 1941 9467011 phenotype NN I-NP O
6 1942 1950 9467011 analysis NN I-NP O
7 1951 1956 9467011 inthe VBP B-VP O
8 1957 1962 9467011 group NN B-NP O
9 1963 1965 9467011 of IN B-PP O
10 1966 1968 9467011 CD NN B-NP B-Disease
11 1969 1977 9467011 families NNS I-NP O
12 1978 1986 9467011 revealed VBD B-VP O
13 1987 1990 9467011 two CD B-NP O
14 1991 1999 9467011 possible JJ I-NP O
15 2000 2012 9467011 associations NNS I-NP O
16 2013 2019 9467011 worthy JJ B-ADJP O
17 2020 2022 9467011 of IN B-PP O
18 2023 2029 9467011 follow VB B-VP O
19 2029 2030 9467011 - HYPH O O
20 2030 2032 9467011 up RP B-PRT O
21 2033 2035 9467011 in IN B-PP O
22 2036 2047 9467011 independent JJ B-NP O
23 2048 2056 9467011 analyses NNS I-NP O
24 2056 2057 9467011 . . O O

1 2058 2061 9467011 The DT B-NP O
2 2062 2067 9467011 first JJ I-NP O
3 2068 2071 9467011 was VBD B-VP O
4 2072 2074 9467011 an DT B-NP O
5 2075 2086 9467011 association NN I-NP O
6 2087 2092 9467011 noted VBN B-VP O
7 2093 2095 9467011 in IN B-PP O
8 2096 2099 9467011 the DT B-NP O
9 2100 2105 9467011 group NN I-NP O
10 2106 2108 9467011 of IN B-PP O
11 2109 2111 9467011 CD NN B-NP B-Disease
12 2112 2120 9467011 families NNS I-NP O
13 2121 2125 9467011 with IN B-PP O
14 2126 2132 9467011 breast NN B-NP B-Disease
15 2133 2140 9467011 disease NN I-NP I-Disease
16 2140 2141 9467011 . . O O

1 2142 2143 9467011 A DT B-NP O
2 2144 2155 9467011 correlation NN I-NP O
3 2156 2159 9467011 was VBD B-VP O
4 2160 2168 9467011 observed VBN I-VP O
5 2169 2176 9467011 between IN B-PP O
6 2177 2180 9467011 the DT B-NP O
7 2181 2189 9467011 presence NN I-NP O
8 2189 2190 9467011 / SYM B-NP O
9 2190 2197 9467011 absence NN I-NP O
10 2198 2200 9467011 of IN B-PP O
11 2201 2202 9467011 a DT B-NP O
12 2203 2207 9467011 PTEN NN I-NP O
13 2208 2216 9467011 mutation NN I-NP O
14 2217 2220 9467011 and CC O O
15 2221 2224 9467011 the DT B-NP O
16 2225 2229 9467011 type NN I-NP O
17 2230 2232 9467011 of IN B-PP O
18 2233 2239 9467011 breast NN B-NP O
19 2240 2251 9467011 involvement NN I-NP O
20 2252 2253 9467011 ( ( O O
21 2253 2263 9467011 unaffected JJ B-ADJP O
22 2264 2270 9467011 versus IN B-PP O
23 2271 2277 9467011 benign JJ B-NP O
24 2278 2284 9467011 versus CC I-NP O
25 2285 2294 9467011 malignant JJ I-NP O
26 2294 2295 9467011 ) ) O O
27 2295 2296 9467011 . . O O

1 2297 2309 9467011 Specifically RB B-ADVP O
2 2310 2313 9467011 and CC O O
3 2314 2318 9467011 more RBR B-ADVP O
4 2319 2327 9467011 directly RB I-ADVP O
5 2327 2328 9467011 , , O O
6 2329 2331 9467011 an DT B-NP O
7 2332 2343 9467011 association NN I-NP O
8 2344 2347 9467011 was VBD B-VP O
9 2348 2352 9467011 also RB I-VP O
10 2353 2361 9467011 observed VBN I-VP O
11 2362 2369 9467011 between IN B-PP O
12 2370 2373 9467011 the DT B-NP O
13 2374 2382 9467011 presence NN I-NP O
14 2383 2385 9467011 of IN B-PP O
15 2386 2387 9467011 a DT B-NP O
16 2388 2392 9467011 PTEN NN I-NP O
17 2393 2401 9467011 mutation NN I-NP O
18 2402 2405 9467011 and CC O O
19 2406 2415 9467011 malignant JJ B-NP B-Disease
20 2416 2422 9467011 breast NN I-NP I-Disease
21 2423 2430 9467011 disease NN I-NP I-Disease
22 2430 2431 9467011 . . O O

1 2432 2440 9467011 Secondly RB B-ADVP O
2 2440 2441 9467011 , , O O
3 2442 2447 9467011 there EX B-NP O
4 2448 2456 9467011 appeared VBD B-VP O
5 2457 2459 9467011 to TO I-VP O
6 2460 2462 9467011 be VB I-VP O
7 2463 2465 9467011 an DT B-NP O
8 2466 2480 9467011 interdependent JJ I-NP O
9 2481 2492 9467011 association NN I-NP O
10 2493 2500 9467011 between IN B-PP O
11 2501 2510 9467011 mutations NNS B-NP O
12 2511 2519 9467011 upstream RB B-ADVP O
13 2520 2523 9467011 and CC O O
14 2524 2530 9467011 within IN B-PP O
15 2531 2534 9467011 the DT B-NP O
16 2535 2541 9467011 PTPase NN I-NP O
17 2542 2546 9467011 core NN I-NP O
18 2547 2552 9467011 motif NN I-NP O
19 2552 2553 9467011 , , O O
20 2554 2557 9467011 the DT B-NP O
21 2558 2562 9467011 core NN I-NP O
22 2563 2568 9467011 motif NN I-NP O
23 2569 2579 9467011 containing VBG B-VP O
24 2580 2583 9467011 the DT B-NP O
25 2584 2592 9467011 majority NN I-NP O
26 2593 2595 9467011 of IN B-PP O
27 2596 2604 9467011 missense JJ B-NP O
28 2605 2614 9467011 mutations NNS I-NP O
29 2614 2615 9467011 , , O O
30 2616 2619 9467011 and CC O O
31 2620 2623 9467011 the DT B-NP O
32 2624 2635 9467011 involvement NN I-NP O
33 2636 2638 9467011 of IN B-PP O
34 2639 2642 9467011 all DT B-NP O
35 2643 2648 9467011 major JJ I-NP O
36 2649 2654 9467011 organ NN I-NP O
37 2655 2662 9467011 systems NNS I-NP O
38 2663 2664 9467011 ( ( O O
39 2664 2671 9467011 central JJ B-NP O
40 2672 2679 9467011 nervous JJ I-NP O
41 2680 2686 9467011 system NN I-NP O
42 2686 2687 9467011 , , O O
43 2688 2695 9467011 thyroid NN B-NP O
44 2695 2696 9467011 , , O O
45 2697 2703 9467011 breast NN B-NP O
46 2703 2704 9467011 , , O O
47 2705 2709 9467011 skin NN B-NP O
48 2710 2713 9467011 and CC O O
49 2714 2730 9467011 gastrointestinal JJ B-NP O
50 2731 2736 9467011 tract NN I-NP O
51 2736 2737 9467011 ) ) O O
52 2737 2738 9467011 . . O O

1 2739 2746 9467011 However RB B-ADVP O
2 2746 2747 9467011 , , O O
3 2748 2753 9467011 these DT B-NP O
4 2754 2766 9467011 observations NNS I-NP O
5 2767 2772 9467011 would MD B-VP O
6 2773 2777 9467011 need VB I-VP O
7 2778 2780 9467011 to TO I-VP O
8 2781 2783 9467011 be VB I-VP O
9 2784 2793 9467011 confirmed VBN I-VP O
10 2794 2796 9467011 by IN B-PP O
11 2797 2805 9467011 studying VBG B-VP O
12 2806 2807 9467011 a DT B-NP O
13 2808 2814 9467011 larger JJR I-NP O
14 2815 2821 9467011 number NN I-NP O
15 2822 2824 9467011 of IN B-PP O
16 2825 2827 9467011 CD NN B-NP B-Disease
17 2828 2836 9467011 families NNS I-NP O
18 2836 2837 9467011 . . O O

1 0 0 9700175 -DOCSTART- -X- -X- O

1 0 4 9700175 Oral JJ B-NP O
2 5 19 9700175 contraceptives NNS I-NP O
3 20 23 9700175 and CC O O
4 24 27 9700175 the DT B-NP O
5 28 32 9700175 risk NN I-NP O
6 33 35 9700175 of IN B-PP O
7 36 46 9700175 hereditary JJ B-NP B-Disease
8 47 54 9700175 ovarian JJ I-NP I-Disease
9 55 61 9700175 cancer NN I-NP I-Disease
10 61 62 9700175 . . O O

1 63 73 9700175 Hereditary NNP B-NP B-Disease
2 74 81 9700175 Ovarian NNP I-NP I-Disease
3 82 88 9700175 Cancer NNP I-NP I-Disease
4 89 97 9700175 Clinical NNP I-NP O
5 98 103 9700175 Study NNP I-NP O
6 104 109 9700175 Group NNP I-NP O
7 109 110 9700175 . . I-NP O
8 111 121 9700175 BACKGROUND NNP I-NP O
9 123 128 9700175 Women NNP I-NP O
10 129 133 9700175 with IN B-PP O
11 134 143 9700175 mutations NNS B-NP O
12 144 146 9700175 in IN B-PP O
13 147 153 9700175 either CC O O
14 154 157 9700175 the DT B-NP O
15 158 163 9700175 BRCA1 NN I-NP O
16 164 166 9700175 or CC O O
17 167 170 9700175 the DT B-NP O
18 171 176 9700175 BRCA2 NN I-NP O
19 177 181 9700175 gene NN I-NP O
20 182 186 9700175 have VBP B-VP O
21 187 188 9700175 a DT B-NP O
22 189 193 9700175 high JJ I-NP O
23 194 202 9700175 lifetime NN I-NP O
24 203 207 9700175 risk NN I-NP O
25 208 210 9700175 of IN B-PP O
26 211 218 9700175 ovarian JJ B-NP B-Disease
27 219 225 9700175 cancer NN I-NP I-Disease
28 225 226 9700175 . . O O

1 227 231 9700175 Oral JJ B-NP O
2 232 246 9700175 contraceptives NNS I-NP O
3 247 254 9700175 protect VBP B-VP O
4 255 262 9700175 against IN B-PP O
5 263 270 9700175 ovarian JJ B-NP B-Disease
6 271 277 9700175 cancer NN I-NP I-Disease
7 278 280 9700175 in IN B-PP O
8 281 288 9700175 general JJ B-ADJP O
9 288 289 9700175 , , O O
10 290 293 9700175 but CC O O
11 294 296 9700175 it PRP B-NP O
12 297 299 9700175 is VBZ B-VP O
13 300 303 9700175 not RB I-VP O
14 304 309 9700175 known VBN I-VP O
15 310 317 9700175 whether IN B-SBAR O
16 318 322 9700175 they PRP B-NP O
17 323 327 9700175 also RB B-ADVP O
18 328 335 9700175 protect VBP B-VP O
19 336 343 9700175 against IN B-PP O
20 344 354 9700175 hereditary JJ B-NP B-Disease
21 355 360 9700175 forms NNS I-NP I-Disease
22 361 363 9700175 of IN B-PP I-Disease
23 364 371 9700175 ovarian JJ B-NP I-Disease
24 372 378 9700175 cancer NN I-NP I-Disease
25 378 379 9700175 . . O O

1 380 387 9700175 METHODS NNS B-NP O
2 389 391 9700175 We PRP B-NP O
3 392 400 9700175 enrolled VBD B-VP O
4 401 404 9700175 207 CD B-NP O
5 405 410 9700175 women NNS I-NP O
6 411 415 9700175 with IN B-PP O
7 416 426 9700175 hereditary JJ B-NP B-Disease
8 427 434 9700175 ovarian JJ I-NP I-Disease
9 435 441 9700175 cancer NN I-NP I-Disease
10 442 445 9700175 and CC O O
11 446 449 9700175 161 CD B-NP O
12 450 452 9700175 of IN B-PP O
13 453 458 9700175 their PRP$ B-NP O
14 459 466 9700175 sisters NNS I-NP O
15 467 469 9700175 as IN B-PP O
16 470 478 9700175 controls NNS B-NP O
17 479 481 9700175 in IN B-PP O
18 482 483 9700175 a DT B-NP O
19 484 488 9700175 case NN I-NP O
20 488 489 9700175 - HYPH B-NP O
21 489 496 9700175 control NN I-NP O
22 497 502 9700175 study NN I-NP O
23 502 503 9700175 . . O O

1 504 507 9700175 All PDT B-NP O
2 508 511 9700175 the DT I-NP O
3 512 520 9700175 patients NNS I-NP O
4 521 528 9700175 carried VBD B-VP O
5 529 530 9700175 a DT B-NP O
6 531 541 9700175 pathogenic JJ I-NP O
7 542 550 9700175 mutation NN I-NP O
8 551 553 9700175 in IN B-PP O
9 554 560 9700175 either CC O O
10 561 566 9700175 BRCA1 NN B-NP O
11 567 568 9700175 ( ( O O
12 568 571 9700175 179 CD B-NP O
13 572 577 9700175 women NNS I-NP O
14 577 578 9700175 ) ) O O
15 579 581 9700175 or CC O O
16 582 587 9700175 BRCA2 NN B-NP O
17 588 589 9700175 ( ( O O
18 589 591 9700175 28 CD B-NP O
19 592 597 9700175 women NNS I-NP O
20 597 598 9700175 ) ) O O
21 598 599 9700175 . . O O

1 600 603 9700175 The DT B-NP O
2 604 611 9700175 control NN I-NP O
3 612 617 9700175 women NNS I-NP O
4 618 622 9700175 were VBD B-VP O
5 623 631 9700175 enrolled VBN I-VP O
6 632 642 9700175 regardless RB B-ADVP O
7 643 645 9700175 of IN B-PP O
8 646 653 9700175 whether IN B-SBAR O
9 654 656 9700175 or CC O O
10 657 660 9700175 not RB O O
11 661 665 9700175 they PRP B-NP O
12 666 669 9700175 had VBD B-VP O
13 670 676 9700175 either DT B-NP O
14 677 685 9700175 mutation NN I-NP O
15 685 686 9700175 . . O O

1 687 695 9700175 Lifetime NN B-NP O
2 696 705 9700175 histories NNS I-NP O
3 706 708 9700175 of IN B-PP O
4 709 713 9700175 oral JJ B-NP O
5 713 714 9700175 - HYPH I-NP O
6 714 727 9700175 contraceptive JJ I-NP O
7 728 731 9700175 use NN I-NP O
8 732 736 9700175 were VBD B-VP O
9 737 745 9700175 obtained VBN I-VP O
10 746 748 9700175 by IN B-PP O
11 749 758 9700175 interview NN B-NP O
12 759 761 9700175 or CC B-PP O
13 762 764 9700175 by IN B-PP O
14 765 772 9700175 written VBN B-NP O
15 773 786 9700175 questionnaire NN I-NP O
16 787 790 9700175 and CC O O
17 791 795 9700175 were VBD B-VP O
18 796 804 9700175 compared VBN I-VP O
19 805 812 9700175 between IN B-PP O
20 813 821 9700175 patients NNS B-NP O
21 822 825 9700175 and CC O O
22 826 833 9700175 control NN B-NP O
23 834 839 9700175 women NNS I-NP O
24 839 840 9700175 , , O O
25 841 846 9700175 after IN B-PP O
26 847 857 9700175 adjustment NN B-NP O
27 858 861 9700175 for IN B-PP O
28 862 866 9700175 year NN B-NP O
29 867 869 9700175 of IN B-PP O
30 870 875 9700175 birth NN B-NP O
31 876 879 9700175 and CC I-NP O
32 880 886 9700175 parity NN I-NP O
33 886 887 9700175 . . O O

1 888 895 9700175 RESULTS NNS B-NP O
2 897 900 9700175 The DT B-NP O
3 901 909 9700175 adjusted VBN I-NP O
4 910 914 9700175 odds VBZ B-VP O
5 915 920 9700175 ratio NN B-NP O
6 921 924 9700175 for IN B-PP O
7 925 932 9700175 ovarian JJ B-NP B-Disease
8 933 939 9700175 cancer NN I-NP I-Disease
9 940 950 9700175 associated VBN B-VP O
10 951 955 9700175 with IN B-PP O
11 956 959 9700175 any DT B-NP O
12 960 964 9700175 past JJ I-NP O
13 965 968 9700175 use NN I-NP O
14 969 971 9700175 of IN B-PP O
15 972 976 9700175 oral JJ B-NP O
16 977 991 9700175 contraceptives NNS I-NP O
17 992 995 9700175 was VBD B-VP O
18 996 997 9700175 0 CD B-NP O
19 997 998 9700175 . . O O

1 999 1000 9700175 5 CD B-NP O
2 1001 1002 9700175 ( ( O O
3 1002 1004 9700175 95 CD B-NP O
4 1005 1012 9700175 percent NN I-NP O
5 1013 1023 9700175 confidence NN I-NP O
6 1024 1032 9700175 interval NN I-NP O
7 1032 1033 9700175 , , O O
8 1034 1035 9700175 0 CD B-NP O
9 1035 1036 9700175 . . O O

1 1037 1038 9700175 3 CD B-NP O
2 1039 1041 9700175 to TO B-PP O
3 1042 1043 9700175 0 CD B-NP O
4 1043 1044 9700175 . . O O

1 1045 1046 9700175 8 CD B-NP O
2 1046 1047 9700175 ) ) O O
3 1047 1048 9700175 . . O O

1 1049 1052 9700175 The DT B-NP O
2 1053 1057 9700175 risk NN I-NP O
3 1058 1067 9700175 decreased VBD B-VP O
4 1068 1072 9700175 with IN B-PP O
5 1073 1083 9700175 increasing VBG B-NP O
6 1084 1092 9700175 duration NN I-NP O
7 1093 1095 9700175 of IN B-PP O
8 1096 1099 9700175 use NN B-NP O
9 1100 1101 9700175 ( ( O O
10 1101 1102 9700175 P NN B-NP O
11 1103 1106 9700175 for IN B-PP O
12 1107 1112 9700175 trend NN B-NP O
13 1112 1113 9700175 , , O O
14 1114 1115 9700175 < SYM B-NP O
15 1116 1117 9700175 0 CD I-NP O
16 1117 1118 9700175 . . O O

1 1119 1122 9700175 001 CD B-NP O
2 1122 1123 9700175 ) ) O O
3 1123 1124 9700175 ; : O O
4 1125 1128 9700175 use NN B-NP O
5 1129 1132 9700175 for IN B-PP O
6 1133 1136 9700175 six CD B-NP O
7 1137 1139 9700175 or CC I-NP O
8 1140 1144 9700175 more JJR I-NP O
9 1145 1150 9700175 years NNS I-NP O
10 1151 1154 9700175 was VBD B-VP O
11 1155 1165 9700175 associated VBN I-VP O
12 1166 1170 9700175 with IN B-PP O
13 1171 1172 9700175 a DT B-NP O
14 1173 1175 9700175 60 CD I-NP O
15 1176 1183 9700175 percent NN I-NP O
16 1184 1193 9700175 reduction NN I-NP O
17 1194 1196 9700175 in IN B-PP O
18 1197 1201 9700175 risk NN B-NP O
19 1201 1202 9700175 . . O O

1 1203 1207 9700175 Oral JJ B-NP O
2 1207 1208 9700175 - HYPH I-NP O
3 1208 1221 9700175 contraceptive JJ I-NP O
4 1222 1225 9700175 use NN I-NP O
5 1226 1235 9700175 protected VBD B-VP O
6 1236 1243 9700175 against IN B-PP O
7 1244 1251 9700175 ovarian JJ B-NP B-Disease
8 1252 1258 9700175 cancer NN I-NP I-Disease
9 1259 1263 9700175 both DT O O
10 1264 1267 9700175 for IN B-PP O
11 1268 1276 9700175 carriers NNS B-NP O
12 1277 1279 9700175 of IN B-PP O
13 1280 1283 9700175 the DT B-NP O
14 1284 1289 9700175 BRCA1 NN I-NP O
15 1290 1298 9700175 mutation NN I-NP O
16 1299 1300 9700175 ( ( O O
17 1300 1304 9700175 odds NNS B-NP O
18 1305 1310 9700175 ratio NN I-NP O
19 1310 1311 9700175 , , O O
20 1312 1313 9700175 0 CD B-NP O
21 1313 1314 9700175 . . O O

1 1315 1316 9700175 5 CD B-NP O
2 1316 1317 9700175 ; : O O
3 1318 1320 9700175 95 CD B-NP O
4 1321 1328 9700175 percent NN I-NP O
5 1329 1339 9700175 confidence NN I-NP O
6 1340 1348 9700175 interval NN I-NP O
7 1348 1349 9700175 , , O O
8 1350 1351 9700175 0 CD B-NP O
9 1351 1352 9700175 . . O O

1 1353 1354 9700175 3 CD B-NP O
2 1355 1357 9700175 to TO B-PP O
3 1358 1359 9700175 0 CD B-NP O
4 1359 1360 9700175 . . O O

1 1361 1362 9700175 9 CD B-NP O
2 1362 1363 9700175 ) ) O O
3 1364 1367 9700175 and CC O O
4 1368 1371 9700175 for IN B-PP O
5 1372 1380 9700175 carriers NNS B-NP O
6 1381 1383 9700175 of IN B-PP O
7 1384 1387 9700175 the DT B-NP O
8 1388 1393 9700175 BRCA2 NN I-NP O
9 1394 1402 9700175 mutation NN I-NP O
10 1403 1404 9700175 ( ( O O
11 1404 1408 9700175 odds NNS B-NP O
12 1409 1414 9700175 ratio NN I-NP O
13 1414 1415 9700175 , , O O
14 1416 1417 9700175 0 CD B-NP O
15 1417 1418 9700175 . . O O

1 1419 1420 9700175 4 CD B-NP O
2 1420 1421 9700175 ; : O O
3 1422 1424 9700175 95 CD B-NP O
4 1425 1432 9700175 percent NN I-NP O
5 1433 1443 9700175 confidence NN I-NP O
6 1444 1452 9700175 interval NN I-NP O
7 1452 1453 9700175 , , O O
8 1454 1455 9700175 0 CD B-NP O
9 1455 1456 9700175 . . O O

1 1457 1458 9700175 2 CD B-NP O
2 1459 1461 9700175 to TO B-PP O
3 1462 1463 9700175 1 CD B-NP O
4 1463 1464 9700175 . . O O

1 1465 1466 9700175 1 LS B-LST O
2 1466 1467 9700175 ) ) O O
3 1467 1468 9700175 . . O O

1 1469 1480 9700175 CONCLUSIONS NNS B-NP O
2 1482 1486 9700175 Oral JJ B-ADJP O
3 1486 1487 9700175 - HYPH B-NP O
4 1487 1500 9700175 contraceptive JJ I-NP O
5 1501 1504 9700175 use NN I-NP O
6 1505 1508 9700175 may MD B-VP O
7 1509 1515 9700175 reduce VB I-VP O
8 1516 1519 9700175 the DT B-NP O
9 1520 1524 9700175 risk NN I-NP O
10 1525 1527 9700175 of IN B-PP O
11 1528 1535 9700175 ovarian JJ B-NP B-Disease
12 1536 1542 9700175 cancer NN I-NP I-Disease
13 1543 1545 9700175 in IN B-PP O
14 1546 1551 9700175 women NNS B-NP O
15 1552 1556 9700175 with IN B-PP O
16 1557 1567 9700175 pathogenic JJ B-NP O
17 1568 1577 9700175 mutations NNS I-NP O
18 1578 1580 9700175 in IN B-PP O
19 1581 1584 9700175 the DT B-NP O
20 1585 1590 9700175 BRCA1 NN I-NP O
21 1591 1593 9700175 or CC I-NP O
22 1594 1599 9700175 BRCA2 NN I-NP O
23 1600 1604 9700175 gene NN I-NP O

1 0 0 9391879 -DOCSTART- -X- -X- O

1 0 3 9391879 Low JJ B-NP O
2 4 13 9391879 frequency NN I-NP O
3 14 16 9391879 of IN B-PP O
4 17 22 9391879 BRCA1 NN B-NP O
5 23 31 9391879 germline NN I-NP O
6 32 41 9391879 mutations NNS I-NP O
7 42 44 9391879 in IN B-PP O
8 45 47 9391879 45 CD B-NP O
9 48 54 9391879 German JJ I-NP O
10 55 61 9391879 breast NN I-NP B-Disease
11 61 62 9391879 / SYM B-NP I-Disease
12 62 69 9391879 ovarian JJ I-NP I-Disease
13 70 76 9391879 cancer NN I-NP I-Disease
14 77 85 9391879 families NNS I-NP O
15 85 86 9391879 . . O O
16 87 89 9391879 In IN B-PP O
17 90 94 9391879 this DT B-NP O
18 95 100 9391879 study NN I-NP O
19 101 103 9391879 we PRP B-NP O
20 104 116 9391879 investigated VBD B-VP O
21 117 119 9391879 45 CD B-NP O
22 120 126 9391879 German JJ I-NP O
23 127 133 9391879 breast NN I-NP B-Disease
24 133 134 9391879 / SYM B-NP I-Disease
25 134 141 9391879 ovarian JJ I-NP I-Disease
26 142 148 9391879 cancer NN I-NP I-Disease
27 149 157 9391879 families NNS I-NP O
28 158 161 9391879 for IN B-PP O
29 162 170 9391879 germline NN B-NP O
30 171 180 9391879 mutations NNS I-NP O
31 181 183 9391879 in IN B-PP O
32 184 187 9391879 the DT B-NP O
33 188 193 9391879 BRCA1 NN I-NP O
34 194 198 9391879 gene NN I-NP O
35 198 199 9391879 . . O O

1 200 202 9391879 We PRP B-NP O
2 203 213 9391879 identified VBD B-VP O
3 214 218 9391879 four CD B-NP O
4 219 227 9391879 germline NN I-NP O
5 228 237 9391879 mutations NNS I-NP O
6 238 240 9391879 in IN B-PP O
7 241 246 9391879 three CD B-NP O
8 247 253 9391879 breast NN I-NP B-Disease
9 254 260 9391879 cancer NN I-NP I-Disease
10 261 269 9391879 families NNS I-NP O
11 270 273 9391879 and CC O O
12 274 276 9391879 in IN B-PP O
13 277 280 9391879 one CD B-NP O
14 281 287 9391879 breast NN I-NP B-Disease
15 287 288 9391879 - HYPH B-NP I-Disease
16 288 295 9391879 ovarian JJ I-NP I-Disease
17 296 302 9391879 cancer NN I-NP I-Disease
18 303 309 9391879 family NN I-NP O
19 309 310 9391879 . . O O

1 311 316 9391879 among IN B-PP O
2 317 322 9391879 these DT B-NP O
3 323 327 9391879 were VBD B-VP O
4 328 331 9391879 one CD B-NP O
5 332 342 9391879 frameshift NN I-NP O
6 343 351 9391879 mutation NN I-NP O
7 351 352 9391879 , , O O
8 353 356 9391879 one CD B-NP O
9 357 365 9391879 nonsense JJ I-NP O
10 366 374 9391879 mutation NN I-NP O
11 374 375 9391879 , , O O
12 376 379 9391879 one CD B-NP O
13 380 385 9391879 novel JJ I-NP O
14 386 392 9391879 splice NN I-NP O
15 393 397 9391879 site NN I-NP O
16 398 406 9391879 mutation NN I-NP O
17 406 407 9391879 , , O O
18 408 411 9391879 and CC O O
19 412 415 9391879 one CD B-NP O
20 416 424 9391879 missense JJ I-NP O
21 425 433 9391879 mutation NN I-NP O
22 433 434 9391879 . . O O

1 435 438 9391879 The DT B-NP O
2 439 447 9391879 missense JJ I-NP O
3 448 456 9391879 mutation NN I-NP O
4 457 460 9391879 was VBD B-VP O
5 461 465 9391879 also RB I-VP O
6 466 471 9391879 found VBN I-VP O
7 472 474 9391879 in IN B-PP O
8 475 476 9391879 2 CD B-NP O
9 476 477 9391879 . . O O
10 478 480 9391879 8% CD B-NP O
11 481 483 9391879 of IN B-PP O
12 484 487 9391879 the DT B-NP O
13 488 495 9391879 general JJ I-NP O
14 496 506 9391879 population NN I-NP O
15 506 507 9391879 , , O O
16 508 518 9391879 suggesting VBG B-VP O
17 519 523 9391879 that IN B-SBAR O
18 524 526 9391879 it PRP B-NP O
19 527 529 9391879 is VBZ B-VP O
20 530 533 9391879 not RB O O
21 534 541 9391879 disease NN B-NP O
22 542 552 9391879 associated VBN B-VP O
23 552 553 9391879 . . O O

1 554 557 9391879 The DT B-NP O
2 558 565 9391879 average JJ I-NP O
3 566 569 9391879 age NN I-NP O
4 570 572 9391879 of IN B-PP O
5 573 580 9391879 disease NN B-NP O
6 581 586 9391879 onset NN I-NP O
7 587 589 9391879 in IN B-PP O
8 590 595 9391879 those DT B-NP O
9 596 604 9391879 families NNS I-NP O
10 605 615 9391879 harbouring VBG B-VP O
11 616 625 9391879 causative JJ B-NP O
12 626 635 9391879 mutations NNS I-NP O
13 636 639 9391879 was VBD B-VP O
14 640 647 9391879 between IN B-PP O
15 648 650 9391879 32 CD B-NP O
16 650 651 9391879 . . O O

1 652 653 9391879 3 CD B-NP O
2 654 657 9391879 and CC I-NP O
3 658 660 9391879 37 CD I-NP O
4 660 661 9391879 . . O O

1 662 663 9391879 4 CD B-NP O
2 664 669 9391879 years NNS I-NP O
3 669 670 9391879 , , O O
4 671 678 9391879 whereas IN O O
5 679 682 9391879 the DT B-NP O
6 683 689 9391879 family NN I-NP O
7 690 700 9391879 harbouring VBG B-VP O
8 701 704 9391879 the DT B-NP O
9 705 713 9391879 missense JJ I-NP O
10 714 722 9391879 mutation NN I-NP O
11 723 726 9391879 had VBD B-VP O
12 727 729 9391879 an DT B-NP O
13 730 737 9391879 average JJ I-NP O
14 738 741 9391879 age NN I-NP O
15 742 744 9391879 of IN B-PP O
16 745 750 9391879 onset NN B-NP O
17 751 753 9391879 of IN B-PP O
18 754 756 9391879 51 CD B-NP O
19 756 757 9391879 . . O O

1 758 759 9391879 2 CD B-NP O
2 760 765 9391879 years NNS I-NP O
3 765 766 9391879 . . O O

1 767 772 9391879 These DT B-NP O
2 773 781 9391879 findings NNS I-NP O
3 782 786 9391879 show VBP B-VP O
4 787 791 9391879 that IN B-SBAR O
5 792 797 9391879 BRCA1 NN B-NP O
6 798 800 9391879 is VBZ B-VP O
7 801 811 9391879 implicated VBN I-VP O
8 812 814 9391879 in IN B-PP O
9 815 816 9391879 a DT B-NP O
10 817 822 9391879 small JJ I-NP O
11 823 831 9391879 fraction NN I-NP O
12 832 834 9391879 of IN B-PP O
13 835 841 9391879 breast NN B-NP B-Disease
14 841 842 9391879 / SYM B-NP I-Disease
15 842 849 9391879 ovarian JJ I-NP I-Disease
16 850 856 9391879 cancer NN I-NP I-Disease
17 857 865 9391879 families NNS I-NP O
18 866 876 9391879 suggesting VBG B-VP O
19 877 880 9391879 the DT B-NP O
20 881 892 9391879 involvement NN I-NP O
21 893 895 9391879 of IN B-PP O
22 896 903 9391879 another DT B-NP O
23 904 918 9391879 susceptibility NN I-NP O
24 919 923 9391879 gene NN I-NP O
25 924 925 9391879 ( ( I-NP O
26 925 926 9391879 s NNS I-NP O
27 926 927 9391879 ) ) O O

1 0 0 9869602 -DOCSTART- -X- -X- O

1 0 10 9869602 Prevalence NN B-NP O
2 11 13 9869602 of IN B-PP O
3 14 17 9869602 the DT B-NP O
4 18 24 9869602 I1307K NN I-NP O
5 25 28 9869602 APC NN I-NP B-Disease
6 29 33 9869602 gene NN I-NP O
7 34 41 9869602 variant NN I-NP O
8 42 44 9869602 in IN B-PP O
9 45 52 9869602 Israeli JJ B-NP O
10 53 57 9869602 Jews NNS I-NP O
11 58 60 9869602 of IN B-PP O
12 61 70 9869602 differing VBG B-VP O
13 71 77 9869602 ethnic JJ B-NP O
14 78 84 9869602 origin NN I-NP O
15 85 88 9869602 and CC I-NP O
16 89 93 9869602 risk NN I-NP O
17 94 97 9869602 for IN B-PP O
18 98 108 9869602 colorectal JJ B-NP B-Disease
19 109 115 9869602 cancer NN I-NP I-Disease
20 115 116 9869602 . . O O
21 117 127 9869602 BACKGROUND NN B-NP O
22 128 129 9869602 & CC I-NP O
23 130 134 9869602 AIMS NNS I-NP O
24 136 143 9869602 Israeli JJ B-NP O
25 144 148 9869602 Jews NNS I-NP O
26 149 151 9869602 of IN B-PP O
27 152 160 9869602 European JJ B-NP O
28 161 166 9869602 birth NN I-NP O
29 166 167 9869602 , , O O
30 168 169 9869602 i NN B-NP O
31 169 170 9869602 . . O O

1 171 172 9869602 e NN B-NP O
2 172 173 9869602 . NN I-NP O
3 173 174 9869602 , , O O
4 175 185 9869602 Ashkenazim NNP B-NP O
5 185 186 9869602 , , O O
6 187 191 9869602 have VBP B-VP O
7 192 195 9869602 the DT B-NP O
8 196 203 9869602 highest JJS I-NP O
9 204 214 9869602 colorectal JJ I-NP B-Disease
10 215 221 9869602 cancer NN I-NP I-Disease
11 222 231 9869602 incidence NN I-NP O
12 232 234 9869602 of IN B-PP O
13 235 238 9869602 any DT B-NP O
14 239 246 9869602 Israeli JJ I-NP O
15 247 253 9869602 ethnic JJ I-NP O
16 254 259 9869602 group NN I-NP O
17 259 260 9869602 . . O O

1 261 264 9869602 The DT B-NP O
2 265 271 9869602 I1307K NN I-NP O
3 272 275 9869602 APC NN I-NP B-Disease
4 276 280 9869602 gene NN I-NP O
5 281 288 9869602 variant NN I-NP O
6 289 292 9869602 was VBD B-VP O
7 293 298 9869602 found VBN I-VP O
8 299 301 9869602 in IN B-PP O
9 302 303 9869602 6 CD B-NP O
10 303 304 9869602 . . O O

1 305 307 9869602 1% CD B-NP O
2 308 310 9869602 of IN B-PP O
3 311 319 9869602 American JJ B-NP O
4 320 324 9869602 Jews NNS I-NP O
5 324 325 9869602 , , O O
6 326 329 9869602 28% CD B-NP O
7 330 332 9869602 of IN B-PP O
8 333 338 9869602 their PRP$ B-NP O
9 339 347 9869602 familial JJ I-NP O
10 348 358 9869602 colorectal JJ I-NP B-Disease
11 359 365 9869602 cancer NN I-NP I-Disease
12 366 371 9869602 cases NNS I-NP O
13 371 372 9869602 , , B-PP O
14 373 376 9869602 but CC I-PP O
15 377 380 9869602 not RB B-PP O
16 381 383 9869602 in IN I-PP O
17 384 387 9869602 non AFX O O
18 387 388 9869602 - HYPH O O
19 388 392 9869602 Jews NNPS B-NP O
20 392 393 9869602 . . O O

1 394 396 9869602 We PRP B-NP O
2 397 405 9869602 assessed VBD B-VP O
3 406 409 9869602 the DT B-NP O
4 410 416 9869602 I1307K NN I-NP O
5 417 427 9869602 prevalence NN I-NP O
6 428 430 9869602 in IN B-PP O
7 431 438 9869602 Israeli JJ B-NP O
8 439 443 9869602 Jews NNS I-NP O
9 444 446 9869602 of IN B-PP O
10 447 456 9869602 differing VBG B-VP O
11 457 463 9869602 ethnic JJ B-NP O
12 464 470 9869602 origin NN I-NP O
13 471 474 9869602 and CC I-NP O
14 475 479 9869602 risk NN I-NP O
15 480 483 9869602 for IN B-PP O
16 484 494 9869602 colorectal JJ B-NP B-Disease
17 495 501 9869602 cancer NN I-NP I-Disease
18 501 502 9869602 . . O O

1 503 510 9869602 METHODS NNS B-NP O
2 512 515 9869602 DNA NN I-NP O
3 516 523 9869602 samples NNS I-NP O
4 524 528 9869602 from IN B-PP O
5 529 532 9869602 500 CD B-NP O
6 533 542 9869602 unrelated JJ I-NP O
7 543 547 9869602 Jews NNS I-NP O
8 548 550 9869602 of IN B-PP O
9 551 559 9869602 European JJ B-NP O
10 560 562 9869602 or CC I-NP O
11 563 566 9869602 non AFX I-NP O
12 566 567 9869602 - HYPH I-NP O
13 567 575 9869602 European JJ I-NP O
14 576 582 9869602 origin NN I-NP O
15 582 583 9869602 , , O O
16 584 588 9869602 with IN B-PP O
17 589 591 9869602 or CC B-PP O
18 592 599 9869602 without IN B-PP O
19 600 601 9869602 a DT B-NP O
20 602 610 9869602 personal JJ I-NP O
21 611 614 9869602 and CC O O
22 614 615 9869602 / SYM B-NP O
23 615 617 9869602 or CC O O
24 618 624 9869602 family NN B-NP O
25 625 632 9869602 history NN I-NP O
26 633 635 9869602 of IN B-PP O
27 636 645 9869602 neoplasia NN B-NP B-Disease
28 645 646 9869602 , , O O
29 647 651 9869602 were VBD B-VP O
30 652 660 9869602 examined VBN I-VP O
31 661 664 9869602 for IN B-PP O
32 665 668 9869602 the DT B-NP O
33 669 675 9869602 I1307K NN I-NP O
34 676 683 9869602 variant NN I-NP O
35 684 686 9869602 by IN B-PP O
36 687 690 9869602 the DT B-NP O
37 691 697 9869602 allele NN I-NP O
38 697 698 9869602 - HYPH B-NP O
39 698 706 9869602 specific JJ I-NP O
40 707 722 9869602 oligonucleotide NN I-NP O
41 723 724 9869602 ( ( O O
42 724 727 9869602 ASO NN B-NP O
43 727 728 9869602 ) ) O O
44 729 735 9869602 method NN B-NP O
45 735 736 9869602 . . O O

1 737 744 9869602 RESULTS NNS B-NP O
2 746 748 9869602 In IN B-PP O
3 749 756 9869602 persons NNS B-NP O
4 757 759 9869602 at IN B-PP O
5 760 767 9869602 average JJ B-NP O
6 768 772 9869602 risk NN I-NP O
7 773 776 9869602 for IN B-PP O
8 777 787 9869602 colorectal JJ B-NP B-Disease
9 788 794 9869602 cancer NN I-NP I-Disease
10 794 795 9869602 , , O O
11 796 802 9869602 I1307K NN B-NP O
12 803 806 9869602 was VBD B-VP O
13 807 812 9869602 found VBN I-VP O
14 813 815 9869602 in IN B-PP O
15 816 817 9869602 5 CD B-NP O
16 817 818 9869602 . . O O
17 819 821 9869602 0% CD B-NP O
18 822 824 9869602 of IN B-PP O
19 825 828 9869602 120 CD B-NP O
20 829 837 9869602 European JJ I-NP O
21 838 841 9869602 and CC I-NP O
22 842 843 9869602 1 CD I-NP O
23 843 844 9869602 . . O O

1 845 847 9869602 6% CD B-NP O
2 848 850 9869602 of IN B-PP O
3 851 854 9869602 188 CD B-NP O
4 855 858 9869602 non AFX O O
5 858 859 9869602 - HYPH O O
6 859 867 9869602 European JJ B-NP O
7 868 872 9869602 Jews NNS I-NP O
8 873 874 9869602 ( ( O O
9 874 875 9869602 P NN B-NP O
10 876 877 9869602 = SYM B-VP O
11 878 879 9869602 0 CD B-NP O
12 879 880 9869602 . . O O

1 881 883 9869602 08 CD B-NP O
2 883 884 9869602 ) ) O O
3 884 885 9869602 . . O O

1 886 888 9869602 It PRP B-NP O
2 889 897 9869602 occurred VBD B-VP O
3 898 900 9869602 in IN B-PP O
4 901 903 9869602 15 CD B-NP O
5 903 904 9869602 . . O O

1 905 907 9869602 4% CD B-NP O
2 908 910 9869602 of IN B-PP O
3 911 913 9869602 52 CD B-NP O
4 914 923 9869602 Ashkenazi NNP I-NP O
5 924 932 9869602 Israelis NNPS I-NP O
6 933 937 9869602 with IN B-PP O
7 938 946 9869602 familial JJ B-NP O
8 947 953 9869602 cancer NN I-NP B-Disease
9 954 955 9869602 ( ( O O
10 955 956 9869602 P NN B-NP O
11 957 958 9869602 = SYM B-VP O
12 959 960 9869602 0 CD B-NP O
13 960 961 9869602 . . O O

1 962 964 9869602 02 LS B-LST O
2 964 965 9869602 ) ) O O
3 966 969 9869602 and CC O O
4 970 973 9869602 was VBD B-VP O
5 974 977 9869602 not RB I-VP O
6 978 986 9869602 detected VBN I-VP O
7 987 989 9869602 in IN B-PP O
8 990 992 9869602 51 CD B-NP O
9 993 996 9869602 non AFX O O
10 996 997 9869602 - HYPH O O
11 997 1005 9869602 European JJ B-NP O
12 1006 1010 9869602 Jews NNS I-NP O
13 1011 1013 9869602 at IN B-PP O
14 1014 1023 9869602 increased VBN B-NP O
15 1024 1030 9869602 cancer NN I-NP B-Disease
16 1031 1035 9869602 risk NN I-NP O
17 1035 1036 9869602 . . O O

1 1037 1047 9869602 Colorectal JJ B-NP B-Disease
2 1048 1057 9869602 neoplasia NN I-NP I-Disease
3 1058 1066 9869602 occurred VBD B-VP O
4 1067 1077 9869602 personally RB B-ADVP O
5 1078 1080 9869602 or CC O O
6 1081 1083 9869602 in IN B-PP O
7 1084 1087 9869602 the DT B-NP O
8 1088 1096 9869602 families NNS I-NP O
9 1097 1099 9869602 of IN B-PP O
10 1100 1102 9869602 13 CD B-NP O
11 1103 1105 9869602 of IN B-PP O
12 1106 1108 9869602 20 CD B-NP O
13 1109 1118 9869602 Ashkenazi NNP I-NP O
14 1119 1125 9869602 I1307K NN I-NP O
15 1126 1134 9869602 carriers NNS I-NP O
16 1134 1135 9869602 , , O O
17 1136 1137 9869602 8 CD B-NP O
18 1138 1140 9869602 of IN B-PP O
19 1141 1145 9869602 whom WP B-NP O
20 1146 1150 9869602 also RB B-ADVP O
21 1151 1154 9869602 had VBD B-VP O
22 1155 1156 9869602 a DT B-NP O
23 1157 1165 9869602 personal JJ I-NP O
24 1166 1168 9869602 or CC I-NP O
25 1169 1175 9869602 family NN I-NP O
26 1176 1183 9869602 history NN I-NP O
27 1184 1186 9869602 of IN B-PP O
28 1187 1197 9869602 noncolonic JJ B-NP O
29 1198 1207 9869602 neoplasia NN I-NP B-Disease
30 1207 1208 9869602 . . O O

1 1209 1220 9869602 CONCLUSIONS NNS B-NP O
2 1222 1225 9869602 The DT B-NP O
3 1226 1232 9869602 I1307K NN I-NP O
4 1233 1236 9869602 APC NN I-NP O
5 1237 1244 9869602 variant NN I-NP O
6 1245 1248 9869602 may MD B-VP O
7 1249 1258 9869602 represent VB I-VP O
8 1259 1260 9869602 a DT B-NP O
9 1261 1275 9869602 susceptibility NN I-NP O
10 1276 1280 9869602 gene NN I-NP O
11 1281 1284 9869602 for IN B-PP O
12 1285 1295 9869602 colorectal JJ B-ADJP B-Disease
13 1295 1296 9869602 , , O I-Disease
14 1297 1299 9869602 or CC O I-Disease
15 1300 1305 9869602 other JJ B-ADJP I-Disease
16 1305 1306 9869602 , , O I-Disease
17 1307 1314 9869602 cancers NNS B-NP I-Disease
18 1315 1317 9869602 in IN B-PP O
19 1318 1327 9869602 Ashkenazi NNP B-NP O
20 1328 1332 9869602 Jews NNP I-NP O
21 1332 1333 9869602 , , O O
22 1334 1337 9869602 and CC O O
23 1338 1347 9869602 partially RB B-VP O
24 1348 1356 9869602 explains VBZ I-VP O
25 1357 1360 9869602 the DT B-NP O
26 1361 1367 9869602 higher JJR I-NP O
27 1368 1377 9869602 incidence NN I-NP O
28 1378 1380 9869602 of IN B-PP O
29 1381 1391 9869602 colorectal JJ B-NP B-Disease
30 1392 1398 9869602 cancer NN I-NP I-Disease
31 1399 1401 9869602 in IN B-PP O
32 1402 1410 9869602 European JJ B-NP O
33 1411 1419 9869602 Israelis NNPS I-NP O
34 1419 1420 9869602 . . O O

1 0 0 9668171 -DOCSTART- -X- -X- O

1 0 7 9668171 Somatic JJ B-NP O
2 8 19 9668171 instability NN I-NP O
3 20 22 9668171 of IN B-PP O
4 23 26 9668171 the DT B-NP O
5 27 30 9668171 CTG NN I-NP O
6 31 37 9668171 repeat NN I-NP O
7 38 40 9668171 in IN B-PP O
8 41 45 9668171 mice NNS B-NP O
9 46 56 9668171 transgenic JJ B-ADJP O
10 57 60 9668171 for IN B-PP O
11 61 64 9668171 the DT B-NP O
12 65 73 9668171 myotonic JJ I-NP B-Disease
13 74 83 9668171 dystrophy NN I-NP I-Disease
14 84 90 9668171 region NN I-NP O
15 91 93 9668171 is VBZ B-VP O
16 94 97 9668171 age NN B-NP O
17 98 107 9668171 dependent JJ I-NP O
18 108 111 9668171 but CC O O
19 112 115 9668171 not RB B-VP O
20 116 126 9668171 correlated VBD I-VP O
21 127 129 9668171 to TO B-PP O
22 130 133 9668171 the DT B-NP O
23 134 142 9668171 relative JJ I-NP O
24 143 154 9668171 intertissue NN I-NP O
25 155 168 9668171 transcription NN I-NP O
26 169 175 9668171 levels NNS I-NP O
27 176 179 9668171 and CC O O
28 180 193 9668171 proliferative JJ B-NP O
29 194 204 9668171 capacities NNS I-NP O
30 204 205 9668171 . . O O
31 206 207 9668171 A NN B-NP O
32 208 209 9668171 ( ( O O
33 209 212 9668171 CTG NN B-NP O
34 212 213 9668171 ) ) O O
35 214 224 9668171 nexpansion NN B-NP O
36 225 227 9668171 in IN B-PP O
37 228 231 9668171 the DT B-NP O
38 232 233 9668171 3 CD I-NP O
39 233 234 9668171 - HYPH I-NP O
40 234 246 9668171 untranslated JJ I-NP O
41 247 253 9668171 region NN I-NP O
42 254 255 9668171 ( ( O O
43 255 258 9668171 UTR NN B-NP O
44 258 259 9668171 ) ) O O
45 260 262 9668171 of IN B-PP O
46 263 266 9668171 the DT B-NP O
47 267 269 9668171 DM NN I-NP O
48 270 277 9668171 protein NN I-NP O
49 278 284 9668171 kinase NN I-NP O
50 285 289 9668171 gene NN I-NP O
51 290 291 9668171 ( ( O O
52 291 295 9668171 DMPK NN B-NP O
53 295 296 9668171 ) ) O O
54 297 299 9668171 is VBZ B-VP O
55 300 311 9668171 responsible JJ B-ADJP O
56 312 315 9668171 for IN B-PP O
57 316 323 9668171 causing VBG B-VP O
58 324 332 9668171 myotonic JJ B-NP B-Disease
59 333 342 9668171 dystrophy NN I-NP I-Disease
60 343 344 9668171 ( ( O O
61 344 346 9668171 DM NN B-NP B-Disease
62 346 347 9668171 ) ) O O
63 347 348 9668171 . . O O

1 349 354 9668171 Major JJ B-NP O
2 355 366 9668171 instability NN I-NP O
3 366 367 9668171 , , O O
4 368 372 9668171 with IN B-PP O
5 373 377 9668171 very RB B-NP O
6 378 383 9668171 large JJ I-NP O
7 384 394 9668171 expansions NNS I-NP O
8 395 402 9668171 between IN B-PP O
9 403 414 9668171 generations NNS B-NP O
10 415 418 9668171 and CC O O
11 419 423 9668171 high JJ B-NP O
12 424 430 9668171 levels NNS I-NP O
13 431 433 9668171 of IN B-PP O
14 434 441 9668171 somatic JJ B-NP O
15 442 451 9668171 mosaicism NN I-NP O
16 451 452 9668171 , , O O
17 453 455 9668171 is VBZ B-VP O
18 456 464 9668171 observed VBN I-VP O
19 465 467 9668171 in IN B-PP O
20 468 476 9668171 patients NNS B-NP O
21 476 477 9668171 . . O O

1 478 483 9668171 There EX B-NP O
2 484 486 9668171 is VBZ B-VP O
3 487 488 9668171 a DT B-NP O
4 489 493 9668171 good JJ I-NP O
5 494 505 9668171 correlation NN I-NP O
6 506 513 9668171 between IN B-PP O
7 514 520 9668171 repeat NN B-NP O
8 521 525 9668171 size NN I-NP O
9 526 527 9668171 ( ( O O
10 527 529 9668171 at IN B-ADVP O
11 530 535 9668171 least JJS I-ADVP O
12 536 538 9668171 in IN B-PP O
13 539 549 9668171 leucocytes NNS B-NP O
14 549 550 9668171 ) ) O O
15 550 551 9668171 , , O O
16 552 560 9668171 clinical JJ B-NP O
17 561 569 9668171 severity NN I-NP O
18 570 573 9668171 and CC O O
19 574 577 9668171 age NN B-NP O
20 578 580 9668171 of IN B-PP O
21 581 586 9668171 onset NN B-NP O
22 586 587 9668171 . . O O

1 588 591 9668171 The DT B-NP O
2 592 605 9668171 trinucleotide NN I-NP O
3 606 612 9668171 repeat NN I-NP O
4 613 624 9668171 instability NN I-NP O
5 625 635 9668171 mechanisms NNS I-NP O
6 636 644 9668171 involved VBN B-VP O
7 645 647 9668171 in IN B-PP O
8 648 650 9668171 DM NN B-NP B-Disease
9 651 654 9668171 and CC O O
10 655 660 9668171 other JJ B-NP O
11 661 666 9668171 human JJ I-NP O
12 667 674 9668171 genetic JJ I-NP B-Disease
13 675 683 9668171 diseases NNS I-NP I-Disease
14 684 687 9668171 are VBP B-VP O
15 688 695 9668171 unknown JJ B-ADJP O
16 695 696 9668171 . . O O

1 697 699 9668171 We PRP B-NP O
2 700 707 9668171 studied VBD B-VP O
3 708 715 9668171 somatic JJ B-NP O
4 716 727 9668171 instability NN I-NP O
5 728 730 9668171 by IN B-PP O
6 731 740 9668171 measuring VBG B-VP O
7 741 744 9668171 the DT B-NP O
8 745 748 9668171 CTG NN I-NP O
9 749 755 9668171 repeat NN I-NP O
10 756 762 9668171 length NN I-NP O
11 763 765 9668171 at IN B-PP O
12 766 773 9668171 several JJ B-NP O
13 774 778 9668171 ages NNS I-NP O
14 779 781 9668171 in IN B-PP O
15 782 789 9668171 various JJ B-NP O
16 790 797 9668171 tissues NNS I-NP O
17 798 800 9668171 of IN B-PP O
18 801 811 9668171 transgenic JJ B-NP O
19 812 816 9668171 mice NNS I-NP O
20 817 825 9668171 carrying VBG B-VP O
21 826 827 9668171 a DT B-NP O
22 828 829 9668171 ( ( O O
23 829 832 9668171 CTG NN O O
24 832 833 9668171 ) ) O O
25 834 845 9668171 55expansion NN B-NP O
26 846 856 9668171 surrounded VBN B-VP O
27 857 859 9668171 by IN B-PP O
28 860 862 9668171 45 CD B-NP O
29 863 865 9668171 kb NN I-NP O
30 866 868 9668171 of IN B-PP O
31 869 872 9668171 the DT B-NP O
32 873 878 9668171 human JJ I-NP O
33 879 881 9668171 DM NN I-NP B-Disease
34 882 888 9668171 region NN I-NP O
35 888 889 9668171 , , O O
36 890 895 9668171 using VBG B-VP O
37 896 901 9668171 small JJ B-NP O
38 901 902 9668171 - HYPH I-NP O
39 902 906 9668171 pool NN I-NP O
40 907 910 9668171 PCR NN I-NP O
41 910 911 9668171 . . O O

1 912 917 9668171 These DT B-NP O
2 918 922 9668171 mice NNS I-NP O
3 923 927 9668171 have VBP B-VP O
4 928 932 9668171 been VBN I-VP O
5 933 938 9668171 shown VBN I-VP O
6 939 941 9668171 to TO I-VP O
7 942 951 9668171 reproduce VB I-VP O
8 952 955 9668171 the DT B-NP O
9 956 973 9668171 intergenerational JJ I-NP O
10 974 977 9668171 and CC I-NP O
11 978 985 9668171 somatic JJ I-NP O
12 986 997 9668171 instability NN I-NP O
13 998 1000 9668171 of IN B-PP O
14 1001 1004 9668171 the DT B-NP O
15 1005 1007 9668171 55 CD I-NP O
16 1008 1011 9668171 CTG NN I-NP O
17 1012 1018 9668171 repeat NN I-NP O
18 1019 1029 9668171 suggesting VBG B-VP O
19 1030 1034 9668171 that IN B-SBAR O
20 1035 1046 9668171 surrounding VBG B-VP O
21 1047 1056 9668171 sequences NNS B-NP O
22 1057 1060 9668171 and CC O O
23 1061 1064 9668171 the DT B-NP O
24 1065 1074 9668171 chromatin NN I-NP O
25 1075 1086 9668171 environment NN I-NP O
26 1087 1090 9668171 are VBP B-VP O
27 1091 1099 9668171 involved VBN I-VP O
28 1100 1102 9668171 in IN B-PP O
29 1103 1114 9668171 instability NN B-NP O
30 1115 1125 9668171 mechanisms NNS I-NP O
31 1125 1126 9668171 . . O O

1 1127 1129 9668171 As IN B-SBAR O
2 1130 1138 9668171 observed VBN B-VP O
3 1139 1141 9668171 in IN B-PP O
4 1142 1146 9668171 some DT B-NP O
5 1147 1149 9668171 of IN B-PP O
6 1150 1153 9668171 the DT B-NP O
7 1154 1161 9668171 tissues NNS I-NP O
8 1162 1164 9668171 of IN B-PP O
9 1165 1167 9668171 DM NN B-NP B-Disease
10 1168 1176 9668171 patients NNS I-NP O
11 1176 1177 9668171 , , O O
12 1178 1183 9668171 there EX B-NP O
13 1184 1186 9668171 is VBZ B-VP O
14 1187 1188 9668171 a DT B-NP O
15 1189 1197 9668171 tendency NN I-NP O
16 1198 1201 9668171 for IN B-PP O
17 1202 1208 9668171 repeat NN B-NP O
18 1209 1215 9668171 length NN I-NP O
19 1216 1219 9668171 and CC O O
20 1220 1227 9668171 somatic JJ B-NP O
21 1228 1237 9668171 mosaicism NN I-NP O
22 1238 1240 9668171 to TO B-VP O
23 1241 1249 9668171 increase VB I-VP O
24 1250 1254 9668171 with IN B-PP O
25 1255 1258 9668171 the DT B-NP O
26 1259 1262 9668171 age NN I-NP O
27 1263 1265 9668171 of IN B-PP O
28 1266 1269 9668171 the DT B-NP O
29 1270 1275 9668171 mouse NN I-NP O
30 1275 1276 9668171 . . O O

1 1277 1288 9668171 Furthermore RB B-ADVP O
2 1288 1289 9668171 , , O O
3 1290 1292 9668171 we PRP B-NP O
4 1293 1301 9668171 observed VBD B-VP O
5 1302 1304 9668171 no DT B-NP O
6 1305 1316 9668171 correlation NN I-NP O
7 1317 1324 9668171 between IN B-PP O
8 1325 1328 9668171 the DT B-NP O
9 1329 1336 9668171 somatic JJ I-NP O
10 1337 1345 9668171 mutation NN I-NP O
11 1346 1350 9668171 rate NN I-NP O
12 1351 1354 9668171 and CC I-NP O
13 1355 1361 9668171 tissue NN I-NP O
14 1362 1375 9668171 proliferation NN I-NP O
15 1376 1384 9668171 capacity NN I-NP O
16 1384 1385 9668171 . . O O

1 1386 1389 9668171 The DT B-NP O
2 1390 1397 9668171 somatic JJ I-NP O
3 1398 1406 9668171 mutation NN I-NP O
4 1407 1412 9668171 rates NNS I-NP O
5 1413 1415 9668171 in IN B-PP O
6 1416 1425 9668171 different JJ B-NP O
7 1426 1433 9668171 tissues NNS I-NP O
8 1434 1438 9668171 were VBD B-VP O
9 1439 1443 9668171 also RB I-VP O
10 1444 1447 9668171 not RB I-VP O
11 1448 1458 9668171 correlated VBN I-VP O
12 1459 1461 9668171 to TO B-PP O
13 1462 1465 9668171 the DT B-NP O
14 1466 1474 9668171 relative JJ I-NP O
15 1475 1480 9668171 inter NN I-NP O
16 1480 1481 9668171 - HYPH B-NP O
17 1481 1487 9668171 tissue NN I-NP O
18 1488 1498 9668171 difference NN I-NP O
19 1499 1501 9668171 in IN B-PP O
20 1502 1517 9668171 transcriptional JJ B-NP O
21 1518 1524 9668171 levels NNS I-NP O
22 1525 1527 9668171 of IN B-PP O
23 1528 1531 9668171 the DT B-NP O
24 1532 1537 9668171 three CD I-NP O
25 1538 1543 9668171 genes NNS I-NP O
26 1544 1545 9668171 ( ( O O
27 1545 1550 9668171 DMAHP NN B-NP O
28 1550 1551 9668171 , , O O
29 1552 1556 9668171 DMPK NN B-NP O
30 1557 1560 9668171 and CC O O
31 1561 1563 9668171 59 CD B-NP O
32 1563 1564 9668171 ) ) O O
33 1565 1576 9668171 surrounding VBG B-VP O
34 1577 1580 9668171 the DT B-NP O
35 1581 1587 9668171 repeat NN I-NP O
36 1587 1588 9668171 . . O O
37 1588 1589 9668171 . . O O

1 0 0 9733027 -DOCSTART- -X- -X- O

1 0 5 9733027 Sperm NN B-NP O
2 6 9 9733027 DNA NN I-NP O
3 10 18 9733027 analysis NN I-NP O
4 19 21 9733027 in IN B-PP O
5 22 23 9733027 a DT B-NP O
6 24 34 9733027 Friedreich NNP I-NP B-Disease
7 35 41 9733027 ataxia NN I-NP I-Disease
8 42 53 9733027 premutation NN I-NP O
9 54 61 9733027 carrier NN I-NP O
10 62 70 9733027 suggests VBZ B-VP O
11 71 75 9733027 both CC O O
12 76 83 9733027 meiotic JJ B-NP O
13 84 87 9733027 and CC I-NP O
14 88 95 9733027 mitotic JJ I-NP O
15 96 105 9733027 expansion NN I-NP O
16 106 108 9733027 in IN B-PP O
17 109 112 9733027 the DT B-NP O
18 113 117 9733027 FRDA NN I-NP B-Disease
19 118 122 9733027 gene NN I-NP O
20 122 123 9733027 . . O O
21 124 134 9733027 Friedreich NNP B-NP B-Disease
22 135 141 9733027 ataxia NN I-NP I-Disease
23 142 144 9733027 is VBZ B-VP O
24 145 152 9733027 usually RB I-VP O
25 153 159 9733027 caused VBN I-VP O
26 160 162 9733027 by IN B-PP O
27 163 165 9733027 an DT B-NP O
28 166 175 9733027 expansion NN I-NP O
29 176 178 9733027 of IN B-PP O
30 179 180 9733027 a DT B-NP O
31 181 184 9733027 GAA NN I-NP O
32 185 198 9733027 trinucleotide NN I-NP O
33 199 205 9733027 repeat NN I-NP O
34 206 208 9733027 in IN B-PP O
35 209 215 9733027 intron NN B-NP O
36 216 217 9733027 1 CD I-NP O
37 218 220 9733027 of IN B-PP O
38 221 224 9733027 the DT B-NP O
39 225 229 9733027 FRDA NN I-NP B-Disease
40 230 234 9733027 gene NN I-NP O
41 234 235 9733027 . . O O

1 236 248 9733027 Occasionally RB B-ADVP O
2 248 249 9733027 , , O O
3 250 251 9733027 a DT B-NP O
4 252 257 9733027 fully RB I-NP O
5 258 266 9733027 expanded VBN I-NP O
6 267 273 9733027 allele NN I-NP O
7 274 277 9733027 has VBZ B-VP O
8 278 282 9733027 been VBN I-VP O
9 283 288 9733027 found VBN I-VP O
10 289 291 9733027 to TO I-VP O
11 292 297 9733027 arise VB I-VP O
12 298 302 9733027 from IN B-PP O
13 303 304 9733027 a DT B-NP O
14 305 316 9733027 premutation NN I-NP O
15 317 319 9733027 of IN B-PP O
16 320 323 9733027 100 CD B-NP O
17 324 326 9733027 or CC I-NP O
18 327 331 9733027 less JJR I-NP O
19 332 339 9733027 triplet JJ I-NP O
20 340 347 9733027 repeats NNS I-NP O
21 347 348 9733027 . . O O

1 349 351 9733027 We PRP B-NP O
2 352 356 9733027 have VBP B-VP O
3 357 365 9733027 examined VBN I-VP O
4 366 369 9733027 the DT B-NP O
5 370 375 9733027 sperm NN I-NP O
6 376 379 9733027 DNA NN I-NP O
7 380 382 9733027 of IN B-PP O
8 383 384 9733027 a DT B-NP O
9 385 396 9733027 premutation NN I-NP O
10 397 404 9733027 carrier NN I-NP O
11 404 405 9733027 . . O O

1 406 410 9733027 This DT B-NP O
2 411 415 9733027 mans VBZ B-VP O
3 416 425 9733027 leucocyte NN B-NP O
4 426 429 9733027 DNA NN I-NP O
5 430 436 9733027 showed VBD B-VP O
6 437 440 9733027 one CD B-NP O
7 441 447 9733027 normal JJ I-NP O
8 448 454 9733027 allele NN I-NP O
9 455 458 9733027 and CC O O
10 459 462 9733027 one CD B-NP O
11 463 469 9733027 allele NN I-NP O
12 470 472 9733027 of IN B-PP O
13 473 486 9733027 approximately RB B-NP O
14 487 490 9733027 100 CD I-NP O
15 491 498 9733027 repeats NNS I-NP O
16 498 499 9733027 . . O O

1 500 503 9733027 His PRP$ B-NP O
2 504 509 9733027 sperm NN I-NP O
3 510 516 9733027 showed VBD B-VP O
4 517 519 9733027 an DT B-NP O
5 520 528 9733027 expanded VBN I-NP O
6 529 535 9733027 allele NN I-NP O
7 536 538 9733027 in IN B-PP O
8 539 540 9733027 a DT B-NP O
9 541 546 9733027 tight JJ I-NP O
10 547 552 9733027 range NN I-NP O
11 553 562 9733027 centering NN I-NP O
12 563 565 9733027 on IN B-PP O
13 566 567 9733027 a DT B-NP O
14 568 572 9733027 size NN I-NP O
15 573 575 9733027 of IN B-PP O
16 576 589 9733027 approximately RB B-NP O
17 590 593 9733027 320 CD I-NP O
18 594 607 9733027 trinucleotide NN I-NP O
19 608 615 9733027 repeats NNS I-NP O
20 615 616 9733027 . . O O

1 617 620 9733027 His PRP$ B-NP O
2 621 629 9733027 affected JJ I-NP O
3 630 633 9733027 son NN I-NP O
4 634 637 9733027 has VBZ B-VP O
5 638 644 9733027 repeat NN B-NP O
6 645 650 9733027 sizes NNS I-NP O
7 651 653 9733027 of IN B-PP O
8 654 658 9733027 1040 CD B-NP O
9 659 662 9733027 and CC I-NP O
10 663 666 9733027 540 CD I-NP O
11 666 667 9733027 . . O O

1 668 673 9733027 These DT B-NP O
2 674 678 9733027 data NNS I-NP O
3 679 686 9733027 suggest VBP B-VP O
4 687 691 9733027 that IN B-SBAR O
5 692 701 9733027 expansion NN B-NP O
6 702 708 9733027 occurs VBZ B-VP O
7 709 711 9733027 in IN B-PP O
8 712 715 9733027 two CD B-NP O
9 716 722 9733027 stages NNS I-NP O
10 722 723 9733027 , , O O
11 724 727 9733027 the DT B-NP O
12 728 733 9733027 first JJ I-NP O
13 734 740 9733027 during IN B-PP O
14 741 748 9733027 meiosis NN B-NP O
15 749 757 9733027 followed VBN B-VP O
16 758 760 9733027 by IN B-PP O
17 761 762 9733027 a DT B-NP O
18 763 769 9733027 second JJ I-NP O
19 770 777 9733027 mitotic JJ I-NP O
20 778 787 9733027 expansion NN I-NP O
21 787 788 9733027 . . O O

1 789 791 9733027 We PRP B-NP O
2 792 796 9733027 also RB B-ADVP O
3 797 801 9733027 show VBP B-VP O
4 802 806 9733027 that IN B-SBAR O
5 807 809 9733027 in IN B-PP O
6 810 813 9733027 all DT B-NP O
7 814 825 9733027 informative JJ I-NP O
8 826 833 9733027 carrier NN I-NP O
9 834 840 9733027 father NN I-NP O
10 841 843 9733027 to TO B-PP O
11 844 852 9733027 affected VBN B-NP O
12 853 858 9733027 child NN I-NP O
13 859 872 9733027 transmissions NNS I-NP O
14 872 873 9733027 , , O O
15 874 878 9733027 with IN B-PP O
16 879 882 9733027 the DT B-NP O
17 883 890 9733027 notable JJ I-NP O
18 891 900 9733027 exception NN I-NP O
19 901 903 9733027 of IN B-PP O
20 904 907 9733027 the DT B-NP O
21 908 919 9733027 premutation NN I-NP O
22 920 927 9733027 carrier NN I-NP O
23 927 928 9733027 , , O O
24 929 932 9733027 the DT B-NP O
25 933 942 9733027 expansion NN I-NP O
26 943 947 9733027 size NN I-NP O
27 948 957 9733027 decreases VBZ B-VP O
28 957 958 9733027 . . O O
29 958 959 9733027 . . O O

1 0 0 9521421 -DOCSTART- -X- -X- O

1 0 9 9521421 Molecular JJ B-NP O
2 10 23 9521421 heterogeneity NN I-NP O
3 24 26 9521421 in IN B-PP O
4 27 48 9521421 mucopolysaccharidosis NN B-NP B-Disease
5 49 52 9521421 IVA NN I-NP I-Disease
6 53 55 9521421 in IN B-PP O
7 56 65 9521421 Australia NNP B-NP O
8 66 69 9521421 and CC I-NP O
9 70 78 9521421 Northern NNP I-NP O
10 79 86 9521421 Ireland NNP I-NP O
11 86 87 9521421 : : O O
12 88 92 9521421 nine CD B-NP O
13 93 98 9521421 novel JJ I-NP O
14 99 108 9521421 mutations NNS I-NP O
15 109 118 9521421 including VBG B-PP O
16 119 124 9521421 T312S NN B-NP O
17 124 125 9521421 , , O O
18 126 127 9521421 a DT B-NP O
19 128 134 9521421 common JJ I-NP O
20 135 141 9521421 allele NN I-NP O
21 142 146 9521421 that WDT B-NP O
22 147 154 9521421 confers VBZ B-VP O
23 155 156 9521421 a DT B-NP O
24 157 161 9521421 mild JJ I-NP O
25 162 171 9521421 phenotype NN I-NP O
26 171 172 9521421 . . O O
27 173 194 9521421 Mucopolysaccharidosis NN B-NP B-Disease
28 195 198 9521421 IVA NN I-NP I-Disease
29 199 200 9521421 ( ( O O
30 200 203 9521421 MPS NN B-NP B-Disease
31 204 207 9521421 IVA NN I-NP I-Disease
32 207 208 9521421 ) ) O O
33 209 211 9521421 is VBZ B-VP O
34 212 214 9521421 an DT B-NP O
35 215 224 9521421 autosomal JJ I-NP B-Disease
36 225 234 9521421 recessive JJ I-NP I-Disease
37 235 244 9521421 lysosomal JJ I-NP I-Disease
38 245 252 9521421 storage NN I-NP I-Disease
39 253 261 9521421 disorder NN I-NP I-Disease
40 262 268 9521421 caused VBN B-VP O
41 269 271 9521421 by IN B-PP O
42 272 273 9521421 a DT B-NP O
43 274 281 9521421 genetic JJ I-NP B-Disease
44 282 288 9521421 defect NN I-NP I-Disease
45 289 291 9521421 in IN B-PP O
46 292 293 9521421 N NN B-NP O
47 293 294 9521421 - HYPH B-NP O
48 294 313 9521421 acetylgalactosamine NN I-NP O
49 313 314 9521421 - HYPH B-NP O
50 314 315 9521421 6 CD I-NP O
51 315 316 9521421 - HYPH I-NP O
52 316 323 9521421 sulfate NN I-NP O
53 324 333 9521421 sulfatase NN I-NP O
54 334 335 9521421 ( ( O O
55 335 340 9521421 GALNS NN B-NP O
56 340 341 9521421 ) ) O O
57 341 342 9521421 . . O O

1 343 351 9521421 Previous JJ B-NP O
2 352 359 9521421 studies NNS I-NP O
3 360 362 9521421 of IN B-PP O
4 363 371 9521421 patients NNS B-NP O
5 372 376 9521421 from IN B-PP O
6 377 378 9521421 a DT B-NP O
7 379 386 9521421 British JJ I-NP O
8 386 387 9521421 - HYPH I-NP O
9 387 392 9521421 Irish JJ I-NP O
10 393 403 9521421 population NN I-NP O
11 404 410 9521421 showed VBD B-VP O
12 411 415 9521421 that IN B-SBAR O
13 416 419 9521421 the DT B-NP O
14 420 425 9521421 I113F NN I-NP O
15 426 434 9521421 mutation NN I-NP O
16 435 437 9521421 is VBZ B-VP O
17 438 441 9521421 the DT B-NP O
18 442 446 9521421 most RBS I-NP O
19 447 453 9521421 common JJ I-NP O
20 454 460 9521421 single JJ I-NP O
21 461 469 9521421 mutation NN I-NP O
22 470 475 9521421 among IN B-PP O
23 476 479 9521421 MPS NN B-NP B-Disease
24 480 483 9521421 IVA NN I-NP I-Disease
25 484 492 9521421 patients NNS I-NP O
26 493 496 9521421 and CC O O
27 497 505 9521421 produces VBZ B-VP O
28 506 507 9521421 a DT B-NP O
29 508 514 9521421 severe JJ I-NP O
30 515 523 9521421 clinical JJ I-NP O
31 524 533 9521421 phenotype NN I-NP O
32 533 534 9521421 . . O O

1 535 537 9521421 We PRP B-NP O
2 538 545 9521421 studied VBD B-VP O
3 546 555 9521421 mutations NNS B-NP O
4 556 558 9521421 in IN B-PP O
5 559 562 9521421 the DT B-NP O
6 563 568 9521421 GALNS NN I-NP O
7 569 573 9521421 gene NN I-NP O
8 574 578 9521421 from IN B-PP O
9 579 581 9521421 23 CD B-NP O
10 582 592 9521421 additional JJ I-NP O
11 593 596 9521421 MPS NN I-NP B-Disease
12 597 600 9521421 IVA NN I-NP I-Disease
13 601 609 9521421 patients NNS I-NP O
14 610 611 9521421 ( ( O O
15 611 613 9521421 15 CD B-NP O
16 614 618 9521421 from IN B-PP O
17 619 628 9521421 Australia NNP B-NP O
18 628 629 9521421 , , O O
19 630 631 9521421 8 CD B-NP O
20 632 636 9521421 from IN B-PP O
21 637 645 9521421 Northern NNP B-NP O
22 646 653 9521421 Ireland NNP I-NP O
23 653 654 9521421 ) ) O O
24 654 655 9521421 , , O O
25 656 660 9521421 with IN B-PP O
26 661 668 9521421 various JJ B-NP O
27 669 677 9521421 clinical JJ I-NP O
28 678 688 9521421 phenotypes NNS I-NP O
29 689 690 9521421 ( ( O O
30 690 696 9521421 severe JJ B-ADJP O
31 696 697 9521421 , , O O
32 698 700 9521421 16 CD B-NP O
33 701 706 9521421 cases NNS I-NP O
34 706 707 9521421 ; : O O
35 708 720 9521421 intermediate NN B-NP O
36 720 721 9521421 , , O O
37 722 723 9521421 4 CD B-NP O
38 724 729 9521421 cases NNS I-NP O
39 729 730 9521421 ; : O O
40 731 735 9521421 mild JJ B-ADJP O
41 735 736 9521421 , , O O
42 737 738 9521421 3 CD B-NP O
43 739 744 9521421 cases NNS I-NP O
44 744 745 9521421 ) ) O O
45 745 746 9521421 . . O O

1 747 749 9521421 We PRP B-NP O
2 750 755 9521421 found VBD B-VP O
3 756 759 9521421 two CD B-NP O
4 760 766 9521421 common JJ I-NP O
5 767 776 9521421 mutations NNS I-NP O
6 777 781 9521421 that WDT B-NP O
7 782 790 9521421 together RB B-ADVP O
8 791 800 9521421 accounted VBD B-VP O
9 801 804 9521421 for IN B-PP O
10 805 808 9521421 32% NN B-NP O
11 809 811 9521421 of IN B-PP O
12 812 815 9521421 the DT B-NP O
13 816 818 9521421 44 CD I-NP O
14 819 828 9521421 unrelated JJ I-NP O
15 829 836 9521421 alleles NNS I-NP O
16 837 839 9521421 in IN B-PP O
17 840 845 9521421 these DT B-NP O
18 846 854 9521421 patients NNS I-NP O
19 854 855 9521421 . . O O

1 856 859 9521421 One CD B-NP O
2 860 862 9521421 is VBZ B-VP O
3 863 866 9521421 the DT B-NP O
4 867 872 9521421 T312S NN I-NP O
5 873 881 9521421 mutation NN I-NP O
6 881 882 9521421 , , O O
7 883 884 9521421 a DT B-NP O
8 885 890 9521421 novel JJ I-NP O
9 891 899 9521421 mutation NN I-NP O
10 900 905 9521421 found VBN B-VP O
11 906 917 9521421 exclusively RB B-ADVP O
12 918 920 9521421 in IN B-PP O
13 921 927 9521421 milder NN B-NP O
14 928 936 9521421 patients NNS I-NP O
15 936 937 9521421 . . O O

1 938 941 9521421 The DT B-NP O
2 942 947 9521421 other JJ I-NP O
3 948 950 9521421 is VBZ B-VP O
4 951 954 9521421 the DT B-NP O
5 955 965 9521421 previously RB I-NP O
6 966 975 9521421 described VBN I-NP O
7 976 981 9521421 I113F NN I-NP O
8 982 986 9521421 that WDT B-NP O
9 987 995 9521421 produces VBZ B-VP O
10 996 997 9521421 a DT B-NP O
11 998 1004 9521421 severe JJ I-NP O
12 1005 1014 9521421 phenotype NN I-NP O
13 1014 1015 9521421 . . O O

1 1016 1019 9521421 The DT B-NP O
2 1020 1025 9521421 I113F NN I-NP O
3 1026 1029 9521421 and CC I-NP O
4 1030 1035 9521421 T312S NN I-NP O
5 1036 1045 9521421 mutations NNS I-NP O
6 1046 1055 9521421 accounted VBD B-VP O
7 1056 1059 9521421 for IN B-PP O
8 1060 1061 9521421 8 CD B-NP O
9 1062 1063 9521421 ( ( O O
10 1063 1066 9521421 18% NN B-NP O
11 1066 1067 9521421 ) ) O O
12 1068 1071 9521421 and CC O O
13 1072 1073 9521421 6 CD B-NP O
14 1074 1075 9521421 ( ( O O
15 1075 1078 9521421 14% NN B-NP O
16 1078 1079 9521421 ) ) O O
17 1080 1082 9521421 of IN B-PP O
18 1083 1085 9521421 44 CD B-NP O
19 1086 1095 9521421 unrelated JJ I-NP O
20 1096 1103 9521421 alleles NNS I-NP O
21 1103 1104 9521421 , , O O
22 1105 1117 9521421 respectively RB B-ADVP O
23 1117 1118 9521421 . . O O

1 1119 1122 9521421 The DT B-NP O
2 1123 1133 9521421 relatively RB I-NP O
3 1134 1138 9521421 high JJ I-NP O
4 1139 1147 9521421 residual JJ I-NP O
5 1148 1153 9521421 GALNS NN I-NP O
6 1154 1162 9521421 activity NN I-NP O
7 1163 1167 9521421 seen VBN B-VP O
8 1168 1172 9521421 when WRB B-ADVP O
9 1173 1176 9521421 the DT B-NP O
10 1177 1182 9521421 T312S NN I-NP O
11 1183 1189 9521421 mutant JJ I-NP O
12 1190 1194 9521421 cDNA NN I-NP O
13 1195 1197 9521421 is VBZ B-VP O
14 1198 1211 9521421 overexpressed VBN I-VP O
15 1212 1214 9521421 in IN B-PP O
16 1215 1221 9521421 mutant JJ B-NP O
17 1222 1227 9521421 cells NNS I-NP O
18 1228 1236 9521421 provides VBZ B-VP O
19 1237 1239 9521421 an DT B-NP O
20 1240 1251 9521421 explanation NN I-NP O
21 1252 1255 9521421 for IN B-PP O
22 1256 1259 9521421 the DT B-NP O
23 1260 1264 9521421 mild JJ I-NP O
24 1265 1274 9521421 phenotype NN I-NP O
25 1275 1277 9521421 in IN B-PP O
26 1278 1286 9521421 patients NNS B-NP O
27 1287 1291 9521421 with IN B-PP O
28 1292 1296 9521421 this DT B-NP O
29 1297 1305 9521421 mutation NN I-NP O
30 1305 1306 9521421 . . O O

1 1307 1310 9521421 The DT B-NP O
2 1311 1323 9521421 distribution NN I-NP O
3 1324 1327 9521421 and CC I-NP O
4 1328 1336 9521421 relative JJ I-NP O
5 1337 1348 9521421 frequencies NNS I-NP O
6 1349 1351 9521421 of IN B-PP O
7 1352 1355 9521421 the DT B-NP O
8 1356 1361 9521421 I113F NN I-NP O
9 1362 1365 9521421 and CC I-NP O
10 1366 1371 9521421 T312S NN I-NP O
11 1372 1381 9521421 mutations NNS I-NP O
12 1382 1384 9521421 in IN B-PP O
13 1385 1394 9521421 Australia NNP B-NP O
14 1395 1407 9521421 corresponded VBD B-VP O
15 1408 1410 9521421 to TO B-PP O
16 1411 1416 9521421 those DT B-NP O
17 1417 1425 9521421 observed VBN B-VP O
18 1426 1428 9521421 in IN B-PP O
19 1429 1437 9521421 Northern NNP B-NP O
20 1438 1445 9521421 Ireland NNP I-NP O
21 1446 1449 9521421 and CC O O
22 1450 1453 9521421 are VBP B-VP O
23 1454 1460 9521421 unique JJ B-ADJP O
24 1461 1463 9521421 to TO B-PP O
25 1464 1469 9521421 these DT B-NP O
26 1470 1473 9521421 two CD I-NP O
27 1474 1485 9521421 populations NNS I-NP O
28 1485 1486 9521421 , , O O
29 1487 1497 9521421 suggesting VBG B-VP O
30 1498 1502 9521421 that IN B-SBAR O
31 1503 1507 9521421 both DT B-NP O
32 1508 1517 9521421 mutations NNS I-NP O
33 1518 1522 9521421 were VBD B-VP O
34 1523 1531 9521421 probably RB I-VP O
35 1532 1542 9521421 introduced VBN I-VP O
36 1543 1545 9521421 to TO B-PP O
37 1546 1555 9521421 Australia NNP B-NP O
38 1556 1558 9521421 by IN B-PP O
39 1559 1564 9521421 Irish JJ B-NP O
40 1565 1573 9521421 migrants NNS I-NP O
41 1574 1580 9521421 during IN B-PP O
42 1581 1584 9521421 the DT B-NP O
43 1585 1589 9521421 19th JJ I-NP O
44 1590 1597 9521421 century NN I-NP O
45 1597 1598 9521421 . . O O

1 1599 1608 9521421 Haplotype NN B-NP O
2 1609 1617 9521421 analysis NN I-NP O
3 1618 1623 9521421 using VBG B-VP O
4 1624 1625 9521421 6 CD B-NP O
5 1626 1631 9521421 RFLPs NNS I-NP O
6 1632 1640 9521421 provides VBZ B-VP O
7 1641 1651 9521421 additional JJ B-NP O
8 1652 1656 9521421 data NNS I-NP O
9 1657 1661 9521421 that IN B-SBAR O
10 1662 1665 9521421 the DT B-NP O
11 1666 1671 9521421 I113F NN I-NP O
12 1672 1680 9521421 mutation NN I-NP O
13 1681 1691 9521421 originated VBD B-VP O
14 1692 1696 9521421 from IN B-PP O
15 1697 1698 9521421 a DT B-NP O
16 1699 1705 9521421 common JJ I-NP O
17 1706 1714 9521421 ancestor NN I-NP O
18 1714 1715 9521421 . . O O

1 1716 1719 9521421 The DT B-NP O
2 1720 1725 9521421 other JJ I-NP O
3 1726 1727 9521421 9 CD I-NP O
4 1728 1733 9521421 novel JJ I-NP O
5 1734 1743 9521421 mutations NNS I-NP O
6 1744 1754 9521421 identified VBN B-VP O
7 1755 1757 9521421 in IN B-PP O
8 1758 1763 9521421 these DT B-NP O
9 1764 1766 9521421 23 CD I-NP O
10 1767 1775 9521421 patients NNS I-NP O
11 1776 1780 9521421 were VBD B-VP O
12 1781 1785 9521421 each DT O O
13 1786 1793 9521421 limited VBN B-VP O
14 1794 1796 9521421 to TO B-PP O
15 1797 1798 9521421 a DT B-NP O
16 1799 1805 9521421 single JJ I-NP O
17 1806 1812 9521421 family NN I-NP O
18 1812 1813 9521421 . . O O

1 1814 1819 9521421 These DT B-NP O
2 1820 1824 9521421 data NNS I-NP O
3 1825 1832 9521421 provide VBP B-VP O
4 1833 1840 9521421 further JJ B-NP O
5 1841 1849 9521421 evidence NN I-NP O
6 1850 1853 9521421 for IN B-PP O
7 1854 1863 9521421 extensive JJ B-NP O
8 1864 1871 9521421 allelic JJ I-NP O
9 1872 1885 9521421 heterogeneity NN I-NP O
10 1886 1888 9521421 in IN B-PP O
11 1889 1892 9521421 MPS NN B-NP B-Disease
12 1893 1896 9521421 IVA NN I-NP I-Disease
13 1897 1899 9521421 in IN B-PP O
14 1900 1907 9521421 British JJ B-NP O
15 1907 1908 9521421 - HYPH I-NP O
16 1908 1913 9521421 Irish JJ I-NP O
17 1914 1922 9521421 patients NNS I-NP O
18 1923 1926 9521421 and CC O O
19 1927 1934 9521421 provide VBP B-VP O
20 1935 1943 9521421 evidence NN B-NP O
21 1944 1947 9521421 for IN B-PP O
22 1948 1953 9521421 their PRP$ B-NP O
23 1954 1966 9521421 transmission NN I-NP O
24 1967 1969 9521421 to TO B-PP O
25 1970 1979 9521421 Australia NNP B-NP O
26 1980 1982 9521421 by IN B-PP O
27 1983 1990 9521421 British JJ B-NP O
28 1990 1991 9521421 - HYPH I-NP O
29 1991 1996 9521421 Irish JJ I-NP O
30 1997 2005 9521421 migrants NNS I-NP O
31 2005 2006 9521421 . . O O
32 2006 2007 9521421 . . O O

1 0 0 9973276 -DOCSTART- -X- -X- O

1 0 9 9973276 Inherited VBN B-NP B-Disease
2 10 20 9973276 colorectal JJ I-NP I-Disease
3 21 30 9973276 polyposis NN I-NP I-Disease
4 31 34 9973276 and CC I-NP O
5 35 41 9973276 cancer NN I-NP B-Disease
6 42 46 9973276 risk NN I-NP O
7 47 49 9973276 of IN B-PP O
8 50 53 9973276 the DT B-NP O
9 54 57 9973276 APC NN I-NP O
10 58 64 9973276 I1307K NN I-NP O
11 65 77 9973276 polymorphism NN I-NP O
12 77 78 9973276 . . O O
13 79 83 9973276 Germ NN B-NP O
14 83 84 9973276 - HYPH I-NP O
15 84 88 9973276 line NN I-NP O
16 89 92 9973276 and CC O O
17 93 100 9973276 somatic JJ B-NP O
18 101 111 9973276 truncating NN I-NP O
19 112 121 9973276 mutations NNS I-NP O
20 122 124 9973276 of IN B-PP O
21 125 128 9973276 the DT B-NP O
22 129 132 9973276 APC NN I-NP B-Disease
23 133 137 9973276 gene NN I-NP O
24 138 141 9973276 are VBP B-VP O
25 142 149 9973276 thought VBN I-VP O
26 150 152 9973276 to TO I-VP O
27 153 161 9973276 initiate VB I-VP O
28 162 172 9973276 colorectal JJ B-NP B-Disease
29 173 178 9973276 tumor NN I-NP I-Disease
30 179 188 9973276 formation NN I-NP O
31 189 191 9973276 in IN B-PP O
32 192 200 9973276 familial JJ B-NP B-Disease
33 201 212 9973276 adenomatous JJ I-NP I-Disease
34 213 222 9973276 polyposis NN I-NP I-Disease
35 223 231 9973276 syndrome NN I-NP I-Disease
36 232 235 9973276 and CC O O
37 236 244 9973276 sporadic JJ B-NP O
38 245 255 9973276 colorectal JJ I-NP O
39 256 270 9973276 carcinogenesis NN I-NP O
40 270 271 9973276 , , O O
41 272 284 9973276 respectively RB B-ADVP O
42 284 285 9973276 . . O O

1 286 294 9973276 Recently RB B-ADVP O
2 294 295 9973276 , , O O
3 296 298 9973276 an DT B-NP O
4 299 309 9973276 isoleucine NN I-NP O
5 309 310 9973276 - SYM B-VP O
6 310 311 9973276 - SYM B-NP O
7 312 313 9973276 > SYM I-NP O
8 314 320 9973276 lysine NN I-NP O
9 321 333 9973276 polymorphism NN I-NP O
10 334 336 9973276 at IN B-PP O
11 337 342 9973276 codon NN B-NP O
12 343 347 9973276 1307 CD I-NP O
13 348 349 9973276 ( ( O O
14 349 355 9973276 I1307K NN B-NP O
15 355 356 9973276 ) ) O O
16 357 359 9973276 of IN B-PP O
17 360 363 9973276 the DT B-NP O
18 364 367 9973276 APC NN I-NP B-Disease
19 368 372 9973276 gene NN I-NP O
20 373 376 9973276 has VBZ B-VP O
21 377 381 9973276 been VBN I-VP O
22 382 392 9973276 identified VBN I-VP O
23 393 395 9973276 in IN B-PP O
24 396 398 9973276 6% NN B-NP O
25 399 400 9973276 - HYPH B-NP O
26 400 402 9973276 7% CD I-NP O
27 403 405 9973276 of IN B-PP O
28 406 409 9973276 the DT B-NP O
29 410 419 9973276 Ashkenazi NNP I-NP O
30 420 426 9973276 Jewish JJ I-NP O
31 427 437 9973276 population NN I-NP O
32 437 438 9973276 . . O O

1 439 441 9973276 To TO B-VP O
2 442 448 9973276 assess VB I-VP O
3 449 452 9973276 the DT B-NP O
4 453 457 9973276 risk NN I-NP O
5 458 460 9973276 of IN B-PP O
6 461 465 9973276 this DT B-NP O
7 466 472 9973276 common JJ I-NP O
8 473 476 9973276 APC NN I-NP B-Disease
9 477 484 9973276 allelic JJ I-NP O
10 485 492 9973276 variant NN I-NP O
11 493 495 9973276 in IN B-PP O
12 496 506 9973276 colorectal JJ B-NP O
13 507 521 9973276 carcinogenesis NN I-NP O
14 521 522 9973276 , , O O
15 523 525 9973276 we PRP B-NP O
16 526 530 9973276 have VBP B-VP O
17 531 539 9973276 analyzed VBN I-VP O
18 540 541 9973276 a DT B-NP O
19 542 547 9973276 large JJ I-NP O
20 548 554 9973276 cohort NN I-NP O
21 555 557 9973276 of IN B-PP O
22 558 568 9973276 unselected JJ B-NP O
23 569 578 9973276 Ashkenazi NNP I-NP O
24 579 585 9973276 Jewish JJ I-NP O
25 586 594 9973276 subjects NNS I-NP O
26 595 599 9973276 with IN B-PP O
27 600 611 9973276 adenomatous JJ B-NP B-Disease
28 612 618 9973276 polyps NNS I-NP I-Disease
29 619 622 9973276 and CC O O
30 622 623 9973276 . . O O

1 624 626 9973276 or CC O O
2 627 637 9973276 colorectal JJ B-NP B-Disease
3 638 644 9973276 cancer NN I-NP I-Disease
4 644 645 9973276 , , O I-Disease
5 646 649 9973276 for IN B-PP O
6 650 653 9973276 the DT B-NP O
7 654 657 9973276 APC NN I-NP O
8 658 664 9973276 I1307K NN I-NP O
9 665 677 9973276 polymorphism NN I-NP O
10 677 678 9973276 . . O O

1 679 682 9973276 The DT B-NP O
2 683 686 9973276 APC NN I-NP O
3 687 693 9973276 I1307K NN I-NP O
4 694 700 9973276 allele NN I-NP O
5 701 704 9973276 was VBD B-VP O
6 705 715 9973276 identified VBN I-VP O
7 716 718 9973276 in IN B-PP O
8 719 721 9973276 48 CD B-NP O
9 722 723 9973276 ( ( O O
10 723 725 9973276 10 CD B-NP O
11 725 726 9973276 . . O O

1 727 729 9973276 1% LS B-LST O
2 729 730 9973276 ) ) O O
3 731 733 9973276 of IN B-PP O
4 734 737 9973276 476 CD B-NP O
5 738 746 9973276 patients NNS I-NP O
6 746 747 9973276 . . O O

1 748 756 9973276 Compared VBN B-PP O
2 757 761 9973276 with IN B-PP O
3 762 765 9973276 the DT B-NP O
4 766 775 9973276 frequency NN I-NP O
5 776 778 9973276 in IN B-PP O
6 779 782 9973276 two CD B-NP O
7 783 791 9973276 separate JJ I-NP O
8 792 802 9973276 population NN I-NP O
9 803 810 9973276 control NN I-NP O
10 811 817 9973276 groups NNS I-NP O
11 817 818 9973276 , , O O
12 819 822 9973276 the DT B-NP O
13 823 826 9973276 APC NN I-NP O
14 827 833 9973276 I1307K NN I-NP O
15 834 840 9973276 allele NN I-NP O
16 841 843 9973276 is VBZ B-VP O
17 844 854 9973276 associated VBN I-VP O
18 855 859 9973276 with IN B-PP O
19 860 862 9973276 an DT B-NP O
20 863 872 9973276 estimated VBN I-NP O
21 873 881 9973276 relative JJ I-NP O
22 882 886 9973276 risk NN I-NP O
23 887 889 9973276 of IN B-PP O
24 890 891 9973276 1 CD B-NP O
25 891 892 9973276 . . O O

1 893 894 9973276 5 CD B-NP O
2 894 895 9973276 - HYPH I-NP O
3 895 896 9973276 1 CD I-NP O
4 896 897 9973276 . . O O

1 898 899 9973276 7 CD B-NP O
2 900 903 9973276 for IN B-PP O
3 904 914 9973276 colorectal JJ B-NP B-Disease
4 915 924 9973276 neoplasia NN I-NP I-Disease
5 925 926 9973276 ( ( O O
6 926 930 9973276 both DT B-NP O
7 931 932 9973276 P NN I-NP O
8 933 934 9973276 = JJ B-ADJP O
9 934 935 9973276 . . O O

1 936 938 9973276 01 CD B-NP O
2 938 939 9973276 ) ) O O
3 939 940 9973276 . . O O

1 941 952 9973276 Furthermore RB B-ADVP O
2 952 953 9973276 , , O O
3 954 962 9973276 compared VBN B-PP O
4 963 967 9973276 with IN B-PP O
5 968 979 9973276 noncarriers NNS B-NP O
6 979 980 9973276 , , O O
7 981 984 9973276 APC NN B-NP O
8 985 991 9973276 I1307K NN I-NP O
9 992 1000 9973276 carriers NNS I-NP O
10 1001 1004 9973276 had VBD B-VP O
11 1005 1014 9973276 increased VBN I-VP O
12 1015 1022 9973276 numbers NNS B-NP O
13 1023 1025 9973276 of IN B-PP O
14 1026 1034 9973276 adenomas NNS B-NP B-Disease
15 1035 1038 9973276 and CC O O
16 1039 1049 9973276 colorectal JJ B-NP B-Disease
17 1050 1057 9973276 cancers NNS I-NP I-Disease
18 1058 1061 9973276 per IN B-PP O
19 1062 1069 9973276 patient NN B-NP O
20 1070 1071 9973276 ( ( O O
21 1071 1072 9973276 P NN B-NP O
22 1073 1074 9973276 = SYM B-VP O
23 1074 1075 9973276 . . O O

1 1076 1078 9973276 03 CD B-NP O
2 1078 1079 9973276 ) ) O O
3 1079 1080 9973276 , , O O
4 1081 1083 9973276 as RB B-CONJP O
5 1084 1088 9973276 well RB I-CONJP O
6 1089 1091 9973276 as IN I-CONJP O
7 1092 1093 9973276 a DT B-NP O
8 1094 1101 9973276 younger JJR I-NP O
9 1102 1105 9973276 age NN I-NP O
10 1106 1108 9973276 at IN B-PP O
11 1109 1118 9973276 diagnosis NN B-NP O
12 1118 1119 9973276 . . O O

1 1120 1122 9973276 We PRP B-NP O
2 1123 1131 9973276 conclude VBP B-VP O
3 1132 1136 9973276 that IN B-SBAR O
4 1137 1140 9973276 the DT B-NP O
5 1141 1144 9973276 APC NN I-NP O
6 1145 1151 9973276 I1307K NN I-NP O
7 1152 1159 9973276 variant NN I-NP O
8 1160 1165 9973276 leads VBZ B-VP O
9 1166 1168 9973276 to TO B-PP O
10 1169 1178 9973276 increased VBN B-NP O
11 1179 1186 9973276 adenoma NN I-NP B-Disease
12 1187 1196 9973276 formation NN I-NP O
13 1197 1200 9973276 and CC O O
14 1201 1209 9973276 directly RB B-VP O
15 1210 1221 9973276 contributes VBZ I-VP O
16 1222 1224 9973276 to TO B-PP O
17 1225 1227 9973276 3% CD B-NP O
18 1228 1229 9973276 - HYPH I-NP O
19 1229 1231 9973276 4% CD I-NP O
20 1232 1234 9973276 of IN B-PP O
21 1235 1238 9973276 all DT B-NP O
22 1239 1248 9973276 Ashkenazi NNP I-NP O
23 1249 1255 9973276 Jewish NNP I-NP O
24 1256 1266 9973276 colorectal JJ I-NP B-Disease
25 1267 1273 9973276 cancer NN I-NP I-Disease
26 1273 1274 9973276 . . O O

1 1275 1278 9973276 The DT B-NP O
2 1279 1288 9973276 estimated VBN I-NP O
3 1289 1297 9973276 relative JJ I-NP O
4 1298 1302 9973276 risk NN I-NP O
5 1303 1306 9973276 for IN B-PP O
6 1307 1315 9973276 carriers NNS B-NP O
7 1316 1319 9973276 may MD B-VP O
8 1320 1327 9973276 justify VB I-VP O
9 1328 1336 9973276 specific JJ B-NP O
10 1337 1345 9973276 clinical JJ I-NP O
11 1346 1355 9973276 screening NN I-NP O
12 1356 1359 9973276 for IN B-PP O
13 1360 1363 9973276 the DT B-NP O
14 1364 1367 9973276 360 CD I-NP O
15 1367 1368 9973276 , , I-NP O
16 1369 1372 9973276 000 CD I-NP O
17 1373 1382 9973276 Americans NNPS I-NP O
18 1383 1391 9973276 expected VBN B-VP O
19 1392 1394 9973276 to TO I-VP O
20 1395 1401 9973276 harbor VB I-VP O
21 1402 1406 9973276 this DT B-NP O
22 1407 1413 9973276 allele NN I-NP O
23 1413 1414 9973276 , , O O
24 1415 1418 9973276 and CC O O
25 1419 1426 9973276 genetic JJ B-NP O
26 1427 1434 9973276 testing NN I-NP O
27 1435 1437 9973276 in IN B-PP O
28 1438 1441 9973276 the DT B-NP O
29 1442 1449 9973276 setting NN I-NP O
30 1450 1452 9973276 of IN B-PP O
31 1453 1457 9973276 long JJ B-NP O
32 1457 1458 9973276 - HYPH I-NP O
33 1458 1462 9973276 term NN I-NP O
34 1462 1463 9973276 - HYPH I-NP O
35 1463 1470 9973276 outcome NN I-NP O
36 1471 1478 9973276 studies NNS I-NP O
37 1479 1482 9973276 may MD B-VP O
38 1483 1489 9973276 impact VB I-VP O
39 1490 1503 9973276 significantly RB B-ADVP O
40 1504 1506 9973276 on IN B-PP O
41 1507 1517 9973276 colorectal JJ B-NP B-Disease
42 1518 1524 9973276 cancer NN I-NP I-Disease
43 1525 1535 9973276 prevention NN I-NP O
44 1536 1538 9973276 in IN B-PP O
45 1539 1543 9973276 this DT B-NP O
46 1544 1554 9973276 population NN I-NP O
47 1554 1555 9973276 . . O O

1 0 0 9888388 -DOCSTART- -X- -X- O

1 0 10 9888388 Systematic JJ B-NP O
2 11 19 9888388 analysis NN I-NP O
3 20 22 9888388 of IN B-PP O
4 23 41 9888388 coproporphyrinogen NN B-NP O
5 42 49 9888388 oxidase NN I-NP O
6 50 54 9888388 gene NN I-NP O
7 55 62 9888388 defects NNS I-NP O
8 63 65 9888388 in IN B-PP O
9 66 76 9888388 hereditary JJ B-NP B-Disease
10 77 91 9888388 coproporphyria NN I-NP I-Disease
11 92 95 9888388 and CC I-NP O
12 96 104 9888388 mutation NN I-NP O
13 105 111 9888388 update NN I-NP O
14 111 112 9888388 . . O O
15 113 123 9888388 Hereditary JJ B-NP B-Disease
16 124 138 9888388 coproporphyria NN I-NP I-Disease
17 139 140 9888388 ( ( O O
18 140 142 9888388 HC NN B-NP B-Disease
19 142 143 9888388 ) ) O O
20 144 146 9888388 is VBZ B-VP O
21 147 149 9888388 an DT B-NP O
22 150 155 9888388 acute JJ I-NP O
23 156 163 9888388 hepatic JJ I-NP B-Disease
24 164 173 9888388 porphyria NN I-NP I-Disease
25 174 178 9888388 with IN B-PP O
26 179 188 9888388 autosomal JJ B-NP O
27 189 197 9888388 dominant JJ I-NP O
28 198 209 9888388 inheritance NN I-NP O
29 210 216 9888388 caused VBN B-VP O
30 217 219 9888388 by IN B-PP O
31 220 229 9888388 deficient JJ B-NP B-Disease
32 230 238 9888388 activity NN I-NP I-Disease
33 239 241 9888388 of IN B-PP I-Disease
34 242 260 9888388 coproporphyrinogen NN B-NP I-Disease
35 261 264 9888388 III CD I-NP I-Disease
36 265 272 9888388 oxidase NN I-NP I-Disease
37 273 274 9888388 ( ( O O
38 274 277 9888388 CPO NN B-NP O
39 277 278 9888388 ) ) O O
40 278 279 9888388 . . O O

1 280 288 9888388 Clinical JJ B-NP O
2 289 303 9888388 manifestations NNS I-NP O
3 304 306 9888388 of IN B-PP O
4 307 310 9888388 the DT B-NP O
5 311 318 9888388 disease NN I-NP O
6 319 322 9888388 are VBP B-VP O
7 323 336 9888388 characterized VBN I-VP O
8 337 339 9888388 by IN B-PP O
9 340 345 9888388 acute JJ B-NP O
10 346 353 9888388 attacks NNS I-NP O
11 354 356 9888388 of IN B-PP O
12 357 369 9888388 neurological JJ B-NP B-Disease
13 370 381 9888388 dysfunction NN I-NP I-Disease
14 382 387 9888388 often RB B-VP O
15 388 400 9888388 precipitated VBN I-VP O
16 401 403 9888388 by IN B-PP O
17 404 409 9888388 drugs NNS B-NP O
18 409 410 9888388 , , O O
19 411 418 9888388 fasting VBG B-VP O
20 418 419 9888388 , , O O
21 420 428 9888388 cyclical JJ B-NP O
22 429 437 9888388 hormonal JJ I-NP O
23 438 445 9888388 changes NNS I-NP O
24 445 446 9888388 , , O O
25 447 449 9888388 or CC O O
26 450 460 9888388 infectious JJ B-NP B-Disease
27 461 469 9888388 diseases NNS I-NP I-Disease
28 469 470 9888388 . . O O

1 471 475 9888388 Skin NN B-NP O
2 476 492 9888388 photosensitivity NN I-NP O
3 493 496 9888388 may MD B-VP O
4 497 501 9888388 also RB I-VP O
5 502 504 9888388 be VB I-VP O
6 505 512 9888388 present JJ B-ADJP O
7 512 513 9888388 . . O O

1 514 517 9888388 The DT B-NP O
2 518 523 9888388 seven CD I-NP O
3 524 529 9888388 exons NNS I-NP O
4 529 530 9888388 , , O O
5 531 534 9888388 the DT B-NP O
6 535 539 9888388 exon NN I-NP O
7 539 540 9888388 / SYM B-VP O
8 540 546 9888388 intron NN B-NP O
9 547 557 9888388 boundaries NNS I-NP O
10 558 561 9888388 and CC O O
11 562 566 9888388 part NN B-NP O
12 567 569 9888388 of IN B-PP O
13 570 571 9888388 3 CD B-NP O
14 572 581 9888388 noncoding JJ I-NP O
15 582 590 9888388 sequence NN I-NP O
16 591 593 9888388 of IN B-PP O
17 594 597 9888388 the DT B-NP O
18 598 601 9888388 CPO NN I-NP O
19 602 606 9888388 gene NN I-NP O
20 607 611 9888388 were VBD B-VP O
21 612 626 9888388 systematically RB I-VP O
22 627 635 9888388 analyzed VBN I-VP O
23 636 638 9888388 by IN B-PP O
24 639 641 9888388 an DT B-NP O
25 642 646 9888388 exon NN I-NP O
26 646 647 9888388 - HYPH B-ADJP O
27 647 649 9888388 by IN B-PP O
28 649 650 9888388 - HYPH B-NP O
29 650 654 9888388 exon NN I-NP O
30 655 665 9888388 denaturing VBG B-VP O
31 666 674 9888388 gradient NN B-NP O
32 675 678 9888388 gel NN I-NP O
33 679 694 9888388 electrophoresis NN I-NP O
34 695 696 9888388 ( ( O O
35 696 700 9888388 DGGE NN B-NP O
36 700 701 9888388 ) ) O O
37 702 710 9888388 strategy NN B-NP O
38 711 719 9888388 followed VBN B-VP O
39 720 722 9888388 by IN B-PP O
40 723 729 9888388 direct JJ B-NP O
41 730 740 9888388 sequencing NN I-NP O
42 741 743 9888388 in IN B-PP O
43 744 749 9888388 seven CD B-NP O
44 750 759 9888388 unrelated JJ I-NP O
45 760 772 9888388 heterozygous JJ I-NP O
46 773 775 9888388 HC NN I-NP B-Disease
47 776 784 9888388 patients NNS I-NP O
48 785 789 9888388 from IN B-PP O
49 790 796 9888388 France NNP B-NP O
50 796 797 9888388 , , O O
51 798 805 9888388 Holland NNP B-NP O
52 805 806 9888388 , , O O
53 807 810 9888388 and CC O O
54 811 816 9888388 Czech NNP B-NP O
55 817 825 9888388 Republic NNP I-NP O
56 825 826 9888388 . . O O

1 827 832 9888388 Seven CD B-NP O
2 833 838 9888388 novel JJ I-NP O
3 839 848 9888388 mutations NNS I-NP O
4 849 852 9888388 and CC O O
5 853 856 9888388 two CD B-NP O
6 857 860 9888388 new JJ I-NP O
7 861 874 9888388 polymorphisms NNS I-NP O
8 875 879 9888388 were VBD B-VP O
9 880 888 9888388 detected VBN I-VP O
10 888 889 9888388 . . O O

1 890 895 9888388 Among IN B-PP O
2 896 901 9888388 these DT B-NP O
3 902 911 9888388 mutations NNS I-NP O
4 913 916 9888388 two CD B-NP O
5 917 920 9888388 are VBP B-VP O
6 921 929 9888388 missense JJ B-ADJP O
7 930 931 9888388 ( ( O O
8 931 936 9888388 G197W NN B-NP O
9 936 937 9888388 , , O O
10 938 943 9888388 W427R NN B-NP O
11 943 944 9888388 ) ) O O
12 944 945 9888388 , , O O
13 946 949 9888388 two CD B-NP O
14 950 953 9888388 are VBP B-VP O
15 954 962 9888388 nonsense JJ B-ADJP O
16 963 964 9888388 ( ( O O
17 964 969 9888388 Q306X NN B-NP O
18 969 970 9888388 , , O O
19 971 976 9888388 Q385X NN B-NP O
20 976 977 9888388 ) ) O O
21 977 978 9888388 , , O O
22 979 982 9888388 two CD B-NP O
23 983 986 9888388 are VBP B-VP O
24 987 992 9888388 small JJ B-NP O
25 993 1002 9888388 deletions NNS I-NP O
26 1003 1004 9888388 ( ( O O
27 1004 1013 9888388 662de14bp NN B-NP O
28 1013 1014 9888388 ; : O O
29 1015 1025 9888388 1168del3bp NN B-NP O
30 1026 1034 9888388 removing VBG B-VP O
31 1035 1036 9888388 a DT B-NP O
32 1037 1044 9888388 glycine NN I-NP O
33 1045 1047 9888388 at IN B-PP O
34 1048 1056 9888388 position NN B-NP O
35 1057 1060 9888388 390 CD I-NP O
36 1060 1061 9888388 ) ) O O
37 1061 1062 9888388 , , O O
38 1063 1066 9888388 and CC O O
39 1067 1070 9888388 one CD B-NP O
40 1071 1073 9888388 is VBZ B-VP O
41 1074 1075 9888388 a DT B-NP O
42 1076 1084 9888388 splicing NN I-NP O
43 1085 1093 9888388 mutation NN I-NP O
44 1094 1095 9888388 ( ( O O
45 1095 1099 9888388 IVS1 NN B-NP O
46 1099 1100 9888388 - HYPH O O
47 1100 1103 9888388 15c SYM B-NP O
48 1103 1104 9888388 - SYM I-NP O
49 1104 1105 9888388 - SYM I-NP O
50 1106 1107 9888388 > SYM I-NP O
51 1108 1109 9888388 g NN I-NP O
52 1109 1110 9888388 ) ) O O
53 1111 1116 9888388 which WDT B-NP O
54 1117 1124 9888388 creates VBZ B-VP O
55 1125 1126 9888388 a DT B-NP O
56 1127 1130 9888388 new JJ I-NP O
57 1131 1139 9888388 acceptor NN I-NP O
58 1140 1146 9888388 splice NN I-NP O
59 1147 1151 9888388 site NN I-NP O
60 1151 1152 9888388 . . O O

1 1153 1156 9888388 The DT B-NP O
2 1157 1169 9888388 pathological JJ I-NP O
3 1170 1182 9888388 significance NN I-NP O
4 1183 1185 9888388 of IN B-PP O
5 1186 1189 9888388 the DT B-NP O
6 1190 1195 9888388 point NN I-NP O
7 1196 1205 9888388 mutations NNS I-NP O
8 1206 1211 9888388 G197W NN I-NP O
9 1211 1212 9888388 , , O O
10 1213 1218 9888388 W427R NN B-NP O
11 1218 1219 9888388 , , O O
12 1220 1223 9888388 and CC O O
13 1224 1227 9888388 the DT B-NP O
14 1228 1230 9888388 in IN B-PP O
15 1230 1231 9888388 - HYPH B-NP O
16 1231 1236 9888388 frame NN I-NP O
17 1237 1245 9888388 deletion NN I-NP O
18 1246 1255 9888388 390delGly NN I-NP O
19 1256 1260 9888388 were VBD B-VP O
20 1261 1269 9888388 assessed VBN I-VP O
21 1270 1272 9888388 by IN B-PP O
22 1273 1278 9888388 their PRP$ B-NP O
23 1279 1289 9888388 respective JJ I-NP O
24 1290 1300 9888388 expression NN I-NP O
25 1301 1303 9888388 in IN B-PP O
26 1304 1305 9888388 a DT B-NP O
27 1306 1317 9888388 prokaryotic JJ I-NP O
28 1318 1324 9888388 system NN I-NP O
29 1325 1330 9888388 using VBG B-VP O
30 1331 1335 9888388 site NN B-NP O
31 1335 1336 9888388 - HYPH O O
32 1336 1344 9888388 directed VBN B-NP O
33 1345 1356 9888388 mutagenesis NN I-NP O
34 1356 1357 9888388 . . O O

1 1358 1363 9888388 These DT B-NP O
2 1364 1373 9888388 mutations NNS I-NP O
3 1374 1382 9888388 resulted VBD B-VP O
4 1383 1385 9888388 in IN B-PP O
5 1386 1389 9888388 the DT B-NP O
6 1390 1397 9888388 absence NN I-NP O
7 1398 1400 9888388 or CC O O
8 1401 1402 9888388 a DT B-NP O
9 1403 1411 9888388 dramatic JJ I-NP O
10 1412 1420 9888388 decrease NN I-NP O
11 1421 1423 9888388 of IN B-PP O
12 1424 1427 9888388 CPO NN B-NP O
13 1428 1436 9888388 activity NN I-NP O
14 1436 1437 9888388 . . O O

1 1438 1441 9888388 The DT B-NP O
2 1442 1445 9888388 two CD I-NP O
3 1446 1459 9888388 polymorphisms NNS I-NP O
4 1460 1464 9888388 were VBD B-VP O
5 1465 1474 9888388 localized VBN I-VP O
6 1475 1477 9888388 in IN B-PP O
7 1478 1487 9888388 noncoding JJ B-NP O
8 1488 1492 9888388 part NN I-NP O
9 1493 1495 9888388 of IN B-PP O
10 1496 1499 9888388 the DT B-NP O
11 1500 1504 9888388 gene NN I-NP O
12 1506 1507 9888388 1 CD I-NP O
13 1507 1508 9888388 ) ) O O
14 1509 1510 9888388 a DT B-NP O
15 1511 1512 9888388 C NN I-NP O
16 1512 1513 9888388 / SYM O O
17 1513 1514 9888388 G NN B-NP O
18 1515 1527 9888388 polymorphism NN I-NP O
19 1528 1530 9888388 in IN B-PP O
20 1531 1534 9888388 the DT B-NP O
21 1535 1543 9888388 promotor NN I-NP O
22 1544 1550 9888388 region NN I-NP O
23 1550 1551 9888388 , , O O
24 1552 1555 9888388 142 CD B-NP O
25 1556 1558 9888388 bp NN I-NP O
26 1559 1567 9888388 upstream RB B-ADVP O
27 1568 1572 9888388 from IN B-PP O
28 1573 1576 9888388 the DT B-NP O
29 1577 1592 9888388 transcriptional JJ I-NP O
30 1593 1603 9888388 initiation NN I-NP O
31 1604 1608 9888388 site NN I-NP O
32 1609 1610 9888388 ( ( O O
33 1610 1611 9888388 - SYM B-NP O
34 1611 1615 9888388 142C NN I-NP O
35 1615 1616 9888388 / SYM I-NP O
36 1616 1617 9888388 G NN I-NP O
37 1617 1618 9888388 ) ) O O
38 1618 1619 9888388 , , O O
39 1620 1623 9888388 and CC O O
40 1624 1625 9888388 2 LS B-LST O
41 1625 1626 9888388 ) ) O O
42 1627 1628 9888388 a DT B-NP O
43 1629 1630 9888388 6 CD I-NP O
44 1631 1633 9888388 bp NN I-NP O
45 1634 1642 9888388 deletion NN I-NP O
46 1643 1655 9888388 polymorphism NN I-NP O
47 1656 1658 9888388 in IN B-PP O
48 1659 1662 9888388 the DT B-NP O
49 1663 1664 9888388 3 CD I-NP O
50 1665 1674 9888388 noncoding JJ I-NP O
51 1675 1679 9888388 part NN I-NP O
52 1680 1682 9888388 of IN B-PP O
53 1683 1686 9888388 the DT B-NP O
54 1687 1690 9888388 CPO NN I-NP O
55 1691 1695 9888388 gene NN I-NP O
56 1695 1696 9888388 , , O O
57 1697 1700 9888388 574 CD B-NP O
58 1701 1703 9888388 bp NN I-NP O
59 1704 1714 9888388 downstream RB B-ADVP O
60 1715 1717 9888388 of IN B-PP O
61 1718 1721 9888388 the DT B-NP O
62 1722 1726 9888388 last JJ I-NP O
63 1727 1731 9888388 base NN I-NP O
64 1732 1734 9888388 of IN B-PP O
65 1735 1738 9888388 the DT B-NP O
66 1739 1745 9888388 normal JJ I-NP O
67 1746 1757 9888388 termination NN I-NP O
68 1758 1763 9888388 codon NN I-NP O
69 1764 1765 9888388 ( ( O O
70 1765 1766 9888388 + SYM B-NP O
71 1767 1770 9888388 574 CD B-NP O
72 1771 1780 9888388 delATTCTT NN I-NP O
73 1780 1781 9888388 ) ) O O
74 1781 1782 9888388 . . O O

1 1783 1787 9888388 Five CD B-NP O
2 1788 1798 9888388 intragenic JJ I-NP O
3 1799 1810 9888388 dimorphisms NNS I-NP O
4 1811 1814 9888388 are VBP B-VP O
5 1815 1818 9888388 now RB I-VP O
6 1819 1823 9888388 well RB I-VP O
7 1824 1837 9888388 characterized VBN I-VP O
8 1838 1841 9888388 and CC O O
9 1842 1845 9888388 the DT B-NP O
10 1846 1850 9888388 high JJ I-NP O
11 1851 1857 9888388 degree NN I-NP O
12 1858 1860 9888388 of IN B-PP O
13 1861 1868 9888388 allelic JJ B-NP O
14 1869 1882 9888388 heterogeneity NN I-NP O
15 1883 1885 9888388 in IN B-PP O
16 1886 1888 9888388 HC NN B-NP B-Disease
17 1889 1891 9888388 is VBZ B-VP O
18 1892 1904 9888388 demonstrated VBN I-VP O
19 1905 1909 9888388 with IN B-PP O
20 1910 1915 9888388 seven CD B-NP O
21 1916 1919 9888388 new JJ I-NP O
22 1920 1929 9888388 different JJ I-NP O
23 1930 1939 9888388 mutations NNS I-NP O
24 1940 1946 9888388 making VBG B-VP O
25 1947 1948 9888388 a DT B-NP O
26 1949 1954 9888388 total NN I-NP O
27 1955 1957 9888388 of IN B-PP O
28 1958 1966 9888388 nineteen CD B-NP O
29 1967 1970 9888388 CPO NN I-NP O
30 1971 1975 9888388 gene NN I-NP B-Disease
31 1976 1983 9888388 defects NNS I-NP I-Disease
32 1984 1992 9888388 reported VBN B-VP O
33 1993 1995 9888388 so RB B-ADVP O
34 1996 1999 9888388 far RB I-ADVP O
35 1999 2000 9888388 . . O O
36 2000 2001 9888388 . . O O

1 0 0 9358014 -DOCSTART- -X- -X- O

1 0 6 9358014 Ethnic JJ B-NP O
2 7 18 9358014 differences NNS I-NP O
3 19 21 9358014 in IN B-PP O
4 22 25 9358014 the DT B-NP O
5 26 29 9358014 HFE NN I-NP O
6 30 35 9358014 codon NN I-NP O
7 36 39 9358014 282 CD I-NP O
8 40 41 9358014 ( ( O O
9 41 44 9358014 Cys NN B-NP O
10 44 45 9358014 / SYM B-NP O
11 45 48 9358014 Tyr NN I-NP O
12 48 49 9358014 ) ) O O
13 50 62 9358014 polymorphism NN B-NP O
14 62 63 9358014 . . O O
15 64 70 9358014 Recent JJ B-NP O
16 71 78 9358014 studies NNS I-NP O
17 79 83 9358014 have VBP B-VP O
18 84 89 9358014 shown VBN I-VP O
19 90 94 9358014 that IN B-SBAR O
20 95 105 9358014 hereditary JJ B-NP B-Disease
21 106 121 9358014 hemochromatosis NN I-NP I-Disease
22 122 123 9358014 ( ( O O
23 123 125 9358014 HH NN B-NP B-Disease
24 125 126 9358014 ) ) O O
25 127 129 9358014 is VBZ B-VP O
26 130 136 9358014 likely JJ B-ADJP O
27 137 139 9358014 to TO B-VP O
28 140 142 9358014 be VB I-VP O
29 143 149 9358014 caused VBN I-VP O
30 150 152 9358014 by IN B-PP O
31 153 165 9358014 homozygosity NN B-NP O
32 166 169 9358014 for IN B-PP O
33 170 171 9358014 a DT B-NP O
34 172 181 9358014 Cys282Tyr NN I-NP O
35 182 190 9358014 mutation NN I-NP O
36 191 193 9358014 in IN B-PP O
37 194 197 9358014 the DT B-NP O
38 198 201 9358014 HFE NN I-NP O
39 202 206 9358014 gene NN I-NP O
40 207 214 9358014 located JJ I-NP O
41 215 216 9358014 4 CD I-NP O
42 216 217 9358014 . . O O
43 218 219 9358014 5 CD B-NP O
44 220 222 9358014 Mb NN I-NP O
45 223 232 9358014 telomeric JJ B-ADJP O
46 233 235 9358014 to TO B-PP O
47 236 239 9358014 HLA NN B-NP O
48 239 240 9358014 - HYPH I-NP O
49 240 241 9358014 A NN I-NP O
50 241 242 9358014 . . O O

1 243 253 9358014 Population NN B-NP O
2 254 261 9358014 studies NNS I-NP O
3 262 264 9358014 of IN B-PP O
4 265 269 9358014 this DT B-NP O
5 270 282 9358014 polymorphism NN I-NP O
6 283 286 9358014 are VBP B-VP O
7 287 298 9358014 facilitated VBN I-VP O
8 299 301 9358014 by IN B-PP O
9 302 305 9358014 the DT B-NP O
10 306 310 9358014 fact NN I-NP O
11 311 315 9358014 that IN B-SBAR O
12 316 319 9358014 the DT B-NP O
13 320 329 9358014 Cys282Tyr NN I-NP O
14 330 338 9358014 mutation NN I-NP O
15 339 346 9358014 creates VBZ B-VP O
16 347 348 9358014 a DT B-NP O
17 349 353 9358014 Rsal JJ I-NP O
18 354 365 9358014 restriction NN I-NP O
19 366 370 9358014 site NN I-NP O
20 370 371 9358014 . . O O

1 372 374 9358014 We PRP B-NP O
2 375 379 9358014 have VBP B-VP O
3 380 387 9358014 studied VBN I-VP O
4 388 391 9358014 the DT B-NP O
5 392 397 9358014 codon NN I-NP O
6 398 401 9358014 282 CD I-NP O
7 402 403 9358014 ( ( O O
8 403 406 9358014 Cys NN B-NP O
9 406 407 9358014 / SYM B-NP O
10 407 410 9358014 Tyr NN I-NP O
11 410 411 9358014 ) ) O O
12 412 424 9358014 polymorphism NN B-NP O
13 425 427 9358014 in IN B-PP O
14 428 437 9358014 different JJ B-NP O
15 438 444 9358014 ethnic JJ I-NP O
16 445 451 9358014 groups NNS I-NP O
17 451 452 9358014 . . O O

1 453 455 9358014 In IN B-PP O
2 456 465 9358014 agreement NN I-PP O
3 466 470 9358014 with IN I-PP O
4 471 479 9358014 previous JJ B-NP O
5 480 492 9358014 observations NNS I-NP O
6 493 496 9358014 the DT B-NP O
7 497 500 9358014 Tyr NN I-NP O
8 501 507 9358014 allele NN I-NP O
9 508 516 9358014 appeared VBD B-VP O
10 517 519 9358014 to TO I-VP O
11 520 522 9358014 be VB I-VP O
12 523 527 9358014 rare JJ B-ADJP O
13 528 530 9358014 or CC I-ADJP O
14 531 537 9358014 absent JJ I-ADJP O
15 538 540 9358014 in IN B-PP O
16 541 548 9358014 Asiatic JJ O O
17 549 550 9358014 ( ( O O
18 550 556 9358014 Indian JJ B-ADJP O
19 556 557 9358014 , , O O
20 558 565 9358014 Chinese JJ B-ADJP O
21 565 566 9358014 ) ) O O
22 567 578 9358014 populations NNS B-NP O
23 578 579 9358014 . . O O

1 580 583 9358014 The DT B-NP O
2 584 591 9358014 highest JJS I-NP O
3 592 598 9358014 allele NN I-NP O
4 599 608 9358014 frequency NN I-NP O
5 609 610 9358014 ( ( O O
6 610 611 9358014 7 CD B-NP O
7 611 612 9358014 . . O O

1 613 615 9358014 5% LS B-LST O
2 615 616 9358014 ) ) O O
3 617 620 9358014 was VBD B-VP O
4 621 626 9358014 found VBN I-VP O
5 627 629 9358014 in IN B-PP O
6 630 636 9358014 Swedes NNP B-NP O
7 636 637 9358014 . . O O

1 638 644 9358014 Saamis NNP B-NP O
2 645 646 9358014 ( ( O O
3 646 648 9358014 2% CD B-NP O
4 648 649 9358014 ) ) O O
5 650 653 9358014 and CC O O
6 654 665 9358014 Mordvinians NNPS B-NP O
7 666 667 9358014 ( ( O O
8 667 668 9358014 1 CD B-NP O
9 668 669 9358014 . . O O

1 670 672 9358014 8% LS B-LST O
2 672 673 9358014 ) ) O O
3 674 677 9358014 had VBD B-VP O
4 678 691 9358014 significantly RB B-NP O
5 692 697 9358014 lower JJR I-NP O
6 698 709 9358014 frequencies NNS I-NP O
7 710 712 9358014 of IN B-PP O
8 713 716 9358014 the DT B-NP O
9 717 720 9358014 Tyr NN I-NP O
10 721 727 9358014 allele NN I-NP O
11 727 728 9358014 . . O O

1 729 740 9358014 Comparisons NNS B-NP O
2 741 745 9358014 with IN B-PP O
3 746 752 9358014 allele NN B-NP O
4 753 764 9358014 frequencies NNS I-NP O
5 765 770 9358014 based VBN B-VP O
6 771 773 9358014 on IN B-PP O
7 774 784 9358014 prevalence NN B-NP O
8 785 794 9358014 estimates NNS I-NP O
9 795 797 9358014 of IN B-PP O
10 798 800 9358014 HH NN B-NP B-Disease
11 801 807 9358014 showed VBD B-VP O
12 808 812 9358014 some DT B-NP O
13 813 826 9358014 disagreements NNS I-NP O
14 827 831 9358014 with IN B-PP O
15 832 835 9358014 the DT B-NP O
16 836 840 9358014 RFLP NN I-NP O
17 841 845 9358014 data NNS I-NP O
18 845 846 9358014 , , O O
19 847 859 9358014 particularly RB B-ADVP O
20 860 862 9358014 in IN B-PP O
21 863 868 9358014 Finns NNS B-NP O
22 868 869 9358014 . . O O

1 870 873 9358014 The DT B-NP O
2 874 879 9358014 newly RB I-NP O
3 880 889 9358014 described VBN I-NP O
4 890 893 9358014 HFE NN I-NP O
5 894 900 9358014 marker NN I-NP O
6 901 909 9358014 provides VBZ B-VP O
7 910 911 9358014 a DT B-NP O
8 912 915 9358014 new JJ I-NP O
9 916 924 9358014 approach NN I-NP O
10 925 927 9358014 to TO B-PP O
11 928 931 9358014 the DT B-NP O
12 932 941 9358014 screening NN I-NP O
13 942 944 9358014 of IN B-PP O
14 945 947 9358014 HH NN B-NP B-Disease
15 948 950 9358014 as RB B-CONJP O
16 951 955 9358014 well RB I-CONJP O
17 956 958 9358014 as IN I-CONJP O
18 959 966 9358014 studies NNS B-NP O
19 967 969 9358014 of IN B-PP O
20 970 973 9358014 the DT B-NP O
21 974 986 9358014 relationship NN I-NP O
22 987 994 9358014 between IN B-PP O
23 995 998 9358014 the DT B-NP O
24 999 1002 9358014 HFE NN I-NP O
25 1003 1006 9358014 Tyr NN I-NP O
26 1007 1013 9358014 allele NN I-NP O
27 1014 1017 9358014 and CC O O
28 1018 1027 9358014 different JJ B-NP O
29 1028 1037 9358014 disorders NNS I-NP O
30 1038 1047 9358014 including VBG B-PP O
31 1048 1054 9358014 cancer NN B-NP B-Disease

1 0 0 9448273 -DOCSTART- -X- -X- O

1 0 3 9448273 The DT B-NP O
2 4 7 9448273 von NNP I-NP B-Disease
3 8 14 9448273 Hippel NNP I-NP I-Disease
4 14 15 9448273 - HYPH I-NP I-Disease
5 15 21 9448273 Lindau NNP I-NP I-Disease
6 22 27 9448273 tumor NN I-NP I-Disease
7 28 38 9448273 suppressor NN I-NP O
8 39 43 9448273 gene NN I-NP O
9 44 46 9448273 is VBZ B-VP O
10 47 55 9448273 required VBN I-VP O
11 56 59 9448273 for IN B-PP O
12 60 64 9448273 cell NN B-NP O
13 65 70 9448273 cycle NN I-NP O
14 71 75 9448273 exit NN I-NP O
15 76 80 9448273 upon IN B-PP O
16 81 86 9448273 serum NN B-NP O
17 87 97 9448273 withdrawal NN I-NP O
18 97 98 9448273 . . O O
19 99 102 9448273 The DT B-NP O
20 103 115 9448273 inactivation NN I-NP O
21 116 118 9448273 of IN B-PP O
22 119 122 9448273 the DT B-NP O
23 123 126 9448273 von NNP I-NP B-Disease
24 127 133 9448273 Hippel NNP I-NP I-Disease
25 133 134 9448273 - HYPH I-NP I-Disease
26 134 140 9448273 Lindau NNP I-NP I-Disease
27 141 142 9448273 ( ( O I-Disease
28 142 145 9448273 VHL NNP O I-Disease
29 145 146 9448273 ) ) O I-Disease
30 147 152 9448273 tumor NN B-NP I-Disease
31 153 163 9448273 suppressor NN I-NP O
32 164 168 9448273 gene NN I-NP O
33 169 180 9448273 predisposes VBZ B-VP O
34 181 189 9448273 affected VBN I-VP O
35 190 201 9448273 individuals NNS B-NP O
36 202 204 9448273 to TO B-PP O
37 205 208 9448273 the DT B-NP O
38 209 214 9448273 human JJ I-NP O
39 215 218 9448273 VHL NN I-NP B-Disease
40 219 225 9448273 cancer NN I-NP I-Disease
41 226 234 9448273 syndrome NN I-NP I-Disease
42 235 238 9448273 and CC O O
43 239 241 9448273 is VBZ B-VP O
44 242 252 9448273 associated VBN I-VP O
45 253 257 9448273 with IN B-PP O
46 258 266 9448273 sporadic JJ B-NP B-Disease
47 267 272 9448273 renal JJ I-NP I-Disease
48 273 277 9448273 cell NN I-NP I-Disease
49 278 288 9448273 carcinomas NNS I-NP I-Disease
50 289 290 9448273 ( ( O O
51 290 293 9448273 RCC NN B-NP B-Disease
52 293 294 9448273 ) ) O O
53 295 298 9448273 and CC O O
54 299 304 9448273 brain NN B-NP B-Disease
55 305 322 9448273 hemangioblastomas NNS I-NP I-Disease
56 322 323 9448273 . . O O

1 324 327 9448273 VHL NN B-NP O
2 327 328 9448273 - HYPH I-NP O
3 328 336 9448273 negative JJ I-NP O
4 337 340 9448273 786 CD I-NP O
5 340 341 9448273 - HYPH I-NP O
6 341 342 9448273 0 CD I-NP O
7 343 346 9448273 RCC NN I-NP B-Disease
8 347 352 9448273 cells NNS I-NP O
9 353 356 9448273 are VBP B-VP O
10 357 368 9448273 tumorigenic JJ B-ADJP O
11 369 371 9448273 in IN B-PP O
12 372 376 9448273 nude JJ B-NP O
13 377 381 9448273 mice NNS I-NP O
14 382 387 9448273 which WDT B-NP O
15 388 390 9448273 is VBZ B-VP O
16 391 401 9448273 suppressed VBN I-VP O
17 402 404 9448273 by IN B-PP O
18 405 408 9448273 the DT B-NP O
19 409 423 9448273 reintroduction NN I-NP O
20 424 426 9448273 of IN B-PP O
21 427 430 9448273 VHL NN B-NP B-Disease
22 430 431 9448273 . . O O

1 432 442 9448273 Remarkably RB B-ADVP O
2 442 443 9448273 , , O O
3 444 448 9448273 this DT B-NP O
4 449 455 9448273 occurs VBZ B-VP O
5 456 463 9448273 without IN B-PP O
6 464 473 9448273 affecting VBG B-VP O
7 474 477 9448273 the DT B-NP O
8 478 484 9448273 growth NN I-NP O
9 485 489 9448273 rate NN I-NP O
10 490 493 9448273 and CC O O
11 494 498 9448273 cell NN B-NP O
12 499 504 9448273 cycle NN I-NP O
13 505 512 9448273 profile NN I-NP O
14 513 515 9448273 of IN B-PP O
15 516 521 9448273 these DT B-NP O
16 522 527 9448273 cells NNS I-NP O
17 528 530 9448273 in IN B-PP O
18 531 538 9448273 culture NN B-NP O
19 538 539 9448273 . . O O

1 540 543 9448273 The DT B-NP O
2 544 547 9448273 786 CD I-NP O
3 547 548 9448273 - HYPH I-NP O
4 548 549 9448273 0 CD I-NP O
5 550 554 9448273 cell NN I-NP O
6 555 559 9448273 line NN I-NP O
7 559 560 9448273 , , O O
8 561 565 9448273 like IN B-PP O
9 566 570 9448273 many JJ B-NP O
10 571 577 9448273 cancer NN I-NP B-Disease
11 578 583 9448273 cells NNS I-NP O
12 583 584 9448273 , , O O
13 585 590 9448273 fails VBZ B-VP O
14 591 593 9448273 to TO I-VP O
15 594 598 9448273 exit VB I-VP O
16 599 602 9448273 the DT B-NP O
17 603 607 9448273 cell NN I-NP O
18 608 613 9448273 cycle NN I-NP O
19 614 618 9448273 upon IN B-PP O
20 619 624 9448273 serum NN B-NP O
21 625 635 9448273 withdrawal NN I-NP O
22 635 636 9448273 . . O O

1 637 641 9448273 Here RB B-ADVP O
2 641 642 9448273 , , O O
3 643 645 9448273 it PRP B-NP O
4 646 648 9448273 is VBZ B-VP O
5 649 654 9448273 shown VBN I-VP O
6 655 659 9448273 that IN B-SBAR O
7 660 674 9448273 reintroduction NN B-NP O
8 675 677 9448273 of IN B-PP O
9 678 681 9448273 the DT B-NP O
10 682 686 9448273 wild JJ I-NP O
11 686 687 9448273 - HYPH I-NP O
12 687 691 9448273 type NN I-NP O
13 692 695 9448273 VHL NN I-NP B-Disease
14 696 700 9448273 gene NN I-NP O
15 701 709 9448273 restores VBZ B-VP O
16 710 713 9448273 the DT B-NP O
17 714 721 9448273 ability NN I-NP O
18 722 724 9448273 of IN B-PP O
19 725 728 9448273 VHL NN B-NP O
20 728 729 9448273 - HYPH B-NP O
21 729 737 9448273 negative JJ I-NP O
22 738 741 9448273 RCC NN I-NP B-Disease
23 742 748 9448273 cancer NN I-NP I-Disease
24 749 754 9448273 cells NNS I-NP O
25 755 757 9448273 to TO B-VP O
26 758 762 9448273 exit VB I-VP O
27 763 766 9448273 the DT B-NP O
28 767 771 9448273 cell NN I-NP O
29 772 777 9448273 cycle NN I-NP O
30 778 781 9448273 and CC O O
31 782 787 9448273 enter NN B-NP O
32 788 790 9448273 G0 NN I-NP O
33 790 791 9448273 / SYM B-NP O
34 791 801 9448273 quiescence NN I-NP O
35 802 804 9448273 in IN B-PP O
36 805 808 9448273 low JJ B-NP O
37 809 814 9448273 serum NN I-NP O
38 814 815 9448273 . . O O

1 816 820 9448273 Both CC O O
2 821 824 9448273 VHL NN B-NP O
3 824 825 9448273 - HYPH B-NP O
4 825 833 9448273 positive JJ I-NP O
5 834 837 9448273 and CC I-NP O
6 838 841 9448273 VHL NN I-NP O
7 841 842 9448273 - HYPH B-NP O
8 842 850 9448273 negative JJ I-NP O
9 851 854 9448273 RCC NN I-NP B-Disease
10 855 860 9448273 cells NNS I-NP O
11 861 865 9448273 exit VBP B-VP O
12 866 869 9448273 the DT B-NP O
13 870 874 9448273 cell NN I-NP O
14 875 880 9448273 cycle NN I-NP O
15 881 883 9448273 by IN B-PP O
16 884 891 9448273 contact NN B-NP O
17 892 902 9448273 inhibition NN I-NP O
18 902 903 9448273 . . O O

1 904 907 9448273 The DT B-NP O
2 908 914 9448273 cyclin NN I-NP O
3 914 915 9448273 - HYPH B-NP O
4 915 924 9448273 dependent JJ I-NP O
5 925 931 9448273 kinase NN I-NP O
6 932 941 9448273 inhibitor NN I-NP O
7 941 942 9448273 , , O O
8 943 946 9448273 p27 NN B-NP O
9 946 947 9448273 , , O O
10 948 959 9448273 accumulates VBZ B-VP O
11 960 964 9448273 upon IN B-PP O
12 965 970 9448273 serum NN B-NP O
13 971 981 9448273 withdrawal NN I-NP O
14 981 982 9448273 , , O O
15 983 987 9448273 only RB B-PP O
16 988 990 9448273 in IN I-PP O
17 991 994 9448273 the DT B-NP O
18 995 1003 9448273 presence NN I-NP O
19 1004 1006 9448273 of IN B-PP O
20 1007 1010 9448273 VHL NN B-NP B-Disease
21 1010 1011 9448273 , , O O
22 1012 1014 9448273 as IN B-PP O
23 1015 1016 9448273 a DT B-NP O
24 1017 1023 9448273 result NN I-NP O
25 1024 1026 9448273 of IN B-PP O
26 1027 1030 9448273 the DT B-NP O
27 1031 1044 9448273 stabilization NN I-NP O
28 1045 1047 9448273 of IN B-PP O
29 1048 1051 9448273 the DT B-NP O
30 1052 1059 9448273 protein NN I-NP O
31 1059 1060 9448273 . . O O

1 1061 1063 9448273 We PRP B-NP O
2 1064 1071 9448273 propose VBP B-VP O
3 1072 1076 9448273 that IN B-SBAR O
4 1077 1080 9448273 the DT B-NP O
5 1081 1085 9448273 loss NN I-NP O
6 1086 1088 9448273 of IN B-PP O
7 1089 1093 9448273 wild JJ B-NP O
8 1093 1094 9448273 - HYPH I-NP O
9 1094 1098 9448273 type NN I-NP O
10 1099 1102 9448273 VHL NN I-NP B-Disease
11 1103 1107 9448273 gene NN I-NP O
12 1108 1115 9448273 results VBZ B-VP O
13 1116 1118 9448273 in IN B-PP O
14 1119 1120 9448273 a DT B-NP O
15 1121 1129 9448273 specific JJ I-NP O
16 1130 1138 9448273 cellular JJ I-NP O
17 1139 1145 9448273 defect NN I-NP O
18 1146 1148 9448273 in IN B-PP O
19 1149 1154 9448273 serum NN B-NP O
20 1154 1155 9448273 - HYPH B-NP O
21 1155 1164 9448273 dependent JJ I-NP O
22 1165 1171 9448273 growth NN I-NP O
23 1172 1179 9448273 control NN I-NP O
24 1179 1180 9448273 , , O O
25 1181 1186 9448273 which WDT B-NP O
26 1187 1190 9448273 may MD B-VP O
27 1191 1199 9448273 initiate VB I-VP O
28 1200 1205 9448273 tumor NN B-NP B-Disease
29 1206 1215 9448273 formation NN I-NP O
30 1215 1216 9448273 . . O O

1 1217 1221 9448273 This DT B-NP O
2 1222 1224 9448273 is VBZ B-VP O
3 1225 1234 9448273 corrected VBN I-VP O
4 1235 1237 9448273 by IN B-PP O
5 1238 1241 9448273 the DT B-NP O
6 1242 1256 9448273 reintroduction NN I-NP O
7 1257 1259 9448273 of IN B-PP O
8 1260 1264 9448273 wild JJ B-NP O
9 1264 1265 9448273 - HYPH I-NP O
10 1265 1269 9448273 type NN I-NP O
11 1270 1273 9448273 VHL NN I-NP B-Disease
12 1273 1274 9448273 , , O O
13 1275 1286 9448273 implicating VBG B-VP O
14 1287 1290 9448273 VHL NN B-NP B-Disease
15 1291 1293 9448273 as IN B-PP O
16 1294 1297 9448273 the DT B-NP O
17 1298 1303 9448273 first JJ I-NP O
18 1304 1309 9448273 tumor NN I-NP B-Disease
19 1310 1320 9448273 suppressor NN I-NP O
20 1321 1329 9448273 involved VBN B-VP O
21 1330 1332 9448273 in IN B-PP O
22 1333 1336 9448273 the DT B-NP O
23 1337 1347 9448273 regulation NN I-NP O
24 1348 1350 9448273 of IN B-PP O
25 1351 1355 9448273 cell NN B-NP O
26 1356 1361 9448273 cycle NN I-NP O
27 1362 1366 9448273 exit NN I-NP O
28 1366 1367 9448273 , , O O
29 1368 1373 9448273 which WDT B-NP O
30 1374 1376 9448273 is VBZ B-VP O
31 1377 1387 9448273 consistent JJ B-ADJP O
32 1388 1392 9448273 with IN B-PP O
33 1393 1396 9448273 its PRP$ B-NP O
34 1397 1407 9448273 gatekeeper NN I-NP O
35 1408 1416 9448273 function NN I-NP O
36 1417 1419 9448273 in IN B-PP O
37 1420 1423 9448273 the DT B-NP O
38 1424 1430 9448273 kidney NN I-NP O
39 1430 1431 9448273 . . O O
40 1431 1432 9448273 . . O O

1 0 0 9288106 -DOCSTART- -X- -X- O

1 0 10 9288106 Clustering NN B-NP O
2 11 13 9288106 of IN B-PP O
3 14 22 9288106 missense JJ B-NP O
4 23 32 9288106 mutations NNS I-NP O
5 33 35 9288106 in IN B-PP O
6 36 39 9288106 the DT B-NP O
7 40 46 9288106 ataxia NN I-NP B-Disease
8 46 47 9288106 - HYPH B-NP I-Disease
9 47 61 9288106 telangiectasia NN I-NP I-Disease
10 62 66 9288106 gene NN I-NP O
11 67 69 9288106 in IN B-PP O
12 70 71 9288106 a DT B-NP O
13 72 80 9288106 sporadic JJ I-NP B-Disease
14 81 82 9288106 T NN I-NP I-Disease
15 82 83 9288106 - HYPH B-NP I-Disease
16 83 87 9288106 cell NN I-NP I-Disease
17 88 97 9288106 leukaemia NN I-NP I-Disease
18 97 98 9288106 . . I-NP O
19 99 105 9288106 Ataxia NN I-NP B-Disease
20 105 106 9288106 - HYPH B-NP I-Disease
21 106 120 9288106 telangiectasia NN I-NP I-Disease
22 121 122 9288106 ( ( O O
23 122 123 9288106 A NN B-NP B-Disease
24 123 124 9288106 - HYPH I-NP I-Disease
25 124 125 9288106 T NN I-NP I-Disease
26 125 126 9288106 ) ) O O
27 127 129 9288106 is VBZ B-VP O
28 130 131 9288106 a DT B-NP O
29 132 141 9288106 recessive JJ I-NP B-Disease
30 142 147 9288106 multi AFX I-NP I-Disease
31 147 148 9288106 - HYPH I-NP I-Disease
32 148 154 9288106 system NN I-NP I-Disease
33 155 163 9288106 disorder NN I-NP I-Disease
34 164 170 9288106 caused VBN B-VP O
35 171 173 9288106 by IN B-PP O
36 174 183 9288106 mutations NNS B-NP O
37 184 186 9288106 in IN B-PP O
38 187 190 9288106 the DT B-NP O
39 191 194 9288106 ATM NN I-NP O
40 195 199 9288106 gene NN I-NP O
41 200 202 9288106 at IN B-PP O
42 203 208 9288106 11q22 NN B-NP O
43 208 209 9288106 - HYPH O O
44 209 212 9288106 q23 NN B-NP O
45 213 214 9288106 ( ( O O
46 214 217 9288106 ref NN B-NP O
47 217 218 9288106 . . O O

1 219 220 9288106 3 LS B-LST O
2 220 221 9288106 ) ) O O
3 221 222 9288106 . . O O

1 223 226 9288106 The DT B-NP O
2 227 231 9288106 risk NN I-NP O
3 232 234 9288106 of IN B-PP O
4 235 241 9288106 cancer NN B-NP B-Disease
5 241 242 9288106 , , O O
6 243 253 9288106 especially RB B-NP O
7 254 262 9288106 lymphoid JJ I-NP B-Disease
8 263 273 9288106 neoplasias NNS I-NP I-Disease
9 273 274 9288106 , , O O
10 275 277 9288106 is VBZ B-VP O
11 278 291 9288106 substantially RB I-VP O
12 292 300 9288106 elevated VBN I-VP O
13 301 303 9288106 in IN B-PP O
14 304 305 9288106 A NN B-NP B-Disease
15 305 306 9288106 - HYPH I-NP I-Disease
16 306 307 9288106 T NN I-NP I-Disease
17 308 316 9288106 patients NNS I-NP O
18 317 320 9288106 and CC O O
19 321 324 9288106 has VBZ B-VP O
20 325 329 9288106 long RB I-VP O
21 330 334 9288106 been VBN I-VP O
22 335 345 9288106 associated VBN I-VP O
23 346 350 9288106 with IN B-PP O
24 351 362 9288106 chromosomal JJ B-NP O
25 363 374 9288106 instability NN I-NP O
26 374 375 9288106 . . O O

1 376 378 9288106 By IN B-PP O
2 379 388 9288106 analysing VBG B-VP O
3 389 395 9288106 tumour NN B-NP B-Disease
4 396 399 9288106 DNA NN I-NP O
5 400 404 9288106 from IN B-PP O
6 405 413 9288106 patients NNS B-NP O
7 414 418 9288106 with IN B-PP O
8 419 427 9288106 sporadic JJ B-NP B-Disease
9 428 429 9288106 T NN I-NP I-Disease
10 429 430 9288106 - HYPH B-NP I-Disease
11 430 434 9288106 cell NN I-NP I-Disease
12 435 449 9288106 prolymphocytic JJ I-NP I-Disease
13 450 459 9288106 leukaemia NN I-NP I-Disease
14 460 461 9288106 ( ( O O
15 461 462 9288106 T NN B-NP B-Disease
16 462 463 9288106 - HYPH B-NP I-Disease
17 463 466 9288106 PLL NN I-NP I-Disease
18 466 467 9288106 ) ) O O
19 467 468 9288106 , , O O
20 469 470 9288106 a DT B-NP O
21 471 475 9288106 rare JJ I-NP O
22 476 482 9288106 clonal JJ I-NP B-Disease
23 483 493 9288106 malignancy NN I-NP I-Disease
24 494 498 9288106 with IN B-PP O
25 499 511 9288106 similarities NNS B-NP O
26 512 514 9288106 to TO B-PP O
27 515 516 9288106 a DT B-NP O
28 517 523 9288106 mature JJ I-NP B-Disease
29 524 525 9288106 T NN I-NP I-Disease
30 525 526 9288106 - HYPH B-NP I-Disease
31 526 530 9288106 cell NN I-NP I-Disease
32 531 540 9288106 leukaemia NN I-NP I-Disease
33 541 545 9288106 seen VBN B-VP O
34 546 548 9288106 in IN B-PP O
35 549 550 9288106 A NN B-NP B-Disease
36 550 551 9288106 - HYPH I-NP I-Disease
37 551 552 9288106 T NN B-NP I-Disease
38 552 553 9288106 , , O O
39 554 556 9288106 we PRP B-NP O
40 557 568 9288106 demonstrate VBP B-VP O
41 569 570 9288106 a DT B-NP O
42 571 575 9288106 high JJ I-NP O
43 576 585 9288106 frequency NN I-NP O
44 586 588 9288106 of IN B-PP O
45 589 592 9288106 ATM NN B-NP O
46 593 602 9288106 mutations NNS I-NP O
47 603 605 9288106 in IN B-PP O
48 606 607 9288106 T NN B-NP B-Disease
49 607 608 9288106 - HYPH I-NP I-Disease
50 608 611 9288106 PLL NN I-NP I-Disease
51 611 612 9288106 . . O O

1 613 615 9288106 In IN B-PP O
2 616 622 9288106 marked JJ B-NP O
3 623 631 9288106 contrast NN I-NP O
4 632 634 9288106 to TO B-PP O
5 635 638 9288106 the DT B-NP O
6 639 642 9288106 ATM NN I-NP O
7 643 651 9288106 mutation NN I-NP O
8 652 659 9288106 pattern NN I-NP O
9 660 662 9288106 in IN B-PP O
10 663 664 9288106 A NN B-NP B-Disease
11 664 665 9288106 - HYPH O I-Disease
12 665 666 9288106 T NN B-NP I-Disease
13 666 667 9288106 , , O O
14 668 671 9288106 the DT B-NP O
15 672 676 9288106 most RBS I-NP O
16 677 685 9288106 frequent JJ I-NP O
17 686 696 9288106 nucleotide NN I-NP O
18 697 704 9288106 changes NNS I-NP O
19 705 707 9288106 in IN B-PP O
20 708 712 9288106 this DT B-NP O
21 713 722 9288106 leukaemia NN I-NP B-Disease
22 723 727 9288106 were VBD B-VP O
23 728 736 9288106 missense JJ B-NP O
24 737 746 9288106 mutations NNS I-NP O
25 746 747 9288106 . . O O

1 748 753 9288106 These DT B-NP O
2 754 763 9288106 clustered VBD B-VP O
3 764 766 9288106 in IN B-PP O
4 767 770 9288106 the DT B-NP O
5 771 777 9288106 region NN I-NP O
6 778 791 9288106 corresponding VBG B-VP O
7 792 794 9288106 to TO B-PP O
8 795 798 9288106 the DT B-NP O
9 799 805 9288106 kinase NN I-NP O
10 806 812 9288106 domain NN I-NP O
11 812 813 9288106 , , O O
12 814 819 9288106 which WDT B-NP O
13 820 822 9288106 is VBZ B-VP O
14 823 829 9288106 highly RB I-VP O
15 830 839 9288106 conserved VBN I-VP O
16 840 842 9288106 in IN B-PP O
17 843 846 9288106 ATM NN B-NP O
18 846 847 9288106 - HYPH B-NP O
19 847 854 9288106 related VBN I-NP O
20 855 863 9288106 proteins NNS I-NP O
21 864 866 9288106 in IN B-PP O
22 867 872 9288106 mouse NN B-NP O
23 872 873 9288106 , , O O
24 874 879 9288106 yeast NN B-NP O
25 880 883 9288106 and CC O O
26 884 894 9288106 Drosophila NN B-NP O
27 894 895 9288106 . . O O

1 896 899 9288106 The DT B-NP O
2 900 909 9288106 resulting VBG I-NP O
3 910 915 9288106 amino JJ I-NP O
4 915 916 9288106 - HYPH I-NP O
5 916 920 9288106 acid NN I-NP O
6 921 934 9288106 substitutions NNS I-NP O
7 935 938 9288106 are VBP B-VP O
8 939 948 9288106 predicted VBN I-VP O
9 949 951 9288106 to TO I-VP O
10 952 961 9288106 interfere VB I-VP O
11 962 966 9288106 with IN B-PP O
12 967 970 9288106 ATP NN B-NP O
13 971 978 9288106 binding NN I-NP O
14 979 981 9288106 or CC O O
15 982 991 9288106 substrate NN B-NP O
16 992 1003 9288106 recognition NN I-NP O
17 1003 1004 9288106 . . O O

1 1005 1008 9288106 Two CD B-NP O
2 1009 1011 9288106 of IN B-PP O
3 1012 1021 9288106 seventeen CD B-NP O
4 1022 1029 9288106 mutated VBN I-NP O
5 1030 1031 9288106 T NN I-NP B-Disease
6 1031 1032 9288106 - HYPH I-NP I-Disease
7 1032 1035 9288106 PLL NN I-NP I-Disease
8 1036 1043 9288106 samples NNS I-NP O
9 1044 1047 9288106 had VBD B-VP O
10 1048 1049 9288106 a DT B-NP O
11 1050 1060 9288106 previously RB I-NP O
12 1061 1069 9288106 reported VBN I-NP O
13 1070 1071 9288106 A NN I-NP B-Disease
14 1071 1072 9288106 - HYPH I-NP I-Disease
15 1072 1073 9288106 T NN I-NP I-Disease
16 1074 1080 9288106 allele NN I-NP O
17 1080 1081 9288106 . . O O

1 1082 1084 9288106 In IN B-PP O
2 1085 1093 9288106 contrast NN B-NP O
3 1093 1094 9288106 , , O O
4 1095 1097 9288106 no DT B-NP O
5 1098 1107 9288106 mutations NNS I-NP O
6 1108 1112 9288106 were VBD B-VP O
7 1113 1121 9288106 detected VBN I-VP O
8 1122 1124 9288106 in IN B-PP O
9 1125 1128 9288106 the DT B-NP O
10 1129 1132 9288106 p53 NN I-NP O
11 1133 1137 9288106 gene NN I-NP O
12 1137 1138 9288106 , , O O
13 1139 1149 9288106 suggesting VBG B-VP O
14 1150 1154 9288106 that IN B-SBAR O
15 1155 1159 9288106 this DT B-NP O
16 1160 1166 9288106 tumour NN I-NP B-Disease
17 1167 1177 9288106 suppressor NN I-NP O
18 1178 1180 9288106 is VBZ B-VP O
19 1181 1184 9288106 not RB I-VP O
20 1185 1195 9288106 frequently RB I-VP O
21 1196 1203 9288106 altered VBN I-VP O
22 1204 1206 9288106 in IN B-PP O
23 1207 1211 9288106 this DT B-NP O
24 1212 1221 9288106 leukaemia NN I-NP B-Disease
25 1221 1222 9288106 . . O O

1 1223 1233 9288106 Occasional JJ B-NP O
2 1234 1242 9288106 missense JJ I-NP O
3 1243 1252 9288106 mutations NNS I-NP O
4 1253 1255 9288106 in IN B-PP O
5 1256 1259 9288106 ATM NN B-NP O
6 1260 1264 9288106 were VBD B-VP O
7 1265 1269 9288106 also RB I-VP O
8 1270 1275 9288106 found VBN I-VP O
9 1276 1278 9288106 in IN B-PP O
10 1279 1285 9288106 tumour NN B-NP B-Disease
11 1286 1289 9288106 DNA NN I-NP O
12 1290 1294 9288106 from IN B-PP O
13 1295 1303 9288106 patients NNS B-NP O
14 1304 1308 9288106 with IN B-PP O
15 1309 1310 9288106 B NN B-NP B-Disease
16 1310 1311 9288106 - HYPH B-NP I-Disease
17 1311 1315 9288106 cell NN I-NP I-Disease
18 1316 1319 9288106 non AFX B-NP I-Disease
19 1319 1320 9288106 - HYPH I-NP I-Disease
20 1320 1328 9288106 Hodgkins NNP I-NP I-Disease
21 1329 1338 9288106 lymphomas NNS I-NP I-Disease
22 1339 1340 9288106 ( ( O O
23 1340 1341 9288106 B NN B-NP B-Disease
24 1341 1342 9288106 - HYPH O I-Disease
25 1342 1345 9288106 NHL NN B-NP I-Disease
26 1345 1346 9288106 ) ) O O
27 1347 1350 9288106 and CC O O
28 1351 1352 9288106 a DT B-NP O
29 1353 1354 9288106 B NN I-NP B-Disease
30 1354 1355 9288106 - HYPH I-NP I-Disease
31 1355 1358 9288106 NHL NN I-NP I-Disease
32 1359 1363 9288106 cell NN I-NP O
33 1364 1368 9288106 line NN I-NP O
34 1368 1369 9288106 . . O O

1 1370 1373 9288106 The DT B-NP O
2 1374 1382 9288106 evidence NN I-NP O
3 1383 1385 9288106 of IN B-PP O
4 1386 1387 9288106 a DT B-NP O
5 1388 1399 9288106 significant JJ I-NP O
6 1400 1410 9288106 proportion NN I-NP O
7 1411 1413 9288106 of IN B-PP O
8 1414 1418 9288106 loss NN B-NP O
9 1418 1419 9288106 - HYPH B-NP O
10 1419 1421 9288106 of IN B-PP O
11 1421 1422 9288106 - HYPH B-NP O
12 1422 1430 9288106 function NN I-NP O
13 1431 1440 9288106 mutations NNS I-NP O
14 1441 1444 9288106 and CC O O
15 1445 1446 9288106 a DT B-NP O
16 1447 1455 9288106 complete JJ I-NP O
17 1456 1463 9288106 absence NN I-NP O
18 1464 1466 9288106 of IN B-PP O
19 1467 1470 9288106 the DT B-NP O
20 1471 1477 9288106 normal JJ I-NP O
21 1478 1482 9288106 copy NN I-NP O
22 1483 1485 9288106 of IN B-PP O
23 1486 1489 9288106 ATM NN B-NP O
24 1490 1492 9288106 in IN B-PP O
25 1493 1496 9288106 the DT B-NP O
26 1497 1505 9288106 majority NN I-NP O
27 1506 1508 9288106 of IN B-PP O
28 1509 1516 9288106 mutated VBN B-NP O
29 1517 1524 9288106 tumours NNS I-NP B-Disease
30 1525 1536 9288106 establishes VBZ B-VP O
31 1537 1544 9288106 somatic JJ B-NP O
32 1545 1557 9288106 inactivation NN I-NP O
33 1558 1560 9288106 of IN B-PP O
34 1561 1565 9288106 this DT B-NP O
35 1566 1570 9288106 gene NN I-NP O
36 1571 1573 9288106 in IN B-PP O
37 1574 1577 9288106 the DT B-NP O
38 1578 1590 9288106 pathogenesis NN I-NP O
39 1591 1593 9288106 of IN B-PP O
40 1594 1602 9288106 sporadic JJ B-NP B-Disease
41 1603 1604 9288106 T NN I-NP I-Disease
42 1604 1605 9288106 - HYPH I-NP I-Disease
43 1605 1608 9288106 PLL NN I-NP I-Disease
44 1609 1612 9288106 and CC O O
45 1613 1621 9288106 suggests VBZ B-VP O
46 1622 1626 9288106 that IN B-SBAR O
47 1627 1630 9288106 ATM NN B-NP O
48 1631 1635 9288106 acts VBZ B-VP O
49 1636 1638 9288106 as IN B-PP O
50 1639 1640 9288106 a DT B-NP O
51 1641 1647 9288106 tumour NN I-NP B-Disease
52 1648 1658 9288106 suppressor NN I-NP O
53 1658 1659 9288106 . . O O

1 1660 1662 9288106 As IN B-SBAR O
2 1663 1677 9288106 constitutional JJ B-NP O
3 1678 1681 9288106 DNA NN I-NP O
4 1682 1685 9288106 was VBD B-VP O
5 1686 1689 9288106 not RB O O
6 1690 1699 9288106 available JJ B-ADJP O
7 1699 1700 9288106 , , O O
8 1701 1702 9288106 a DT B-NP O
9 1703 1711 9288106 putative JJ I-NP O
10 1712 1722 9288106 hereditary JJ I-NP O
11 1723 1737 9288106 predisposition NN I-NP O
12 1738 1740 9288106 to TO B-PP O
13 1741 1742 9288106 T NN B-NP B-Disease
14 1742 1743 9288106 - HYPH B-NP I-Disease
15 1743 1746 9288106 PLL NN I-NP I-Disease
16 1747 1751 9288106 will MD B-VP O
17 1752 1759 9288106 require VB I-VP O
18 1760 1767 9288106 further JJR B-NP O
19 1768 1781 9288106 investigation NN I-NP O
20 1781 1782 9288106 . . O O
21 1782 1783 9288106 . . O O

1 0 0 9703418 -DOCSTART- -X- -X- O

1 0 8 9703418 Nonsense NN B-NP O
2 9 17 9703418 mutation NN I-NP O
3 18 20 9703418 in IN B-PP O
4 21 25 9703418 exon NN B-NP O
5 26 27 9703418 4 CD I-NP O
6 28 30 9703418 of IN B-PP O
7 31 36 9703418 human JJ B-NP O
8 37 47 9703418 complement NN I-NP O
9 48 50 9703418 C9 NN I-NP O
10 51 55 9703418 gene NN I-NP O
11 56 58 9703418 is VBZ B-VP O
12 59 62 9703418 the DT B-NP O
13 63 68 9703418 major JJ I-NP O
14 69 74 9703418 cause NN I-NP O
15 75 77 9703418 of IN B-PP O
16 78 86 9703418 Japanese JJ B-NP O
17 87 97 9703418 complement NN I-NP B-Disease
18 98 100 9703418 C9 NN I-NP I-Disease
19 101 111 9703418 deficiency NN I-NP I-Disease
20 111 112 9703418 . . I-NP O
21 113 123 9703418 Deficiency NN I-NP B-Disease
22 124 126 9703418 of IN B-PP I-Disease
23 127 130 9703418 the DT B-NP I-Disease
24 131 136 9703418 ninth JJ I-NP I-Disease
25 137 146 9703418 component NN I-NP I-Disease
26 147 149 9703418 of IN B-PP I-Disease
27 150 155 9703418 human JJ B-NP I-Disease
28 156 166 9703418 complement NN I-NP I-Disease
29 167 168 9703418 ( ( O O
30 168 170 9703418 C9 NN B-NP O
31 170 171 9703418 ) ) O O
32 172 174 9703418 is VBZ B-VP O
33 175 178 9703418 the DT B-NP O
34 179 183 9703418 most RBS I-NP O
35 184 190 9703418 common JJ I-NP O
36 191 201 9703418 complement NN I-NP B-Disease
37 202 212 9703418 deficiency NN I-NP I-Disease
38 213 215 9703418 in IN B-PP O
39 216 221 9703418 Japan NNP B-NP O
40 222 225 9703418 but CC O O
41 226 228 9703418 is VBZ B-VP O
42 229 233 9703418 rare JJ B-ADJP O
43 234 236 9703418 in IN B-PP O
44 237 242 9703418 other JJ B-NP O
45 243 252 9703418 countries NNS I-NP O
46 252 253 9703418 . . O O

1 254 256 9703418 We PRP B-NP O
2 257 264 9703418 studied VBD B-VP O
3 265 268 9703418 the DT B-NP O
4 269 278 9703418 molecular JJ I-NP O
5 279 284 9703418 basis NN I-NP O
6 285 287 9703418 of IN B-PP O
7 288 290 9703418 C9 NN B-NP B-Disease
8 291 301 9703418 deficiency NN I-NP I-Disease
9 302 304 9703418 in IN B-PP O
10 305 309 9703418 four CD B-NP O
11 310 318 9703418 Japanese JJ I-NP O
12 319 321 9703418 C9 NN I-NP B-Disease
13 321 322 9703418 - HYPH O I-Disease
14 322 331 9703418 deficient JJ B-NP I-Disease
15 332 340 9703418 patients NNS I-NP O
16 341 344 9703418 who WP B-NP O
17 345 348 9703418 had VBD B-VP O
18 349 357 9703418 suffered VBN I-VP O
19 358 362 9703418 from IN B-PP O
20 363 376 9703418 meningococcal JJ B-NP B-Disease
21 377 387 9703418 meningitis NN I-NP I-Disease
22 387 388 9703418 . . O O

1 389 395 9703418 Direct JJ B-NP O
2 396 406 9703418 sequencing NN I-NP O
3 407 409 9703418 of IN B-PP O
4 410 419 9703418 amplified VBN B-NP O
5 420 422 9703418 C9 NN I-NP O
6 423 427 9703418 cDNA NN I-NP O
7 428 431 9703418 and CC I-NP O
8 432 435 9703418 DNA NN I-NP O
9 436 444 9703418 revealed VBD B-VP O
10 445 446 9703418 a DT B-NP O
11 447 455 9703418 nonsense JJ I-NP O
12 456 468 9703418 substitution NN I-NP O
13 469 470 9703418 ( ( O O
14 470 473 9703418 CGA NN B-NP O
15 473 474 9703418 - SYM O O
16 474 475 9703418 - HYPH B-NP O
17 476 477 9703418 > SYM I-NP O
18 478 481 9703418 TGA NN I-NP O
19 481 482 9703418 ) ) O O
20 483 485 9703418 at IN B-PP O
21 486 491 9703418 codon NN B-NP O
22 492 494 9703418 95 CD I-NP O
23 495 497 9703418 in IN B-PP O
24 498 502 9703418 exon NN B-NP O
25 503 504 9703418 4 CD I-NP O
26 505 507 9703418 in IN B-PP O
27 508 511 9703418 the DT B-NP O
28 512 516 9703418 four CD I-NP O
29 517 519 9703418 C9 NN I-NP B-Disease
30 519 520 9703418 - HYPH I-NP I-Disease
31 520 529 9703418 deficient JJ I-NP I-Disease
32 530 541 9703418 individuals NNS I-NP O
33 541 542 9703418 . . O O

1 543 545 9703418 An DT B-NP O
2 546 552 9703418 allele NN I-NP O
3 552 553 9703418 - HYPH B-NP O
4 553 561 9703418 specific JJ I-NP O
5 562 572 9703418 polymerase NN I-NP O
6 573 578 9703418 chain NN I-NP O
7 579 587 9703418 reaction NN I-NP O
8 588 594 9703418 system NN I-NP O
9 595 603 9703418 designed VBN B-VP O
10 604 606 9703418 to TO B-VP O
11 607 613 9703418 detect VB I-VP O
12 614 625 9703418 exclusively RB B-ADVP O
13 626 630 9703418 only RB B-NP O
14 631 634 9703418 one CD I-NP O
15 635 637 9703418 of IN B-PP O
16 638 641 9703418 the DT B-NP O
17 642 648 9703418 normal JJ I-NP O
18 649 652 9703418 and CC I-NP O
19 653 659 9703418 mutant JJ I-NP O
20 660 667 9703418 alleles NNS I-NP O
21 668 677 9703418 indicated VBD B-VP O
22 678 682 9703418 that IN B-SBAR O
23 683 686 9703418 all PDT B-NP O
24 687 690 9703418 the DT I-NP O
25 691 695 9703418 four CD I-NP O
26 696 704 9703418 patients NNS I-NP O
27 705 709 9703418 were VBD B-VP O
28 710 720 9703418 homozygous JJ B-ADJP O
29 721 724 9703418 for IN B-PP O
30 725 728 9703418 the DT B-NP O
31 729 737 9703418 mutation NN I-NP O
32 738 740 9703418 in IN B-PP O
33 741 745 9703418 exon NN B-NP O
34 746 747 9703418 4 CD I-NP O
35 748 751 9703418 and CC O O
36 752 756 9703418 that IN B-SBAR O
37 757 760 9703418 the DT B-NP O
38 761 768 9703418 parents NNS I-NP O
39 769 771 9703418 of IN B-PP O
40 772 779 9703418 patient NN B-NP O
41 780 781 9703418 2 CD I-NP O
42 782 786 9703418 were VBD B-VP O
43 787 799 9703418 heterozygous JJ B-ADJP O
44 799 800 9703418 . . O O

1 801 804 9703418 The DT B-NP O
2 805 811 9703418 common JJ I-NP O
3 812 820 9703418 mutation NN I-NP O
4 821 823 9703418 at IN B-PP O
5 824 829 9703418 codon NN B-NP O
6 830 832 9703418 95 CD I-NP O
7 833 835 9703418 in IN B-PP O
8 836 840 9703418 exon NN B-NP O
9 841 842 9703418 4 CD I-NP O
10 843 848 9703418 might MD B-VP O
11 849 851 9703418 be VB I-VP O
12 852 863 9703418 responsible JJ B-ADJP O
13 864 867 9703418 for IN B-PP O
14 868 872 9703418 most JJS B-NP O
15 873 881 9703418 Japanese JJ I-NP O
16 882 884 9703418 C9 NN I-NP B-Disease
17 885 895 9703418 deficiency NN I-NP I-Disease
18 895 896 9703418 . . O O
19 896 897 9703418 . . O O

1 0 0 9863607 -DOCSTART- -X- -X- O

1 0 11 9863607 Segregation NN B-NP O
2 12 22 9863607 distortion NN I-NP O
3 23 25 9863607 in IN B-PP O
4 26 34 9863607 myotonic JJ B-NP B-Disease
5 35 44 9863607 dystrophy NN I-NP I-Disease
6 44 45 9863607 . . O O
7 46 54 9863607 Myotonic JJ B-NP B-Disease
8 55 64 9863607 dystrophy NN I-NP I-Disease
9 65 66 9863607 ( ( O O
10 66 68 9863607 DM NN B-NP B-Disease
11 68 69 9863607 ) ) O O
12 70 72 9863607 is VBZ B-VP O
13 73 75 9863607 an DT B-NP O
14 76 85 9863607 autosomal JJ I-NP B-Disease
15 86 94 9863607 dominant JJ I-NP I-Disease
16 95 102 9863607 disease NN I-NP I-Disease
17 103 108 9863607 which WDT B-NP O
18 108 109 9863607 , , O O
19 110 112 9863607 in IN B-PP O
20 113 116 9863607 the DT B-NP O
21 117 124 9863607 typical JJ I-NP O
22 125 133 9863607 pedigree NN I-NP O
23 133 134 9863607 , , O O
24 135 140 9863607 shows VBZ B-VP O
25 141 142 9863607 a DT B-NP O
26 143 148 9863607 three CD I-NP O
27 149 159 9863607 generation NN I-NP O
28 160 172 9863607 anticipation NN I-NP O
29 173 180 9863607 cascade NN I-NP O
30 180 181 9863607 . . O O

1 182 186 9863607 This DT B-NP O
2 187 194 9863607 results VBZ B-VP O
3 195 197 9863607 in IN B-PP O
4 198 209 9863607 infertility NN B-NP B-Disease
5 210 213 9863607 and CC O O
6 214 224 9863607 congenital JJ B-NP B-Disease
7 225 233 9863607 myotonic JJ I-NP I-Disease
8 234 243 9863607 dystrophy NN I-NP I-Disease
9 244 245 9863607 ( ( O O
10 245 248 9863607 CDM NN B-NP B-Disease
11 248 249 9863607 ) ) O O
12 250 254 9863607 with IN B-PP O
13 255 258 9863607 the DT B-NP O
14 259 272 9863607 disappearance NN I-NP O
15 273 275 9863607 of IN B-PP O
16 276 278 9863607 DM NN B-NP B-Disease
17 279 281 9863607 in IN B-PP O
18 282 286 9863607 that DT B-NP O
19 287 295 9863607 pedigree NN I-NP O
20 295 296 9863607 . . O O

1 297 300 9863607 The DT B-NP O
2 301 308 9863607 concept NN I-NP O
3 309 311 9863607 of IN B-PP O
4 312 323 9863607 segregation NN B-NP O
5 324 334 9863607 distortion NN I-NP O
6 334 335 9863607 , , O O
7 336 341 9863607 where WRB B-ADVP O
8 342 347 9863607 there EX B-NP O
9 348 350 9863607 is VBZ B-VP O
10 351 363 9863607 preferential JJ B-NP O
11 364 376 9863607 transmission NN I-NP O
12 377 379 9863607 of IN B-PP O
13 380 383 9863607 the DT B-NP O
14 384 390 9863607 larger JJR I-NP O
15 391 397 9863607 allele NN I-NP O
16 398 400 9863607 at IN B-PP O
17 401 404 9863607 the DT B-NP O
18 405 407 9863607 DM NN I-NP B-Disease
19 408 413 9863607 locus NN I-NP O
20 413 414 9863607 , , O O
21 415 418 9863607 has VBZ B-VP O
22 419 423 9863607 been VBN I-VP O
23 424 427 9863607 put VBN I-VP O
24 428 435 9863607 forward RB B-ADVP O
25 436 438 9863607 to TO B-VP O
26 439 446 9863607 explain VB I-VP O
27 447 456 9863607 partially RB B-ADVP O
28 457 460 9863607 the DT B-NP O
29 461 472 9863607 maintenance NN I-NP O
30 473 475 9863607 of IN B-PP O
31 476 478 9863607 DM NN B-NP B-Disease
32 479 481 9863607 in IN B-PP O
33 482 485 9863607 the DT B-NP O
34 486 496 9863607 population NN I-NP O
35 496 497 9863607 . . O O

1 498 500 9863607 In IN B-PP O
2 501 502 9863607 a DT B-NP O
3 503 509 9863607 survey NN I-NP O
4 510 512 9863607 of IN B-PP O
5 513 515 9863607 DM NN B-NP B-Disease
6 516 518 9863607 in IN B-PP O
7 519 527 9863607 Northern NNP B-NP O
8 528 535 9863607 Ireland NNP I-NP O
9 535 536 9863607 , , O O
10 537 539 9863607 59 CD B-NP O
11 540 549 9863607 pedigrees NNS I-NP O
12 550 554 9863607 were VBD B-VP O
13 555 566 9863607 ascertained VBN I-VP O
14 566 567 9863607 . . O O

1 568 576 9863607 Sibships NNS B-NP O
2 577 582 9863607 where WRB B-ADVP O
3 583 586 9863607 the DT B-NP O
4 587 593 9863607 status NN I-NP O
5 594 596 9863607 of IN B-PP O
6 597 600 9863607 all PDT B-NP O
7 601 604 9863607 the DT I-NP O
8 605 612 9863607 members NNS I-NP O
9 613 616 9863607 had VBD B-VP O
10 617 621 9863607 been VBN I-VP O
11 622 632 9863607 identified VBN I-VP O
12 633 637 9863607 were VBD B-VP O
13 638 646 9863607 examined VBN I-VP O
14 647 649 9863607 to TO B-VP O
15 650 659 9863607 determine VB I-VP O
16 660 663 9863607 the DT B-NP O
17 664 676 9863607 transmission NN I-NP O
18 677 679 9863607 of IN B-PP O
19 680 683 9863607 the DT B-NP O
20 684 686 9863607 DM NN I-NP B-Disease
21 687 696 9863607 expansion NN I-NP O
22 697 701 9863607 from IN B-PP O
23 702 710 9863607 affected VBN B-NP O
24 711 718 9863607 parents NNS I-NP O
25 719 721 9863607 to TO B-PP O
26 722 727 9863607 their PRP$ B-NP O
27 728 737 9863607 offspring NN I-NP O
28 737 738 9863607 . . O O

1 739 744 9863607 Where WRB B-ADVP O
2 745 748 9863607 the DT B-NP O
3 749 761 9863607 transmitting VBG I-NP O
4 762 768 9863607 parent NN I-NP O
5 769 772 9863607 was VBD B-VP O
6 773 777 9863607 male JJ B-ADJP O
7 777 778 9863607 , , O O
8 779 781 9863607 58 CD B-NP O
9 781 782 9863607 . . O O

1 783 785 9863607 3% CD B-NP O
2 786 788 9863607 of IN B-PP O
3 789 792 9863607 the DT B-NP O
4 793 802 9863607 offspring NN I-NP O
5 803 807 9863607 were VBD B-VP O
6 808 816 9863607 affected VBN I-VP O
7 816 817 9863607 , , O O
8 818 821 9863607 and CC O O
9 822 824 9863607 in IN B-PP O
10 825 828 9863607 the DT B-NP O
11 829 833 9863607 case NN I-NP O
12 834 836 9863607 of IN B-PP O
13 837 838 9863607 a DT B-NP O
14 839 845 9863607 female JJ I-NP O
15 846 858 9863607 transmitting JJ I-NP O
16 859 865 9863607 parent NN I-NP O
17 865 866 9863607 , , O O
18 867 869 9863607 68 CD B-NP O
19 869 870 9863607 . . O O

1 871 873 9863607 7% CD B-NP O
2 874 878 9863607 were VBD B-VP O
3 879 887 9863607 affected VBN I-VP O
4 887 888 9863607 . . O O

1 889 896 9863607 Studies NNS B-NP O
2 897 899 9863607 on IN B-PP O
3 900 907 9863607 meiotic JJ B-NP O
4 908 913 9863607 drive NN I-NP O
5 914 916 9863607 in IN B-PP O
6 917 919 9863607 DM NN B-NP B-Disease
7 920 924 9863607 have VBP B-VP O
8 925 930 9863607 shown VBN I-VP O
9 931 940 9863607 increased VBN B-NP O
10 941 953 9863607 transmission NN I-NP O
11 954 956 9863607 of IN B-PP O
12 957 960 9863607 the DT B-NP O
13 961 967 9863607 larger JJR I-NP O
14 968 974 9863607 allele NN I-NP O
15 975 977 9863607 at IN B-PP O
16 978 981 9863607 the DT B-NP O
17 982 984 9863607 DM NN I-NP B-Disease
18 985 990 9863607 locus NN I-NP O
19 991 993 9863607 in IN B-PP O
20 994 997 9863607 non AFX B-NP O
21 997 998 9863607 - HYPH I-NP O
22 998 1000 9863607 DM NN I-NP O
23 1001 1014 9863607 heterozygotes NNS I-NP O
24 1015 1018 9863607 for IN B-PP O
25 1019 1023 9863607 CTGn NN B-NP O
26 1023 1024 9863607 . . O O

1 1025 1029 9863607 This DT B-NP O
2 1030 1035 9863607 study NN I-NP O
3 1036 1044 9863607 provides VBZ B-VP O
4 1045 1052 9863607 further JJ B-NP O
5 1053 1061 9863607 evidence NN I-NP O
6 1062 1066 9863607 that IN B-SBAR O
7 1067 1070 9863607 the DT B-NP O
8 1071 1073 9863607 DM NN I-NP B-Disease
9 1074 1083 9863607 expansion NN I-NP O
10 1084 1089 9863607 tends VBZ B-VP O
11 1090 1092 9863607 to TO I-VP O
12 1093 1095 9863607 be VB I-VP O
13 1096 1107 9863607 transmitted VBN I-VP O
14 1108 1122 9863607 preferentially RB B-ADVP O
15 1122 1123 9863607 . . O O

1 0 0 9391889 -DOCSTART- -X- -X- O

1 0 8 9391889 Paternal JJ B-NP O
2 9 21 9391889 transmission NN I-NP O
3 22 24 9391889 of IN B-PP O
4 25 35 9391889 congenital JJ B-NP B-Disease
5 36 44 9391889 myotonic JJ I-NP I-Disease
6 45 54 9391889 dystrophy NN I-NP I-Disease
7 54 55 9391889 . . O O
8 56 58 9391889 We PRP B-NP O
9 59 65 9391889 report VBP B-VP O
10 66 67 9391889 a DT B-NP O
11 68 72 9391889 rare JJ I-NP O
12 73 77 9391889 case NN I-NP O
13 78 80 9391889 of IN B-PP O
14 81 91 9391889 paternally RB B-NP O
15 92 103 9391889 transmitted VBN I-NP O
16 104 114 9391889 congenital JJ I-NP B-Disease
17 115 123 9391889 myotonic JJ I-NP I-Disease
18 124 133 9391889 dystrophy NN I-NP I-Disease
19 134 135 9391889 ( ( O O
20 135 137 9391889 DM NN B-NP B-Disease
21 137 138 9391889 ) ) O O
22 138 139 9391889 . . O O

1 140 143 9391889 The DT B-NP O
2 144 151 9391889 proband NN I-NP O
3 152 154 9391889 is VBZ B-VP O
4 155 156 9391889 a DT B-NP O
5 157 159 9391889 23 CD I-NP O
6 160 164 9391889 year NN I-NP O
7 165 168 9391889 old JJ B-ADJP O
8 168 169 9391889 , , O O
9 170 178 9391889 mentally RB B-NP B-Disease
10 179 187 9391889 retarded JJ I-NP I-Disease
11 188 192 9391889 male NN I-NP O
12 193 196 9391889 who WP B-NP O
13 197 204 9391889 suffers VBZ B-VP O
14 205 211 9391889 severe JJ B-NP O
15 212 220 9391889 muscular JJ I-NP B-Disease
16 221 229 9391889 weakness NN I-NP I-Disease
17 229 230 9391889 . . O O

1 231 233 9391889 He PRP B-NP O
2 234 243 9391889 presented VBD B-VP O
3 244 248 9391889 with IN B-PP O
4 249 260 9391889 respiratory JJ B-NP O
5 261 264 9391889 and CC I-NP O
6 265 272 9391889 feeding NN I-NP O
7 273 285 9391889 difficulties NNS I-NP O
8 286 288 9391889 at IN B-PP O
9 289 294 9391889 birth NN B-NP O
10 294 295 9391889 . . O O

1 296 299 9391889 His PRP$ B-NP O
2 300 303 9391889 two CD I-NP O
3 304 308 9391889 sibs NNS I-NP O
4 309 315 9391889 suffer VBP B-VP O
5 316 320 9391889 from IN B-PP O
6 321 330 9391889 childhood NN B-NP O
7 331 336 9391889 onset NN I-NP O
8 337 339 9391889 DM NN I-NP B-Disease
9 339 340 9391889 . . O O

1 341 346 9391889 Their PRP$ B-NP O
2 347 351 9391889 late JJ I-NP O
3 352 358 9391889 father NN I-NP O
4 359 362 9391889 had VBD B-VP O
5 363 366 9391889 the DT B-NP O
6 367 372 9391889 adult JJ I-NP O
7 373 377 9391889 type NN I-NP O
8 378 380 9391889 of IN B-PP O
9 381 383 9391889 DM NN B-NP B-Disease
10 383 384 9391889 , , O O
11 385 389 9391889 with IN B-PP O
12 390 395 9391889 onset NN B-NP O
13 396 402 9391889 around IN B-PP O
14 403 405 9391889 30 CD B-NP O
15 406 411 9391889 years NNS I-NP O
16 411 412 9391889 . . O O

1 413 417 9391889 Only RB B-NP O
2 418 421 9391889 six CD I-NP O
3 422 427 9391889 other JJ I-NP O
4 428 433 9391889 cases NNS I-NP O
5 434 436 9391889 of IN B-PP O
6 437 445 9391889 paternal JJ B-NP O
7 446 458 9391889 transmission NN I-NP O
8 459 461 9391889 of IN B-PP O
9 462 472 9391889 congenital JJ B-NP B-Disease
10 473 475 9391889 DM NN I-NP I-Disease
11 476 480 9391889 have VBP B-VP O
12 481 485 9391889 been VBN I-VP O
13 486 494 9391889 reported VBN I-VP O
14 495 503 9391889 recently RB B-ADVP O
15 503 504 9391889 . . O O

1 505 507 9391889 We PRP B-NP O
2 508 514 9391889 review VBP B-VP O
3 515 518 9391889 the DT B-NP O
4 519 522 9391889 sex NN I-NP O
5 523 530 9391889 related VBN B-VP O
6 531 538 9391889 effects NNS B-NP O
7 539 541 9391889 on IN B-PP O
8 542 554 9391889 transmission NN B-NP O
9 555 557 9391889 of IN B-PP O
10 558 568 9391889 congenital JJ B-NP B-Disease
11 569 571 9391889 DM NN I-NP I-Disease
12 571 572 9391889 . . O O

1 573 582 9391889 Decreased VBN B-NP O
2 583 592 9391889 fertility NN I-NP O
3 593 595 9391889 of IN B-PP O
4 596 601 9391889 males NNS B-NP O
5 602 606 9391889 with IN B-PP O
6 607 612 9391889 adult JJ B-NP O
7 613 618 9391889 onset NN I-NP O
8 619 621 9391889 DM NN I-NP B-Disease
9 622 625 9391889 and CC I-NP O
10 626 637 9391889 contraction NN I-NP O
11 638 640 9391889 of IN B-PP O
12 641 644 9391889 the DT B-NP O
13 645 651 9391889 repeat NN I-NP O
14 652 656 9391889 upon IN B-PP O
15 657 661 9391889 male JJ B-NP O
16 662 674 9391889 transmission NN I-NP O
17 675 685 9391889 contribute VBP B-VP O
18 686 688 9391889 to TO B-PP O
19 689 692 9391889 the DT B-NP O
20 693 699 9391889 almost RB I-NP O
21 700 706 9391889 absent JJ I-NP O
22 707 717 9391889 occurrence NN I-NP O
23 718 720 9391889 of IN B-PP O
24 721 729 9391889 paternal JJ B-NP O
25 730 742 9391889 transmission NN I-NP O
26 743 745 9391889 of IN B-PP O
27 746 756 9391889 congenital JJ B-NP B-Disease
28 757 759 9391889 DM NN I-NP I-Disease
29 759 760 9391889 . . O O

1 761 765 9391889 Also RB B-ADVP O
2 766 769 9391889 the DT B-NP O
3 770 777 9391889 fathers NNS I-NP O
4 778 780 9391889 of IN B-PP O
5 781 784 9391889 the DT B-NP O
6 785 793 9391889 reported VBN I-NP O
7 794 806 9391889 congenitally RB I-NP O
8 807 815 9391889 affected VBN I-NP O
9 816 824 9391889 children NNS I-NP O
10 825 831 9391889 showed VBD B-VP O
11 831 832 9391889 , , O O
12 833 835 9391889 on IN B-PP O
13 836 843 9391889 average NN B-NP O
14 843 844 9391889 , , O O
15 845 852 9391889 shorter JJR B-NP O
16 853 856 9391889 CTG NN I-NP O
17 857 863 9391889 repeat NN I-NP O
18 864 871 9391889 lengths NNS I-NP O
19 872 875 9391889 and CC O O
20 876 881 9391889 hence RB B-NP O
21 882 886 9391889 less RBR I-NP O
22 887 893 9391889 severe JJ I-NP O
23 894 902 9391889 clinical JJ I-NP O
24 903 911 9391889 symptoms NNS I-NP O
25 912 916 9391889 than IN B-PP O
26 917 920 9391889 the DT B-NP O
27 921 928 9391889 mothers NNS I-NP O
28 929 931 9391889 of IN B-PP O
29 932 940 9391889 children NNS B-NP O
30 941 945 9391889 with IN B-PP O
31 946 956 9391889 congenital JJ B-NP B-Disease
32 957 959 9391889 DM NN I-NP I-Disease
33 959 960 9391889 . . O O

1 961 963 9391889 We PRP B-NP O
2 964 972 9391889 conclude VBP B-VP O
3 973 977 9391889 that IN B-SBAR O
4 978 986 9391889 paternal JJ B-NP O
5 987 999 9391889 transmission NN I-NP O
6 1000 1002 9391889 of IN B-PP O
7 1003 1013 9391889 congenital JJ B-NP B-Disease
8 1014 1016 9391889 DM NN I-NP I-Disease
9 1017 1019 9391889 is VBZ B-VP O
10 1020 1024 9391889 rare JJ B-ADJP O
11 1025 1028 9391889 and CC O O
12 1029 1043 9391889 preferentially RB B-VP O
13 1044 1050 9391889 occurs VBZ I-VP O
14 1051 1055 9391889 with IN B-PP O
15 1056 1061 9391889 onset NN B-NP O
16 1062 1064 9391889 of IN B-PP O
17 1065 1067 9391889 DM NN B-NP B-Disease
18 1068 1072 9391889 past JJ B-NP O
19 1073 1075 9391889 30 CD I-NP O
20 1076 1081 9391889 years NNS I-NP O
21 1082 1084 9391889 in IN B-PP O
22 1085 1088 9391889 the DT B-NP O
23 1089 1095 9391889 father NN I-NP O
24 1095 1096 9391889 . . O O
25 1096 1097 9391889 . . O O

1 0 0 9888390 -DOCSTART- -X- -X- O

1 0 11 9888390 Coincidence NN B-NP O
2 12 14 9888390 of IN B-PP O
3 15 18 9888390 two CD B-NP O
4 19 24 9888390 novel JJ I-NP O
5 25 38 9888390 arylsulfatase NN I-NP O
6 39 40 9888390 A NN I-NP O
7 41 48 9888390 alleles NNS I-NP O
8 49 52 9888390 and CC O O
9 53 61 9888390 mutation NN B-NP O
10 62 65 9888390 459 CD I-NP O
11 65 66 9888390 + SYM I-NP O
12 66 68 9888390 1G NN I-NP O
13 68 69 9888390 > SYM I-NP O
14 69 70 9888390 A NN I-NP O
15 71 77 9888390 within IN B-PP O
16 78 79 9888390 a DT B-NP O
17 80 86 9888390 family NN I-NP O
18 87 91 9888390 with IN B-PP O
19 92 105 9888390 metachromatic JJ B-NP B-Disease
20 106 120 9888390 leukodystrophy NN I-NP I-Disease
21 120 121 9888390 : : O O
22 122 131 9888390 molecular JJ B-NP O
23 132 137 9888390 basis NN I-NP O
24 138 140 9888390 of IN B-PP O
25 141 151 9888390 phenotypic JJ B-NP O
26 152 165 9888390 heterogeneity NN I-NP O
27 165 166 9888390 . . O O
28 167 169 9888390 In IN B-PP O
29 170 171 9888390 a DT B-NP O
30 172 178 9888390 family NN I-NP O
31 179 183 9888390 with IN B-PP O
32 184 189 9888390 three CD B-NP O
33 190 198 9888390 siblings NNS I-NP O
34 198 199 9888390 , , O O
35 200 203 9888390 one CD B-NP O
36 204 213 9888390 developed VBD B-VP O
37 214 223 9888390 classical JJ B-NP O
38 224 228 9888390 late JJ I-NP O
39 229 238 9888390 infantile JJ I-NP O
40 239 252 9888390 metachromatic JJ I-NP B-Disease
41 253 267 9888390 leukodystrophy NN I-NP I-Disease
42 268 269 9888390 ( ( O O
43 269 272 9888390 MLD NN B-NP B-Disease
44 272 273 9888390 ) ) O O
45 273 274 9888390 , , O O
46 275 280 9888390 fatal JJ B-ADJP O
47 281 283 9888390 at IN B-PP O
48 284 287 9888390 age NN B-NP O
49 288 289 9888390 5 CD B-NP O
50 290 295 9888390 years NNS I-NP O
51 295 296 9888390 , , O O
52 297 301 9888390 with IN B-PP O
53 302 311 9888390 deficient JJ B-NP O
54 312 325 9888390 arylsulfatase NN I-NP O
55 326 327 9888390 A NN I-NP O
56 328 329 9888390 ( ( O O
57 329 333 9888390 ARSA NN B-NP O
58 333 334 9888390 ) ) O O
59 335 343 9888390 activity NN B-NP O
60 344 347 9888390 and CC O O
61 348 357 9888390 increased VBN B-NP O
62 358 377 9888390 galactosylsulfatide NN I-NP O
63 378 379 9888390 ( ( I-NP O
64 379 381 9888390 GS NN I-NP O
65 381 382 9888390 ) ) I-NP O
66 383 392 9888390 excretion NN I-NP O
67 392 393 9888390 . . O O

1 394 397 9888390 The DT B-NP O
2 398 401 9888390 two CD I-NP O
3 402 407 9888390 other JJ I-NP O
4 408 416 9888390 siblings NNS I-NP O
5 416 417 9888390 , , O O
6 418 428 9888390 apparently RB B-ADJP O
7 429 436 9888390 healthy JJ I-ADJP O
8 437 439 9888390 at IN B-PP O
9 440 442 9888390 12 CD B-NP O
10 443 444 9888390 ( ( O O
11 444 445 9888390 1 CD B-NP O
12 445 446 9888390 / SYM I-NP O
13 446 447 9888390 2 CD I-NP O
14 447 448 9888390 ) ) O O
15 449 452 9888390 and CC O O
16 453 455 9888390 15 CD B-NP O
17 456 461 9888390 years NNS I-NP O
18 461 462 9888390 , , O O
19 463 475 9888390 respectively RB B-ADVP O
20 475 476 9888390 , , O O
21 477 480 9888390 and CC O O
22 481 486 9888390 their PRP$ B-NP O
23 487 493 9888390 father NN I-NP O
24 493 494 9888390 , , O O
25 495 505 9888390 apparently RB B-ADJP O
26 506 513 9888390 healthy JJ I-ADJP O
27 514 516 9888390 as IN B-ADVP O
28 517 521 9888390 well RB I-ADVP O
29 521 522 9888390 , , O O
30 523 532 9888390 presented VBN B-NP O
31 533 537 9888390 ARSA NN I-NP O
32 538 541 9888390 and CC I-NP O
33 542 544 9888390 GS NN I-NP O
34 545 551 9888390 values NNS I-NP O
35 552 558 9888390 within IN B-PP O
36 559 562 9888390 the DT B-NP O
37 563 568 9888390 range NN I-NP O
38 569 571 9888390 of IN B-PP O
39 572 575 9888390 MLD NN B-NP B-Disease
40 576 584 9888390 patients NNS I-NP O
41 584 585 9888390 . . O O

1 586 594 9888390 Mutation NN B-NP O
2 595 604 9888390 screening NN I-NP O
3 605 608 9888390 and CC O O
4 609 617 9888390 sequence NN B-NP O
5 618 626 9888390 analysis NN I-NP O
6 627 636 9888390 disclosed VBD B-VP O
7 637 640 9888390 the DT B-NP O
8 641 652 9888390 involvement NN I-NP O
9 653 655 9888390 of IN B-PP O
10 656 661 9888390 three CD B-NP O
11 662 671 9888390 different JJ I-NP O
12 672 676 9888390 ARSA NN I-NP O
13 677 686 9888390 mutations NNS I-NP O
14 687 692 9888390 being VBG B-VP O
15 693 696 9888390 the DT B-NP O
16 697 706 9888390 molecular JJ I-NP O
17 707 712 9888390 basis NN I-NP O
18 713 715 9888390 of IN B-PP O
19 716 729 9888390 intrafamilial JJ B-NP O
20 730 740 9888390 phenotypic JJ I-NP O
21 741 754 9888390 heterogeneity NN I-NP O
22 754 755 9888390 . . O O

1 756 759 9888390 The DT B-NP O
2 760 764 9888390 late JJ I-NP O
3 765 774 9888390 infantile JJ I-NP O
4 775 782 9888390 patient NN I-NP O
5 783 792 9888390 inherited VBN B-VP O
6 793 797 9888390 from IN B-PP O
7 798 801 9888390 his PRP$ B-NP O
8 802 808 9888390 mother NN I-NP O
9 809 812 9888390 the DT B-NP O
10 813 821 9888390 frequent JJ I-NP O
11 822 823 9888390 0 CD I-NP O
12 823 824 9888390 - HYPH I-NP O
13 824 828 9888390 type NN I-NP O
14 829 837 9888390 mutation NN I-NP O
15 838 841 9888390 459 CD I-NP O
16 842 843 9888390 + SYM I-NP O
17 844 846 9888390 1G NN I-NP O
18 847 848 9888390 > SYM I-NP O
19 849 850 9888390 A NN I-NP O
20 850 851 9888390 , , B-PP O
21 852 855 9888390 and CC I-PP O
22 856 860 9888390 from IN B-PP O
23 861 864 9888390 his PRP$ B-NP O
24 865 871 9888390 father NN I-NP O
25 872 873 9888390 a DT B-NP O
26 874 879 9888390 novel JJ I-NP O
27 879 880 9888390 , , I-NP O
28 881 887 9888390 single JJ I-NP O
29 888 896 9888390 basepair NN I-NP O
30 897 910 9888390 microdeletion NN I-NP O
31 911 913 9888390 of IN B-PP O
32 914 921 9888390 guanine NN B-NP O
33 922 924 9888390 at IN B-PP O
34 925 935 9888390 nucleotide NN B-NP O
35 936 937 9888390 7 CD I-NP O
36 938 940 9888390 in IN B-PP O
37 941 945 9888390 exon NN B-NP O
38 946 947 9888390 1 CD I-NP O
39 948 949 9888390 ( ( O O
40 949 954 9888390 7delG NN B-NP O
41 954 955 9888390 ) ) O O
42 955 956 9888390 . . O O

1 957 960 9888390 The DT B-NP O
2 961 964 9888390 two CD I-NP O
3 965 975 9888390 clinically RB I-NP O
4 976 986 9888390 unaffected JJ I-NP O
5 987 995 9888390 siblings NNS I-NP O
6 996 1003 9888390 carried VBD B-VP O
7 1004 1007 9888390 the DT B-NP O
8 1008 1016 9888390 maternal JJ I-NP O
9 1017 1025 9888390 mutation NN I-NP O
10 1026 1029 9888390 459 CD I-NP O
11 1030 1031 9888390 + SYM I-NP O
12 1032 1034 9888390 1G NN I-NP O
13 1035 1036 9888390 > SYM B-NP O
14 1037 1038 9888390 A NN I-NP O
15 1039 1042 9888390 and CC O O
16 1042 1043 9888390 , , O O
17 1044 1046 9888390 on IN B-PP O
18 1047 1052 9888390 their PRP$ B-NP O
19 1053 1061 9888390 paternal JJ I-NP O
20 1062 1068 9888390 allele NN I-NP O
21 1068 1069 9888390 , , O O
22 1070 1071 9888390 a DT B-NP O
23 1072 1077 9888390 novel JJ I-NP O
24 1078 1086 9888390 cytosine NN I-NP O
25 1087 1089 9888390 to TO B-PP O
26 1090 1099 9888390 thymidine NN B-NP O
27 1100 1110 9888390 transition NN I-NP O
28 1111 1113 9888390 at IN B-PP O
29 1114 1124 9888390 nucleotide NN B-NP O
30 1125 1129 9888390 2435 CD I-NP O
31 1130 1132 9888390 in IN B-PP O
32 1133 1137 9888390 exon NN B-NP O
33 1138 1139 9888390 8 CD I-NP O
34 1139 1140 9888390 , , O O
35 1141 1150 9888390 resulting VBG B-VP O
36 1151 1153 9888390 in IN B-PP O
37 1154 1166 9888390 substitution NN B-NP O
38 1167 1169 9888390 of IN B-PP O
39 1170 1177 9888390 alanine NN B-NP O
40 1178 1181 9888390 464 CD I-NP O
41 1182 1184 9888390 by IN B-PP O
42 1185 1191 9888390 valine NN B-NP O
43 1192 1193 9888390 ( ( O O
44 1193 1198 9888390 A464V NN B-NP O
45 1198 1199 9888390 ) ) O O
46 1199 1200 9888390 . . O O

1 1201 1204 9888390 The DT B-NP O
2 1205 1212 9888390 fathers NNS I-NP O
3 1213 1221 9888390 genotype NN I-NP O
4 1222 1226 9888390 thus RB B-ADVP O
5 1227 1230 9888390 was VBD B-VP O
6 1231 1236 9888390 7delG NN B-NP O
7 1236 1237 9888390 / SYM B-NP O
8 1237 1242 9888390 A464V NN I-NP O
9 1242 1243 9888390 . . O O

1 1244 1252 9888390 Mutation NN B-NP O
2 1253 1258 9888390 A464V NN I-NP O
3 1259 1262 9888390 was VBD B-VP O
4 1263 1266 9888390 not RB I-VP O
5 1267 1272 9888390 found VBN I-VP O
6 1273 1275 9888390 in IN B-PP O
7 1276 1278 9888390 18 CD B-NP O
8 1279 1288 9888390 unrelated JJ I-NP O
9 1289 1292 9888390 MLD NN I-NP B-Disease
10 1293 1301 9888390 patients NNS I-NP O
11 1302 1305 9888390 and CC O O
12 1306 1308 9888390 50 CD B-NP O
13 1309 1317 9888390 controls NNS I-NP O
14 1317 1318 9888390 . . O O

1 1319 1324 9888390 A464V NN B-NP O
2 1324 1325 9888390 , , O O
3 1326 1334 9888390 although IN B-SBAR O
4 1335 1342 9888390 clearly RB B-ADVP O
5 1343 1352 9888390 modifying VBG B-VP O
6 1353 1357 9888390 ARSA NN B-NP O
7 1358 1361 9888390 and CC I-NP O
8 1362 1364 9888390 GS NN I-NP O
9 1365 1371 9888390 levels NNS I-NP O
10 1371 1372 9888390 , , O O
11 1373 1383 9888390 apparently RB B-ADVP O
12 1384 1389 9888390 bears VBZ B-VP O
13 1390 1396 9888390 little JJ B-NP O
14 1397 1409 9888390 significance NN I-NP O
15 1410 1413 9888390 for IN B-PP O
16 1414 1422 9888390 clinical JJ B-NP O
17 1423 1436 9888390 manifestation NN I-NP O
18 1437 1439 9888390 of IN B-PP O
19 1440 1443 9888390 MLD NN B-NP B-Disease
20 1443 1444 9888390 , , O O
21 1445 1454 9888390 mimicking VBG B-VP O
22 1455 1458 9888390 the DT B-NP O
23 1459 1467 9888390 frequent JJ I-NP O
24 1468 1472 9888390 ARSA NN I-NP O
25 1473 1489 9888390 pseudodeficiency NN I-NP O
26 1490 1496 9888390 allele NN I-NP O
27 1496 1497 9888390 . . O O

1 1498 1501 9888390 Our PRP$ B-NP O
2 1502 1509 9888390 results NNS I-NP O
3 1510 1521 9888390 demonstrate VBP B-VP O
4 1522 1526 9888390 that IN B-SBAR O
5 1527 1529 9888390 in IN B-PP O
6 1530 1537 9888390 certain JJ B-NP O
7 1538 1545 9888390 genetic JJ I-NP O
8 1546 1556 9888390 conditions NNS I-NP O
9 1557 1560 9888390 MLD NN I-NP B-Disease
10 1560 1561 9888390 - HYPH B-NP O
11 1561 1565 9888390 like JJ I-NP O
12 1566 1570 9888390 ARSA NN I-NP O
13 1571 1574 9888390 and CC I-NP O
14 1575 1577 9888390 GS NN I-NP O
15 1578 1584 9888390 values NNS I-NP O
16 1585 1589 9888390 need VBP B-VP O
17 1590 1593 9888390 not RB I-VP O
18 1594 1596 9888390 be VB I-VP O
19 1597 1607 9888390 paralleled VBN I-VP O
20 1608 1610 9888390 by IN B-PP O
21 1611 1619 9888390 clinical JJ B-NP O
22 1620 1627 9888390 disease NN I-NP O
23 1627 1628 9888390 , , O O
24 1629 1630 9888390 a DT B-NP O
25 1631 1638 9888390 finding NN I-NP O
26 1639 1643 9888390 with IN B-PP O
27 1644 1651 9888390 serious JJ B-NP O
28 1652 1662 9888390 diagnostic JJ I-NP O
29 1663 1666 9888390 and CC I-NP O
30 1667 1677 9888390 prognostic JJ I-NP O
31 1678 1690 9888390 implications NNS I-NP O
32 1690 1691 9888390 . . O O

1 1692 1700 9888390 Moreover RB B-ADVP O
2 1700 1701 9888390 , , O O
3 1702 1709 9888390 further JJ B-NP O
4 1710 1714 9888390 ARSA NN I-NP O
5 1715 1722 9888390 alleles NNS I-NP O
6 1723 1735 9888390 functionally RB B-ADJP O
7 1736 1743 9888390 similar JJ I-ADJP O
8 1744 1746 9888390 to TO B-PP O
9 1747 1752 9888390 A464V NN B-NP O
10 1753 1758 9888390 might MD B-VP O
11 1759 1764 9888390 exist VB I-VP O
12 1765 1770 9888390 which WDT B-NP O
13 1770 1771 9888390 , , O O
14 1772 1780 9888390 together RB B-ADVP O
15 1781 1785 9888390 with IN B-PP O
16 1786 1787 9888390 0 CD B-NP O
17 1787 1788 9888390 - HYPH I-NP O
18 1788 1792 9888390 type NN I-NP O
19 1793 1802 9888390 mutations NNS I-NP O
20 1802 1803 9888390 , , O O
21 1804 1807 9888390 may MD B-VP O
22 1808 1813 9888390 cause VB I-VP O
23 1814 1826 9888390 pathological JJ B-NP O
24 1827 1831 9888390 ARSA NN I-NP O
25 1832 1835 9888390 and CC I-NP O
26 1836 1838 9888390 GS NN I-NP O
27 1839 1845 9888390 levels NNS I-NP O
28 1845 1846 9888390 , , O O
29 1847 1850 9888390 but CC B-CONJP O
30 1851 1854 9888390 not RB I-CONJP O
31 1855 1863 9888390 clinical JJ B-NP O
32 1864 1872 9888390 outbreak NN I-NP O
33 1873 1875 9888390 of IN B-PP O
34 1876 1879 9888390 the DT B-NP O
35 1880 1887 9888390 disease NN I-NP O
36 1887 1888 9888390 . . O O
37 1888 1889 9888390 . . O O

1 0 0 9852676 -DOCSTART- -X- -X- O

1 0 7 9852676 Further JJ B-NP O
2 8 16 9852676 evidence NN I-NP O
3 17 20 9852676 for IN B-PP O
4 21 22 9852676 a DT B-NP O
5 23 28 9852676 major JJ I-NP O
6 29 36 9852676 ancient JJ I-NP O
7 37 45 9852676 mutation NN I-NP O
8 46 56 9852676 underlying VBG B-VP O
9 57 65 9852676 myotonic JJ B-NP B-Disease
10 66 75 9852676 dystrophy NN I-NP I-Disease
11 76 80 9852676 from IN B-PP O
12 81 88 9852676 linkage NN B-NP O
13 89 103 9852676 disequilibrium NN I-NP O
14 104 111 9852676 studies NNS I-NP O
15 112 114 9852676 in IN B-PP O
16 115 118 9852676 the DT B-NP O
17 119 127 9852676 Japanese JJ I-NP O
18 128 138 9852676 population NN I-NP O
19 138 139 9852676 . . O O
20 140 143 9852676 The DT B-NP O
21 144 152 9852676 myotonic JJ I-NP B-Disease
22 153 162 9852676 dystrophy NN I-NP I-Disease
23 163 164 9852676 ( ( O O
24 164 166 9852676 DM NN B-NP B-Disease
25 166 167 9852676 ) ) O O
26 168 176 9852676 mutation NN B-NP O
27 177 179 9852676 is VBZ B-VP O
28 180 182 9852676 an DT B-NP O
29 183 191 9852676 unstable JJ I-NP O
30 192 193 9852676 ( ( O O
31 193 196 9852676 CTG NN B-NP O
32 196 197 9852676 ) ) O O
33 198 199 9852676 n NN B-NP O
34 200 206 9852676 repeat NN I-NP O
35 206 207 9852676 , , O O
36 208 215 9852676 present JJ B-ADJP O
37 216 218 9852676 at IN B-PP O
38 219 220 9852676 a DT B-NP O
39 221 225 9852676 copy NN I-NP O
40 226 232 9852676 number NN I-NP O
41 233 235 9852676 of IN B-PP O
42 236 237 9852676 5 CD B-NP O
43 237 238 9852676 - HYPH I-NP O
44 238 240 9852676 37 CD I-NP O
45 241 248 9852676 repeats NNS I-NP O
46 249 251 9852676 on IN B-PP O
47 252 258 9852676 normal JJ B-NP O
48 259 270 9852676 chromosomes NNS I-NP O
49 271 274 9852676 but CC O O
50 275 284 9852676 amplified VBN B-VP O
51 285 287 9852676 to TO B-PP O
52 288 290 9852676 50 CD B-NP O
53 290 291 9852676 - HYPH I-NP O
54 291 295 9852676 3000 CD I-NP O
55 296 302 9852676 copies NNS I-NP O
56 303 305 9852676 on IN B-PP O
57 306 308 9852676 DM NN B-NP B-Disease
58 309 320 9852676 chromosomes NNS I-NP O
59 320 321 9852676 . . O O

1 322 330 9852676 Previous JJ B-NP O
2 331 339 9852676 findings NNS I-NP O
3 340 342 9852676 in IN B-PP O
4 343 352 9852676 Caucasian JJ B-NP O
5 353 364 9852676 populations NNS I-NP O
6 365 367 9852676 of IN B-PP O
7 368 369 9852676 a DT B-NP O
8 370 372 9852676 DM NN I-NP B-Disease
9 373 380 9852676 founder NN I-NP O
10 381 391 9852676 chromosome NN I-NP O
11 392 397 9852676 raise VBP B-VP O
12 398 399 9852676 a DT B-NP O
13 400 408 9852676 question NN I-NP O
14 409 414 9852676 about IN B-PP O
15 415 418 9852676 the DT B-NP O
16 419 428 9852676 molecular JJ I-NP O
17 429 435 9852676 events NNS I-NP O
18 436 444 9852676 involved VBN B-VP O
19 445 447 9852676 in IN B-PP O
20 448 451 9852676 the DT B-NP O
21 452 461 9852676 expansion NN I-NP O
22 462 470 9852676 mutation NN I-NP O
23 470 471 9852676 . . O O

1 472 474 9852676 To TO B-VP O
2 475 486 9852676 investigate VB I-VP O
3 487 494 9852676 whether IN B-SBAR O
4 495 496 9852676 a DT B-NP O
5 497 504 9852676 founder NN I-NP O
6 505 515 9852676 chromosome NN I-NP O
7 516 519 9852676 for IN B-PP O
8 520 523 9852676 the DT B-NP O
9 524 526 9852676 DM NN I-NP B-Disease
10 527 535 9852676 mutation NN I-NP O
11 536 542 9852676 exists VBZ B-VP O
12 543 545 9852676 in IN B-PP O
13 546 549 9852676 the DT B-NP O
14 550 558 9852676 Japanese JJ I-NP O
15 559 569 9852676 population NN I-NP O
16 569 570 9852676 , , O O
17 571 573 9852676 we PRP B-NP O
18 574 583 9852676 genotyped VBD B-VP O
19 584 592 9852676 families NNS B-NP O
20 593 598 9852676 using VBG B-VP O
21 599 610 9852676 polymorphic JJ B-NP O
22 611 618 9852676 markers NNS I-NP O
23 619 623 9852676 near IN B-PP O
24 624 627 9852676 the DT B-NP O
25 628 629 9852676 ( ( O O
26 629 632 9852676 CTG NN O O
27 632 633 9852676 ) ) O O
28 634 635 9852676 n NN B-NP O
29 636 642 9852676 repeat NN I-NP O
30 643 649 9852676 region NN I-NP O
31 650 653 9852676 and CC O O
32 654 665 9852676 constructed VBN B-NP O
33 666 676 9852676 haplotypes NNS I-NP O
34 676 677 9852676 . . O O

1 678 681 9852676 Six CD B-NP O
2 682 691 9852676 different JJ I-NP O
3 692 702 9852676 haplotypes NNS I-NP O
4 703 707 9852676 were VBD B-VP O
5 708 713 9852676 found VBN I-VP O
6 714 717 9852676 and CC O O
7 718 720 9852676 DM NN B-NP B-Disease
8 721 728 9852676 alleles NNS I-NP O
9 729 733 9852676 were VBD B-VP O
10 734 740 9852676 always RB B-ADVP O
11 741 750 9852676 haplotype NN B-NP O
12 751 752 9852676 A NN I-NP O
13 752 753 9852676 . . O O

1 754 756 9852676 To TO B-VP O
2 757 761 9852676 find VB I-VP O
3 762 764 9852676 an DT B-NP O
4 765 771 9852676 origin NN I-NP O
5 772 774 9852676 of IN B-PP O
6 775 778 9852676 the DT B-NP O
7 779 780 9852676 ( ( O O
8 780 783 9852676 CTG NN O O
9 783 784 9852676 ) ) O O
10 785 786 9852676 n NN B-NP O
11 787 793 9852676 repeat NN I-NP O
12 794 802 9852676 mutation NN I-NP O
13 803 806 9852676 and CC O O
14 807 809 9852676 to TO B-VP O
15 810 821 9852676 investigate VB I-VP O
16 822 825 9852676 the DT B-NP O
17 826 835 9852676 mechanism NN I-NP O
18 836 838 9852676 of IN B-PP O
19 839 842 9852676 the DT B-NP O
20 843 852 9852676 expansion NN I-NP O
21 853 861 9852676 mutation NN I-NP O
22 862 864 9852676 in IN B-PP O
23 865 868 9852676 the DT B-NP O
24 869 877 9852676 Japanese JJ I-NP O
25 878 888 9852676 population NN I-NP O
26 889 891 9852676 we PRP B-NP O
27 892 896 9852676 have VBP B-VP O
28 897 904 9852676 studied VBN I-VP O
29 905 907 9852676 90 CD B-NP O
30 908 916 9852676 Japanese JJ I-NP O
31 917 919 9852676 DM NN I-NP B-Disease
32 920 928 9852676 families NNS I-NP O
33 929 939 9852676 comprising VBG B-VP O
34 940 943 9852676 190 CD B-NP O
35 944 952 9852676 affected VBN B-VP O
36 953 956 9852676 and CC O O
37 957 960 9852676 130 CD B-NP O
38 961 971 9852676 unaffected JJ I-NP O
39 972 979 9852676 members NNS I-NP O
40 979 980 9852676 . . O O

1 981 984 9852676 The DT B-NP O
2 985 992 9852676 results NNS I-NP O
3 993 1000 9852676 suggest VBP B-VP O
4 1001 1005 9852676 that IN B-SBAR O
5 1006 1007 9852676 a DT B-NP O
6 1008 1011 9852676 few JJ I-NP O
7 1012 1018 9852676 common JJ I-NP O
8 1019 1028 9852676 ancestral JJ I-NP O
9 1029 1038 9852676 mutations NNS I-NP O
10 1039 1041 9852676 in IN B-PP O
11 1042 1046 9852676 both CC B-NP O
12 1047 1056 9852676 Caucasian JJ I-NP O
13 1057 1060 9852676 and CC I-NP O
14 1061 1069 9852676 Japanese JJ I-NP O
15 1070 1081 9852676 populations NNS I-NP O
16 1082 1086 9852676 have VBP B-VP O
17 1087 1097 9852676 originated VBN I-VP O
18 1098 1100 9852676 by IN B-PP O
19 1101 1110 9852676 expansion NN B-NP O
20 1111 1113 9852676 of IN B-PP O
21 1114 1116 9852676 an DT B-NP O
22 1117 1126 9852676 ancestral JJ I-NP O
23 1127 1128 9852676 n NN I-NP O
24 1129 1130 9852676 = SYM B-VP O
25 1131 1132 9852676 5 CD B-NP O
26 1133 1139 9852676 repeat NN I-NP O
27 1140 1142 9852676 to TO B-PP O
28 1143 1144 9852676 n NN B-NP O
29 1145 1146 9852676 = SYM B-VP O
30 1147 1149 9852676 19 CD B-NP O
31 1149 1150 9852676 - HYPH I-NP O
32 1150 1152 9852676 37 CD I-NP O
33 1153 1159 9852676 copies NNS I-NP O
34 1159 1160 9852676 . . O O

1 1161 1166 9852676 These DT B-NP O
2 1167 1171 9852676 data NNS I-NP O
3 1172 1179 9852676 support VBP B-VP O
4 1180 1189 9852676 multistep JJ B-NP O
5 1190 1196 9852676 models NNS I-NP O
6 1197 1199 9852676 of IN B-PP O
7 1200 1207 9852676 triplet JJ B-NP O
8 1208 1214 9852676 repeat NN I-NP O
9 1215 1224 9852676 expansion NN I-NP O
10 1225 1229 9852676 that WDT B-NP O
11 1230 1234 9852676 have VBP B-VP O
12 1235 1239 9852676 been VBN I-VP O
13 1240 1248 9852676 proposed VBN I-VP O
14 1249 1252 9852676 for IN B-PP O
15 1253 1257 9852676 both CC O O
16 1258 1260 9852676 DM NN B-NP B-Disease
17 1261 1264 9852676 and CC I-NP O
18 1265 1276 9852676 Friedreichs NNS I-NP B-Disease
19 1277 1283 9852676 ataxia NN I-NP I-Disease
20 1283 1284 9852676 . . O O
21 1284 1285 9852676 . . O O

1 0 0 9800909 -DOCSTART- -X- -X- O

1 0 3 9800909 Are VBP O O
2 4 8 9800909 Dp71 NN B-NP O
3 9 12 9800909 and CC I-NP O
4 13 18 9800909 Dp140 NN I-NP O
5 19 24 9800909 brain NN I-NP O
6 25 35 9800909 dystrophin NN I-NP O
7 36 44 9800909 isoforms NNS I-NP O
8 45 52 9800909 related VBN B-VP O
9 53 55 9800909 to TO B-PP O
10 56 65 9800909 cognitive JJ B-NP B-Disease
11 66 76 9800909 impairment NN I-NP I-Disease
12 77 79 9800909 in IN B-PP O
13 80 88 9800909 Duchenne NNP B-NP B-Disease
14 89 97 9800909 muscular JJ I-NP I-Disease
15 98 107 9800909 dystrophy NN I-NP I-Disease
16 107 108 9800909 ? . O O
17 109 118 9800909 Molecular JJ B-NP O
18 119 124 9800909 study NN I-NP O
19 125 128 9800909 and CC O O
20 129 147 9800909 neuropsychological JJ B-NP O
21 148 156 9800909 analysis NN I-NP O
22 157 161 9800909 were VBD B-VP O
23 162 171 9800909 performed VBN I-VP O
24 172 184 9800909 concurrently RB B-ADVP O
25 185 187 9800909 on IN B-PP O
26 188 190 9800909 49 CD B-NP O
27 191 199 9800909 patients NNS I-NP O
28 200 204 9800909 with IN B-PP O
29 205 213 9800909 Duchenne JJ B-NP B-Disease
30 214 222 9800909 muscular JJ I-NP I-Disease
31 223 232 9800909 dystrophy NN I-NP I-Disease
32 233 234 9800909 ( ( O O
33 234 237 9800909 DMD NN B-NP B-Disease
34 237 238 9800909 ) ) O O
35 239 241 9800909 in IN B-SBAR O
36 242 247 9800909 order NN O O
37 248 250 9800909 to TO B-VP O
38 251 255 9800909 find VB I-VP O
39 256 257 9800909 a DT B-NP O
40 258 267 9800909 molecular JJ I-NP O
41 268 279 9800909 explanation NN I-NP O
42 280 283 9800909 for IN B-PP O
43 284 287 9800909 the DT B-NP O
44 288 297 9800909 cognitive JJ I-NP B-Disease
45 298 308 9800909 impairment NN I-NP I-Disease
46 309 317 9800909 observed VBN B-VP O
47 318 320 9800909 in IN B-PP O
48 321 325 9800909 most JJS B-NP O
49 326 329 9800909 DMD NN I-NP B-Disease
50 330 338 9800909 patients NNS I-NP O
51 338 339 9800909 . . O O

1 340 348 9800909 Complete JJ B-NP O
2 349 357 9800909 analysis NN I-NP O
3 358 360 9800909 of IN B-PP O
4 361 364 9800909 the DT B-NP O
5 365 375 9800909 dystrophin NN I-NP O
6 376 380 9800909 gene NN I-NP O
7 381 384 9800909 was VBD B-VP O
8 385 394 9800909 performed VBN I-VP O
9 395 397 9800909 to TO I-VP O
10 398 404 9800909 define VB I-VP O
11 405 408 9800909 the DT B-NP O
12 409 421 9800909 localization NN I-NP O
13 422 424 9800909 of IN B-PP O
14 425 434 9800909 deletions NNS B-NP O
15 435 438 9800909 and CC I-NP O
16 439 451 9800909 duplications NNS I-NP O
17 452 454 9800909 in IN B-PP O
18 455 463 9800909 relation NN B-NP O
19 464 466 9800909 to TO B-PP O
20 467 470 9800909 the DT B-NP O
21 471 480 9800909 different JJ I-NP O
22 481 484 9800909 DMD NN I-NP B-Disease
23 485 494 9800909 promoters NNS I-NP O
24 494 495 9800909 . . O O

1 496 507 9800909 Qualitative JJ B-NP O
2 508 516 9800909 analysis NN I-NP O
3 517 519 9800909 of IN B-PP O
4 520 523 9800909 the DT B-NP O
5 524 528 9800909 Dp71 NN I-NP O
6 529 539 9800909 transcript NN I-NP O
7 540 543 9800909 and CC I-NP O
8 544 551 9800909 testing NN I-NP O
9 552 555 9800909 for IN B-PP O
10 556 559 9800909 the DT B-NP O
11 560 568 9800909 specific JJ I-NP O
12 569 574 9800909 first JJ I-NP O
13 575 579 9800909 exon NN I-NP O
14 580 582 9800909 of IN B-PP O
15 583 588 9800909 Dp140 NN B-NP O
16 589 593 9800909 were VBD B-VP O
17 594 598 9800909 also RB I-VP O
18 599 606 9800909 carried VBN I-VP O
19 607 610 9800909 out RP B-PRT O
20 610 611 9800909 . . O O

1 612 630 9800909 Neuropsychological JJ B-NP O
2 631 639 9800909 analysis NN I-NP O
3 640 648 9800909 assessed VBD B-VP O
4 649 655 9800909 verbal JJ B-NP O
5 656 659 9800909 and CC I-NP O
6 660 672 9800909 visuospatial JJ I-NP O
7 673 685 9800909 intelligence NN I-NP O
8 685 686 9800909 , , O O
9 687 693 9800909 verbal JJ B-NP O
10 694 700 9800909 memory NN I-NP O
11 700 701 9800909 , , O O
12 702 705 9800909 and CC O O
13 706 713 9800909 reading VBG B-VP O
14 714 720 9800909 skills NNS B-NP O
15 720 721 9800909 . . O O

1 722 732 9800909 Comparison NN B-NP O
2 733 735 9800909 of IN B-PP O
3 736 745 9800909 molecular JJ B-NP O
4 746 749 9800909 and CC I-NP O
5 750 762 9800909 psychometric JJ I-NP O
6 763 771 9800909 findings NNS I-NP O
7 772 784 9800909 demonstrated VBD B-VP O
8 785 789 9800909 that IN B-SBAR O
9 790 799 9800909 deletions NNS B-NP O
10 800 803 9800909 and CC I-NP O
11 804 816 9800909 duplications NNS I-NP O
12 817 821 9800909 that WDT B-NP O
13 822 826 9800909 were VBD B-VP O
14 827 836 9800909 localized JJ I-VP O
15 837 839 9800909 in IN B-PP O
16 840 843 9800909 the DT B-NP O
17 844 850 9800909 distal JJ I-NP O
18 851 855 9800909 part NN I-NP O
19 856 858 9800909 of IN B-PP O
20 859 862 9800909 the DT B-NP O
21 863 867 9800909 gene NN I-NP O
22 868 874 9800909 seemed VBD B-VP O
23 875 877 9800909 to TO I-VP O
24 878 880 9800909 be VB I-VP O
25 881 895 9800909 preferentially RB I-VP O
26 896 906 9800909 associated VBN I-VP O
27 907 911 9800909 with IN B-PP O
28 912 921 9800909 cognitive JJ B-NP B-Disease
29 922 932 9800909 impairment NN I-NP I-Disease
30 932 933 9800909 . . O O

1 934 937 9800909 Two CD B-NP O
2 938 945 9800909 altered JJ I-NP O
3 946 950 9800909 Dp71 NN I-NP O
4 951 962 9800909 transcripts NNS I-NP O
5 963 966 9800909 and CC O O
6 967 970 9800909 two CD B-NP O
7 971 978 9800909 deleted JJ I-NP O
8 979 984 9800909 Dp140 NN I-NP O
9 985 988 9800909 DNA NN I-NP O
10 989 998 9800909 sequences NNS I-NP O
11 999 1003 9800909 were VBD B-VP O
12 1004 1009 9800909 found VBN I-VP O
13 1010 1012 9800909 in IN B-PP O
14 1013 1017 9800909 four CD B-NP O
15 1018 1026 9800909 patients NNS I-NP O
16 1027 1031 9800909 with IN B-PP O
17 1032 1038 9800909 severe JJ B-NP O
18 1039 1047 9800909 cerebral JJ I-NP B-Disease
19 1048 1059 9800909 dysfunction NN I-NP I-Disease
20 1059 1060 9800909 . . O O

1 1061 1066 9800909 These DT B-NP O
2 1067 1075 9800909 findings NNS I-NP O
3 1076 1083 9800909 suggest VBP B-VP O
4 1084 1088 9800909 that IN B-SBAR O
5 1089 1093 9800909 some DT B-NP O
6 1094 1103 9800909 sequences NNS I-NP O
7 1104 1111 9800909 located VBN B-VP O
8 1112 1114 9800909 in IN B-PP O
9 1115 1118 9800909 the DT B-NP O
10 1119 1125 9800909 distal JJ I-NP O
11 1126 1130 9800909 part NN I-NP O
12 1131 1133 9800909 of IN B-PP O
13 1134 1137 9800909 the DT B-NP O
14 1138 1142 9800909 gene NN I-NP O
15 1143 1146 9800909 and CC O O
16 1146 1147 9800909 , , O O
17 1148 1150 9800909 in IN B-PP O
18 1151 1161 9800909 particular JJ B-ADJP O
19 1161 1162 9800909 , , O O
20 1163 1167 9800909 some DT B-NP O
21 1168 1171 9800909 DMD NN I-NP B-Disease
22 1172 1180 9800909 isoforms NNS I-NP O
23 1181 1190 9800909 expressed VBN B-VP O
24 1191 1193 9800909 in IN B-PP O
25 1194 1197 9800909 the DT B-NP O
26 1198 1203 9800909 brain NN I-NP O
27 1204 1207 9800909 may MD B-VP O
28 1208 1210 9800909 be VB I-VP O
29 1211 1218 9800909 related JJ B-ADJP O
30 1219 1221 9800909 to TO B-PP O
31 1222 1225 9800909 the DT B-NP O
32 1226 1235 9800909 cognitive JJ I-NP B-Disease
33 1236 1246 9800909 impairment NN I-NP I-Disease
34 1247 1257 9800909 associated VBN B-VP O
35 1258 1262 9800909 with IN B-PP O
36 1263 1266 9800909 DMD NN B-NP B-Disease
37 1266 1267 9800909 . . O O
38 1267 1268 9800909 . . O O

1 0 0 9311732 -DOCSTART- -X- -X- O

1 0 14 9311732 Constitutional JJ B-NP O
2 15 18 9311732 RB1 NN I-NP O
3 18 19 9311732 - HYPH I-NP O
4 19 23 9311732 gene NN I-NP O
5 24 33 9311732 mutations NNS I-NP O
6 34 36 9311732 in IN B-PP O
7 37 45 9311732 patients NNS B-NP O
8 46 50 9311732 with IN B-PP O
9 51 59 9311732 isolated VBN B-NP O
10 60 70 9311732 unilateral JJ I-NP B-Disease
11 71 85 9311732 retinoblastoma NN I-NP I-Disease
12 85 86 9311732 . . O O
13 87 89 9311732 In IN B-PP O
14 90 94 9311732 most JJS B-NP O
15 95 103 9311732 patients NNS I-NP O
16 104 108 9311732 with IN B-PP O
17 109 117 9311732 isolated VBN B-NP O
18 118 128 9311732 unilateral JJ I-NP B-Disease
19 129 143 9311732 retinoblastoma NN I-NP I-Disease
20 143 144 9311732 , , O O
21 145 150 9311732 tumor NN B-NP B-Disease
22 151 162 9311732 development NN I-NP O
23 163 165 9311732 is VBZ B-VP O
24 166 175 9311732 initiated VBN I-VP O
25 176 178 9311732 by IN B-PP O
26 179 186 9311732 somatic JJ B-NP O
27 187 199 9311732 inactivation NN I-NP O
28 200 202 9311732 of IN B-PP O
29 203 207 9311732 both DT B-NP O
30 208 215 9311732 alleles NNS I-NP O
31 216 218 9311732 of IN B-PP O
32 219 222 9311732 the DT B-NP O
33 223 226 9311732 RB1 NN I-NP O
34 227 231 9311732 gene NN I-NP O
35 231 232 9311732 . . O O

1 233 240 9311732 However RB B-ADVP O
2 240 241 9311732 , , O O
3 242 246 9311732 some DT B-NP O
4 247 249 9311732 of IN B-PP O
5 250 255 9311732 these DT B-NP O
6 256 264 9311732 patients NNS I-NP O
7 265 268 9311732 can MD B-VP O
8 269 277 9311732 transmit VB I-VP O
9 278 292 9311732 retinoblastoma NN B-NP B-Disease
10 293 307 9311732 predisposition NN I-NP O
11 308 310 9311732 to TO B-PP O
12 311 316 9311732 their PRP$ B-NP O
13 317 326 9311732 offspring NN I-NP O
14 326 327 9311732 . . O O

1 328 330 9311732 To TO B-VP O
2 331 340 9311732 determine VB I-VP O
3 341 344 9311732 the DT B-NP O
4 345 354 9311732 frequency NN I-NP O
5 355 358 9311732 and CC I-NP O
6 359 365 9311732 nature NN I-NP O
7 366 368 9311732 of IN B-PP O
8 369 383 9311732 constitutional JJ B-NP O
9 384 387 9311732 RB1 NN I-NP O
10 387 388 9311732 - HYPH B-NP O
11 388 392 9311732 gene NN I-NP O
12 393 402 9311732 mutations NNS I-NP O
13 403 405 9311732 in IN B-PP O
14 406 414 9311732 patients NNS B-NP O
15 415 419 9311732 with IN B-PP O
16 420 428 9311732 isolated VBN B-NP O
17 429 439 9311732 unilateral JJ I-NP B-Disease
18 440 454 9311732 retinoblastoma NN I-NP I-Disease
19 454 455 9311732 , , O O
20 456 458 9311732 we PRP B-NP O
21 459 467 9311732 analyzed VBD B-VP O
22 468 471 9311732 DNA NN B-NP O
23 472 476 9311732 from IN B-PP O
24 477 487 9311732 peripheral JJ B-NP O
25 488 493 9311732 blood NN I-NP O
26 494 497 9311732 and CC B-PP O
27 498 502 9311732 from IN B-PP O
28 503 508 9311732 tumor NN B-NP B-Disease
29 509 515 9311732 tissue NN I-NP O
30 515 516 9311732 . . O O

1 517 520 9311732 The DT B-NP O
2 521 529 9311732 analysis NN I-NP O
3 530 532 9311732 of IN B-PP O
4 533 539 9311732 tumors NNS B-NP B-Disease
5 540 544 9311732 from IN B-PP O
6 545 547 9311732 54 CD B-NP O
7 548 549 9311732 ( ( O O
8 549 552 9311732 71% CD B-NP O
9 552 553 9311732 ) ) O O
10 554 556 9311732 of IN B-PP O
11 557 559 9311732 76 CD B-NP O
12 560 571 9311732 informative JJ I-NP O
13 572 580 9311732 patients NNS I-NP O
14 581 587 9311732 showed VBD B-VP O
15 588 592 9311732 loss NN B-NP O
16 593 595 9311732 of IN B-PP O
17 596 610 9311732 constitutional JJ B-NP O
18 611 625 9311732 heterozygosity NN I-NP O
19 626 627 9311732 ( ( O O
20 627 630 9311732 LOH NN B-NP O
21 630 631 9311732 ) ) O O
22 632 634 9311732 at IN B-PP O
23 635 645 9311732 intragenic JJ B-NP O
24 646 650 9311732 loci NNS I-NP O
25 650 651 9311732 . . O O

1 652 657 9311732 Three CD B-NP O
2 658 660 9311732 of IN B-PP O
3 661 663 9311732 13 CD B-NP O
4 664 677 9311732 uninformative JJ I-NP O
5 678 686 9311732 patients NNS I-NP O
6 687 690 9311732 had VBD B-VP O
7 691 705 9311732 constitutional JJ B-NP O
8 706 715 9311732 deletions NNS I-NP O
9 715 716 9311732 . . O O

1 717 720 9311732 For IN B-PP O
2 721 723 9311732 39 CD B-NP O
3 724 732 9311732 randomly RB I-NP O
4 733 741 9311732 selected VBN I-NP O
5 742 748 9311732 tumors NNS I-NP B-Disease
6 748 749 9311732 , , O O
7 750 754 9311732 SSCP NN B-NP O
8 754 755 9311732 , , O O
9 756 762 9311732 hetero AFX B-NP O
10 762 763 9311732 - HYPH I-NP O
11 763 769 9311732 duplex NN I-NP O
12 770 778 9311732 analysis NN I-NP O
13 778 779 9311732 , , O O
14 780 790 9311732 sequencing NN B-NP O
15 790 791 9311732 , , O O
16 792 795 9311732 and CC O O
17 796 804 9311732 Southern JJ B-NP O
18 805 809 9311732 blot NN I-NP O
19 810 818 9311732 analysis NN I-NP O
20 819 823 9311732 were VBD B-VP O
21 824 828 9311732 used VBN I-VP O
22 829 831 9311732 to TO B-VP O
23 832 840 9311732 identify VB I-VP O
24 841 850 9311732 mutations NNS B-NP O
25 850 851 9311732 . . O O

1 852 861 9311732 Mutations NNS B-NP O
2 862 866 9311732 were VBD B-VP O
3 867 875 9311732 detected VBN I-VP O
4 876 878 9311732 in IN B-PP O
5 879 881 9311732 21 CD B-NP O
6 882 883 9311732 ( ( O O
7 883 886 9311732 91% CD B-NP O
8 886 887 9311732 ) ) O O
9 888 890 9311732 of IN B-PP O
10 891 893 9311732 23 CD B-NP O
11 894 900 9311732 tumors NNS I-NP B-Disease
12 901 905 9311732 with IN B-PP O
13 906 909 9311732 LOH NN B-NP O
14 909 910 9311732 . . O O

1 911 913 9311732 In IN B-PP O
2 914 915 9311732 6 CD B-NP O
3 916 917 9311732 ( ( O O
4 917 920 9311732 38% NN B-NP O
5 920 921 9311732 ) ) O O
6 922 924 9311732 of IN B-PP O
7 925 927 9311732 16 CD B-NP O
8 928 934 9311732 tumors NNS I-NP B-Disease
9 935 942 9311732 without IN B-PP O
10 943 946 9311732 LOH NN B-NP O
11 946 947 9311732 , , O O
12 948 951 9311732 one CD B-NP O
13 952 960 9311732 mutation NN I-NP O
14 961 964 9311732 was VBD B-VP O
15 965 973 9311732 detected VBN I-VP O
16 973 974 9311732 , , O O
17 975 978 9311732 and CC O O
18 979 981 9311732 in IN B-PP O
19 982 983 9311732 9 CD B-NP O
20 984 985 9311732 ( ( O O
21 985 988 9311732 56% NN B-NP O
22 988 989 9311732 ) ) O O
23 990 992 9311732 of IN B-PP O
24 993 996 9311732 the DT B-NP O
25 997 1003 9311732 tumors NNS I-NP B-Disease
26 1004 1011 9311732 without IN B-PP O
27 1012 1015 9311732 LOH NN B-NP O
28 1015 1016 9311732 , , O O
29 1017 1021 9311732 both DT B-NP O
30 1022 1031 9311732 mutations NNS I-NP O
31 1032 1036 9311732 were VBD B-VP O
32 1037 1042 9311732 found VBN I-VP O
33 1042 1043 9311732 . . O O

1 1044 1048 9311732 Thus RB B-ADVP O
2 1048 1049 9311732 , , O O
3 1050 1051 9311732 a DT B-NP O
4 1052 1057 9311732 total NN I-NP O
5 1058 1060 9311732 of IN B-PP O
6 1061 1063 9311732 45 CD B-NP O
7 1064 1073 9311732 mutations NNS I-NP O
8 1074 1078 9311732 were VBD B-VP O
9 1079 1089 9311732 identified VBN I-VP O
10 1090 1092 9311732 in IN B-PP O
11 1093 1099 9311732 tumors NNS B-NP B-Disease
12 1100 1102 9311732 of IN B-PP O
13 1103 1105 9311732 36 CD B-NP O
14 1106 1114 9311732 patients NNS I-NP O
15 1114 1115 9311732 . . O O

1 1116 1122 9311732 Thirty CD B-NP O
2 1122 1123 9311732 - HYPH I-NP O
3 1123 1127 9311732 nine CD I-NP O
4 1128 1130 9311732 of IN B-PP O
5 1131 1134 9311732 the DT B-NP O
6 1135 1144 9311732 mutations NNS I-NP O
7 1144 1145 9311732 - HYPH B-PP O
8 1145 1154 9311732 including VBG B-PP O
9 1155 1157 9311732 34 CD B-NP O
10 1158 1163 9311732 small JJ I-NP O
11 1164 1173 9311732 mutations NNS I-NP O
12 1173 1174 9311732 , , O O
13 1175 1176 9311732 2 CD B-NP O
14 1177 1182 9311732 large JJ I-NP O
15 1183 1193 9311732 structural JJ I-NP O
16 1194 1205 9311732 alterations NNS I-NP O
17 1205 1206 9311732 , , O O
18 1207 1210 9311732 and CC O O
19 1211 1227 9311732 hypermethylation NN B-NP O
20 1228 1230 9311732 in IN B-PP O
21 1231 1232 9311732 3 CD B-NP O
22 1233 1239 9311732 tumors NNS I-NP O
23 1239 1240 9311732 - HYPH B-NP O
24 1240 1244 9311732 were VBD B-VP O
25 1245 1248 9311732 not RB I-VP O
26 1249 1257 9311732 detected VBN I-VP O
27 1258 1260 9311732 in IN B-PP O
28 1261 1264 9311732 the DT B-NP O
29 1265 1278 9311732 corresponding VBG I-NP O
30 1279 1289 9311732 peripheral JJ I-NP O
31 1290 1295 9311732 blood NN I-NP O
32 1296 1299 9311732 DNA NN I-NP O
33 1299 1300 9311732 . . O O

1 1301 1303 9311732 In IN B-PP O
2 1304 1305 9311732 6 CD B-NP O
3 1306 1307 9311732 ( ( O O
4 1307 1310 9311732 17% NN B-NP O
5 1310 1311 9311732 ) ) O O
6 1312 1314 9311732 of IN B-PP O
7 1315 1318 9311732 the DT B-NP O
8 1319 1321 9311732 36 CD I-NP O
9 1322 1330 9311732 patients NNS I-NP O
10 1330 1331 9311732 , , O O
11 1332 1333 9311732 a DT B-NP O
12 1334 1342 9311732 mutation NN I-NP O
13 1343 1346 9311732 was VBD B-VP O
14 1347 1355 9311732 detected VBN I-VP O
15 1356 1358 9311732 in IN B-PP O
16 1359 1373 9311732 constitutional JJ B-NP O
17 1374 1377 9311732 DNA NN I-NP O
18 1377 1378 9311732 , , O O
19 1379 1382 9311732 and CC O O
20 1383 1384 9311732 1 CD B-NP O
21 1385 1387 9311732 of IN B-PP O
22 1388 1393 9311732 these DT B-NP O
23 1394 1403 9311732 mutations NNS I-NP O
24 1404 1406 9311732 is VBZ B-VP O
25 1407 1412 9311732 known VBN I-VP O
26 1413 1415 9311732 to TO I-VP O
27 1416 1418 9311732 be VB I-VP O
28 1419 1429 9311732 associated VBN I-VP O
29 1430 1434 9311732 with IN B-PP O
30 1435 1442 9311732 reduced VBN B-NP O
31 1443 1455 9311732 expressivity NN I-NP O
32 1455 1456 9311732 . . O O

1 1457 1460 9311732 The DT B-NP O
2 1461 1469 9311732 presence NN I-NP O
3 1470 1472 9311732 of IN B-PP O
4 1473 1474 9311732 a DT B-NP O
5 1475 1489 9311732 constitutional JJ I-NP O
6 1490 1498 9311732 mutation NN I-NP O
7 1499 1502 9311732 was VBD B-VP O
8 1503 1506 9311732 not RB I-VP O
9 1507 1517 9311732 associated VBN I-VP O
10 1518 1522 9311732 with IN B-PP O
11 1523 1525 9311732 an DT B-NP O
12 1526 1531 9311732 early JJ I-NP O
13 1532 1535 9311732 age NN I-NP O
14 1536 1538 9311732 at IN B-PP O
15 1539 1548 9311732 treatment NN B-NP O
16 1548 1549 9311732 . . O O

1 1550 1552 9311732 In IN B-PP O
2 1553 1554 9311732 1 CD B-NP O
3 1555 1562 9311732 patient NN I-NP O
4 1562 1563 9311732 , , O O
5 1564 1571 9311732 somatic JJ B-NP O
6 1572 1581 9311732 mosaicism NN I-NP O
7 1582 1585 9311732 was VBD B-VP O
8 1586 1598 9311732 demonstrated VBN I-VP O
9 1599 1601 9311732 by IN B-PP O
10 1602 1611 9311732 molecular JJ B-NP O
11 1612 1620 9311732 analysis NN I-NP O
12 1621 1623 9311732 of IN B-PP O
13 1624 1627 9311732 DNA NN B-NP O
14 1628 1631 9311732 and CC I-NP O
15 1632 1635 9311732 RNA NN I-NP O
16 1636 1640 9311732 from IN B-PP O
17 1641 1651 9311732 peripheral JJ B-NP O
18 1652 1657 9311732 blood NN I-NP O
19 1657 1658 9311732 . . O O

1 1659 1661 9311732 In IN B-PP O
2 1662 1663 9311732 2 CD B-NP O
3 1664 1672 9311732 patients NNS I-NP O
4 1673 1680 9311732 without IN B-PP O
5 1681 1682 9311732 a DT B-NP O
6 1683 1693 9311732 detectable JJ I-NP O
7 1694 1702 9311732 mutation NN I-NP O
8 1703 1705 9311732 in IN B-PP O
9 1706 1716 9311732 peripheral JJ B-NP O
10 1717 1722 9311732 blood NN I-NP O
11 1722 1723 9311732 , , O O
12 1724 1733 9311732 mosaicism NN B-NP O
13 1734 1737 9311732 was VBD B-VP O
14 1738 1747 9311732 suggested VBN I-VP O
15 1748 1755 9311732 because IN B-SBAR O
16 1756 1757 9311732 1 CD B-NP O
17 1758 1760 9311732 of IN B-PP O
18 1761 1764 9311732 the DT B-NP O
19 1765 1773 9311732 patients NNS I-NP O
20 1774 1780 9311732 showed VBD B-VP O
21 1781 1791 9311732 multifocal JJ B-NP O
22 1792 1798 9311732 tumors NNS I-NP B-Disease
23 1799 1802 9311732 and CC O O
24 1803 1806 9311732 the DT B-NP O
25 1807 1812 9311732 other JJ I-NP O
26 1813 1818 9311732 later RB B-ADVP O
27 1819 1828 9311732 developed VBD B-VP O
28 1829 1838 9311732 bilateral JJ B-NP B-Disease
29 1839 1853 9311732 retinoblastoma NN I-NP I-Disease
30 1853 1854 9311732 . . O O

1 1855 1857 9311732 In IN B-PP O
2 1858 1868 9311732 conclusion NN B-NP O
3 1868 1869 9311732 , , O O
4 1870 1873 9311732 our PRP$ B-NP O
5 1874 1881 9311732 results NNS I-NP O
6 1882 1891 9311732 emphasize VBP B-VP O
7 1892 1896 9311732 that IN B-SBAR O
8 1897 1900 9311732 the DT B-NP O
9 1901 1914 9311732 manifestation NN I-NP O
10 1915 1918 9311732 and CC I-NP O
11 1919 1935 9311732 transmissibility NN I-NP O
12 1936 1938 9311732 of IN B-PP O
13 1939 1953 9311732 retinoblastoma NN B-NP B-Disease
14 1954 1960 9311732 depend VBP B-VP O
15 1961 1963 9311732 on IN B-PP O
16 1964 1967 9311732 the DT B-NP O
17 1968 1974 9311732 nature NN I-NP O
18 1975 1977 9311732 of IN B-PP O
19 1978 1981 9311732 the DT B-NP O
20 1982 1987 9311732 first JJ I-NP O
21 1988 1996 9311732 mutation NN I-NP O
22 1996 1997 9311732 , , O O
23 1998 2001 9311732 its PRP$ B-NP O
24 2002 2006 9311732 time NN I-NP O
25 2007 2009 9311732 in IN B-PP O
26 2010 2021 9311732 development NN B-NP O
27 2021 2022 9311732 , , O O
28 2023 2026 9311732 and CC O O
29 2027 2030 9311732 the DT B-NP O
30 2031 2037 9311732 number NN I-NP O
31 2038 2041 9311732 and CC O O
32 2042 2047 9311732 types NNS B-NP O
33 2048 2050 9311732 of IN B-PP O
34 2051 2056 9311732 cells NNS B-NP O
35 2057 2061 9311732 that WDT B-NP O
36 2062 2065 9311732 are VBP B-VP O
37 2066 2074 9311732 affected VBN I-VP O
38 2074 2075 9311732 . . O O
39 2075 2076 9311732 . . O O

1 0 0 9536083 -DOCSTART- -X- -X- O

1 0 3 9536083 The DT B-NP O
2 4 12 9536083 185delAG NN I-NP O
3 13 18 9536083 BRCA1 NN I-NP O
4 19 27 9536083 mutation NN I-NP O
5 28 38 9536083 originated VBD B-VP O
6 39 45 9536083 before IN B-SBAR O
7 46 49 9536083 the DT B-NP O
8 50 60 9536083 dispersion NN I-NP O
9 61 63 9536083 of IN B-PP O
10 64 68 9536083 Jews NNPS B-NP O
11 69 71 9536083 in IN B-PP O
12 72 75 9536083 the DT B-NP O
13 76 84 9536083 diaspora NN I-NP O
14 85 88 9536083 and CC O O
15 89 91 9536083 is VBZ B-VP O
16 92 95 9536083 not RB I-VP O
17 96 103 9536083 limited VBN I-VP O
18 104 106 9536083 to TO B-PP O
19 107 117 9536083 Ashkenazim NNP B-NP O
20 117 118 9536083 . . O O
21 119 122 9536083 The DT B-NP O
22 123 131 9536083 185delAG NN I-NP O
23 132 140 9536083 mutation NN I-NP O
24 141 143 9536083 in IN B-PP O
25 144 149 9536083 BRCA1 NN B-NP O
26 150 152 9536083 is VBZ B-VP O
27 153 161 9536083 detected VBN I-VP O
28 162 164 9536083 in IN B-PP O
29 165 174 9536083 Ashkenazi NNP B-NP O
30 175 179 9536083 Jews NNP I-NP O
31 180 184 9536083 both CC B-PP O
32 185 187 9536083 in IN B-PP O
33 188 196 9536083 familial JJ B-NP B-Disease
34 197 203 9536083 breast NN I-NP I-Disease
35 204 207 9536083 and CC O I-Disease
36 208 215 9536083 ovarian JJ B-NP I-Disease
37 216 222 9536083 cancer NN I-NP I-Disease
38 223 226 9536083 and CC B-PP O
39 227 229 9536083 in IN B-PP O
40 230 233 9536083 the DT B-NP O
41 234 241 9536083 general JJ I-NP O
42 242 252 9536083 population NN I-NP O
43 252 253 9536083 . . O O

1 254 257 9536083 All DT B-NP O
2 258 264 9536083 tested VBN I-NP O
3 265 274 9536083 Ashkenazi NNP I-NP O
4 275 283 9536083 mutation NN I-NP O
5 284 292 9536083 carriers NNS I-NP O
6 293 298 9536083 share VBP B-VP O
7 299 302 9536083 the DT B-NP O
8 303 307 9536083 same JJ I-NP O
9 308 315 9536083 allelic JJ I-NP O
10 316 323 9536083 pattern NN I-NP O
11 324 326 9536083 at IN B-PP O
12 327 330 9536083 the DT B-NP O
13 331 336 9536083 BRCA1 NN I-NP O
14 337 342 9536083 locus NN I-NP O
15 342 343 9536083 . . O O

1 344 347 9536083 Our PRP$ B-NP O
2 348 356 9536083 previous JJ I-NP O
3 357 362 9536083 study NN I-NP O
4 363 369 9536083 showed VBD B-VP O
5 370 374 9536083 that IN B-SBAR O
6 375 379 9536083 this DT B-NP O
7 380 389 9536083 Ashkenazi NNP I-NP O
8 390 398 9536083 mutation NN I-NP O
9 399 403 9536083 also RB B-ADVP O
10 404 410 9536083 occurs VBZ B-VP O
11 411 413 9536083 in IN B-PP O
12 414 419 9536083 Iraqi NNP B-NP O
13 420 424 9536083 Jews NNPS I-NP O
14 425 429 9536083 with IN B-PP O
15 430 431 9536083 a DT B-NP O
16 432 439 9536083 similar JJ I-NP O
17 440 447 9536083 allelic JJ I-NP O
18 448 455 9536083 pattern NN I-NP O
19 455 456 9536083 . . O O

1 457 459 9536083 We PRP B-NP O
2 460 468 9536083 extended VBD B-VP O
3 469 472 9536083 our PRP$ B-NP O
4 473 481 9536083 analysis NN I-NP O
5 482 484 9536083 to TO B-PP O
6 485 490 9536083 other JJ B-NP O
7 491 494 9536083 non AFX I-NP O
8 494 495 9536083 - HYPH I-NP O
9 495 504 9536083 Ashkenazi NN I-NP O
10 505 512 9536083 subsets NNS I-NP O
11 514 517 9536083 354 CD B-NP O
12 518 520 9536083 of IN B-PP O
13 521 529 9536083 Moroccan NNP B-NP O
14 530 536 9536083 origin NN I-NP O
15 536 537 9536083 , , O O
16 538 541 9536083 200 CD B-NP O
17 542 551 9536083 Yemenites NNS I-NP O
18 552 555 9536083 and CC O O
19 556 559 9536083 150 CD B-NP O
20 560 567 9536083 Iranian JJ I-NP O
21 568 572 9536083 Jews NNS I-NP O
22 572 573 9536083 . . O O

1 574 586 9536083 Heteroduplex NN B-NP O
2 587 595 9536083 analysis NN I-NP O
3 596 608 9536083 complemented VBN B-VP O
4 609 611 9536083 by IN B-PP O
5 612 618 9536083 direct JJ B-NP O
6 619 622 9536083 DNA NN I-NP O
7 623 633 9536083 sequencing NN I-NP O
8 634 636 9536083 of IN B-PP O
9 637 647 9536083 abnormally RB B-VP O
10 648 657 9536083 migrating VBG I-VP O
11 658 663 9536083 bands NNS B-NP O
12 664 668 9536083 were VBD B-VP O
13 669 677 9536083 employed VBN I-VP O
14 677 678 9536083 . . O O

1 679 683 9536083 Four CD B-NP O
2 684 686 9536083 of IN B-PP O
3 687 695 9536083 Moroccan NN B-NP O
4 696 702 9536083 origin NN I-NP O
5 703 704 9536083 ( ( O O
6 704 705 9536083 1 CD B-NP O
7 705 706 9536083 . . O O

1 707 709 9536083 1% LS B-LST O
2 709 710 9536083 ) ) O O
3 711 714 9536083 and CC O O
4 715 719 9536083 none NN B-NP O
5 720 722 9536083 of IN B-PP O
6 723 726 9536083 the DT B-NP O
7 727 736 9536083 Yemenites NNPS I-NP O
8 737 739 9536083 or CC I-NP O
9 740 748 9536083 Iranians NNPS I-NP O
10 749 752 9536083 was VBD B-VP O
11 753 754 9536083 a DT B-NP O
12 755 762 9536083 carrier NN I-NP O
13 763 765 9536083 of IN B-PP O
14 766 769 9536083 the DT B-NP O
15 770 778 9536083 185delAG NN I-NP O
16 779 787 9536083 mutation NN I-NP O
17 787 788 9536083 . . O O

1 789 794 9536083 BRCA1 NN B-NP O
2 795 802 9536083 allelic JJ I-NP O
3 803 811 9536083 patterns NNS I-NP O
4 812 816 9536083 were VBD B-VP O
5 817 827 9536083 determined VBN I-VP O
6 828 831 9536083 for IN B-PP O
7 832 836 9536083 four CD B-NP O
8 837 839 9536083 of IN B-PP O
9 840 845 9536083 these DT B-NP O
10 846 857 9536083 individuals NNS I-NP O
11 858 861 9536083 and CC O O
12 862 865 9536083 for IN B-PP O
13 866 868 9536083 12 CD B-NP O
14 869 879 9536083 additional JJ I-NP O
15 880 883 9536083 non AFX I-NP O
16 883 884 9536083 - HYPH I-NP O
17 884 893 9536083 Ashkenazi NN I-NP O
18 894 902 9536083 185delAG NN I-NP O
19 903 911 9536083 mutation NN I-NP O
20 912 920 9536083 carriers NNS I-NP O
21 921 924 9536083 who WP B-NP O
22 925 928 9536083 had VBD B-VP O
23 929 935 9536083 breast NN B-NP B-Disease
24 935 936 9536083 / SYM O I-Disease
25 936 943 9536083 ovarian JJ B-NP I-Disease
26 944 950 9536083 cancer NN I-NP I-Disease
27 950 951 9536083 . . O O

1 952 955 9536083 Six CD B-NP O
2 956 959 9536083 non AFX I-NP O
3 959 960 9536083 - HYPH I-NP O
4 960 969 9536083 Ashkenazi NN I-NP O
5 970 981 9536083 individuals NNS I-NP O
6 982 988 9536083 shared VBD B-VP O
7 989 992 9536083 the DT B-NP O
8 993 999 9536083 common JJ I-NP O
9 1000 1009 9536083 Ashkenazi NNP I-NP O
10 1010 1019 9536083 haplotype NN I-NP O
11 1019 1020 9536083 , , O O
12 1021 1025 9536083 four CD B-NP O
13 1026 1029 9536083 had VBD B-VP O
14 1030 1031 9536083 a DT B-NP O
15 1032 1039 9536083 closely RB I-NP O
16 1040 1047 9536083 related JJ I-NP O
17 1048 1055 9536083 pattern NN I-NP O
18 1055 1056 9536083 , , O O
19 1057 1060 9536083 and CC O O
20 1061 1064 9536083 the DT B-NP O
21 1065 1069 9536083 rest NN I-NP O
22 1070 1071 9536083 ( ( O O
23 1071 1072 9536083 n NN B-NP O
24 1073 1074 9536083 = SYM B-VP O
25 1075 1076 9536083 6 CD B-NP O
26 1076 1077 9536083 ) ) O O
27 1078 1087 9536083 displayed VBD B-VP O
28 1088 1089 9536083 a DT B-NP O
29 1090 1098 9536083 distinct JJ I-NP O
30 1099 1104 9536083 BRCA1 NN I-NP O
31 1105 1112 9536083 allelic JJ I-NP O
32 1113 1120 9536083 pattern NN I-NP O
33 1120 1121 9536083 . . O O

1 1122 1124 9536083 We PRP B-NP O
2 1125 1133 9536083 conclude VBP B-VP O
3 1134 1138 9536083 that IN B-SBAR O
4 1139 1142 9536083 the DT B-NP O
5 1143 1151 9536083 185delAG NN I-NP O
6 1152 1157 9536083 BRCA1 NN I-NP O
7 1158 1166 9536083 mutation NN I-NP O
8 1167 1173 9536083 occurs VBZ B-VP O
9 1174 1176 9536083 in IN B-PP O
10 1177 1181 9536083 some DT B-NP O
11 1182 1185 9536083 non AFX I-NP O
12 1185 1186 9536083 - HYPH I-NP O
13 1186 1195 9536083 Ashkenazi NN I-NP O
14 1196 1207 9536083 populations NNS I-NP O
15 1208 1210 9536083 at IN B-PP O
16 1211 1216 9536083 rates NNS B-NP O
17 1217 1227 9536083 comparable JJ B-ADJP O
18 1228 1232 9536083 with IN B-PP O
19 1233 1237 9536083 that DT B-NP O
20 1238 1240 9536083 of IN B-PP O
21 1241 1251 9536083 Ashkenazim NN B-NP O
22 1251 1252 9536083 . . O O

1 1253 1256 9536083 The DT B-NP O
2 1257 1265 9536083 majority NN I-NP O
3 1266 1268 9536083 of IN B-PP O
4 1269 1275 9536083 Jewish JJ B-NP O
5 1276 1284 9536083 185delAG NN I-NP O
6 1285 1293 9536083 mutation NN I-NP O
7 1294 1302 9536083 carriers NNS I-NP O
8 1303 1307 9536083 have VBP B-VP O
9 1308 1309 9536083 a DT B-NP O
10 1310 1316 9536083 common JJ I-NP O
11 1317 1324 9536083 allelic JJ I-NP O
12 1325 1332 9536083 pattern NN I-NP O
13 1332 1333 9536083 , , O O
14 1334 1344 9536083 supporting VBG B-VP O
15 1345 1348 9536083 the DT B-NP O
16 1349 1356 9536083 founder NN I-NP O
17 1357 1363 9536083 effect NN I-NP O
18 1364 1370 9536083 notion NN I-NP O
19 1370 1371 9536083 , , O O
20 1372 1375 9536083 but CC O O
21 1376 1382 9536083 dating VBG B-VP O
22 1383 1386 9536083 the DT B-NP O
23 1387 1396 9536083 mutations NNS I-NP O
24 1397 1403 9536083 origin VBP B-VP O
25 1404 1406 9536083 to TO B-PP O
26 1407 1409 9536083 an DT B-NP O
27 1410 1417 9536083 earlier JJR I-NP O
28 1418 1422 9536083 date NN I-NP O
29 1423 1427 9536083 than IN B-SBAR O
30 1428 1437 9536083 currently RB B-ADVP O
31 1438 1447 9536083 estimated VBN B-VP O
32 1447 1448 9536083 . . O O

1 1449 1456 9536083 However RB B-ADVP O
2 1456 1457 9536083 , , O O
3 1458 1461 9536083 the DT B-NP O
4 1462 1471 9536083 different JJ I-NP O
5 1472 1479 9536083 allelic JJ I-NP O
6 1480 1487 9536083 pattern NN I-NP O
7 1488 1490 9536083 at IN B-PP O
8 1491 1494 9536083 the DT B-NP O
9 1495 1500 9536083 BRCA1 NN I-NP O
10 1501 1506 9536083 locus NN I-NP O
11 1507 1511 9536083 even RB B-ADVP O
12 1512 1514 9536083 in IN B-PP O
13 1515 1519 9536083 some DT B-NP O
14 1520 1526 9536083 Jewish JJ I-NP O
15 1527 1535 9536083 mutation NN I-NP O
16 1536 1544 9536083 carriers NNS I-NP O
17 1544 1545 9536083 , , O O
18 1546 1551 9536083 might MD B-VP O
19 1552 1559 9536083 suggest VB I-VP O
20 1560 1564 9536083 that IN B-SBAR O
21 1565 1568 9536083 the DT B-NP O
22 1569 1577 9536083 mutation NN I-NP O
23 1578 1583 9536083 arose VBD B-VP O
24 1584 1597 9536083 independently RB B-ADVP O
25 1597 1598 9536083 . . O O
26 1598 1599 9536083 . . O O

1 0 0 9585583 -DOCSTART- -X- -X- O

1 0 7 9585583 Genetic JJ B-NP O
2 8 21 9585583 heterogeneity NN I-NP O
3 22 24 9585583 of IN B-PP O
4 25 32 9585583 Saethre NNP B-NP B-Disease
5 32 33 9585583 - HYPH I-NP I-Disease
6 33 40 9585583 Chotzen NNP I-NP I-Disease
7 41 49 9585583 syndrome NN I-NP I-Disease
8 49 50 9585583 , , O O
9 51 54 9585583 due IN B-PP O
10 55 57 9585583 to TO I-PP O
11 58 63 9585583 TWIST NN B-NP O
12 64 67 9585583 and CC I-NP O
13 68 72 9585583 FGFR NN I-NP O
14 73 82 9585583 mutations NNS I-NP O
15 82 83 9585583 . . O O
16 84 90 9585583 Thirty CD B-NP O
17 90 91 9585583 - HYPH I-NP O
18 91 94 9585583 two CD I-NP O
19 95 104 9585583 unrelated JJ I-NP O
20 105 113 9585583 patients NNS I-NP O
21 114 118 9585583 with IN B-PP O
22 119 127 9585583 features NNS B-NP O
23 128 130 9585583 of IN B-PP O
24 131 138 9585583 Saethre NNP B-NP B-Disease
25 138 139 9585583 - HYPH I-NP I-Disease
26 139 146 9585583 Chotzen NNP I-NP I-Disease
27 147 155 9585583 syndrome NN I-NP I-Disease
28 155 156 9585583 , , O O
29 157 158 9585583 a DT B-NP O
30 159 165 9585583 common JJ I-NP O
31 166 175 9585583 autosomal JJ I-NP B-Disease
32 176 184 9585583 dominant JJ I-NP I-Disease
33 185 194 9585583 condition NN I-NP I-Disease
34 195 197 9585583 of IN B-PP O
35 198 214 9585583 craniosynostosis NN B-NP B-Disease
36 215 218 9585583 and CC I-NP O
37 219 223 9585583 limb NN I-NP B-Disease
38 224 233 9585583 anomalies NNS I-NP I-Disease
39 233 234 9585583 , , O O
40 235 239 9585583 were VBD B-VP O
41 240 248 9585583 screened VBN I-VP O
42 249 252 9585583 for IN B-PP O
43 253 262 9585583 mutations NNS B-NP O
44 263 265 9585583 in IN B-PP O
45 266 271 9585583 TWIST NN B-NP O
46 271 272 9585583 , , O O
47 273 278 9585583 FGFR2 NN B-NP O
48 278 279 9585583 , , O O
49 280 283 9585583 and CC O O
50 284 289 9585583 FGFR3 NN B-NP O
51 289 290 9585583 . . O O

1 291 295 9585583 Nine CD B-NP O
2 296 301 9585583 novel JJ I-NP O
3 302 305 9585583 and CC I-NP O
4 306 311 9585583 three CD I-NP O
5 312 321 9585583 recurrent JJ I-NP O
6 322 327 9585583 TWIST NN I-NP O
7 328 337 9585583 mutations NNS I-NP O
8 338 342 9585583 were VBD B-VP O
9 343 348 9585583 found VBN I-VP O
10 349 351 9585583 in IN B-PP O
11 352 354 9585583 12 CD B-NP O
12 355 363 9585583 families NNS I-NP O
13 363 364 9585583 . . O O

1 365 370 9585583 Seven CD B-NP O
2 371 379 9585583 families NNS I-NP O
3 380 384 9585583 were VBD B-VP O
4 385 390 9585583 found VBN I-VP O
5 391 393 9585583 to TO I-VP O
6 394 398 9585583 have VB I-VP O
7 399 402 9585583 the DT B-NP O
8 403 408 9585583 FGFR3 NN I-NP O
9 409 414 9585583 P250R NN I-NP O
10 415 423 9585583 mutation NN I-NP O
11 423 424 9585583 , , O O
12 425 428 9585583 and CC O O
13 429 432 9585583 one CD B-NP O
14 433 443 9585583 individual NN I-NP O
15 444 447 9585583 was VBD B-VP O
16 448 453 9585583 found VBN I-VP O
17 454 456 9585583 to TO I-VP O
18 457 461 9585583 have VB I-VP O
19 462 464 9585583 an DT B-NP O
20 465 470 9585583 FGFR2 NN I-NP O
21 471 476 9585583 VV269 NN I-NP O
22 476 477 9585583 - HYPH O O
23 477 480 9585583 270 CD B-NP O
24 481 489 9585583 deletion NN I-NP O
25 489 490 9585583 . . O O

1 491 493 9585583 To TO B-PP O
2 494 498 9585583 date NN B-NP O
3 498 499 9585583 , , O O
4 500 503 9585583 our PRP$ B-NP O
5 504 513 9585583 detection NN I-NP O
6 514 518 9585583 rate NN I-NP O
7 519 522 9585583 for IN B-PP O
8 523 528 9585583 TWIST NN B-NP O
9 529 531 9585583 or CC I-NP O
10 532 536 9585583 FGFR NN I-NP O
11 537 546 9585583 mutations NNS I-NP O
12 547 549 9585583 is VBZ B-VP O
13 550 553 9585583 68% CD B-NP O
14 554 556 9585583 in IN B-PP O
15 557 560 9585583 our PRP$ B-NP O
16 561 568 9585583 Saethre NNP I-NP B-Disease
17 568 569 9585583 - HYPH I-NP I-Disease
18 569 576 9585583 Chotzen NNP I-NP I-Disease
19 577 585 9585583 syndrome NN I-NP I-Disease
20 586 594 9585583 patients NNS I-NP O
21 594 595 9585583 , , O O
22 596 605 9585583 including VBG B-PP O
23 606 609 9585583 our PRP$ B-NP O
24 610 614 9585583 five CD I-NP O
25 615 623 9585583 patients NNS I-NP O
26 624 633 9585583 elsewhere RB B-VP O
27 634 642 9585583 reported VBN I-VP O
28 643 647 9585583 with IN B-PP O
29 648 653 9585583 TWIST NN B-NP O
30 654 663 9585583 mutations NNS I-NP O
31 663 664 9585583 . . O O

1 665 669 9585583 More JJR B-NP O
2 670 674 9585583 than IN I-NP O
3 675 677 9585583 35 CD I-NP O
4 678 687 9585583 different JJ I-NP O
5 688 693 9585583 TWIST NN I-NP O
6 694 703 9585583 mutations NNS I-NP O
7 704 707 9585583 are VBP B-VP O
8 708 711 9585583 now RB I-VP O
9 712 717 9585583 known VBN I-VP O
10 718 720 9585583 in IN B-PP O
11 721 724 9585583 the DT B-NP O
12 725 735 9585583 literature NN I-NP O
13 735 736 9585583 . . O O

1 737 740 9585583 The DT B-NP O
2 741 745 9585583 most RBS I-NP O
3 746 752 9585583 common JJ I-NP O
4 753 763 9585583 phenotypic JJ I-NP O
5 764 772 9585583 features NNS I-NP O
6 772 773 9585583 , , O O
7 774 781 9585583 present JJ B-ADJP O
8 782 784 9585583 in IN B-PP O
9 785 789 9585583 more JJR B-NP O
10 790 794 9585583 than IN I-NP O
11 795 796 9585583 a DT I-NP O
12 797 802 9585583 third JJ I-NP O
13 803 805 9585583 of IN B-PP O
14 806 809 9585583 our PRP$ B-NP O
15 810 818 9585583 patients NNS I-NP O
16 819 823 9585583 with IN B-PP O
17 824 829 9585583 TWIST NN B-NP O
18 830 839 9585583 mutations NNS I-NP O
19 839 840 9585583 , , O O
20 841 844 9585583 are VBP B-VP O
21 845 852 9585583 coronal JJ B-NP B-Disease
22 853 863 9585583 synostosis NN I-NP I-Disease
23 863 864 9585583 , , O O
24 865 878 9585583 brachycephaly RB B-ADVP B-Disease
25 878 879 9585583 , , O O
26 880 883 9585583 low JJ B-NP B-Disease
27 884 891 9585583 frontal JJ I-NP I-Disease
28 892 900 9585583 hairline NN I-NP I-Disease
29 900 901 9585583 , , O O
30 902 908 9585583 facial JJ B-NP B-Disease
31 909 918 9585583 asymmetry NN I-NP I-Disease
32 918 919 9585583 , , O O
33 920 926 9585583 ptosis NN B-NP B-Disease
34 926 927 9585583 , , O O
35 928 941 9585583 hypertelorism NN B-NP B-Disease
36 941 942 9585583 , , O O
37 943 948 9585583 broad JJ B-NP B-Disease
38 949 954 9585583 great JJ I-NP I-Disease
39 955 959 9585583 toes NNS I-NP I-Disease
40 959 960 9585583 , , O O
41 961 964 9585583 and CC O O
42 965 977 9585583 clinodactyly RB B-ADVP B-Disease
43 977 978 9585583 . . O O

1 979 990 9585583 Significant JJ B-NP O
2 991 996 9585583 intra AFX I-NP O
3 996 997 9585583 - HYPH I-NP O
4 998 1001 9585583 and CC I-NP O
5 1002 1015 9585583 interfamilial JJ I-NP O
6 1016 1026 9585583 phenotypic JJ I-NP O
7 1027 1038 9585583 variability NN I-NP O
8 1039 1041 9585583 is VBZ B-VP O
9 1042 1049 9585583 present JJ B-ADJP O
10 1050 1053 9585583 for IN B-PP O
11 1054 1060 9585583 either DT B-NP O
12 1061 1066 9585583 TWIST NN I-NP O
13 1067 1076 9585583 mutations NNS I-NP O
14 1077 1079 9585583 or CC O O
15 1080 1084 9585583 FGFR NN B-NP O
16 1085 1094 9585583 mutations NNS I-NP O
17 1094 1095 9585583 . . O O

1 1096 1099 9585583 The DT B-NP O
2 1100 1107 9585583 overlap NN I-NP O
3 1108 1110 9585583 in IN B-PP O
4 1111 1119 9585583 clinical JJ B-NP O
5 1120 1128 9585583 features NNS I-NP O
6 1129 1132 9585583 and CC O O
7 1133 1136 9585583 the DT B-NP O
8 1137 1145 9585583 presence NN I-NP O
9 1145 1146 9585583 , , O O
10 1147 1149 9585583 in IN B-PP O
11 1150 1153 9585583 the DT B-NP O
12 1154 1158 9585583 same JJ I-NP O
13 1159 1164 9585583 genes NNS I-NP O
14 1164 1165 9585583 , , O O
15 1166 1168 9585583 of IN B-PP O
16 1169 1178 9585583 mutations NNS B-NP O
17 1179 1182 9585583 for IN B-PP O
18 1183 1187 9585583 more JJR B-NP O
19 1188 1192 9585583 than IN I-NP O
20 1193 1196 9585583 one CD I-NP O
21 1197 1213 9585583 craniosynostotic JJ I-NP B-Disease
22 1214 1223 9585583 condition NN I-NP I-Disease
23 1223 1224 9585583 - HYPH B-VP O
24 1224 1228 9585583 such JJ B-PP O
25 1229 1231 9585583 as IN I-PP O
26 1232 1239 9585583 Saethre NNP B-NP B-Disease
27 1239 1240 9585583 - HYPH O I-Disease
28 1240 1247 9585583 Chotzen NNP B-NP I-Disease
29 1247 1248 9585583 , , O I-Disease
30 1249 1256 9585583 Crouzon NNP B-NP I-Disease
31 1256 1257 9585583 , , O I-Disease
32 1258 1261 9585583 and CC O I-Disease
33 1262 1270 9585583 Pfeiffer NN B-NP I-Disease
34 1271 1280 9585583 syndromes NNS I-NP I-Disease
35 1280 1281 9585583 - HYPH O O
36 1281 1288 9585583 support VBP B-VP O
37 1289 1292 9585583 the DT B-NP O
38 1293 1303 9585583 hypothesis NN I-NP O
39 1304 1308 9585583 that IN B-SBAR O
40 1309 1314 9585583 TWIST NN B-NP O
41 1315 1318 9585583 and CC I-NP O
42 1319 1324 9585583 FGFRs NNS I-NP O
43 1325 1328 9585583 are VBP B-VP O
44 1329 1339 9585583 components NNS B-NP O
45 1340 1342 9585583 of IN B-PP O
46 1343 1346 9585583 the DT B-NP O
47 1347 1351 9585583 same JJ I-NP O
48 1352 1361 9585583 molecular JJ I-NP O
49 1362 1369 9585583 pathway NN I-NP O
50 1370 1378 9585583 involved VBN B-VP O
51 1379 1381 9585583 in IN B-PP O
52 1382 1385 9585583 the DT B-NP O
53 1386 1396 9585583 modulation NN I-NP O
54 1397 1399 9585583 of IN B-PP O
55 1400 1412 9585583 craniofacial JJ B-NP O
56 1413 1416 9585583 and CC I-NP O
57 1417 1421 9585583 limb NN I-NP O
58 1422 1433 9585583 development NN I-NP O
59 1434 1436 9585583 in IN B-PP O
60 1437 1443 9585583 humans NNS B-NP O
61 1443 1444 9585583 . . O O
62 1444 1445 9585583 . . O O

1 0 0 9729124 -DOCSTART- -X- -X- O

1 0 7 9729124 Genomic JJ B-NP O
2 8 17 9729124 structure NN I-NP O
3 18 20 9729124 of IN B-PP O
4 21 24 9729124 the DT B-NP O
5 25 30 9729124 human JJ I-NP O
6 31 41 9729124 congenital JJ I-NP B-Disease
7 42 50 9729124 chloride NN I-NP I-Disease
8 51 59 9729124 diarrhea NN I-NP I-Disease
9 60 61 9729124 ( ( O O
10 61 64 9729124 CLD NN B-NP B-Disease
11 64 65 9729124 ) ) O O
12 66 70 9729124 gene NN B-NP O
13 70 71 9729124 . . O O
14 72 82 9729124 Congenital JJ B-NP B-Disease
15 83 91 9729124 chloride NN I-NP I-Disease
16 92 100 9729124 diarrhea NN I-NP I-Disease
17 101 102 9729124 ( ( O O
18 102 105 9729124 CLD NN B-NP B-Disease
19 105 106 9729124 ) ) O O
20 107 109 9729124 is VBZ B-VP O
21 110 116 9729124 caused VBN I-VP O
22 117 119 9729124 by IN B-PP O
23 120 129 9729124 mutations NNS B-NP O
24 130 132 9729124 in IN B-PP O
25 133 134 9729124 a DT B-NP O
26 135 139 9729124 gene NN I-NP O
27 140 145 9729124 which WDT B-NP O
28 146 153 9729124 encodes VBZ B-VP O
29 154 156 9729124 an DT B-NP O
30 157 167 9729124 intestinal JJ I-NP O
31 168 173 9729124 anion NN I-NP O
32 174 185 9729124 transporter NN I-NP O
33 185 186 9729124 . . O O

1 187 189 9729124 We PRP B-NP O
2 190 196 9729124 report VBP B-VP O
3 197 201 9729124 here RB B-ADVP O
4 202 205 9729124 the DT B-NP O
5 206 214 9729124 complete JJ I-NP O
6 215 222 9729124 genomic JJ I-NP O
7 223 235 9729124 organization NN I-NP O
8 236 238 9729124 of IN B-PP O
9 239 242 9729124 the DT B-NP O
10 243 248 9729124 human JJ I-NP O
11 249 252 9729124 CLD NN I-NP B-Disease
12 253 257 9729124 gene NN I-NP O
13 258 263 9729124 which WDT B-NP O
14 264 269 9729124 spans VBZ B-VP O
15 270 283 9729124 approximately RB B-ADJP O
16 284 288 9729124 39kb JJ I-ADJP O
17 288 289 9729124 , , O O
18 290 293 9729124 and CC O O
19 294 303 9729124 comprises VBZ B-VP O
20 304 306 9729124 21 CD B-NP O
21 307 312 9729124 exons NNS I-NP O
22 312 313 9729124 . . O O

1 314 317 9729124 All DT B-NP O
2 318 322 9729124 exon NN I-NP O
3 322 323 9729124 / SYM B-VP O
4 323 329 9729124 intron NN B-NP O
5 330 340 9729124 boundaries NNS I-NP O
6 341 348 9729124 conform VBP B-VP O
7 349 351 9729124 to TO B-PP O
8 352 355 9729124 the DT B-NP O
9 356 358 9729124 GT NN I-NP O
10 358 359 9729124 / SYM B-VP O
11 359 361 9729124 AG NN B-NP O
12 362 366 9729124 rule NN I-NP O
13 366 367 9729124 . . O O

1 368 370 9729124 An DT B-NP O
2 371 379 9729124 analysis NN I-NP O
3 380 382 9729124 of IN B-PP O
4 383 386 9729124 the DT B-NP O
5 387 395 9729124 putative JJ I-NP O
6 396 404 9729124 promoter NN I-NP O
7 405 411 9729124 region NN I-NP O
8 412 420 9729124 sequence NN I-NP O
9 421 426 9729124 shows VBZ B-VP O
10 427 428 9729124 a DT B-NP O
11 429 437 9729124 putative JJ I-NP O
12 438 442 9729124 TATA NN I-NP O
13 443 446 9729124 box NN I-NP O
14 447 450 9729124 and CC O O
15 451 459 9729124 predicts VBZ B-VP O
16 460 468 9729124 multiple JJ B-NP O
17 469 482 9729124 transcription NN I-NP O
18 483 489 9729124 factor NN I-NP O
19 490 497 9729124 binding NN I-NP O
20 498 503 9729124 sites NNS I-NP O
21 503 504 9729124 . . O O

1 505 508 9729124 The DT B-NP O
2 509 516 9729124 genomic JJ I-NP O
3 517 526 9729124 structure NN I-NP O
4 527 530 9729124 was VBD B-VP O
5 531 541 9729124 determined VBN I-VP O
6 542 547 9729124 using VBG B-VP O
7 548 551 9729124 DNA NN B-NP O
8 552 556 9729124 from IN B-PP O
9 557 564 9729124 several JJ B-NP O
10 565 572 9729124 sources NNS I-NP O
11 573 582 9729124 including VBG B-PP O
12 583 591 9729124 multiple JJ B-NP O
13 592 597 9729124 large JJ I-NP O
14 597 598 9729124 - HYPH I-NP O
15 598 604 9729124 insert NN I-NP O
16 605 613 9729124 libaries NNS I-NP O
17 614 617 9729124 and CC O O
18 618 625 9729124 genomic JJ B-NP O
19 626 629 9729124 DNA NN I-NP O
20 630 634 9729124 from IN B-PP O
21 635 642 9729124 Finnish JJ B-NP O
22 643 646 9729124 CLD NN I-NP B-Disease
23 647 655 9729124 patients NNS I-NP O
24 656 659 9729124 and CC I-NP O
25 660 668 9729124 controls NNS I-NP O
26 668 669 9729124 . . O O

1 670 674 9729124 Exon NN B-NP O
2 674 675 9729124 - HYPH I-NP O
3 675 683 9729124 specific JJ I-NP O
4 684 691 9729124 primers NNS I-NP O
5 692 701 9729124 developed VBN B-VP O
6 702 704 9729124 in IN B-PP O
7 705 709 9729124 this DT B-NP O
8 710 715 9729124 study NN I-NP O
9 716 720 9729124 will MD B-VP O
10 721 731 9729124 facilitate VB I-VP O
11 732 740 9729124 mutation NN B-NP O
12 741 750 9729124 screening NN I-NP O
13 751 758 9729124 studies NNS I-NP O
14 759 761 9729124 of IN B-PP O
15 762 770 9729124 patients NNS B-NP O
16 771 775 9729124 with IN B-PP O
17 776 779 9729124 the DT B-NP O
18 780 787 9729124 disease NN I-NP O
19 787 788 9729124 . . O O

1 789 796 9729124 Genomic JJ B-NP O
2 797 807 9729124 sequencing NN I-NP O
3 808 810 9729124 of IN B-PP O
4 811 812 9729124 a DT B-NP O
5 813 816 9729124 BAC NN I-NP O
6 817 822 9729124 clone NN I-NP O
7 823 833 9729124 H_RG364P16 NN I-NP O
8 834 842 9729124 revealed VBD B-VP O
9 843 846 9729124 the DT B-NP O
10 847 855 9729124 presence NN I-NP O
11 856 858 9729124 of IN B-PP O
12 859 866 9729124 another DT B-NP O
13 866 867 9729124 , , O O
14 868 874 9729124 highly RB B-NP O
15 875 885 9729124 homologous JJ I-NP O
16 886 890 9729124 gene NN I-NP O
17 891 892 9729124 3 CD I-NP O
18 893 895 9729124 of IN B-PP O
19 896 899 9729124 the DT B-NP O
20 900 903 9729124 CLD NN I-NP B-Disease
21 904 908 9729124 gene NN I-NP O
22 908 909 9729124 , , O O
23 910 914 9729124 with IN B-PP O
24 915 916 9729124 a DT B-NP O
25 917 924 9729124 similar JJ I-NP O
26 925 932 9729124 genomic JJ I-NP O
27 933 942 9729124 structure NN I-NP O
28 942 943 9729124 , , O O
29 944 952 9729124 recently RB B-VP O
30 953 963 9729124 identified VBN I-VP O
31 964 966 9729124 as IN B-PP O
32 967 970 9729124 the DT B-NP O
33 971 978 9729124 Pendred NNP I-NP B-Disease
34 979 987 9729124 syndrome NN I-NP I-Disease
35 988 992 9729124 gene NN I-NP O
36 993 994 9729124 ( ( O O
37 994 997 9729124 PDS NN B-NP B-Disease
38 997 998 9729124 ) ) O O
39 998 999 9729124 . . O O
40 999 1000 9729124 . . O O

1 0 0 9731533 -DOCSTART- -X- -X- O

1 0 3 9731533 The DT B-NP O
2 4 13 9731533 APCI1307K NN I-NP O
3 14 20 9731533 allele NN I-NP O
4 21 24 9731533 and CC O O
5 25 31 9731533 cancer NN B-NP B-Disease
6 32 36 9731533 risk NN I-NP O
7 37 39 9731533 in IN B-PP O
8 40 41 9731533 a DT B-NP O
9 42 51 9731533 community NN I-NP O
10 51 52 9731533 - HYPH O O
11 52 57 9731533 based VBN B-NP O
12 58 63 9731533 study NN I-NP O
13 64 66 9731533 of IN B-PP O
14 67 76 9731533 Ashkenazi NNP B-NP O
15 77 81 9731533 Jews NNP I-NP O
16 81 82 9731533 . . I-NP O
17 83 92 9731533 Mutations NNS I-NP O
18 93 95 9731533 in IN B-PP O
19 96 99 9731533 APC NN B-NP O
20 100 103 9731533 are VBP B-VP O
21 104 115 9731533 classically RB I-VP O
22 116 126 9731533 associated VBN I-VP O
23 127 131 9731533 with IN B-PP O
24 132 140 9731533 familial JJ B-NP B-Disease
25 141 152 9731533 adenomatous JJ I-NP I-Disease
26 153 162 9731533 polyposis NN I-NP I-Disease
27 163 164 9731533 ( ( O O
28 164 167 9731533 FAP NN B-NP B-Disease
29 167 168 9731533 ) ) O O
30 168 169 9731533 , , O O
31 170 171 9731533 a DT B-NP O
32 172 178 9731533 highly RB I-NP O
33 179 188 9731533 penetrant JJ I-NP O
34 189 198 9731533 autosomal JJ I-NP B-Disease
35 199 207 9731533 dominant JJ I-NP I-Disease
36 208 216 9731533 disorder NN I-NP I-Disease
37 217 230 9731533 characterized VBN B-VP O
38 231 233 9731533 by IN B-PP O
39 234 242 9731533 multiple JJ B-NP O
40 243 253 9731533 intestinal JJ I-NP O
41 254 260 9731533 polyps NNS I-NP B-Disease
42 261 264 9731533 and CC O O
43 264 265 9731533 , , O O
44 266 273 9731533 without IN B-PP O
45 274 282 9731533 surgical JJ B-NP O
46 283 295 9731533 intervention NN I-NP O
47 295 296 9731533 , , O O
48 297 300 9731533 the DT B-NP O
49 301 312 9731533 development NN I-NP O
50 313 315 9731533 of IN B-PP O
51 316 326 9731533 colorectal JJ B-NP B-Disease
52 327 333 9731533 cancer NN I-NP I-Disease
53 334 335 9731533 ( ( O O
54 335 338 9731533 CRC NN B-NP B-Disease
55 338 339 9731533 ) ) O O
56 339 340 9731533 . . O O

1 341 344 9731533 APC NN B-NP B-Disease
2 345 347 9731533 is VBZ B-VP O
3 348 349 9731533 a DT B-NP O
4 350 356 9731533 tumour NN I-NP O
5 356 357 9731533 - HYPH I-NP O
6 357 367 9731533 suppressor NN I-NP O
7 368 372 9731533 gene NN I-NP O
8 372 373 9731533 , , O O
9 374 377 9731533 and CC O O
10 378 385 9731533 somatic JJ B-NP O
11 386 390 9731533 loss NN I-NP O
12 391 397 9731533 occurs VBZ B-VP O
13 398 400 9731533 in IN B-PP O
14 401 408 9731533 tumours NNS B-NP B-Disease
15 408 409 9731533 . . O O

1 410 413 9731533 The DT B-NP O
2 414 422 9731533 germline NN I-NP O
3 423 424 9731533 T NN I-NP O
4 424 425 9731533 - HYPH B-ADJP O
5 425 427 9731533 to TO B-PP O
6 427 428 9731533 - HYPH B-NP O
7 428 429 9731533 A NN I-NP O
8 430 442 9731533 transversion NN I-NP O
9 443 454 9731533 responsible JJ B-ADJP O
10 455 458 9731533 for IN B-PP O
11 459 462 9731533 the DT B-NP O
12 463 466 9731533 APC NN I-NP O
13 467 473 9731533 I1307K NN I-NP O
14 474 480 9731533 allele NN I-NP O
15 481 489 9731533 converts VBZ B-VP O
16 490 493 9731533 the DT B-NP O
17 494 498 9731533 wild JJ I-NP O
18 498 499 9731533 - HYPH I-NP O
19 499 503 9731533 type NN I-NP O
20 504 512 9731533 sequence NN I-NP O
21 513 515 9731533 to TO B-PP O
22 516 517 9731533 a DT B-NP O
23 518 529 9731533 homopolymer NN I-NP O
24 530 535 9731533 tract NN I-NP O
25 536 537 9731533 ( ( O O
26 537 539 9731533 A8 NN B-NP O
27 539 540 9731533 ) ) O O
28 541 545 9731533 that WDT B-NP O
29 546 548 9731533 is VBZ B-VP O
30 549 560 9731533 genetically RB B-ADJP O
31 561 569 9731533 unstable JJ I-ADJP O
32 570 573 9731533 and CC I-ADJP O
33 574 579 9731533 prone JJ I-ADJP O
34 580 582 9731533 to TO B-PP O
35 583 590 9731533 somatic JJ B-NP O
36 591 599 9731533 mutation NN I-NP O
37 599 600 9731533 . . O O

1 601 604 9731533 The DT B-NP O
2 605 611 9731533 I1307K NN I-NP O
3 612 618 9731533 allele NN I-NP O
4 619 622 9731533 was VBD B-VP O
5 623 628 9731533 found VBN I-VP O
6 629 631 9731533 in IN B-PP O
7 632 633 9731533 6 CD B-NP O
8 633 634 9731533 . . O O

1 635 637 9731533 1% CD B-NP O
2 638 640 9731533 of IN B-PP O
3 641 651 9731533 unselected JJ B-NP O
4 652 661 9731533 Ashkenazi NNP I-NP O
5 662 666 9731533 Jews NNPS I-NP O
6 667 670 9731533 and CC O O
7 671 677 9731533 higher JJR B-NP O
8 678 689 9731533 proportions NNS I-NP O
9 690 692 9731533 of IN B-PP O
10 693 703 9731533 Ashkenazim NN B-NP O
11 704 708 9731533 with IN B-PP O
12 709 715 9731533 family NN B-NP O
13 716 718 9731533 or CC O O
14 719 727 9731533 personal JJ B-NP O
15 728 737 9731533 histories NNS I-NP O
16 738 740 9731533 of IN B-PP O
17 741 744 9731533 CRC NN B-NP B-Disease
18 745 746 9731533 ( ( O O
19 746 749 9731533 ref NN B-NP O
20 749 750 9731533 . . O O

1 751 752 9731533 2 LS B-LST O
2 752 753 9731533 ) ) O O
3 753 754 9731533 . . O O

1 755 757 9731533 To TO B-VP O
2 758 766 9731533 evaluate VB I-VP O
3 767 770 9731533 the DT B-NP O
4 771 775 9731533 role NN I-NP O
5 776 778 9731533 of IN B-PP O
6 779 785 9731533 I1307K NN B-NP O
7 786 788 9731533 in IN B-PP O
8 789 795 9731533 cancer NN B-NP B-Disease
9 795 796 9731533 , , O O
10 797 799 9731533 we PRP B-NP O
11 800 809 9731533 genotyped VBD B-VP O
12 810 811 9731533 5 CD B-NP O
13 811 812 9731533 , , O O
14 813 816 9731533 081 CD B-NP O
15 817 826 9731533 Ashkenazi NNP I-NP O
16 827 837 9731533 volunteers NNS I-NP O
17 838 840 9731533 in IN B-PP O
18 841 842 9731533 a DT B-NP O
19 843 852 9731533 community NN I-NP O
20 853 859 9731533 survey NN I-NP O
21 859 860 9731533 . . O O

1 861 865 9731533 Risk NN B-NP O
2 866 868 9731533 of IN B-PP O
3 869 879 9731533 developing VBG B-VP O
4 880 890 9731533 colorectal JJ B-NP B-Disease
5 890 891 9731533 , , I-NP I-Disease
6 892 898 9731533 breast NN I-NP I-Disease
7 899 902 9731533 and CC O I-Disease
8 903 908 9731533 other JJ B-NP I-Disease
9 909 916 9731533 cancers NNS I-NP I-Disease
10 917 921 9731533 were VBD B-VP O
11 922 930 9731533 compared VBN I-VP O
12 931 938 9731533 between IN B-PP O
13 939 948 9731533 genotyped VBN B-NP O
14 949 955 9731533 I1307K NN I-NP O
15 956 964 9731533 carriers NNS I-NP O
16 965 968 9731533 and CC O O
17 969 972 9731533 non AFX B-NP O
18 972 973 9731533 - HYPH I-NP O
19 973 981 9731533 carriers NNS I-NP O
20 982 985 9731533 and CC O O
21 986 991 9731533 their PRP$ B-NP O
22 992 997 9731533 first JJ I-NP O
23 997 998 9731533 - HYPH I-NP O
24 998 1004 9731533 degree NN I-NP O
25 1005 1014 9731533 relatives NNS I-NP O
26 1014 1015 9731533 . . O O

1 0 0 9563950 -DOCSTART- -X- -X- O

1 0 10 9563950 Disruption NN B-NP O
2 11 13 9563950 of IN B-PP O
3 14 22 9563950 splicing NN B-NP O
4 23 32 9563950 regulated VBN B-VP O
5 33 35 9563950 by IN B-PP O
6 36 37 9563950 a DT B-NP O
7 38 41 9563950 CUG NN I-NP O
8 41 42 9563950 - HYPH O O
9 42 49 9563950 binding VBG B-NP O
10 50 57 9563950 protein NN I-NP O
11 58 60 9563950 in IN B-PP O
12 61 69 9563950 myotonic JJ B-NP B-Disease
13 70 79 9563950 dystrophy NN I-NP I-Disease
14 79 80 9563950 . . O O
15 81 89 9563950 Myotonic JJ B-NP B-Disease
16 90 99 9563950 dystrophy NN I-NP I-Disease
17 100 101 9563950 ( ( O O
18 101 103 9563950 DM NN B-NP B-Disease
19 103 104 9563950 ) ) O O
20 105 107 9563950 is VBZ B-VP O
21 108 114 9563950 caused VBN I-VP O
22 115 117 9563950 by IN B-PP O
23 118 119 9563950 a DT B-NP O
24 120 123 9563950 CTG NN I-NP O
25 124 133 9563950 expansion NN I-NP O
26 134 136 9563950 in IN B-PP O
27 137 140 9563950 the DT B-NP O
28 141 142 9563950 3 CD I-NP O
29 143 155 9563950 untranslated JJ I-NP O
30 156 162 9563950 region NN I-NP O
31 163 165 9563950 of IN B-PP O
32 166 169 9563950 the DT B-NP O
33 170 172 9563950 DM NN I-NP B-Disease
34 173 177 9563950 gene NN I-NP O
35 177 178 9563950 . . O O

1 179 182 9563950 One CD B-NP O
2 183 188 9563950 model NN I-NP O
3 189 191 9563950 of IN B-PP O
4 192 194 9563950 DM NN B-NP B-Disease
5 195 207 9563950 pathogenesis NN I-NP O
6 208 216 9563950 suggests VBZ B-VP O
7 217 221 9563950 that IN B-SBAR O
8 222 226 9563950 RNAs NNS B-NP O
9 227 231 9563950 from IN B-PP O
10 232 235 9563950 the DT B-NP O
11 236 244 9563950 expanded VBN I-NP O
12 245 251 9563950 allele NN I-NP O
13 252 258 9563950 create VB B-VP O
14 259 260 9563950 a DT B-NP O
15 261 265 9563950 gain NN I-NP O
16 265 266 9563950 - HYPH B-NP O
17 266 268 9563950 of IN B-PP O
18 268 269 9563950 - HYPH B-NP O
19 269 277 9563950 function NN I-NP O
20 278 286 9563950 mutation NN I-NP O
21 287 289 9563950 by IN B-PP O
22 290 293 9563950 the DT B-NP O
23 294 307 9563950 inappropriate JJ I-NP O
24 308 315 9563950 binding NN I-NP O
25 316 318 9563950 of IN B-PP O
26 319 327 9563950 proteins NNS B-NP O
27 328 330 9563950 to TO B-PP O
28 331 334 9563950 the DT B-NP O
29 335 338 9563950 CUG NN I-NP O
30 339 346 9563950 repeats NNS I-NP O
31 346 347 9563950 . . O O

1 348 352 9563950 Data NNS B-NP O
2 353 362 9563950 presented VBN B-VP O
3 363 367 9563950 here RB B-ADVP O
4 368 376 9563950 indicate VBP B-VP O
5 377 381 9563950 that IN B-SBAR O
6 382 385 9563950 the DT B-NP O
7 386 395 9563950 conserved VBN I-NP O
8 396 409 9563950 heterogeneous JJ I-NP O
9 410 417 9563950 nuclear JJ I-NP O
10 418 435 9563950 ribonucleoprotein NN I-NP O
11 435 436 9563950 , , O O
12 437 440 9563950 CUG NN B-NP O
13 440 441 9563950 - HYPH O O
14 441 448 9563950 binding VBG B-VP O
15 449 456 9563950 protein NN B-NP O
16 457 458 9563950 ( ( O O
17 458 461 9563950 CUG NN B-NP O
18 461 462 9563950 - HYPH B-NP O
19 462 464 9563950 BP NN I-NP O
20 464 465 9563950 ) ) O O
21 465 466 9563950 , , O O
22 467 470 9563950 may MD B-VP O
23 471 478 9563950 mediate VB I-VP O
24 479 482 9563950 the DT B-NP O
25 483 488 9563950 trans AFX I-NP O
26 488 489 9563950 - HYPH I-NP O
27 489 497 9563950 dominant JJ I-NP O
28 498 504 9563950 effect NN I-NP O
29 505 507 9563950 of IN B-PP O
30 508 511 9563950 the DT B-NP O
31 512 515 9563950 RNA NN I-NP O
32 515 516 9563950 . . O O

1 517 520 9563950 CUG NN B-NP O
2 520 521 9563950 - HYPH I-NP O
3 521 523 9563950 BP NN I-NP O
4 524 527 9563950 was VBD B-VP O
5 528 533 9563950 found VBN I-VP O
6 534 536 9563950 to TO I-VP O
7 537 541 9563950 bind VB I-VP O
8 542 544 9563950 to TO B-PP O
9 545 548 9563950 the DT B-NP O
10 549 554 9563950 human JJ I-NP O
11 555 562 9563950 cardiac JJ I-NP O
12 563 571 9563950 troponin NN I-NP O
13 572 573 9563950 T NN I-NP O
14 574 575 9563950 ( ( O O
15 575 579 9563950 cTNT NN B-NP O
16 579 580 9563950 ) ) O O
17 581 584 9563950 pre AFX O O
18 584 585 9563950 - HYPH O O
19 585 594 9563950 messenger NN B-NP O
20 595 598 9563950 RNA NN I-NP O
21 599 602 9563950 and CC O O
22 603 611 9563950 regulate VB B-VP O
23 612 615 9563950 its PRP$ B-NP O
24 616 627 9563950 alternative JJ I-NP O
25 628 636 9563950 splicing NN I-NP O
26 636 637 9563950 . . O O

1 638 646 9563950 Splicing NN B-NP O
2 647 649 9563950 of IN B-PP O
3 650 654 9563950 cTNT NN B-NP O
4 655 658 9563950 was VBD B-VP O
5 659 668 9563950 disrupted VBN I-VP O
6 669 671 9563950 in IN B-PP O
7 672 674 9563950 DM NN B-NP B-Disease
8 675 683 9563950 striated VBN I-NP O
9 684 690 9563950 muscle NN I-NP O
10 691 694 9563950 and CC B-PP O
11 695 697 9563950 in IN B-PP O
12 698 704 9563950 normal JJ B-NP O
13 705 710 9563950 cells NNS I-NP O
14 711 721 9563950 expressing VBG B-VP O
15 722 733 9563950 transcripts NNS B-NP O
16 734 738 9563950 that WDT B-NP O
17 739 746 9563950 contain VBP B-VP O
18 747 750 9563950 CUG NN B-NP O
19 751 758 9563950 repeats NNS I-NP O
20 758 759 9563950 . . O O

1 760 767 9563950 Altered VBN B-NP O
2 768 778 9563950 expression NN I-NP O
3 779 781 9563950 of IN B-PP O
4 782 787 9563950 genes NNS B-NP O
5 788 797 9563950 regulated VBN B-VP O
6 798 819 9563950 posttranscriptionally RB B-ADVP O
7 820 822 9563950 by IN B-PP O
8 823 826 9563950 CUG NN B-NP O
9 826 827 9563950 - HYPH I-NP O
10 827 829 9563950 BP NN I-NP O
11 830 839 9563950 therefore RB B-ADVP O
12 840 843 9563950 may MD B-VP O
13 844 854 9563950 contribute VB I-VP O
14 855 857 9563950 to TO B-PP O
15 858 860 9563950 DM NN B-NP B-Disease
16 861 873 9563950 pathogenesis NN I-NP O
17 873 874 9563950 . . O O
18 874 875 9563950 . . O O

1 0 0 9585605 -DOCSTART- -X- -X- O

1 0 8 9585605 Mutation NN B-NP O
2 9 17 9585605 analysis NN I-NP O
3 18 20 9585605 of IN B-PP O
4 21 26 9585605 UBE3A NN B-NP O
5 27 29 9585605 in IN B-PP O
6 30 38 9585605 Angelman NNP B-NP B-Disease
7 39 47 9585605 syndrome NN I-NP I-Disease
8 48 56 9585605 patients NNS I-NP O
9 56 57 9585605 . . O O
10 58 66 9585605 Angelman NNP B-NP B-Disease
11 67 75 9585605 syndrome NN I-NP I-Disease
12 76 77 9585605 ( ( O O
13 77 79 9585605 AS NN B-NP B-Disease
14 79 80 9585605 ) ) O O
15 81 83 9585605 is VBZ B-VP O
16 84 90 9585605 caused VBN I-VP O
17 91 93 9585605 by IN B-PP O
18 94 104 9585605 chromosome NN B-NP O
19 105 110 9585605 15q11 CD I-NP O
20 110 111 9585605 - HYPH I-NP O
21 111 114 9585605 q13 NN I-NP O
22 115 124 9585605 deletions NNS I-NP O
23 125 127 9585605 of IN B-PP O
24 128 136 9585605 maternal JJ B-NP O
25 137 143 9585605 origin NN I-NP O
26 143 144 9585605 , , O O
27 145 147 9585605 by IN B-PP O
28 148 156 9585605 paternal JJ B-NP O
29 157 168 9585605 uniparental JJ I-NP B-Disease
30 169 175 9585605 disomy NN I-NP I-Disease
31 176 177 9585605 ( ( O O
32 177 180 9585605 UPD NN B-NP B-Disease
33 180 181 9585605 ) ) O O
34 182 184 9585605 15 CD B-NP O
35 184 185 9585605 , , O O
36 186 188 9585605 by IN B-PP O
37 189 199 9585605 imprinting VBG B-VP O
38 200 207 9585605 defects NNS B-NP O
39 207 208 9585605 , , O O
40 209 212 9585605 and CC O O
41 213 215 9585605 by IN B-PP O
42 216 225 9585605 mutations NNS B-NP O
43 226 228 9585605 in IN B-PP O
44 229 232 9585605 the DT B-NP O
45 233 238 9585605 UBE3A NN I-NP O
46 239 243 9585605 gene NN I-NP O
47 243 244 9585605 . . O O

1 245 250 9585605 UBE3A NN B-NP O
2 251 258 9585605 encodes VBZ B-VP O
3 259 260 9585605 a DT B-NP O
4 261 270 9585605 ubiquitin NN I-NP O
5 270 271 9585605 - HYPH B-NP O
6 271 278 9585605 protein NN I-NP O
7 279 285 9585605 ligase NN I-NP O
8 286 289 9585605 and CC O O
9 290 295 9585605 shows VBZ B-VP O
10 296 301 9585605 brain NN B-NP O
11 301 302 9585605 - HYPH I-NP O
12 302 310 9585605 specific JJ I-NP O
13 311 321 9585605 imprinting NN I-NP O
14 321 322 9585605 . . O O

1 323 327 9585605 Here RB B-ADVP O
2 328 330 9585605 we PRP B-NP O
3 331 339 9585605 describe VBP B-VP O
4 340 345 9585605 UBE3A NN B-NP O
5 346 352 9585605 coding NN I-NP O
6 352 353 9585605 - HYPH B-NP O
7 353 359 9585605 region NN I-NP O
8 360 369 9585605 mutations NNS I-NP O
9 370 378 9585605 detected VBN B-VP O
10 379 381 9585605 by IN B-PP O
11 382 386 9585605 SSCP NN B-NP O
12 387 395 9585605 analysis NN I-NP O
13 396 398 9585605 in IN B-PP O
14 399 401 9585605 13 CD B-NP O
15 402 404 9585605 AS JJ I-NP B-Disease
16 405 416 9585605 individuals NNS I-NP O
17 417 419 9585605 or CC I-NP O
18 420 428 9585605 families NNS I-NP O
19 428 429 9585605 . . O O

1 430 433 9585605 Two CD B-NP O
2 434 443 9585605 identical JJ I-NP O
3 444 446 9585605 de FW I-NP O
4 447 451 9585605 novo FW I-NP O
5 452 453 9585605 5 CD I-NP O
6 453 454 9585605 - HYPH I-NP O
7 454 456 9585605 bp NN I-NP O
8 457 469 9585605 duplications NNS I-NP O
9 470 472 9585605 in IN B-PP O
10 473 477 9585605 exon NN B-NP O
11 478 480 9585605 16 CD I-NP O
12 481 485 9585605 were VBD B-VP O
13 486 491 9585605 found VBN I-VP O
14 491 492 9585605 . . O O

1 493 498 9585605 Among IN B-PP O
2 499 502 9585605 the DT B-NP O
3 503 508 9585605 other JJ I-NP O
4 509 511 9585605 11 CD I-NP O
5 512 518 9585605 unique JJ I-NP O
6 519 528 9585605 mutations NNS I-NP O
7 528 529 9585605 , , O O
8 530 531 9585605 8 CD B-NP O
9 532 536 9585605 were VBD B-VP O
10 537 542 9585605 small JJ B-NP O
11 543 552 9585605 deletions NNS I-NP O
12 553 555 9585605 or CC I-NP O
13 556 566 9585605 insertions NNS I-NP O
14 567 576 9585605 predicted VBN B-VP O
15 577 579 9585605 to TO B-VP O
16 580 585 9585605 cause VB I-VP O
17 586 597 9585605 frameshifts NNS B-NP O
18 597 598 9585605 , , O O
19 599 600 9585605 1 CD B-NP O
20 601 604 9585605 was VBD B-VP O
21 605 606 9585605 a DT B-NP O
22 607 615 9585605 mutation NN I-NP O
23 616 618 9585605 to TO B-PP O
24 619 620 9585605 a DT B-NP O
25 621 625 9585605 stop NN I-NP O
26 626 631 9585605 codon NN I-NP O
27 631 632 9585605 , , O O
28 633 634 9585605 1 CD B-NP O
29 635 638 9585605 was VBD B-VP O
30 639 640 9585605 a DT B-NP O
31 641 649 9585605 missense JJ I-NP O
32 650 658 9585605 mutation NN I-NP O
33 658 659 9585605 , , O O
34 660 663 9585605 and CC O O
35 664 665 9585605 1 CD B-NP O
36 666 669 9585605 was VBD B-VP O
37 670 679 9585605 predicted VBN I-VP O
38 680 682 9585605 to TO I-VP O
39 683 688 9585605 cause VB I-VP O
40 689 698 9585605 insertion NN B-NP O
41 699 701 9585605 of IN B-PP O
42 702 704 9585605 an DT B-NP O
43 705 715 9585605 isoleucine NN I-NP O
44 716 718 9585605 in IN B-PP O
45 719 722 9585605 the DT B-NP O
46 723 727 9585605 hect NN I-NP O
47 728 734 9585605 domain NN I-NP O
48 735 737 9585605 of IN B-PP O
49 738 741 9585605 the DT B-NP O
50 742 747 9585605 UBE3A NN I-NP O
51 748 755 9585605 protein NN I-NP O
52 755 756 9585605 , , O O
53 757 762 9585605 which WDT B-NP O
54 763 772 9585605 functions VBZ B-VP O
55 773 775 9585605 in IN B-PP O
56 776 778 9585605 E2 NN B-NP O
57 779 786 9585605 binding NN I-NP O
58 787 790 9585605 and CC O O
59 791 800 9585605 ubiquitin NN B-NP O
60 801 809 9585605 transfer NN I-NP O
61 809 810 9585605 . . O O

1 811 816 9585605 Eight CD B-NP O
2 817 819 9585605 of IN B-PP O
3 820 823 9585605 the DT B-NP O
4 824 829 9585605 cases NNS I-NP O
5 830 834 9585605 were VBD B-VP O
6 835 843 9585605 familial JJ B-ADJP O
7 843 844 9585605 , , O O
8 845 848 9585605 and CC O O
9 849 853 9585605 five CD B-NP O
10 854 858 9585605 were VBD B-VP O
11 859 867 9585605 sporadic JJ B-ADJP O
12 867 868 9585605 . . O O

1 869 871 9585605 In IN B-PP O
2 872 875 9585605 two CD B-NP O
3 876 884 9585605 familial JJ I-NP O
4 885 890 9585605 cases NNS I-NP O
5 891 894 9585605 and CC O O
6 895 898 9585605 one CD B-NP O
7 899 907 9585605 sporadic JJ I-NP O
8 908 912 9585605 case NN I-NP O
9 912 913 9585605 , , O O
10 914 923 9585605 mosaicism NN B-NP O
11 924 927 9585605 for IN B-PP O
12 928 933 9585605 UBE3A NN B-NP O
13 934 943 9585605 mutations NNS I-NP O
14 944 947 9585605 was VBD B-VP O
15 948 956 9585605 detected VBN I-VP O
16 958 960 9585605 in IN B-PP O
17 961 964 9585605 the DT B-NP O
18 965 971 9585605 mother NN I-NP O
19 972 974 9585605 of IN B-PP O
20 975 980 9585605 three CD B-NP O
21 981 983 9585605 AS JJ I-NP B-Disease
22 984 988 9585605 sons NNS I-NP O
23 988 989 9585605 , , O O
24 990 992 9585605 in IN B-PP O
25 993 996 9585605 the DT B-NP O
26 997 1005 9585605 maternal JJ I-NP O
27 1006 1017 9585605 grandfather NN I-NP O
28 1018 1020 9585605 of IN B-PP O
29 1021 1024 9585605 two CD B-NP O
30 1025 1027 9585605 AS JJ I-NP B-Disease
31 1028 1033 9585605 first JJ I-NP O
32 1034 1041 9585605 cousins NNS I-NP O
33 1041 1042 9585605 , , O O
34 1043 1046 9585605 and CC O O
35 1047 1049 9585605 in IN B-PP O
36 1050 1053 9585605 the DT B-NP O
37 1054 1060 9585605 mother NN I-NP O
38 1061 1063 9585605 of IN B-PP O
39 1064 1066 9585605 an DT B-NP O
40 1067 1069 9585605 AS JJ I-NP B-Disease
41 1070 1078 9585605 daughter NN I-NP O
42 1078 1079 9585605 . . O O

1 1080 1083 9585605 The DT B-NP O
2 1084 1095 9585605 frequencies NNS I-NP O
3 1096 1100 9585605 with IN B-PP O
4 1101 1106 9585605 which WDT B-NP O
5 1107 1109 9585605 we PRP B-NP O
6 1110 1118 9585605 detected VBD B-VP O
7 1119 1128 9585605 mutations NNS B-NP O
8 1129 1133 9585605 were VBD B-VP O
9 1134 1135 9585605 5 CD B-NP O
10 1136 1137 9585605 ( ( O O
11 1137 1140 9585605 14% NN B-NP O
12 1140 1141 9585605 ) ) O O
13 1142 1144 9585605 of IN B-PP O
14 1145 1147 9585605 35 CD B-NP O
15 1148 1150 9585605 in IN B-PP O
16 1151 1159 9585605 sporadic JJ B-NP O
17 1160 1165 9585605 cases NNS I-NP O
18 1166 1169 9585605 and CC O O
19 1170 1171 9585605 8 CD B-NP O
20 1172 1173 9585605 ( ( O O
21 1173 1176 9585605 80% CD B-NP O
22 1176 1177 9585605 ) ) O O
23 1178 1180 9585605 of IN B-PP O
24 1181 1183 9585605 10 CD B-NP O
25 1184 1186 9585605 in IN B-PP O
26 1187 1195 9585605 familial JJ B-NP O
27 1196 1201 9585605 cases NNS I-NP O
28 1201 1202 9585605 . . O O
29 1202 1203 9585605 . . O O

1 0 0 9585606 -DOCSTART- -X- -X- O

1 0 3 9585606 The DT B-NP O
2 4 19 9585606 hemochromatosis NN I-NP B-Disease
3 20 23 9585606 845 CD I-NP O
4 24 25 9585606 G NN I-NP O
5 25 26 9585606 - SYM B-NP O
6 26 27 9585606 - HYPH B-NP O
7 27 28 9585606 > SYM I-NP O
8 28 29 9585606 A NN I-NP O
9 30 33 9585606 and CC O O
10 34 37 9585606 187 CD B-NP O
11 38 39 9585606 C NN I-NP O
12 39 40 9585606 - SYM B-NP O
13 40 41 9585606 - HYPH B-NP O
14 41 42 9585606 > SYM I-NP O
15 42 43 9585606 G NN I-NP O
16 44 53 9585606 mutations NNS I-NP O
17 53 54 9585606 : : O O
18 55 65 9585606 prevalence NN B-NP O
19 66 68 9585606 in IN B-PP O
20 69 72 9585606 non AFX B-NP O
21 72 73 9585606 - HYPH I-NP O
22 73 82 9585606 Caucasian JJ I-NP O
23 83 94 9585606 populations NNS I-NP O
24 94 95 9585606 . . O O
25 96 111 9585606 Hemochromatosis NNP B-NP B-Disease
26 111 112 9585606 , , O O
27 113 116 9585606 the DT B-NP O
28 117 126 9585606 inherited VBN I-NP B-Disease
29 127 135 9585606 disorder NN I-NP I-Disease
30 136 138 9585606 of IN B-PP I-Disease
31 139 143 9585606 iron NN B-NP I-Disease
32 144 154 9585606 metabolism NN I-NP I-Disease
33 154 155 9585606 , , O O
34 156 161 9585606 leads VBZ B-VP O
35 161 162 9585606 , , O O
36 163 165 9585606 if IN B-SBAR O
37 166 175 9585606 untreated JJ B-ADJP O
38 175 176 9585606 , , O O
39 177 179 9585606 to TO B-PP O
40 180 191 9585606 progressive JJ B-NP O
41 192 196 9585606 iron NN I-NP B-Disease
42 197 205 9585606 overload NN I-NP I-Disease
43 206 209 9585606 and CC O O
44 210 219 9585606 premature JJ B-NP B-Disease
45 220 225 9585606 death NN I-NP I-Disease
46 225 226 9585606 . . O O

1 227 230 9585606 The DT B-NP O
2 231 246 9585606 hemochromatosis NN I-NP B-Disease
3 247 251 9585606 gene NN I-NP O
4 251 252 9585606 , , O O
5 253 256 9585606 HFE NN B-NP O
6 256 257 9585606 , , O O
7 258 266 9585606 recently RB B-ADVP O
8 267 270 9585606 has VBZ B-VP O
9 271 275 9585606 been VBN I-VP O
10 276 286 9585606 identified VBN I-VP O
11 286 287 9585606 , , O O
12 288 291 9585606 and CC O O
13 292 308 9585606 characterization NN B-NP O
14 309 311 9585606 of IN B-PP O
15 312 316 9585606 this DT B-NP O
16 317 321 9585606 gene NN I-NP O
17 322 325 9585606 has VBZ B-VP O
18 326 331 9585606 shown VBN I-VP O
19 332 336 9585606 that IN B-SBAR O
20 337 339 9585606 it PRP B-NP O
21 340 348 9585606 contains VBZ B-VP O
22 349 352 9585606 two CD B-NP O
23 353 362 9585606 mutations NNS I-NP O
24 363 367 9585606 that WDT B-NP O
25 368 374 9585606 result VBP B-VP O
26 375 377 9585606 in IN B-PP O
27 378 383 9585606 amino JJ B-NP O
28 384 388 9585606 acid NN I-NP O
29 389 402 9585606 substitutions NNS I-NP O
30 402 403 9585606 - HYPH B-NP O
31 403 407 9585606 cDNA NN I-NP O
32 408 419 9585606 nucleotides NNS I-NP O
33 420 423 9585606 845 CD B-NP O
34 424 425 9585606 G NN I-NP O
35 425 426 9585606 - SYM O O
36 426 427 9585606 - HYPH O O
37 428 429 9585606 > SYM O O
38 430 431 9585606 A NN B-NP O
39 432 433 9585606 ( ( O O
40 433 438 9585606 C282Y NN B-NP O
41 438 439 9585606 ) ) O O
42 440 443 9585606 and CC O O
43 444 447 9585606 187 CD B-NP O
44 448 449 9585606 C NN I-NP O
45 449 450 9585606 - SYM O O
46 450 451 9585606 - HYPH O O
47 452 453 9585606 > SYM O O
48 454 455 9585606 G NN B-NP O
49 456 457 9585606 ( ( O O
50 457 461 9585606 H63D NN B-NP O
51 461 462 9585606 ) ) O O
52 462 463 9585606 . . O O

1 464 472 9585606 Although IN B-SBAR O
2 473 488 9585606 hemochromatosis NN B-NP B-Disease
3 489 491 9585606 is VBZ B-VP O
4 492 498 9585606 common JJ B-ADJP O
5 499 501 9585606 in IN B-PP O
6 502 512 9585606 Caucasians NNPS B-NP O
7 512 513 9585606 , , O O
8 514 523 9585606 affecting VBG B-VP O
9 524 525 9585606 > SYM B-NP O
10 526 527 9585606 = SYM B-VP O
11 528 529 9585606 1 CD B-NP O
12 529 530 9585606 / SYM O O
13 530 533 9585606 300 CD B-NP O
14 534 545 9585606 individuals NNS I-NP O
15 546 548 9585606 of IN B-PP O
16 549 557 9585606 northern JJ B-NP O
17 558 566 9585606 European JJ I-NP O
18 567 573 9585606 origin NN I-NP O
19 573 574 9585606 , , O O
20 575 577 9585606 it PRP B-NP O
21 578 581 9585606 has VBZ B-VP O
22 582 585 9585606 not RB I-VP O
23 586 590 9585606 been VBN I-VP O
24 591 601 9585606 recognized VBN I-VP O
25 602 604 9585606 in IN B-PP O
26 605 610 9585606 other JJ B-NP O
27 611 622 9585606 populations NNS I-NP O
28 622 623 9585606 . . O O

1 624 627 9585606 The DT B-NP O
2 628 635 9585606 present JJ I-NP O
3 636 641 9585606 study NN I-NP O
4 642 646 9585606 used VBD B-VP O
5 647 650 9585606 PCR NN B-NP O
6 651 654 9585606 and CC I-NP O
7 655 666 9585606 restriction NN I-NP O
8 666 667 9585606 - HYPH B-NP O
9 667 673 9585606 enzyme NN I-NP O
10 674 683 9585606 digestion NN I-NP O
11 684 686 9585606 to TO B-VP O
12 687 694 9585606 analyze VB I-VP O
13 695 698 9585606 the DT B-NP O
14 699 708 9585606 frequency NN I-NP O
15 709 711 9585606 of IN B-PP O
16 712 715 9585606 the DT B-NP O
17 716 719 9585606 845 CD I-NP O
18 720 721 9585606 G NN I-NP O
19 721 722 9585606 - SYM B-NP O
20 722 723 9585606 - HYPH B-NP O
21 724 725 9585606 > SYM I-NP O
22 726 727 9585606 A NN I-NP O
23 728 731 9585606 and CC O O
24 732 735 9585606 187 CD B-NP O
25 736 737 9585606 C NN I-NP O
26 737 738 9585606 - SYM B-NP O
27 738 739 9585606 - HYPH B-NP O
28 740 741 9585606 > SYM I-NP O
29 742 743 9585606 G NN I-NP O
30 744 753 9585606 mutations NNS I-NP O
31 754 756 9585606 in IN B-PP O
32 757 760 9585606 HLA NN B-NP O
33 760 761 9585606 - HYPH B-NP O
34 761 766 9585606 typed VBN I-NP O
35 767 774 9585606 samples NNS I-NP O
36 775 779 9585606 from IN B-PP O
37 780 783 9585606 non AFX B-NP O
38 783 784 9585606 - HYPH I-NP O
39 784 793 9585606 Caucasian JJ I-NP O
40 794 805 9585606 populations NNS I-NP O
41 805 806 9585606 , , O O
42 807 817 9585606 comprising VBG B-VP O
43 818 828 9585606 Australian JJ B-NP O
44 829 839 9585606 Aboriginal NNP I-NP O
45 839 840 9585606 , , O O
46 841 848 9585606 Chinese NNP B-NP O
47 848 849 9585606 , , O O
48 850 853 9585606 and CC O O
49 854 861 9585606 Pacific NNP B-NP O
50 862 871 9585606 Islanders NNPS I-NP O
51 871 872 9585606 . . O O

1 873 880 9585606 Results NNS B-NP O
2 881 887 9585606 showed VBD B-VP O
3 888 892 9585606 that IN B-SBAR O
4 893 896 9585606 the DT B-NP O
5 897 900 9585606 845 CD I-NP O
6 901 902 9585606 G NN I-NP O
7 902 903 9585606 - SYM B-NP O
8 903 904 9585606 - HYPH B-NP O
9 905 906 9585606 > SYM I-NP O
10 907 908 9585606 A NN I-NP O
11 909 917 9585606 mutation NN I-NP O
12 918 921 9585606 was VBD B-VP O
13 922 929 9585606 present JJ B-ADJP O
14 930 932 9585606 in IN B-PP O
15 933 938 9585606 these DT B-NP O
16 939 950 9585606 populations NNS I-NP O
17 951 952 9585606 ( ( O O
18 952 958 9585606 allele NN B-NP O
19 959 968 9585606 frequency NN I-NP O
20 969 970 9585606 0 CD I-NP O
21 970 971 9585606 . . O O

1 972 975 9585606 32% LS B-LST O
2 975 976 9585606 ) ) O O
3 976 977 9585606 , , O O
4 978 981 9585606 and CC O O
5 981 982 9585606 , , O O
6 983 994 9585606 furthermore RB B-ADVP O
7 994 995 9585606 , , O O
8 996 998 9585606 it PRP B-NP O
9 999 1002 9585606 was VBD B-VP O
10 1003 1009 9585606 always RB I-VP O
11 1010 1014 9585606 seen VBN I-VP O
12 1015 1017 9585606 in IN B-PP O
13 1018 1029 9585606 conjunction NN B-NP O
14 1030 1034 9585606 with IN B-PP O
15 1035 1038 9585606 HLA NN B-NP O
16 1039 1049 9585606 haplotypes NNS I-NP O
17 1050 1056 9585606 common JJ B-ADJP O
18 1057 1059 9585606 in IN B-PP O
19 1060 1070 9585606 Caucasians NNPS B-NP O
20 1070 1071 9585606 , , O O
21 1072 1082 9585606 suggesting VBG B-VP O
22 1083 1087 9585606 that IN B-SBAR O
23 1088 1091 9585606 845 CD B-NP O
24 1092 1093 9585606 G NN I-NP O
25 1093 1094 9585606 - SYM B-NP O
26 1094 1095 9585606 - HYPH B-NP O
27 1096 1097 9585606 > SYM I-NP O
28 1098 1099 9585606 A NN I-NP O
29 1100 1103 9585606 may MD B-VP O
30 1104 1108 9585606 have VB I-VP O
31 1109 1113 9585606 been VBN I-VP O
32 1114 1124 9585606 introduced VBN I-VP O
33 1125 1129 9585606 into IN B-PP O
34 1130 1135 9585606 these DT B-NP O
35 1136 1147 9585606 populations NNS I-NP O
36 1148 1150 9585606 by IN B-PP O
37 1151 1160 9585606 Caucasian JJ B-NP O
38 1161 1170 9585606 admixture NN I-NP O
39 1170 1171 9585606 . . O O

1 1172 1175 9585606 187 CD B-NP O
2 1176 1177 9585606 C JJ I-NP O
3 1177 1178 9585606 - SYM I-NP O
4 1178 1179 9585606 - HYPH I-NP O
5 1180 1181 9585606 > SYM I-NP O
6 1182 1183 9585606 G NN B-NP O
7 1184 1187 9585606 was VBD B-VP O
8 1188 1195 9585606 present JJ B-ADJP O
9 1196 1198 9585606 at IN B-PP O
10 1199 1201 9585606 an DT B-NP O
11 1202 1208 9585606 allele NN I-NP O
12 1209 1218 9585606 frequency NN I-NP O
13 1219 1221 9585606 of IN B-PP O
14 1222 1223 9585606 2 CD B-NP O
15 1223 1224 9585606 . . O O
16 1225 1228 9585606 68% CD B-NP O
17 1229 1231 9585606 in IN B-PP O
18 1232 1235 9585606 the DT B-NP O
19 1236 1239 9585606 two CD I-NP O
20 1240 1251 9585606 populations NNS I-NP O
21 1252 1260 9585606 analyzed VBN B-VP O
22 1261 1262 9585606 ( ( O O
23 1262 1272 9585606 Australian JJ B-NP O
24 1273 1283 9585606 Aboriginal JJ I-NP O
25 1284 1287 9585606 and CC I-NP O
26 1288 1295 9585606 Chinese JJ I-NP O
27 1295 1296 9585606 ) ) O O
28 1296 1297 9585606 . . O O

1 1298 1300 9585606 In IN B-PP O
2 1301 1304 9585606 the DT B-NP O
3 1305 1315 9585606 Australian JJ I-NP O
4 1316 1326 9585606 Aboriginal JJ I-NP O
5 1327 1334 9585606 samples NNS I-NP O
6 1334 1335 9585606 , , O O
7 1336 1339 9585606 187 CD B-NP O
8 1340 1341 9585606 C JJ I-NP O
9 1341 1342 9585606 - SYM I-NP O
10 1342 1343 9585606 - HYPH I-NP O
11 1344 1345 9585606 > SYM I-NP O
12 1346 1347 9585606 G NN I-NP O
13 1348 1351 9585606 was VBD B-VP O
14 1352 1357 9585606 found VBN I-VP O
15 1358 1360 9585606 to TO I-VP O
16 1361 1363 9585606 be VB I-VP O
17 1364 1374 9585606 associated VBN I-VP O
18 1375 1379 9585606 with IN B-PP O
19 1380 1383 9585606 HLA NN B-NP O
20 1384 1394 9585606 haplotypes NNS I-NP O
21 1395 1401 9585606 common JJ B-ADJP O
22 1402 1404 9585606 in IN B-PP O
23 1405 1415 9585606 Caucasians NNPS B-NP O
24 1415 1416 9585606 , , O O
25 1417 1427 9585606 suggesting VBG B-VP O
26 1428 1432 9585606 that IN B-SBAR O
27 1433 1435 9585606 it PRP B-NP O
28 1436 1439 9585606 was VBD B-VP O
29 1440 1450 9585606 introduced VBN I-VP O
30 1451 1453 9585606 by IN B-PP O
31 1454 1460 9585606 recent JJ B-NP O
32 1461 1470 9585606 admixture NN I-NP O
33 1470 1471 9585606 . . O O

1 1472 1474 9585606 In IN B-PP O
2 1475 1478 9585606 the DT B-NP O
3 1479 1486 9585606 Chinese JJ I-NP O
4 1487 1494 9585606 samples NNS I-NP O
5 1495 1503 9585606 analyzed VBN B-VP O
6 1503 1504 9585606 , , O O
7 1505 1508 9585606 187 CD B-NP O
8 1509 1510 9585606 C JJ I-NP O
9 1510 1511 9585606 - SYM I-NP O
10 1511 1512 9585606 - HYPH I-NP O
11 1513 1514 9585606 > SYM I-NP O
12 1515 1516 9585606 G NN B-NP O
13 1517 1520 9585606 was VBD B-VP O
14 1521 1528 9585606 present JJ B-ADJP O
15 1529 1531 9585606 in IN B-PP O
16 1532 1543 9585606 association NN B-NP O
17 1544 1548 9585606 with IN B-PP O
18 1549 1550 9585606 a DT B-NP O
19 1551 1555 9585606 wide JJ I-NP O
20 1556 1563 9585606 variety NN I-NP O
21 1564 1566 9585606 of IN B-PP O
22 1567 1570 9585606 HLA NN B-NP O
23 1571 1581 9585606 haplotypes NNS I-NP O
24 1581 1582 9585606 , , O O
25 1583 1590 9585606 showing VBG B-VP O
26 1591 1595 9585606 this DT B-NP O
27 1596 1604 9585606 mutation NN I-NP O
28 1605 1607 9585606 to TO B-VP O
29 1608 1610 9585606 be VB I-VP O
30 1611 1621 9585606 widespread JJ B-ADJP O
31 1622 1625 9585606 and CC I-ADJP O
32 1626 1632 9585606 likely JJ I-ADJP O
33 1633 1635 9585606 to TO B-VP O
34 1636 1643 9585606 predate VB I-VP O
35 1644 1647 9585606 the DT O O
36 1648 1652 9585606 more RBR B-ADVP O
37 1653 1664 9585606 genetically RB I-ADVP O
38 1665 1675 9585606 restricted JJ B-NP O
39 1676 1679 9585606 845 CD I-NP O
40 1680 1681 9585606 G NN I-NP O
41 1681 1682 9585606 - SYM B-NP O
42 1682 1683 9585606 - HYPH B-VP O
43 1684 1685 9585606 > SYM B-NP O
44 1686 1687 9585606 A DT B-NP O
45 1688 1696 9585606 mutation NN I-NP O
46 1696 1697 9585606 . . O O

1 0 0 9439660 -DOCSTART- -X- -X- O

1 0 9 9439660 Detection NN B-NP O
2 10 12 9439660 of IN B-PP O
3 13 25 9439660 heterozygous JJ B-NP O
4 26 34 9439660 carriers NNS I-NP O
5 35 37 9439660 of IN B-PP O
6 38 41 9439660 the DT B-NP O
7 42 48 9439660 ataxia NN I-NP B-Disease
8 48 49 9439660 - HYPH O I-Disease
9 49 63 9439660 telangiectasia NN B-NP I-Disease
10 64 65 9439660 ( ( O O
11 65 68 9439660 ATM NN B-NP O
12 68 69 9439660 ) ) O O
13 70 74 9439660 gene NN B-NP O
14 75 77 9439660 by IN B-PP O
15 78 80 9439660 G2 NN B-NP O
16 81 86 9439660 phase NN I-NP O
17 87 98 9439660 chromosomal JJ I-NP O
18 99 115 9439660 radiosensitivity NN I-NP O
19 116 118 9439660 of IN B-PP O
20 119 129 9439660 peripheral JJ B-NP O
21 130 135 9439660 blood NN I-NP O
22 136 147 9439660 lymphocytes NNS I-NP O
23 147 148 9439660 . . O O
24 149 151 9439660 In IN B-PP O
25 152 158 9439660 ataxia NN B-NP B-Disease
26 158 159 9439660 - HYPH O I-Disease
27 159 173 9439660 telangiectasia NN B-NP I-Disease
28 174 175 9439660 ( ( O O
29 175 176 9439660 A NN B-NP B-Disease
30 176 177 9439660 - HYPH I-NP I-Disease
31 177 178 9439660 T NN I-NP I-Disease
32 178 179 9439660 ) ) O O
33 180 188 9439660 patients NNS B-NP O
34 188 189 9439660 , , O O
35 190 199 9439660 mutations NNS B-NP O
36 200 202 9439660 in IN B-PP O
37 203 204 9439660 a DT B-NP O
38 205 211 9439660 single JJ I-NP O
39 212 216 9439660 gene NN I-NP O
40 216 217 9439660 , , O O
41 218 221 9439660 ATM NN B-NP O
42 221 222 9439660 , , O O
43 223 229 9439660 result VBP B-VP O
44 230 232 9439660 in IN B-PP O
45 233 235 9439660 an DT B-NP O
46 236 245 9439660 autosomal JJ I-NP B-Disease
47 246 255 9439660 recessive JJ I-NP I-Disease
48 256 264 9439660 syndrome NN I-NP I-Disease
49 265 269 9439660 that WDT B-NP O
50 270 278 9439660 embraces VBZ B-VP O
51 279 280 9439660 a DT B-NP O
52 281 288 9439660 variety NN I-NP O
53 289 291 9439660 of IN B-PP O
54 292 300 9439660 clinical JJ B-NP O
55 301 309 9439660 features NNS I-NP O
56 310 313 9439660 and CC O O
57 314 323 9439660 manifests VBZ B-VP O
58 324 331 9439660 extreme JJ B-NP O
59 332 348 9439660 radiosensitivity NN I-NP O
60 349 352 9439660 and CC O O
61 353 354 9439660 a DT B-NP O
62 355 361 9439660 strong JJ I-NP O
63 362 365 9439660 pre AFX I-NP O
64 365 366 9439660 - HYPH I-NP O
65 366 377 9439660 disposition NN I-NP O
66 378 380 9439660 to TO B-PP O
67 381 391 9439660 malignancy NN B-NP B-Disease
68 391 392 9439660 . . O O

1 393 406 9439660 Heterozygotes NNS B-NP O
2 407 410 9439660 for IN B-PP O
3 411 414 9439660 the DT B-NP O
4 415 418 9439660 ATM NN I-NP O
5 419 423 9439660 gene NN I-NP O
6 424 428 9439660 have VBP B-VP O
7 429 431 9439660 no DT B-NP O
8 432 440 9439660 clinical JJ I-NP O
9 441 451 9439660 expression NN I-NP O
10 452 454 9439660 of IN B-PP O
11 455 456 9439660 A NN B-NP B-Disease
12 456 457 9439660 - HYPH I-NP I-Disease
13 457 458 9439660 T NN I-NP I-Disease
14 459 462 9439660 but CC O O
15 463 466 9439660 may MD B-VP O
16 467 469 9439660 be VB I-VP O
17 470 476 9439660 cancer NN B-NP B-Disease
18 477 482 9439660 prone NN I-NP O
19 483 487 9439660 with IN B-PP O
20 488 489 9439660 a DT B-NP O
21 490 498 9439660 moderate JJ I-NP O
22 499 507 9439660 increase NN I-NP O
23 508 510 9439660 in IN B-PP O
24 511 513 9439660 in FW B-NP O
25 514 519 9439660 vitro FW I-NP O
26 520 536 9439660 radiosensitivity NN I-NP O
27 536 537 9439660 . . O O

1 538 540 9439660 We PRP B-NP O
2 541 550 9439660 performed VBD B-VP O
3 551 552 9439660 a DT B-NP O
4 553 558 9439660 blind JJ I-NP O
5 559 570 9439660 chromosomal JJ I-NP O
6 571 579 9439660 analysis NN I-NP O
7 580 582 9439660 on IN B-PP O
8 583 585 9439660 G2 NN B-NP O
9 585 586 9439660 - HYPH B-NP O
10 586 591 9439660 phase NN I-NP O
11 592 603 9439660 lymphocytes NNS I-NP O
12 604 608 9439660 from IN B-PP O
13 609 610 9439660 7 CD B-NP O
14 611 620 9439660 unrelated JJ I-NP O
15 621 622 9439660 A NN I-NP B-Disease
16 622 623 9439660 - HYPH I-NP I-Disease
17 623 624 9439660 T NN I-NP I-Disease
18 625 633 9439660 patients NNS I-NP O
19 633 634 9439660 , , O O
20 635 637 9439660 13 CD B-NP O
21 638 646 9439660 obligate NN I-NP O
22 647 648 9439660 A NN I-NP B-Disease
23 648 649 9439660 - HYPH I-NP I-Disease
24 649 650 9439660 T NN I-NP I-Disease
25 651 664 9439660 heterozygotes NNS I-NP O
26 665 666 9439660 ( ( O O
27 666 673 9439660 parents NNS B-NP O
28 674 676 9439660 of IN B-PP O
29 677 680 9439660 the DT B-NP O
30 681 689 9439660 patients NNS I-NP O
31 689 690 9439660 ) ) O O
32 690 691 9439660 , , O O
33 692 695 9439660 and CC O O
34 696 698 9439660 14 CD B-NP O
35 699 705 9439660 normal JJ I-NP O
36 706 714 9439660 controls NNS I-NP O
37 715 724 9439660 following VBG B-VP O
38 725 726 9439660 X NN B-NP O
39 726 727 9439660 - HYPH O O
40 727 738 9439660 irradiation NN B-NP O
41 739 743 9439660 with IN B-PP O
42 744 745 9439660 1 CD B-NP O
43 746 748 9439660 Gy NN I-NP O
44 749 751 9439660 in IN B-SBAR O
45 752 757 9439660 order NN O O
46 758 760 9439660 to TO B-VP O
47 761 769 9439660 evaluate VB I-VP O
48 770 774 9439660 this DT B-NP O
49 775 786 9439660 cytogenetic JJ I-NP O
50 787 793 9439660 method NN I-NP O
51 794 796 9439660 as IN B-PP O
52 797 798 9439660 a DT B-NP O
53 799 803 9439660 tool NN I-NP O
54 804 807 9439660 for IN B-PP O
55 808 817 9439660 detection NN B-NP O
56 818 820 9439660 of IN B-PP O
57 821 824 9439660 ATM NN B-NP O
58 825 833 9439660 carriers NNS I-NP O
59 833 834 9439660 . . O O

1 835 839 9439660 Both CC O O
2 840 841 9439660 A NN B-NP B-Disease
3 841 842 9439660 - HYPH I-NP I-Disease
4 842 843 9439660 T NN I-NP I-Disease
5 844 855 9439660 homozygotes NNS I-NP O
6 856 859 9439660 and CC I-NP O
7 860 873 9439660 heterozygotes NNS I-NP O
8 874 880 9439660 showed VBD B-VP O
9 881 894 9439660 significantly RB B-NP O
10 895 904 9439660 increased VBN I-NP O
11 905 911 9439660 levels NNS I-NP O
12 912 914 9439660 of IN B-PP O
13 915 924 9439660 radiation NN B-NP O
14 924 925 9439660 - HYPH B-NP O
15 925 932 9439660 induced VBN I-NP O
16 933 942 9439660 chromatid NN I-NP O
17 943 949 9439660 damage NN I-NP O
18 950 958 9439660 relative JJ B-ADVP O
19 959 961 9439660 to TO B-PP O
20 962 966 9439660 that DT B-NP O
21 967 969 9439660 of IN B-PP O
22 970 976 9439660 normal JJ B-NP O
23 977 985 9439660 controls NNS I-NP O
24 985 986 9439660 . . O O

1 987 992 9439660 These DT B-NP O
2 993 1000 9439660 results NNS I-NP O
3 1001 1005 9439660 show VBP B-VP O
4 1006 1010 9439660 that IN B-SBAR O
5 1011 1014 9439660 the DT B-NP O
6 1015 1017 9439660 G2 NN I-NP O
7 1017 1018 9439660 - HYPH B-NP O
8 1018 1023 9439660 phase NN I-NP O
9 1024 1035 9439660 chromosomal JJ I-NP O
10 1036 1052 9439660 radiosensitivity NN I-NP O
11 1053 1058 9439660 assay NN I-NP O
12 1059 1062 9439660 can MD B-VP O
13 1063 1065 9439660 be VB I-VP O
14 1066 1070 9439660 used VBN I-VP O
15 1071 1074 9439660 for IN B-PP O
16 1075 1078 9439660 the DT B-NP O
17 1079 1088 9439660 detection NN I-NP O
18 1089 1091 9439660 of IN B-PP O
19 1092 1093 9439660 A NN B-NP B-Disease
20 1093 1094 9439660 - HYPH I-NP I-Disease
21 1094 1095 9439660 T NN I-NP I-Disease
22 1096 1109 9439660 heterozygotes NNS I-NP O
23 1109 1110 9439660 . . O O

1 1111 1113 9439660 In IN B-PP O
2 1114 1125 9439660 combination NN B-NP O
3 1126 1130 9439660 with IN B-PP O
4 1131 1140 9439660 molecular JJ B-NP O
5 1141 1148 9439660 genetic JJ I-NP O
6 1149 1157 9439660 analyses NNS I-NP O
7 1157 1158 9439660 , , O O
8 1159 1163 9439660 this DT B-NP O
9 1164 1168 9439660 test NN I-NP O
10 1169 1172 9439660 may MD B-VP O
11 1173 1175 9439660 be VB I-VP O
12 1176 1178 9439660 of IN B-PP O
13 1179 1184 9439660 value NN B-NP O
14 1185 1187 9439660 in IN B-PP O
15 1188 1195 9439660 studies NNS B-NP O
16 1196 1198 9439660 of IN B-PP O
17 1199 1207 9439660 familial JJ B-NP B-Disease
18 1208 1211 9439660 and CC I-NP I-Disease
19 1212 1220 9439660 sporadic JJ I-NP I-Disease
20 1221 1228 9439660 cancers NNS I-NP I-Disease
21 1229 1234 9439660 aimed VBN B-VP O
22 1235 1237 9439660 at IN B-PP O
23 1238 1251 9439660 determination NN B-NP O
24 1252 1254 9439660 of IN B-PP O
25 1255 1258 9439660 the DT B-NP O
26 1259 1268 9439660 potential JJ I-NP O
27 1269 1280 9439660 involvement NN I-NP O
28 1281 1283 9439660 of IN B-PP O
29 1284 1287 9439660 ATM NN B-NP O
30 1288 1297 9439660 mutations NNS I-NP O
31 1298 1300 9439660 in IN B-PP O
32 1301 1306 9439660 tumor NN B-NP B-Disease
33 1307 1311 9439660 risk NN I-NP O
34 1312 1314 9439660 or CC I-NP O
35 1315 1326 9439660 development NN I-NP O
36 1326 1327 9439660 . . O O
37 1327 1328 9439660 . . O O

1 0 0 9554743 -DOCSTART- -X- -X- O

1 0 14 9554743 Identification NN B-NP O
2 15 17 9554743 of IN B-PP O
3 18 23 9554743 three CD B-NP O
4 24 29 9554743 novel JJ I-NP O
5 30 39 9554743 mutations NNS I-NP O
6 40 43 9554743 and CC O O
7 44 45 9554743 a DT B-NP O
8 46 50 9554743 high JJ I-NP O
9 51 60 9554743 frequency NN I-NP O
10 61 63 9554743 of IN B-PP O
11 64 67 9554743 the DT B-NP O
12 68 77 9554743 Arg778Leu NN I-NP O
13 78 86 9554743 mutation NN I-NP O
14 87 89 9554743 in IN B-PP O
15 90 96 9554743 Korean JJ B-NP O
16 97 105 9554743 patients NNS I-NP O
17 106 110 9554743 with IN B-PP O
18 111 117 9554743 Wilson NNP B-NP B-Disease
19 118 125 9554743 disease NN I-NP I-Disease
20 125 126 9554743 . . O O
21 127 131 9554743 Four CD B-NP O
22 132 141 9554743 mutations NNS I-NP O
23 141 142 9554743 - SYM O O
24 142 143 9554743 - HYPH O O
25 143 148 9554743 R778L NN B-NP O
26 148 149 9554743 , , O O
27 150 155 9554743 A874V NN B-NP O
28 155 156 9554743 , , O O
29 157 163 9554743 L1083F NN B-NP O
30 163 164 9554743 , , O O
31 165 168 9554743 and CC O O
32 169 177 9554743 2304delC NN B-NP O
33 177 178 9554743 - HYPH O O
34 178 179 9554743 - SYM B-NP O
35 179 181 9554743 in IN B-PP O
36 182 185 9554743 the DT B-NP O
37 186 192 9554743 copper NN I-NP O
38 192 193 9554743 - HYPH O O
39 193 205 9554743 transporting VBG B-VP O
40 206 212 9554743 enzyme NN B-NP O
41 212 213 9554743 , , O O
42 214 215 9554743 P NN B-NP O
43 215 216 9554743 - HYPH I-NP O
44 216 220 9554743 type NN I-NP O
45 221 227 9554743 ATPase NN I-NP O
46 228 229 9554743 ( ( O O
47 229 234 9554743 ATP7B NN B-NP O
48 234 235 9554743 ) ) O O
49 235 236 9554743 , , O O
50 237 241 9554743 were VBD B-VP O
51 242 252 9554743 identified VBN I-VP O
52 253 255 9554743 in IN B-PP O
53 256 262 9554743 Korean JJ B-NP O
54 263 271 9554743 Patients NNS I-NP O
55 272 276 9554743 with IN B-PP O
56 277 283 9554743 Wilson NNP B-NP B-Disease
57 284 291 9554743 disease NN I-NP I-Disease
58 291 292 9554743 . . O O

1 293 302 9554743 Arg778Leu NN B-NP O
2 302 303 9554743 , , O O
3 304 307 9554743 the DT B-NP O
4 308 312 9554743 most RBS I-NP O
5 313 323 9554743 frequently RB I-NP O
6 324 332 9554743 reported VBN I-NP O
7 333 341 9554743 mutation NN I-NP O
8 342 344 9554743 of IN B-PP O
9 345 349 9554743 this DT B-NP O
10 350 356 9554743 enzyme NN I-NP O
11 356 357 9554743 , , O O
12 358 361 9554743 was VBD B-VP O
13 362 367 9554743 found VBN I-VP O
14 368 370 9554743 in IN B-PP O
15 371 374 9554743 six CD B-NP O
16 375 377 9554743 of IN B-PP O
17 378 383 9554743 eight CD B-NP O
18 384 393 9554743 unrelated JJ I-NP O
19 394 402 9554743 patients NNS I-NP O
20 403 410 9554743 studied VBN B-VP O
21 410 411 9554743 , , O O
22 412 414 9554743 an DT B-NP O
23 415 421 9554743 allele NN I-NP O
24 422 431 9554743 frequency NN I-NP O
25 432 434 9554743 of IN B-PP O
26 435 437 9554743 37 CD B-NP O
27 437 438 9554743 . . O O

1 439 441 9554743 5% LS B-LST O
2 441 442 9554743 , , O O
3 443 448 9554743 which WDT B-NP O
4 449 451 9554743 is VBZ B-VP O
5 452 464 9554743 considerably RB B-ADJP O
6 465 471 9554743 higher JJR I-ADJP O
7 472 476 9554743 than IN B-PP O
8 477 482 9554743 those DT B-NP O
9 483 485 9554743 in IN B-PP O
10 486 491 9554743 other JJ B-NP O
11 492 497 9554743 Asian JJ I-NP O
12 498 509 9554743 populations NNS I-NP O
13 509 510 9554743 . . O O

1 511 514 9554743 The DT B-NP O
2 515 520 9554743 novel JJ I-NP O
3 521 527 9554743 single JJ I-NP O
4 528 538 9554743 nucleotide NN I-NP O
5 539 547 9554743 deletion NN I-NP O
6 547 548 9554743 , , O O
7 549 557 9554743 2304delC NN B-NP O
8 557 558 9554743 , , O O
9 559 562 9554743 was VBD B-VP O
10 563 568 9554743 found VBN I-VP O
11 569 571 9554743 in IN B-PP O
12 572 575 9554743 one CD B-NP O
13 576 583 9554743 patient NN I-NP O
14 583 584 9554743 . . O O

1 585 590 9554743 Since IN B-SBAR O
2 591 592 9554743 a DT B-NP O
3 593 601 9554743 mutation NN I-NP O
4 602 604 9554743 at IN B-PP O
5 605 609 9554743 cDNA NN B-NP O
6 610 620 9554743 nucleotide NN I-NP O
7 621 625 9554743 2302 CD I-NP O
8 626 627 9554743 ( ( O O
9 627 635 9554743 2302insC NN B-NP O
10 635 636 9554743 ) ) O O
11 637 640 9554743 had VBD B-VP O
12 641 645 9554743 been VBN I-VP O
13 646 656 9554743 previously RB I-VP O
14 657 666 9554743 described VBN I-VP O
15 666 667 9554743 , , O O
16 668 672 9554743 this DT B-NP O
17 673 679 9554743 region NN I-NP O
18 680 682 9554743 of IN B-PP O
19 683 686 9554743 the DT B-NP O
20 687 692 9554743 ATP7B NN I-NP O
21 693 697 9554743 gene NN I-NP O
22 698 701 9554743 may MD B-VP O
23 702 704 9554743 be VB I-VP O
24 705 716 9554743 susceptible JJ B-ADJP O
25 717 719 9554743 to TO B-PP O
26 720 724 9554743 gene NN B-NP O
27 725 739 9554743 rearrangements NNS I-NP O
28 740 747 9554743 causing VBG B-VP O
29 748 754 9554743 Wilson NNP B-NP B-Disease
30 755 762 9554743 disease NN I-NP I-Disease
31 762 763 9554743 . . O O

1 0 0 9689113 -DOCSTART- -X- -X- O

1 0 1 9689113 A DT B-NP O
2 2 7 9689113 mouse NN I-NP O
3 8 13 9689113 model NN I-NP O
4 14 16 9689113 of IN B-PP O
5 17 23 9689113 severe JJ B-NP O
6 24 27 9689113 von NN I-NP B-Disease
7 28 38 9689113 Willebrand NN I-NP I-Disease
8 39 46 9689113 disease NN I-NP I-Disease
9 46 47 9689113 : : O O
10 48 55 9689113 defects NNS B-NP O
11 56 58 9689113 in IN B-PP O
12 59 69 9689113 hemostasis NN B-NP O
13 70 73 9689113 and CC I-NP O
14 74 84 9689113 thrombosis NN I-NP B-Disease
15 84 85 9689113 . . O O
16 86 89 9689113 von NN B-NP B-Disease
17 90 100 9689113 Willebrand NN I-NP I-Disease
18 101 107 9689113 factor NN I-NP I-Disease
19 108 109 9689113 ( ( O I-Disease
20 109 112 9689113 vWf NN B-NP I-Disease
21 112 113 9689113 ) ) O I-Disease
22 114 124 9689113 deficiency NN B-NP I-Disease
23 125 131 9689113 causes VBZ B-VP O
24 132 138 9689113 severe JJ B-NP O
25 139 142 9689113 von NN I-NP B-Disease
26 143 153 9689113 Willebrand NN I-NP I-Disease
27 154 161 9689113 disease NN I-NP I-Disease
28 162 164 9689113 in IN B-PP O
29 165 171 9689113 humans NNS B-NP O
30 171 172 9689113 . . O O

1 173 175 9689113 We PRP B-NP O
2 176 185 9689113 generated VBD B-VP O
3 186 187 9689113 a DT B-NP O
4 188 193 9689113 mouse NN I-NP O
5 194 199 9689113 model NN I-NP O
6 200 203 9689113 for IN B-PP O
7 204 208 9689113 this DT B-NP O
8 209 216 9689113 disease NN I-NP O
9 217 219 9689113 by IN B-PP O
10 220 225 9689113 using VBG B-VP O
11 226 230 9689113 gene NN B-NP O
12 231 240 9689113 targeting NN I-NP O
13 240 241 9689113 . . O O

1 242 245 9689113 vWf NN B-NP B-Disease
2 245 246 9689113 - HYPH I-NP I-Disease
3 246 255 9689113 deficient JJ I-NP I-Disease
4 256 260 9689113 mice NNS I-NP O
5 261 269 9689113 appeared VBD B-VP O
6 270 276 9689113 normal JJ B-ADJP O
7 277 279 9689113 at IN B-PP O
8 280 285 9689113 birth NN B-NP O
9 285 286 9689113 ; : O O
10 287 291 9689113 they PRP B-NP O
11 292 296 9689113 were VBD B-VP O
12 297 303 9689113 viable JJ B-ADJP O
13 304 307 9689113 and CC I-ADJP O
14 308 315 9689113 fertile JJ I-ADJP O
15 315 316 9689113 . . O O

1 317 324 9689113 Neither CC O O
2 325 328 9689113 vWf NN B-NP O
3 329 332 9689113 nor CC O O
4 333 336 9689113 vWf NN B-NP O
5 337 351 9689113 propolypeptide NN I-NP O
6 352 353 9689113 ( ( O O
7 353 356 9689113 von NN B-NP B-Disease
8 357 367 9689113 Willebrand NN I-NP I-Disease
9 368 375 9689113 antigen NN I-NP O
10 376 378 9689113 II CD I-NP O
11 378 379 9689113 ) ) O O
12 380 384 9689113 were VBD B-VP O
13 385 395 9689113 detectable JJ B-ADJP O
14 396 398 9689113 in IN B-PP O
15 399 405 9689113 plasma NN B-NP O
16 405 406 9689113 , , O O
17 407 416 9689113 platelets NNS B-NP O
18 416 417 9689113 , , O O
19 418 420 9689113 or CC O O
20 421 432 9689113 endothelial JJ B-NP O
21 433 438 9689113 cells NNS I-NP O
22 439 441 9689113 of IN B-PP O
23 442 445 9689113 the DT B-NP O
24 446 456 9689113 homozygous JJ I-NP O
25 457 463 9689113 mutant JJ I-NP O
26 464 468 9689113 mice NNS I-NP O
27 468 469 9689113 . . O O

1 470 473 9689113 The DT B-NP O
2 474 480 9689113 mutant JJ I-NP O
3 481 485 9689113 mice NNS I-NP O
4 486 495 9689113 exhibited VBD B-VP O
5 496 503 9689113 defects NNS B-NP O
6 504 506 9689113 in IN B-PP O
7 507 517 9689113 hemostasis NN B-NP O
8 518 522 9689113 with IN B-PP O
9 523 524 9689113 a DT B-NP O
10 525 531 9689113 highly RB I-NP O
11 532 541 9689113 prolonged JJ I-NP O
12 542 550 9689113 bleeding NN I-NP O
13 551 555 9689113 time NN I-NP O
14 556 559 9689113 and CC O O
15 560 571 9689113 spontaneous JJ B-NP O
16 572 580 9689113 bleeding VBG I-NP O
17 581 587 9689113 events NNS I-NP O
18 588 590 9689113 in IN B-PP O
19 591 604 9689113 approximately RB B-NP O
20 605 608 9689113 10% CD I-NP O
21 609 611 9689113 of IN B-PP O
22 612 620 9689113 neonates NNS B-NP O
23 620 621 9689113 . . O O

1 622 624 9689113 As IN B-PP O
2 625 627 9689113 in IN B-PP O
3 628 631 9689113 the DT B-NP O
4 632 637 9689113 human JJ I-NP O
5 638 645 9689113 disease NN I-NP O
6 645 646 9689113 , , O O
7 647 650 9689113 the DT B-NP O
8 651 657 9689113 factor NN I-NP O
9 658 662 9689113 VIII CD I-NP O
10 663 668 9689113 level NN I-NP O
11 669 671 9689113 in IN B-PP O
12 672 677 9689113 these DT B-NP O
13 678 682 9689113 mice NNS I-NP O
14 683 686 9689113 was VBD B-VP O
15 687 694 9689113 reduced VBN I-VP O
16 695 703 9689113 strongly RB B-ADVP O
17 704 706 9689113 as IN B-PP O
18 707 708 9689113 a DT B-NP O
19 709 715 9689113 result NN I-NP O
20 716 718 9689113 of IN B-PP O
21 719 722 9689113 the DT B-NP O
22 723 727 9689113 lack NN I-NP O
23 728 730 9689113 of IN B-PP O
24 731 741 9689113 protection NN B-NP O
25 742 750 9689113 provided VBN B-VP O
26 751 753 9689113 by IN B-PP O
27 754 757 9689113 vWf NN B-NP O
28 757 758 9689113 . . O O

1 759 768 9689113 Defective JJ B-NP O
2 769 779 9689113 thrombosis NN I-NP B-Disease
3 780 782 9689113 in IN B-PP O
4 783 789 9689113 mutant JJ B-NP O
5 790 794 9689113 mice NNS I-NP O
6 795 798 9689113 was VBD B-VP O
7 799 803 9689113 also RB B-ADVP O
8 804 811 9689113 evident JJ B-ADJP O
9 812 814 9689113 in IN B-PP O
10 815 817 9689113 an DT B-NP O
11 818 820 9689113 in FW I-NP O
12 821 825 9689113 vivo FW I-NP O
13 826 831 9689113 model NN I-NP O
14 832 834 9689113 of IN B-PP O
15 835 843 9689113 vascular JJ B-NP B-Disease
16 844 850 9689113 injury NN I-NP I-Disease
17 850 851 9689113 . . O O

1 852 854 9689113 In IN B-PP O
2 855 859 9689113 this DT B-NP O
3 860 865 9689113 model NN I-NP O
4 865 866 9689113 , , O O
5 867 870 9689113 the DT B-NP O
6 871 883 9689113 exteriorized VBN I-NP O
7 884 893 9689113 mesentery NN I-NP O
8 894 897 9689113 was VBD B-VP O
9 898 908 9689113 superfused VBN I-VP O
10 909 913 9689113 with IN B-PP O
11 914 920 9689113 ferric JJ B-NP O
12 921 929 9689113 chloride NN I-NP O
13 930 933 9689113 and CC O O
14 934 937 9689113 the DT B-NP O
15 938 950 9689113 accumulation NN I-NP O
16 951 953 9689113 of IN B-PP O
17 954 967 9689113 fluorescently RB B-NP O
18 968 975 9689113 labeled VBN I-NP O
19 976 985 9689113 platelets NNS I-NP O
20 986 989 9689113 was VBD B-VP O
21 990 998 9689113 observed VBN I-VP O
22 999 1001 9689113 by IN B-PP O
23 1002 1012 9689113 intravital JJ B-NP O
24 1013 1023 9689113 microscopy NN I-NP O
25 1023 1024 9689113 . . O O

1 1025 1027 9689113 We PRP B-NP O
2 1028 1036 9689113 conclude VBP B-VP O
3 1037 1041 9689113 that IN B-SBAR O
4 1042 1047 9689113 these DT B-NP O
5 1048 1052 9689113 mice NNS I-NP O
6 1053 1057 9689113 very RB B-NP O
7 1058 1065 9689113 closely RB I-NP O
8 1066 1071 9689113 mimic JJ I-NP O
9 1072 1078 9689113 severe JJ I-NP O
10 1079 1084 9689113 human JJ I-NP O
11 1085 1088 9689113 von NN I-NP B-Disease
12 1089 1099 9689113 Willebrand NN I-NP I-Disease
13 1100 1107 9689113 disease NN I-NP I-Disease
14 1108 1111 9689113 and CC O O
15 1112 1116 9689113 will MD B-VP O
16 1117 1119 9689113 be VB I-VP O
17 1120 1124 9689113 very RB B-ADJP O
18 1125 1131 9689113 useful JJ I-ADJP O
19 1132 1135 9689113 for IN B-PP O
20 1136 1149 9689113 investigating VBG B-VP O
21 1150 1153 9689113 the DT B-NP O
22 1154 1158 9689113 role NN I-NP O
23 1159 1161 9689113 of IN B-PP O
24 1162 1165 9689113 vWf NN B-NP O
25 1166 1168 9689113 in IN B-PP O
26 1169 1175 9689113 normal JJ B-NP O
27 1176 1186 9689113 physiology NN I-NP O
28 1187 1190 9689113 and CC B-PP O
29 1191 1193 9689113 in IN B-PP O
30 1194 1201 9689113 disease NN B-NP O
31 1202 1208 9689113 models NNS I-NP O
32 1208 1209 9689113 . . O O
33 1209 1210 9689113 . . O O

1 0 0 9521325 -DOCSTART- -X- -X- O

1 0 7 9521325 Genetic JJ B-NP O
2 8 13 9521325 basis NN I-NP O
3 14 17 9521325 and CC O O
4 18 27 9521325 molecular JJ B-NP O
5 28 37 9521325 mechanism NN I-NP O
6 38 41 9521325 for IN B-PP O
7 42 52 9521325 idiopathic JJ B-NP B-Disease
8 53 64 9521325 ventricular JJ I-NP I-Disease
9 65 77 9521325 fibrillation NN I-NP I-Disease
10 77 78 9521325 . . O O
11 79 90 9521325 Ventricular JJ B-NP B-Disease
12 91 103 9521325 fibrillation NN I-NP I-Disease
13 104 110 9521325 causes VBZ B-VP O
14 111 115 9521325 more JJR B-NP O
15 116 120 9521325 than IN I-NP O
16 121 124 9521325 300 CD I-NP O
17 124 125 9521325 , , I-NP O
18 126 129 9521325 000 CD I-NP O
19 130 136 9521325 sudden JJ I-NP O
20 137 143 9521325 deaths NNS I-NP O
21 144 148 9521325 each DT B-NP O
22 149 153 9521325 year NN I-NP O
23 154 156 9521325 in IN B-PP O
24 157 160 9521325 the DT B-NP O
25 161 164 9521325 USA NNP I-NP O
26 165 170 9521325 alone RB B-ADVP O
27 170 171 9521325 . . O O

1 172 174 9521325 In IN B-PP O
2 175 188 9521325 approximately RB B-NP O
3 189 190 9521325 5 CD I-NP O
4 190 191 9521325 - HYPH I-NP O
5 191 194 9521325 12% CD I-NP O
6 195 197 9521325 of IN B-PP O
7 198 203 9521325 these DT B-NP O
8 204 209 9521325 cases NNS I-NP O
9 209 210 9521325 , , O O
10 211 216 9521325 there EX B-NP O
11 217 220 9521325 are VBP B-VP O
12 221 223 9521325 no DT B-NP O
13 224 236 9521325 demonstrable JJ I-NP O
14 237 244 9521325 cardiac JJ I-NP O
15 245 247 9521325 or CC I-NP O
16 248 251 9521325 non AFX I-NP O
17 251 252 9521325 - HYPH I-NP O
18 252 259 9521325 cardiac JJ I-NP O
19 260 266 9521325 causes NNS I-NP O
20 267 269 9521325 to TO B-VP O
21 270 277 9521325 account VB I-VP O
22 278 281 9521325 for IN B-PP O
23 282 285 9521325 the DT B-NP O
24 286 293 9521325 episode NN I-NP O
25 293 294 9521325 , , O O
26 295 300 9521325 which WDT B-NP O
27 301 303 9521325 is VBZ B-VP O
28 304 313 9521325 therefore RB I-VP O
29 314 324 9521325 classified VBN I-VP O
30 325 327 9521325 as IN B-PP O
31 328 338 9521325 idiopathic JJ B-NP B-Disease
32 339 350 9521325 ventricular JJ I-NP I-Disease
33 351 363 9521325 fibrillation NN I-NP I-Disease
34 364 365 9521325 ( ( O O
35 365 368 9521325 IVF NN B-NP B-Disease
36 368 369 9521325 ) ) O O
37 369 370 9521325 . . O O

1 371 372 9521325 A DT B-NP O
2 373 381 9521325 distinct JJ I-NP O
3 382 387 9521325 group NN I-NP O
4 388 390 9521325 of IN B-PP O
5 391 394 9521325 IVF NN B-NP B-Disease
6 395 403 9521325 patients NNS I-NP O
7 404 407 9521325 has VBZ B-VP O
8 408 412 9521325 been VBN I-VP O
9 413 418 9521325 found VBN I-VP O
10 419 421 9521325 to TO I-VP O
11 422 429 9521325 present VB I-VP O
12 430 434 9521325 with IN B-PP O
13 435 436 9521325 a DT B-NP O
14 437 451 9521325 characteristic JJ I-NP O
15 452 472 9521325 electrocardiographic JJ I-NP O
16 473 480 9521325 pattern NN I-NP O
17 480 481 9521325 . . O O

1 482 489 9521325 Because IN B-PP O
2 490 492 9521325 of IN I-PP O
3 493 496 9521325 the DT B-NP O
4 497 502 9521325 small JJ I-NP O
5 503 507 9521325 size NN I-NP O
6 508 510 9521325 of IN B-PP O
7 511 515 9521325 most JJS B-NP O
8 516 525 9521325 pedigrees NNS I-NP O
9 526 529 9521325 and CC O O
10 530 533 9521325 the DT B-NP O
11 534 538 9521325 high JJ I-NP O
12 539 548 9521325 incidence NN I-NP O
13 549 551 9521325 of IN B-PP O
14 552 558 9521325 sudden JJ B-NP B-Disease
15 559 564 9521325 death NN I-NP I-Disease
16 564 565 9521325 , , O O
17 566 573 9521325 however RB B-ADVP O
18 573 574 9521325 , , O O
19 575 584 9521325 molecular JJ B-NP O
20 585 592 9521325 genetic JJ I-NP O
21 593 600 9521325 studies NNS I-NP O
22 601 603 9521325 of IN B-PP O
23 604 607 9521325 IVF NN B-NP B-Disease
24 608 612 9521325 have VBP B-VP O
25 613 616 9521325 not RB I-VP O
26 617 620 9521325 yet RB I-VP O
27 621 625 9521325 been VBN I-VP O
28 626 630 9521325 done VBN I-VP O
29 630 631 9521325 . . O O

1 632 639 9521325 Because IN B-SBAR O
2 640 643 9521325 IVF NN B-NP B-Disease
3 644 650 9521325 causes VBZ B-VP O
4 651 658 9521325 cardiac JJ B-NP O
5 659 665 9521325 rhythm NN I-NP O
6 666 677 9521325 disturbance NN I-NP O
7 677 678 9521325 , , O O
8 679 681 9521325 we PRP B-NP O
9 682 694 9521325 investigated VBD B-VP O
10 695 702 9521325 whether IN B-SBAR O
11 703 714 9521325 malfunction NN B-NP O
12 715 717 9521325 of IN B-PP O
13 718 721 9521325 ion NN B-NP O
14 722 730 9521325 channels NNS I-NP O
15 731 736 9521325 could MD B-VP O
16 737 742 9521325 cause VB I-VP O
17 743 746 9521325 the DT B-NP O
18 747 755 9521325 disorder NN I-NP O
19 756 758 9521325 by IN B-PP O
20 759 767 9521325 studying VBG B-VP O
21 768 777 9521325 mutations NNS B-NP O
22 778 780 9521325 in IN B-PP O
23 781 784 9521325 the DT B-NP O
24 785 792 9521325 cardiac JJ I-NP O
25 793 799 9521325 sodium NN I-NP O
26 800 807 9521325 channel NN I-NP O
27 808 812 9521325 gene NN I-NP O
28 813 818 9521325 SCN5A NN I-NP O
29 818 819 9521325 . . O O

1 820 822 9521325 We PRP B-NP O
2 823 827 9521325 have VBP B-VP O
3 828 831 9521325 now RB I-VP O
4 832 842 9521325 identified VBN I-VP O
5 843 844 9521325 a DT B-NP O
6 845 853 9521325 missense JJ I-NP O
7 854 862 9521325 mutation NN I-NP O
8 862 863 9521325 , , O O
9 864 865 9521325 a DT B-NP O
10 866 872 9521325 splice NN I-NP O
11 872 873 9521325 - HYPH I-NP O
12 873 878 9521325 donor NN I-NP O
13 879 887 9521325 mutation NN I-NP O
14 887 888 9521325 , , O O
15 889 892 9521325 and CC O O
16 893 894 9521325 a DT B-NP O
17 895 905 9521325 frameshift NN I-NP O
18 906 914 9521325 mutation NN I-NP O
19 915 917 9521325 in IN B-PP O
20 918 921 9521325 the DT B-NP O
21 922 928 9521325 coding VBG I-NP O
22 929 935 9521325 region NN I-NP O
23 936 938 9521325 of IN B-PP O
24 939 944 9521325 SCN5A NN B-NP O
25 945 947 9521325 in IN B-PP O
26 948 953 9521325 three CD B-NP O
27 954 957 9521325 IVF NN I-NP B-Disease
28 958 966 9521325 families NNS I-NP O
29 966 967 9521325 . . O O

1 968 970 9521325 We PRP B-NP O
2 971 975 9521325 show VBP B-VP O
3 976 980 9521325 that IN B-SBAR O
4 981 987 9521325 sodium NN B-NP O
5 988 996 9521325 channels NNS I-NP O
6 997 1001 9521325 with IN B-PP O
7 1002 1005 9521325 the DT B-NP O
8 1006 1014 9521325 missense JJ I-NP O
9 1015 1023 9521325 mutation NN I-NP O
10 1024 1031 9521325 recover NN I-NP O
11 1032 1036 9521325 from IN B-PP O
12 1037 1049 9521325 inactivation NN B-NP O
13 1050 1054 9521325 more RBR B-ADVP O
14 1055 1062 9521325 rapidly RB I-ADVP O
15 1063 1067 9521325 than IN B-PP O
16 1068 1074 9521325 normal JJ B-ADJP O
17 1075 1078 9521325 and CC O O
18 1079 1083 9521325 that IN B-SBAR O
19 1084 1087 9521325 the DT B-NP O
20 1088 1098 9521325 frameshift NN I-NP O
21 1099 1107 9521325 mutation NN I-NP O
22 1108 1114 9521325 causes VBZ B-VP O
23 1115 1118 9521325 the DT B-NP O
24 1119 1125 9521325 sodium NN I-NP O
25 1126 1133 9521325 channel NN I-NP O
26 1134 1136 9521325 to TO B-VP O
27 1137 1139 9521325 be VB I-VP O
28 1140 1143 9521325 non AFX B-ADJP O
29 1143 1144 9521325 - HYPH I-ADJP O
30 1144 1154 9521325 functional JJ I-ADJP O
31 1154 1155 9521325 . . O O

1 1156 1159 9521325 Our PRP$ B-NP O
2 1160 1167 9521325 results NNS I-NP O
3 1168 1176 9521325 indicate VBP B-VP O
4 1177 1181 9521325 that IN B-SBAR O
5 1182 1191 9521325 mutations NNS B-NP O
6 1192 1194 9521325 in IN B-PP O
7 1195 1202 9521325 cardiac JJ B-NP O
8 1203 1206 9521325 ion NN I-NP O
9 1206 1207 9521325 - HYPH B-NP O
10 1207 1214 9521325 channel NN I-NP O
11 1215 1220 9521325 genes NNS I-NP O
12 1221 1231 9521325 contribute VBP B-VP O
13 1232 1234 9521325 to TO B-PP O
14 1235 1238 9521325 the DT B-NP O
15 1239 1243 9521325 risk NN I-NP O
16 1244 1246 9521325 of IN B-PP O
17 1247 1257 9521325 developing VBG B-VP O
18 1258 1261 9521325 IVF NN B-NP B-Disease
19 1261 1262 9521325 . . O O
20 1262 1263 9521325 . . O O

1 0 0 9705283 -DOCSTART- -X- -X- O

1 0 10 9705283 Truncation NN B-NP O
2 11 20 9705283 mutations NNS I-NP O
3 21 23 9705283 in IN B-PP O
4 24 27 9705283 the DT B-NP O
5 28 43 9705283 transactivation NN I-NP O
6 44 50 9705283 region NN I-NP O
7 51 53 9705283 of IN B-PP O
8 54 58 9705283 PAX6 NN B-NP O
9 59 65 9705283 result VBP B-VP O
10 66 68 9705283 in IN B-PP O
11 69 77 9705283 dominant JJ B-NP O
12 77 78 9705283 - HYPH I-NP O
13 78 86 9705283 negative JJ I-NP O
14 87 94 9705283 mutants NNS I-NP O
15 94 95 9705283 . . I-NP O
16 96 100 9705283 PAX6 NN I-NP O
17 101 103 9705283 is VBZ B-VP O
18 104 105 9705283 a DT B-NP O
19 106 119 9705283 transcription NN I-NP O
20 120 126 9705283 factor NN I-NP O
21 127 131 9705283 with IN B-PP O
22 132 135 9705283 two CD B-NP O
23 136 139 9705283 DNA NN I-NP O
24 139 140 9705283 - HYPH B-VP O
25 140 147 9705283 binding VBG B-NP O
26 148 155 9705283 domains NNS I-NP O
27 156 157 9705283 ( ( O O
28 157 163 9705283 paired JJ B-NP O
29 164 167 9705283 box NN I-NP O
30 168 171 9705283 and CC O O
31 172 180 9705283 homeobox NN B-NP O
32 180 181 9705283 ) ) O O
33 182 185 9705283 and CC O O
34 186 187 9705283 a DT B-NP O
35 188 195 9705283 proline NN I-NP O
36 195 196 9705283 - HYPH B-NP O
37 196 202 9705283 serine NN I-NP O
38 202 203 9705283 - HYPH O O
39 203 212 9705283 threonine NN B-NP O
40 213 214 9705283 ( ( O O
41 214 217 9705283 PST NN B-NP O
42 217 218 9705283 ) ) O O
43 219 220 9705283 - HYPH B-NP O
44 220 224 9705283 rich JJ I-NP O
45 225 240 9705283 transactivation NN I-NP O
46 241 247 9705283 domain NN I-NP O
47 247 248 9705283 . . O O

1 249 253 9705283 PAX6 NN B-NP O
2 254 263 9705283 regulates VBZ B-VP O
3 264 267 9705283 eye NN B-NP O
4 268 279 9705283 development NN I-NP O
5 280 282 9705283 in IN B-PP O
6 283 290 9705283 animals NNS B-NP O
7 291 298 9705283 ranging VBG B-VP O
8 299 303 9705283 from IN B-PP O
9 304 313 9705283 jellyfish NN B-NP O
10 314 316 9705283 to TO B-PP O
11 317 327 9705283 Drosophila FW B-NP O
12 328 330 9705283 to TO B-PP O
13 331 337 9705283 humans NNS B-NP O
14 337 338 9705283 . . O O

1 339 351 9705283 Heterozygous JJ B-NP O
2 352 361 9705283 mutations NNS I-NP O
3 362 364 9705283 in IN B-PP O
4 365 368 9705283 the DT B-NP O
5 369 374 9705283 human JJ I-NP O
6 375 379 9705283 PAX6 NN I-NP O
7 380 384 9705283 gene NN I-NP O
8 385 391 9705283 result VBP B-VP O
9 392 394 9705283 in IN B-PP O
10 395 402 9705283 various JJ B-NP O
11 403 413 9705283 phenotypes NNS I-NP O
12 413 414 9705283 , , O O
13 415 424 9705283 including VBG B-PP O
14 425 433 9705283 aniridia NN B-NP B-Disease
15 433 434 9705283 , , O O
16 435 441 9705283 Peters NNP B-NP B-Disease
17 442 449 9705283 anomaly RB B-ADVP I-Disease
18 449 450 9705283 , , O O
19 451 460 9705283 autosomal JJ B-NP B-Disease
20 461 469 9705283 dominant JJ I-NP I-Disease
21 470 479 9705283 keratitis NN I-NP I-Disease
22 479 480 9705283 , , O O
23 481 484 9705283 and CC O O
24 485 493 9705283 familial JJ B-NP B-Disease
25 494 500 9705283 foveal JJ I-NP I-Disease
26 501 510 9705283 dysplasia NN I-NP I-Disease
27 510 511 9705283 . . O O

1 512 514 9705283 It PRP B-NP O
2 515 517 9705283 is VBZ B-VP O
3 518 526 9705283 believed VBN I-VP O
4 527 531 9705283 that IN B-SBAR O
5 532 535 9705283 the DT B-NP O
6 536 543 9705283 mutated VBN I-NP O
7 544 550 9705283 allele NN I-NP O
8 551 553 9705283 of IN B-PP O
9 554 558 9705283 PAX6 NN B-NP O
10 559 567 9705283 produces VBZ B-VP O
11 568 570 9705283 an DT B-NP O
12 571 579 9705283 inactive JJ I-NP O
13 580 587 9705283 protein NN I-NP O
14 588 591 9705283 and CC I-NP O
15 592 600 9705283 aniridia NN I-NP B-Disease
16 601 603 9705283 is VBZ B-VP O
17 604 610 9705283 caused VBN I-VP O
18 611 614 9705283 due JJ B-ADJP O
19 615 617 9705283 to TO B-PP O
20 618 625 9705283 genetic JJ B-NP O
21 626 644 9705283 haploinsufficiency NN I-NP O
22 644 645 9705283 . . O O

1 646 653 9705283 However RB B-ADVP O
2 653 654 9705283 , , O O
3 655 662 9705283 several JJ B-NP O
4 663 673 9705283 truncation NN I-NP O
5 674 683 9705283 mutations NNS I-NP O
6 684 688 9705283 have VBP B-VP O
7 689 693 9705283 been VBN I-VP O
8 694 699 9705283 found VBN I-VP O
9 700 702 9705283 to TO I-VP O
10 703 708 9705283 occur VB I-VP O
11 709 711 9705283 in IN B-PP O
12 712 715 9705283 the DT B-NP O
13 716 717 9705283 C NN I-NP O
14 717 718 9705283 - HYPH B-NP O
15 718 726 9705283 terminal JJ I-NP O
16 727 731 9705283 half NN I-NP O
17 732 734 9705283 of IN B-PP O
18 735 739 9705283 PAX6 NN B-NP O
19 740 742 9705283 in IN B-PP O
20 743 751 9705283 patients NNS B-NP O
21 752 756 9705283 with IN B-PP O
22 757 765 9705283 Aniridia NNP B-NP B-Disease
23 766 775 9705283 resulting VBG B-VP O
24 776 778 9705283 in IN B-PP O
25 779 785 9705283 mutant JJ B-NP O
26 786 794 9705283 proteins NNS I-NP O
27 795 799 9705283 that WDT B-NP O
28 800 806 9705283 retain VBP B-VP O
29 807 810 9705283 the DT B-NP O
30 811 814 9705283 DNA NN I-NP O
31 814 815 9705283 - HYPH B-VP O
32 815 822 9705283 binding VBG B-NP O
33 823 830 9705283 domains NNS I-NP O
34 831 834 9705283 but CC O O
35 835 839 9705283 have VBP B-VP O
36 840 844 9705283 lost VBN I-VP O
37 845 849 9705283 most JJS B-NP O
38 850 852 9705283 of IN B-PP O
39 853 856 9705283 the DT B-NP O
40 857 872 9705283 transactivation NN I-NP O
41 873 879 9705283 domain NN I-NP O
42 879 880 9705283 . . O O

1 881 883 9705283 It PRP B-NP O
2 884 886 9705283 is VBZ B-VP O
3 887 890 9705283 not RB O O
4 891 896 9705283 clear JJ B-ADJP O
5 897 904 9705283 whether IN B-SBAR O
6 905 909 9705283 such JJ B-NP O
7 910 917 9705283 mutants NNS I-NP O
8 918 924 9705283 really RB B-ADVP O
9 925 931 9705283 behave VBP B-VP O
10 932 934 9705283 as IN B-PP O
11 935 939 9705283 loss NN B-NP O
12 939 940 9705283 - HYPH B-NP O
13 940 942 9705283 of IN B-PP O
14 942 943 9705283 - HYPH B-NP O
15 943 951 9705283 function NN I-NP O
16 952 959 9705283 mutants NNS I-NP O
17 960 962 9705283 as IN B-SBAR O
18 963 972 9705283 predicted VBN B-VP O
19 973 975 9705283 by IN B-PP O
20 976 994 9705283 haploinsufficiency NN B-NP O
21 994 995 9705283 . . O O

1 996 1004 9705283 Contrary JJ B-ADJP O
2 1005 1007 9705283 to TO B-PP O
3 1008 1012 9705283 this DT B-NP O
4 1013 1019 9705283 theory NN I-NP O
5 1019 1020 9705283 , , O O
6 1021 1024 9705283 our PRP$ B-NP O
7 1025 1029 9705283 data NNS I-NP O
8 1030 1036 9705283 showed VBD B-VP O
9 1037 1041 9705283 that IN B-SBAR O
10 1042 1047 9705283 these DT B-NP O
11 1048 1055 9705283 mutants NNS I-NP O
12 1056 1059 9705283 are VBP B-VP O
13 1060 1068 9705283 dominant JJ B-ADJP O
14 1068 1069 9705283 - HYPH B-ADJP O
15 1069 1077 9705283 negative JJ I-ADJP O
16 1078 1080 9705283 in IN B-PP O
17 1081 1090 9705283 transient JJ B-NP O
18 1091 1103 9705283 transfection NN I-NP O
19 1104 1110 9705283 assays NNS I-NP O
20 1111 1115 9705283 when WRB B-ADVP O
21 1116 1120 9705283 they PRP B-NP O
22 1121 1124 9705283 are VBP B-VP O
23 1125 1136 9705283 coexpressed VBN I-VP O
24 1137 1141 9705283 with IN B-PP O
25 1142 1146 9705283 wild JJ B-NP O
26 1146 1147 9705283 - HYPH I-NP O
27 1147 1151 9705283 type NN I-NP O
28 1152 1156 9705283 PAX6 NN I-NP O
29 1156 1157 9705283 . . O O

1 1158 1160 9705283 We PRP B-NP O
2 1161 1166 9705283 found VBD B-VP O
3 1167 1171 9705283 that IN B-SBAR O
4 1172 1175 9705283 the DT B-NP O
5 1176 1184 9705283 dominant JJ I-NP O
6 1184 1185 9705283 - HYPH I-NP O
7 1185 1193 9705283 negative JJ I-NP O
8 1194 1201 9705283 effects NNS I-NP O
9 1202 1208 9705283 result VBP B-VP O
10 1209 1213 9705283 from IN B-PP O
11 1214 1217 9705283 the DT B-NP O
12 1218 1226 9705283 enhanced VBN I-NP O
13 1227 1230 9705283 DNA NN I-NP O
14 1231 1238 9705283 binding NN I-NP O
15 1239 1246 9705283 ability NN I-NP O
16 1247 1249 9705283 of IN B-PP O
17 1250 1255 9705283 these DT B-NP O
18 1256 1263 9705283 mutants NNS I-NP O
19 1263 1264 9705283 . . O O

1 1265 1272 9705283 Kinetic JJ B-NP O
2 1273 1280 9705283 studies NNS I-NP O
3 1281 1283 9705283 of IN B-PP O
4 1284 1291 9705283 binding NN B-NP O
5 1292 1295 9705283 and CC I-NP O
6 1296 1308 9705283 dissociation NN I-NP O
7 1309 1317 9705283 revealed VBD B-VP O
8 1318 1322 9705283 that IN B-SBAR O
9 1323 1330 9705283 various JJ B-NP O
10 1331 1341 9705283 truncation NN I-NP O
11 1342 1349 9705283 mutants NNS I-NP O
12 1350 1354 9705283 have VBP B-VP O
13 1355 1356 9705283 3 CD B-NP O
14 1356 1357 9705283 - HYPH I-NP O
15 1357 1358 9705283 5 CD I-NP O
16 1358 1359 9705283 - HYPH O O
17 1359 1363 9705283 fold RB B-NP O
18 1364 1370 9705283 higher JJR I-NP O
19 1371 1379 9705283 affinity NN I-NP O
20 1380 1382 9705283 to TO B-PP O
21 1383 1390 9705283 various JJ B-NP O
22 1391 1394 9705283 DNA NN I-NP O
23 1394 1395 9705283 - HYPH B-VP O
24 1395 1402 9705283 binding VBG B-NP O
25 1403 1408 9705283 sites NNS I-NP O
26 1409 1413 9705283 when WRB B-ADVP O
27 1414 1422 9705283 compared VBN B-PP O
28 1423 1427 9705283 with IN B-PP O
29 1428 1431 9705283 the DT B-NP O
30 1432 1436 9705283 wild JJ I-NP O
31 1436 1437 9705283 - HYPH I-NP O
32 1437 1441 9705283 type NN I-NP O
33 1442 1446 9705283 PAX6 NN I-NP O
34 1446 1447 9705283 . . O O

1 1448 1453 9705283 These DT B-NP O
2 1454 1461 9705283 results NNS I-NP O
3 1462 1469 9705283 provide VBP B-VP O
4 1470 1471 9705283 a DT B-NP O
5 1472 1475 9705283 new JJ I-NP O
6 1476 1483 9705283 insight NN I-NP O
7 1484 1488 9705283 into IN B-PP O
8 1489 1492 9705283 the DT B-NP O
9 1493 1497 9705283 role NN I-NP O
10 1498 1500 9705283 of IN B-PP O
11 1501 1507 9705283 mutant JJ B-NP O
12 1508 1512 9705283 PAX6 NN I-NP O
13 1513 1515 9705283 in IN B-PP O
14 1516 1523 9705283 causing VBG B-VP O
15 1524 1532 9705283 aniridia NN B-NP B-Disease
16 1532 1533 9705283 . . O O
17 1533 1534 9705283 . . O O

1 0 0 9702690 -DOCSTART- -X- -X- O

1 0 1 9702690 A DT B-NP O
2 2 10 9702690 Japanese JJ I-NP O
3 11 17 9702690 family NN I-NP O
4 18 22 9702690 with IN B-PP O
5 23 43 9702690 adrenoleukodystrophy NN B-NP B-Disease
6 44 48 9702690 with IN B-PP O
7 49 50 9702690 a DT B-NP O
8 51 56 9702690 codon NN I-NP O
9 57 60 9702690 291 CD I-NP O
10 61 69 9702690 deletion NN I-NP O
11 69 70 9702690 : : O O
12 71 72 9702690 a DT B-NP O
13 73 81 9702690 clinical JJ I-NP O
14 81 82 9702690 , , I-NP O
15 83 94 9702690 biochemical JJ I-NP O
16 94 95 9702690 , , I-NP O
17 96 108 9702690 pathological JJ I-NP O
18 108 109 9702690 , , O O
19 110 113 9702690 and CC O O
20 114 121 9702690 genetic JJ B-NP O
21 122 128 9702690 report NN I-NP O
22 128 129 9702690 . . O O
23 130 132 9702690 We PRP B-NP O
24 133 139 9702690 report VBP B-VP O
25 140 141 9702690 a DT B-NP O
26 142 150 9702690 Japanese JJ I-NP O
27 151 157 9702690 family NN I-NP O
28 158 162 9702690 with IN B-PP O
29 163 183 9702690 adrenoleukodystrophy NN B-NP B-Disease
30 184 185 9702690 ( ( O O
31 185 188 9702690 ALD NN B-NP B-Disease
32 188 189 9702690 ) ) O O
33 190 194 9702690 with IN B-PP O
34 195 196 9702690 a DT B-NP O
35 197 202 9702690 three CD I-NP O
36 203 207 9702690 base NN I-NP O
37 208 212 9702690 pair NN I-NP O
38 213 221 9702690 deletion NN I-NP O
39 222 223 9702690 ( ( O O
40 223 229 9702690 delGAG NN B-NP O
41 230 233 9702690 291 CD I-NP O
42 233 234 9702690 ) ) O O
43 235 237 9702690 in IN B-PP O
44 238 241 9702690 the DT B-NP O
45 242 245 9702690 ALD NN I-NP B-Disease
46 246 250 9702690 gene NN I-NP O
47 250 251 9702690 . . O O

1 252 253 9702690 A DT B-NP O
2 254 261 9702690 variety NN I-NP O
3 262 264 9702690 of IN B-PP O
4 265 275 9702690 phenotypes NNS B-NP O
5 276 280 9702690 were VBD B-VP O
6 281 289 9702690 observed VBN I-VP O
7 290 296 9702690 within IN B-PP O
8 297 301 9702690 this DT B-NP O
9 302 308 9702690 family NN I-NP O
10 308 309 9702690 . . O O

1 310 315 9702690 While IN B-SBAR O
2 316 319 9702690 the DT B-NP O
3 320 327 9702690 proband NN I-NP O
4 328 329 9702690 ( ( O O
5 329 336 9702690 patient NN B-NP O
6 337 338 9702690 1 CD I-NP O
7 338 339 9702690 ) ) O O
8 340 343 9702690 was VBD B-VP O
9 344 354 9702690 classified VBN I-VP O
10 355 357 9702690 as IN B-PP O
11 358 364 9702690 having VBG B-VP O
12 365 366 9702690 a DT B-NP O
13 367 371 9702690 rare JJ I-NP O
14 372 384 9702690 intermediate JJ I-NP O
15 385 389 9702690 type NN I-NP O
16 390 392 9702690 of IN B-PP O
17 393 398 9702690 adult JJ B-NP O
18 399 407 9702690 cerebral JJ I-NP O
19 408 411 9702690 and CC I-NP O
20 412 421 9702690 cerebello AFX I-NP O
21 421 422 9702690 - HYPH I-NP O
22 422 427 9702690 brain NN I-NP O
23 428 432 9702690 stem NN I-NP O
24 433 438 9702690 forms NNS I-NP O
25 438 439 9702690 , , O O
26 440 443 9702690 his PRP$ B-NP O
27 444 451 9702690 younger JJR I-NP O
28 452 459 9702690 brother NN I-NP O
29 460 461 9702690 ( ( O O
30 461 468 9702690 patient NN B-NP O
31 469 470 9702690 2 CD I-NP O
32 470 471 9702690 ) ) O O
33 472 475 9702690 and CC O O
34 476 482 9702690 nephew NN B-NP O
35 483 484 9702690 ( ( O O
36 484 491 9702690 patient NN B-NP O
37 492 493 9702690 3 CD I-NP O
38 493 494 9702690 ) ) O O
39 495 498 9702690 had VBD B-VP O
40 499 500 9702690 a DT B-NP O
41 501 510 9702690 childhood NN I-NP O
42 511 514 9702690 ALD NN I-NP B-Disease
43 515 519 9702690 type NN I-NP O
44 519 520 9702690 . . O O

1 521 528 9702690 Another DT B-NP O
2 529 535 9702690 nephew JJ I-NP O
3 536 537 9702690 ( ( O O
4 537 544 9702690 patient NN B-NP O
5 545 546 9702690 4 CD I-NP O
6 546 547 9702690 ) ) O O
7 548 550 9702690 of IN B-PP O
8 551 558 9702690 patient NN B-NP O
9 559 560 9702690 1 CD I-NP O
10 561 564 9702690 was VBD B-VP O
11 565 575 9702690 classified VBN I-VP O
12 576 578 9702690 as IN B-PP O
13 579 585 9702690 having VBG B-VP O
14 586 588 9702690 an DT B-NP O
15 589 599 9702690 adolescent JJ I-NP O
16 600 604 9702690 form NN I-NP O
17 604 605 9702690 . . O O

1 606 609 9702690 The DT B-NP O
2 610 613 9702690 tau SYM I-NP O
3 614 619 9702690 level NN I-NP O
4 620 622 9702690 in IN B-PP O
5 623 626 9702690 the DT B-NP O
6 627 640 9702690 cerebrospinal JJ I-NP O
7 641 646 9702690 fluid NN I-NP O
8 647 648 9702690 ( ( O O
9 648 651 9702690 CSF NN B-NP O
10 651 652 9702690 ) ) O O
11 653 655 9702690 in IN B-PP O
12 656 663 9702690 patient NN B-NP O
13 664 665 9702690 1 CD I-NP O
14 666 669 9702690 was VBD B-VP O
15 670 672 9702690 as RB B-ADJP O
16 673 677 9702690 high JJ I-ADJP O
17 678 680 9702690 as IN B-PP O
18 681 685 9702690 that DT B-NP O
19 686 688 9702690 of IN B-PP O
20 689 697 9702690 patients NNS B-NP O
21 698 702 9702690 with IN B-PP O
22 703 713 9702690 Alzheimers NNS B-NP B-Disease
23 714 721 9702690 disease NN B-NP I-Disease
24 722 723 9702690 ( ( O O
25 723 725 9702690 AD NN B-NP B-Disease
26 725 726 9702690 ) ) O O
27 726 727 9702690 . . O O

1 728 731 9702690 His PRP$ B-NP O
2 732 737 9702690 brain NN I-NP O
3 738 746 9702690 magnetic JJ I-NP O
4 747 756 9702690 resonance NN I-NP O
5 757 762 9702690 image NN I-NP O
6 763 764 9702690 ( ( O O
7 764 767 9702690 MRI NN B-NP O
8 767 768 9702690 ) ) O O
9 769 775 9702690 showed VBD B-VP O
10 776 789 9702690 abnormalities NNS B-NP B-Disease
11 790 792 9702690 in IN B-PP I-Disease
12 793 796 9702690 the DT B-NP I-Disease
13 797 806 9702690 bilateral JJ I-NP I-Disease
14 807 817 9702690 cerebellar JJ I-NP I-Disease
15 818 829 9702690 hemispheres NNS I-NP I-Disease
16 830 833 9702690 and CC O O
17 834 839 9702690 brain NN B-NP O
18 840 844 9702690 stem NN I-NP O
19 844 845 9702690 , , O O
20 846 849 9702690 but CC B-PP O
21 850 853 9702690 not RB B-PP O
22 854 856 9702690 in IN I-PP O
23 857 860 9702690 the DT B-NP O
24 861 869 9702690 cerebral JJ I-NP O
25 870 875 9702690 white JJ I-NP O
26 876 882 9702690 matter NN I-NP O
27 882 883 9702690 , , O O
28 884 889 9702690 where WRB B-ADVP O
29 890 896 9702690 marked JJ B-NP O
30 897 907 9702690 reductions NNS I-NP O
31 908 910 9702690 of IN B-PP O
32 911 914 9702690 the DT B-NP O
33 915 923 9702690 cerebral JJ I-NP O
34 924 929 9702690 blood NN I-NP O
35 930 934 9702690 flow NN I-NP O
36 935 938 9702690 and CC O O
37 939 945 9702690 oxygen NN B-NP O
38 946 956 9702690 metabolism NN I-NP O
39 957 961 9702690 were VBD B-VP O
40 962 969 9702690 clearly RB I-VP O
41 970 982 9702690 demonstrated VBN I-VP O
42 983 985 9702690 by IN B-PP O
43 986 994 9702690 positron NN B-NP O
44 995 1003 9702690 emission NN I-NP O
45 1004 1014 9702690 tomography NN I-NP O
46 1015 1016 9702690 ( ( O O
47 1016 1019 9702690 PET NN B-NP O
48 1019 1020 9702690 ) ) O O
49 1020 1021 9702690 . . O O

1 1022 1024 9702690 In IN B-PP O
2 1025 1033 9702690 patients NNS B-NP O
3 1034 1035 9702690 2 CD B-NP O
4 1036 1039 9702690 and CC I-NP O
5 1040 1041 9702690 3 CD I-NP O
6 1041 1042 9702690 , , O O
7 1043 1046 9702690 the DT B-NP O
8 1047 1054 9702690 autopsy NN I-NP O
9 1055 1063 9702690 findings NNS I-NP O
10 1064 1070 9702690 showed VBD B-VP O
11 1071 1078 9702690 massive JJ B-NP O
12 1079 1092 9702690 demyelination NN I-NP B-Disease
13 1093 1095 9702690 of IN B-PP I-Disease
14 1096 1099 9702690 the DT B-NP I-Disease
15 1100 1108 9702690 cerebral JJ I-NP I-Disease
16 1109 1114 9702690 white JJ I-NP I-Disease
17 1115 1121 9702690 matter NN I-NP I-Disease
18 1122 1126 9702690 with IN B-PP O
19 1127 1134 9702690 sparing VBG B-NP O
20 1135 1137 9702690 of IN B-PP O
21 1138 1141 9702690 the DT B-NP O
22 1142 1143 9702690 U NN I-NP O
23 1143 1144 9702690 - HYPH B-NP O
24 1144 1150 9702690 fibers NNS I-NP O
25 1150 1151 9702690 , , O O
26 1152 1162 9702690 compatible JJ B-ADJP O
27 1163 1167 9702690 with IN B-PP O
28 1168 1171 9702690 the DT B-NP O
29 1172 1180 9702690 findings NNS I-NP O
30 1181 1183 9702690 of IN B-PP O
31 1184 1193 9702690 childhood NN B-NP O
32 1194 1197 9702690 ALD NN I-NP B-Disease
33 1197 1198 9702690 . . O O

1 1199 1204 9702690 Oleic JJ B-NP O
2 1205 1208 9702690 and CC I-NP O
3 1209 1215 9702690 erucic JJ I-NP O
4 1216 1221 9702690 acids NNS I-NP O
5 1222 1223 9702690 ( ( O O
6 1223 1231 9702690 Lorenzos NNP B-NP O
7 1232 1235 9702690 Oil NNP I-NP O
8 1235 1236 9702690 ) ) O O
9 1237 1241 9702690 were VBD B-VP O
10 1242 1254 9702690 administered VBN I-VP O
11 1255 1257 9702690 to TO B-PP O
12 1258 1266 9702690 patients NNS B-NP O
13 1267 1268 9702690 1 CD I-NP O
14 1269 1272 9702690 and CC I-NP O
15 1273 1274 9702690 4 CD I-NP O
16 1274 1275 9702690 , , O O
17 1276 1279 9702690 but CC O O
18 1280 1290 9702690 sufficient JJ B-NP O
19 1291 1304 9702690 effectiveness NN I-NP O
20 1305 1308 9702690 was VBD B-VP O
21 1309 1312 9702690 not RB I-VP O
22 1313 1321 9702690 obtained VBN I-VP O
23 1321 1322 9702690 . . O O

1 1323 1326 9702690 The DT B-NP O
2 1327 1335 9702690 findings NNS I-NP O
3 1336 1338 9702690 in IN B-PP O
4 1339 1343 9702690 this DT B-NP O
5 1344 1350 9702690 family NN I-NP O
6 1351 1358 9702690 suggest VBP B-VP O
7 1359 1363 9702690 that IN B-SBAR O
8 1364 1373 9702690 delGAG291 NN B-NP O
9 1374 1376 9702690 is VBZ B-VP O
10 1377 1381 9702690 part NN B-NP O
11 1382 1384 9702690 of IN B-PP O
12 1385 1388 9702690 the DT B-NP O
13 1389 1394 9702690 cause NN I-NP O
14 1395 1397 9702690 of IN B-PP O
15 1398 1406 9702690 Japanese JJ B-NP O
16 1407 1410 9702690 ALD NN I-NP B-Disease
17 1411 1415 9702690 with IN B-PP O
18 1416 1426 9702690 phenotypic JJ B-NP O
19 1427 1437 9702690 variations NNS I-NP O
20 1437 1438 9702690 . . O O

1 1439 1447 9702690 Moreover RB B-ADVP O
2 1447 1448 9702690 , , O O
3 1449 1457 9702690 although IN B-SBAR O
4 1458 1461 9702690 the DT B-NP O
5 1462 1467 9702690 scale NN I-NP O
6 1468 1470 9702690 of IN B-PP O
7 1471 1474 9702690 the DT B-NP O
8 1475 1480 9702690 study NN I-NP O
9 1481 1483 9702690 is VBZ B-VP O
10 1484 1491 9702690 limited VBN I-VP O
11 1491 1492 9702690 , , O O
12 1493 1498 9702690 there EX B-NP O
13 1499 1501 9702690 is VBZ B-VP O
14 1502 1503 9702690 a DT B-NP O
15 1504 1515 9702690 possibility NN I-NP O
16 1516 1520 9702690 that IN B-SBAR O
17 1521 1524 9702690 PET NN B-NP O
18 1525 1528 9702690 can MD B-VP O
19 1529 1535 9702690 detect VB I-VP O
20 1536 1538 9702690 an DT B-NP O
21 1539 1548 9702690 insidious JJ I-NP B-Disease
22 1549 1555 9702690 lesion NN I-NP I-Disease
23 1556 1561 9702690 which WDT B-NP O
24 1562 1564 9702690 is VBZ B-VP O
25 1565 1577 9702690 undetectable JJ B-ADJP O
26 1578 1580 9702690 by IN B-PP O
27 1581 1589 9702690 computed VBN B-NP O
28 1590 1598 9702690 tomogram NN I-NP O
29 1599 1600 9702690 ( ( O O
30 1600 1602 9702690 CT NN B-NP O
31 1602 1603 9702690 ) ) O O
32 1604 1606 9702690 or CC O O
33 1607 1610 9702690 MRI NN B-NP O
34 1611 1619 9702690 analysis NN I-NP O
35 1619 1620 9702690 , , O O
36 1621 1624 9702690 and CC O O
37 1625 1629 9702690 that IN B-SBAR O
38 1630 1633 9702690 the DT B-NP O
39 1634 1640 9702690 higher JJR I-NP O
40 1641 1646 9702690 level NN I-NP O
41 1647 1649 9702690 of IN B-PP O
42 1650 1653 9702690 tau SYM B-NP O
43 1654 1662 9702690 reflects VBZ B-VP O
44 1663 1666 9702690 the DT B-NP O
45 1667 1674 9702690 process NN I-NP O
46 1675 1677 9702690 of IN B-PP O
47 1678 1686 9702690 neuronal JJ B-NP B-Disease
48 1687 1699 9702690 degeneration NN I-NP I-Disease
49 1700 1702 9702690 in IN B-PP O
50 1703 1706 9702690 ALD NN B-NP B-Disease
51 1706 1707 9702690 . . O O

1 1708 1716 9702690 Lorenzos NNP B-NP O
2 1717 1720 9702690 Oil NNP I-NP O
3 1721 1727 9702690 should MD B-VP O
4 1728 1730 9702690 be VB I-VP O
5 1731 1736 9702690 given VBN I-VP O
6 1737 1739 9702690 in IN B-PP O
7 1740 1743 9702690 the DT B-NP O
8 1744 1749 9702690 early JJ I-NP O
9 1750 1755 9702690 stage NN I-NP O
10 1755 1756 9702690 . . O O
11 1756 1757 9702690 . . O O

1 0 0 9790667 -DOCSTART- -X- -X- O

1 0 1 9790667 A DT B-NP O
2 2 7 9790667 novel JJ I-NP O
3 8 17 9790667 Arg362Ser NN I-NP O
4 18 26 9790667 mutation NN I-NP O
5 27 29 9790667 in IN B-PP O
6 30 33 9790667 the DT B-NP O
7 34 40 9790667 sterol NN I-NP O
8 41 43 9790667 27 CD I-NP O
9 43 44 9790667 - HYPH I-NP O
10 44 55 9790667 hydroxylase NN I-NP O
11 56 60 9790667 gene NN I-NP O
12 61 62 9790667 ( ( O O
13 62 67 9790667 CYP27 NN B-NP O
14 67 68 9790667 ) ) O O
15 68 69 9790667 : : O O
16 70 73 9790667 its PRP$ B-NP O
17 74 81 9790667 effects NNS I-NP O
18 82 84 9790667 on IN B-PP O
19 85 88 9790667 pre AFX B-NP O
20 88 89 9790667 - HYPH I-NP O
21 89 93 9790667 mRNA NN I-NP O
22 94 102 9790667 splicing NN I-NP O
23 103 106 9790667 and CC O O
24 107 113 9790667 enzyme NN B-NP O
25 114 122 9790667 activity NN I-NP O
26 122 123 9790667 . . O O
27 124 125 9790667 A DT B-NP O
28 126 131 9790667 novel JJ I-NP O
29 132 133 9790667 C NN I-NP O
30 134 136 9790667 to TO B-PP O
31 137 138 9790667 A NN B-NP O
32 139 147 9790667 mutation NN I-NP O
33 148 150 9790667 in IN B-PP O
34 151 154 9790667 the DT B-NP O
35 155 161 9790667 sterol NN I-NP O
36 162 164 9790667 27 CD I-NP O
37 164 165 9790667 - HYPH I-NP O
38 165 176 9790667 hydroxylase NN I-NP O
39 177 181 9790667 gene NN I-NP O
40 182 183 9790667 ( ( O O
41 183 188 9790667 CYP27 NN B-NP O
42 188 189 9790667 ) ) O O
43 190 193 9790667 was VBD B-VP O
44 194 204 9790667 identified VBN I-VP O
45 205 207 9790667 by IN B-PP O
46 208 218 9790667 sequencing VBG B-VP O
47 219 228 9790667 amplified VBN B-NP O
48 229 234 9790667 CYP27 NN I-NP O
49 235 239 9790667 gene NN I-NP O
50 240 248 9790667 products NNS I-NP O
51 249 253 9790667 from IN B-PP O
52 254 255 9790667 a DT B-NP O
53 256 263 9790667 patient NN I-NP O
54 264 268 9790667 with IN B-PP O
55 269 285 9790667 cerebrotendinous JJ B-NP B-Disease
56 286 299 9790667 xanthomatosis NN I-NP I-Disease
57 300 301 9790667 ( ( O O
58 301 304 9790667 CTX NN B-NP B-Disease
59 304 305 9790667 ) ) O O
60 305 306 9790667 . . O O

1 307 310 9790667 The DT B-NP O
2 311 319 9790667 mutation NN I-NP O
3 320 327 9790667 changed VBD B-VP O
4 328 331 9790667 the DT B-NP O
5 332 343 9790667 adrenodoxin NN I-NP O
6 344 352 9790667 cofactor NN I-NP O
7 353 360 9790667 binding NN I-NP O
8 361 368 9790667 residue NN I-NP O
9 369 375 9790667 362Arg NN I-NP O
10 376 378 9790667 to TO B-PP O
11 379 385 9790667 362Ser NN B-NP O
12 386 387 9790667 ( ( O O
13 387 390 9790667 CGT NN B-NP O
14 391 397 9790667 362Arg NN I-NP O
15 398 400 9790667 to TO B-PP O
16 401 404 9790667 AGT NN B-NP O
17 405 411 9790667 362Ser NN I-NP O
18 411 412 9790667 ) ) O O
19 412 413 9790667 , , O O
20 414 417 9790667 and CC O O
21 418 421 9790667 was VBD B-VP O
22 422 433 9790667 responsible JJ B-ADJP O
23 434 437 9790667 for IN B-PP O
24 438 448 9790667 deficiency NN B-NP O
25 449 451 9790667 in IN B-PP O
26 452 455 9790667 the DT B-NP O
27 456 462 9790667 sterol NN I-NP O
28 463 465 9790667 27 CD I-NP O
29 465 466 9790667 - HYPH I-NP O
30 466 477 9790667 hydroxylase NN I-NP O
31 478 486 9790667 activity NN I-NP O
32 486 487 9790667 , , O O
33 488 490 9790667 as IN B-SBAR O
34 491 500 9790667 confirmed VBN B-VP O
35 501 503 9790667 by IN B-PP O
36 504 514 9790667 expression NN B-NP O
37 515 517 9790667 of IN B-PP O
38 518 524 9790667 mutant JJ B-NP O
39 525 529 9790667 cDNA NN I-NP O
40 530 534 9790667 into IN B-PP O
41 535 538 9790667 COS NN B-NP O
42 538 539 9790667 - HYPH B-NP O
43 539 540 9790667 1 CD I-NP O
44 541 546 9790667 cells NNS I-NP O
45 546 547 9790667 . . O O

1 548 560 9790667 Quantitative JJ B-NP O
2 561 569 9790667 analysis NN I-NP O
3 570 576 9790667 showed VBD B-VP O
4 577 581 9790667 that IN B-SBAR O
5 582 585 9790667 the DT B-NP O
6 586 596 9790667 expression NN I-NP O
7 597 599 9790667 of IN B-PP O
8 600 605 9790667 CYP27 NN B-NP O
9 606 610 9790667 gene NN I-NP O
10 611 615 9790667 mRNA NN I-NP O
11 616 618 9790667 in IN B-PP O
12 619 622 9790667 the DT B-NP O
13 623 630 9790667 patient NN I-NP O
14 631 642 9790667 represented VBD B-VP O
15 643 645 9790667 52 CD B-NP O
16 645 646 9790667 . . O O

1 647 649 9790667 5% CD B-NP O
2 650 652 9790667 of IN B-PP O
3 653 656 9790667 the DT B-NP O
4 657 663 9790667 normal JJ I-NP O
5 664 669 9790667 level NN I-NP O
6 669 670 9790667 . . O O

1 671 673 9790667 As IN B-SBAR O
2 674 677 9790667 the DT B-NP O
3 678 686 9790667 mutation NN I-NP O
4 687 695 9790667 occurred VBD B-VP O
5 696 698 9790667 at IN B-PP O
6 699 702 9790667 the DT B-NP O
7 703 714 9790667 penultimate JJ I-NP O
8 715 725 9790667 nucleotide NN I-NP O
9 726 728 9790667 of IN B-PP O
10 729 733 9790667 exon NN B-NP O
11 734 735 9790667 6 CD I-NP O
12 736 737 9790667 ( ( O O
13 737 738 9790667 - SYM O O
14 738 739 9790667 2 CD B-NP O
15 740 748 9790667 position NN I-NP O
16 749 751 9790667 of IN B-PP O
17 752 756 9790667 exon NN B-NP O
18 757 758 9790667 6 CD I-NP O
19 758 759 9790667 - HYPH I-NP O
20 759 765 9790667 intron NN I-NP O
21 766 767 9790667 6 CD I-NP O
22 768 774 9790667 splice NN I-NP O
23 775 779 9790667 site NN I-NP O
24 779 780 9790667 ) ) O O
25 781 783 9790667 of IN B-PP O
26 784 787 9790667 the DT B-NP O
27 788 792 9790667 gene NN I-NP O
28 792 793 9790667 , , O O
29 794 796 9790667 we PRP B-NP O
30 797 809 9790667 hypothesized VBD B-VP O
31 810 814 9790667 that IN B-SBAR O
32 815 818 9790667 the DT B-NP O
33 819 827 9790667 mutation NN I-NP O
34 828 831 9790667 may MD B-VP O
35 832 841 9790667 partially RB I-VP O
36 842 848 9790667 affect VB I-VP O
37 849 852 9790667 the DT B-NP O
38 853 859 9790667 normal JJ I-NP O
39 860 868 9790667 splicing NN I-NP O
40 869 879 9790667 efficiency NN I-NP O
41 880 882 9790667 in IN B-PP O
42 883 887 9790667 exon NN B-NP O
43 888 889 9790667 6 CD I-NP O
44 890 893 9790667 and CC O O
45 894 899 9790667 cause VB B-VP O
46 900 911 9790667 alternative JJ B-NP O
47 912 920 9790667 splicing NN I-NP O
48 921 930 9790667 elsewhere RB B-ADVP O
49 930 931 9790667 , , O O
50 932 937 9790667 which WDT B-NP O
51 938 946 9790667 resulted VBD B-VP O
52 947 949 9790667 in IN B-PP O
53 950 959 9790667 decreased VBN B-NP O
54 960 970 9790667 transcript NN I-NP O
55 971 973 9790667 in IN B-PP O
56 974 977 9790667 the DT B-NP O
57 978 985 9790667 patient NN I-NP O
58 985 986 9790667 . . O O

1 987 999 9790667 Transfection NN B-NP O
2 1000 1002 9790667 of IN B-PP O
3 1003 1014 9790667 constructed VBN B-NP O
4 1015 1024 9790667 minigenes NNS I-NP O
5 1024 1025 9790667 , , O O
6 1026 1030 9790667 with IN B-PP O
7 1031 1033 9790667 or CC B-PP O
8 1034 1041 9790667 without IN B-PP O
9 1042 1045 9790667 the DT B-NP O
10 1046 1054 9790667 mutation NN I-NP O
11 1054 1055 9790667 , , O O
12 1056 1060 9790667 into IN B-PP O
13 1061 1064 9790667 COS NN B-NP O
14 1064 1065 9790667 - HYPH B-NP O
15 1065 1066 9790667 1 CD I-NP O
16 1067 1072 9790667 cells NNS I-NP O
17 1073 1082 9790667 confirmed VBD B-VP O
18 1083 1087 9790667 that IN B-SBAR O
19 1088 1091 9790667 the DT B-NP O
20 1092 1098 9790667 mutant JJ I-NP O
21 1099 1107 9790667 minigene NN I-NP O
22 1108 1111 9790667 was VBD B-VP O
23 1112 1123 9790667 responsible JJ B-ADJP O
24 1124 1127 9790667 for IN B-PP O
25 1128 1129 9790667 a DT B-NP O
26 1130 1134 9790667 mRNA NN I-NP O
27 1135 1142 9790667 species NNS I-NP O
28 1143 1156 9790667 alternatively RB B-VP O
29 1157 1164 9790667 spliced VBN I-VP O
30 1165 1167 9790667 at IN B-PP O
31 1168 1170 9790667 an DT B-NP O
32 1171 1180 9790667 activated VBN I-NP O
33 1181 1188 9790667 cryptic JJ I-NP O
34 1189 1190 9790667 5 CD I-NP O
35 1191 1197 9790667 splice NN I-NP O
36 1198 1202 9790667 site NN I-NP O
37 1203 1205 9790667 88 CD I-NP O
38 1206 1208 9790667 bp NN I-NP O
39 1209 1217 9790667 upstream RB B-ADVP O
40 1218 1222 9790667 from IN B-PP O
41 1223 1226 9790667 the DT B-NP O
42 1227 1228 9790667 3 CD I-NP O
43 1229 1232 9790667 end NN I-NP O
44 1233 1235 9790667 of IN B-PP O
45 1236 1240 9790667 exon NN B-NP O
46 1241 1242 9790667 6 CD I-NP O
47 1242 1243 9790667 . . O O

1 1244 1247 9790667 Our PRP$ B-NP O
2 1248 1252 9790667 data NNS I-NP O
3 1253 1260 9790667 suggest VBP B-VP O
4 1261 1265 9790667 that IN B-SBAR O
5 1266 1269 9790667 the DT B-NP O
6 1270 1271 9790667 C NN I-NP O
7 1272 1274 9790667 to TO B-PP O
8 1275 1276 9790667 A NN B-NP O
9 1277 1285 9790667 mutation NN I-NP O
10 1286 1288 9790667 at IN B-PP O
11 1289 1292 9790667 the DT B-NP O
12 1293 1304 9790667 penultimate JJ I-NP O
13 1305 1315 9790667 nucleotide NN I-NP O
14 1316 1318 9790667 of IN B-PP O
15 1319 1323 9790667 exon NN B-NP O
16 1324 1325 9790667 6 CD I-NP O
17 1326 1328 9790667 of IN B-PP O
18 1329 1332 9790667 the DT B-NP O
19 1333 1338 9790667 CYP27 NN I-NP O
20 1339 1343 9790667 gene NN I-NP O
21 1344 1347 9790667 not RB B-CONJP O
22 1348 1352 9790667 only RB I-CONJP O
23 1353 1359 9790667 causes VBZ B-VP O
24 1360 1363 9790667 the DT B-NP O
25 1364 1374 9790667 deficiency NN I-NP B-Disease
26 1375 1377 9790667 in IN B-PP I-Disease
27 1378 1381 9790667 the DT B-NP I-Disease
28 1382 1388 9790667 sterol NN I-NP I-Disease
29 1389 1391 9790667 27 CD I-NP I-Disease
30 1391 1392 9790667 - HYPH I-NP I-Disease
31 1392 1403 9790667 hydroxylase NN I-NP I-Disease
32 1404 1412 9790667 activity NN I-NP I-Disease
33 1412 1413 9790667 , , O O
34 1414 1417 9790667 but CC O O
35 1418 1422 9790667 also RB B-ADVP O
36 1423 1432 9790667 partially RB B-ADVP O
37 1433 1438 9790667 leads VBZ B-VP O
38 1439 1441 9790667 to TO B-PP O
39 1442 1453 9790667 alternative JJ B-NP O
40 1454 1457 9790667 pre AFX I-NP O
41 1457 1458 9790667 - HYPH I-NP O
42 1458 1462 9790667 mRNA NN I-NP O
43 1463 1471 9790667 splicing NN I-NP O
44 1472 1474 9790667 of IN B-PP O
45 1475 1478 9790667 the DT B-NP O
46 1479 1483 9790667 gene NN I-NP O
47 1483 1484 9790667 . . O O

1 1485 1487 9790667 To TO B-PP O
2 1488 1491 9790667 our PRP$ B-NP O
3 1492 1501 9790667 knowledge NN I-NP O
4 1501 1502 9790667 , , O O
5 1503 1507 9790667 this DT B-NP O
6 1508 1510 9790667 is VBZ B-VP O
7 1511 1514 9790667 the DT B-NP O
8 1515 1520 9790667 first JJ I-NP O
9 1521 1527 9790667 report NN I-NP O
10 1528 1537 9790667 regarding VBG B-PP O
11 1538 1545 9790667 effects NNS B-NP O
12 1546 1548 9790667 on IN B-PP O
13 1549 1552 9790667 pre AFX B-NP O
14 1552 1553 9790667 - HYPH I-NP O
15 1553 1557 9790667 mRNA NN I-NP O
16 1558 1566 9790667 splicing NN I-NP O
17 1567 1569 9790667 of IN B-PP O
18 1570 1571 9790667 a DT B-NP O
19 1572 1580 9790667 mutation NN I-NP O
20 1581 1583 9790667 at IN B-PP O
21 1584 1587 9790667 the DT B-NP O
22 1588 1589 9790667 - SYM I-NP O
23 1589 1590 9790667 2 CD I-NP O
24 1591 1599 9790667 position NN I-NP O
25 1600 1602 9790667 of IN B-PP O
26 1603 1604 9790667 a DT B-NP O
27 1605 1606 9790667 5 CD I-NP O
28 1607 1613 9790667 splice NN I-NP O
29 1614 1618 9790667 site NN I-NP O
30 1618 1619 9790667 . . O O

1 0 0 9457914 -DOCSTART- -X- -X- O

1 0 1 9457914 A DT B-NP O
2 2 10 9457914 deletion NN I-NP O
3 11 19 9457914 mutation NN I-NP O
4 20 22 9457914 in IN B-PP O
5 23 30 9457914 COL17A1 NN B-NP O
6 31 33 9457914 in IN B-PP O
7 34 38 9457914 five CD B-NP O
8 39 47 9457914 Austrian JJ I-NP O
9 48 56 9457914 families NNS I-NP O
10 57 61 9457914 with IN B-PP O
11 62 73 9457914 generalized VBN B-NP O
12 74 82 9457914 atrophic JJ I-NP B-Disease
13 83 89 9457914 benign JJ I-NP I-Disease
14 90 103 9457914 epidermolysis NN I-NP I-Disease
15 104 111 9457914 bullosa NN I-NP I-Disease
16 112 122 9457914 represents VBZ B-VP O
17 123 134 9457914 propagation NN B-NP O
18 135 137 9457914 of IN B-PP O
19 138 140 9457914 an DT B-NP O
20 141 150 9457914 ancestral JJ I-NP O
21 151 157 9457914 allele NN I-NP O
22 157 158 9457914 . . I-NP O
23 159 167 9457914 Patients NNPS I-NP O
24 168 172 9457914 with IN B-PP O
25 173 184 9457914 generalized VBN B-NP O
26 185 193 9457914 atrophic JJ I-NP B-Disease
27 194 200 9457914 benign JJ I-NP I-Disease
28 201 214 9457914 epidermolysis NN I-NP I-Disease
29 215 222 9457914 bullosa NN I-NP I-Disease
30 222 223 9457914 , , O O
31 224 225 9457914 a DT B-NP O
32 226 233 9457914 usually RB I-NP O
33 234 243 9457914 nonlethal JJ I-NP O
34 244 248 9457914 form NN I-NP O
35 249 251 9457914 of IN B-PP O
36 252 262 9457914 junctional JJ B-NP B-Disease
37 263 276 9457914 epidermolysis NN I-NP I-Disease
38 277 284 9457914 bullosa NN I-NP I-Disease
39 284 285 9457914 , , O O
40 286 290 9457914 have VBP B-VP O
41 291 302 9457914 generalized VBN I-VP O
42 303 313 9457914 blistering NN B-NP B-Disease
43 313 314 9457914 , , O O
44 315 319 9457914 nail NN B-NP B-Disease
45 320 329 9457914 dystrophy NN I-NP I-Disease
46 329 330 9457914 , , O O
47 331 337 9457914 patchy NN B-NP B-Disease
48 338 346 9457914 alopecia NN I-NP I-Disease
49 346 347 9457914 , , O O
50 348 351 9457914 and CC O O
51 352 358 9457914 dental JJ B-NP B-Disease
52 359 372 9457914 abnormalities NNS I-NP I-Disease
53 372 373 9457914 . . O O

1 374 378 9457914 Skin NN B-NP B-Disease
2 379 388 9457914 fragility NN I-NP I-Disease
3 389 391 9457914 in IN B-PP O
4 392 396 9457914 most JJS B-NP O
5 397 402 9457914 cases NNS I-NP O
6 403 405 9457914 is VBZ B-VP O
7 406 409 9457914 due IN B-PP O
8 410 412 9457914 to TO B-PP O
9 413 422 9457914 mutations NNS B-NP O
10 423 425 9457914 in IN B-PP O
11 426 429 9457914 the DT B-NP O
12 430 434 9457914 gene NN I-NP O
13 435 443 9457914 encoding VBG B-VP O
14 444 448 9457914 type NN B-NP O
15 449 453 9457914 XVII NN I-NP O
16 454 462 9457914 collagen NN I-NP O
17 463 464 9457914 ( ( O O
18 464 471 9457914 COL17A1 NN B-NP O
19 471 472 9457914 ) ) O O
20 472 473 9457914 . . O O

1 474 482 9457914 Recently RB B-ADVP O
2 482 483 9457914 , , O O
3 484 486 9457914 we PRP B-NP O
4 487 495 9457914 reported VBD B-VP O
5 496 500 9457914 five CD B-NP O
6 501 509 9457914 Austrian JJ I-NP O
7 510 518 9457914 families NNS I-NP O
8 519 523 9457914 with IN B-PP O
9 524 535 9457914 generalized VBN B-NP O
10 536 544 9457914 atrophic JJ I-NP B-Disease
11 545 551 9457914 benign JJ I-NP I-Disease
12 552 565 9457914 epidermolysis NN I-NP I-Disease
13 566 573 9457914 bullosa NN I-NP I-Disease
14 574 577 9457914 who WP B-NP O
15 578 583 9457914 share VBP B-VP O
16 584 587 9457914 the DT B-NP O
17 588 592 9457914 same JJ I-NP O
18 593 600 9457914 COL17A1 NN I-NP O
19 601 609 9457914 mutation NN I-NP O
20 609 610 9457914 . . O O

1 611 619 9457914 Affected VBN B-NP O
2 620 631 9457914 individuals NNS I-NP O
3 632 634 9457914 in IN B-PP O
4 635 640 9457914 three CD B-NP O
5 641 649 9457914 families NNS I-NP O
6 650 653 9457914 are VBP B-VP O
7 654 664 9457914 homozygous JJ B-ADJP O
8 665 668 9457914 for IN B-PP O
9 669 678 9457914 4003delTC NN B-NP O
10 678 679 9457914 , , O O
11 680 687 9457914 whereas IN O O
12 688 693 9457914 those DT B-NP O
13 694 696 9457914 in IN B-PP O
14 697 700 9457914 two CD B-NP O
15 701 707 9457914 others NNS I-NP O
16 708 711 9457914 are VBP B-VP O
17 712 720 9457914 compound NN B-NP O
18 721 734 9457914 heterozygotes NNS I-NP O
19 734 735 9457914 . . O O

1 736 738 9457914 To TO B-VP O
2 739 748 9457914 determine VB I-VP O
3 749 751 9457914 if IN B-SBAR O
4 752 755 9457914 the DT B-NP O
5 756 766 9457914 occurrence NN I-NP O
6 767 769 9457914 of IN B-PP O
7 770 779 9457914 4003delTC NN B-NP O
8 780 782 9457914 in IN B-PP O
9 783 788 9457914 these DT B-NP O
10 789 798 9457914 unrelated JJ I-NP O
11 799 807 9457914 families NNS I-NP O
12 808 817 9457914 signifies VBZ B-VP O
13 818 829 9457914 propagation NN B-NP O
14 830 832 9457914 of IN B-PP O
15 833 835 9457914 an DT B-NP O
16 836 845 9457914 ancestral JJ I-NP O
17 846 852 9457914 allele NN I-NP O
18 853 855 9457914 or CC O O
19 856 857 9457914 a DT B-NP O
20 858 868 9457914 mutational JJ I-NP O
21 869 872 9457914 hot JJ I-NP O
22 873 877 9457914 spot NN I-NP O
23 877 878 9457914 , , O O
24 879 889 9457914 haplotypes NNS B-NP O
25 890 894 9457914 were VBD B-VP O
26 895 905 9457914 determined VBN I-VP O
27 906 909 9457914 for IN B-PP O
28 910 923 9457914 polymorphisms NNS B-NP O
29 924 928 9457914 both CC B-PP O
30 929 935 9457914 within IN B-PP O
31 936 939 9457914 and CC O O
32 940 948 9457914 flanking VBG B-VP O
33 949 956 9457914 COL17A1 NN B-NP O
34 956 957 9457914 . . O O

1 958 962 9457914 Five CD B-NP O
2 963 973 9457914 intragenic JJ I-NP O
3 974 987 9457914 polymorphisms NNS I-NP O
4 988 992 9457914 were VBD B-VP O
5 993 999 9457914 chosen VBN I-VP O
6 1000 1005 9457914 based VBN B-PP O
7 1006 1008 9457914 on IN B-PP O
8 1009 1014 9457914 their PRP$ B-NP O
9 1015 1030 9457914 informativeness NN I-NP O
10 1030 1031 9457914 . . O O

1 1032 1035 9457914 One CD B-NP O
2 1036 1038 9457914 of IN B-PP O
3 1039 1044 9457914 these DT B-NP O
4 1044 1045 9457914 , , O O
5 1046 1049 9457914 not RB O O
6 1050 1060 9457914 previously RB B-VP O
7 1061 1069 9457914 reported VBN I-VP O
8 1069 1070 9457914 , , O O
9 1071 1074 9457914 was VBD B-VP O
10 1075 1079 9457914 2988 CD B-NP O
11 1080 1081 9457914 A NN I-NP O
12 1082 1084 9457914 or CC I-NP O
13 1085 1086 9457914 C NN I-NP O
14 1087 1091 9457914 that WDT B-NP O
15 1092 1102 9457914 introduces VBZ B-VP O
16 1103 1104 9457914 a DT B-NP O
17 1105 1108 9457914 new JJ I-NP O
18 1109 1120 9457914 restriction NN I-NP O
19 1121 1125 9457914 site NN I-NP O
20 1126 1129 9457914 for IN B-PP O
21 1130 1137 9457914 Eco0109 NN B-NP O
22 1138 1139 9457914 I CD I-NP O
23 1139 1140 9457914 . . O O

1 1141 1144 9457914 All PDT B-NP O
2 1145 1148 9457914 the DT I-NP O
3 1149 1158 9457914 4003delTC NN I-NP O
4 1159 1166 9457914 alleles NNS I-NP O
5 1167 1173 9457914 showed VBD B-VP O
6 1174 1177 9457914 the DT B-NP O
7 1178 1182 9457914 same JJ I-NP O
8 1183 1192 9457914 haplotype NN I-NP O
9 1193 1196 9457914 for IN B-PP O
10 1197 1202 9457914 these DT B-NP O
11 1203 1207 9457914 five CD I-NP O
12 1208 1219 9457914 polymorphic JJ I-NP O
13 1220 1227 9457914 markers NNS I-NP O
14 1227 1228 9457914 . . O O

1 1229 1237 9457914 Fourteen CD B-NP O
2 1238 1252 9457914 microsatellite NN I-NP O
3 1253 1266 9457914 polymorphisms NNS I-NP O
4 1267 1271 9457914 were VBD B-VP O
5 1272 1280 9457914 selected VBN I-VP O
6 1281 1286 9457914 based VBN B-PP O
7 1287 1289 9457914 on IN B-PP O
8 1290 1295 9457914 their PRP$ B-NP O
9 1296 1300 9457914 high JJ I-NP O
10 1301 1315 9457914 heterozygosity NN I-NP O
11 1316 1319 9457914 and CC O O
12 1320 1325 9457914 their PRP$ B-NP O
13 1326 1334 9457914 location NN I-NP O
14 1335 1341 9457914 within IN B-PP O
15 1342 1347 9457914 10q23 CD B-NP O
16 1347 1348 9457914 - HYPH I-NP O
17 1348 1351 9457914 q25 NN I-NP O
18 1352 1356 9457914 near IN B-PP O
19 1357 1364 9457914 COL17A1 NN B-NP O
20 1364 1365 9457914 . . O O

1 1366 1371 9457914 Three CD B-NP O
2 1372 1380 9457914 families NNS I-NP O
3 1381 1387 9457914 shared VBD B-VP O
4 1388 1402 9457914 microsatellite NN B-NP O
5 1403 1416 9457914 polymorphisms NNS I-NP O
6 1417 1425 9457914 covering VBG B-VP O
7 1426 1428 9457914 at IN B-PP O
8 1429 1433 9457914 most JJS B-NP O
9 1434 1436 9457914 19 CD I-NP O
10 1437 1439 9457914 cM NN I-NP O
11 1439 1440 9457914 , , O O
12 1441 1448 9457914 whereas IN O O
13 1449 1452 9457914 the DT B-NP O
14 1453 1459 9457914 others NNS I-NP O
15 1460 1466 9457914 shared VBD B-VP O
16 1467 1474 9457914 smaller JJR B-NP O
17 1475 1482 9457914 regions NNS I-NP O
18 1483 1493 9457914 consistent JJ B-ADJP O
19 1494 1498 9457914 with IN B-PP O
20 1499 1504 9457914 cross AFX B-NP O
21 1504 1505 9457914 - HYPH I-NP O
22 1505 1509 9457914 over IN B-PP O
23 1510 1516 9457914 events NNS B-NP O
24 1517 1523 9457914 during IN B-PP O
25 1524 1531 9457914 passage NN B-NP O
26 1532 1534 9457914 of IN B-PP O
27 1535 1539 9457914 this DT B-NP O
28 1540 1548 9457914 mutation NN I-NP O
29 1549 1556 9457914 through IN B-PP O
30 1557 1564 9457914 several JJ B-NP O
31 1565 1576 9457914 generations NNS I-NP O
32 1576 1577 9457914 . . O O

1 1578 1583 9457914 These DT B-NP O
2 1584 1591 9457914 results NNS I-NP O
3 1592 1600 9457914 indicate VBP B-VP O
4 1601 1605 9457914 that IN B-SBAR O
5 1606 1615 9457914 4003delTC NN B-NP O
6 1616 1622 9457914 occurs VBZ B-VP O
7 1623 1625 9457914 on IN B-PP O
8 1626 1627 9457914 a DT B-NP O
9 1628 1634 9457914 single JJ I-NP O
10 1635 1644 9457914 ancestral JJ I-NP O
11 1645 1651 9457914 allele NN I-NP O
12 1651 1652 9457914 . . O O
13 1652 1653 9457914 . . O O

1 0 0 941901 -DOCSTART- -X- -X- O

1 0 3 941901 Low JJ B-NP O
2 4 10 941901 levels NNS I-NP O
3 11 13 941901 of IN B-PP O
4 14 18 941901 beta NN B-NP O
5 19 33 941901 hexosaminidase NN I-NP O
6 34 35 941901 A NN I-NP O
7 36 38 941901 in IN B-PP O
8 39 46 941901 healthy JJ B-NP O
9 47 58 941901 individuals NNS I-NP O
10 59 63 941901 with IN B-PP O
11 64 72 941901 apparent JJ B-NP O
12 73 83 941901 deficiency NN I-NP O
13 84 86 941901 of IN B-PP O
14 87 91 941901 this DT B-NP O
15 92 98 941901 enzyme NN I-NP O
16 98 99 941901 . . O O
17 100 111 941901 Appreciable JJ B-NP O
18 112 116 941901 beta NN I-NP O
19 117 131 941901 hexosaminidase NN I-NP O
20 132 133 941901 A NN I-NP O
21 134 135 941901 ( ( O O
22 135 138 941901 hex NN B-NP O
23 139 140 941901 A NN I-NP O
24 140 141 941901 ) ) O O
25 142 150 941901 activity NN B-NP O
26 151 154 941901 has VBZ B-VP O
27 155 159 941901 been VBN I-VP O
28 160 168 941901 detected VBN I-VP O
29 169 171 941901 in IN B-PP O
30 172 180 941901 cultured VBN B-NP O
31 181 185 941901 skin NN I-NP O
32 186 197 941901 fibroblasts NNS I-NP O
33 198 201 941901 and CC O O
34 202 210 941901 melanoma NN B-NP B-Disease
35 211 217 941901 tissue NN I-NP O
36 218 222 941901 from IN B-PP O
37 223 230 941901 healthy JJ B-NP O
38 231 242 941901 individuals NNS I-NP O
39 243 253 941901 previously RB B-VP O
40 254 262 941901 reported VBN I-VP O
41 263 265 941901 as IN B-PP O
42 266 272 941901 having VBG B-VP O
43 273 283 941901 deficiency NN B-NP B-Disease
44 284 286 941901 of IN B-PP I-Disease
45 287 290 941901 hex NN B-NP I-Disease
46 291 292 941901 A NN I-NP I-Disease
47 293 301 941901 activity NN I-NP O
48 302 319 941901 indistinguishable JJ B-ADJP O
49 320 324 941901 from IN B-PP O
50 325 329 941901 that DT B-NP O
51 330 332 941901 of IN B-PP O
52 333 341 941901 patients NNS B-NP O
53 342 346 941901 with IN B-PP O
54 347 350 941901 Tay NNP B-NP B-Disease
55 350 351 941901 - HYPH B-NP I-Disease
56 351 356 941901 Sachs NNP I-NP I-Disease
57 357 364 941901 disease NN I-NP I-Disease
58 365 366 941901 ( ( O O
59 366 369 941901 TSD NN B-NP B-Disease
60 369 370 941901 ) ) O O
61 370 371 941901 . . O O

1 372 386 941901 Identification NN B-NP O
2 387 390 941901 and CC I-NP O
3 391 403 941901 quantitation NN I-NP O
4 404 406 941901 of IN B-PP O
5 407 410 941901 hex NN B-NP O
6 411 412 941901 A NN I-NP O
7 412 413 941901 , , O O
8 414 423 941901 amounting VBG B-VP O
9 424 426 941901 to TO B-PP O
10 427 428 941901 3 CD B-NP O
11 428 429 941901 . . O O
12 430 432 941901 5% CD B-NP O
13 433 434 941901 - : O O
14 434 435 941901 6 CD B-NP O
15 435 436 941901 . . O O

1 437 439 941901 9% CD B-NP O
2 440 442 941901 of IN B-PP O
3 443 448 941901 total JJ B-NP O
4 449 453 941901 beta SYM I-NP O
5 454 468 941901 hexosaminidase NN I-NP O
6 469 477 941901 activity NN I-NP O
7 477 478 941901 , , O O
8 479 482 941901 has VBZ B-VP O
9 483 487 941901 been VBN I-VP O
10 488 496 941901 obtained VBN I-VP O
11 497 499 941901 by IN B-PP O
12 500 509 941901 cellulose NN B-NP O
13 510 517 941901 acetate NN I-NP O
14 518 521 941901 gel NN I-NP O
15 522 537 941901 electrophoresis NN I-NP O
16 537 538 941901 , , O O
17 539 543 941901 DEAE NN B-NP O
18 543 544 941901 - HYPH O O
19 544 553 941901 cellulose NN B-NP O
20 554 557 941901 ion NN I-NP O
21 557 558 941901 - HYPH B-NP O
22 558 566 941901 exchange NN I-NP O
23 567 581 941901 chromatography NN I-NP O
24 581 582 941901 , , O O
25 583 589 941901 radial JJ B-NP O
26 590 605 941901 immunodiffusion NN I-NP O
27 605 606 941901 , , O O
28 607 610 941901 and CC O O
29 611 627 941901 radioimmunoassay NN B-NP O
30 627 628 941901 . . O O

1 629 637 941901 Previous JJ B-NP O
2 638 644 941901 family NN I-NP O
3 645 652 941901 studies NNS I-NP O
4 653 662 941901 suggested VBD B-VP O
5 663 667 941901 that IN B-SBAR O
6 668 673 941901 these DT B-NP O
7 674 685 941901 individuals NNS I-NP O
8 686 689 941901 may MD B-VP O
9 690 692 941901 be VB I-VP O
10 693 701 941901 compound JJ B-NP O
11 702 715 941901 heterozygotes NNS I-NP O
12 716 719 941901 for IN B-PP O
13 720 723 941901 the DT B-NP O
14 724 730 941901 common JJ I-NP O
15 731 737 941901 mutant JJ I-NP O
16 738 741 941901 TSD NN I-NP B-Disease
17 742 746 941901 gene NN I-NP O
18 747 750 941901 and CC O O
19 751 752 941901 a DT B-NP O
20 753 757 941901 rare JJ I-NP O
21 758 759 941901 ( ( O O
22 759 766 941901 allelic JJ B-ADJP O
23 766 767 941901 ) ) O O
24 768 774 941901 mutant JJ B-NP O
25 775 779 941901 gene NN I-NP O
26 779 780 941901 . . O O

1 781 785 941901 Thus RB B-ADVP O
2 785 786 941901 , , O O
3 787 790 941901 the DT B-NP O
4 791 801 941901 postulated VBN I-NP O
5 802 806 941901 rate NN I-NP O
6 807 813 941901 mutant JJ I-NP O
7 814 818 941901 gene NN I-NP O
8 819 826 941901 appears VBZ B-VP O
9 827 829 941901 to TO I-VP O
10 830 834 941901 code VB I-VP O
11 835 838 941901 for IN B-PP O
12 839 842 941901 the DT B-NP O
13 843 853 941901 expression NN I-NP O
14 854 856 941901 of IN B-PP O
15 857 860 941901 low JJ B-NP O
16 861 868 941901 amounts NNS I-NP O
17 869 871 941901 of IN B-PP O
18 872 875 941901 hex NN B-NP O
19 876 877 941901 A NN I-NP O
20 877 878 941901 . . O O

1 879 892 941901 Heterozygotes NNS B-NP O
2 893 896 941901 for IN B-PP O
3 897 900 941901 the DT B-NP O
4 901 905 941901 rare JJ I-NP O
5 906 912 941901 mutant NN I-NP O
6 913 916 941901 may MD B-VP O
7 917 919 941901 be VB I-VP O
8 920 937 941901 indistinguishable JJ B-ADJP O
9 938 942 941901 from IN B-PP O
10 943 956 941901 heterozygotes NNS B-NP O
11 957 960 941901 for IN B-PP O
12 961 964 941901 the DT B-NP O
13 965 971 941901 common JJ I-NP O
14 972 975 941901 TSD NN I-NP B-Disease
15 976 982 941901 mutant NN I-NP O
16 982 983 941901 . . O O

1 984 991 941901 However RB B-ADVP O
2 991 992 941901 , , O O
3 993 999 941901 direct JJ B-NP O
4 1000 1013 941901 visualization NN I-NP O
5 1014 1017 941901 and CC I-NP O
6 1018 1030 941901 quantitation NN I-NP O
7 1031 1033 941901 of IN B-PP O
8 1034 1037 941901 hex NN B-NP O
9 1038 1039 941901 A NN I-NP O
10 1040 1042 941901 by IN B-PP O
11 1043 1046 941901 the DT B-NP O
12 1047 1054 941901 methods NNS I-NP O
13 1055 1064 941901 described VBN B-VP O
14 1065 1068 941901 may MD B-VP O
15 1069 1076 941901 prevent VB I-VP O
16 1077 1082 941901 false JJ B-NP O
17 1082 1083 941901 - HYPH I-NP O
18 1083 1091 941901 positive JJ I-NP O
19 1092 1100 941901 prenatal JJ I-NP O
20 1101 1110 941901 diagnosis NN I-NP O
21 1111 1113 941901 of IN B-PP O
22 1114 1117 941901 TSD NN B-NP B-Disease
23 1118 1120 941901 in IN B-PP O
24 1121 1128 941901 fetuses NNS B-NP O
25 1129 1135 941901 having VBG B-VP O
26 1136 1139 941901 the DT B-NP O
27 1140 1150 941901 incomplete JJ I-NP O
28 1151 1154 941901 hex NN I-NP B-Disease
29 1155 1156 941901 A NN I-NP I-Disease
30 1157 1167 941901 deficiency NN I-NP I-Disease
31 1168 1170 941901 of IN B-PP O
32 1171 1174 941901 the DT B-NP O
33 1175 1179 941901 type NN I-NP O
34 1180 1189 941901 described VBN B-VP O
35 1190 1192 941901 in IN B-PP O
36 1193 1196 941901 the DT B-NP O
37 1197 1201 941901 four CD I-NP O
38 1202 1209 941901 healthy JJ I-NP O
39 1210 1221 941901 individuals NNS I-NP O

1 0 0 9457913 -DOCSTART- -X- -X- O

1 0 13 9457913 Cycloheximide NN B-NP O
2 14 25 9457913 facilitates VBZ B-VP O
3 26 29 9457913 the DT B-NP O
4 30 44 9457913 identification NN I-NP O
5 45 47 9457913 of IN B-PP O
6 48 56 9457913 aberrant JJ B-NP O
7 57 68 9457913 transcripts NNS I-NP O
8 69 78 9457913 resulting VBG B-VP O
9 79 83 9457913 from IN B-PP O
10 84 85 9457913 a DT B-NP O
11 86 91 9457913 novel JJ I-NP O
12 92 98 9457913 splice NN I-NP O
13 98 99 9457913 - HYPH B-NP O
14 99 103 9457913 site NN I-NP O
15 104 112 9457913 mutation NN I-NP O
16 113 115 9457913 in IN B-PP O
17 116 123 9457913 COL17A1 NN B-NP O
18 124 126 9457913 in IN B-PP O
19 127 128 9457913 a DT B-NP O
20 129 136 9457913 patient NN I-NP O
21 137 141 9457913 with IN B-PP O
22 142 153 9457913 generalized VBN B-NP O
23 154 162 9457913 atrophic JJ I-NP B-Disease
24 163 169 9457913 benign JJ I-NP I-Disease
25 170 183 9457913 epidermolysis NN I-NP I-Disease
26 184 191 9457913 bullosa NN I-NP I-Disease
27 191 192 9457913 . . I-NP O
28 193 201 9457913 Patients NNPS I-NP O
29 202 206 9457913 with IN B-PP O
30 207 218 9457913 generalized VBN B-NP O
31 219 227 9457913 atrophic JJ I-NP B-Disease
32 228 234 9457913 benign JJ I-NP I-Disease
33 235 248 9457913 epidermolysis NN I-NP I-Disease
34 249 256 9457913 bullosa NN I-NP I-Disease
35 257 262 9457913 often RB B-ADVP O
36 263 267 9457913 show VBP B-VP O
37 268 277 9457913 decreased VBN B-NP O
38 278 288 9457913 expression NN I-NP O
39 289 291 9457913 of IN B-PP O
40 292 296 9457913 type NN B-NP O
41 297 301 9457913 XVII CD I-NP O
42 302 310 9457913 collagen NN I-NP O
43 310 311 9457913 , , O O
44 312 313 9457913 a DT B-NP O
45 314 327 9457913 transmembrane NN I-NP O
46 328 342 9457913 hemidesmosomal JJ I-NP O
47 343 350 9457913 protein NN I-NP O
48 351 358 9457913 encoded VBN B-VP O
49 359 361 9457913 by IN B-PP O
50 362 369 9457913 COL17A1 NN B-NP O
51 369 370 9457913 . . O O

1 371 375 9457913 This DT B-NP O
2 376 382 9457913 report NN I-NP O
3 383 392 9457913 documents VBZ B-VP O
4 393 394 9457913 a DT B-NP O
5 395 400 9457913 novel JJ I-NP O
6 401 407 9457913 splice NN I-NP O
7 407 408 9457913 - HYPH B-NP O
8 408 412 9457913 site NN I-NP O
9 413 421 9457913 mutation NN I-NP O
10 422 424 9457913 in IN B-PP O
11 425 432 9457913 COL17A1 NN B-NP O
12 433 435 9457913 in IN B-PP O
13 436 437 9457913 a DT B-NP O
14 438 445 9457913 patient NN I-NP O
15 446 450 9457913 with IN B-PP O
16 451 462 9457913 generalized VBN B-NP O
17 463 471 9457913 atrophic JJ I-NP B-Disease
18 472 478 9457913 benign JJ I-NP I-Disease
19 479 492 9457913 epidermolysis NN I-NP I-Disease
20 493 500 9457913 bullosa NN I-NP I-Disease
21 500 501 9457913 , , O O
22 502 505 9457913 and CC O O
23 506 513 9457913 applies VBZ B-VP O
24 514 515 9457913 a DT B-NP O
25 516 519 9457913 new JJ I-NP O
26 520 531 9457913 methodology NN I-NP O
27 532 534 9457913 to TO B-VP O
28 535 541 9457913 define VB I-VP O
29 542 545 9457913 and CC I-VP O
30 546 558 9457913 characterize VB I-VP O
31 559 562 9457913 the DT B-NP O
32 563 572 9457913 resulting VBG I-NP O
33 573 577 9457913 mRNA NN I-NP O
34 578 584 9457913 splice NN I-NP O
35 585 593 9457913 variants NNS I-NP O
36 593 594 9457913 . . O O

1 595 605 9457913 Mutational JJ B-NP O
2 606 614 9457913 analysis NN I-NP O
3 615 617 9457913 of IN B-PP O
4 618 625 9457913 COL17A1 NN B-NP O
5 626 636 9457913 identified VBD B-VP O
6 637 638 9457913 a DT B-NP O
7 639 649 9457913 maternally RB I-NP O
8 650 659 9457913 inherited VBN I-NP O
9 660 661 9457913 G NN I-NP O
10 661 662 9457913 - HYPH B-ADVP O
11 662 664 9457913 to TO B-PP O
12 664 665 9457913 - HYPH B-NP O
13 665 666 9457913 T NN I-NP O
14 667 679 9457913 transversion NN I-NP O
15 680 682 9457913 at IN B-PP O
16 683 686 9457913 the DT B-NP O
17 687 688 9457913 - HYPH I-NP O
18 688 689 9457913 1 CD I-NP O
19 690 698 9457913 position NN I-NP O
20 699 701 9457913 of IN B-PP O
21 702 706 9457913 exon NN B-NP O
22 707 709 9457913 32 CD I-NP O
23 709 710 9457913 . . O O

1 711 715 9457913 This DT B-NP O
2 716 724 9457913 acceptor NN I-NP O
3 725 731 9457913 splice NN I-NP O
4 731 732 9457913 - HYPH B-NP O
5 732 736 9457913 site NN I-NP O
6 737 745 9457913 mutation NN I-NP O
7 746 749 9457913 led VBD B-VP O
8 750 752 9457913 to TO B-PP O
9 753 756 9457913 the DT B-NP O
10 757 766 9457913 formation NN I-NP O
11 767 769 9457913 of IN B-PP O
12 770 778 9457913 aberrant JJ B-NP O
13 779 790 9457913 transcripts NNS I-NP O
14 791 798 9457913 present VBP B-VP O
15 799 801 9457913 at IN B-PP O
16 802 811 9457913 extremely RB B-NP O
17 812 815 9457913 low JJ I-NP O
18 816 822 9457913 levels NNS I-NP O
19 822 823 9457913 . . O O

1 824 829 9457913 Based VBN B-PP O
2 830 832 9457913 on IN B-PP O
3 833 836 9457913 our PRP$ B-NP O
4 837 843 9457913 recent JJ I-NP O
5 844 851 9457913 finding NN I-NP O
6 852 856 9457913 that IN B-SBAR O
7 857 870 9457913 cycloheximide NN B-NP O
8 871 881 9457913 stabilized VBD B-VP O
9 882 888 9457913 mutant JJ B-NP O
10 889 896 9457913 COL17A1 NN I-NP O
11 897 908 9457913 transcripts NNS I-NP O
12 909 911 9457913 in IN B-PP O
13 912 925 9457913 keratinocytes NNS B-NP O
14 926 936 9457913 homozygous JJ B-ADJP O
15 937 940 9457913 for IN B-PP O
16 941 942 9457913 a DT B-NP O
17 943 953 9457913 frameshift NN I-NP O
18 954 962 9457913 mutation NN I-NP O
19 962 963 9457913 , , O O
20 964 967 9457913 the DT B-NP O
21 968 975 9457913 effects NNS I-NP O
22 976 978 9457913 of IN B-PP O
23 979 982 9457913 the DT B-NP O
24 983 989 9457913 splice NN I-NP O
25 989 990 9457913 - HYPH B-NP O
26 990 994 9457913 site NN I-NP O
27 995 1003 9457913 mutation NN I-NP O
28 1004 1006 9457913 on IN B-PP O
29 1007 1015 9457913 splicing NN B-NP O
30 1016 1018 9457913 of IN B-PP O
31 1019 1026 9457913 COL17A1 NN B-NP O
32 1027 1038 9457913 transcripts NNS I-NP O
33 1039 1043 9457913 were VBD B-VP O
34 1044 1054 9457913 determined VBN I-VP O
35 1055 1060 9457913 using VBG B-VP O
36 1061 1068 9457913 reverse JJ B-NP O
37 1069 1082 9457913 transcriptase NN I-NP O
38 1083 1093 9457913 polymerase NN I-NP O
39 1094 1099 9457913 chain NN I-NP O
40 1100 1108 9457913 reaction NN I-NP O
41 1109 1111 9457913 of IN B-PP O
42 1112 1117 9457913 total JJ B-NP O
43 1118 1121 9457913 RNA NN I-NP O
44 1122 1126 9457913 from IN B-PP O
45 1127 1140 9457913 keratinocytes NNS B-NP O
46 1141 1150 9457913 incubated VBN B-VP O
47 1151 1154 9457913 for IN B-PP O
48 1155 1156 9457913 2 CD B-NP O
49 1156 1157 9457913 . . O O
50 1158 1159 9457913 5 CD B-NP O
51 1160 1161 9457913 h NN I-NP O
52 1162 1164 9457913 in IN B-PP O
53 1165 1168 9457913 the DT B-NP O
54 1169 1177 9457913 presence NN I-NP O
55 1178 1180 9457913 or CC I-NP O
56 1181 1188 9457913 absence NN I-NP O
57 1189 1191 9457913 of IN B-PP O
58 1192 1194 9457913 10 CD B-NP O
59 1195 1201 9457913 microg NN I-NP O
60 1202 1215 9457913 cycloheximide NN I-NP O
61 1216 1219 9457913 per IN B-PP O
62 1220 1222 9457913 ml NN B-NP O
63 1222 1223 9457913 . . O O

1 1224 1229 9457913 Using VBG B-VP O
2 1230 1234 9457913 this DT B-NP O
3 1235 1243 9457913 approach NN I-NP O
4 1243 1244 9457913 , , O O
5 1245 1247 9457913 an DT B-NP O
6 1248 1258 9457913 abnormally RB I-NP O
7 1259 1266 9457913 spliced VBN I-NP O
8 1267 1277 9457913 transcript NN I-NP O
9 1278 1281 9457913 was VBD B-VP O
10 1282 1292 9457913 identified VBN I-VP O
11 1293 1297 9457913 that WDT B-NP O
12 1298 1306 9457913 contains VBZ B-VP O
13 1307 1309 9457913 an DT B-NP O
14 1310 1315 9457913 extra JJ I-NP O
15 1316 1319 9457913 264 CD I-NP O
16 1320 1325 9457913 bases NNS I-NP O
17 1326 1334 9457913 upstream JJ B-ADJP O
18 1335 1339 9457913 from IN B-PP O
19 1340 1344 9457913 exon NN B-NP O
20 1345 1347 9457913 32 CD I-NP O
21 1347 1348 9457913 , , O O
22 1349 1358 9457913 resulting VBG B-VP O
23 1359 1361 9457913 in IN B-PP O
24 1362 1363 9457913 a DT B-NP O
25 1364 1373 9457913 premature JJ I-NP O
26 1374 1385 9457913 termination NN I-NP O
27 1386 1391 9457913 codon NN I-NP O
28 1392 1394 9457913 27 CD I-NP O
29 1395 1397 9457913 bp NN I-NP O
30 1398 1408 9457913 downstream RB B-ADVP O
31 1409 1413 9457913 from IN B-PP O
32 1414 1417 9457913 the DT B-NP O
33 1418 1425 9457913 cryptic JJ I-NP O
34 1426 1432 9457913 splice NN I-NP O
35 1433 1437 9457913 site NN I-NP O
36 1437 1438 9457913 . . O O

1 1439 1444 9457913 Three CD B-NP O
2 1445 1450 9457913 other JJ I-NP O
3 1451 1457 9457913 splice NN I-NP O
4 1458 1466 9457913 variants NNS I-NP O
5 1466 1467 9457913 , , O O
6 1468 1477 9457913 including VBG B-PP O
7 1478 1481 9457913 one CD B-NP O
8 1482 1489 9457913 derived VBN B-VP O
9 1490 1494 9457913 from IN B-PP O
10 1495 1498 9457913 the DT B-NP O
11 1499 1507 9457913 skipping NN I-NP O
12 1508 1510 9457913 of IN B-PP O
13 1511 1515 9457913 exon NN B-NP O
14 1516 1518 9457913 32 CD I-NP O
15 1518 1519 9457913 , , O O
16 1520 1524 9457913 were VBD B-VP O
17 1525 1529 9457913 also RB I-VP O
18 1530 1540 9457913 identified VBN I-VP O
19 1540 1541 9457913 . . O O

1 1542 1547 9457913 These DT B-NP O
2 1548 1555 9457913 results NNS I-NP O
3 1556 1564 9457913 indicate VBP B-VP O
4 1565 1568 9457913 the DT B-NP O
5 1569 1579 9457913 usefulness NN I-NP O
6 1580 1582 9457913 of IN B-PP O
7 1583 1596 9457913 cycloheximide NN B-NP O
8 1597 1606 9457913 treatment NN I-NP O
9 1607 1609 9457913 in IN B-PP O
10 1610 1620 9457913 evaluating VBG B-VP O
11 1621 1624 9457913 the DT B-NP O
12 1625 1633 9457913 abnormal JJ I-NP O
13 1634 1644 9457913 processing NN I-NP O
14 1645 1647 9457913 of IN B-PP O
15 1648 1652 9457913 mRNA NN B-NP O
16 1653 1656 9457913 due JJ B-ADJP O
17 1657 1659 9457913 to TO B-PP O
18 1660 1666 9457913 splice NN B-NP O
19 1666 1667 9457913 - HYPH I-NP O
20 1667 1671 9457913 site NN I-NP O
21 1672 1681 9457913 mutations NNS I-NP O
22 1681 1682 9457913 , , O O
23 1683 1690 9457913 because IN B-SBAR O
24 1692 1695 9457913 (i) LS B-NP O
25 1696 1704 9457913 aberrant JJ I-NP O
26 1705 1713 9457913 splicing NN I-NP O
27 1714 1719 9457913 often RB B-ADVP O
28 1720 1729 9457913 generates VBZ B-VP O
29 1730 1731 9457913 a DT B-NP O
30 1732 1741 9457913 premature JJ I-NP O
31 1742 1753 9457913 termination NN I-NP O
32 1754 1759 9457913 codon NN I-NP O
33 1759 1760 9457913 , , O O
34 1761 1765 9457913 (ii) LS B-LST O
35 1766 1777 9457913 transcripts NNS B-NP O
36 1778 1782 9457913 with IN B-PP O
37 1783 1792 9457913 premature JJ B-NP O
38 1793 1804 9457913 termination NN I-NP O
39 1805 1811 9457913 codons NNS I-NP O
40 1812 1815 9457913 can MD B-VP O
41 1816 1821 9457913 occur VB I-VP O
42 1822 1824 9457913 at IN B-PP O
43 1825 1828 9457913 low JJ B-NP O
44 1829 1831 9457913 or CC I-NP O
45 1832 1844 9457913 undetectable JJ I-NP O
46 1845 1851 9457913 levels NNS I-NP O
47 1852 1855 9457913 due JJ B-ADJP O
48 1856 1858 9457913 to TO B-PP O
49 1859 1867 9457913 nonsense NN B-NP O
50 1867 1868 9457913 - HYPH O O
51 1868 1876 9457913 mediated VBN B-NP O
52 1877 1881 9457913 mRNA NN I-NP O
53 1882 1887 9457913 decay NN I-NP O
54 1887 1888 9457913 , , O O
55 1889 1892 9457913 and CC O O
56 1893 1898 9457913 (iii) LS O O
57 1899 1902 9457913 the DT B-NP O
58 1903 1909 9457913 levels NNS I-NP O
59 1910 1912 9457913 of IN B-PP O
60 1913 1918 9457913 these DT B-NP O
61 1919 1930 9457913 transcripts NNS I-NP O
62 1931 1934 9457913 can MD B-VP O
63 1935 1937 9457913 be VB I-VP O
64 1938 1947 9457913 increased VBN I-VP O
65 1948 1950 9457913 by IN B-PP O
66 1951 1964 9457913 cycloheximide NN B-NP O
67 1964 1965 9457913 . . O O

1 0 0 9585611 -DOCSTART- -X- -X- O

1 0 8 9585611 Genotype NN B-NP O
2 8 9 9585611 - HYPH I-NP O
3 9 18 9585611 phenotype NN I-NP O
4 19 31 9585611 correlations NNS I-NP O
5 32 34 9585611 in IN B-PP O
6 35 45 9585611 attenuated VBN B-NP B-Disease
7 46 57 9585611 adenomatous JJ I-NP I-Disease
8 58 67 9585611 polyposis NN I-NP I-Disease
9 68 72 9585611 coli NN I-NP I-Disease
10 72 73 9585611 . . B-NP O
11 74 78 9585611 Germ NN I-NP O
12 78 79 9585611 - HYPH B-NP O
13 79 83 9585611 line NN I-NP O
14 84 93 9585611 mutations NNS I-NP O
15 94 96 9585611 of IN B-PP O
16 97 100 9585611 the DT B-NP O
17 101 106 9585611 tumor NN I-NP B-Disease
18 107 117 9585611 suppressor NN I-NP O
19 118 121 9585611 APC NN I-NP O
20 122 125 9585611 are VBP B-VP O
21 126 136 9585611 implicated VBN I-VP O
22 137 139 9585611 in IN B-PP O
23 140 150 9585611 attenuated VBN B-NP B-Disease
24 151 162 9585611 adenomatous JJ I-NP I-Disease
25 163 172 9585611 polyposis NN I-NP I-Disease
26 173 177 9585611 coli NN I-NP I-Disease
27 178 179 9585611 ( ( O O
28 179 183 9585611 AAPC NN B-NP B-Disease
29 183 184 9585611 ) ) O O
30 184 185 9585611 , , O O
31 186 187 9585611 a DT B-NP O
32 188 195 9585611 variant NN I-NP O
33 196 198 9585611 of IN B-PP O
34 199 207 9585611 familial JJ B-NP B-Disease
35 208 219 9585611 adenomatous JJ I-NP I-Disease
36 220 229 9585611 polyposis NN I-NP I-Disease
37 230 231 9585611 ( ( O O
38 231 234 9585611 FAP NN B-NP B-Disease
39 234 235 9585611 ) ) O O
40 235 236 9585611 . . O O

1 237 241 9585611 AAPC NN B-NP B-Disease
2 242 244 9585611 is VBZ B-VP O
3 245 255 9585611 recognized VBN I-VP O
4 256 258 9585611 by IN B-PP O
5 259 262 9585611 the DT B-NP O
6 263 273 9585611 occurrence NN I-NP O
7 274 276 9585611 of IN B-PP O
8 277 278 9585611 < SYM B-NP O
9 279 282 9585611 100 CD I-NP O
10 283 290 9585611 colonic JJ I-NP B-Disease
11 291 299 9585611 adenomas NNS I-NP I-Disease
12 300 303 9585611 and CC O O
13 304 305 9585611 a DT B-NP O
14 306 311 9585611 later JJ I-NP O
15 312 317 9585611 onset NN I-NP O
16 318 320 9585611 of IN B-PP O
17 321 331 9585611 colorectal JJ B-NP B-Disease
18 332 338 9585611 cancer NN I-NP I-Disease
19 339 340 9585611 ( ( O O
20 340 343 9585611 age NN B-NP O
21 344 345 9585611 > SYM O O
22 346 348 9585611 40 CD B-NP O
23 349 354 9585611 years NNS I-NP O
24 354 355 9585611 ) ) O O
25 355 356 9585611 . . O O

1 357 360 9585611 The DT B-NP O
2 361 364 9585611 aim NN I-NP O
3 365 367 9585611 of IN B-PP O
4 368 372 9585611 this DT B-NP O
5 373 378 9585611 study NN I-NP O
6 379 382 9585611 was VBD B-VP O
7 383 385 9585611 to TO B-VP O
8 386 392 9585611 assess VB I-VP O
9 393 401 9585611 genotype NN B-NP O
10 401 402 9585611 - HYPH B-NP O
11 402 411 9585611 phenotype NN I-NP O
12 412 424 9585611 correlations NNS I-NP O
13 425 427 9585611 in IN B-PP O
14 428 432 9585611 AAPC NN B-NP B-Disease
15 433 441 9585611 families NNS I-NP O
16 441 442 9585611 . . O O

1 443 445 9585611 By IN B-PP O
2 446 453 9585611 protein NN B-NP O
3 453 454 9585611 - HYPH O O
4 454 464 9585611 truncation NN B-NP O
5 465 469 9585611 test NN I-NP O
6 470 471 9585611 ( ( O O
7 471 474 9585611 PTT NN B-NP O
8 474 475 9585611 ) ) O O
9 476 481 9585611 assay NN B-NP O
10 481 482 9585611 , , O O
11 483 486 9585611 the DT B-NP O
12 487 493 9585611 entire JJ I-NP O
13 494 500 9585611 coding VBG I-NP O
14 501 507 9585611 region NN I-NP O
15 508 510 9585611 of IN B-PP O
16 511 514 9585611 the DT B-NP O
17 515 518 9585611 APC NN I-NP B-Disease
18 519 523 9585611 gene NN I-NP O
19 524 527 9585611 was VBD B-VP O
20 528 536 9585611 screened VBN I-VP O
21 537 539 9585611 in IN B-PP O
22 540 548 9585611 affected VBN B-NP O
23 549 560 9585611 individuals NNS I-NP O
24 561 565 9585611 from IN B-PP O
25 566 568 9585611 11 CD B-NP O
26 569 573 9585611 AAPC NN I-NP B-Disease
27 574 582 9585611 kindreds NNS I-NP O
28 582 583 9585611 , , O O
29 584 587 9585611 and CC O O
30 588 593 9585611 their PRP$ B-NP O
31 594 604 9585611 phenotypic JJ I-NP O
32 605 616 9585611 differences NNS I-NP O
33 617 621 9585611 were VBD B-VP O
34 622 630 9585611 examined VBN I-VP O
35 630 631 9585611 . . O O

1 632 636 9585611 Five CD B-NP O
2 637 642 9585611 novel JJ I-NP O
3 643 647 9585611 germ NN I-NP O
4 647 648 9585611 - HYPH I-NP O
5 648 652 9585611 line NN I-NP O
6 653 656 9585611 APC NN I-NP B-Disease
7 657 666 9585611 mutations NNS I-NP O
8 667 671 9585611 were VBD B-VP O
9 672 682 9585611 identified VBN I-VP O
10 683 685 9585611 in IN B-PP O
11 686 691 9585611 seven CD B-NP O
12 692 700 9585611 kindreds NNS I-NP O
13 700 701 9585611 . . O O

1 702 711 9585611 Mutations NNS B-NP O
2 712 716 9585611 were VBD B-VP O
3 717 724 9585611 located VBN I-VP O
4 725 727 9585611 in IN B-PP O
5 728 733 9585611 three CD B-NP O
6 734 743 9585611 different JJ I-NP O
7 744 751 9585611 regions NNS I-NP O
8 752 754 9585611 of IN B-PP O
9 755 758 9585611 the DT B-NP O
10 759 762 9585611 APC NN I-NP B-Disease
11 763 767 9585611 gene NN I-NP O
12 769 770 9585611 ( ( O O
13 770 771 9585611 1 CD B-NP O
14 771 772 9585611 ) ) O O
15 773 775 9585611 at IN B-PP O
16 776 779 9585611 the DT B-NP O
17 780 781 9585611 5 CD I-NP O
18 782 785 9585611 end NN I-NP O
19 786 794 9585611 spanning VBG B-VP O
20 795 800 9585611 exons NNS B-NP O
21 801 802 9585611 4 CD B-NP O
22 803 806 9585611 and CC I-NP O
23 807 808 9585611 5 CD I-NP O
24 808 809 9585611 , , O O
25 810 811 9585611 ( ( B-LST O
26 811 812 9585611 2 LS I-LST O
27 812 813 9585611 ) ) O O
28 814 820 9585611 within IN B-PP O
29 821 825 9585611 exon NN B-NP O
30 826 827 9585611 9 CD I-NP O
31 827 828 9585611 , , O O
32 829 832 9585611 and CC O O
33 833 834 9585611 ( ( B-LST O
34 834 835 9585611 3 LS I-LST O
35 835 836 9585611 ) ) O O
36 837 839 9585611 at IN B-PP O
37 840 843 9585611 the DT B-NP O
38 844 845 9585611 3 CD I-NP O
39 846 852 9585611 distal JJ I-NP O
40 853 856 9585611 end NN I-NP O
41 857 859 9585611 of IN B-PP O
42 860 863 9585611 the DT B-NP O
43 864 868 9585611 gene NN I-NP O
44 868 869 9585611 . . O O

1 870 881 9585611 Variability NN B-NP O
2 882 884 9585611 in IN B-PP O
3 885 888 9585611 the DT B-NP O
4 889 895 9585611 number NN I-NP O
5 896 898 9585611 of IN B-PP O
6 899 909 9585611 colorectal JJ B-NP B-Disease
7 910 918 9585611 adenomas NNS I-NP I-Disease
8 919 922 9585611 was VBD B-VP O
9 923 927 9585611 most RBS B-ADJP O
10 928 936 9585611 apparent JJ I-ADJP O
11 937 939 9585611 in IN B-PP O
12 940 951 9585611 individuals NNS B-NP O
13 952 956 9585611 with IN B-PP O
14 957 966 9585611 mutations NNS B-NP O
15 967 969 9585611 in IN B-PP O
16 970 976 9585611 region NN B-NP O
17 977 978 9585611 1 CD I-NP O
18 978 979 9585611 , , O O
19 980 983 9585611 and CC O O
20 984 989 9585611 upper JJ B-NP O
21 989 990 9585611 - HYPH I-NP O
22 990 1006 9585611 gastrointestinal JJ I-NP O
23 1007 1021 9585611 manifestations NNS I-NP O
24 1022 1026 9585611 were VBD B-VP O
25 1027 1031 9585611 more RBR B-ADJP O
26 1032 1038 9585611 severe JJ I-ADJP O
27 1039 1041 9585611 in IN B-PP O
28 1042 1046 9585611 them PRP B-NP O
29 1046 1047 9585611 . . O O

1 1048 1050 9585611 In IN B-PP O
2 1051 1062 9585611 individuals NNS B-NP O
3 1063 1067 9585611 with IN B-PP O
4 1068 1077 9585611 mutations NNS B-NP O
5 1078 1080 9585611 in IN B-PP O
6 1081 1087 9585611 either CC O O
7 1088 1094 9585611 region NN B-NP O
8 1095 1096 9585611 2 CD I-NP O
9 1097 1099 9585611 or CC O O
10 1100 1106 9585611 region NN B-NP O
11 1107 1108 9585611 3 CD I-NP O
12 1108 1109 9585611 , , O O
13 1110 1113 9585611 the DT B-NP O
14 1114 1121 9585611 average JJ I-NP O
15 1122 1128 9585611 number NN I-NP O
16 1129 1131 9585611 of IN B-PP O
17 1132 1140 9585611 adenomas NNS B-NP B-Disease
18 1141 1147 9585611 tended VBD B-VP O
19 1148 1150 9585611 to TO I-VP O
20 1151 1153 9585611 be VB I-VP O
21 1154 1159 9585611 lower JJR B-ADJP O
22 1160 1164 9585611 than IN B-PP O
23 1165 1170 9585611 those DT B-NP O
24 1171 1173 9585611 in IN B-PP O
25 1174 1185 9585611 individuals NNS B-NP O
26 1186 1190 9585611 with IN B-PP O
27 1191 1200 9585611 mutations NNS B-NP O
28 1201 1203 9585611 in IN B-PP O
29 1204 1210 9585611 region NN B-NP O
30 1211 1212 9585611 1 CD I-NP O
31 1212 1213 9585611 , , O O
32 1214 1222 9585611 although IN B-SBAR O
33 1223 1226 9585611 age NN B-NP O
34 1227 1229 9585611 at IN B-PP O
35 1230 1239 9585611 diagnosis NN B-NP O
36 1240 1243 9585611 was VBD B-VP O
37 1244 1251 9585611 similar JJ B-ADJP O
38 1251 1252 9585611 . . O O

1 1253 1255 9585611 In IN B-PP O
2 1256 1259 9585611 all DT B-NP O
3 1260 1264 9585611 AAPC NN I-NP B-Disease
4 1265 1273 9585611 kindreds NNS I-NP O
5 1273 1274 9585611 , , O O
6 1275 1276 9585611 a DT B-NP O
7 1277 1289 9585611 predominance NN I-NP O
8 1290 1292 9585611 of IN B-PP O
9 1293 1298 9585611 right JJ B-NP O
10 1298 1299 9585611 - HYPH I-NP O
11 1299 1304 9585611 sided JJ I-NP O
12 1305 1315 9585611 colorectal JJ I-NP B-Disease
13 1316 1324 9585611 adenomas NNS I-NP I-Disease
14 1325 1328 9585611 and CC O O
15 1329 1335 9585611 rectal JJ B-NP B-Disease
16 1336 1341 9585611 polyp NN I-NP I-Disease
17 1342 1349 9585611 sparing NN I-NP O
18 1350 1353 9585611 was VBD B-VP O
19 1354 1362 9585611 observed VBN I-VP O
20 1362 1363 9585611 . . O O

1 1364 1366 9585611 No DT B-NP O
2 1367 1374 9585611 desmoid JJ I-NP B-Disease
3 1375 1381 9585611 tumors NNS I-NP I-Disease
4 1382 1386 9585611 were VBD B-VP O
5 1387 1392 9585611 found VBN I-VP O
6 1393 1395 9585611 in IN B-PP O
7 1396 1401 9585611 these DT B-NP O
8 1402 1410 9585611 kindreds NNS I-NP O
9 1410 1411 9585611 . . O O

1 1412 1415 9585611 Our PRP$ B-NP O
2 1416 1420 9585611 data NNS I-NP O
3 1421 1428 9585611 suggest VBP B-VP O
4 1429 1433 9585611 that IN B-SBAR O
5 1433 1434 9585611 , , O O
6 1435 1437 9585611 in IN B-PP O
7 1438 1442 9585611 AAPC NN B-NP B-Disease
8 1443 1451 9585611 families NNS I-NP O
9 1451 1452 9585611 , , O O
10 1453 1456 9585611 the DT B-NP O
11 1457 1465 9585611 location NN I-NP O
12 1466 1468 9585611 of IN B-PP O
13 1469 1472 9585611 the DT B-NP O
14 1473 1476 9585611 APC NN I-NP B-Disease
15 1477 1485 9585611 mutation NN I-NP O
16 1486 1489 9585611 may MD B-VP O
17 1490 1499 9585611 partially RB I-VP O
18 1500 1507 9585611 predict VB I-VP O
19 1508 1516 9585611 specific JJ B-NP O
20 1517 1527 9585611 phenotypic JJ I-NP O
21 1528 1538 9585611 expression NN I-NP O
22 1538 1539 9585611 . . O O

1 1540 1544 9585611 This DT B-NP O
2 1545 1551 9585611 should MD B-VP O
3 1552 1556 9585611 help VB I-VP O
4 1557 1559 9585611 in IN B-PP O
5 1560 1563 9585611 the DT B-NP O
6 1564 1570 9585611 design NN I-NP O
7 1571 1573 9585611 of IN B-PP O
8 1574 1582 9585611 tailored VBN B-NP O
9 1583 1591 9585611 clinical JJ I-NP O
10 1591 1592 9585611 - HYPH I-NP O
11 1592 1602 9585611 management NN I-NP O
12 1603 1612 9585611 protocols NNS I-NP O
13 1613 1615 9585611 in IN B-PP O
14 1616 1620 9585611 this DT B-NP O
15 1621 1627 9585611 subset NN I-NP O
16 1628 1630 9585611 of IN B-PP O
17 1631 1634 9585611 FAP NN B-NP B-Disease
18 1635 1643 9585611 patients NNS I-NP O
19 1643 1644 9585611 . . O O
20 1644 1645 9585611 . . O O

